

Randomised trial of cholesterol lowering in 4444 patients: the Scandinavian Simvastatin Survival Study (4S)

Lancet, The

344, 1383-9

Citation Report

#	ARTICLE	IF	CITATIONS
1	Selective release of newly synthesised and newly captured GABA from synaptosomes by potassium depolarisation. <i>Nature</i> , 1975, 258, 254-256.	13.7	41
2	Cardiologists rebuked. <i>Lancet, The</i> , 1994, 344, 1557.	6.3	8
3	Comparative Evaluation of the Safety and Efficacy of HMG-CoA Reductase Inhibitor Monotherapy in the Treatment of Primary Hypercholesterolemia. <i>Annals of Pharmacotherapy</i> , 1995, 29, 743-759.	0.9	136
4	Prevention of Macrovascular Disease: Absolute Proof or Absolute Risk?. <i>Diabetic Medicine</i> , 1995, 12, 561-562.	1.2	0
5	Prescribing Patterns of Anttlipemic Drugs and Prevalence of Hypercholesterolemia in the Nova Scotia Population More than 65 Years Old. <i>Annals of Pharmacotherapy</i> , 1995, 29, 576-581.	0.9	3
6	Cholesterol and psyche. <i>Acta Neuropsychiatrica</i> , 1995, 7, 122-126.	1.0	2
7	Drugs affecting lipid metabolism. <i>Side Effects of Drugs Annual</i> , 1995, 19, 407-410.	0.6	0
8	Clinical perspectives on primary and secondary prevention of coronary atherosclerosis. <i>Medical Clinics of North America</i> , 1995, 79, 973-998.	1.1	20
9	Coronary risk factors and their modification: Lipids, smoking, hypertension, estrogen, and the elderly. <i>Current Problems in Cardiology</i> , 1995, 20, 539-610.	1.1	13
10	Clustering of cardiovascular risk factors: Targeting high-risk individuals. <i>American Journal of Cardiology</i> , 1995, 76, 8A-20A.	0.7	112
11	Fluvastatin in severe hypercholesterolemia:Analysis of a clinical trial database. <i>American Journal of Cardiology</i> , 1995, 76, 71A-75A.	0.7	6
12	Fluvastatin for dyslipoproteinemia,with or without concomitant chronic renal insufficiency. <i>American Journal of Cardiology</i> , 1995, 76, 97A-101A.	0.7	27
13	Secondary Prevention of Coronary Heart Disease in Practice. <i>Physiotherapy</i> , 1995, 81, 398.	0.2	1
14	Atherosclerosis, oxidative stress, and antioxidant protection in endothelium-derived relaxing factor action. <i>Progress in Cardiovascular Diseases</i> , 1995, 38, 129-154.	1.6	174
15	Cost-effectiveness analysis in heart disease, part II: Preventive therapies. <i>Progress in Cardiovascular Diseases</i> , 1995, 37, 243-271.	1.6	65
16	Design features and baseline characteristics of the LIPID (long-term intervention with pravastatin in) Tj ETQq1 1 0.784314 rgBT /Overlo and/or unstable angina pectoris. <i>American Journal of Cardiology</i> , 1995, 76, 474-479.	0.7	104
17	Screening experience and baseline characteristics in the West of Scotland coronary prevention study. <i>American Journal of Cardiology</i> , 1995, 76, 485-491.	0.7	65
18	Low incidence of assessment and modification of risk factors in acute care patients at high risk for cardiovascular events, particularly among females and the elderly. <i>American Journal of Cardiology</i> , 1995, 76, 570-573.	0.7	53

#	ARTICLE	IF	CITATIONS
19	Design, rationale, and baseline characteristics of the Prospective Pravastatin Pooling (PPP) project—A combined analysis of three large-scale randomized trials: Long-Term Intervention With Pravastatin in Ischemic Disease (LIPID), Cholesterol and Recurrent Events (CARE), and West of Scotland Coronary Prevention Study (WOSCOPS). <i>American Journal of Cardiology</i> , 1995, 76, 899-905.	0.7	46
20	Cholesterol reduction and its impact on coronary artery disease and total mortality. <i>American Journal of Cardiology</i> , 1995, 76, 10C-17C.	0.7	52
21	Reduction in coronary events during treatment with pravastatin. <i>American Journal of Cardiology</i> , 1995, 76, 60C-63C.	0.7	42
22	Reducing the risk of coronary events: Evidence from the Scandinavian Simvastatin survival study (4S). <i>American Journal of Cardiology</i> , 1995, 76, 64C-68C.	0.7	145
23	Range of serum cholesterol values in the population developing coronary artery disease. <i>American Journal of Cardiology</i> , 1995, 76, 69C-77C.	0.7	262
24	What benefit can be derived from treating normocholesterolemic patients with coronary artery disease?. <i>American Journal of Cardiology</i> , 1995, 76, 93C-97C.	0.7	9
25	Cholesterol and recurrent events: A secondary prevention trial for normolipidemic patients. <i>American Journal of Cardiology</i> , 1995, 76, 98C-106C.	0.7	110
26	Management of the long-term intervention with pravastatin in ischaemic disease (LIPID) study after the scandinavian simvastatin survival study (4S). <i>American Journal of Cardiology</i> , 1995, 76, 107C-112C.	0.7	37
27	Extending the benefit of lipid-regulating therapy to primary prevention. <i>American Journal of Cardiology</i> , 1995, 76, 118C-121C.	0.7	4
28	Prospective meta-analysis of cholesterol-lowering studies: The prospective pravastatin pooling (PPP) project and the cholesterol treatment trialists (CTT) collaboration. <i>American Journal of Cardiology</i> , 1995, 76, 122C-126C.	0.7	51
29	Baseline characteristics in the Cholesterol and Recurrent Events (CARE) trial of secondary prevention in patients with average serum cholesterol levels. <i>American Journal of Cardiology</i> , 1995, 75, 621-623.	0.7	39
30	Reporting of coronary risk factors. <i>American Journal of Cardiology</i> , 1995, 75, 716-717.	0.7	4
31	Why cardiologists must be interested in lipids. <i>American Journal of Cardiology</i> , 1995, 75, 1067-1068.	0.7	7
32	Coronary risk factors in women six months after coronary artery bypass grafting. <i>American Journal of Cardiology</i> , 1995, 75, 1092-1095.	0.7	20
33	Prevalence of dyslipidemic phenotypes in ischemic heart disease (prospective results from the Quebec) Tj ETQq0 0.0 rgBT /Overlock 10	0.7	149
34	Distribution of lipids in 8,500 men with coronary artery disease. <i>American Journal of Cardiology</i> , 1995, 75, 1196-1201.	0.7	219
35	Cholesterol-raising effects of coffee: clues to regulation of cholesterol metabolism. <i>Journal of Internal Medicine</i> , 1995, 238, 475-477.	2.7	4
36	Treatment for survivors of acute myocardial infarction: What have we learned from large intervention trials?. <i>Cardiovascular Drugs and Therapy</i> , 1995, 9, 495-502.	1.3	1

#	ARTICLE	IF	CITATIONS
37	Coadministration of calcium antagonists and ACE inhibitors?Is a skeptic convinced?: A personal view. <i>Cardiovascular Drugs and Therapy</i> , 1995, 9, 525-528.	1.3	1
38	Heretical report on the efficacy of blood pressure treatment in a population setting. <i>Cardiovascular Drugs and Therapy</i> , 1995, 9, 373-374.	1.3	0
39	Many roads lead to atheroma. <i>Nature Medicine</i> , 1995, 1, 22-23.	15.2	23
40	Paradox of placebo effect. <i>Nature</i> , 1995, 375, 530-530.	13.7	35
41	Synthesis and biological activity of J-104,118, a novel, potent inhibitor of squalene synthase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1995, 5, 1989-1994.	1.0	18
42	Cholesterol in patients with coronary heart disease. <i>Journal of General Internal Medicine</i> , 1995, 10, 464-471.	1.3	7
43	New targets for lipid lowering and atherosclerosis prevention. , 1995, 67, 433-447.		6
44	Economics of lipid lowering with HMG CoA reductase inhibitors: To the editor. <i>Clinical Cardiology</i> , 1995, 18, 295-296.	0.7	0
45	Editor's note: Chelation therapy for atherosclerosis: One man's view. <i>Clinical Cardiology</i> , 1995, 18, 545-545.	0.7	2
46	Role of thrombosis in atherosclerosis and its complications. <i>American Journal of Cardiology</i> , 1995, 75, 5B-11B.	0.7	94
47	Association of Postprandial Triglyceride and Retinyl Palmitate Responses With Newly Diagnosed Exercise-Induced Myocardial Ischemia in Middle-Aged Men and Women. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1995, 15, 1829-1838.	1.1	120
48	Reduction of Serum Cholesterol Levels Alters Lesional Composition of Atherosclerotic Plaques. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1995, 15, 1938-1944.	1.1	125
49	A Rational Policy for Measuring and Lowering Cholesterol. <i>Vascular Medicine Review</i> , 1995, vmr-6, 193-203.	0.2	0
50	Nutritional disorders in the elderly. <i>Medical Journal of Australia</i> , 1995, 163, 376-381.	0.8	22
51	Four Yearsâ€™ Treatment Efficacy of Patients with Severe Hyperlipidemia. Lipid Lowering Drugs versus LDL-Apheresis. <i>International Journal of Artificial Organs</i> , 1995, 18, 786-793.	0.7	6
52	Niacin for lipid disorders. <i>Postgraduate Medicine</i> , 1995, 98, 185-193.	0.9	14
53	Comment: Comparison of Hmg-Coa Reductase Inhibitors. <i>Annals of Pharmacotherapy</i> , 1995, 29, 1304-1304.	0.9	1
54	overused in Angina patients?. <i>Postgraduate Medicine</i> , 1995, 98, 125-142.	0.9	2

#	ARTICLE	IF	CITATIONS
55	Diet in The Prevention and Treatment of Atherosclerosis. Clinics in Geriatric Medicine, 1995, 11, 591-612.	1.0	6
56	The Effect of Cholesterol-Lowering and Antioxidant Therapy on Endothelium-Dependent Coronary Vasomotion. New England Journal of Medicine, 1995, 332, 488-493.	13.9	1,085
57	Long-term safety of statin-fibrate combination treatment in the management of hypercholesterolaemia in patients with coronary artery disease.. Heart, 1995, 74, 14-17.	1.2	48
58	Prospective study of patients aged 55 years or less with acute myocardial infarction between 1981 and 1985: outcome 7 years and beyond.. Heart, 1995, 74, 604-610.	1.2	10
59	Cholesterol lowering does have a role in secondary prevention.. Heart, 1995, 73, 4-5.	1.2	6
60	Insights Into the Pathogenesis and Prevention of Coronary Artery Disease. Mayo Clinic Proceedings, 1995, 70, 69-79.	1.4	40
61	Lowering Cholesterol with Drugs and Diet. New England Journal of Medicine, 1995, 333, 1350-1351.	13.9	40
62	Rhabdomyolysis from the Coadministration of Lovastatin and the Antifungal Agent Itraconazole. New England Journal of Medicine, 1995, 333, 664-665.	13.9	137
63	Evaluating the Efficiency of Cholesterol Modification for Coronary Heart Disease with Decision Analytic Models: A Case Study. Drug Information Journal, 1995, 29, 1441-1457.	0.5	3
64	Mortality in participants and non-participants of a multifactorial prevention study of cardiovascular diseases: a 28 year follow up of the Helsinki Businessmen Study.. Heart, 1995, 74, 449-454.	1.2	55
65	Choosing drugs for secondary prevention after myocardial infarction: a pragmatic approach.. Postgraduate Medical Journal, 1995, 71, 321-322.	0.9	2
66	Angiographic trials of lipid-lowering therapy: end of an era?. Heart, 1995, 74, 343-347.	1.2	17
67	Statins: is there a need for alternative or adjunctive therapy?. Heart, 1995, 74, 13-13.	1.2	6
68	Abnormal membrane concentrations of 20 and 22-carbon essential fatty acids: A common link between risk factors and coronary and peripheral vascular disease?. Prostaglandins Leukotrienes and Essential Fatty Acids, 1995, 53, 385-396.	1.0	47
69	Occupational medicine for policing. Journal of Clinical Forensic and Legal Medicine, 1995, 2, 105-110.	0.9	5
70	Effects of 3-hydroxy-methylglutaryl coenzyme A reductase inhibitors on mitochondrial respiration in ischaemic dog hearts. British Journal of Pharmacology, 1995, 116, 1894-1898.	2.7	52
71	Preventing and arresting coronary atherosclerosis. American Heart Journal, 1995, 130, 580-600.	1.2	59
72	Comparison of the effects of simvastatin versus hormone replacement therapy in the treatment of postmenopausal women with primary hypercholesterolemia. Current Therapeutic Research, 1995, 56, 515-529.	0.5	3

#	ARTICLE	IF	CITATIONS
73	Contemporary management of acute myocardial infarction. American Journal of Medicine, 1995, 99, 195-206.	0.6	18
74	American Heart Association consensus panel statement on preventing heart attack and death in patients with coronary disease. Journal of the American College of Cardiology, 1995, 26, 291.	1.2	0
75	Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): Reduction in atherosclerosis progression and clinical events. Journal of the American College of Cardiology, 1995, 26, 1133-1139.	1.2	411
76	Cost-effectiveness analysis and clinical practice. Journal of the American College of Cardiology, 1995, 26, 920-921.	1.2	0
77	Risk factors of coronary heart disease and total mortality among elderly men with and without preexisting coronary heart disease. Journal of the American College of Cardiology, 1995, 26, 1623-1629.	1.2	44
78	Physician use of beta-adrenergic blocking therapy: a changing perspective. Journal of the American College of Cardiology, 1995, 26, 547-552.	1.2	57
79	Cholesterol Reduction in Cardiovascular Disease – Clinical Benefits and Possible Mechanisms. New England Journal of Medicine, 1995, 332, 512-521.	13.9	645
80	Screening for Cardiovascular Risks – In Whose Interest do we Act?. European Journal of General Practice, 1995, 1, 101-102.	0.9	6
81	Acute Cerebral Infarction. Drugs and Aging, 1995, 6, 445-455.	1.3	6
82	Prevention of Complications in Non-Insulin-Dependent Diabetes Mellitus (NIDDM). Drugs, 1995, 50, 263-288.	4.9	39
83	Simvastatin. Drugs, 1995, 50, 334-363.	4.9	92
84	Mood Disorders and Cholesterol-Lowering Drugs. CNS Drugs, 1995, 3, 409-415.	2.7	0
85	Effect of Pravastatin, Cholestyramine or their Combination in the Treatment of Hypercholesterolaemia in Elderly Hypertensive Patients. Clinical Drug Investigation, 1995, 9, 314-323.	1.1	1
86	Double-Blind Comparison of the Efficacy and Tolerability of Simvastatin and Fluvastatin in Patients with Primary Hypercholesterolaemia. Clinical Drug Investigation, 1995, 10, 127-138.	1.1	25
88	Secondary prevention of atherosclerosis: Emphasizing risk factor management to patients. Annals of Thoracic Surgery, 1995, 60, 1.	0.7	9
89	Risk factors for coronary heart disease in the prospective Dubbo Study of Australian elderly. Atherosclerosis, 1995, 117, 107-118.	0.4	42
90	Long-term efficacy and tolerability of simvastatin in a large cohort of elderly hypercholesterolemic patients. Atherosclerosis, 1995, 116, 153-162.	0.4	19
91	Coronary atherosclerosis stabilization: an achievable goal. Atherosclerosis, 1995, 118, S91-S101.	0.4	12

#	ARTICLE	IF	CITATIONS
92	Does diet or alcohol explain the French paradox?. Lancet, The, 1995, 345, 527-528.	6.3	10
93	A suitable case for treatment. Lancet, The, 1995, 345, 1051.	6.3	3
94	Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet, The, 1995, 345, 1274-1275.	6.3	287
95	Implications of 4S evidence on baseline lipid levels. Lancet, The, 1995, 346, 181-182.	6.3	9
96	Non-invasive management of coronary artery disease. Lancet, The, 1995, 346, 750-753.	6.3	6
97	Statins prevent coronary heart disease. Lancet, The, 1995, 346, 1378-1379.	6.3	28
98	Evidence-based management of dyslipidaemia. Lancet, The, 1995, 346, 1440-1442.	6.3	27
99	Sheffield risk and treatment table for cholesterol lowering for primary prevention of coronary heart disease. Lancet, The, 1995, 346, 1467-1471.	6.3	121
100	Cholesterol, diastolic blood pressure, and stroke: 13 000 strokes in 450 000 people in 45 prospective cohorts. Lancet, The, 1995, 346, 1647-1653.	6.3	821
101	Angioplasty versus bypass surgery. Lancet, The, 1995, 346, 1174-1175.	6.3	18
102	Familial hypercholesterolaemia: Mutations in the gene for the low-density-lipoprotein receptor. Trends in Molecular Medicine, 1995, 1, 90-97.	2.6	3
103	The genetic determinants of plasma cholesterol and response to diet. Bailliere's Clinical Endocrinology and Metabolism, 1995, 9, 797-823.	1.0	7
104	Currently available hypolipidaemic drugs and future therapeutic developments. Bailliere's Clinical Endocrinology and Metabolism, 1995, 9, 825-847.	1.0	28
105	Lipoproteins and the progression/regression of atherosclerosis. Bailliere's Clinical Endocrinology and Metabolism, 1995, 9, 849-866.	1.0	11
106	Review of new guidelines for management of dyslipidaemia. Bailliere's Clinical Endocrinology and Metabolism, 1995, 9, 867-890.	1.0	6
107	Adjunctive Therapy in the Management of Patients With Acute Myocardial Infarction. Mayo Clinic Proceedings, 1995, 70, 464-468.	1.4	5
108	Insights Into the Pathogenesis and Prevention of Coronary Artery Disease. Mayo Clinic Proceedings, 1995, 70, 69-79.	1.4	35
109	PATHOPHYSIOLOGY OF PLAQUE RUPTURE AND THE CONCEPT OF PLAQUE STABILIZATION. Cardiology Clinics, 1996, 14, 17-29.	0.9	64

#	ARTICLE	IF	CITATIONS
110	The New Paradigm for Coronary Artery Disease: Altering Risk Factors, Atherosclerotic Plaques, and Clinical Prognosis. Mayo Clinic Proceedings, 1996, 71, 957-965.	1.4	5
111	INTRAVASCULAR AND INTRACARDIAC ULTRASOUND. Critical Care Clinics, 1996, 12, 451-470.	1.0	6
112	LESSONS FROM CORONARY ATHEROSCLEROSIS "REGRESSION" TRIALS. Cardiology Clinics, 1996, 14, 31-50.	0.9	10
113	BARRIERS TO LIFESTYLE CHANGE, AND THE NEED TO DEVELOP AN INTEGRATED APPROACH TO PREVENTION. Cardiology Clinics, 1996, 14, 159-169.	0.9	18
114	Coronary Revascularization: Importance of Observational Data. Mayo Clinic Proceedings, 1996, 71, 1016-1017.	1.4	8
115	PATHOPHYSIOLOGY AND INFLAMMATORY ASPECTS OF PLAQUE RUPTURE. Cardiology Clinics, 1996, 14, 211-220.	0.9	31
116	LIPID LOWERING. Cardiology Clinics, 1996, 14, 117-130.	0.9	7
117	Simvastatin increases plasma NO <sub>2</sub> <sup>-</sup> and NO <sub>3</sub> <sup>-</sup> levels in patients with hypercholesterolemia. Atherosclerosis, 1996, 127, 43-47.	0.4	10
118	Effects of regular and extended-release gemfibrozil on plasma lipoproteins and apolipoproteins in hypercholesterolemic patients with decreased HDL cholesterol levels. Atherosclerosis, 1996, 127, 113-122.	0.4	21
119	Spirals, paradigms, and the progression of heart failure. Journal of Cardiac Failure, 1996, 2, 1-4.	0.7	10
120	Myocardial infarction patients in the 1990s—their risk factors, stratification and survival in Canada: The Canadian assessment of myocardial infarction (CAMI) study. Journal of the American College of Cardiology, 1996, 27, 1119-1127.	1.2	241
121	Silent ST-T changes in an epidemiologic cohort study—a marker of hypertension or coronary heart disease, or both: The Reykjavik study. Journal of the American College of Cardiology, 1996, 27, 1140-1147.	1.2	76
122	Task force 1. Pathogenesis of coronary disease: The biologic role of risk factors. Journal of the American College of Cardiology, 1996, 27, 964-976.	1.2	181
123	Coronary bypass graft fate and patient outcome: Angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. Journal of the American College of Cardiology, 1996, 28, 616-626.	1.2	1,125
124	Contemporary practice of coronary revascularization in U.S. hospitals and hospitals participating in the bypass angioplasty revascularization investigation (BARI). Journal of the American College of Cardiology, 1996, 28, 609-615.	1.2	25
125	Task force 3. Spectrum of risk factors for coronary heart disease. Journal of the American College of Cardiology, 1996, 27, 978-990.	1.2	98
126	Task force 4. Efficacy of risk factor management. Journal of the American College of Cardiology, 1996, 27, 991-1006.	1.2	48
127	Task force 7. Evaluation and management of risk factors for the individual patient (case management). Journal of the American College of Cardiology, 1996, 27, 1030-1039.	1.2	13



#	ARTICLE	IF	CITATIONS
128	Cholesterol lowering and cerebrospinal fluid neurotransmitters: Increased levels of the anxiogenic cholecystokinin-tetrapeptide during simvastatin administration to healthy male volunteers. <i>Biological Psychiatry</i> , 1996, 40, 302-304.	0.7	11
129	The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels. <i>New England Journal of Medicine</i> , 1996, 335, 1001-1009.	13.9	7,059
130	Pharmacologic profile of survivors of acute myocardial infarction at United States academic hospitals. <i>American Heart Journal</i> , 1996, 131, 872-878.	1.2	19
131	Uncoupling clinical outcomes and coronary angiography: A review and perspective of recent trials in coronary artery disease. <i>American Heart Journal</i> , 1996, 132, 910-920.	1.2	6
132	Management of acute myocardial infarction: Evaluating the past, practicing in the present, elaborating the future. <i>American Heart Journal</i> , 1996, 132, 465-470.	1.2	8
133	Inadequate treatment with HMG-CoA reductase inhibitors by health care providers. <i>American Journal of Medicine</i> , 1996, 100, 605-610.	0.6	161
134	Risk stratification in coronary artery disease and special populations. <i>American Journal of Medicine</i> , 1996, 101, 17S-24S.	0.6	55
135	Guest commentary. <i>American Journal of Medicine</i> , 1996, 101, 3S-5S.	0.6	0
136	The clinical and economic significance of atherosclerosis. <i>American Journal of Medicine</i> , 1996, 101, 6S-9S.	0.6	28
137	Pathogenetic mechanisms of atherosclerosis: effect of lipid lowering on the biology of atherosclerosis. <i>American Journal of Medicine</i> , 1996, 101, 10S-16S.	0.6	25
138	Review of cholesterol-lowering therapy: Coronary angiographic and events trials. <i>American Journal of Medicine</i> , 1996, 101, 34S-39S.	0.6	21
139	Lipid management: Current diet and drug treatment options. <i>American Journal of Medicine</i> , 1996, 101, 40S-49S.	0.6	49
140	Pharmacologic therapies after myocardial infarction. <i>American Journal of Medicine</i> , 1996, 101, 61S-70S.	0.6	23
141	Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic Mediterranean population: The Carotid Atherosclerosis Italian Ultrasound Study. <i>American Journal of Medicine</i> , 1996, 101, 627-634.	0.6	250
142	Inhibitory effects of fluvastatin, a new HMG-CoA reductase inhibitor, on the increase in vascular ACE activity in cholesterol-fed rabbits. <i>British Journal of Pharmacology</i> , 1996, 119, 1269-1275.	2.7	54
143	Drug Therapy of Severe Hypercholesterolemia in Patients with Coronary Artery Disease. <i>Artificial Organs</i> , 1996, 20, 286-291.	1.0	1
144	H.E.L.P. Apheresis Therapy in the Treatment of Severe Hypercholesterolemia: 10 Years of Clinical Experience. <i>Artificial Organs</i> , 1996, 20, 303-310.	1.0	28
145	Heparin-Induced Extracorporeal Low-Density Lipoprotein Precipitation and Low-Density Lipoprotein Chemoadsorption onto Dextran Sulfate: A Comparison. <i>Artificial Organs</i> , 1996, 20, 328-331.	1.0	1

#	ARTICLE	IF	CITATIONS
146	Treatment of Severe Hyperlipidemia: Six Years' Experience with Low-Density Lipoprotein Apheresis. <i>Artificial Organs</i> , 1996, 20, 336-339.	1.0	5
147	Lipid Apheresis: From a Heroic Treatment to Routine Clinical Practice. <i>Artificial Organs</i> , 1996, 20, 414-419.	1.0	10
148	Dietary fats and coronary heart disease. <i>Biomedicine and Pharmacotherapy</i> , 1996, 50, 261-268.	2.5	38
149	Women and mexican Americans receive fewer cardiovascular drugs following myocardial infarction than men and non-hispanic whites: The Corpus Christi Heart Project, 1988-1990. <i>Journal of Clinical Epidemiology</i> , 1996, 49, 279-287.	2.4	41
150	Prevalence of hypercholesterolemia in Saudi Arabia, epidemiological study. <i>International Journal of Cardiology</i> , 1996, 54, 41-49.	0.8	37
151	The pathogenesis of atherosclerosis. <i>Clinica Chimica Acta</i> , 1996, 246, 21-38.	0.5	94
152	Inhibition of squalene synthase of rat liver by novel 3-substituted quinuclidines. <i>Biochemical Pharmacology</i> , 1996, 51, 1477-1487.	2.0	43
153	Inhibition of squalene synthase in vitro by 3-(biphenyl-4-yl)-quinuclidine. <i>Biochemical Pharmacology</i> , 1996, 51, 1489-1501.	2.0	17
154	Lovastatin reduces expression of the combined adhesion and scavenger receptor CD36 in human monocytic cells. <i>Biochemical Pharmacology</i> , 1996, 52, 433-439.	2.0	77
155	Clinical pharmacology and clinical trials in Japan. <i>Journal of Molecular Medicine</i> , 1996, 74, 479-486.	1.7	8
156	Beneficial effects of statins. <i>Lancet, The</i> , 1996, 348, 1582.	6.3	4
157	West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials. <i>Lancet, The</i> , 1996, 348, 1339-1342.	6.3	458
158	Statins do more than just lower cholesterol. <i>Lancet, The</i> , 1996, 348, 1079-1082.	6.3	672
159	Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table. <i>Lancet, The</i> , 1996, 348, 387-388.	6.3	162
160	Sheffield risk and treatment table for cholesterol lowering in prevention of coronary heart disease. <i>Lancet, The</i> , 1996, 347, 466-469.	6.3	5
161	Statin therapy and CHD. <i>Lancet, The</i> , 1996, 347, 128.	6.3	4
162	Is vascular smooth muscle cell proliferation beneficial?. <i>Lancet, The</i> , 1996, 347, 305-307.	6.3	118
163	Spontaneously low LDL cholesterol and reaction to exercise-induced stress. <i>Lancet, The</i> , 1996, 347, 405.	6.3	4

#	ARTICLE	IF	CITATIONS
164	The governance of clinical trials. <i>Lancet</i> , The, 1996, 347, 1387-1388.	6.3	9
165	Statins and coronary heart disease. <i>Lancet</i> , The, 1996, 347, 1389-1390.	6.3	15
166	Statins, cholesterol, and mevalonate pathways?. <i>Lancet</i> , The, 1996, 347, 551.	6.3	5
167	Detecting vulnerable coronary plaques. <i>Lancet</i> , The, 1996, 347, 1422-1423.	6.3	34
168	Atheroma: more than mush. <i>Lancet</i> , The, 1996, 348, S4-S7.	6.3	59
169	CHD prevention in clinical practice. <i>Lancet</i> , The, 1996, 348, S26-S28.	6.3	19
170	If I woke with central chest pain â€¦. <i>Lancet</i> , The, 1996, 348, S29-S31.	6.3	1
171	ACC/AHA guidelines for the management of patients with acute myocardial infarction. <i>Journal of the American College of Cardiology</i> , 1996, 28, 1328-1419.	1.2	1,473
172	Cardiovascular, pulmonary, and cancer rehabilitation. 1. Cardiac rehabilitation. <i>Archives of Physical Medicine and Rehabilitation</i> , 1996, 77, S38-S44.	0.5	4
173	Effects of growth hormone on serum lipids and lipoproteins: Possible significance of increased peripheral conversion of thyroxine to triiodothyronine. <i>Metabolism: Clinical and Experimental</i> , 1996, 45, 1016-1020.	1.5	9
174	Effects of HMG-CoA reductase inhibition on erythrocyte membrane cholesterol and acyl chain composition. <i>Clinica Chimica Acta</i> , 1996, 256, 53-63.	0.5	22
175	Decrease in plasma cholesteryl-ester transfer protein activity with simvastatin treatment in patients with type IIa hypercholesterolemia. <i>Current Therapeutic Research</i> , 1996, 57, 42-47.	0.5	3
176	A 4-year trial of simvastatin in the treatment of patients with heterozygous familial hypercholesterolemia. <i>Current Therapeutic Research</i> , 1996, 57, 62-71.	0.5	0
177	Efficacy and safety of simvastatin in current clinical practice: the italian family physician simvastatin study. <i>Current Therapeutic Research</i> , 1996, 57, 418-429.	0.5	4
178	Low serum cholesterol and the risk of cerebral haemorrhage. <i>Atherosclerosis</i> , 1996, 119, 1-6.	0.4	29
179	The effects of the apolipoprotein B signal peptide (ins/del) and XbaI polymorphisms on plasma lipid responses to dietary change. <i>Atherosclerosis</i> , 1996, 122, 1-10.	0.4	34
180	Lipids and atherogenesis in diabetes mellitus. <i>Atherosclerosis</i> , 1996, 124, S43-S47.	0.4	15
181	Can the clinical efficacy of the HMG CoA reductase inhibitors be explained solely by their effects on LDL-cholesterol?. <i>Atherosclerosis</i> , 1996, 125, 267-269.	0.4	24

#	ARTICLE	IF	CITATIONS
182	Effects of vitamin E on endothelium-dependent coronary flow in hypercholesterolemic dogs. <i>Atherosclerosis</i> , 1996, 126, 43-51.	0.4	6
183	Clinical pharmacologic concepts for the rational selection and use of drugs for the management of dyslipidemia. <i>Clinical Therapeutics</i> , 1996, 18, 392-410.	1.1	6
184	Incidence and significance of cardiac arrhythmia in geriatric oral surgery patients. <i>Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics</i> , 1996, 82, 42-46.	1.6	21
185	Recent trends in the consumption of lipid-lowering drugs in Finland. <i>Journal of Clinical Epidemiology</i> , 1996, 49, 1453-1457.	2.4	16
186	Iron versus cholesterol—Perspectives on the iron and heart disease debate. <i>Journal of Clinical Epidemiology</i> , 1996, 49, 1345-1352.	2.4	41
187	Hyperlipidemia versus iron overload and coronary artery disease: Yet more arguments on the cholesterol debate. <i>Journal of Clinical Epidemiology</i> , 1996, 49, 1353-1358.	2.4	7
188	Cholesterol and coronary heart disease. <i>Heart, Lung and Circulation</i> , 1996, 5, 105-110.	0.1	0
189	Heart Attacks: Gone with the Century?. <i>Science</i> , 1996, 272, 629-0.	6.0	128
190	Bile acid transport systems as pharmaceutical targets. <i>European Journal of Clinical Investigation</i> , 1996, 26, 715-732.	1.7	71
191	Coronary heart disease risk factors in older persons. <i>Aging Clinical and Experimental Research</i> , 1996, 8, 75-89.	1.4	16
192	HMG-CoA Reductase Inhibitors Issues in Assessing Their Benefits in Coronary Heart Disease. <i>Drug Safety</i> , 1996, 14, 8-10.	1.4	1
193	Benefits and Risks of HMG-CoA Reductase Inhibitors in the Prevention of Coronary Heart Disease A Reappraisal. <i>Drug Safety</i> , 1996, 14, 11-24.	1.4	92
194	Age-Related Changes Affecting Atherosclerotic Risk. <i>Drugs and Aging</i> , 1996, 8, 275-298.	1.3	8
195	Optimal Treatment of Angina in Older Patients. <i>Drugs and Aging</i> , 1996, 8, 349-357.	1.3	6
196	Diabetes Mellitus in Older Patients. <i>Drugs and Aging</i> , 1996, 8, 401-407.	1.3	6
197	Clinical Pharmacokinetics of 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitors. <i>Clinical Pharmacokinetics</i> , 1996, 31, 348-371.	1.6	149
198	Fluvastatin. <i>Drugs</i> , 1996, 51, 433-459.	4.9	121
199	The 4S Study. <i>Drugs</i> , 1996, 51, 507-514.	4.9	8

#	ARTICLE	IF	CITATIONS
200	Recognition and Treatment of Unstable Angina. <i>Drugs</i> , 1996, 52, 196-208.	4.9	13
201	Choosing the Right Lipid-Regulating Agent. <i>Drugs</i> , 1996, 52, 649-661.	4.9	38
202	The 4S Study and its Pharmacoeconomic Implications. <i>Pharmacoeconomics</i> , 1996, 9, 101-105.	1.7	13
203	Pilot Study of the Effect of the Simvastatin-Ciprofibrate Combination on Myocardial Infarction Risk Profile in Patients with Refractory Familial Combined Hyperlipidaemia. <i>Clinical Drug Investigation</i> , 1996, 11, 196-204.	1.1	1
204	Efficacy and Tolerability of Fluvastatin and Simvastatin in Hypercholesterolaemic Patients. <i>Clinical Drug Investigation</i> , 1996, 12, 119-126.	1.1	12
205	Apparent discontinuation rates in patients prescribed lipid-lowering drugs. <i>Medical Journal of Australia</i> , 1996, 164, 208-211.	0.8	192
206	Dyslipidemia and Coronary Artery Disease in the Elderly. <i>Clinics in Geriatric Medicine</i> , 1996, 12, 33-40.	1.0	10
207	Pathophysiology of Coronary Artery Disease. <i>Clinics in Geriatric Medicine</i> , 1996, 12, 1-21.	1.0	7
208	Management of Postmyocardial Infarction in the Elderly Patient. <i>Clinics in Geriatric Medicine</i> , 1996, 12, 169-180.	1.0	3
209	Section Review: Cardiovascular & Renal: Treatment of severe and/or drug-resistant hyperlipidaemia. <i>Expert Opinion on Investigational Drugs</i> , 1996, 5, 513-520.	1.9	0
210	Effects of Simvastatin on Plasma Lipids and Apolipoproteins in Familial Hypercholesterolemic Swine. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1996, 16, 137-143.	1.1	21
211	Multiple Risk Intervention in High-Risk Hypertensive Patients. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1996, 16, 462-470.	1.1	29
212	Cardiovascular Disease in Peritoneal Dialysis. <i>Peritoneal Dialysis International</i> , 1996, 16, 19-22.	1.1	20
213	Coronary disease prevention: A study. <i>Practice Nursing</i> , 1996, 7, 36-38.	0.1	1
214	The American College of Physicians Versus the National Cholesterol Education Program: Should Endocrinologists Listen?. <i>Endocrine Practice</i> , 1996, 2, 348-351.	1.1	0
215	The New Paradigm for Coronary Artery Disease: Altering Risk Factors, Atherosclerotic Plaques, and Clinical Prognosis. <i>Mayo Clinic Proceedings</i> , 1996, 71, 957-965.	1.4	27
216	What Are Outcomes?. <i>Journal of the American Pharmacists Association</i> , 1996, 36, 39-49.	0.6	13
217	Lipid Management: An Opportunity for Pharmacy Service. <i>Journal of the American Pharmacists Association</i> , 1996, 36, 609-622.	0.6	0

#	ARTICLE	IF	CITATIONS
218	Effectiveness and Safety of Low-Dose Pravastatin and Squalene, Alone and in Combination, in Elderly Patients with Hypercholesterolemia. <i>Journal of Clinical Pharmacology</i> , 1996, 36, 422-427.	1.0	75
219	Treating Elevated Cholesterol Levels: The Great Satan in Perspective. <i>Journal of Clinical Pharmacology</i> , 1996, 36, 189-197.	1.0	3
220	Advances in treatment of cholesterol abnormalities. <i>Postgraduate Medicine</i> , 1996, 100, 61-72.	0.9	0
221	Atorvastatin, a New HMG-CoA Reductase Inhibitor as Monotherapy and Combined With Colestipol. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 1996, 1, 117-122.	1.0	23
222	Hyperlipidemia. <i>Postgraduate Medicine</i> , 1996, 100, 138-149.	0.9	0
223	The Statin Trials: Closing Arguments in the Case against Cholesterol?. <i>Scottish Medical Journal</i> , 1996, 41, 99-100.	0.7	0
224	More on Comparison of HMG-CoA Reductase Inhibitors. <i>Annals of Pharmacotherapy</i> , 1996, 30, 414-415.	0.9	1
225	Prevention and Regression of Atherosclerosis: Effects of Hmg-CoA Reductase Inhibitors. <i>Annals of Pharmacotherapy</i> , 1996, 30, 1304-1315.	0.9	4
226	Editorial Cardiovascular & Renal: Anti-atherosclerotic patents following the success of HMG-CoA reductase inhibitors. <i>Expert Opinion on Therapeutic Patents</i> , 1996, 6, 427-430.	2.4	1
227	Centripetal cholesterol flux from extrahepatic organs to the liver is independent of the concentration of high density lipoprotein-cholesterol in plasma.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1996, 93, 4114-4119.	3.3	80
228	Cholesterol-Lowering Therapy: Is There really a Controversy?. <i>Annals of Pharmacotherapy</i> , 1996, 30, 539-542.	0.9	6
229	Is there an association among low untreated serum lipid levels, anger, and hazardous driving?. <i>International Journal of Behavioral Medicine</i> , 1996, 3, 321-336.	0.8	2
230	Monotherapy with hMG-CoA reductase inhibitors and secondary prevention in coronary artery disease. <i>Clinical Cardiology</i> , 1996, 19, 683-689.	0.7	29
231	A review of the use of risk factor modification in the management of atherosclerotic arterial disease. <i>International Journal of Angiology</i> , 1996, 5, 226-232.	0.2	0
232	Physician extenders for cost-effective management of hypercholesterolemia. <i>Journal of General Internal Medicine</i> , 1996, 11, 277-286.	1.3	47
233	Lowering cholesterol for primary prevention of coronary heart disease: Extrapolation beyond the facts?. <i>ACC Current Journal Review</i> , 1996, 5, 9-11.	0.1	0
234	Relevance of dyslipidemia in the elderly. <i>ACC Current Journal Review</i> , 1996, 5, 14-15.	0.1	2
235	Primary prevention "Have we gone too far?". <i>ACC Current Journal Review</i> , 1996, 5, 15-18.	0.1	0

#	ARTICLE	IF	CITATIONS
237	New insights into the pathogenesis, prevention and management of acute coronary syndromes. Australian and New Zealand Journal of Medicine, 1996, 26, 344-348.	0.5	3
238	Predictive value of lipid profile for salutary coronary angiographic changes in patients on a low-fat diet and physical exercise program. American Journal of Cardiology, 1996, 78, 163-167.	0.7	17
239	Cost of lipid-lowering statin drugs. American Journal of Cardiology, 1996, 77, 225-226.	0.7	3
240	The effect of Simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. American Journal of Cardiology, 1996, 77, 851-854.	0.7	160
241	Verapamil following uncomplicated myocardial infarction: Promising, but not proven. American Journal of Cardiology, 1996, 77, 421-422.	0.7	22
242	Relative survival benefits of risk factor modifications. American Journal of Cardiology, 1996, 77, 298-299.	0.7	10
243	Direct measurement of serum low-density lipoprotein cholesterol in patients with acute myocardial infarction on admission to the emergency room. American Journal of Cardiology, 1996, 77, 1232-1234.	0.7	7
244	Treatment of hyperlipidemia after heart transplantation and rationale for the heart transplant lipid registry. American Journal of Cardiology, 1996, 78, 532-535.	0.7	18
245	The veterans affairs high-density lipoprotein intervention trial: Baseline characteristics of normocholesterolemic men with coronary artery disease and low levels of high-density lipoprotein cholesterol. American Journal of Cardiology, 1996, 78, 572-575.	0.7	59
246	Effects of Cardiac Rehabilitation and Exercise Training Programs in Patients ≥ 75 Years of Age. American Journal of Cardiology, 1996, 78, 675-677.	0.7	83
247	Atherosclerosis and restenosis: Reflections on the lovastatin restenosis trial and scandinavian simvastatin survival study. American Journal of Cardiology, 1996, 78, 1036-1038.	0.7	10
248	Results of intensive long-term treatment of familial hypercholesterolemia. American Journal of Cardiology, 1996, 78, 1369-1374.	0.7	30
249	Prognostic role of cardiovascular risk factors for men with cardiomegaly (the Reykjavik study). American Journal of Cardiology, 1996, 78, 1355-1361.	0.7	11
250	Rationale for Effective Treatment of Hypercholesterolemia. American Journal of Cardiology, 1996, 78, 4-12.	0.7	24
251	Review of the Major Intervention Trials of Lowering Coronary Artery Disease Risk Through Cholesterol Reduction. American Journal of Cardiology, 1996, 78, 13-19.	0.7	19
252	Meeting National Cholesterol Education Goals in Clinical Practice—A Comparison of Lovastatin and Fluvastatin in Primary Prevention. American Journal of Cardiology, 1996, 78, 26-31.	0.7	38
253	Cost-Effectiveness of 3-Hydroxy-3-Methylglutaryl-Coenzyme A (HMG-CoA) Reductase Inhibitor Therapy in the Managed Care Era. American Journal of Cardiology, 1996, 78, 32-41.	0.7	20
254	Modern management of acute myocardial infarction. Current Problems in Cardiology, 1996, 21, 585-667.	1.1	6

#	ARTICLE	IF	CITATIONS
255	Unstable angina: New insights into pathophysiologic characteristics, prognosis, and management strategies. <i>Current Problems in Cardiology</i> , 1996, 21, 669-731.	1.1	8
256	The Lipoprotein and Coronary Atherosclerosis Study (LCAS): Design, methods, and baseline data of a trial of fluvastatin in patients without severe hypercholesterolemia. <i>Contemporary Clinical Trials</i> , 1996, 17, 550-583.	2.0	31
257	Nutrition and coronary heart disease in the elderly: Low fat or Laissez-Faire?. <i>Nutrition</i> , 1996, 12, 376-377.	1.1	0
258	Genetic diagnosis of familial hypercholesterolemia in affected relatives using pedigree tracing. <i>Clinical Biochemistry</i> , 1996, 29, 371-377.	0.8	4
259	Stereoselective synthesis of J-104,118 and J-104,123, novel, potent inhibitors of squalene synthase. <i>Tetrahedron</i> , 1996, 52, 13881-13894.	1.0	13
260	J-104,123, a novel and orally-active inhibitor of squalene synthase: Stereoselective synthesis and cholesterol lowering effects in dogs. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1996, 6, 463-466.	1.0	15
261	Effective lovastatin therapy in elderly hypercholesterolemic patients – an antioxidative impact?. <i>Archives of Gerontology and Geriatrics</i> , 1996, 22, 207-221.	1.4	15
262	Jejunal permeability and hepatic extraction of fluvastatin in humans. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 60, 493-503.	2.3	76
263	Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 60, 54-61.	2.3	254
264	Hyperlipidaemia, diet and simvastatin therapy in steroid-resistant nephrotic syndrome of childhood. <i>Pediatric Nephrology</i> , 1996, 10, 171-174.	0.9	50
265	Effect of ACE inhibitors on endothelial dysfunction: Unanswered questions and implications for further investigation and therapy. <i>Cardiovascular Drugs and Therapy</i> , 1996, 10, 469-473.	1.3	12
266	Pravastatin reduces restenosis after coronary angioplasty of high grade stenotic lesions: Results of SHIPS (SHIga Pravastatin Study). <i>Cardiovascular Drugs and Therapy</i> , 1996, 10, 475-483.	1.3	14
267	Acute myocardial infarction in Canada: New epidemiologic insights on incidence, therapy, and risk. <i>Journal of Thrombosis and Thrombolysis</i> , 1996, 3, 101-105.	1.0	4
268	Oligonucleotide ligation assay (OLA) for the diagnosis of familial hypercholesterolemia. <i>Nature Biotechnology</i> , 1996, 14, 1279-1282.	9.4	82
269	The one-stop coronary cholesterol clinic: a multidisciplinary approach to implementing evidence-based treatment.. <i>Postgraduate Medical Journal</i> , 1996, 72, 744-748.	0.9	2
270	Serum lipids four weeks after acute myocardial infarction are a valid basis for lipid lowering intervention in patients receiving thrombolysis.. <i>Heart</i> , 1996, 75, 213-214.	1.2	0
271	Squatting revisited: comparison of haemodynamic responses in normal individuals and heart transplant recipients.. <i>Heart</i> , 1996, 75, 213-213.	1.2	0
272	Prevalence and Correlates of Symptomatic Peripheral Atherosclerosis in Individuals with Coronary Heart Disease and Cholesterol Levels Less Than 240 mg/dL: Baseline Results from the Cholesterol And Recurrent Events (CARE) Study. <i>Angiology</i> , 1996, 47, 533-541.	0.8	13



#	ARTICLE	IF	CITATIONS
273	Comparative efficacy and safety of ciprofibrate and sustained-release bezafibrate in patients with type II hyperlipidaemia.. Postgraduate Medical Journal, 1996, 72, 739-743.	0.9	9
274	Nutrition and health: what is new?. Reviews in Clinical Gerontology, 1996, 6, 147-168.	0.5	3
275	Cost effectiveness and equity of a community based cardiovascular disease prevention programme in Norsjo, Sweden.. Journal of Epidemiology and Community Health, 1996, 50, 190-195.	2.0	33
276	Prevention of Coronary Heart Disease with Pravastatin. New England Journal of Medicine, 1996, 334, 1333-1335.	13.9	9
277	Association of Serum Cholesterol and Triglyceride Levels with Agitation and Cognitive Function in a Geropsychiatry Unit. Journal of Geriatric Psychiatry and Neurology, 1996, 9, 53-56.	1.2	12
278	A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events).. Heart, 1996, 75, 334-342.	1.2	261
279	A prospective cardiovascular population study used in genetic epidemiology. The Copenhagen City Heart Study. Scandinavian Journal of Clinical and Laboratory Investigation, 1996, 56, 65-71.	0.6	5
280	Current and Future Therapeutic Approaches to Hyperlipidemia. Advances in Pharmacology, 1996, 35, 79-114.	1.2	12
281	The Impact of Gender and General Risk Factors on the Occurrence of Atherosclerotic Vascular Disease in Non-insulin-dependent Diabetes Mellitus. Annals of Medicine, 1996, 28, 323-333.	1.5	89
282	Primary and Secondary Prevention of Myocardial Infarction. Clinical and Experimental Hypertension, 1996, 18, 547-558.	0.5	2
283	Will Correction of Dyslipoproteinaemia Reduce Coronary Heart Disease Risk in Patients with Non-insulin-dependent Diabetes? Need for Trial Evidence. Annals of Medicine, 1996, 28, 357-362.	1.5	10
284	The Cholesterol Controversy. Annals of Pharmacotherapy, 1996, 30, 495-500.	0.9	13
285	Beyond cholesterol reduction in coronary heart disease: is vitamin E the answer?. Heart, 1996, 76, 293-294.	1.2	2
286	Lipid screening in an elderly population: difficulty in interpretation and in detection of occult metabolic disease.. Journal of Clinical Pathology, 1996, 49, 278-283.	1.0	9
287	The St Vincent Task Force for diabetes: report of the cardiovascular disease subgroup.. Heart, 1996, 76, 107-108.	1.2	2
288	Delayed Progression or Regression of Coronary Atherosclerosis with Intensive Risk Factor Modification. Sports Medicine, 1996, 22, 306-320.	3.1	38
289	A Randomized Multicenter Trial Comparing the Efficacy of Simvastatin and Fluvastatin. Journal of Cardiovascular Pharmacology and Therapeutics, 1996, 1, 23-29.	1.0	29
290	Cardiovascular Risk Factors in the Older Adult. Hospital Practice (1995), 1996, 31, 135-150.	0.5	7

#	ARTICLE	IF	CITATIONS
291	Aspirin and Coronary Disease. <i>New England Journal of Medicine</i> , 1996, 335, 1161-1162.	13.9	2
292	More on Pravastatin and Coronary Disease. <i>New England Journal of Medicine</i> , 1996, 335, 1239-1240.	13.9	2
293	Advances in Coronary Angioplasty. <i>New England Journal of Medicine</i> , 1996, 335, 1290-1302.	13.9	230
294	7 Squalene Synthase Inhibitors: Their Potential as Hypocholesterolaemic Agents. <i>Progress in Medicinal Chemistry</i> , 1996, 33, 331-378.	4.1	33
295	Anti-atherosclerotics - Bile acid sequestrants, cholesterol absorption and fibrates. <i>Pharmacotherapy Library</i> , 1997, , 451-459.	0.1	0
296	Medical cardiovascular treatment trials: Relevant to medical ophthalmology in 1997?. <i>Eye</i> , 1997, 11, 3-11.	1.1	21
297	Use of Coronary Angiography and Revascularization after Acute Myocardial Infarction. <i>New England Journal of Medicine</i> , 1997, 336, 1024-1025.	13.9	0
298	Coronary Risk Factors and Plaque Morphology in Men with Coronary Disease Who Died Suddenly. <i>New England Journal of Medicine</i> , 1997, 336, 1276-1282.	13.9	1,576
299	Adjunctive Drug Therapy for Acute Myocardial Infarction. <i>New England Journal of Medicine</i> , 1997, 336, 1455-1456.	13.9	1
300	Recent developments in the treatment of dyslipidaemia. <i>Expert Opinion on Therapeutic Patents</i> , 1997, 7, 441-455.	2.4	4
301	Estrogen and Progestin Compared with Simvastatin for Hypercholesterolemia in Postmenopausal Women. <i>New England Journal of Medicine</i> , 1997, 337, 595-601.	13.9	189
302	Post-transplant hyperlipidaemia.. <i>Postgraduate Medical Journal</i> , 1997, 73, 785-793.	0.9	19
304	The Case for Aggressive Lipid Regulation. <i>Hospital Practice (1995)</i> , 1997, 32, 145-156.	0.5	3
305	Discrepancies between Meta-Analyses and Subsequent Large Randomized, Controlled Trials. <i>New England Journal of Medicine</i> , 1997, 337, 536-542.	13.9	1,261
306	Cerivastatin, a New Potent Synthetic HMG Co-A Reductase Inhibitor: Effect of 0.2 mg Daily in Subjects With Primary Hypercholesterolemia. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 1997, 2, 7-16.	1.0	50
307	The Composition of Coronary-Artery Plaques. <i>New England Journal of Medicine</i> , 1997, 336, 1312-1314.	13.9	199
308	The Iterative Use of Economic Evaluation as Part of the Process of Health Technology Assessment. <i>Journal of Health Services Research and Policy</i> , 1997, 2, 26-30.	0.8	161
309	Cardiovascular Medicine at the Turn of the Millennium: Triumphs, Concerns, and Opportunities. <i>New England Journal of Medicine</i> , 1997, 337, 1360-1369.	13.9	1,273

#	ARTICLE	IF	CITATIONS
310	Isolated Low High-Density Lipoprotein Cholesterol. <i>Annals of Pharmacotherapy</i> , 1997, 31, 89-97.	0.9	4
311	Lipoprotein Disorders in Women: Which Women are the Best Candidates for Hormone Replacement Therapy?. <i>Annals of Pharmacotherapy</i> , 1997, 31, 98-107.	0.9	5
312	Effect of Pharmacologic Lipid Lowering on Health-Related Quality of Life in Older Persons: Results from the Cholesterol Reduction in Seniors Program (CRISP) Pilot Study. <i>Journal of the American Geriatrics Society</i> , 1997, 45, 8-14.	1.3	93
313	Mortality over Four Years in SHEP Participants with a Low Ankle-Arm Index. <i>Journal of the American Geriatrics Society</i> , 1997, 45, 1472-1478.	1.3	151
314	The Role of Tobacco Cessation, Antiplatelet and Lipid-Lowering Therapies in the Treatment of Peripheral Arterial Disease. <i>Vascular Medicine</i> , 1997, 2, 243-251.	0.8	101
315	The Impact of Thiazide Diuretics on the Initiation of Lipid-Reducing Agents in Older People: A Population-Based Analysis. <i>Journal of the American Geriatrics Society</i> , 1997, 45, 71-75.	1.3	10
316	Squalene synthase inhibitors. <i>Expert Opinion on Emerging Drugs</i> , 1997, 2, 93-108.	1.1	7
317	Psychological Distress in HIV-1 Disease in Relationship to Hypcholesterolemia. <i>International Journal of Psychiatry in Medicine</i> , 1997, 27, 159-171.	0.8	8
318	Effect of Simvastatin Therapy on Cell Membrane Cholesterol Content and Membrane Function as Assessed by Polymorphonuclear Cell NADPH Oxidase Activity. <i>Annals of Clinical Biochemistry</i> , 1997, 34, 269-275.	0.8	27
319	Preventive Medicine and Screening in Older Adults. <i>Journal of the American Geriatrics Society</i> , 1997, 45, 344-354.	1.3	83
320	Evidence-Based Medicine Holds the Key to the Future for Geriatric Medicine. <i>Journal of the American Geriatrics Society</i> , 1997, 45, 1268-1272.	1.3	10
321	Impact of combined hormone replacement therapy on serum lipid metabolism: New aspects. <i>Gynecological Endocrinology</i> , 1997, 11, 281-288.	0.7	5
322	Lipids, thrombosis and cardiovascular disease in diabetes. <i>Proceedings of the Nutrition Society</i> , 1997, 56, 273-280.	0.4	1
323	Triacylglycerol and coronary heart disease. <i>Proceedings of the Nutrition Society</i> , 1997, 56, 667-670.	0.4	37
324	Short-Term Safety and Efficacy of Low-Dose Simvastatin in Elderly Patients with Hypertensive Hypercholesterolemia and Fasting Hyperinsulinemia. <i>Journal of Clinical Pharmacology</i> , 1997, 37, 496-501.	1.0	11
325	Design of Cost-Effective Packages of Care for Non-Insulin-Dependent Diabetes Mellitus: Defining the Information Needs. <i>International Journal of Technology Assessment in Health Care</i> , 1997, 13, 395-410.	0.2	6
326	Lovastatin-Induced Rhabdomyolysis Possibly Associated with Clarithromycin and Azithromycin. <i>Annals of Pharmacotherapy</i> , 1997, 31, 859-863.	0.9	77
327	Preventing Heart Disease. <i>Practice Nursing</i> , 1997, 8, 28-30.	0.1	0

#	ARTICLE	IF	CITATIONS
328	Prognostic Value of Serum Cholesterol Level in Japanese Patients With Coronary Artery Disease. Japanese Circulation Journal, 1997, 61, 139-144.	1.0	7
330	Chapter 29 Mode of action of lipid-lowering drugs. Principles of Medical Biology, 1997, , 561-575.	0.1	0
331	Chapter 10. Emerging Opportunities in the Treatment of Atherosclerosis. Annual Reports in Medicinal Chemistry, 1997, 32, 101-110.	0.5	2
332	Fifteen years with clinical guidelines in the treatment of hypertension-still discrepancies between intentions and practice. Scandinavian Journal of Primary Health Care, 1997, 15, 134-140.	0.6	23
333	Simvastatin. Pharmacoeconomics, 1997, 11, 89-110.	1.7	15
334	A Predictive Model of the Health Benefits and Cost Effectiveness of Celiprolol and Atenolol in Primary Prevention of Cardiovascular Disease in Hypertensive Patients. Pharmacoeconomics, 1997, 12, 384-408.	1.7	4
335	Hyperlipidaemia. Drugs and Therapy Perspectives, 1997, 9, 7-13.	0.3	1
336	Are HMG-CoA reductase inhibitors cost effective?. Drugs and Therapy Perspectives, 1997, 9, 14-16.	0.3	0
337	Lipids and Lipoproteins in Women. Mayo Clinic Proceedings, 1997, 72, 235-244.	1.4	45
338	Cardiovascular new drug discovery of the future: Molecules, genes, and machines. Pharmacochimistry Library, 1997, , 461-476.	0.1	0
339	Pharmacodynamics and Pharmacokinetics of the HMG-CoA Reductase Inhibitors. Clinical Pharmacokinetics, 1997, 32, 403-425.	1.6	447
340	Pravastatin. Drugs, 1997, 53, 299-336.	4.9	74
341	Atorvastatin. Drugs, 1997, 53, 828-847.	4.9	259
342	Primary Prevention of Coronary Heart Disease. Drugs, 1997, 54, 1-8.	4.9	161
343	Antiarrhythmic Therapies for the Prevention of Sudden Cardiac Death. Drugs, 1997, 54, 235-252.	4.9	34
344	Micronised Fenofibrate. Drugs, 1997, 54, 615-633.	4.9	127
345	A Rational Approach to Treating Hypercholesterolaemia in Children Weighing the Risks and Benefits. Drug Safety, 1997, 16, 330-341.	1.4	19
346	Effects of low-dose pravastatin sodium on plasma cholesterol levels and aortic atherosclerosis of heterozygous WHHL rabbits fed a low cholesterol (0.03%) enriched diet for one year. Atherosclerosis, 1997, 128, 139-147.	0.4	9

#	ARTICLE	IF	CITATIONS
347	Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. <i>Atherosclerosis</i> , 1997, 130, 191-197.	0.4	132
348	Expanded-dose simvastatin is effective in homozygous familial hypercholesterolaemia. <i>Atherosclerosis</i> , 1997, 135, 249-256.	0.4	94
349	A brief review paper of the efficacy and safety of atorvastatin in early clinical trials. <i>Atherosclerosis</i> , 1997, 131, 17-23.	0.4	44
350	Cholesterol and prevention of coronary heart disease. <i>Lancet, The</i> , 1997, 349, 210.	6.3	0
351	Cholesterol and prevention of coronary heart disease. <i>Lancet, The</i> , 1997, 349, 210-211.	6.3	1
352	CAPRIE trial. <i>Lancet, The</i> , 1997, 349, 354.	6.3	3
353	Indicators of Quality in Health Care. <i>European Journal of General Practice</i> , 1997, 3, 103-108.	0.9	170
354	The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. <i>Journal of Cardiac Failure</i> , 1997, 3, 249-254.	0.7	334
355	Optimising Outcomes in Secondary Prevention of Coronary Heart Disease. <i>Disease Management and Health Outcomes</i> , 1997, 2, 281-290.	0.3	0
356	Optimising Outcomes in Primary Prevention of Coronary Heart Disease. <i>Disease Management and Health Outcomes</i> , 1997, 2, 238-247.	0.3	0
357	Evidence-Based Performance and Outcome Measures for Diabetes Care. <i>Disease Management and Health Outcomes</i> , 1997, 2, 124-133.	0.3	4
358	Management of Lower Limb Intermittent Claudication. <i>Disease Management and Health Outcomes</i> , 1997, 2, 18-29.	0.3	0
359	Maximising Health Outcomes in Stroke. <i>Disease Management and Health Outcomes</i> , 1997, 1, 95-104.	0.3	0
360	Plasma Homocysteine Levels and Mortality in Patients with Coronary Artery Disease. <i>New England Journal of Medicine</i> , 1997, 337, 230-237.	13.9	1,626
361	Endothelial Dysfunction and Atherothrombotic Occlusive Disease. <i>Drugs</i> , 1997, 54, 41-50.	4.9	12
362	Management of Lipid Disorders in the Elderly. <i>Drugs and Aging</i> , 1997, 10, 444-462.	1.3	13
363	Planned, ongoing and recently completed clinical trials for atherosclerosis prevention and regression: an update. <i>Expert Opinion on Investigational Drugs</i> , 1997, 6, 31-50.	1.9	4
364	Angiographic deterioration of target coronary artery narrowing as a result of percutaneous balloon angioplasty. <i>American Heart Journal</i> , 1997, 133, 575-579.	1.2	0

#	ARTICLE	IF	CITATIONS
365	The Secondary Prevention of Coronary Artery Disease. American Journal of Medicine, 1997, 102, 572-581.	0.6	38
366	The Efficacy of Lovastatin in Lowering Cholesterol in African Americans with Primary Hypercholesterolemia. American Journal of Medicine, 1997, 102, 387-391.	0.6	11
367	Hypercholesterolemia in the United States: How far have we come?. American Journal of Medicine, 1997, 102, 3-6.	0.6	686
368	Management of high serum cholesterol and related disorders in patients at risk for coronary heart disease. American Journal of Medicine, 1997, 102, 15-22.	0.6	39
369	Cholesterol screening should be targeted. American Journal of Medicine, 1997, 102, 26-30.	0.6	11
370	Adults aged 20 and older should have their cholesterol measured. American Journal of Medicine, 1997, 102, 31-36.	0.6	10
371	Current status of cholesterol treatment in the community: The Minnesota heart survey. American Journal of Medicine, 1997, 102, 37-42.	0.6	28
372	Healthcare decisions and product labeling: Results of a consumer comprehension study of prototype labeling for proposed over-the-counter cholestyramine. American Journal of Medicine, 1997, 102, 50-56.	0.6	20
373	Aortic atherosclerosis and stroke. Journal of Stroke and Cerebrovascular Diseases, 1997, 6, 125-129.	0.7	1
374	Cardiovascular complications following renal transplantation. Transplantation Reviews, 1997, 11, 111-126.	1.2	12
375	Mild myocardial infarction—A classification problem in epidemiologic studies. Journal of Clinical Epidemiology, 1997, 50, 3-13.	2.4	34
376	Lipid lowering in patients with coronary artery disease: low density lipoprotein cholesterol and beyond. Evidence-based Cardiovascular Medicine, 1997, 1, 34-35.	0.0	0
377	From journal to bedside: quantifying the benefits of treatment. Evidence-based Cardiovascular Medicine, 1997, 1, 57-58.	0.0	2
378	A model practice. Coronary Health Care, 1997, 1, 158-160.	0.4	0
379	Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Molecular Aspects of Medicine, 1997, 18, 137-144.	2.7	175
380	Women at cardiac risk: is HRT the route to maintaining cardiovascular health?. International Journal of Gynecology and Obstetrics, 1997, 59, S19-S27.	1.0	12
381	The effect of Simvastatin on the plasma antioxidant concentrations in patients with hypercholesterolaemia. Clinica Chimica Acta, 1997, 263, 67-77.	0.5	54
382	Comparative effects of two once-daily regimens of policosanol in patients with type II hypercholesterolemia. Current Therapeutic Research, 1997, 58, 154-162.	0.5	9

#	ARTICLE	IF	CITATIONS
383	Increased thrombin generation and complement activation in patients with type IIA hyperlipoproteinemia: effects of simvastatin treatment. <i>Current Therapeutic Research</i> , 1997, 58, 706-723.	0.5	10
384	Revascularization of patients with coronary artery disease: The interventional cardiologist's perspective. <i>Annals of Thoracic Surgery</i> , 1997, 63, S23-S27.	0.7	5
385	Prospective 10-year evaluation of hypobetalipoproteinemia in a cohort of 772 firefighters and cross-sectional evaluation of hypocholesterolemia in 1,479 men in the National Health and Nutrition Examination Survey I. <i>Metabolism: Clinical and Experimental</i> , 1997, 46, 625-633.	1.5	34
386	An audit of secondary prevention of ischaemic heart disease using aspirin and cholesterol-lowering. <i>Coronary Health Care</i> , 1997, 1, 27-29.	0.4	0
387	CHOLESTEROL-LOWERING DRUGS FOR PRIMARY PREVENTION? THE WOSCOP STUDY. <i>Pharmacological Research</i> , 1997, 35, 169-170.	3.1	6
388	CHOLESTEROL AND CORONARY HEART DISEASE: NEW DATA FROM THE WOSCOP STUDY. <i>Pharmacological Research</i> , 1997, 35, 171-172.	3.1	2
389	THE 4S STUDY:A CRITICAL REVIEW. <i>Pharmacological Research</i> , 1997, 35, 165-166.	3.1	1
390	Simvastatin reduces monocyte-tissue-factor expression type Ila hypercholesterolaemia. <i>Lancet, The</i> , 1997, 350, 1222.	6.3	64
391	Statins and hypercholesterolaemia: UK Standing Medical Advisory Committee guidelines. <i>Lancet, The</i> , 1997, 350, 1174-1175.	6.3	11
392	Interpretation of IST and CAST stroke trials. <i>Lancet, The</i> , 1997, 350, 442.	6.3	3
393	Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial. <i>Lancet, The</i> , 1997, 350, 461-468.	6.3	499
394	Women's hearts are hard to break. <i>Lancet, The</i> , 1997, 349, S3-S6.	6.3	15
395	Variations in Cholesterol Management Practices of U.S. Physicians. <i>Journal of the American College of Cardiology</i> , 1997, 29, 139-146.	1.2	126
396	Preservation of Endogenous Antioxidant Activity and Inhibition of Lipid Peroxidation as Common Mechanisms of Antiatherosclerotic Effects of Vitamin E, Lovastatin and Amlodipine. <i>Journal of the American College of Cardiology</i> , 1997, 30, 569-575.	1.2	197
397	Endothelial Dysfunction: Does It Matter? Is It Reversible?. <i>Journal of the American College of Cardiology</i> , 1997, 30, 325-333.	1.2	599
398	Effect of Pravastatin on Angiographic Restenosis After Coronary Balloon Angioplasty <sup>1</sup> This study was supported by a grant from Bristol Myers Squibb Laboratories, Paris.. <i>Journal of the American College of Cardiology</i> , 1997, 30, 863-869.	1.2	133
399	HMG-CoA Reductase Inhibitors Decrease CD11b Expression and CD11b-Dependent Adhesion of Monocytes to Endothelium and Reduce Increased Adhesiveness of Monocytes Isolated From Patients With Hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , 1997, 30, 1212-1217.	1.2	393
400	Predictors of Graft Patency 3 Years After Coronary Artery Bypass Graft Surgery <sup>1</sup> This research was supported by the Cooperative Studies Program of the Medical Research Service, Department of Veterans Affairs Central Office, Washington, D.C.. <i>Journal of the American College of Cardiology</i> , 1997, 29, 1563-1568.	1.2	48

#	ARTICLE	IF	CITATIONS
401	Plant-derived anticancer agents. <i>Biochemical Pharmacology</i> , 1997, 53, 121-133.	2.0	458
402	The pathogenesis of atherosclerosis. <i>International Journal of Cardiology</i> , 1997, 62, S3-S7.	0.8	33
403	Calcium antagonists and atherosclerosis. <i>International Journal of Cardiology</i> , 1997, 62, S9-S15.	0.8	32
404	Effect of simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, on the haemostatic balance of familial hypercholesterolaemic subjects. <i>Fibrinolysis and Proteolysis</i> , 1997, 11, 91-96.	1.1	6
406	Aggressive cholesterol management: Role of the lipid nurse specialist. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 1997, 26, 337-344.	0.8	18
407	Efficacy of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in the treatment of patients with hypercholesterolemia: a meta-analysis of clinical trials. <i>Clinical Therapeutics</i> , 1997, 19, 778-797.	1.1	30
408	Effects of low-dose simvastatin therapy on serum lipid levels in patients with moderate hypercholesterolemia: a 12-month study. <i>Clinical Therapeutics</i> , 1997, 19, 487-497.	1.1	14
409	Cost-effectiveness of initial therapy with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors to treat hypercholesterolemia in a primary care setting of a managed-care organization. <i>Clinical Therapeutics</i> , 1997, 19, 582-602.	1.1	20
410	The postmenopausal estrogen/progestin interventions study: primary outcomes in adherent women. <i>Maturitas</i> , 1997, 27, 261-274.	1.0	118
411	Cardiovascular disease prevention in postmenopausal women: a clinician's perspective. <i>Maturitas</i> , 1997, 27, 1-3.	1.0	4
412	Lipoproteins and Cardiovascular Risk-from Genetics to CHD Prevention. <i>Journal of Atherosclerosis and Thrombosis</i> , 1997, 4, 51-58.	0.9	21
413	Renovascular Disease: The Fifth Frontier. <i>Journal of the Royal Society of Medicine</i> , 1997, 90, 315-318.	1.1	1
414	DYSLIPIDEMIA AS A RISK FACTOR FOR CORONARY DISEASE IN PATIENTS WITH DIABETES. <i>Endocrine Practice</i> , 1997, 3, 244-247.	1.1	2
416	Prevention of Primary Event. <i>Neurosurgery Clinics of North America</i> , 1997, 8, 165-178.	0.8	4
417	Coronary Revascularization in Women. <i>Critical Care Nursing Clinics of North America</i> , 1997, 9, 497-509.	0.4	4
419	Guidelines for managing patients with unstable angina Rating the evidence and rationale for treatment. <i>Medical Journal of Australia</i> , 1997, 166, 644-647.	0.8	8
420	Strategies for the Management of Hypercholesterolaemia: A Systematic Review of the Cost-Effectiveness Literature. <i>Journal of Health Services Research and Policy</i> , 1997, 2, 231-250.	0.8	19
421	Cost-Effective Strategies for the Management of Vascular Disease. <i>Vascular Medicine</i> , 1997, 2, 25-29.	0.8	15



#	ARTICLE	IF	CITATIONS
422	Cholesterol management in patients with heart disease. <i>Postgraduate Medicine</i> , 1997, 102, 81-90.	0.9	11
423	In Vivo Formation of 8-Epi-Prostaglandin F $_{2\pm}$ Is Increased in Hypercholesterolemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997, 17, 3230-3235.	1.1	356
424	Isoprostanes: Potential Markers of Oxidant Stress in Atherothrombotic Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997, 17, 2309-2315.	1.1	437
425	The Unstable Atheroma. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997, 17, 1859-1867.	1.1	503
426	Effect of Phenotype on the Transcription of the Genes for Platelet-Derived Growth Factor (PDGF) Isoforms in Human Smooth Muscle Cells, Monocyte-Derived Macrophages, and Endothelial Cells In Vitro. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997, 17, 2897-2903.	1.1	22
427	Efficacy and Safety of a New Hydroxymethylglutaryl-Coenzyme A Reductase Inhibitor, Atorvastatin, in Patients with Combined Hyperlipidemia: Comparison with Fenofibrate. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997, 17, 1793-1799.	1.1	66
428	Lovastatin Decreases De Novo Cholesterol Synthesis and LDL Apo B-100 Production Rates in Combined-Hyperlipidemic Males. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997, 17, 1910-1917.	1.1	57
429	Cholesterol Reduction and Clinical Benefit. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997, 17, 3527-3533.	1.1	51
430	Hyperlipidemias: National Cholesterol Education Program Recommendations, Treatment Regimens, and Pharmacoeconomic Implications. <i>Baylor University Medical Center Proceedings</i> , 1997, 10, 185-187.	0.2	0
431	Rhabdomyolysis after lung transplantation. <i>Australian and New Zealand Journal of Medicine</i> , 1997, 27, 186-186.	0.5	2
432	Chronic renal disease and cardiovascular complications: inevitable or preventable? Now is the time for some intervention studies. <i>Australian and New Zealand Journal of Medicine</i> , 1997, 27, 273-274.	0.5	0
433	The effect of treating people with reversible ischaemic attacks of the brain and eye on the incidence of stroke in Australia. <i>Australian and New Zealand Journal of Medicine</i> , 1997, 27, 420-430.	0.5	9
434	Do codeine and caffeine enhance the analgesic effect of aspirin?-A systematic overview. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 1997, 22, 79-97.	0.7	49
435	Non-pharmacological modification of cardiac risk factors: part 2. The role of diet. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 1997, 22, 99-108.	0.7	3
436	Prescription of statins: cost implications of evidence-based treatment applied to a health authority population. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 1997, 22, 379-389.	0.7	3
437	Prehospital Thrombolysis in Acute Myocardial Infarction Salvages Myocardium. <i>Journal of Interventional Cardiology</i> , 1997, 10, 315-325.	0.5	0
438	Molecular Determinants of Atherosclerotic Plaque Vulnerability. <i>Annals of the New York Academy of Sciences</i> , 1997, 811, 134-145.	1.8	81
439	LDL Apheresis in Clinical Practice: Long-Term Treatment of Severe Hyperlipidemia. <i>Therapeutic Apheresis and Dialysis</i> , 1997, 1, 49-54.	0.6	4

#	ARTICLE	IF	CITATIONS
440	Apheresis Technology for Prevention and Regression of Atherosclerosis: An Overview. Therapeutic Apheresis and Dialysis, 1997, 1, 233-241.	0.6	17
441	Clinical Experience and Future Directions for Low-Density Lipoprotein Apheresis in the United States. Therapeutic Apheresis and Dialysis, 1997, 1, 249-252.	0.6	6
442	Gene Activation, Apolipoprotein A-II/High Density Lipoprotein, Atherosclerosis Prevention and Longevity. Basic and Clinical Pharmacology and Toxicology, 1997, 81, 57-64.	0.0	41
443	Can single photon emission computed tomography myocardial perfusion imaging monitor the potential benefit of aggressive treatment of hyperlipidemia?. Journal of Nuclear Cardiology, 1997, 4, 555-568.	1.4	8
444	Risk-sensitive therapeutic strategies for coronary artery disease: Toward testing-driven therapy in stable angina patients with low-to-intermediate risk cardiac imaging results. Journal of Nuclear Cardiology, 1997, 4, 409-417.	1.4	4
445	Effect of lacidipine on cholesterol esterification: in vivo and in vitro studies. British Journal of Pharmacology, 1997, 122, 1209-1215.	2.7	18
446	Cardiac complications in non-insulin-dependent diabetes mellitus. Journal of Diabetes and Its Complications, 1997, 11, 123-130.	1.2	29
447	Dyslipidemia, morbidity, and mortality in non-insulin-dependent diabetes mellitus. Journal of Diabetes and Its Complications, 1997, 11, 137-141.	1.2	25
448	Baseline Risk Factors and their Association With Outcome in the West of Scotland Coronary Prevention Study. American Journal of Cardiology, 1997, 79, 756-762.	0.7	115
449	Use of Evidence-Based Medical Therapy in Patients Undergoing Percutaneous Coronary Revascularization in the United States, Europe, and Canada. American Journal of Cardiology, 1997, 79, 867-872.	0.7	24
450	Effects of Intensive Diet and Exercise Intervention in Patients Taking Cholesterol-Lowering Drugs. American Journal of Cardiology, 1997, 79, 1112-1114.	0.7	47
451	Comparison of Pravastatin With Crystalline Nicotinic Acid Monotherapy in Treatment of Combined Hyperlipidemia. American Journal of Cardiology, 1997, 79, 1298-1301.	0.7	19
452	Cell dysfunction in atherosclerosis and the ischemic manifestations of coronary artery disease. American Journal of Cardiology, 1997, 79, 17-23.	0.7	45
453	The potential use of angiotensin-converting enzyme inhibitors in patients with hyperlipidemia. American Journal of Cardiology, 1997, 79, 24-28.	0.7	27
454	The clinical therapeutic implications of the Scandinavian Simvastatin Survival Study. American Journal of Cardiology, 1997, 79, 1387-1388.	0.7	4
455	Results of Recent Large Cholesterol-Lowering Trials and Implications for Clinical Management. American Journal of Cardiology, 1997, 79, 1663-1666.	0.7	26
456	A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. American Journal of Cardiology, 1997, 80, 39-44.	0.7	205
457	Design & Rationale of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). American Journal of Cardiology, 1997, 80, 287-293.	0.7	72

#	ARTICLE	IF	CITATIONS
458	New Insights into the Pathogenesis and Prevention of Acute Coronary Syndromes. American Journal of Cardiology, 1997, 79, 17-23.	0.7	106
459	Management of Patients With Chronic Stable Angina at Low Risk for Serious Cardiac Events. American Journal of Cardiology, 1997, 79, 24-30.	0.7	20
460	Incremental Prognostic Value of Adenosine Stress Myocardial Perfusion Single-Photon Emission Computed Tomography and Impact on Subsequent Management in Patients With or Suspected of Having Myocardial Ischemia. American Journal of Cardiology, 1997, 80, 426-433.	0.7	123
461	Safety and Efficacy of Long-Term Statin-Fibrate Combinations in Patients With Refractory Familial Combined Hyperlipidemia. American Journal of Cardiology, 1997, 80, 608-613.	0.7	149
462	The Way Ahead in the Management of Unstable Coronary Artery Disease. American Journal of Cardiology, 1997, 80, 64E-67E.	0.7	2
463	Pravastatin Alone and in Combination With Low-Dose Cholestyramine in Patients With Primary Hypercholesterolemia and Coronary Artery Disease. American Journal of Cardiology, 1997, 80, 799-802.	0.7	11
464	Treatment of Hyperlipidemia by Specialists Versus Generalists as Secondary Prevention of Coronary Artery Disease. American Journal of Cardiology, 1997, 80, 1345-1347.	0.7	13
465	Effects of Lovastatin on the Immune System. American Journal of Cardiology, 1997, 80, 1391-1394.	0.7	33
466	Role of Endothelial Dysfunction in Coronary Artery Disease and Implications for Therapy. American Journal of Cardiology, 1997, 80, 111-161.	0.7	126
467	Pathophysiology and Treatment of Single-Vessel Coronary Artery Disease. American Journal of Cardiology, 1997, 80, 2I-10I.	0.7	3
468	Management of Hypercholesterolemia: Practice Patterns for Primary Care Providers and Cardiologists. American Journal of Cardiology, 1997, 80, 39H-44H.	0.7	44
469	Performance Assessment Model for Guideline-Recommended Pharmacotherapy in the Secondary Prevention of Coronary Artery Disease and Treatment of Left Ventricular Dysfunction. American Journal of Cardiology, 1997, 80, 53H-56H.	0.7	15
470	Implementing Quality Assurance Programs in MultiGroup Practices for Treating Hypercholesterolemia in Patients With Coronary Artery Disease. American Journal of Cardiology, 1997, 80, 57H-61H.	0.7	22
471	Symposium Summary Remarks. American Journal of Cardiology, 1997, 80, 89H-90H.	0.7	0
472	The Efficacy and Six-Week Tolerability of Simvastatin 80 and 160 mg/Day. American Journal of Cardiology, 1997, 79, 38-42.	0.7	204
473	Modified bile acids as carriers for peptides and drugs. Journal of Controlled Release, 1997, 46, 17-30.	4.8	37
474	A study to determine the response of coronary atherosclerosis to raising low high density lipoprotein cholesterol with a fibric-acid derivative in men after coronary bypass surgery. Contemporary Clinical Trials, 1997, 18, 93-119.	2.0	22
475	Clinical perspectives on the use of composite endpoints. Contemporary Clinical Trials, 1997, 18, 517-529.	2.0	53

#	ARTICLE	IF	CITATIONS
476	Clinical trials with multiple outcomes: A statistical perspective on their design, analysis, and interpretation. <i>Contemporary Clinical Trials</i> , 1997, 18, 530-545.	2.0	146
477	Determinants of coronary vascular disease in patients with type ii diabetes mellitus and their therapeutic implications. <i>Clinical Cardiology</i> , 1997, 20, 433-440.	0.7	27
478	Immune System Differences in Men with Hypo- or Hypercholesterolemia. <i>Clinical Immunology and Immunopathology</i> , 1997, 84, 145-149.	2.1	76
479	Acute Coronary Syndromes: Molecular Basis for Cardiac Risk Factors. , 1997, 4, 167-175.		4
484	The genetic basis of atherosclerosis. <i>International Journal of Clinical and Laboratory Research</i> , 1997, 27, 2-13.	1.0	38
485	Behavioral issues in the efficacy versus effectiveness of pharmacologic agents in the prevention of cardiovascular disease. <i>Annals of Behavioral Medicine</i> , 1997, 19, 230-238.	1.7	17
486	Compliance with cardiovascular disease prevention strategies: A review of the research. <i>Annals of Behavioral Medicine</i> , 1997, 19, 239-263.	1.7	250
487	Simvastatin impairs mitogen-induced proliferation of malignant B-lymphocytes from humansâ€”in vitro and in vivo studies. <i>Lipids</i> , 1997, 32, 255-262.	0.7	37
488	Synthesis and Biological Activity of Methanesulfonamide Pyrimidine- and N-Methanesulfonyl Pyrrole-Substituted 3,5-Dihydroxy-6-heptenoates, a Novel Series of HMG-CoA Reductase Inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 1997, 5, 437-444.	1.4	160
489	Determination of simvastatin and its active metabolite in human plasma by column-switching high-performance liquid chromatography with fluorescence detection after derivatization with 1-bromoacetylpyrene. <i>Biomedical Applications</i> , 1997, 694, 211-217.	1.7	58
490	Cardiac ischaemia: possibilities for future drug therapy. <i>European Journal of Medicinal Chemistry</i> , 1997, 32, 687-707.	2.6	7
491	The risk and cost-effective individual patient management: The challenge of a new generation of clinical trials. <i>Cardiovascular Drugs and Therapy</i> , 1997, 10, 751-758.	1.3	6
492	Alternatives to mega-trials in cardiovascular disease. <i>Cardiovascular Drugs and Therapy</i> , 1997, 10, 759-765.	1.3	6
493	A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia. <i>Cardiovascular Drugs and Therapy</i> , 1997, 10, 787-794.	1.3	22
494	Screening, prevention, counseling, and treatment for the complications of type II diabetes mellitus. <i>Journal of General Internal Medicine</i> , 1997, 12, 567-580.	1.3	84
495	The interaction of diltiazem with lovastatin and pravastatin*. <i>Clinical Pharmacology and Therapeutics</i> , 1998, 64, 369-377.	2.3	173
496	Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole*. <i>Clinical Pharmacology and Therapeutics</i> , 1998, 63, 332-341.	2.3	389
497	Hyperlipidaemia: differences in management practices and attitudes in two regions in Europe--Sicily and the Stockholm area. <i>European Journal of Epidemiology</i> , 1998, 14, 477-482.	2.5	5

#	ARTICLE	IF	CITATIONS
498	Endothelial function: strategies for early intervention. , 1998, 12, 125-134.		13
499	The limits of evidence-based cardiovascular therapy. , 1998, 12, 487-491.		0
500	Therapeutic options and cost considerations in the treatment of ischemic heart disease. , 1998, 12, 225-232.		9
501	Comparison of the effect of bezafibrate on improvement of atherogenic lipoproteins in Japanese familial combined hyperlipidemic patients with or without impaired glucose tolerance. Cardiovascular Drugs and Therapy, 1998, 12, 3-12.	1.3	8
502	Selection of drug therapy in stable angina pectoris. , 1998, 12, 197-210.		13
503	Effect of lipid-lowering therapy on myocardial ischemia. , 1998, 12, 135-139.		2
504	The controversy surrounding cholesterol treatment in older people. , 1998, 8, 11-14.		1
505	Plaque Disruption: Pathogenesis and Prevention. Journal of Thrombosis and Thrombolysis, 1998, 5, S89-S97.	1.0	0
506	The Importance of lowering cholesterol in patients with coronary heart disease. Clinical Cardiology, 1998, 21, 81-84.	0.7	11
507	The need for a prognosis trial of revascularization and aggressive medical therapy in patients with asymptomatic cardiac ischemia. Clinical Cardiology, 1998, 21, 154-156.	0.7	1
508	Pathophysiologic bases for adjunctive therapies in the treatment and secondary prevention of acute myocardial infarction. Clinical Cardiology, 1998, 21, 161-168.	0.7	14
509	Hormones and the cardiologist. Clinical Cardiology, 1998, 21, 218-222.	0.7	4
510	Management Strategies for a Better Outcome in Unstable Coronary Artery Disease. Clinical Cardiology, 1998, 21, 314-322.	0.7	40
511	Comparison of atorvastatin alone <i>versus</i> simvastatin ± cholestyramine in the management of severe primary hypercholesterolemia (The Six Cities Study). Australian and New Zealand Journal of Medicine, 1998, 28, 327-333.	0.5	18
512	Effects of pravastatin on cholesterol metabolism of cholesterol-fed heterozygous WHHL rabbits. British Journal of Pharmacology, 1998, 124, 277-282.	2.7	4
513	Low-Density Lipoprotein Apheresis Using the Liposorber System: Features of the System and Clinical Benefits. Therapeutic Apheresis and Dialysis, 1998, 2, 25-30.	0.6	7
514	LDL-Apheresis for the Treatment of Severe Hypercholesterolemia Refractory to Conventional Therapy. Therapeutic Apheresis and Dialysis, 1998, 2, 142-146.	0.6	12
515	Design of the Women's Health Initiative Clinical Trial and Observational Study. Contemporary Clinical Trials, 1998, 19, 61-109.	2.0	2,421

#	ARTICLE	IF	CITATIONS
516	Effect of Simvastatin on Ischemic Signs and Symptoms in the Scandinavian Simvastatin Survival Study (4S). American Journal of Cardiology, 1998, 81, 333-335.	0.7	465
517	Rationale and Design of the Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering (MIRACL) Study <sup>11</sup> See Appendix A for the list of participants in the MIRACL study. That Evaluates Atorvastatin in Unstable Angina Pectoris and in Non-Q-Wave Acute Myocardial Infarction. American Journal of Cardiology, 1998, 81, 578-581.	0.7	87
518	Dyslipidemias Have a Detrimental Effect on Left Ventricular Systolic Function in Patients With a First Acute Myocardial Infarction. American Journal of Cardiology, 1998, 81, 531-537.	0.7	34
519	Aggressive Lipid Lowering in Postcoronary Angioplasty Patients With Elevated Cholesterol (the Tj ETQq1 1 0.784314 rgBT /Overlock 10	0.7	13
520	Hypertriglyceridemia, Atherogenic Dyslipidemia, and the Metabolic Syndrome. American Journal of Cardiology, 1998, 81, 18B-25B.	0.7	451
521	Effect of Statins on Metabolism of Apo-B-Containing Lipoproteins in Hypertriglyceridemic Men. American Journal of Cardiology, 1998, 81, 36B-42B.	0.7	54
522	Role of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors (Statins) in Familial Combined Hyperlipidemia. American Journal of Cardiology, 1998, 81, 43B-46B.	0.7	15
523	Treatment of Diabetic Dyslipidemia. American Journal of Cardiology, 1998, 81, 47B-51B.	0.7	44
524	Serum Triglycerides and Clinical Benefit in Lipid-Lowering Trials. American Journal of Cardiology, 1998, 81, 70B-73B.	0.7	17
525	Serum Cholesterol Levels Are Underevaluated and Undertreated. American Journal of Cardiology, 1998, 81, 1353-1356.	0.7	30
526	Lipid-Lowering Therapy After Coronary Revascularization: The Interventional Cardiologist's Perspective <sup>11</sup> This work was supported by the Cardiology Research Foundation, Washington, DC.. American Journal of Cardiology, 1998, 81, 55E-62E.	0.7	4
527	Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible united states adults. American Journal of Cardiology, 1998, 82, 61-65.	0.7	169
528	Early Efficacy and Safety Studies. American Journal of Cardiology, 1998, 81, 13F-16F.	0.7	0
529	Results of percutaneous coronary angioplasty in patients < 40 years of age. American Journal of Cardiology, 1998, 82, 135-139.	0.7	12
530	Underutilization of lipid-lowering drugs in older persons with prior myocardial infarction and a serum low-density lipoprotein cholesterol > 125 mg/dl. American Journal of Cardiology, 1998, 82, 668-669.	0.7	45
531	Efficacy and safety of Simvastatin 80 mg/day in hypercholesterolemic patients. American Journal of Cardiology, 1998, 82, 311-316.	0.7	73
532	Current and future treatment of hyperlipidemia: the role of statins. American Journal of Cardiology, 1998, 82, 3J-10J.	0.7	147
533	Cerivastatin in primary hyperlipidemia: a multicenter analysis of efficacy and safety. American Journal of Cardiology, 1998, 82, 40J-46J.	0.7	39

#	ARTICLE	IF	CITATIONS
534	Review of trials in the treatment of coronary artery disease: theoretical expectations versus lack of practical success— how can we explain the differences?. American Journal of Cardiology, 1998, 82, 15-20.	0.7	4
535	Assessing the benefits of lipid-lowering therapy. American Journal of Cardiology, 1998, 82, 2M-4M.	0.7	13
536	Clinical trial endpoints: angiograms, events, and plaque instability. American Journal of Cardiology, 1998, 82, 5M-11M.	0.7	54
537	Coronary arteriography and lipid lowering: limitations, new concepts, and new paradigms in cardiovascular medicine. American Journal of Cardiology, 1998, 82, 12M-21M.	0.7	4
538	Economic implications of lipid-lowering trials: current considerations in selecting a statin. American Journal of Cardiology, 1998, 82, 26M-31M.	0.7	15
539	Future of lipid-lowering trials: what else do we need to know?. American Journal of Cardiology, 1998, 82, 32M-38M.	0.7	2
540	Cost-effectiveness of statins. American Journal of Cardiology, 1998, 82, 1357-1363.	0.7	61
541	Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. American Journal of Cardiology, 1998, 82, 1489-1495.	0.7	269
542	Foreword: changing the treatment paradigm for coronary artery disease. American Journal of Cardiology, 1998, 82, 2-4.	0.7	711
543	Need for a paradigm shift: the importance of risk factor reduction therapy in treating patients with cardiovascular disease. American Journal of Cardiology, 1998, 82, 10-13.	0.7	52
544	Why cholesterol as a central theme in coronary artery disease?. American Journal of Cardiology, 1998, 82, 14-17.	0.7	45
545	Is aggressive cholesterol control justified? review of the post—coronary artery bypass graft trial. American Journal of Cardiology, 1998, 82, 45-48.	0.7	15
546	Importance of endothelial function in mediating the benefits of lipid-lowering therapy. American Journal of Cardiology, 1998, 82, 49-52.	0.7	87
547	Coronary artery disease: the Scandinavian Simvastatin Survival Study Experience. American Journal of Cardiology, 1998, 82, 53-56.	0.7	35
548	Preventing coronary artery disease in the West of Scotland: implications for primary prevention. American Journal of Cardiology, 1998, 82, 57-59.	0.7	120
549	From heart surgery to prevention. American Journal of Cardiology, 1998, 82, 66-71.	0.7	33
550	A new extended-release niacin (niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients. American Journal of Cardiology, 1998, 82, 29U-34U.	0.7	128
552	Low-density lipoproteins and risk for coronary artery disease. American Journal of Cardiology, 1998, 82, 3-12.	0.7	303

#	ARTICLE	IF	CITATIONS
553	Primary and secondary prevention of coronary artery disease: trials of lipid lowering with statins. American Journal of Cardiology, 1998, 82, 28S-30S.	0.7	9
554	The antiatherogenic role of high-density lipoprotein cholesterol. American Journal of Cardiology, 1998, 82, 13-21.	0.7	185
555	Treatment of hyperlipidemia with combined niacin+statin regimens. American Journal of Cardiology, 1998, 82, 82U-84U.	0.7	85
556	State-of-the-art update and review: clinical trials of lipid-lowering agents. American Journal of Cardiology, 1998, 82, 3U-17U.	0.7	46
557	Primary and secondary prevention of coronary artery disease: Trials of lipid lowering with statins. American Journal of Cardiology, 1998, 82, S28-S30.	0.7	7
558	The role of myocardial revascularization preceding noncardiac surgery. Progress in Cardiovascular Diseases, 1998, 40, 383-404.	1.6	11
559	Metabolism and Drug Interactions of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors in Transplant Patients. , 1998, 80, 1-34.		214
560	Vascular morbidity and mortality during long-term follow-up in claudicants selected for peripheral bypass surgery. European Journal of Vascular and Endovascular Surgery, 1998, 16, 292-300.	0.8	11
561	The management of hypercholesterolemia in patients with coronary artery disease: Guidelines for primary care. Clinical Cornerstone, 1998, 1, 51-64.	1.0	4
562	Diabetes Atherosclerosis Intervention Study (DAIS): Quantitative coronary angiographic analysis of coronary artery atherosclerosis. , 1998, 44, 249-256.		17
563	Effect of HMG-CoA reductase inhibitors on plasma polyunsaturated fatty acid concentrations in patients with hyperlipidemia. International Journal of Clinical and Laboratory Research, 1998, 28, 192-195.	1.0	44
567	The benefit of lowering cholesterol:Relative risk can be absolutely misleading!. Irish Journal of Medical Science, 1998, 167, 92-93.	0.8	1
568	Prognostic characterization of patients with mild coronary artery disease with myocardial perfusion single photon emission computed tomography: Validation of an outcomes-based strategy. Journal of Nuclear Cardiology, 1998, 5, 90-95.	1.4	5
569	Editorial: Do we need population monitoring laboratories to evaluate community-based prevention of cardiovascular disease in developing countries?. Tropical Medicine and International Health, 1998, 3, 251-255.	1.0	2
570	Landmark Trials in Lipid Reduction. Value in Health, 1998, 1, 110-114.	0.1	3
571	Prevention of Heart Disease: Is LDL Reduction the Outcome of Choice? Absolutely Yes. Value in Health, 1998, 1, 115-119.	0.1	2
572	Cardiovascular Disease and Lipoproteins: Available Evidence and Remaining Questions. Reactor Panel and Open Forum. Value in Health, 1998, 1, 125-130.	0.1	3
573	The Economics of Hypercholesterolemia and Lipid-Lowering Therapy: A Brief Historical Tour. Value in Health, 1998, 1, 159-165.	0.1	2



#	ARTICLE	IF	CITATIONS
574	Lipid-Lowering Pharmacoeconomic Studies. Reactor Panel and Open Forum. Value in Health, 1998, 1, 167-170.	0.1	0
575	Compliance in the Real World. Value in Health, 1998, 1, 171-173.	0.1	15
576	Use of Surrogate Measures in Cost-Effectiveness Analyses of Lipid-Lowering Therapies. Value in Health, 1998, 1, 175-180.	0.1	4
577	Clinical Trials and External Validity. Value in Health, 1998, 1, 181-185.	0.1	2
578	Methodology Issues in Lipid Pharmacoeconomic Investigations. Reactor Panel and Open Forum. Value in Health, 1998, 1, 195-200.	0.1	0
579	What Is Happening in the Real World in Lipid Therapy and Is It Appropriate? The Need for a Paradigm Shift. Value in Health, 1998, 1, 204-207.	0.1	1
580	Commentary on Langley and McKenney Papers. Value in Health, 1998, 1, 216-217.	0.1	0
581	A Canadian Perspective. Value in Health, 1998, 1, 218-223.	0.1	1
582	A UK Perspective. Value in Health, 1998, 1, 224-227.	0.1	0
583	From Research into Practice: How Should Healthcare Organizations/Governments Decide about Lipid Therapy and Who Will Pay? Reactor Panel and Open Forum. Value in Health, 1998, 1, 243-250.	0.1	0
584	Lipoprotein(a) Apheresis in Severe Coronary Heart Disease: an Immunoabsorption Method. Artificial Organs, 1998, 22, 135-139.	1.0	15
585	Does cholesterol lowering prevent stroke?. Journal of Clinical Pharmacy and Therapeutics, 1998, 23, 337-344.	0.7	5
586	An evaluation of the antioxidant activity of a standardized grape seed extract, Leucoselect®. Journal of Clinical Pharmacy and Therapeutics, 1998, 23, 385-389.	0.7	89
587	Effects of Simvastatin and omega-3 fatty acids on plasma lipoproteins and lipid peroxidation in patients with combined hyperlipidaemia. Journal of Internal Medicine, 1998, 243, 163-170.	2.7	95
588	Diet and pravastatin in moderate hypercholesterolaemia: a randomized trial in 215 middle-aged men free from cardiovascular disease. Journal of Internal Medicine, 1998, 244, 371-378.	2.7	22
589	Effects of atorvastatin on serum lipids of patients with familial hypercholesterolaemia. Journal of Internal Medicine, 1998, 244, 143-147.	2.7	15
590	Lipid disorders in NIDDM: implications for treatment. Journal of Internal Medicine, 1998, 244, 361-370.	2.7	21
591	DALI-the first human whole-blood low-density lipoprotein and lipoprotein (a) apheresis system in clinical use: procedure and clinical results. European Journal of Clinical Investigation, 1998, 28, 994-1002.	1.7	68

#	ARTICLE	IF	CITATIONS
592	Carotid intima-media thickness and plaque in patients with familial hypercholesterolaemia mutations and control subjects. <i>European Journal of Clinical Investigation</i> , 1998, 28, 971-979.	1.7	50
593	Influence of bilateral oophorectomy upon lipid metabolism. <i>Maturitas</i> , 1998, 29, 147-154.	1.0	19
594	Evidence based treatment of chronic stable angina. <i>International Journal of Cardiology</i> , 1998, 63, 21-25.	0.8	2
595	Thrombolysis in acute myocardial infarction improves prognosis and prolongs life but will increase the prevalence of heart failure in the geriatric population. <i>International Journal of Cardiology</i> , 1998, 65, S29-S35.	0.8	2
596	Predictors of death during 5 years after hospital discharge among patients with a suspected acute coronary syndrome with particular emphasis on whether an infarction was developed. <i>International Journal of Cardiology</i> , 1998, 66, 73-80.	0.8	31
597	Statins for prevention of stroke. <i>Lancet, The</i> , 1998, 352, 909-910.	6.3	3
598	Statins for prevention of stroke. <i>Lancet, The</i> , 1998, 351, 1002-1003.	6.3	13
599	Fatal lupus-like syndrome and ARDS induced by fluvastatin. <i>Lancet, The</i> , 1998, 352, 114.	6.3	35
600	Prevention of stroke. <i>Lancet, The</i> , 1998, 352, S15-S18.	6.3	39
601	Overview of atherosclerosis. <i>Clinical Therapeutics</i> , 1998, 20, B2-B17.	1.1	44
602	Effects of cerivastatin sodium, a new HMG-CoA reductase inhibitor, on biliary lipid metabolism in patients with hypercholesterolemia. <i>Clinical Therapeutics</i> , 1998, 20, 477-485.	1.1	5
603	A long-term comparative trial of cerivastatin sodium, a new HMG-CoA reductase inhibitor, in patients with primary hypercholesterolemia. <i>Clinical Therapeutics</i> , 1998, 20, 539-548.	1.1	6
604	Conversion from fluvastatin to simvastatin therapy at a dose ratio of 8 to 1: effect on serum lipid levels and cost. <i>Clinical Therapeutics</i> , 1998, 20, 340-346.	1.1	9
606	Prediction of Coronary Heart Disease Using Risk Factor Categories. <i>Circulation</i> , 1998, 97, 1837-1847.	1.6	8,099
607	Lipid Lowering by Diet Reduces Matrix Metalloproteinase Activity and Increases Collagen Content of Rabbit Atheroma. <i>Circulation</i> , 1998, 97, 2433-2444.	1.6	547
608	Cardiovascular gene therapy. <i>Heart, Lung and Circulation</i> , 1998, 7, 114-120.	0.1	0
609	An elderly woman with hypercholesterolaemia but no symptoms. <i>Coronary Health Care</i> , 1998, 2, 39-44.	0.4	0
610	The implementation of multiprofessional guidelines for cardiac rehabilitation: a pilot study. <i>Coronary Health Care</i> , 1998, 2, 60-71.	0.4	6

#	ARTICLE	IF	CITATIONS
611	Prevalence of Cardiovascular Risk Factors in South Korean Adults: Results from the Korea Medical Insurance Corporation (KMIC) Study. <i>Annals of Epidemiology</i> , 1998, 8, 14-21.	0.9	64
612	Long-term effect of low-density lipoprotein apheresis on plasma lipoproteins and coronary heart disease in native vessels and coronary bypass in severe heterozygous familial hypercholesterolemia. <i>Metabolism: Clinical and Experimental</i> , 1998, 47, 863-868.	1.5	47
613	Synthesis of 4 $\beta$ -(2-propenyl)-5,6-secocholestan-3 $\beta$ -ol, a Novel B-ring Seco Analog of the Hypocholesterolemic Agent 4 $\beta$ -(2-propenyl)-5 $\beta$ -cholestan-3 $\beta$ -ol. <i>Steroids</i> , 1998, 63, 202-207.	0.8	2
614	Treatment of early onset atherosclerosis. <i>Surgery</i> , 1998, 123, 720-721.	1.0	0
615	Iatrogenic problems caused by immunosuppressive drugs in transplant recipients. <i>Transplantation Proceedings</i> , 1998, 30, 14S-19S.	0.3	5
616	Open-label study of the efficacy, safety, and tolerability of policosanol in patients with high global coronary risk. <i>Current Therapeutic Research</i> , 1998, 59, 737-745.	0.5	9
617	Aggressive medical therapy for the prevention and treatment of coronary artery disease. <i>Disease-a-Month</i> , 1998, 44, 1-40.	0.4	1
618	Critical Analysis of Coronary Artery Bypass Graft Surgery: A 30-Year Journey. <i>Journal of the American College of Cardiology</i> , 1998, 31, 1B-63B.	1.2	106
620	Additional benefit of vitamin E supplementation to simvastatin therapy on vasoreactivity of the brachial artery of hypercholesterolemic men. <i>Journal of the American College of Cardiology</i> , 1998, 32, 711-716.	1.2	108
621	Specialty differences in cardiovascular disease prevention practices. <i>Journal of the American College of Cardiology</i> , 1998, 32, 1238-1243.	1.2	28
622	The effect of hormone replacement therapy alone and in combination with simvastatin on plasma lipids of hypercholesterolemic postmenopausal women with coronary artery disease. <i>Journal of the American College of Cardiology</i> , 1998, 32, 1244-1250.	1.2	50
623	HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. <i>Journal of the American College of Cardiology</i> , 1998, 32, 2057-2064.	1.2	402
624	Decreased blood oxygen diffusion in hypercholesterolemia. <i>Surgery</i> , 1998, 124, 692-698.	1.0	18
625	Candidate-Gene Studies of the Atherogenic Lipoprotein Phenotype: A Sib-Pair Linkage Analysis of DZ Women Twins. <i>American Journal of Human Genetics</i> , 1998, 62, 406-419.	2.6	67
626	DYSLIPOPROTEINEMIA AND DIABETES. <i>Endocrinology and Metabolism Clinics of North America</i> , 1998, 27, 613-625.	1.2	23
627	Role of inflammation and metalloproteinases in plaque disruption and thrombosis. <i>Vascular Medicine</i> , 1998, 3, 199-206.	0.8	93
628	CLINICAL TRIALS OF REDUCING LOW-DENSITY LIPOPROTEIN CONCENTRATIONS. <i>Endocrinology and Metabolism Clinics of North America</i> , 1998, 27, 585-595.	1.2	9
629	Genetics in childhood atherosclerosis. <i>Progress in Pediatric Cardiology</i> , 1998, 9, 213-224.	0.2	0

#	ARTICLE	IF	CITATIONS
630	CARDIOVASCULAR DISEASES IN WOMEN. Medical Clinics of North America, 1998, 82, 1-19.	1.1	13
631	CONTROL OF LIPID DISORDERS IN PATIENTS WITH ATHEROSCLEROTIC VASCULAR DISEASE. Surgical Clinics of North America, 1998, 78, 431-446.	0.5	1
632	GENDER DIFFERENCES IN CARDIAC REHABILITATION. Cardiology Clinics, 1998, 16, 37-43.	0.9	45
633	New prospects for lipid-lowering drugs. Expert Opinion on Investigational Drugs, 1998, 7, 715-727.	1.9	4
634	Do Lipid Lowering Drugs Reduce the Risk of Coronary Heart Disease?. Critical Reviews in Clinical Laboratory Sciences, 1998, 35, 603-621.	2.7	15
635	Serum Cholesterol, Lifestyle, Working Capacity and Quality of Life in Patients with Coronary Artery Disease. Experiences from a Hospital-based Secondary Prevention Programme. Scandinavian Cardiovascular Journal, 1998, 32, 1-20.	0.4	30
636	Risk Indicators for Recurrence Among Patients with Coronary Artery Disease: Problems Associated with their Modification. Scandinavian Cardiovascular Journal, 1998, 32, 9-16.	0.4	3
637	Cost-Effectiveness Analysis of Treatments to Reduce Cholesterol Levels, Blood Pressure and Smoking for the Prevention of Coronary Heart Disease. Pharmacoeconomics, 1998, 13, 623-643.	1.7	25
638	Impact of Dyslipidaemia. Pharmacoeconomics, 1998, 14, 1-9.	1.7	3
639	Resource Utilisation in the Management of Dyslipidaemia. Pharmacoeconomics, 1998, 14, 11-18.	1.7	7
640	The Cost of Treating Dyslipidaemia Using National Cholesterol Education Program (NCEP) Guidelines. Pharmacoeconomics, 1998, 14, 19-28.	1.7	19
641	Clinical Positioning of HMG-CoA Reductase Inhibitors in Lipid Management Protocols. Pharmacoeconomics, 1998, 14, 29-38.	1.7	8
642	The Cost of Reaching National Cholesterol Education Program (NCEP) Goals in Hypercholesterolaemic Patients. Pharmacoeconomics, 1998, 14, 59-70.	1.7	51
643	Pravastatin. Pharmacoeconomics, 1998, 14, 217-236.	1.7	10
644	Common Errors and Controversies in Pharmacoeconomic Analyses. Pharmacoeconomics, 1998, 14, 709-714.	1.7	0
645	Pathogenesis, Diagnosis and Epidemiology of Stroke. CNS Drugs, 1998, 9, 1-9.	2.7	2
646	Economic Impact of Stroke and Implications for Interventions. CNS Drugs, 1998, 9, 19-39.	2.7	2
647	Secondary Prevention after Myocardial Infarction. European Journal of General Practice, 1998, 4, 6-10.	0.9	8

#	ARTICLE	IF	CITATIONS
648	An Introduction to Markov Modelling for Economic Evaluation. <i>Pharmacoeconomics</i> , 1998, 13, 397-409.	1.7	713
649	Normal Growth in High-Risk Hyperlipidemic Children and Adolescents with Dietary Intervention. <i>Preventive Medicine</i> , 1998, 27, 775-780.	1.6	32
650	Visceral obesity and the risk of ischaemic heart disease: insights from the QuÃ©bec Cardiovascular Study. <i>Growth Hormone and IGF Research</i> , 1998, 8, 1-8.	0.5	44
651	Comparison of the Heart and Estrogen/Progestin Replacement Study (HERS) cohort with women with coronary disease from the National Health and Nutrition Examination Survey III (NHANES III). <i>American Heart Journal</i> , 1998, 136, 115-124.	1.2	39
652	Cholesterol Lowering in the Management of Coronary Artery Disease: The Clinical Implications of Recent Trials. <i>American Journal of Medicine</i> , 1998, 104, 2S-5S.	0.6	80
653	Risk Factor Modification: Rationale for Management of Dyslipidemia. <i>American Journal of Medicine</i> , 1998, 104, 6S-8S.	0.6	24
654	Therapeutic Efficacy of the Lipid-Lowering Armamentarium: The Clinical Benefits of Aggressive Lipid-Lowering Therapy. <i>American Journal of Medicine</i> , 1998, 104, 9S-13S.	0.6	42
655	New concepts and paradigms in cardiovascular medicine: the noninvasive management of coronary artery disease. <i>American Journal of Medicine</i> , 1998, 104, 2S-17S.	0.6	167
656	The future: screening and effective intervention. <i>American Journal of Medicine</i> , 1998, 104, 54S-59S.	0.6	2
657	Biologic markers as predictors of cardiovascular disease. <i>American Journal of Medicine</i> , 1998, 104, 18S-27S.	0.6	102
658	Lessons from cholesterol-lowering trials. <i>American Journal of Medicine</i> , 1998, 104, 28S-32S.	0.6	15
659	The lipoprotein and coronary atherosclerosis study (LCAS): lipid and metabolic factors related to atheroma and clinical events. <i>American Journal of Medicine</i> , 1998, 104, 42S-49S.	0.6	17
660	The American College of Physicians guidelines for screening blood cholesterol levels: a commentary. <i>American Journal of Medicine</i> , 1998, 105, 75S-76S.	0.6	3
661	Benefit of aggressive lipid-lowering therapy: insights from the post coronary artery bypass graft study and other trials. <i>American Journal of Medicine</i> , 1998, 105, 63S-68S.	0.6	9
662	A perspective on hyperlipidemia: concepts of management in the prevention of coronary artery disease. <i>American Journal of Medicine</i> , 1998, 105, 69S-74S.	0.6	11
663	Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial Infarction. <i>New England Journal of Medicine</i> , 1998, 339, 229-234.	13.9	6,163
664	Drug Administration in Patients with Diabetes Mellitus. <i>Drug Safety</i> , 1998, 18, 441-455.	1.4	16
665	Choosing the Most Appropriate Treatment for Stable Angina. <i>Drug Safety</i> , 1998, 19, 23-44.	1.4	42

#	ARTICLE	IF	CITATIONS
666	Cerivastatin. <i>Drugs</i> , 1998, 55, 415-420.	4.9	36
667	Are There Potential Non-Lipid-Lowering Uses of Statins?. <i>Drugs</i> , 1998, 56, 517-522.	4.9	50
668	Effect of Atorvastatin versus Simvastatin on Lipid Profile and Plasma Fibrinogen in Patients with Hypercholesterolaemia. <i>Clinical Drug Investigation</i> , 1998, 16, 219-227.	1.1	20
669	Effects of reducing LDL and increasing HDL with gemfibrozil in experimental coronary lesion development and thrombotic risk. <i>Atherosclerosis</i> , 1998, 136, 333-345.	0.4	24
670	Effects of atorvastatin monotherapy and simvastatin plus cholestyramine on arterial endothelial function in patients with severe primary hypercholesterolaemia. <i>Atherosclerosis</i> , 1998, 137, 197-203.	0.4	113
671	Evidence based approach for the management of mixed hyperlipidaemia. <i>Atherosclerosis</i> , 1998, 137, S97-S100.	0.4	10
672	Direct vascular effects of HMG-CoA reductase inhibitors. <i>Atherosclerosis</i> , 1998, 137, S101-S109.	0.4	193
673	Cost-effectiveness of pravastatin in secondary prevention of coronary heart disease: comparison between Belgium and the United States of a projected risk model. <i>Atherosclerosis</i> , 1998, 137, S111-S116.	0.4	34
674	HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials data. <i>Atherosclerosis</i> , 1998, 138, 11-24.	0.4	106
675	The atherogenic lipoprotein phenotype and vascular endothelial dysfunction. <i>Atherosclerosis</i> , 1998, 138, 229-235.	0.4	151
676	HMG-CoA reductase and ACAT inhibitors act synergistically to lower plasma cholesterol and limit atherosclerotic lesion development in the cholesterol-fed rabbit. <i>Atherosclerosis</i> , 1998, 139, 21-30.	0.4	59
677	Effect of HELP-LDL-apheresis on outcomes in patients with advanced coronary atherosclerosis and severe hypercholesterolemia. <i>Atherosclerosis</i> , 1998, 139, 401-409.	0.4	20
678	Association of apo B lipoproteins with arterial proteoglycans: Pathological significance and molecular basis. <i>Atherosclerosis</i> , 1998, 139, 205-222.	0.4	299
679	Can we afford to treat hyperlipidaemia as we should?. <i>Atherosclerosis</i> , 1998, 139, 1-5.	0.4	57
680	Cerivastatin in primary hyperlipidemia—a multicenter analysis of efficacy and safety. Reprinted from the <i>American Journal of Cardiology</i> with permission. <i>Atherosclerosis</i> , 1998, 139, 15-22.	0.4	18
681	Metabolic modes of action of the statins in the hyperlipoproteinemias. <i>Atherosclerosis</i> , 1998, 141, 203-207.	0.4	60
682	Triglycerides are more important in atherosclerosis than epidemiology has suggested. <i>Atherosclerosis</i> , 1998, 141, S57-S62.	0.4	63
683	Prevention of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. <i>European Society of Cardiology, European Atherosclerosis Society, European Society of Hypertension, International Society of Behavioural Medicine, European Society of General Practice/Family Medicine, European Heart Network.</i> Published simultaneously in the <i>European Heart Journal</i> 1998;19:1434-1503 and the <i>Journal of Hypertension (Summary only)</i> 1998. <i>Atherosclerosis</i> , 1998, 140, 199-270.	0.4	760

#	ARTICLE	IF	CITATIONS
685	Effects of Diet and Exercise in Men and Postmenopausal Women with Low Levels of HDL Cholesterol and High Levels of LDL Cholesterol. <i>New England Journal of Medicine</i> , 1998, 339, 12-20.	13.9	525
686	DETECTION AND EVALUATION OF DYSLIPOPROTEINEMIA. <i>Endocrinology and Metabolism Clinics of North America</i> , 1998, 27, 597-611.	1.2	12
687	WOMEN, DYSLIPOPROTEINEMIA, AND ESTROGENS. <i>Endocrinology and Metabolism Clinics of North America</i> , 1998, 27, 627-639.	1.2	5
688	RISK FACTORS FOR CORONARY HEART DISEASE IN WOMEN. <i>Cardiology Clinics</i> , 1998, 16, 1-8.	0.9	39
689	The Role of Lipid-Lowering Therapy in Multiple Risk Factor Management. <i>Drugs</i> , 1998, 56, 1-7.	4.9	19
690	Extending Therapy Options in Treating Lipid Disorders. <i>Drugs</i> , 1998, 56, 25-31.	4.9	32
691	Guidelines for the Prevention of Coronary Heart Disease. <i>Disease Management and Health Outcomes</i> , 1998, 4, 217-224.	0.3	0
692	Pharmacoeconomic Models in Disease Management. <i>Disease Management and Health Outcomes</i> , 1998, 4, 119-134.	0.3	15
693	Management of Dyslipidaemias. <i>Disease Management and Health Outcomes</i> , 1998, 3, 293-311.	0.3	2
694	Upregulation of Endothelial Nitric Oxide Synthase by HMG CoA Reductase Inhibitors. <i>Circulation</i> , 1998, 97, 1129-1135.	1.6	1,736
695	Association of Mutations in the Apolipoprotein B Gene with Hypercholesterolemia and the Risk of Ischemic Heart Disease. <i>New England Journal of Medicine</i> , 1998, 338, 1577-1584.	13.9	166
696	Differential Effects of Lovastatin on the Trafficking of Endogenous and Lipoprotein-Derived Cholesterol in Human Monocyte-Derived Macrophages. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1998, 18, 1322-1329.	1.1	29
697	Implications of Serum Cholesterol Measurement for the Vascular Surgeon. <i>Vascular Surgery</i> , 1998, 32, 241-244.	0.3	1
698	Insulin and Coronary Artery Disease: Is Syndrome X the Unifying Hypothesis?. <i>Annals of Pharmacotherapy</i> , 1998, 32, 233-247.	0.9	26
699	Coronary artery surgery: the end of the beginning <sup>1</sup> . <i>European Journal of Cardio-thoracic Surgery</i> , 1998, 14, 554-571.	0.6	43
700	Guidelines for Carotid Endarterectomy. <i>Stroke</i> , 1998, 29, 554-562.	1.0	380
701	Economic evaluation of cholesterol-related interventions in general practice. An appraisal of the evidence. <i>Journal of Epidemiology and Community Health</i> , 1998, 52, 586-594.	2.0	16
702	Cholesterol Reduction Yields Clinical Benefit. <i>Circulation</i> , 1998, 97, 946-952.	1.6	401

#	ARTICLE	IF	CITATIONS
703	Medical Therapy for Coronary Artery Disease: Primary and Secondary Prevention. Asian Cardiovascular and Thoracic Annals, 1998, 6, 245-249.	0.2	1
704	Secondary prevention in coronary heart disease: baseline survey of provision in general practice. BMJ: British Medical Journal, 1998, 316, 1430-1434.	2.4	197
705	Statin Trials and Goals of Cholesterol-Lowering Therapy. Circulation, 1998, 97, 1436-1439.	1.6	187
706	Use of Lipid-Lowering Drugs With Acute Myocardial Infarction Patients: An Examination of Physician Prescribing Behaviors. Journal of Cardiovascular Pharmacology and Therapeutics, 1998, 3, 217-221.	1.0	3
707	Perspectives in the Treatment of Dyslipidemias in the Prevention of Coronary Heart Disease. Angiology, 1998, 49, 339-348.	0.8	12
708	Suppressive Effect of Simvastatin on Intramural Small Coronary Arterial Lesions in Cholesterol-Fed Rabbits. Angiology, 1998, 49, 211-220.	0.8	0
709	Thrombolytic Therapy in Acute Myocardial Infarction Part II: 1997 Update. Asian Cardiovascular and Thoracic Annals, 1998, 6, 3-10.	0.2	1
710	Guidelines for Carotid Endarterectomy. Circulation, 1998, 97, 501-509.	1.6	373
711	Vasodilatory Capacity of Forearm Resistance Vessels Is Augmented in Hypercholesterolemic Patients After Treatment with Fluvastatin. Angiology, 1998, 49, 743-748.	0.8	12
712	Post-transcriptional Regulation of Endothelial Nitric Oxide Synthase mRNA Stability by Rho GTPase. Journal of Biological Chemistry, 1998, 273, 24266-24271.	1.6	941
713	Rationale for antiplatelet therapy in patients with atherothrombotic disease. Vascular Medicine, 1998, 3, 253-255.	0.8	5
714	Review : Recent Advances in the Prevention of Coronary Artery Disease: Focus on Primary Prevention. Journal of Cardiovascular Pharmacology and Therapeutics, 1998, 3, 77-83.	1.0	1
715	Increasing Burden of Cardiovascular Disease. Circulation, 1998, 97, 1095-1102.	1.6	254
716	Effects of Short-Term Treatment of Hyperlipidemia on Coronary Vasodilator Function and Myocardial Perfusion in Regions Having Substantial Impairment of Baseline Dilator Reserve. Circulation, 1998, 98, 1291-1296.	1.6	133
717	Associations Between Lipoproteins and the Progression of Coronary and Vein-Graft Atherosclerosis in a Controlled Trial With Gemfibrozil in Men With Low Baseline Levels of HDL Cholesterol. Circulation, 1998, 98, 1993-1999.	1.6	72
718	Lipid Lowering Promotes Accumulation of Mature Smooth Muscle Cells Expressing Smooth Muscle Myosin Heavy Chain Isoforms in Rabbit Atheroma. Circulation Research, 1998, 83, 1015-1026.	2.0	143
719	Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels. New England Journal of Medicine, 1998, 339, 1349-1357.	13.9	5,230
720	3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase and Isoprenylation Inhibitors Induce Apoptosis of Vascular Smooth Muscle Cells in Culture. Circulation Research, 1998, 83, 490-500.	2.0	379



#	ARTICLE	IF	CITATIONS
721	Reversal of Abnormal Coronary Vasomotion by Calcium Antagonists in Patients With Hypercholesterolemia. <i>Circulation</i> , 1998, 97, 1348-1354.	1.6	29
722	The potential role of soluble fibre in the treatment of hypercholesterolaemia.. <i>Postgraduate Medical Journal</i> , 1998, 74, 391-394.	0.9	13
723	Recognition and management of hypercholesterolaemia in patients awaiting elective coronary artery bypass grafting.. <i>Postgraduate Medical Journal</i> , 1998, 74, 157-160.	0.9	1
724	New Targeted AHA Research Program. <i>Circulation</i> , 1998, 97, 1221-1222.	1.6	7
725	Cholesterol and coronary heart disease: screening and treatment. <i>Quality and Safety in Health Care</i> , 1998, 7, 232-239.	2.5	24
726	Primary Prevention of Coronary Heart Disease: Guidance From Framingham. <i>Circulation</i> , 1998, 97, 1876-1887.	1.6	520
727	Atherothrombosis: mechanisms and clinical therapeutic approaches. <i>Vascular Medicine</i> , 1998, 3, 231-239.	0.8	56
728	The use of HMG Co-A reductase inhibitors following acute myocardial infarction in hospital practice.. <i>Postgraduate Medical Journal</i> , 1998, 74, 600-601.	0.9	10
729	Controlling Blood Lipids. <i>Physician and Sportsmedicine</i> , 1998, 26, 56-65.	1.0	0
730	Polymorphism of the Cholesteryl Ester Transfer Protein Gene. <i>New England Journal of Medicine</i> , 1998, 338, 1624-1626.	13.9	4
731	Management of Nonâ€“Q-Wave Myocardial Infarction. <i>New England Journal of Medicine</i> , 1998, 339, 1395-1398.	13.9	1
732	Recent advances: Cardiology. <i>BMJ: British Medical Journal</i> , 1998, 316, 911-915.	2.4	2
733	The Atherogenic Significance of an Elevated Plasma Triglyceride Level. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 1998, 35, 489-516.	2.7	35
734	Endothelial Dysfunction: Implications for Therapy of Cardiovascular Diseases. <i>Annals of Pharmacotherapy</i> , 1998, 32, 459-470.	0.9	28
735	Preventing Coronary Disease in Women: Brief Observations from the Clinical Data. <i>Journal of Women's Health</i> , 1998, 7, 195-197.	0.9	1
736	Trends in the Incidence of Myocardial Infarction and in Mortality Due to Coronary Heart Disease, 1987 to 1994. <i>New England Journal of Medicine</i> , 1998, 339, 861-867.	13.9	689
737	Chronic Heart Failure in the United States. <i>Circulation</i> , 1998, 97, 282-289.	1.6	721
738	Cardiovascular Disease Prevention. <i>Circulation</i> , 1998, 98, 2103-2104.	1.6	11

#	ARTICLE	IF	CITATIONS
739	Relationship Between Plasma LDL Concentrations During Treatment With Pravastatin and Recurrent Coronary Events in the Cholesterol and Recurrent Events Trial. <i>Circulation</i> , 1998, 97, 1446-1452.	1.6	363
740	Animal Model That Mimics Atherosclerotic Plaque Rupture. <i>Circulation Research</i> , 1998, 83, 705-713.	2.0	77
741	Echo-Lucency of Computerized Ultrasound Images of Carotid Atherosclerotic Plaques Are Associated With Increased Levels of Triglyceride-Rich Lipoproteins as Well as Increased Plaque Lipid Content. <i>Circulation</i> , 1998, 97, 34-40.	1.6	190
742	Effects of Lowering Average or Below-Average Cholesterol Levels on the Progression of Carotid Atherosclerosis. <i>Circulation</i> , 1998, 97, 1784-1790.	1.6	238
743	Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23). <i>BMJ: British Medical Journal</i> , 1998, 316, 823-828.	2.4	1,706
744	Atorvastatin in the Treatment of Primary Hypercholesterolemia and Mixed Dyslipidemias. <i>Annals of Pharmacotherapy</i> , 1998, 32, 1030-1043.	0.9	43
745	IDL Composition and Angiographically Determined Progression of Atherosclerotic Lesions During Simvastatin Therapy. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1998, 18, 577-583.	1.1	14
746	Clinical Criteria Versus DNA Diagnosis in Heterozygous Familial Hypercholesterolemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1998, 18, 331-332.	1.1	13
747	Serum Cholesterol Distribution and Coronary Heart Disease Risk. <i>Circulation</i> , 1998, 97, 1087-1094.	1.6	83
748	Lipoprotein Changes and Reduction in the Incidence of Major Coronary Heart Disease Events in the Scandinavian Simvastatin Survival Study (4S). <i>Circulation</i> , 1998, 97, 1453-1460.	1.6	585
749	Physician Noncompliance With the 1993 National Cholesterol Education Program (NCEP-ATPII) Guidelines. <i>Circulation</i> , 1998, 98, 851-855.	1.6	174
750	3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Increase Fibrinolytic Activity in Rat Aortic Endothelial Cells. <i>Circulation Research</i> , 1998, 83, 683-690.	2.0	313
751	HMG-CoA Reductase Inhibitors Reduce MMP-9 Secretion by Macrophages. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1998, 18, 1671-1678.	1.1	477
752	Esterified Cholesterol Accumulation Induced by Aggregated LDL Uptake in Human Vascular Smooth Muscle Cells Is Reduced by HMG-CoA Reductase Inhibitors. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1998, 18, 738-746.	1.1	59
753	Present Status of HMG Reductase Inhibitors in Treatment of Dyslipidemia. <i>Angiology</i> , 1998, 49, 801-805.	0.8	1
754	Invited Review. <i>Vascular Surgery</i> , 1998, 32, 245-247.	0.3	4
755	Incremental Prognostic Value of Myocardial Perfusion Single Photon Emission Computed Tomography for the Prediction of Cardiac Death. <i>Circulation</i> , 1998, 97, 535-543.	1.6	1,123
756	Coronary heart disease epidemiology: a look towards the south. <i>Journal of Epidemiology and Community Health</i> , 1998, 52, 706-706.	2.0	1

#	ARTICLE	IF	CITATIONS
757	Influence of Pravastatin and Plasma Lipids on Clinical Events in the West of Scotland Coronary Prevention Study (WOSCOPS). <i>Circulation</i> , 1998, 97, 1440-1445.	1.6	766
758	Performance indicators for primary care groups: an evidence based approach. <i>BMJ: British Medical Journal</i> , 1998, 317, 1354-1360.	2.4	106
759	Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998, 95, 8880-8885.	3.3	929
760	Time trend analysis and variations in prescribing lipid lowering drugs in general practice. <i>BMJ: British Medical Journal</i> , 1998, 317, 1134-1135.	2.4	53
761	Detecting and Correcting Hyperlipidemia. <i>Hospital Practice (1995)</i> , 1998, 33, 83-102.	0.5	0
762	Underutilization of Measurement of Serum Low-Density Lipoprotein Cholesterol Levels and of Lipid-Lowering Therapy in Older Patients with Manifest Atherosclerotic Disease. <i>Journal of the American Geriatrics Society</i> , 1998, 46, 1128-1131.	1.3	34
763	Systemic Immune Reactions to HMG-CoA Reductase Inhibitors: Report of 4 Cases and Review of the Literature. <i>Medicine (United States)</i> , 1998, 77, 378-383.	0.4	35
764	Contemporary Practice: Treatment Gap in Lipid-Lowering Therapy. <i>Journal of Pharmacy Practice</i> , 1998, 11, 318-322.	0.5	0
765	Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study. <i>BMJ: British Medical Journal</i> , 1998, 316, 1127-1130.	2.4	229
766	Interim Report from Project ImPACT: Hyperlipidemia. <i>Journal of the American Pharmacists Association</i> , 1998, 38, 529-534.	0.6	19
767	From trial data to practical knowledge: qualitative study of how general practitioners have accessed and used evidence about statin drugs in their management of hypercholesterolaemia. <i>BMJ: British Medical Journal</i> , 1998, 317, 1130-1134.	2.4	115
768	Cardiac rehabilitation: structure, effectiveness and the future. <i>British Journal of Nursing</i> , 1998, 7, 1033-1040.	0.3	9
769	Calcium channel blockers. <i>BMJ: British Medical Journal</i> , 1998, 316, 1471-1473.	2.4	28
770	Management of hyperlipidaemia after coronary revascularisation: follow up study. <i>BMJ: British Medical Journal</i> , 1998, 316, 1499-1500.	2.4	13
771	Implications of applying widely accepted cholesterol screening and management guidelines to a British adult population: cross sectional study of cardiovascular disease and risk factors. <i>BMJ: British Medical Journal</i> , 1998, 317, 1125-1130.	2.4	41
772	Dietary Fatty Acids and the Regulation of Plasma Low Density Lipoprotein Cholesterol Concentrations. <i>Journal of Nutrition</i> , 1998, 128, 444S-448S.	1.3	193
773	Fortnightly review: Secondary prevention in acute myocardial infarction. <i>BMJ: British Medical Journal</i> , 1998, 316, 838-842.	2.4	38
774	Communicating the risk reduction achieved by cholesterol reducing drugs. <i>BMJ: British Medical Journal</i> , 1998, 316, 1956-1958.	2.4	91

#	ARTICLE	IF	CITATIONS
775	Management of Older Persons After Myocardial Infarction. Journal of the American Geriatrics Society, 1998, 46, 1459-1468.	1.3	12
776	Fighting Heart Disease and Stroke. Stroke, 1998, 29, 1272-1273.	1.0	9
777	Prevalence of Coronary Artery Disease, Atherothrombotic Brain Infarction, and Peripheral Arterial Disease: Associated Risk Factors in Older Hispanics in an Academic Hospital-Based Geriatrics Practice. Journal of the American Geriatrics Society, 1998, 46, 481-483.	1.3	23
779	Guidelines for coronary heart disease in general practice. Practice-based audit: results from a dissemination and implementation programme. Journal of Clinical Effectiveness, 1998, 3, 161-165.	0.2	1
780	Cost-Effectiveness of Cardiovascular Prevention Programs in Spain. International Journal of Technology Assessment in Health Care, 1998, 14, 320-330.	0.2	48
781	Phyto-oestrogens: where are we now?. British Journal of Nutrition, 1998, 79, 393-406.	1.2	350
782	Survival in treated hypertension: follow up study after two decades. BMJ: British Medical Journal, 1998, 317, 167-171.	2.4	179
783	The Search for Novel Antiarrhythmic Strategies. Japanese Circulation Journal, 1998, 62, 633-648.	1.0	7
784	Relationship Between Serum Cholesterol and the Risk of Acute Myocardial Infarction in a Screened Cohort in Okinawa, Japan. Japanese Circulation Journal, 1998, 62, 7-14.	1.0	49
786	Modulators of dyslipidaemia. Expert Opinion on Emerging Drugs, 1998, 3, 147-172.	1.1	20
787	Management of lipids in the elderly. Journal of the Royal Society of Medicine, 1998, 91, 189-191.	1.1	4
788	Effects of probiotics and prebiotics on blood lipids. British Journal of Nutrition, 1998, 80, S225-S230.	1.2	93
789	Plasma apolipoproteins A-I and B in survivors of myocardial infarction and in a control group. Clinical Chemistry, 1998, 44, 134-140.	1.5	25
790	Plasma lipoprotein profiles change significantly during cardiac catheterization. Clinical Chemistry, 1998, 44, 517-521.	1.5	13
791	Endothelium and acute coronary syndromes. Clinical Chemistry, 1998, 44, 1799-1808.	1.5	89
792	Coronary risk factors 6-12 months after coronary arter bypass surgery. Medical Journal of Australia, 1998, 169, 174-175.	0.8	0
793	Coronary atherosclerosis and its effect on cardiac structure and function: evaluation by electron beam computed tomography. Clinical Chemistry, 1998, 44, 1871-1881.	1.5	7
794	Effects of Continuous and Cyclic Hormone Replacement Therapy on the Lipoprotein Profile in Postmenopausal Women. Journal of Pharmacy Technology, 1998, 14, 12-17.	0.5	0

#	ARTICLE	IF	CITATIONS
795	Cholesterol management in high-risk patients without heart disease. <i>Postgraduate Medicine</i> , 1998, 104, 117-129.	0.9	5
796	Does 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase Inhibitor Therapy Exert a Direct Anti-Ischemic Effect?. <i>Circulation</i> , 1998, 97, 937-937.	1.6	3
797	Revisiting the effectiveness of the National Cholesterol Education Program's Step I and Step II diets: cholesterol-lowering diets in a pharmaceutically driven world. <i>American Journal of Clinical Nutrition</i> , 1999, 69, 581-582.	2.2	9
798	Improved One-Year Survival after Acute Myocardial Infarction in Iceland between 1986 and 1996. <i>Cardiology</i> , 1999, 91, 210-214.	0.6	4
799	Statins as Cellular Antithrombotics. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 1999, 29, 166-169.	0.5	11
800	Switching to statins: a challenge for primary care. <i>Journal of the Royal Society of Medicine</i> , 1999, 92, 522-524.	1.1	1
801	Is there a Place for LDL-apheresis in Non-Homozygous Patients?. <i>International Journal of Artificial Organs</i> , 1999, 22, 723-725.	0.7	3
802	Cholesterol reduction using manufactured foods high in monounsaturated fatty acids: a randomized crossover study. <i>British Journal of Nutrition</i> , 1999, 81, 439-446.	1.2	43
803	Efficacy and Safety of 300 mg and 400 mg Cerivastatin Once Daily in Patients with Primary Hypercholesterolemia: A Multicentre, Randomized, Double-Blind, Placebo-Controlled Study. <i>Journal of International Medical Research</i> , 1999, 27, 115-129.	0.4	18
804	Outcomes Improvement Following Minimally Invasive Direct Coronary Artery Bypass Surgery. <i>Critical Care Nursing Clinics of North America</i> , 1999, 11, 177-188.	0.4	4
806	The Role of Chlamydia Pneumoniae in the Pathogenesis of Coronary Heart Disease. <i>Journal of Pharmacy Technology</i> , 1999, 15, 157-161.	0.5	0
807	2. Cholesterol in perspective. <i>Medical Journal of Australia</i> , 1999, 170, 385-390.	0.8	1
808	Familial Hypercholesterolemia in Utah Kindred with Novel 2412-6 Ins G Mutations in Exon 17 of the LDL Receptor Gene. <i>International Heart Journal</i> , 1999, 40, 435-441.	0.6	4
810	Pathophysiology and clinical significance of atherosclerotic plaque rupture. <i>Cardiovascular Research</i> , 1999, 41, 323-333.	1.8	124
811	Long-term clinical outcome after stent implantation in coronary arteries. <i>International Journal of Cardiovascular Interventions</i> , 1999, 2, 27-34.	0.5	2
812	Strategies to achieve coronary arterial plaque stabilization. <i>Cardiovascular Research</i> , 1999, 41, 402-417.	1.8	114
813	Multiple risk factor interventions for primary prevention of coronary heart disease. , 1999, , CD001561.		22
814	Explaining risk factors to patients during a general practice consultation: Conveying group-based epidemiological knowledge to individual patients. <i>Scandinavian Journal of Primary Health Care</i> , 1999, 17, 3-5.	0.6	16

#	ARTICLE	IF	CITATIONS
815	Nifedipine improves endothelial function in hypercholesterolemia, independently of an effect on blood pressure or plasma lipids. <i>Cardiovascular Research</i> , 1999, 42, 752-760.	1.8	82
816	Lipid Profiles in Patients with Atherosclerotic Renal Artery Stenosis. <i>Nephron</i> , 1999, 83, 117-121.	0.9	20
817	Anti-oxidant therapy for the treatment of coronary artery disease. <i>Expert Opinion on Investigational Drugs</i> , 1999, 8, 1763-1784.	1.9	10
818	Chronic selective hypertriglyceridemia impairs endothelium-dependent vasodilatation in rats. <i>Cardiovascular Research</i> , 1999, 42, 783-793.	1.8	45
819	Where Are We Going?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 1798-1799.	1.8	52
820	Aggressive Lipid-Lowering Therapy Compared with Angioplasty in Stable Coronary Artery Disease. <i>New England Journal of Medicine</i> , 1999, 341, 70-76.	13.9	858
821	Upregulation of Endothelial Receptor for Oxidized Low-Density Lipoprotein (LOX-1) in Cultured Human Coronary Artery Endothelial Cells by Angiotensin II Type 1 Receptor Activation. <i>Circulation Research</i> , 1999, 84, 1043-1049.	2.0	304
822	Statins and Blockers of the Renin-Angiotensin System. <i>Hypertension</i> , 1999, 34, 987-996.	1.3	129
823	Numbers needed to treat derived from meta-analyses--sometimes informative, usually misleading. <i>BMJ: British Medical Journal</i> , 1999, 318, 1548-1551.	2.4	258
824	Coronary Heart Disease: Reducing the Risk. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1999, 19, 1819-1824.	1.1	139
825	A review of recent dietary intervention trials in the United Kingdom to reduce blood cholesterol levels. <i>Annals of Human Biology</i> , 1999, 26, 427-442.	0.4	0
826	Effect of the HMG-CoA Reductase Inhibitors on Blood Pressure in Patients With Essential Hypertension and Primary Hypercholesterolemia. <i>Hypertension</i> , 1999, 34, 1281-1286.	1.3	267
827	Delayed Response of Myocardial Flow Reserve to Lipid-Lowering Therapy With Fluvastatin. <i>Circulation</i> , 1999, 99, 475-481.	1.6	153
828	Incidence and determinants of mortality and cardiovascular events in diabetes mellitus: a meta-analysis. <i>Vascular Medicine</i> , 1999, 4, 67-75.	0.8	43
829	Effect of cholesterol lowering treatment on positive exercise tests in patients with hypercholesterolaemia and normal coronary angiograms. <i>Heart</i> , 1999, 82, 689-693.	1.2	15
830	Statins and cerebrovascular disease: plaque attack to prevent brain attack. <i>Vascular Medicine</i> , 1999, 4, 269-272.	0.8	11
831	Gemfibrozil for the Secondary Prevention of Coronary Heart Disease in Men with Low Levels of High-Density Lipoprotein Cholesterol. <i>New England Journal of Medicine</i> , 1999, 341, 410-418.	13.9	3,271
832	Dietary Lipid Lowering Reduces Tissue Factor Expression in Rabbit Atheroma. <i>Circulation</i> , 1999, 100, 1215-1222.	1.6	148

#	ARTICLE	IF	CITATIONS
833	Simvastatin Inhibits Leukocyte-Endothelial Cell Interactions and Protects Against Inflammatory Processes in Normocholesterolemic Rats. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1999, 19, 2894-2900.	1.1	215
834	Low Cholesterol as a Risk Factor for Primary Intracerebral Hemorrhage: A Case-Control Study. <i>Neuroepidemiology</i> , 1999, 18, 185-193.	1.1	89
835	Intracranial Arteries of Human Fetuses Are More Resistant to Hypercholesterolemia-Induced Fatty Streak Formation Than Extracranial Arteries. <i>Circulation</i> , 1999, 99, 2003-2010.	1.6	139
836	Contribution of modern cardiovascular treatment and risk factor changes to the decline in coronary heart disease mortality in Scotland between 1975 and 1994. <i>Heart</i> , 1999, 81, 380-386.	1.2	244
838	Long-Term Effects of Pravastatin on Plasma Concentration of C-reactive Protein. <i>Circulation</i> , 1999, 100, 230-235.	1.6	1,423
839	Preoperative lipid-control with simvastatin reduces the risk of postoperative thrombocytosis and thrombotic complications following CABG1. <i>European Journal of Cardio-thoracic Surgery</i> , 1999, 15, 394-400.	0.6	101
840	Systematic Review on the Risk and Benefit of Different Cholesterol-Lowering Interventions. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1999, 19, 187-195.	1.1	195
841	Clinical utility of lipid and lipoprotein levels during hospitalization for acute myocardial infarction. <i>Vascular Medicine</i> , 1999, 4, 227-231.	0.8	16
842	Primary Prevention of Coronary Heart Disease. <i>Circulation</i> , 1999, 100, 988-998.	1.6	204
843	Evidence for a New Pathophysiological Mechanism for Coronary Artery Disease Regression. <i>Circulation</i> , 1999, 99, 1959-1964.	1.6	250
844	Reduction of Stroke Incidence After Myocardial Infarction With Pravastatin. <i>Circulation</i> , 1999, 99, 216-223.	1.6	410
845	Sex, Age, Cardiovascular Risk Factors, and Coronary Heart Disease. <i>Circulation</i> , 1999, 99, 1165-1172.	1.6	731
846	Factors associated with the use of various medications amongst patients with severe coronary artery disease. <i>Journal of Internal Medicine</i> , 1999, 245, 143-153.	2.7	8
847	Risk Factors for Stroke in Different Levels of Cerebral Arterial Disease. <i>European Neurology</i> , 1999, 42, 150-156.	0.6	32
848	Urinary Albumin Excretion. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1999, 19, 1992-1997.	1.1	382
849	Concurrent use of simvastatin and estrogen-progestin therapy compared with each therapy alone for hypercholesterolemia in postmenopausal women. <i>Climacteric</i> , 1999, 2, 181-188.	1.1	14
850	Genetic prediction of coronary heart disease: Lessons from Canada. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 1999, 59, 153-167.	0.6	1
851	Estimating the population impact of an intervention: a decision-analytic approach. <i>Statistical Methods in Medical Research</i> , 1999, 8, 311-330.	0.7	14

#	ARTICLE	IF	CITATIONS
852	Assessment of Cardiovascular Risk by Use of Multiple-Risk-Factor Assessment Equations. <i>Circulation</i> , 1999, 100, 1481-1492.	1.6	991
853	MRI of Rabbit Atherosclerosis in Response to Dietary Cholesterol Lowering. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1999, 19, 1956-1959.	1.1	93
854	Meta-Analysis of Randomized Trials for Medical Prevention of Calcium Oxalate Nephrolithiasis. <i>Journal of Endourology</i> , 1999, 13, 679-685.	1.1	184
855	Inhibition of Arterial Thrombus Formation by ApoA1 Milano. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1999, 19, 378-383.	1.1	138
856	Lipides et risque cardiovasculaire au cours de l'insuffisance r�onale chronique. <i>Nutrition Clinique Et Metabolisme</i> , 1999, 13, 187-190.	0.2	1
857	A double-blind placebo controlled trial of simvastatin for the treatment of dyslipidaemia in renal allograft recipients. <i>Clinical Transplantation</i> , 1999, 13, 520-525.	0.8	22
858	Enhanced cholesterol reduction by simvastatin in diltiazem-treated patients. <i>British Journal of Clinical Pharmacology</i> , 1999, 48, 610-615.	1.1	28
859	A comparison of the use, effectiveness and safety of bezafibrate, gemfibrozil and simvastatin in normal clinical practice using the New Zealand Intensive Medicines Monitoring Programme (IMMP). <i>British Journal of Clinical Pharmacology</i> , 1999, 47, 99-104.	1.1	21
860	LDL particle size: an important drug target?. <i>British Journal of Clinical Pharmacology</i> , 1999, 48, 125-133.	1.1	54
861	Effect of inhibiting HMG-CoA reductase on 7�-hydroxy-4-cholesten-3-one, a marker of bile acid synthesis: contrasting findings in patients with and without prior up-regulation of the latter pathway. <i>European Journal of Clinical Investigation</i> , 1999, 29, 404-412.	1.7	18
862	Developing risk stratification charts for diabetic and nondiabetic subjects. <i>Diabetic Medicine</i> , 1999, 16, 219-227.	1.2	49
863	Intensive lipid-lowering strategy in patients with diabetes mellitus. <i>Diabetic Medicine</i> , 1999, 16, 500-508.	1.2	21
864	Lack of effect of simvastatin on insulin sensitivity in Type 2 diabetic patients with hypercholesterolaemia: results from a double-blind, randomized, placebo-controlled crossover study. <i>Diabetic Medicine</i> , 1999, 16, 749-754.	1.2	21
865	Non�lipid properties of statins. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 1999, 24, 3-5.	0.7	8
866	Angina and its treatment. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 1999, 24, 171-179.	0.7	0
867	Fluvastatin in combination with cyclosporin in renal transplant recipients: a review of clinical and safety experience. REVIEW ARTICLE. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 1999, 24, 397-408.	0.7	52
868	Clinical importance of coronary endothelial vasodilator dysfunction and therapeutic options. <i>Journal of Internal Medicine</i> , 1999, 245, 315-327.	2.7	84
869	Atherosclerosis seems not to be associated with hyperinsulinaemia in patients with familial hypercholesterolaemia. <i>Journal of Internal Medicine</i> , 1999, 246, 75-80.	2.7	15



#	ARTICLE	IF	CITATIONS
870	Serum cholesterol is a risk factor for myocardial infarction in elderly men and women: the Rotterdam Study. <i>Journal of Internal Medicine</i> , 1999, 246, 25-33.	2.7	38
871	Simvastatin in nephrotic syndrome. <i>Kidney International</i> , 1999, 56, S113-S116.	2.6	46
872	Effecacy of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors for prevention of stroke. <i>Journal of General Internal Medicine</i> , 1999, 14, 763-774.	1.3	32
873	Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease. <i>Journal of General Internal Medicine</i> , 1999, 14, 711-717.	1.3	111
874	Three Low Density Lipoprotein Apheresis Techniques in Treatment of Patients with Familial Hypercholesterolemia: A Longâ€Term Evaluation. <i>Therapeutic Apheresis and Dialysis</i> , 1999, 3, 203-208.	0.6	32
875	Review: The Oxidant/Antioxidant Balance During Regular Low Density Lipoprotein Apheresis. <i>Therapeutic Apheresis and Dialysis</i> , 1999, 3, 219-226.	0.6	38
876	Type 2 diabetes towards the new millennium â€ the relative importance of glycaemic <i>versus</i> lipid control. <i>Australian and New Zealand Journal of Medicine</i> , 1999, 29, 249-253.	0.5	1
877	Endothelial dysfunction, insulin resistance and diabetes: exploring the web of causality. <i>Australian and New Zealand Journal of Medicine</i> , 1999, 29, 523-534.	0.5	16
878	Lipoproteins, atherogenicity, age and risk of myocardial infarction. <i>Australian and New Zealand Journal of Public Health</i> , 1999, 23, 441-442.	0.8	0
879	Mibefradil, a potent CYP3A inhibitor, does not alter pravastatin pharmacokinetics. <i>Fundamental and Clinical Pharmacology</i> , 1999, 13, 232-236.	1.0	18
880	Effect of cerivastatin sodium, a new inhibitor of HMG-CoA reductase, on plasma lipid levels, progression of atherosclerosis, and the lesional composition in the plaques of WHHL rabbits. <i>British Journal of Pharmacology</i> , 1999, 126, 961-968.	2.7	56
881	Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca <sup>2+</sup> signalling and insulin secretion due to blockade of L-type Ca <sup>2+</sup> channels in rat islet Î²-cells. <i>British Journal of Pharmacology</i> , 1999, 126, 1205-1213.	2.7	209
882	Coronary Health Issues for Lesbians. <i>Journal of the Gay and Lesbian Medical Association</i> , 1999, 3, 59-66.	0.6	1
883	New information on the role of beta-blockers in cardiac therapy. , 1999, 13, 469-477.		3
884	Advances in the medical management of acute coronary syndromes. , 1999, 7, 171-189.		7
885	Platelet PIA2 polymorphism and thromboembolic events: from inherited risk to pharmacogenetics. <i>Journal of Thrombosis and Thrombolysis</i> , 1999, 8, 89-103.	1.0	15
886	Pathogenesis and pathology of coronary heart disease syndromes. , 1999, 8, 167-189.		15
887	The importance of randomized clinical trials and evidenceâ€based medicine: A clinician's perspective. <i>Clinical Cardiology</i> , 1999, 22, 6-12.	0.7	21

#	ARTICLE	IF	CITATIONS
888	Electron beam computed tomography: Screening for coronary artery disease. <i>Clinical Cardiology</i> , 1999, 22, 554-558.	0.7	30
893	Lipid lowering and beyond: Results from the CARE study on lipoproteins and inflammation. <i>Herz</i> , 1999, 24, 51-56.	0.4	20
899	Effect of cholesterol-lowering diets on indices of depression and hostility. <i>Annals of Behavioral Medicine</i> , 1999, 21, 98-101.	1.7	2
900	Hyperlipidemia under treatment with proteinase inhibitors. <i>Infection</i> , 1999, 27, 77-81.	2.3	72
901	Joint effects of HMG-CoA reductase inhibitors and eicosapentaenoic acids on serum lipid profile and plasma fatty acid concentrations in patients with hyperlipidemia. <i>International Journal of Clinical and Laboratory Research</i> , 1999, 29, 22-25.	1.0	45
902	Prevention of cardiovascular events in elderly hypercholesterolemic patients. <i>Current Atherosclerosis Reports</i> , 1999, 1, 9-15.	2.0	3
903	New developments in the treatment of low high-density lipoprotein cholesterol. <i>Current Atherosclerosis Reports</i> , 1999, 1, 24-30.	2.0	4
904	Recent developments in the treatment of hypertriglyceridemia. <i>Current Atherosclerosis Reports</i> , 1999, 1, 31-37.	2.0	8
905	The air force/texas coronary atherosclerosis prevention study: implications for preventive cardiology in the general adult US population. <i>Current Atherosclerosis Reports</i> , 1999, 1, 38-43.	2.0	5
906	Effect of lipid-lowering therapy on vasomotion and endothelial function. <i>Current Cardiology Reports</i> , 1999, 1, 238-243.	1.3	14
907	Combination drug therapy for combined hyperlipidemia. <i>Current Cardiology Reports</i> , 1999, 1, 244-250.	1.3	19
908	The hypertension optimal treatment study: What did it give us?. <i>Current Hypertension Reports</i> , 1999, 1, 337-341.	1.5	3
909	New insights into the pharmacodynamic and pharmacokinetic properties of statins. , 1999, 84, 413-428.		674
910	Which strategy is best after myocardial infarction? the beta-blocker strategy plus implantable cardioverter defibrillator trial: rationale and study design <sup>11</sup> This work was sponsored by Guidant Italia, S.r.l., Milan, Italy. Data coordination by INNOVEX s.r.l., Milan, Italy. For a complete list of steering committee members and participating centers, see Appendix.. <i>American Journal of Cardiology</i> , 1999, 83, 104-111.	0.7	26
911	Simvastatin decreases aldehyde production derived from lipoprotein oxidation. <i>American Journal of Cardiology</i> , 1999, 83, 846-851.	0.7	109
912	Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis. <i>American Journal of Cardiology</i> , 1999, 83, 852-856.	0.7	135
913	Low-density lipoprotein cholesterol bulk is the pivotal determinant of atherosclerosis in familial hypercholesterolemia. <i>American Journal of Cardiology</i> , 1999, 83, 1330-1333.	0.7	50
914	Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. <i>American Journal of Cardiology</i> , 1999, 83, 1303-1307.	0.7	242

#	ARTICLE	IF	CITATIONS
915	Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I. American Journal of Cardiology, 1999, 83, 1476-1477.	0.7	118
916	Safety of low-density lipoprotein cholesterol reduction with atorvastatin versus simvastatin in a coronary heart disease population (the TARGET TANGIBLE Trial). American Journal of Cardiology, 1999, 84, 7-13.	0.7	47
917	Frequency of lipid-lowering therapy after a coronary event in Helsinki, Finland. American Journal of Cardiology, 1999, 84, 95.	0.7	2
918	Diabetes, hyperlipidemia, and coronary artery disease. American Journal of Cardiology, 1999, 83, 17-21.	0.7	84
919	Association of lipids and lipoprotein level with total mortality and mortality caused by cardiovascular and cancer diseases (Poland and United States collaborative study on cardiovascular) Tj ETQq0 0 0 mg BT /Overlook 10 TF 5	0.7	12
920	Relation between low-density lipoprotein cholesterol and thoracic aortic atherosclerosis. American Journal of Cardiology, 1999, 84, 603-605.	0.7	24
921	Gender differences in blood thrombogenicity in hyperlipidemic patients and response to pravastatin. American Journal of Cardiology, 1999, 84, 639-643.	0.7	33
922	Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. American Journal of Cardiology, 1999, 84, 811-815.	0.7	128
923	Implantable defibrillators and antiarrhythmic drugs in patients at risk for lethal arrhythmias. American Journal of Cardiology, 1999, 84, 63-68.	0.7	14
924	Effects of hormone replacement therapy on hemostatic cardiovascular risk factors. American Journal of Obstetrics and Gynecology, 1999, 180, 283-289.	0.7	46
925	Current status of calcium channel blockers in patients with cardiovascular disease. Current Problems in Cardiology, 1999, 24, 229-340.	1.1	13
926	Sudden cardiac death. Current Problems in Cardiology, 1999, 24, 461-538.	1.1	15
927	Diagnosis and management of patients with unstable angina. Current Problems in Cardiology, 1999, 24, 681-744.	1.1	15
928	Baseline diene conjugation in LDL lipids. Free Radical Biology and Medicine, 1999, 27, 1141-1150.	1.3	60
929	Retinal and optic nerve head ischemic disorders and atherosclerosis. Progress in Retinal and Eye Research, 1999, 18, 191-221.	7.3	74
930	Is extravasation a Fas-regulated process?. Trends in Molecular Medicine, 1999, 5, 61-67.	2.6	47
931	Pathophysiological Events during Pregnancy Influence the Development of Atherosclerosis in Humans. Trends in Cardiovascular Medicine, 1999, 9, 205-214.	2.3	53
932	Late Survival After Abdominal Aortic Aneurysm Repair. European Journal of Vascular and Endovascular Surgery, 1999, 17, 338-342.	0.8	47

#	ARTICLE	IF	CITATIONS
933	Lipid levels and emotional distress among healthy male college students. <i>Stress and Health</i> , 1999, 15, 159-165.	0.7	3
934	United Kingdom Prospective Diabetes Study (UKPDS): what now or so what?. <i>Diabetes/Metabolism Research and Reviews</i> , 1999, 15, 65-71.	1.7	35
935	Attending the diabetes center is associated with reduced cardiovascular mortality in Type 2 diabetic patients: the Verona Diabetes Study. <i>Diabetes/Metabolism Research and Reviews</i> , 1999, 15, 170-174.	1.7	14
936	Cardiovascular Pharmacology of Hormone Replacement Therapy. <i>Drugs and Aging</i> , 1999, 15, 219-234.	1.3	24
937	Intermittent Claudication in Older Patients. <i>Drugs and Aging</i> , 1999, 14, 247-259.	1.3	10
938	PLAQUE DISRUPTION AND THROMBOSIS. <i>Cardiology Clinics</i> , 1999, 17, 271-281.	0.9	66
939	THE HEALTH CARE BURDEN OF UNSTABLE ANGINA. <i>Cardiology Clinics</i> , 1999, 17, 247-261.	0.9	9
940	THE TREATMENT OF HYPERTENSION AND DYSLIPIDEMIA IN DIABETES MELLITUS. <i>Primary Care - Clinics in Office Practice</i> , 1999, 26, 951-964.	0.7	5
941	Neuroprotective Properties of Statins in Cerebral Ischemia and Stroke. <i>Stroke</i> , 1999, 30, 1969-1973.	1.0	361
942	Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP): A Randomized Trial Design of the Effect of a Community Pharmacist Intervention Program on Serum Cholesterol Risk. <i>Annals of Pharmacotherapy</i> , 1999, 33, 910-919.	0.9	50
943	Pharmacoeconomics of Lipid-Lowering Agents for Primary and Secondary Prevention of Coronary Artery Disease. <i>Pharmacoeconomics</i> , 1999, 15, 47-74.	1.7	77
944	Pharmacoeconomic Consequences of Variable Patient Compliance With Prescribed Drug Regimens. <i>Pharmacoeconomics</i> , 1999, 15, 217-228.	1.7	55
945	Simvastatin After Orthotopic Heart Transplantation. <i>Pharmacoeconomics</i> , 1999, 15, 279-289.	1.7	3
946	1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. <i>Clinical and Experimental Hypertension</i> , 1999, 21, 1009-1060.	0.5	471
948	Lipid management in ischaemic heart disease. <i>Coronary Health Care</i> , 1999, 3, 62-66.	0.4	1
949	Efficacy and safety of atorvastatin and pravastatin in patients with hypercholesterolemia. <i>European Journal of Internal Medicine</i> , 1999, 10, 33-39.	1.0	9
950	Prevention of mortality from coronary heart disease with pravastatin. <i>Biomedicine and Pharmacotherapy</i> , 1999, 53, 405-408.	2.5	0
951	Quality measurement issues in heart disease in women. <i>Women's Health Issues</i> , 1999, 9, 241-249.	0.9	0

#	ARTICLE	IF	CITATIONS
952	Cholesterol management: a review of literature and national cholesterol education program guidelines. Primary Care Update for Ob/Gyns, 1999, 6, 186-191.	0.1	2
953	Lipid-Lowering Medication and Risk of Cancer. Journal of Clinical Epidemiology, 1999, 52, 167-169.	2.4	29
954	Compliance with Fluvastatin Treatment Characterization of the Noncompliant Population within a Population of 3845 Patients with Hyperlipidemia. Journal of Clinical Epidemiology, 1999, 52, 589-594.	2.4	54
955	Lipid-Lowering Medication and Risk of Injury. Journal of Clinical Epidemiology, 1999, 52, 1197-1200.	2.4	1
956	Pharmacological profile of survivors of acute myocardial infarction at Turkish academic hospitals. International Journal of Cardiology, 1999, 68, 309-316.	0.8	8
957	Statin + fibrate combination therapy. International Journal of Cardiology, 1999, 69, 237-244.	0.8	55
958	A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. American Journal of Kidney Diseases, 1999, 33, 694-701.	2.1	271
961	Bilan d'extension de la maladie athéromateuse au cours de la coronaropathie. Étude rétrospective chez 146 patients coronariens en centre de réadaptation. Annales De Réadaptation Et De Médecine Physique: Revue Scientifique De La Société Française De Rééducation Fonctionnelle De Réadaptation Et De Médecine Physique. 1999, 42, 76-81.	0.8	1
962	Coronary risk assessment methods and cholesterol lowering. Lancet, The, 1999, 353, 1096-1097.	6.3	0
963	Benefit of $\beta$ -blockers for heart failure. Lancet, The, 1999, 354, 682.	6.3	1
964	Better coronary risk assessment in women. Lancet, The, 1999, 353, 1637-1638.	6.3	11
965	Indications for cholesterol-lowering medication: comparison of risk-assessment methods. Lancet, The, 1999, 353, 278-281.	6.3	94
966	Clinical trials, consensus conferences, and clinical practice. Lancet, The, 1999, 354, 327-330.	6.3	51
967	Influence of maternal hypercholesterolaemia during pregnancy on progression of early atherosclerotic lesions in childhood: Fate of Early Lesions in Children (FELIC) study. Lancet, The, 1999, 354, 1234-1241.	6.3	564
968	Acute coronary syndromes: Drug treatments. Lancet, The, 1999, 353, s20-s23.	6.3	13
969	Changes in cholesterol levels in women after coronary artery bypass surgery. Heart and Lung: Journal of Acute and Critical Care, 1999, 28, 270-275.	0.8	3
970	Effectiveness of antihyperlipidemic drug management in clinical practice. Clinical Therapeutics, 1999, 21, 1973-1987.	1.1	12
971	Assessment of the impact of fibrates and diet on survival and their cost-effectiveness: evidence from randomized, controlled trials in coronary heart disease and health economic evaluations. Clinical Therapeutics, 1999, 21, 2027-2035.	1.1	7

#	ARTICLE	IF	CITATIONS
972	Use of diagnostic cluster methodology for therapeutic costing and drug surveillance of HMG-CoA reductase-inhibitor therapy. <i>Clinical Therapeutics</i> , 1999, 21, 218-235.	1.1	2
973	Use of a tiered review for evaluation of appropriate use of hydroxymethylglutaryl coenzyme a reductase-inhibitor therapy. <i>Clinical Therapeutics</i> , 1999, 21, 422-429.	1.1	2
974	Double-masked comparison of the quality of life of hypercholesterolemic men treated with simvastatin or pravastatin. <i>Clinical Therapeutics</i> , 1999, 21, 1758-1770.	1.1	6
975	A comparative economic analysis of simvastatin versus atorvastatin: Results of the surrogate marker cost-efficacy (SMaC) study. <i>Clinical Therapeutics</i> , 1999, 21, 1788-1796.	1.1	10
976	Diabetes and Cardiovascular Disease. <i>Circulation</i> , 1999, 100, 1134-1146.	1.6	1,903
977	Influence of baseline lipids on effectiveness of pravastatin in the CARE trial. <i>Journal of the American College of Cardiology</i> , 1999, 33, 125-130.	1.2	81
978	Gender differences in myocardial blood flow dynamics. <i>Journal of the American College of Cardiology</i> , 1999, 33, 463-470.	1.2	75
979	The effects of pravastatin on hospital admission in hypercholesterolemic middle-aged men Appendix. <i>Journal of the American College of Cardiology</i> , 1999, 33, 909-915.	1.2	12
980	A long-term, open-label study of the efficacy and tolerability of policosanol in patients with high global coronary risk. <i>Current Therapeutic Research</i> , 1999, 60, 379-391.	0.5	31
981	NK-104, a potent new 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, enhances posttranslational catabolism of apolipoprotein B-100 and inhibits secretion of apolipoprotein B-100 and triacylglycerols from HepG2 cells. <i>Current Therapeutic Research</i> , 1999, 60, 423-434.	0.5	18
982	Pharmacoepidemiologic study of policosanol. <i>Current Therapeutic Research</i> , 1999, 60, 458-467.	0.5	24
983	Role of the surgeon in managing hypercholesterolemia. <i>Surgery</i> , 1999, 125, 465-467.	1.0	2
984	The effects of lipids on graft outcome. <i>Transplantation Proceedings</i> , 1999, 31, 14-15.	0.3	26
985	Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. <i>Life Sciences</i> , 1999, 65, 1329-1337.	2.0	103
986	Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor on sterol absorption in hypercholesterolemic subjects. <i>Metabolism: Clinical and Experimental</i> , 1999, 48, 68-73.	1.5	13
987	Low-density lipoprotein particle size and coronary artery disease in a childhood-onset type 1 diabetes population. <i>Metabolism: Clinical and Experimental</i> , 1999, 48, 531-534.	1.5	22
988	IMPLICATIONS OF THE UNITED KINGDOM PROSPECTIVE DIABETES STUDY. <i>Primary Care - Clinics in Office Practice</i> , 1999, 26, 809-827.	0.7	12
989	LDL-apheresis: questions for the future. <i>Transfusion Science</i> , 1999, 20, 43-47.	0.6	6

#	ARTICLE	IF	CITATIONS
990	EVALUATING THE CHEST PAIN PATIENT. <i>Cardiology Clinics</i> , 1999, 17, 307-326.	0.9	5
991	IMAGING OF CORONARY ARTERY CALCIFICATION. <i>Radiologic Clinics of North America</i> , 1999, 37, 257-272.	0.9	31
992	THROMBOSIS AND COAGULATION ABNORMALITIES IN THE ACUTE CORONARY SYNDROMES. <i>Cardiology Clinics</i> , 1999, 17, 283-294.	0.9	20
993	Angor estable e inestable: fisiopatología, diagnóstico y modalidades terapéuticas. <i>EMC - Tratado De Medicina</i> , 1999, 1-3, 1-8.	0.0	0
994	Achieving National Cholesterol Education Program Goals for Low-Density Lipoprotein Cholesterol in Cardiac Patients: Importance of Diet, Exercise, Weight Control, and Drug Therapy. <i>Mayo Clinic Proceedings</i> , 1999, 74, 466-473.	1.4	29
995	COST-EFFECTIVENESS OF STRESS-ECHOCARDIOGRAPHY. <i>Cardiology Clinics</i> , 1999, 17, 583-595.	0.9	1
996	HEART FAILURE. <i>Cardiology Clinics</i> , 1999, 17, 123-135.	0.9	30
997	CARDIAC REHABILITATION AND PREVENTIVE CARDIOLOGY IN THE ELDERLY. <i>Cardiology Clinics</i> , 1999, 17, 233-242.	0.9	14
998	Fluvastatin. <i>Drugs</i> , 1999, 57, 583-606.	4.9	66
999	How to Use Calcium Antagonists in Hypertension. <i>Drugs</i> , 1999, 58, 579-587.	4.9	14
1000	Cost of Treating to a Modified European Atherosclerosis Society LDL-C Target. <i>Clinical Drug Investigation</i> , 1999, 17, 185-193.	1.1	22
1001	Evidence-Based Treatments and Prescription Variability after Acute Myocardial Infarction. <i>Clinical Drug Investigation</i> , 1999, 17, 241-250.	1.1	0
1002	Comparison of the Lipid-Lowering Effects of Fluvastatin, Lovastatin and Simvastatin in Patients with Hyperlipoproteinaemia. <i>Clinical Drug Investigation</i> , 1999, 18, 209-215.	1.1	1
1003	A Pooled Efficacy Analysis of Cerivastatin in the Treatment of Primary Hyperlipidaemia. <i>Clinical Drug Investigation</i> , 1999, 18, 433-444.	1.1	13
1004	The Use of Meta-Analysis in Cost-Effectiveness Analysis. <i>Pharmacoeconomics</i> , 1999, 15, 1-8.	1.7	20
1005	Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile. <i>Journal of the American College of Cardiology</i> , 1999, 33, 1294-1304.	1.2	184
1006	Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , 1999, 33, 1286-1293.	1.2	129
1007	<i>The Framingham Offspring Study: a commentary on 50th Anniversary Historical Article</i> INTRODUCTION In this edition of the Journal, we release the fifth in a series of reviews of influential articles that have been previously published in ACC journals, including the American Journal of Cardiology (from 1958 to) Tj ETQq1 1 0,784314,rgBT /Over ACC's 50th anniversary commemoration, which highlights 50 years of leadership in cardiovascular care and ed. <i>Journal of the American College of Cardiology</i> , 1999, 33, 1136-1140.	1.2	112

#	ARTICLE	IF	CITATIONS
1008	Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations. <i>Journal of the American College of Cardiology</i> , 1999, 34, 106-112.	1.2	93
1009	<a href="#">ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina</a>   This document was approved by the American College of Cardiology Board of Trustees in March 1999, the American Heart Association Science Advisory and Coordinating Committee in March 1999, and the American College of Physicians-American Society of Internal Medicine Board of Regents in February 1999. When citing this document, please use the following citation format: Gibbons RJ, Chatterjee K, Daley J, Douglas JS, Fihn SD, G. <i>Journal of the American College of Cardiology</i> , 1999, 33, 2092-2197.	1.2	608
1010	Survival 12 years after randomization to streptokinase: the influence of thrombolysis in myocardial infarction flow at three to four weeks. <i>Journal of the American College of Cardiology</i> , 1999, 34, 62-69.	1.2	35
1011	Cause of death in clinical research. <i>Journal of the American College of Cardiology</i> , 1999, 34, 618-620.	1.2	550
1012	The relative influence of secondary versus primary prevention using the National Cholesterol Education Program Adult Treatment Panel II guidelines. <i>Journal of the American College of Cardiology</i> , 1999, 34, 768-776.	1.2	28
1013	Folic acid improves arterial endothelial function in adults with hyperhomocystinemia. <i>Journal of the American College of Cardiology</i> , 1999, 34, 2002-2006.	1.2	287
1014	Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. <i>Atherosclerosis</i> , 1999, 142, 105-112.	0.4	383
1015	Plasma lipoprotein distribution and lipid transfer activities in patients with type IIb hyperlipidemia treated with simvastatin. <i>Atherosclerosis</i> , 1999, 143, 415-425.	0.4	33
1016	Differential cholesteryl ester accumulation in two human vascular smooth muscle cell subpopulations exposed to aggregated LDL: effect of PDGF-stimulation and HMG-CoA reductase inhibition. <i>Atherosclerosis</i> , 1999, 144, 335-342.	0.4	18
1017	Heart rate variability and plasma lipids in men with and without ischaemic heart disease. <i>Atherosclerosis</i> , 1999, 145, 181-186.	0.4	61
1018	Atherogenicity of lipoprotein(a) and oxidized low density lipoprotein: insight from in vivo studies of arterial wall influx, degradation and efflux. <i>Atherosclerosis</i> , 1999, 143, 229-243.	0.4	93
1019	Nitric oxide synthase II (NOS II) gene expression correlates with atherosclerotic intimal thickening. Preventive effects of HMG-CoA reductase inhibitors. <i>Atherosclerosis</i> , 1999, 145, 325-331.	0.4	58
1020	Best practice "ongoing polemics. <i>Atherosclerosis</i> , 1999, 143, S3-S6.	0.4	3
1021	Guidelines "a missed opportunity. <i>Atherosclerosis</i> , 1999, 143, S7-S12.	0.4	5
1022	The effects of dyslipidemia on left ventricular systolic function in patients with stable angina pectoris. <i>Atherosclerosis</i> , 1999, 146, 117-124.	0.4	29
1023	Triglyceride-rich lipoproteins: are links with atherosclerosis mediated by a procoagulant and proinflammatory phenotype?. <i>Atherosclerosis</i> , 1999, 145, 1-15.	0.4	34
1024	Hypolipidemic effect of NK-104, a potent HMG-CoA reductase inhibitor, in guinea pigs. <i>Atherosclerosis</i> , 1999, 146, 259-270.	0.4	64
1025	Spectrum of LDL receptor gene mutations in Denmark: implications for molecular diagnostic strategy in heterozygous familial hypercholesterolemia. <i>Atherosclerosis</i> , 1999, 146, 337-344.	0.4	39



#	ARTICLE	IF	CITATIONS
1026	Mechanisms modifying atherosclerotic disease " from lipids to vascular biology. <i>Atherosclerosis</i> , 1999, 147, S3-S10.	0.4	54
1027	Beyond lipids " the role of the endothelium in coronary artery disease. <i>Atherosclerosis</i> , 1999, 147, S11-S16.	0.4	40
1028	Evidence for the benefit of early intervention with pravastatin for secondary prevention of cardiovascular events. <i>Atherosclerosis</i> , 1999, 147, S17-S21.	0.4	17
1029	After 4S, CARE and LIPID " is evidence-based medicine being practised?. <i>Atherosclerosis</i> , 1999, 147, S39-S44.	0.4	21
1030	Diabetic dyslipidaemia. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 1999, 13, 265-278.	2.2	19
1031	Diabetes and myocardial infarction. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 1999, 13, 331-343.	2.2	8
1032	Haemostatic function, arterial disease and the prevention of arterial thrombosis. <i>Best Practice and Research in Clinical Haematology</i> , 1999, 12, 577-599.	0.7	18
1033	The role of nuclear cardiology in clinical decision making. <i>Seminars in Nuclear Medicine</i> , 1999, 29, 280-297.	2.5	62
1034	Atherosclerotic disease in non-insulin-dependent diabetes mellitus: Role of abnormal lipids and the place for lipid-altering therapies. <i>American Heart Journal</i> , 1999, 138, S406-S412.	1.2	2
1035	Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders. <i>American Heart Journal</i> , 1999, 138, 151-155.	1.2	70
1036	Diet and atherosclerosis. <i>American Heart Journal</i> , 1999, 138, S426-S430.	1.2	4
1037	Secondary prevention trials for coronary artery disease with antibiotic treatment for <i>Chlamydia pneumoniae</i> : Design issues. <i>American Heart Journal</i> , 1999, 138, S545-S549.	1.2	20
1038	Statin trials and goals of cholesterol-lowering therapy after AMI. <i>American Heart Journal</i> , 1999, 138, S177-S182.	1.2	23
1039	Trends in clinical and economic outcomes of coronary angioplasty from 1992 to 1995: A population-based analysis. <i>American Heart Journal</i> , 1999, 137, 1012-1018.	1.2	8
1040	Comparative economic data regarding lipid-lowering drugs. <i>American Heart Journal</i> , 1999, 137, S97-S104.	1.2	6
1041	Economics and cost-effectiveness in evaluating the value of cardiovascular therapy: Lipid-lowering therapies " an industry perspective. <i>American Heart Journal</i> , 1999, 137, S105-S110.	1.2	4
1042	Primary prevention of coronary heart disease: selection of patients for aggressive cholesterol management. <i>American Journal of Medicine</i> , 1999, 107, 2-6.	0.6	7
1043	Lipid management in patients at moderate risk for coronary heart disease: insights from the Air Force/Texas coronary atherosclerosis prevention study (AFCAPS/TexCAPS). <i>American Journal of Medicine</i> , 1999, 107, 36-39.	0.6	16

#	ARTICLE	IF	CITATIONS
1044	Cholesterol lowering and endothelial function. American Journal of Medicine, 1999, 107, 479-487.	0.6	130
1045	Effects of dietary phytosterols on cholesterol metabolism and atherosclerosis: clinical and experimental evidence. American Journal of Medicine, 1999, 107, 588-594.	0.6	236
1046	Retrobulbar and peripheral capillary blood flow in hypercholesterolemic subjects. American Journal of Ophthalmology, 1999, 128, 310-316.	1.7	10
1047	Low Density Lipoprotein (LDL)-Mediated Suppression of Lewis Lung Carcinoma in Hypercholesterolemic LDL Receptor-Deficient Mice. Biochemical and Biophysical Research Communications, 1999, 255, 377-381.	1.0	4
1048	Cardiovascular Risk Factors in Italy. Preventive Medicine, 1999, 29, S111-S118.	1.6	6
1049	Issues for Cardiovascular Disease Risk Factor Development in Europe. Preventive Medicine, 1999, 29, S96-S101.	1.6	3
1050	Cancer and Low Levels of Plasma Cholesterol: The Relevance of Cholesterol Precursors and Products to Incidence of Cancer. Preventive Medicine, 1999, 29, 383-390.	1.6	20
1051	How the Health Care System Can Influence Cardiovascular Disease Risk Factors. Preventive Medicine, 1999, 29, S66-S71.	1.6	1
1052	Secondary Prevention with Lipid Lowering Therapy in Familial Hypercholesterolemia: A Correlation between New Evolution of Stenotic Lesion and Achieved Cholesterol Levels after Revascularization Procedures.. Internal Medicine, 1999, 38, 330-335.	0.3	5
1053	Role of Hyperinsulinemia in Atherosclerotic Coronary Arterial Disease. Studies of Semi-quantitative Coronary Angiography.. Internal Medicine, 1999, 38, 691-697.	0.3	27
1054	Periodic Health Examination and Screening Tests in Adults. Hospital Practice (1995), 1999, 34, 117-126.	0.5	5
1055	A simple computer program for guiding management of cardiovascular risk factors and prescribing. BMJ: British Medical Journal, 1999, 318, 101-105.	2.4	100
1056	THE L-ARGININE - NITRIC OXIDE PATHWAY: ROLE AS AN ANTIOXIDANT MECHANISM IN ATHEROSCLEROSIS. , 1999, , 46-51.		0
1057	Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. American Journal of Clinical Nutrition, 1999, 69, 231-236.	2.2	453
1058	The Effect of the Menopause on Women at Risk of Heart Disease. The Journal of the British Menopause Society, 1999, 5, 30-35.	1.3	0
1059	The Effect of Converting from Pravastatin to Simvastatin on the Pharmacodynamics of Warfarin. Journal of Clinical Pharmacology, 1999, 39, 86-90.	1.0	27
1060	Electronic Monitoring of Compliance to Lipid-Lowering Therapy in Clinical Practice. Journal of Clinical Pharmacology, 1999, 39, 402-409.	1.0	72
1061	Individually randomized intervention trials for disease prevention and control. Statistical Methods in Medical Research, 1999, 8, 287-309.	0.7	14

#	ARTICLE	IF	CITATIONS
1062	Achieving National Cholesterol Education Program Goals for Low-Density Lipoprotein Cholesterol in Cardiac Patients: Importance of Diet, Exercise, Weight Control, and Drug Therapy. Mayo Clinic Proceedings, 1999, 74, 466-473.	1.4	43
1063	Increased cardiovascular mortality in hypertensive patients with renal artery stenosis. Relation to sympathetic activation, renal function and treatment regimens. Journal of Hypertension, 1999, 17, 1743-1750.	0.3	103
1064	Does the Intervention of Identifying Homeless Clients Who Should Receive Lipid Altering Therapy Decrease the Occurrence of Cardiovascular Events?. Journal of Pharmacy Practice, 1999, 12, 166-169.	0.5	0
1065	Less heat, more light. Current Opinion in Lipidology, 1999, 10, 219-224.	1.2	2
1066	Underutilization of Cardiac Medications in the Pacemaker Selection in the Elderly Study. Journal of the American Geriatrics Society, 1999, 47, 252-255.	1.3	2
1067	1999 World Health Organization "International Society of Hypertension Guidelines for the Management of Hypertension. Blood Pressure, 1999, 8, 9-43.	0.7	303
1068	Association of low serum total cholesterol with major depression and suicide. British Journal of Psychiatry, 1999, 175, 259-262.	1.7	204
1069	Managing Dyslipidemia in Older Adults <sup>1</sup> . Journal of the American Geriatrics Society, 1999, 47, 1458-1465.	1.3	20
1070	The Treatment and Prevention of Coronary Heart Disease in Canada: Do Older Patients Receive Efficacious Therapies?. Journal of the American Geriatrics Society, 1999, 47, 811-818.	1.3	38
1071	Implication of recent trials with b-hydroxy-b-methylglutaryl coenzyme A reductase inhibitors for hypertension management. Journal of Hypertension, 1999, 17, 1641-1646.	0.3	1
1072	Nutrition. Current Opinion in Lipidology, 1999, 10, 1-2.	1.2	0
1073	Pharmacological Effects of HMG CoA Reductase Inhibitors Other Than Lipoprotein Modulation. Journal of Clinical Pharmacology, 1999, 39, 111-118.	1.0	41
1074	Cholesterol Paradox in Patients with Paroxysmal Atrial Fibrillation. Cardiology, 1999, 92, 21-27.	0.6	74
1078	Development of Acute Coronary Syndrome and Progression of Coronary Artery Disease. A Serial Clinical-angiographic Analysis.. Internal Medicine, 2000, 39, 331-333.	0.3	1
1079	Treatment of Hyperlipidemia.. Internal Medicine, 2000, 39, 765-772.	0.3	3
1082	Economics notes: Use of unequal randomisation to aid the economic efficiency of clinical trials. BMJ: British Medical Journal, 2000, 321, 759-759.	2.4	24
1083	Ten year audit of secondary prevention in coronary bypass patients. BMJ: British Medical Journal, 2000, 321, 22-23.	2.4	14
1084	Cost-Effectiveness of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor Therapy in Older Patients with Myocardial Infarction. Annals of Internal Medicine, 2000, 132, 780.	2.0	84

#	ARTICLE	IF	CITATIONS
1085	Improving Diabetes Care in a Large Health Care System: An Enhanced Primary Care Approach. The Joint Commission Journal on Quality Improvement, 2000, 26, 615-622.	1.5	75
1086	Risk Factors and Stroke Prevention. Cerebrovascular Diseases, 2000, 10, 12-21.	0.8	46
1087	Cholesterol Reduction and Stroke Occurrence: An Overview of Randomized Clinical Trials. Cerebrovascular Diseases, 2000, 10, 85-92.	0.8	97
1088	Preventing ischemic stroke. Postgraduate Medicine, 2000, 107, 34-50.	0.9	18
1089	n-6/n-3 Ratio of Dietary Fatty Acids Rather Than Hypercholesterolemia As the Major Risk Factor for Atherosclerosis and Coronary Heart Disease.. Journal of Health Science, 2000, 46, 157-177.	0.9	31
1090	Risk Factors for Non-Fatal Acute Myocardial Infarction in Middle-Aged and Older Japanese. Japanese Circulation Journal, 2000, 64, 103-109.	1.0	33
1091	Effect of Long-Term Cholesterol-Lowering Treatment With HMG-CoA Reductase Inhibitor (Simvastatin) on Myocardial Perfusion Evaluated by Thallium-201 Single Photon Emission Computed Tomography. Japanese Circulation Journal, 2000, 64, 177-182.	1.0	9
1092	Origin of atherosclerosis in childhood and adolescence. American Journal of Clinical Nutrition, 2000, 72, 1307s-1315s.	2.2	480
1093	Treatment of stable angina. BMJ: British Medical Journal, 2000, 321, 62-63.	2.4	8
1094	Statins: where are we now?. British Journal of Hospital Medicine, 2000, 61, 789-792.	0.3	2
1095	Cholesterol Lowering With Pravastatin Improves Resistance Artery Endothelial Function. Chest, 2000, 118, 756-760.	0.4	23
1096	Use of statins in general practices, 1996-8: cross sectional study. BMJ: British Medical Journal, 2000, 320, 1583-1584.	2.4	38
1097	Treating dyslipidaemia in primary care. BMJ: British Medical Journal, 2000, 321, 1299-1300.	2.4	20
1098	Identifying patients with ischaemic heart disease in general practice: cross sectional study of paper and computerised medical records. BMJ: British Medical Journal, 2000, 321, 548-550.	2.4	54
1099	Percutaneous transluminal coronary angioplasty versus medical treatment for non-acute coronary heart disease: meta-analysis of randomised controlled trials. BMJ: British Medical Journal, 2000, 321, 73-77.	2.4	209
1100	Lipoprotein(a), Other Lipoproteins and Hemostatic Profiles in Patients with Ischemic Stroke: The Relation to Cardiogenic Embolism. Cerebrovascular Diseases, 2000, 10, 110-117.	0.8	29
1101	Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey. BMJ: British Medical Journal, 2000, 321, 1322-1325.	2.4	138
1102	Lipid-lowering drug therapy: more knowledge leads to more problems for composers of guidelines. Current Opinion in Lipidology, 2000, 11, 345-349.	1.2	4

#	ARTICLE	IF	CITATIONS
1103	EPIDEMIOLOGIC DATA IN CLINICAL PRACTICE. Journal of the American Geriatrics Society, 2000, 48, 1157-1162.	1.3	51
1104	Is Hypercholesterolemia a Risk Factor and Should it Be Treated in the Elderly?. American Journal of Health Promotion, 2000, 14, 347-356.	0.9	13
1105	Incorporation of Lean Red Meat into a National Cholesterol Education Program Step I Diet: A Long-Term, Randomized Clinical Trial in Free-Living Persons with Hypercholesterolemia. Journal of the American College of Nutrition, 2000, 19, 351-360.	1.1	40
1106	Pharmaceutical Care Services and Results in Project ImPACT: Hyperlipidemia. Journal of the American Pharmacists Association, 2000, 40, 157-165.	0.6	194
1107	Smoking cessation for the secondary prevention of coronary heart disease. , 2000, , CD003041.		27
1109	Emerging concepts in metabolic abnormalities associated with coronary artery disease. Current Opinion in Cardiology, 2000, 15, 416-421.	0.8	50
1110	Quantification of the physiological relevance of a coronary stenosis using myocardial contrast echocardiography. Coronary Artery Disease, 2000, 11, 203-209.	0.3	3
1111	Pravastatin Treatment of Very Low Density, Intermediate Density and Low Density Lipoproteins in Hypercholesterolemia and Combined Hyperlipidemia Secondary to the Nephrotic Syndrome. American Journal of Nephrology, 2000, 20, 12-17.	1.4	13
1112	At what level of coronary heart disease risk should a statin be prescribed?. Current Opinion in Lipidology, 2000, 11, 363-367.	1.2	12
1113	Therapeutic approaches to reducing the LDL- and HDL-associated risks of coronary heart disease. Current Opinion in Lipidology, 2000, 11, 567-570.	1.2	5
1114	Flow Cytometric Assessment of Effects of Fluvastatin on Low-Density Lipoprotein Receptor Activity in Stimulated T-Lymphocytes from Patients with Heterozygous Familial Hypercholesterolemia. Journal of Clinical Pharmacology, 2000, 40, 421-429.	1.0	5
1115	Lipid-lowering drug therapies: the evidence. Proceedings of the Nutrition Society, 2000, 59, 423-424.	0.4	0
1116	The prescribing of lipid lowering drugs during a 1-year period: analysis of 7490 health insurance files. , 2000, 9, 119-126.		6
1117	MANAGING DYSLIPIDAEMIA IN TYPE 2 DIABETES IN PRIMARY CARE. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2000, 17, S1-S8.	0.2	1
1118	Commentary: Pharmacoeconomics and Outcomes Research: Expanding the Healthcare "Outcomes" Market. Value in Health, 2000, 3, 181-185.	0.1	1
1119	Predictors of Long-term Persistence on Statins in a Subsidized Clinical Population. Value in Health, 2000, 3, 417-426.	0.1	101
1120	Health Promotion Practices of the Older Adult. Public Health Nursing, 2000, 17, 160-168.	0.7	34
1121	Low Density Lipoprotein Apheresis in Treatment of Hyperlipidemia: Experience with Four Different Technologies. Therapeutic Apheresis and Dialysis, 2000, 4, 213-217.	0.6	17

#	ARTICLE	IF	CITATIONS
1122	Diabetes and vascular disease. <i>Diabetes, Obesity and Metabolism</i> , 2000, 2, 1-5.	2.2	9
1123	Vascular disease prevention in patients with diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2000, 2, 25-36.	2.2	5
1124	Ethnicity and risk factors for coronary heart disease in diabetes mellitus. <i>Diabetes, Obesity and Metabolism</i> , 2000, 2, 91-97.	2.2	28
1125	Implications of cardiovascular risk in patients with type 2 diabetes who have abnormal lipid profiles: is lower enough?. <i>Diabetes, Obesity and Metabolism</i> , 2000, 2, 263-270.	2.2	4
1126	Comparative efficacy study of atorvastatin vs. simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia. <i>Diabetes, Obesity and Metabolism</i> , 2000, 2, 355-362.	2.2	56
1127	Letters. <i>Diabetic Medicine</i> , 2000, 17, 623-624.	1.2	4
1128	Evidence-based patient information in diabetes. <i>Diabetic Medicine</i> , 2000, 17, 823-829.	1.2	54
1129	Lack of adherence to lipid-lowering drug treatment. A comparison of utilization patterns in defined populations in Funen, Denmark and Bologna, Italy. <i>British Journal of Clinical Pharmacology</i> , 2000, 49, 463-471.	1.1	49
1130	Effects of policosanol treatment on the susceptibility of low density lipoprotein (LDL) isolated from healthy volunteers to oxidative modification in vitro. <i>British Journal of Clinical Pharmacology</i> , 2000, 50, 255-262.	1.1	64
1131	Therapeutics Drugs used in secondary prevention after myocardial infarction: Case presentation. <i>British Journal of Clinical Pharmacology</i> , 2000, 50, 405-417.	1.1	3
1132	Additive effects of Simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients. <i>European Journal of Clinical Investigation</i> , 2000, 30, 980-987.	1.7	122
1133	Factors associated with low compliance with lipid-lowering drugs in hyperlipidemic patients. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2000, 25, 445-451.	0.7	116
1134	Bezafibrate and simvastatin combination therapy for diabetic dyslipidaemia: efficacy and safety. <i>Journal of Internal Medicine</i> , 2000, 247, 563-569.	2.7	93
1135	Effects of simvastatin on hepatic cholesterol metabolism, bile lithogenicity and bile acid hydrophobicity in patients with gallstones. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15, 871-879.	1.4	29
1136	Are statins anti-inflammatory?. <i>Current Controlled Trials in Cardiovascular Medicine</i> , 2000, 1, 161.	1.5	84
1137	Reproducibility of volumetric quantification in intravascular ultrasound images. <i>Ultrasound in Medicine and Biology</i> , 2000, 26, 367-374.	0.7	25
1138	Endothelial Nitric Oxide Synthase-Dependent Cerebral Blood Flow Augmentation by L-Arginine After Chronic Statin Treatment. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2000, 20, 709-717.	2.4	134
1139	The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals.. <i>Nature Medicine</i> , 2000, 6, 1004-1010.	15.2	1,355

#	ARTICLE	IF	CITATIONS
1140	Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. <i>British Journal of Pharmacology</i> , 2000, 129, 1748-1754.	2.7	292
1141	Characterization of endothelial factors involved in the vasodilatory effect of simvastatin in aorta and small mesenteric artery of the rat. <i>British Journal of Pharmacology</i> , 2000, 131, 1179-1187.	2.7	54
1142	Inhibition of Monocyte Chemotactic Protein-1 Synthesis by Statins. <i>Laboratory Investigation</i> , 2000, 80, 1095-1100.	1.7	282
1143	The influence of cholesterol on mortality after transplantation is age dependent. <i>Transplant International</i> , 2000, 13, S117-S119.	0.8	1
1144	Progress in Interventional Cardiology. <i>Journal of Interventional Cardiology</i> , 2000, 13, 73-76.	0.5	0
1145	Plant Stanol/Sterol Ester-Containing Foods and Cardiovascular Disease Risk. <i>Nutrition in Clinical Care: an Official Publication of Tufts University</i> , 2000, 3, 274-278.	0.2	6
1147	Optimising care of acute myocardial infarction: Results of a regional quality improvement project. <i>Journal of Quality in Clinical Practice</i> , 2000, 20, 12-19.	0.5	25
1148	Food for prevention of coronary heart disease: Beyond the low fat, low cholesterol diet. <i>Asia Pacific Journal of Clinical Nutrition</i> , 2000, 9, S86-S90.	0.3	2
1149	HMG-CoA reductase activity in human liver microsomes: comparative inhibition by statins. <i>Experimental and Toxicologic Pathology</i> , 2000, 52, 145-148.	2.1	29
1150	Obesity and cardiovascular disease. <i>Journal of Diabetes and Its Complications</i> , 2000, 14, 154-174.	1.2	123
1151	Modern Management of Acute Myocardial Infarction. <i>Current Problems in Cardiology</i> , 2000, 25, 677-782.	1.1	10
1152	Relationship between Benign Prostatic Hyperplasia and History of Coronary Artery Disease in Elderly Men. <i>Pharmacotherapy</i> , 2000, 20, 383-386.	1.2	29
1153	Impact of Pharmacy Counseling on Compliance and Effectiveness of Combination Lipid-Lowering Therapy in Patients Undergoing Coronary Artery Revascularization: A Randomized, Controlled Trial. <i>Pharmacotherapy</i> , 2000, 20, 410-416.	1.2	107
1154	The prevalence and prognostic significance of electrocardiographic abnormalities. <i>Current Problems in Cardiology</i> , 2000, 25, 1-72.	1.1	87
1155	Update in Internal Medicine. <i>Archives of Medical Research</i> , 2000, 31, 329-352.	1.5	0
1156	Low cholesterol and violent crime. <i>Journal of Psychiatric Research</i> , 2000, 34, 301-309.	1.5	108
1157	Coronary artery bypass surgery with arterial grafts in familial hypercholesterolemia. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2000, 119, 1008-1014.	0.4	8
1158	A novel telephone-based system for management of secondary prevention to a low-density lipoprotein cholesterol $\geq 100$ mg/dl. <i>American Journal of Cardiology</i> , 2000, 85, 305-308.	0.7	39

#	ARTICLE	IF	CITATIONS
1159	Raising low levels of high-density lipoprotein cholesterol is an important target of therapy. American Journal of Cardiology, 2000, 85, 645-650.	0.7	49
1160	Effect of statin therapy on restenosis after coronary stent implantation. American Journal of Cardiology, 2000, 85, 962-968.	0.7	141
1161	Cholesterol management in the era of managed care. American Journal of Cardiology, 2000, 85, 3-9.	0.7	20
1162	Rationale and design of the cardiac hospitalization atherosclerosis management program at the University of California Los Angeles. American Journal of Cardiology, 2000, 85, 10-17.	0.7	76
1163	Secondary prevention in a cardiology group practice and hospital setting after a heart-care initiative. American Journal of Cardiology, 2000, 85, 23-29.	0.7	15
1164	Strategies for implementing lipid-lowering therapy: pharmacy-based approach. American Journal of Cardiology, 2000, 85, 30-35.	0.7	25
1165	Optimizing treatment of dyslipidemia in patients with coronary artery disease in the managed-care environment (the Rocky Mountain Kaiser Permanente Experience). American Journal of Cardiology, 2000, 85, 36-42.	0.7	34
1166	Is It Wise to Restrict Fat in the Diets of Children?. Journal of the American Dietetic Association, 2000, 100, 28-32.	1.3	32
1167	Dietitian Intervention Improves Lipid Values and Saves Medication Costs in Men with Combined Hyperlipidemia and a History of Niacin Noncompliance. Journal of the American Dietetic Association, 2000, 100, 218-224.	1.3	43
1168	Post-hospitalization management of high-risk coronary patients. American Journal of Cardiology, 2000, 85, 13-20.	0.7	121
1169	Noninvasive strategies for the estimation of cardiac risk in stable chest pain patients. American Journal of Cardiology, 2000, 86, 1-7.	0.7	79
1170	Management of coronary risk factors by registered nurses versus usual care in patients with unstable angina pectoris (a chest pain evaluation in the emergency room [CHEER] substudy). American Journal of Cardiology, 2000, 86, 133-138.	0.7	47
1171	Aggressive lipid-lowering initiation abates new cardiac events (ALLIANCE)â€”rationale and design of atorvastatin versus usual care in hypercholesterolemic patients with coronary artery disease. American Journal of Cardiology, 2000, 86, 250-252.	0.7	28
1172	Follow-up study of patients randomized in the scandinavian simvastatin survival study (4S) of cholesterol lowering. American Journal of Cardiology, 2000, 86, 257-262.	0.7	255
1173	Effects of age, sex, race, diagnosis-related group, and hospital setting on lipid management in patients with coronary artery disease. American Journal of Cardiology, 2000, 86, 328-330.	0.7	11
1174	Bridging the treatment gap. American Journal of Cardiology, 2000, 85, 3-7.	0.7	86
1175	Population benefits of cholesterol reduction: epidemiology, economics, and ethics. American Journal of Cardiology, 2000, 85, 20-23.	0.7	33
1176	Lipid-lowering therapy after coronary revascularization. American Journal of Cardiology, 2000, 86, 18H-28H.	0.7	16



#	ARTICLE	IF	CITATIONS
1177	Cholesterol lowering in atherosclerosis. American Journal of Cardiology, 2000, 86, 29H-34H.	0.7	18
1178	Development of tachyphylaxis among patients taking HMG CoA reductase inhibitors. American Journal of Cardiology, 2000, 86, 1123-1127.	0.7	22
1179	Effect of lovastatin on cardiovascular resource utilization and costs in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). American Journal of Cardiology, 2000, 86, 1176-1181.	0.7	34
1180	Lipid treatment goals achieved in patients treated with statin drugs in Norwegian general practice. American Journal of Cardiology, 2000, 86, 1250-1253.	0.7	27
1181	Should intensive cholesterol lowering play a role in the management of acute coronary syndromes?. American Journal of Cardiology, 2000, 86, 35-42.	0.7	6
1182	Exploring new strategies for the management of acute coronary syndromes. American Journal of Cardiology, 2000, 86, 44-49.	0.7	13
1183	Beneficial effects of pravastatin (±colestyramine/niacin) initiated immediately after a coronary event (the randomized lipid-coronary artery disease [L-CAD] study). American Journal of Cardiology, 2000, 86, 1293-1298.	0.7	145
1184	Matching cardiac rhythm management technology to patient needs: pacing/ablation/implantable cardioverter defibrillators. American Journal of Cardiology, 2000, 86, K58-K70.	0.7	1
1185	Coronary artery injury and the biology of atherosclerosis: inflammation, thrombosis, and stabilization. American Journal of Cardiology, 2000, 86, 3-8.	0.7	190
1186	Medical therapy of unstable angina and non-“q-wave myocardial infarction. American Journal of Cardiology, 2000, 86, 24-33.	0.7	12
1187	Introduction. American Journal of Cardiology, 2000, 86, 1-4.	0.7	1
1188	Serum lipid levels during and after adjuvant toremifene or tamoxifen therapy for breast cancer. Breast Cancer Research and Treatment, 2000, 63, 225-234.	1.1	46
1189	Is it advantageous to lower cholesterol in the elderly hypertensive?. Cardiovascular Drugs and Therapy, 2000, 14, 397-405.	1.3	22
1190	Early experience with intravascular ultrasound in evaluating the effect of statins on femoropopliteal arterial disease: hypothesis-generating observations in humans. Cardiovascular Drugs and Therapy, 2000, 14, 635-641.	1.3	6
1191	Drug interactions with colesevelam hydrochloride, a novel, potent lipid-lowering agent. Cardiovascular Drugs and Therapy, 2000, 14, 681-690.	1.3	83
1192	Other primary prevention trials-what is clinically and economically necessary?. , 2000, 4, 109-115.		3
1193	The effects of soy protein in women and men with elevated plasma lipids. BioFactors, 2000, 12, 251-257.	2.6	50
1194	Overview of the relationship between ischemia and congestive heart failure. Clinical Cardiology, 2000, 23, IV-4-IV-8.	0.7	33

#	ARTICLE	IF	CITATIONS
1195	Comparison of the efficacy and tolerability of simvastatin and atorvastatin in the treatment of hypercholesterolemia. <i>Clinical Cardiology</i> , 2000, 23, 682-688.	0.7	28
1196	Pathophysiology of atherosclerosis: Development, regression, restenosis. <i>Current Atherosclerosis Reports</i> , 2000, 2, 251-258.	2.0	7
1197	Percutaneous coronary intervention versus medical therapy for coronary heart disease. <i>Current Atherosclerosis Reports</i> , 2000, 2, 290-296.	2.0	8
1198	Treating ambulatory ischemia in coronary disease by manipulating the cell biology of atherosclerosis. <i>Current Atherosclerosis Reports</i> , 2000, 2, 321-326.	2.0	4
1199	Insulin resistance in human partial lipodystrophy. <i>Current Atherosclerosis Reports</i> , 2000, 2, 397-404.	2.0	12
1200	Lipid modulation and atherosclerotic events: Extending the clinical spectrum with fibrates and statins. <i>Current Atherosclerosis Reports</i> , 2000, 2, 11-13.	2.0	1
1201	Do pleiotropic effects of statins beyond lipid alterations exist in vivo? What are they and how do they differ between statins?. <i>Current Atherosclerosis Reports</i> , 2000, 2, 20-25.	2.0	20
1202	Re-emergence of fibrates in the management of dyslipidemia and cardiovascular risk. <i>Current Atherosclerosis Reports</i> , 2000, 2, 29-35.	2.0	46
1203	Nonpharmacologic and pharmacologic treatment of patients with low levels of high-density lipoprotein cholesterol. <i>Current Atherosclerosis Reports</i> , 2000, 2, 58-63.	2.0	6
1204	Cholesterol, stroke risk, and stroke prevention. <i>Current Atherosclerosis Reports</i> , 2000, 2, 92-96.	2.0	35
1205	Basic mechanisms of stroke prevention with lipid-lowering therapy. <i>Current Atherosclerosis Reports</i> , 2000, 2, 120-125.	2.0	2
1206	Benefits of lipid-lowering agents in stroke and coronary heart disease: Pharmacoeconomics. <i>Current Atherosclerosis Reports</i> , 2000, 2, 144-150.	2.0	4
1207	Global risk assessment for lipid therapy to prevent coronary heart disease. <i>Current Cardiology Reports</i> , 2000, 2, 424-432.	1.3	0
1208	Implications of the Atorvastatin. <i>Current Cardiology Reports</i> , 2000, 2, 433-438.	1.3	5
1209	Primary prevention of coronary heart disease: Implications of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). <i>Current Cardiology Reports</i> , 2000, 2, 439-444.	1.3	4
1210	The role of fibric acid derivatives in the secondary prevention of coronary heart disease. <i>Current Cardiology Reports</i> , 2000, 2, 452-458.	1.3	4
1211	Are statins anti-inflammatory? Issues in the design and conduct of the pravastatin inflammation C-reactive protein evaluation. <i>Current Cardiology Reports</i> , 2000, 2, 269-273.	1.3	15
1212	Hypercholesterolemia and dyslipidemia. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2000, 2, 173-187.	0.4	8

#	ARTICLE	IF	CITATIONS
1213	Ischemic heart disease. Current Treatment Options in Cardiovascular Medicine, 2000, 2, 27-35.	0.4	0
1214	Unstable angina. Current Treatment Options in Cardiovascular Medicine, 2000, 2, 37-53.	0.4	0
1215	Current concepts in secondary prevention after acute myocardial infarction. Herz, 2000, 25, 47-60.	0.4	6
1217	Thrombolytic therapy in acute myocardial infarction: Third Irish Working Party Consensus. Irish Journal of Medical Science, 2000, 169, 97-99.	0.8	2
1218	The potential for drug interactions with statin therapy in Ireland. Irish Journal of Medical Science, 2000, 169, 176-179.	0.8	40
1219	Role of platelets in tissue factor expression by monocytes in normal and hypercholesterolemic subjects. In vitro effect of cerivastatin. International Journal of Clinical and Laboratory Research, 2000, 30, 147-156.	1.0	27
1220	Cholesterol and strokes. BMJ: British Medical Journal, 2000, 320, 459-460.	2.4	27
1221	Indications for Treatment of Asymptomatic Carotid Stenosis. Neurosurgery Clinics of North America, 2000, 11, 247-264.	0.8	2
1222	Analytical and Clinical Evaluation of Two Homogeneous Assays for LDL-Cholesterol in Hyperlipidemic Patients. Clinical Chemistry, 2000, 46, 1121-1131.	1.5	61
1223	Pravastatin Use and Risk of Coronary Events and Cerebral Infarction in Japanese Men with Moderate Hypercholesterolemia : The Kyushu Lipid Intervention Study. Journal of Atherosclerosis and Thrombosis, 2000, 7, 110-121.	0.9	78
1224	nâ~3 Fatty acids and the prevention of coronary atherosclerosis. American Journal of Clinical Nutrition, 2000, 71, 224S-227S.	2.2	138
1225	Relative Induction of mRNA for HMG CoA Reductase and LDL Receptor by Five Different HMG-CoA Reductase Inhibitors in Cultured Human Cells. Journal of Atherosclerosis and Thrombosis, 2000, 7, 138-144.	0.9	67
1226	Dietary fat and adult diseases and the implications for childhood nutrition: an epidemiologic approach. American Journal of Clinical Nutrition, 2000, 72, 1291s-1296s.	2.2	81
1227	Interim Monitoring in Clinical Trials: Its Necessity. Japanese Journal of Biometrics, 2000, 21, S1-S25.	0.0	0
1228	Hypertriglyceridemia and Coronary Heart Disease. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2098-2105.	1.8	14
1229	Pravastatin Attenuates Cardiovascular Inflammatory and Proliferative Changes in a Rat Model of Chronic Inhibition of Nitric Oxide Synthesis by Its Cholesterol-Lowering Independent Actions.. Hypertension Research, 2000, 23, 353-358.	1.5	34
1230	Direct Effects of Statins on Cells Primarily Involved in Atherosclerosis.. Hypertension Research, 2000, 23, 187-192.	1.5	39
1231	Simvastatin upregulates coronary vascular endothelial nitric oxide production in conscious dogs. American Journal of Physiology - Heart and Circulatory Physiology, 2000, 279, H2649-H2657.	1.5	82

#	ARTICLE	IF	CITATIONS
1232	Special Turku Coronary Risk Factor Intervention Project for Babies (STRIP). <i>American Journal of Clinical Nutrition</i> , 2000, 72, 1316s-1331s.	2.2	51
1233	Prognostic Factors for Acute Myocardial Infarction with Cardiogenic Shock. <i>The Showa University Journal of Medical Sciences</i> , 2000, 12, 175-180.	0.1	0
1234	Regular review: Treatment possibilities for unstable angina. <i>BMJ: British Medical Journal</i> , 2000, 321, 1269-1275.	2.4	8
1235	Management of Resistant Hypertension in Patients with Carotid Stenosis: High Prevalence of Renovascular Hypertension. <i>Cerebrovascular Diseases</i> , 2000, 10, 249-254.	0.8	28
1236	Comparison of the Effect of Blood Pressure on the Development of Stroke, Acute Myocardial Infarction, and End-Stage Renal Disease.. <i>Hypertension Research</i> , 2000, 23, 143-149.	1.5	37
1237	What is the optimal age for starting lipid lowering treatment? A mathematical model. <i>BMJ: British Medical Journal</i> , 2000, 320, 1134-1140.	2.4	34
1238	Evaluation of a Homogeneous Direct LDL-Cholesterol Assay in Diabetic Patients: Effect of Glycemic Control. <i>Clinical Chemistry</i> , 2000, 46, 1848-1851.	1.5	23
1239	Opportunistic Discovery of Occult Disease by Use of Test Panels in New, Symptomatic Primary Care Outpatients: Yield and Cost of Case Finding. <i>Clinical Chemistry</i> , 2000, 46, 1091-1098.	1.5	6
1240	Evaluation of Two Different Homogeneous Assays for LDL-Cholesterol in Lipoprotein-X-positive Serum. <i>Clinical Chemistry</i> , 2000, 46, 1351-1356.	1.5	37
1241	Cholesterol Screening in Children and Adolescents. <i>Pediatrics</i> , 2000, 105, 637-638.	1.0	35
1242	Indications for Treatment of Symptomatic Atherosclerotic Carotid Artery Disease. <i>Neurosurgery Clinics of North America</i> , 2000, 11, 235-246.	0.8	0
1243	Metabolic Changes in Persons After Spinal Cord Injury. <i>Physical Medicine and Rehabilitation Clinics of North America</i> , 2000, 11, 109-140.	0.7	189
1244	Reply to EG Bliznakov. <i>American Journal of Clinical Nutrition</i> , 2000, 71, 153-154.	2.2	0
1246	Cost-Effectiveness of Treating Hyperlipidemia in the Presence of Diabetes. <i>Circulation</i> , 2000, 102, 722-727.	1.6	67
1247	VALVE DISEASE: Anticoagulation in valvar heart disease: new aspects and management during non-cardiac surgery. <i>British Heart Journal</i> , 2000, 84, 567-572.	2.2	34
1248	Effect of Cholesterol-Lowering Therapy on Coronary Endothelial Vasomotor Function in Patients With Coronary Artery Disease. <i>Circulation</i> , 2000, 102, 846-851.	1.6	118
1249	Efficacy and Safety of Cerivastatin 0.8 mg in Patients with Hypercholesterolaemia: The Pivotal Placebo-Controlled Clinical Trial. <i>Journal of International Medical Research</i> , 2000, 28, 47-68.	0.4	50
1250	Hypercholesterolemia Increases Coronary Endothelial Dysfunction, Lipid Content, and Accelerated Atherosclerosis After Heart Transplantation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000, 20, 728-736.	1.1	41

#	ARTICLE	IF	CITATIONS
1251	Long-Term Effects of Cholesterol Lowering and Angiotensin-Converting Enzyme Inhibition on Coronary Atherosclerosis. <i>Circulation</i> , 2000, 102, 1748-1754.	1.6	260
1252	Preoperative Cholesterol and Thrombotic Complications after Coronary Bypass. <i>Asian Cardiovascular and Thoracic Annals</i> , 2000, 8, 315-321.	0.2	0
1253	How well are patients with atherosclerotic disease treated? Secondary prevention in primary care. <i>Scandinavian Journal of Primary Health Care</i> , 2000, 18, 232-236.	0.6	9
1254	Cholesterol-Lowering Treatment Is Associated With Improvement in Coronary Vascular Remodeling and Endothelial Function in Patients With Normal or Mildly Diseased Coronary Arteries. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000, 20, 737-743.	1.1	57
1255	Evidence-based therapy for type 2 diabetes. <i>Postgraduate Medicine</i> , 2000, 107, 27-47.	0.9	6
1256	Standardization of Lipoprotein Reporting. <i>American Journal of Clinical Pathology</i> , 2000, 114, 696-702.	0.4	8
1257	Reviews: Fluvastatin: Effects Beyond Cholesterol Lowering. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2000, 5, 161-175.	1.0	44
1258	Primary Prevention of Coronary Heart Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 2089-2092.	1.8	63
1259	Hyperfibrinogenemia Is Associated With Specific Histocytological Composition and Complications of Atherosclerotic Carotid Plaques in Patients Affected by Transient Ischemic Attacks. <i>Circulation</i> , 2000, 101, 744-750.	1.6	75
1260	Cerivastatin: the low-dose HMG-COA reductase inhibitor. <i>Expert Opinion on Investigational Drugs</i> , 2000, 9, 161-166.	1.9	3
1261	The Management of Chronic Ischemic Heart Disease in the Elderly. <i>The American Journal of Geriatric Cardiology</i> , 2000, 9, 145-151.	0.7	0
1262	Atorvastatin Upregulates Type III Nitric Oxide Synthase in Thrombocytes, Decreases Platelet Activation, and Protects From Cerebral Ischemia in Normocholesterolemic Mice. <i>Stroke</i> , 2000, 31, 2442-2449.	1.0	359
1263	Non-lipid-related effects of statins. <i>Annals of Medicine</i> , 2000, 32, 164-176.	1.5	300
1264	Hormone Replacement Therapy for Prevention or Treatment of Atherosclerosis in Postmenopausal Women: Promises, Controversies, and Clinical Trials. <i>The American Journal of Geriatric Cardiology</i> , 2000, 9, 81-90.	0.7	4
1265	Cardiovascular Disease Mortality in Familial Forms of Hypertriglyceridemia: A 20-Year Prospective Study. <i>Circulation</i> , 2000, 101, 2777-2782.	1.6	225
1266	Lipoprotein (a) and stroke. <i>Journal of Clinical Pathology</i> , 2000, 53, 487-496.	1.0	91
1267	Fluvastatin Upregulates Inducible Nitric Oxide Synthase Expression in Cytokine-Stimulated Vascular Smooth Muscle Cells. <i>Hypertension</i> , 2000, 36, 923-928.	1.3	46
1268	The Association of Low Serum Cholesterol with Depression and Suicidal Behaviours: New Hypotheses for the Missing Link. <i>Journal of International Medical Research</i> , 2000, 28, 247-257.	0.4	36

#	ARTICLE	IF	CITATIONS
1269	How accelerated atherosclerosis in SLE has changed our management of the disorder. <i>Lupus</i> , 2000, 9, 228-231.	0.8	21
1270	Hypercholesterolemia Causes Mechanical Weakening of Rabbit Atheroma. <i>Circulation Research</i> , 2000, 86, 101-108.	2.0	75
1271	Effect of Amlodipine on the Progression of Atherosclerosis and the Occurrence of Clinical Events. <i>Circulation</i> , 2000, 102, 1503-1510.	1.6	598
1272	Obesity Is Associated With Tissue-Specific Activation of Renal Angiotensin-Converting Enzyme In Vivo. <i>Hypertension</i> , 2000, 35, 329-336.	1.3	117
1273	Relation Between Baseline and On-Treatment Lipid Parameters and First Acute Major Coronary Events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). <i>Circulation</i> , 2000, 101, 477-484.	1.6	523
1274	Secondary Prevention by Raising HDL Cholesterol and Reducing Triglycerides in Patients With Coronary Artery Disease. <i>Circulation</i> , 2000, 102, 21-27.	1.6	1,246
1275	Aspirin Use Is Low Among United States Outpatients With Coronary Artery Disease. <i>Circulation</i> , 2000, 101, 1097-1101.	1.6	104
1276	Effects of Lovastatin and Pravastatin on the Survival of Hamsters With Inherited Cardiomyopathy. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2000, 5, 275-279.	1.0	33
1277	Oral L-Arginine in Patients With Coronary Artery Disease on Medical Management. <i>Circulation</i> , 2000, 101, 2160-2164.	1.6	154
1278	Noncholesterol Sterols and Cholesterol Lowering by Long-Term Simvastatin Treatment in Coronary Patients. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000, 20, 1340-1346.	1.1	198
1279	Beneficial Effects of Statins in Coronary Artery Disease – Beyond Lowering Cholesterol. <i>Annals of Pharmacotherapy</i> , 2000, 34, 1432-1439.	0.9	52
1280	Acute Renal Failure After Cardiopulmonary Bypass: A Possible Association With Drugs of the Fibrate Group. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2000, 5, 33-39.	1.0	18
1281	HMG CoA Reductase Inhibitors Reduce Plasminogen Activator Inhibitor-1 Expression by Human Vascular Smooth Muscle and Endothelial Cells. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000, 20, 556-562.	1.1	265
1282	Usefulness of HMG-CoA Reductase Inhibitor in Japanese Hyperlipidemic Women within Seven Years of Menopause. <i>Hormone Research in Paediatrics</i> , 2000, 53, 120-124.	0.8	3
1283	Explanation for the Decline in Coronary Heart Disease Mortality Rates in Auckland, New Zealand, Between 1982 and 1993. <i>Circulation</i> , 2000, 102, 1511-1516.	1.6	195
1284	Apolipoprotein Concentrations During Treatment and Recurrent Coronary Artery Disease Events. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000, 20, 2408-2413.	1.1	147
1285	Differential Effect of National Cholesterol Education Program (NCEP) Step II Diet on HDL Cholesterol, Its Subfractions, and Apoprotein A-I Levels in Hypercholesterolemic Women and Men After 1 Year. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000, 20, 1580-1587.	1.1	62
1286	Cholesterol and Arterial Distensibility in the First Decade of Life. <i>Circulation</i> , 2000, 101, 1533-1538.	1.6	103

#	ARTICLE	IF	CITATIONS
1287	Secondary Prevention of Coronary Heart Disease. <i>Circulation</i> , 2000, 102, 2-4.	1.6	53
1288	Association of Coronary Heart Disease Risk Factors With Microscopic Qualities of Coronary Atherosclerosis in Youth. <i>Circulation</i> , 2000, 102, 374-379.	1.6	306
1289	High Density Lipoprotein and Coronary Heart Disease: Lessons From Recent Intervention Trials. <i>Preventive Cardiology</i> , 2000, 3, 33-39.	1.1	4
1290	Determinants of outcome in patients with sustained ventricular tachyarrhythmias: The Antiarrhythmics Versus Implantable Defibrillators (AVID) study registry. <i>American Heart Journal</i> , 2000, 139, 804-813.	1.2	27
1291	Statins: Effective antiatherosclerotic therapy. <i>American Heart Journal</i> , 2000, 139, 577-583.	1.2	148
1292	The role of clinical nonfatal end points in cardiovascular phase II/III clinical trials. <i>American Heart Journal</i> , 2000, 139, S143-S154.	1.2	11
1293	Guidelines for the diagnosis and management of unstable angina and non-Q-wave myocardial infarction: Proposed revisions. <i>American Heart Journal</i> , 2000, 139, 461-475.	1.2	57
1294	Use of cholesterol-lowering medications in the United States from 1991 to 1997 The views expressed in this paper do not necessarily represent the views of the Department of Veterans Affairs or of the United States Government.. <i>American Journal of Medicine</i> , 2000, 108, 496-499.	0.6	54
1295	Effects of lovastatin on cognitive function and psychological well-being—Access the Journal Club discussion of this paper at <a href="http://www.elsevier.com/locate/ajmselect/">http://www.elsevier.com/locate/ajmselect/</a> . <i>American Journal of Medicine</i> , 2000, 108, 538-546.	0.6	279
1296	Benefits of lipid lowering on vascular reactivity in patients with coronary artery disease and average cholesterol levels: A mechanism for reducing clinical events?. <i>American Heart Journal</i> , 2000, 139, 734-738.	1.2	37
1297	Estimation of contribution of changes in coronary care to improving survival, event rates, and coronary heart disease mortality across the WHO MONICA Project populations. <i>Lancet</i> , The, 2000, 355, 688-700.	6.3	459
1298	Benefits of early lipid-lowering intervention in high-risk patients: The lipid intervention strategies for coronary patients study. <i>Clinical Therapeutics</i> , 2000, 22, 949-960.	1.1	11
1299	The influence of treatment of hypercholesterolemic patients with simvastatin on plasma chemotactic activity and adherence of neutrophils. <i>International Journal of Cardiology</i> , 2000, 75, 85-90.	0.8	6
1300	Effects of HMG-CoA reductase inhibitor on hemostasis. <i>International Journal of Cardiology</i> , 2000, 76, 23-32.	0.8	47
1301	Lipid lowering improves endothelial functions. <i>International Journal of Cardiology</i> , 2000, 74, S3-S10.	0.8	32
1302	Comparison of the risk factors for coronary artery spasm with those for organic stenosis in a Japanese population: role of cigarette smoking. <i>International Journal of Cardiology</i> , 2000, 72, 121-126.	0.8	99
1303	Secondary prevention in early coronary disease. <i>International Journal of Cardiology</i> , 2000, 72, 291-292.	0.8	5
1304	Correlation between apolipoprotein B and endothelin-1-induced vasoconstriction in humans. <i>Peptides</i> , 2000, 21, 871-874.	1.2	8

#	ARTICLE	IF	CITATIONS
1305	Secondary prevention after myocardial infarction: reducing the risk of further cardiovascular events. <i>Coronary Health Care</i> , 2000, 4, 82-91.	0.4	5
1306	A large proportion of dyslipidemic patients receiving lipid-lowering therapy did not reach NCEP LDL-C goals. <i>Evidence-based Cardiovascular Medicine</i> , 2000, 4, 52.	0.0	0
1307	Subgroups, treatment effects, and baseline risks: Some lessons from major cardiovascular trials. <i>American Heart Journal</i> , 2000, 139, 952-961.	1.2	52
1308	Atorvastatin Versus Revascularization Treatment (AVERT): Fact or fancy?. <i>American Heart Journal</i> , 2000, 140, 6-9.	1.2	11
1309	Current perspectives on the management of hypertriglyceridemia. <i>American Heart Journal</i> , 2000, 140, 232-240.	1.2	40
1310	Effective and safe modification of multiple atherosclerotic risk factors in patients with peripheral arterial disease. <i>American Heart Journal</i> , 2000, 140, 792-803.	1.2	21
1311	Discrepancies among megatrials. <i>Journal of Clinical Epidemiology</i> , 2000, 53, 1193-1199.	2.4	41
1312	Computerised systematic secondary prevention in ischaemic heart disease. <i>Public Health</i> , 2000, 114, 169-175.	1.4	8
1313	Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2000, 19, 529-537.	0.3	89
1314	Statins after cardiac transplantation: which statin, what dose, and how low should we go?. <i>Journal of Heart and Lung Transplantation</i> , 2000, 19, 515-517.	0.3	22
1315	Systematic, immediate in-hospital initiation of lipid-lowering drugs during acute coronary events improves lipid control. <i>European Journal of Internal Medicine</i> , 2000, 11, 309-316.	1.0	6
1316	Postoperative drug therapy to extend survival after coronary artery bypass grafting. <i>Annals of Thoracic Surgery</i> , 2000, 69, 1315-1316.	0.7	9
1317	Clinical relevance of the oxidative stress concept. <i>Metabolism: Clinical and Experimental</i> , 2000, 49, 30-34.	1.5	43
1318	Effects of simvastatin and pravastatin on gonadal function in male hypercholesterolemic patients. <i>Metabolism: Clinical and Experimental</i> , 2000, 49, 115-121.	1.5	58
1319	Lipoprotein abnormalities in patients with asymptomatic acute porphyria. <i>Clinica Chimica Acta</i> , 2000, 294, 37-43.	0.5	12
1320	Effects of bezafibrate plus policosanol or placebo in patients with combined dyslipidemia: A pilot study. <i>Current Therapeutic Research</i> , 2000, 61, 346-357.	0.5	10
1321	Efficacy and tolerability of policosanol compared with lovastatin in patients with type II hypercholesterolemia and concomitant coronary risk factors. <i>Current Therapeutic Research</i> , 2000, 61, 137-146.	0.5	28
1322	Dose-dependent cholesterol-lowering effects of d-003 on normocholesterolemic rabbits. <i>Current Therapeutic Research</i> , 2000, 61, 460-468.	0.5	34



#	ARTICLE	IF	CITATIONS
1323	Design and baseline characteristics of a cohort study in Japanese patients with hypercholesterolemia: the Japan lipid intervention trial (J-LIT). <i>Current Therapeutic Research</i> , 2000, 61, 219-243.	0.5	16
1324	Preventing, stopping, or reversing coronary artery disease—triglyceride-rich lipoproteins and associated lipoprotein and metabolic abnormalities: The need for recognition and treatment. <i>Disease-a-Month</i> , 2000, 46, 421-503.	0.4	5
1325	Effects of cerivastatin on lipid profiles, lipid peroxidation and platelet and endothelial activation in renal transplant recipients. <i>Transplantation Proceedings</i> , 2000, 32, 2787-2788.	0.3	3
1326	Incidence and risk reduction of long-term outcomes: a comparison of benign prostatic hyperplasia with several other disease areas. <i>Urology</i> , 2000, 56, 9-18.	0.5	7
1327	Acute relief or future prevention: is urology ready for preventive health care?. <i>Urology</i> , 2000, 56, 12-19.	0.5	17
1328	Role of WHO-MONICA Project in unravelling of the cardiovascular puzzle. <i>Lancet, The</i> , 2000, 355, 668-669.	6.3	13
1329	Effects of pravastatin in 3260 patients with unstable angina: results from the LIPID study. <i>Lancet, The</i> , 2000, 356, 1871-1875.	6.3	72
1331	Risk factor modification through nonpharmacological interventions in patients with coronary heart disease. <i>Journal of Psychosomatic Research</i> , 2000, 48, 425-441.	1.2	55
1332	Pravastatin Therapy and the Risk of Stroke. <i>New England Journal of Medicine</i> , 2000, 343, 317-326.	13.9	302
1333	Treatment of intermittent claudication. <i>Journal of Vascular Surgery</i> , 2000, 31, S77-S89.	0.6	5
1334	Reduced or modified dietary fat for preventing cardiovascular disease. , 2000, , CD002137.		64
1335	Lipid Clinics as Disease Management Programmes in the United States. <i>Disease Management and Health Outcomes</i> , 2000, 8, 65-78.	0.3	0
1336	Differential Pharmacokinetics of Digoxin in Elderly Patients. <i>Drugs and Aging</i> , 2000, 17, 353-362.	1.3	74
1337	The Relationship Between Cholesterol and Stroke. <i>Drugs and Aging</i> , 2000, 17, 33-51.	1.3	16
1338	Risks of Coronary Heart Disease in Women: Current Understanding and Evolving Concepts. <i>Mayo Clinic Proceedings</i> , 2000, 75, 1289-1303.	1.4	37
1340	Prevention of coronary artery disease with statin therapy is usually cost effective. <i>Drugs and Therapy Perspectives</i> , 2000, 15, 13-16.	0.3	0
1341	Role of Lipid-Lowering Pharmacotherapy in Children. <i>Paediatric Drugs</i> , 2000, 2, 11-22.	1.3	18
1342	Novel lipid-regulating drugs. <i>Expert Opinion on Investigational Drugs</i> , 2000, 9, 2619-2628.	1.9	24

#	ARTICLE	IF	CITATIONS
1343	Current Perspectives on Statins. <i>Circulation</i> , 2000, 101, 207-213.	1.6	1,078
1344	Modern adjunctive pharmacotherapy of myocardial infarction. <i>Expert Opinion on Pharmacotherapy</i> , 2000, 1, 405-418.	0.9	4
1345	Testing for endothelial dysfunction. <i>Annals of Medicine</i> , 2000, 32, 293-304.	1.5	111
1346	High-density lipoprotein: gene-based approaches to the prevention of atherosclerosis. <i>Annals of Medicine</i> , 2000, 32, 642-651.	1.5	14
1347	Potential of adenosine receptor agonists for the prevention and treatment of coronary artery disease and acute myocardial infarction. <i>Expert Opinion on Emerging Drugs</i> , 2000, 5, 89-108.	1.1	4
1348	Colesevelam hydrochloride: a non-absorbed, polymeric cholesterol-lowering agent. <i>Expert Opinion on Investigational Drugs</i> , 2000, 9, 2663-2671.	1.9	46
1349	Angiotensin AT1 receptor over-expression in hypercholesterolaemia. <i>Annals of Medicine</i> , 2000, 32, 386-389.	1.5	81
1350	Has Interest in Secondary Prevention Increased Among Physicians After the 4S Study?. <i>Scandinavian Cardiovascular Journal</i> , 2000, 34, 164-167.	0.4	5
1351	Lipids, cardiovascular disease and atherosclerosis in systemic lupus erythematosus. <i>Lupus</i> , 2000, 9, 194-201.	0.8	37
1352	Pharmacotherapy of hypercholesterolaemia: statins in clinical practice. <i>Expert Opinion on Pharmacotherapy</i> , 2000, 1, 683-695.	0.9	27
1353	Long-Term Follow-Up of Patients With Mild Coronary Artery Disease and Endothelial Dysfunction. <i>Circulation</i> , 2000, 101, 948-954.	1.6	1,898
1356	CARDIAC REHABILITATION AND SECONDARY PREVENTION PROGRAMS FOR ELDERLY CARDIAC PATIENTS. <i>Clinics in Geriatric Medicine</i> , 2000, 16, 619-629.	1.0	9
1359	STROKE PREVENTION. <i>Neurologic Clinics</i> , 2000, 18, 309-319.	0.8	42
1360	HYPERLIPIDEMIA. <i>Primary Care - Clinics in Office Practice</i> , 2000, 27, 541-587.	0.7	30
1363	Decreasing Mortality With Primary Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction: The Mayo Clinic Experience From 1991 Through 1997. <i>Mayo Clinic Proceedings</i> , 2000, 75, 994-1001.	1.4	13
1364	Randomized Comparison of the Efficacy and Safety of Cerivastatin and Pravastatin in 1030 Hypercholesterolemic Patients. <i>Mayo Clinic Proceedings</i> , 2000, 75, 1124-1132.	1.4	25
1365	MANAGEMENT OF HYPERCHOLESTEROLEMIA. <i>Medical Clinics of North America</i> , 2000, 84, 23-42.	1.1	59
1366	PUTTING PREVENTION INTO DAILY PRACTICE. <i>Medical Clinics of North America</i> , 2000, 84, 267-278.	1.1	4

#	ARTICLE	IF	CITATIONS
1368	Le rôle de ses activateurs dans la régulation de l'expression des gènes impliqués dans le métabolisme des lipoprotéines, l'inflammation vasculaire et l'athérosclérose. Annales De L'Institut Pasteur / Actualités, 2000, 11, 89-106.	0.1	0
1369	Chronic Subclinical Inflammation as Part of the Insulin Resistance Syndrome. Circulation, 2000, 102, 42-47.	1.6	2,113
1371	PREMATURE ATHEROSCLEROSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS. Rheumatic Disease Clinics of North America, 2000, 26, 257-278.	0.8	154
1372	Helicobacter pylori is an aetiological factor for ischaemic heart disease: the case against. Digestive and Liver Disease, 2000, 32, 65-68.	0.4	17
1373	Prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal mucosal injury: risk factors for serious complications. Digestive and Liver Disease, 2000, 32, 138-151.	0.4	16
1375	HMG-CoA Reductase Inhibitors and Myotoxicity. Drug Safety, 2000, 22, 441-457.	1.4	249
1376	Comparative Tolerability of the HMG-CoA Reductase Inhibitors. Drug Safety, 2000, 23, 197-213.	1.4	160
1377	Clinical Pharmacokinetics of Cerivastatin. Clinical Pharmacokinetics, 2000, 39, 99-116.	1.6	105
1378	HMG-CoA Reductase Inhibitors in the Prevention of Stroke. Drugs, 2000, 59, 1-6.	4.9	14
1379	Lipid-Lowering Treatment in Coronary Artery Disease. Drugs, 2000, 59, 1127-1135.	4.9	5
1380	Cerivastatin. Drugs, 2000, 60, 1179-1206.	4.9	30
1381	A Working-Day Evaluation of Dyslipidaemia in a Spanish Population (JADE Study). Clinical Drug Investigation, 2000, 19, 131-142.	1.1	8
1382	LIPI-WATCH, a Belgian/Luxembourg Survey on Achievement of European Atherosclerosis Society Lipid Goals. Clinical Drug Investigation, 2000, 19, 219-229.	1.1	23
1383	Antihyperlipidaemic Drugs. Clinical Drug Investigation, 2000, 19, 457-464.	1.1	1
1384	Rationale, Design and Baseline Characteristics of a Clinical Trial Comparing the Effects of Robust vs Conventional Cholesterol Lowering and Intima Media Thickness in Patients with Familial Hypercholesterolaemia. Clinical Drug Investigation, 2000, 20, 67-79.	1.1	28
1385	Cost-Effectiveness Analysis for Statin Therapies in the Primary Prevention of Coronary Heart Disease in Italy. Clinical Drug Investigation, 2000, 20, 109-121.	1.1	7
1386	Utilisation of Lipid-Lowering Drugs in Spain between 1986 and 1998. Clinical Drug Investigation, 2000, 20, 197-201.	1.1	5
1387	Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study). Atherosclerosis, 2000, 150, 429-436.	0.4	64

#	ARTICLE	IF	CITATIONS
1388	The effects of lifestrol (K12.148) on the cholesterol metabolism of cultured cells: evidence for sterol independent stimulation of the LDL receptor pathway. <i>Atherosclerosis</i> , 2000, 153, 69-80.	0.4	8
1389	Cardiovascular risk changes after lipid lowering medications: are they predictable?. <i>Atherosclerosis</i> , 2000, 152, 1-8.	0.4	14
1390	The revised joint guidelines. <i>Atherosclerosis Supplements</i> , 2000, 1, 3-7.	1.2	3
1391	The benefit of aggressive lipid lowering. <i>Atherosclerosis Supplements</i> , 2000, 1, 15-19.	1.2	2
1392	Treating to target with statins. <i>Atherosclerosis Supplements</i> , 2000, 1, 21-25.	1.2	6
1393	Additive effects of another kind of HMG-CoA reductase inhibitor with different pharmacokinetics in the treatment of heterozygous familial hypercholesterolemia. <i>Atherosclerosis</i> , 2000, 153, 525-526.	0.4	3
1394	Governance of the concentration of plasma LDL: a reevaluation of the LDL receptor paradigm. <i>Atherosclerosis</i> , 2000, 148, 215-229.	0.4	38
1395	Inhibition of tissue-factor-mediated thrombin generation by simvastatin. <i>Atherosclerosis</i> , 2000, 149, 111-116.	0.4	97
1396	Safety profile of atorvastatin-treated patients with low LDL-cholesterol levels. <i>Atherosclerosis</i> , 2000, 149, 123-129.	0.4	34
1397	Effects of reserpine on expression of the LDL receptor in liver and on plasma and tissue lipids, low density lipoprotein and fibrinogen in rabbits in vivo. <i>Atherosclerosis</i> , 2000, 149, 267-275.	0.4	7
1398	Differences in the effects of HMG-CoA reductase inhibitors on proliferation and viability of smooth muscle cells in culture. <i>Atherosclerosis</i> , 2000, 150, 331-341.	0.4	44
1399	Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia. <i>Atherosclerosis</i> , 2000, 150, 421-428.	0.4	85
1400	Inhibitors of HMG-CoA reductase sensitize human smooth muscle cells to Fas-ligand and cytokine-induced cell death. <i>Atherosclerosis</i> , 2000, 152, 217-227.	0.4	93
1401	Pioneer research in Britain into atherosclerosis and coronary heart disease – an historical review. <i>Atherosclerosis</i> , 2000, 150, 1-12.	0.4	10
1402	Risk stratification in unstable coronary artery disease. <i>Journal of the American College of Cardiology</i> , 2000, 35, 1791-1800.	1.2	23
1403	Techniques characterizing the coronary atherosclerotic plaque: influence on clinical decision making?. <i>Journal of the American College of Cardiology</i> , 2000, 36, 13-21.	1.2	148
1404	Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , 2000, 36, 427-431.	1.2	183
1405	Lipid lowering drugs and recurrences of life-threatening ventricular arrhythmias in high-risk patients. <i>Journal of the American College of Cardiology</i> , 2000, 36, 766-772.	1.2	119

#	ARTICLE	IF	CITATIONS
1407	The aggressive low density lipoprotein lowering controversy. Journal of the American College of Cardiology, 2000, 36, 1419-1425.	1.2	23
1408	How deadly is the "deadly quartet"? Journal of the American College of Cardiology, 2000, 36, 1159-1165.	1.2	43
1409	Prediction of coronary events with electron beam computed tomography. Journal of the American College of Cardiology, 2000, 36, 1253-1260.	1.2	717
1410	HMG-CoA reductase inhibition improves endothelial cell function and inhibits smooth muscle cell proliferation in human saphenous veins. Journal of the American College of Cardiology, 2000, 36, 1691-1697.	1.2	103
1411	Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease. Journal of the American College of Cardiology, 2000, 36, 1774-1780.	1.2	125
1412	Exercise performance-based outcomes of medically treated patients with coronary artery disease and profound ST segment depression. Journal of the American College of Cardiology, 2000, 36, 2140-2145.	1.2	27
1413	The framingham offspring study: A commentary. Journal of the American College of Cardiology, 2000, 35, 13B-17B.	1.2	4
1414	The evolving role of statins in the management of atherosclerosis. Journal of the American College of Cardiology, 2000, 35, 1-10.	1.2	534
1415	Effects of hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin on smooth muscle cell proliferation in vitro and neointimal formation in vivo after vascular injury. Journal of the American College of Cardiology, 2000, 35, 214-221.	1.2	129
1416	Morphology of vulnerable coronary plaque: insights from follow-up of patients examined by intravascular ultrasound before an acute coronary syndrome. Journal of the American College of Cardiology, 2000, 35, 106-111.	1.2	408
1417	Gemfibrozil, nicotinic acid and combination therapy in patients with isolated hypoalphalipoproteinemia: a randomized, open-label, crossover study. Journal of the American College of Cardiology, 2000, 35, 640-646.	1.2	24
1418	The Angiotensin-converting Enzyme Inhibition Post Revascularization Study (APRES). Journal of the American College of Cardiology, 2000, 35, 881-888.	1.2	101
1419	Diabetes mellitus: the disease. , 2000, , 1-24.		0
1420	Effect of computerized coronary heart disease risk assessment on the use of lipid-lowering therapy in general practice patients. Coronary Health Care, 2001, 5, 4-8.	0.4	6
1421	Clinical Pharmacokinetics of Fluvastatin. Clinical Pharmacokinetics, 2001, 40, 263-281.	1.6	142
1422	Safety Profiles for the HMG-CoA Reductase Inhibitors. Drugs, 2001, 61, 197-206.	4.9	97
1423	Atorvastatin. Drugs, 2001, 61, 1835-1881.	4.9	132
1424	Comparison of the Efficacy, Safety and Tolerability of Policosanol versus Fluvastatin in Elderly Hypercholesterolaemic Women. Clinical Drug Investigation, 2001, 21, 103-113.	1.1	24

#	ARTICLE	IF	CITATIONS
1425	Effects of Policosanol on Lipid Profile and Cardiac Events in Older Hypercholesterolaemic Patients with Coronary Disease. <i>Clinical Drug Investigation</i> , 2001, 21, 485-497.	1.1	23
1426	Treatment of Dyslipidaemia with Fluvastatin in Patients with Type 2 Diabetes Mellitus. <i>Clinical Drug Investigation</i> , 2001, 21, 671-678.	1.1	5
1427	Lipid-Lowering Efficacy, Safety, and Costs of a Large-Scale Therapeutic Statin Formulary Conversion Program. <i>Pharmacotherapy</i> , 2001, 21, 1130-1139.	1.2	23
1428	The effect of amlodipine on endothelial function in young adults with a strong family history of premature coronary artery disease: a randomised double blind study. <i>Atherosclerosis</i> , 2001, 154, 171-177.	0.4	8
1429	Cerivastatin prevents tumor necrosis factor- $\alpha$ -induced downregulation of endothelial nitric oxide synthase: role of endothelial cytosolic proteins. <i>Atherosclerosis</i> , 2001, 155, 61-70.	0.4	42
1430	F 12511, a novel ACAT inhibitor, and atorvastatin regulate endogenous hypercholesterolemia in a synergistic manner in New Zealand rabbits fed a casein-enriched diet. <i>Atherosclerosis</i> , 2001, 155, 131-142.	0.4	26
1431	Oxidized LDL and thickness of carotid intima-media are associated with coronary atherosclerosis in middle-aged men: lower levels of oxidized LDL with statin therapy. <i>Atherosclerosis</i> , 2001, 155, 403-412.	0.4	100
1432	A HMG-CoA reductase inhibitor possesses a potent anti-atherosclerotic effect other than serum lipid lowering effects – the relevance of endothelial nitric oxide synthase and superoxide anion scavenging action. <i>Atherosclerosis</i> , 2001, 155, 347-357.	0.4	102
1433	Sustained long-term improvement of arterial endothelial function in heterozygous familial hypercholesterolemia patients treated with simvastatin. <i>Atherosclerosis</i> , 2001, 157, 423-429.	0.4	64
1434	Effect of simvastatin on monocyte adhesion molecule expression in patients with hypercholesterolemia. <i>Atherosclerosis</i> , 2001, 157, 505-512.	0.4	44
1435	Cholesterol and other lipids predict coronary heart disease and ischaemic stroke in the elderly, but only in those below 70 years. <i>Atherosclerosis</i> , 2001, 159, 201-208.	0.4	94
1436	Atorvastatin improves blood rheology in patients with familial hypercholesterolemia (FH) on long-term LDL apheresis treatment. <i>Atherosclerosis</i> , 2001, 159, 513-519.	0.4	41
1437	Intermittent claudication: an objective office-based assessment. <i>Journal of the American College of Cardiology</i> , 2001, 37, 1381-1385.	1.2	59
1438	Extensive development of vulnerable plaques as a pan-coronary process in patients with myocardial infarction: an angioscopic study. <i>Journal of the American College of Cardiology</i> , 2001, 37, 1284-1288.	1.2	363
1439	Independent contribution of myocardial perfusion defects to exercise capacity and heart rate recovery for prediction of all-cause mortality in patients with known or suspected coronary heart disease. <i>Journal of the American College of Cardiology</i> , 2001, 37, 1558-1564.	1.2	88
1440	Plaque burden, arterial remodeling and plaque vulnerability: determined by systemic factors?. <i>Journal of the American College of Cardiology</i> , 2001, 38, 718-723.	1.2	66
1441	Statin therapy, inflammation and recurrent coronary events in patients following coronary stent implantation. <i>Journal of the American College of Cardiology</i> , 2001, 38, 2006-2012.	1.2	111
1442	Use of statins in CNS disorders. <i>Journal of the Neurological Sciences</i> , 2001, 187, 81-89.	0.3	116

#	ARTICLE	IF	CITATIONS
1443	USE OF BIOMARKERS AND SURROGATE ENDPOINTS IN DRUG DEVELOPMENT AND REGULATORY DECISION MAKING: Criteria, Validation, Strategies. Annual Review of Pharmacology and Toxicology, 2001, 41, 347-366.	4.2	430
1444	Lipids and atherosclerosis: clinical management of hypercholesterolaemia. Expert Opinion on Pharmacotherapy, 2001, 2, 419-430.	0.9	10
1445	Estudio observacional en el Área 10: manejo de la hipercolesterolemia en ancianos diabéticos. Revista Española De Geriatria Y Gerontología, 2001, 36, 221-227.	0.2	0
1446	Tratamiento hipolipemiante en ancianos. Revista Española De Geriatria Y Gerontología, 2001, 36, 195-209.	0.2	0
1448	How Well Tolerated Are Lipid-Lowering Drugs?. Drugs and Aging, 2001, 18, 665-683.	1.3	29
1449	Contemporary Management of Chronic Stable Angina. Drugs and Aging, 2001, 18, 109-121.	1.3	10
1450	Management of Type 2 Diabetes Mellitus in the Elderly. Drugs and Aging, 2001, 18, 31-44.	1.3	88
1451	Cardiac Rehabilitation and Secondary Prevention of Coronary Heart Disease. New England Journal of Medicine, 2001, 345, 892-902.	13.9	671
1452	Global Burden of Cardiovascular Diseases. Circulation, 2001, 104, 2746-2753.	1.6	2,337
1453	Prognostic Significance of Endothelial Dysfunction in Hypertensive Patients. Circulation, 2001, 104, 191-196.	1.6	1,001
1454	A Comparison of NCEP and Absolute Risk Stratification Methods for Lipid-Lowering Therapy in Middle-Aged Adults: The ARIC Study. Preventive Cardiology, 2001, 4, 148-157.	1.1	2
1455	Direct Measurement of Low-Density-Lipoprotein Cholesterol Is More Effective Than Total Cholesterol for the Purpose of Lipoprotein Screening. Preventive Medicine, 2001, 32, 224-229.	1.6	13
1456	The Last Frontier in Cardiovascular Health: A Landmark Lecture for the XVII World Congress of the International Society for Heart Research. Journal of Molecular and Cellular Cardiology, 2001, 33, 2063-2069.	0.9	1
1457	Pravastatin, A 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor, Attenuates Renal Injury in an Experimental Model of Ischemia-Reperfusion. Journal of Surgical Research, 2001, 101, 79-84.	0.8	77
1458	Efficacy and safety of combination simvastatin and colesvelam in patients with primary hypercholesterolemia. American Journal of Medicine, 2001, 110, 352-360.	0.6	196
1459	Current utilization trends for $\beta$ -blockers in cardiovascular disease. American Journal of Medicine, 2001, 110, 2-6.	0.6	18
1460	Clinical context: Current concepts of coronary heart disease management. American Journal of Medicine, 2001, 110, 3-11.	0.6	35
1461	A means to an end: An overview of a hyperlipidemia outcomes management program. American Journal of Medicine, 2001, 110, 12-16.	0.6	52

#	ARTICLE	IF	CITATIONS
1462	A case-management program of medium intensity does not improve cardiovascular risk factor control in coronary artery disease patients: the Heartcare I Trial. American Journal of Medicine, 2001, 110, 543-550.	0.6	20
1463	Do statins cause cancer? A meta-analysis of large randomized clinical trials. American Journal of Medicine, 2001, 110, 716-723.	0.6	185
1464	Quality of ambulatory care after myocardial infarction among medicare patients by type of insurance and region. American Journal of Medicine, 2001, 111, 24-32.	0.6	23
1465	Statins and cancer: a case of meta-uncertainty. American Journal of Medicine, 2001, 110, 738-740.	0.6	13
1466	Medical therapy or coronary artery bypass graft surgery for chronic stable angina: an update using decision analysis. American Journal of Medicine, 2001, 111, 89-95.	0.6	21
1467	Achieving and maintaining national cholesterol education program low-density lipoprotein cholesterol goals with five statins. American Journal of Medicine, 2001, 111, 185-191.	0.6	166
1468	Clinically relevant differences between the statins: implications for therapeutic selection. American Journal of Medicine, 2001, 111, 390-400.	0.6	177
1469	Measurement of health status after transmyocardial laser revascularization: critical but not the final answer. American Journal of Medicine, 2001, 111, 405-406.	0.6	1
1470	Prognosis determination in heart failure. American Journal of Medicine, 2001, 110, 14-35.	0.6	90
1471	Mechanisms of acute coronary syndromes and the potential role of statins. Atherosclerosis Supplements, 2001, 2, 9-14.	1.2	21
1472	Clinical relevance of statins: instituting treatment early in acute coronary syndrome patients. Atherosclerosis Supplements, 2001, 2, 15-19.	1.2	15
1473	Clinical relevance of statins: their role in secondary prevention. Atherosclerosis Supplements, 2001, 2, 21-25.	1.2	10
1474	Changing the practice of cardiovascular medicine. Atherosclerosis Supplements, 2001, 2, 27-30.	1.2	4
1475	Ppars, metabolic disease and atherosclerosis. Pharmacological Research, 2001, 44, 345-352.	3.1	110
1476	Atorvastatin prevented early recurrence of ischemic events and death in patients with unstable angina or non-Q-wave MI. Evidence-based Cardiovascular Medicine, 2001, 5, 43-45.	0.0	0
1477	Cholesterol: an important but relatively overemphasized risk factor for ischemic heart disease. Medical Hypotheses, 2001, 57, 593-601.	0.8	5
1478	Drug therapy or coronary angioplasty for the treatment of coronary artery disease: New insights. American Heart Journal, 2001, 141, S22-S25.	1.2	10
1479	Aggressive versus moderate lipid-lowering therapy in postmenopausal women with hypercholesterolemia: Rationale and design of the Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES) trial. American Heart Journal, 2001, 141, 722-726.	1.2	35



#	ARTICLE	IF	CITATIONS
1480	Noninvasive tests of vascular function and structure: Why and how to perform them. American Heart Journal, 2001, 141, 694-703.	1.2	83
1481	Randomized clinical trials and recent patterns in the use of statins. American Heart Journal, 2001, 141, 957-963.	1.2	35
1482	Long-term survival in 11,661 patients with multivessel coronary artery disease in the era of stenting: A report from the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease (APPROACH) Investigators. American Heart Journal, 2001, 142, 119-126.	1.2	124
1483	The effect of pravastatin and atorvastatin on coenzyme Q10. American Heart Journal, 2001, 142, 13A-18A.	1.2	72
1484	The A-to-Z Trial: Methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy. American Heart Journal, 2001, 142, 211-217.	1.2	90
1485	Primary percutaneous coronary interventions in patients with acute myocardial infarction and prior coronary artery bypass grafting. American Heart Journal, 2001, 142, 452-459.	1.2	51
1486	Challenges of subgroup analyses in multinational clinical trials: Experiences from the MERIT-HF trial. American Heart Journal, 2001, 142, 502-511.	1.2	115
1487	Effectiveness of a planned strategy using cardiac rehabilitation nurses for the management of dyslipidemia in patients with coronary artery disease. American Heart Journal, 2001, 142, 975-981.	1.2	16
1488	Multifactorial cardiovascular disease prevention in patients aged 75 years and older: A randomized controlled trial. American Heart Journal, 2001, 142, 945-951.	1.2	54
1489	Monogenic Dyslipidemias: Window on Determinants of Plasma Lipoprotein Metabolism. American Journal of Human Genetics, 2001, 69, 1161-1177.	2.6	73
1490	Efficacy and tolerability of fluvastatin extended-release delivery system: a pooled analysis. Clinical Therapeutics, 2001, 23, 177-192.	1.1	71
1491	Cost-minimization analysis of simvastatin versus atorvastatin for maintenance therapy in patients with coronary or peripheral vascular disease. Clinical Therapeutics, 2001, 23, 276-283.	1.1	8
1492	A comparison of the efficacy and tolerability of titrate-to-goal regimens of simvastatin and fluvastatin: a randomized, double-blind study in adult patients at moderate to high risk for cardiovascular disease. Clinical Therapeutics, 2001, 23, 467-478.	1.1	6
1493	STATT: a titrate-to-goal study of simvastatin in asian patients with coronary heart disease. Clinical Therapeutics, 2001, 23, 858-870.	1.1	18
1494	STATINS & NEWER HOPE FOR ATHEROSCLEROSIS ASSOCIATED DISEASES. Medical Journal Armed Forces India, 2001, 57, 129-130.	0.3	0
1495	The endothelium: a gynecological and obstetric point of view. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2001, 94, 180-185.	0.5	7
1496	Stimulation of inflammatory responses in vitro and in vivo by lipophilic HMG-CoA reductase inhibitors. International Immunopharmacology, 2001, 1, 105-118.	1.7	117
1497	Cholesterol, A $\beta$ 2 and Alzheimer's disease. Trends in Neurosciences, 2001, 24, S45-S48.	4.2	88

#	ARTICLE	IF	CITATIONS
1498	Cholesterol, A $\beta$ and Alzheimer's disease. Trends in Neurosciences, 2001, 24, 45-48.	4.2	65
1499	Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. International Journal of Cardiology, 2001, 77, 247-253.	0.8	170
1500	Pravastatin reduces myocardial lesions induced by acute inhibition of nitric oxide biosynthesis in normocholesterolemic rats. International Journal of Cardiology, 2001, 79, 215-221.	0.8	15
1501	Molecular genetics and gene expression in atherosclerosis. International Journal of Cardiology, 2001, 80, 161-172.	0.8	43
1502	â€œNatural historyâ€•clinical trials: An enduring contribution to modern medical practice. Advances in Protein Chemistry, 2001, 56, 1-12.	4.4	1
1503	HMG-CoA reductase inhibitors. Advances in Protein Chemistry, 2001, 56, 77-114.	4.4	38
1504	Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency. American Journal of Kidney Diseases, 2001, 37, 484-489.	2.1	184
1505	Plasma phospholipid transfer protein activity in patients with low HDL and cardiovascular disease treated with simvastatin and niacin. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2001, 1537, 117-124.	1.8	17
1506	Coronary heart disease in the statin and aspirin era: are results of clinical trials being put into practice?. European Journal of Internal Medicine, 2001, 12, 490-495.	1.0	3
1507	If cardiac patients benefit from statins, why not commonly prescribe them and follow up their use?. European Journal of Internal Medicine, 2001, 12, 475-476.	1.0	1
1508	LpAI in HDL subfractions: serum levels in men and women with coronary heart disease and changes under hypolipemic therapy. Clinica Chimica Acta, 2001, 306, 43-49.	0.5	5
1509	A double-blind trial on the effects of atorvastatin on glycemic control in Japanese diabetic patients with hypercholesterolemia. Clinica Chimica Acta, 2001, 312, 41-47.	0.5	23
1510	Comparison of two regimens of policosanol administered at 20 mg/d in patients with type II hypercholesterolemia: a randomized, double-blind, placebo-controlled study. Current Therapeutic Research, 2001, 62, 194-208.	0.5	8
1511	Comparison of the effects of D-003 and policosanol on lipid profile and endothelial cells in normocholesterolemic rabbits. Current Therapeutic Research, 2001, 62, 209-220.	0.5	25
1512	Randomized, controlled trial of secondary prevention of coronary sclerosis in normocholesterolemic patients using pravastatin: two-year follow-up of the prevention of coronary sclerosis study. Current Therapeutic Research, 2001, 62, 473-485.	0.5	7
1513	Effects of atorvastatin on lipid profile and coagulation parameters. Current Therapeutic Research, 2001, 62, 691-698.	0.5	9
1514	Optimal medical management of patients with chronic ischemic heart disease. Disease-a-Month, 2001, 47, 150-196.	0.4	0
1515	Safety and efficacy of simvastatin for hyperlipidemia in renal transplant recipients: a double-blind, randomized, placebo-controlled study. Transplantation Proceedings, 2001, 33, 1194-1195.	0.3	27

#	ARTICLE	IF	CITATIONS
1516	Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP): a prospective, randomised, double-blind trial. <i>Lancet, The</i> , 2001, 357, 577-581.	6.3	901
1517	Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. <i>Lancet, The</i> , 2001, 357, 995-1001.	6.3	730
1518	Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. <i>Lancet, The</i> , 2001, 357, 1063-1068.	6.3	293
1519	Measurement of atherosclerosis progression. <i>Lancet, The</i> , 2001, 358, 328-329.	6.3	1
1520	Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: a cohort study. <i>Lancet, The</i> , 2001, 358, 351-355.	6.3	375
1521	Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. <i>Lancet, The</i> , 2001, 358, 1033-1041.	6.3	3,062
1522	Economics of drug treatment: for which patients is it costeffective to lower cholesterol?. <i>Lancet, The</i> , 2001, 358, 1251-1256.	6.3	25
1523	Learning from the cerivastatin experience. <i>Lancet, The</i> , 2001, 358, 1383-1385.	6.3	102
1525	Los fitosteroles, el colesterol y la prevenci3n de las enfermedades cardiovasculares. <i>Cl3nica E Investigaci3n En Arteriosclerosis</i> , 2001, 13, 209-218.	0.4	7
1526	Eficacia y seguridad de la atorvastatina en la pr3ctica m3dica habitual en Espa3a (estudio Zar). <i>Cl3nica E Investigaci3n En Arteriosclerosis</i> , 2001, 13, 19-25.	0.4	0
1529	Estatinas: 2est3 justificada su prescripci3n para indicaciones distintas a la hipercolesterolemia?. <i>FMC Formacion Medica Continuada En Atencion Primaria</i> , 2001, 8, 404-413.	0.0	0
1530	Low-Density Lipoprotein Apheresis for the Treatment of Refractory Hyperlipidemia. <i>Mayo Clinic Proceedings</i> , 2001, 76, 1039-1046.	1.4	27
1531	Hiperhomocisteinemia. Diagn3stico y tratamiento. <i>Cl3nica E Investigaci3n En Arteriosclerosis</i> , 2001, 13, 36-42.	0.4	1
1533	Efectividad del tratamiento hipocolesterolemiante a largo plazo. <i>Cl3nica E Investigaci3n En Arteriosclerosis</i> , 2001, 13, 118-120.	0.4	0
1535	Smoking Diminishes the Beneficial Effect of Statins: Observations from the Landmark Trials. <i>Angiology</i> , 2001, 52, 575-587.	0.8	52
1537	Involvement of Oxidation-Sensitive Mechanisms in the Cardiovascular Effects of Hypercholesterolemia. <i>Mayo Clinic Proceedings</i> , 2001, 76, 619-631.	1.4	45
1538	Developing Guidance for Budget Impact Analysis. <i>Pharmacoeconomics</i> , 2001, 19, 609-621.	1.7	177
1539	HMG-CoA Reductase Inhibitor Modulates Monocyte-Endothelial Cell Interaction Under Physiological Flow Conditions In Vitro. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2001, 21, 1165-1171.	1.1	179

#	ARTICLE	IF	CITATIONS
1541	Evidence-based treatment of patients with ischemic cerebrovascular disease. <i>Neurologic Clinics</i> , 2001, 19, 79-105.	0.8	7
1542	Complicaciones de la diabetes mellitus. Diagnóstico y tratamiento. <i>Semergen</i> , 2001, 27, 132-145.	0.2	6
1544	Effectiveness of Colesevelam Hydrochloride in Decreasing LDL Cholesterol in Patients With Primary Hypercholesterolemia: A 24-Week Randomized Controlled Trial. <i>Mayo Clinic Proceedings</i> , 2001, 76, 971-982.	1.4	133
1547	Adjunctive Therapies in the Treatment of Acute Coronary Syndromes. <i>Mayo Clinic Proceedings</i> , 2001, 76, 391-405.	1.4	5
1549	MANAGEMENT OF HYPERCHOLESTEROLEMIA. <i>Cardiology Clinics</i> , 2001, 19, 295-310.	0.9	1
1550	Pharmacology and clinical experience with simvastatin. <i>Expert Opinion on Pharmacotherapy</i> , 2001, 2, 153-163.	0.9	25
1551	The Natural History of Coronary Heart Disease is Changing - Why?. <i>Scandinavian Cardiovascular Journal</i> , 2001, 35, 4-6.	0.4	0
1552	Novel agents for managing dyslipidaemia. <i>Expert Opinion on Investigational Drugs</i> , 2001, 10, 1901-1911.	1.9	8
1553	Cost-Effectiveness Analysis of n-3 Polyunsaturated Fatty Acids (PUFA) after Myocardial Infarction. <i>Pharmacoeconomics</i> , 2001, 19, 411-420.	1.7	46
1554	Do Statins Afford Neuroprotection in Patients with Cerebral Ischaemia and Stroke?. <i>CNS Drugs</i> , 2001, 15, 589-596.	2.7	30
1555	HMG-CoA reductase inhibitors: useful in stroke prevention?. <i>Drugs and Therapy Perspectives</i> , 2001, 17, 10-12.	0.3	0
1556	The HMG-CoA reductase inhibitors - new safety concerns?. <i>Drugs and Therapy Perspectives</i> , 2001, 17, 11-15.	0.3	0
1557	Correlation Between C677T MTHFR Gene Polymorphism, Plasma Homocysteine Levels and the Incidence of CAD. <i>American Journal of Cardiovascular Drugs</i> , 2001, 1, 353-361.	1.0	32
1558	The role of nicorandil in the treatment of myocardial ischaemia. <i>Expert Opinion on Pharmacotherapy</i> , 2001, 2, 845-856.	0.9	10
1559	Dietary fat intake and prevention of cardiovascular disease: systematic review. <i>BMJ: British Medical Journal</i> , 2001, 322, 757-763.	2.4	300
1560	In Vivo Anti-Inflammatory Effect of Statins Is Mediated by Nonsterol Mevalonate Products. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2001, 21, 1327-1332.	1.1	203
1561	HMG-CoA reductase inhibition protects the diabetic myocardium from ischemia-reperfusion injury. <i>FASEB Journal</i> , 2001, 15, 1454-1456.	0.2	83
1562	Hypolipidaemic and antiplatelet agents. <i>Expert Opinion on Therapeutic Patents</i> , 2001, 11, 1301-1327.	2.4	2

#	ARTICLE	IF	CITATIONS
1563	Statins in the 21st century: end of the simple story?. Expert Opinion on Investigational Drugs, 2001, 10, 1755-1766.	1.9	22
1564	Dose Dependency of Fluvastatin Pharmacokinetics in Serum Determined by Reversed Phase HPLC. Journal of Cardiovascular Pharmacology and Therapeutics, 2001, 6, 137-145.	1.0	30
1565	Guidelines for the Management of Hypertension for General Practitioners.. Hypertension Research, 2001, 24, 613-634.	1.5	116
1566	A Randomized, Double-blind, Placebo-controlled, 8-week Study to Evaluate the Efficacy and Safety of Once Daily Atrovastatin (10 mg) in Patients with Elevated LDL-cholesterol.. International Heart Journal, 2001, 42, 725-738.	0.6	23
1567	Rapid assessment of chest pain. BMJ: British Medical Journal, 2001, 323, 586-587.	2.4	19
1568	Simvastatin: building on success. British Journal of Hospital Medicine, 2001, 62, 29-32.	0.3	0
1569	A Comparison of Low Versus Standard Dose Pravastatin Therapy for the Prevention of Cardiovascular Events in the Elderly : The Pravastatin Anti-atherosclerosis Trial in the Elderly (PATE). Journal of Atherosclerosis and Thrombosis, 2001, 8, 33-44.	0.9	73
1570	Global Perspectives of Familial Hypercholesterolemia. Public Health Genomics, 2001, 4, 61-67.	1.0	3
1571	Fluvastatin inhibits O <sub>2</sub> â <sup>•</sup> and ICAM-1 levels in a rat model with aortic remodeling induced by pressure overload. American Journal of Physiology - Heart and Circulatory Physiology, 2001, 281, H655-H660.	1.5	17
1572	Coronary Atherosclerosis and Restenosis. , 2001, , 967-1009.		0
1573	The Discovery of the Pathophysiological Aspects of Atherosclerosis â€” A Review. Acta Chirurgica Belgica, 2001, 101, 162-169.	0.2	38
1574	Lipid-lowering therapy following major cardiac events: progress and deficits. Medical Journal of Australia, 2001, 175, 138-140.	0.8	5
1575	Lipophilic Statins Augment Inducible Nitric Oxide Synthase Expression in Cytokine-Stimulated Cardiac Myocytes. Journal of Cardiovascular Pharmacology, 2001, 38, 69-77.	0.8	53
1576	Action of an HMG CoA Reductase Inhibitor, Lovastatin, on Apoptosis of Untransformed and ts-SV40 Transformed Human Smooth Muscle Cells Derived from Saphenous Vein. Journal of Cardiovascular Pharmacology, 2001, 38, 161-173.	0.8	9
1577	Endothelial Function and Cardiovascular Prevention: Role of Blood Lipids, Exercise, and Other Risk Factors. Cardiology in Review, 2001, 9, 282-286.	0.6	20
1578	Major Trauma in Elderly Adults Receiving Lipid-Lowering Medications. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 50, 678-683.	1.1	7
1579	Adjunctive Therapies in the Treatment of Acute Coronary Syndromes. Mayo Clinic Proceedings, 2001, 76, 391-405.	1.4	9
1580	Title is missing!. European Journal of Cardiovascular Prevention and Rehabilitation, 2001, 8, 63-71.	1.5	59

#	ARTICLE	IF	CITATIONS
1581	Title is missing!. European Journal of Cardiovascular Prevention and Rehabilitation, 2001, 8, 291-297.	1.5	100
1582	Relatively low red cell folate levels and acute coronary syndromes. Coronary Artery Disease, 2001, 12, 665-668.	0.3	10
1583	Reduction of LDL Cholesterol in Patients with Primary Hypercholesterolemia by SCH 48461: Results of a Multicenter Dose-Ranging Study. Journal of Clinical Pharmacology, 2001, 41, 70-78.	1.0	15
1584	The Effects of Converting from Simvastatin to Atorvastatin on Plasminogen Activator Inhibitor Type-1. Journal of Clinical Pharmacology, 2001, 41, 779-782.	1.0	4
1585	Colombian Study to Assess the Use of Noninvasive Determination of Endothelium-Mediated Vasodilatation (CANDEV). Normal Values and Factors Associated. Endothelium: Journal of Endothelial Cell Research, 2001, 8, 157-166.	1.7	49
1586	Safety, Tolerability, and Pharmacokinetics of an Extended-Release Formulation of Fluvastatin Administered Once Daily to Patients with Primary Hypercholesterolemia. Journal of Cardiovascular Pharmacology, 2001, 37, 502-511.	0.8	38
1587	Lipid disorders in patients with type 2 diabetes. Postgraduate Medicine, 2001, 110, 111-123.	0.9	7
1588	Long-Term Prognosis after Recovery from Myocardial Infarction: A Community-Based Survey in Yamagata, Japan.. Internal Medicine, 2001, 40, 589-593.	0.3	3
1589	Regulation of Endothelial Nitric Oxide Synthase and Endothelin-1 Expression by Fluvastatin in Human Vascular Endothelial Cells. The Japanese Journal of Pharmacology, 2001, 85, 147-154.	1.2	17
1590	Effects of Fluvastatin and Its Major Metabolites on Low-Density Lipoprotein Oxidation and Cholesterol Esterification in Macrophages. The Japanese Journal of Pharmacology, 2001, 86, 289-296.	1.2	8
1591	Angiotensin II antagonists in systolic blood pressure control. British Journal of Hospital Medicine, 2001, 62, 773-777.	0.3	6
1592	Advantages of Lipid-Lowering Therapy in Cerebral Ischemia: Role of HMG-CoA Reductase Inhibitors. Cerebrovascular Diseases, 2001, 11, 85-95.	0.8	31
1593	Role of Hypertension, Dyslipidemia and Diabetes Mellitus in the Development of Coronary Atherosclerosis in Japan. Japanese Circulation Journal, 2001, 65, 731-737.	1.0	29
1598	Myocardial Infarction in Men and Women under 65 Years of Age: No Evidence of Gender Bias. Scottish Medical Journal, 2001, 46, 73-78.	0.7	6
1599	Relationship of Early Carotid Artery Disease With Lipoprotein (a), Apolipoprotein B, and Fibrinogen in Asymptomatic Essential Hypertensive Patients and Normotensive Subjects. Journal of Investigative Medicine, 2001, 49, 505-513.	0.7	7
1600	Perspectives on Vascular Biology and Diabetes. Journal of Investigative Medicine, 2001, 49, 100-103.	0.7	4
1601	Analisi costi-efficacia del trattamento con n-3 PUFA nel post-infarto miocardico: i risultati dello studio GISSI-Prevenzione. Pharmacoeconomics Italian Research Articles, 2001, 3, 105-114.	0.2	1
1602	Involvement of Oxidation-Sensitive Mechanisms in the Cardiovascular Effects of Hypercholesterolemia. Mayo Clinic Proceedings, 2001, 76, 619-631.	1.4	67

#	ARTICLE	IF	CITATIONS
1603	Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. <i>Journal of Hypertension</i> , 2001, 19, 1139-1147.	0.3	234
1604	Prevention of Cardiovascular Disease in Women: Evidence for the Use of Hormone Replacement Therapy. <i>The Journal of the British Menopause Society</i> , 2001, 7, 8-11.	1.3	0
1605	Primary Prevention of Ischemic Stroke. <i>Stroke</i> , 2001, 32, 280-299.	1.0	512
1606	Sex inequalities in ischaemic heart disease in general practice: cross sectional survey. <i>BMJ: British Medical Journal</i> , 2001, 322, 832-832.	2.4	140
1607	Gender May Affect the Action of Garlic Oil on Plasma Cholesterol and Glucose Levels of Normal Subjects. <i>Journal of Nutrition</i> , 2001, 131, 1471-1478.	1.3	66
1608	Exploiting the Vascular Protective Effects of High-Density Lipoprotein and Its Apolipoproteins. <i>Circulation</i> , 2001, 104, 2376-2383.	1.6	233
1609	Antithrombotic secondary prevention after stroke. <i>Current Treatment Options in Neurology</i> , 2001, 3, 451-462.	0.7	4
1610	Statin trials in progress: Unanswered questions. <i>Current Atherosclerosis Reports</i> , 2001, 3, 9-13.	2.0	7
1611	Diabetes: Statins, fibrates, or both?. <i>Current Atherosclerosis Reports</i> , 2001, 3, 19-28.	2.0	19
1612	Statins, hormones, and women: Benefits and drawbacks for atherosclerosis and osteoporosis. <i>Current Atherosclerosis Reports</i> , 2001, 3, 35-42.	2.0	12
1613	Herbs and atherosclerosis. <i>Current Atherosclerosis Reports</i> , 2001, 3, 93-96.	2.0	37
1614	Prevention of strokes. <i>Current Atherosclerosis Reports</i> , 2001, 3, 321-327.	2.0	5
1615	Diet and drug therapy: A dynamic duo for reducing coronary heart disease risk. <i>Current Atherosclerosis Reports</i> , 2001, 3, 507-513.	2.0	6
1616	Clinical trial evidence for the cardioprotective effects of omega-3 fatty acids. <i>Current Atherosclerosis Reports</i> , 2001, 3, 174-179.	2.0	31
1617	New developments in atherosclerosis imaging: Electron beam tomography. <i>Current Atherosclerosis Reports</i> , 2001, 3, 417-424.	2.0	5
1618	Potential use of Ca <sup>++</sup> scanning to determine the need for and intensity of lipid-lowering therapy in asymptomatic adults. <i>Current Cardiology Reports</i> , 2001, 3, 408-415.	1.3	7
1619	Actual practice in hypertension: Implications for persistence with and effectiveness of therapy. <i>Current Hypertension Reports</i> , 2001, 3, 481-487.	1.5	11
1620	Statins and blood pressure regulation. <i>Current Hypertension Reports</i> , 2001, 3, 281-288.	1.5	49

#	ARTICLE	IF	CITATIONS
1621	Choices in medical management for prevention of acute ischemic stroke. <i>Current Neurology and Neuroscience Reports</i> , 2001, 1, 33-38.	2.0	3
1622	Transplant coronary vasculopathy. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2001, 3, 55-63.	0.4	5
1623	Dyslipidemia. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2001, 3, 347-357.	0.4	2
1626	Debate: "How low should LDL cholesterol be lowered?" Viewpoint: "It doesn't need to be very low". <i>Current Controlled Trials in Cardiovascular Medicine</i> , 2001, 2, 8.	1.5	6
1627	Debate: "How low should LDL cholesterol be lowered for optimum prevention of vascular disease?" Viewpoint: "Below 100 mg/dl". , 2001, 2, 12.		5
1628	A review of clinical trials in dietary interventions to decrease the incidence of coronary artery disease. <i>Current Controlled Trials in Cardiovascular Medicine</i> , 2001, 2, 123.	1.5	11
1629	Design and intermediate results of the Lower Extremity Arterial Disease Event Reduction (LEADER)* trial of bezafibrate in men with lower extremity arterial disease [ISRCTN4119421]. , 2001, 2, 195.		28
1630	Debate: Should statin be used in patients with heart failure?. , 2001, 2, 266.		11
1631	Debate: Statins should be used in patients with heart failure. , 2001, 2, 268.		12
1632	Cardioprotective actions of acute HMG-CoA reductase inhibition in the setting of myocardial infarction. <i>Acta Physiologica Scandinavica</i> , 2001, 173, 139-143.	2.3	39
1633	Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes. <i>British Journal of Clinical Pharmacology</i> , 2001, 51, 461-470.	1.1	64
1634	Effect of fluvastatin on acute renal allograft rejection: A randomized multicenter trial. <i>Kidney International</i> , 2001, 60, 1990-1997.	2.6	95
1635	Idiopathic membranous glomerulonephritis. <i>Kidney International</i> , 2001, 59, 1983-1994.	2.6	121
1636	Using an electronic medical record to identify opportunities to improve compliance with cholesterol guidelines. <i>Journal of General Internal Medicine</i> , 2001, 16, 531-537.	1.3	50
1637	Medicare prescription coverage and congressional gridlock. <i>Journal of General Internal Medicine</i> , 2001, 16, 864-866.	1.3	18
1638	Effects of Low-Density Lipoprotein Apheresis on Coronary and Carotid Atherosclerosis and Diabetic Scleredema in Patients with Severe Hypercholesterolemia. <i>Therapeutic Apheresis and Dialysis</i> , 2001, 5, 244-251.	0.4	11
1639	Current Topics on Low-Density Lipoprotein Apheresis. <i>Therapeutic Apheresis and Dialysis</i> , 2001, 5, 293-300.	0.4	17
1640	Factors Associated with Healthy Aging: The Cardiovascular Health Study. <i>Journal of the American Geriatrics Society</i> , 2001, 49, 254-262.	1.3	151



#	ARTICLE	IF	CITATIONS
1641	Comparative accuracy of cardiovascular risk prediction methods in patients with diabetes mellitus. <i>Diabetes, Obesity and Metabolism</i> , 2001, 3, 279-286.	2.2	17
1642	Therapeutic considerations for postprandial dyslipidaemia. <i>Diabetes, Obesity and Metabolism</i> , 2001, 3, 143-156.	2.2	7
1643	Vascular risk factors and erectile dysfunction. <i>BJU International</i> , 2001, 87, 838-845.	1.3	182
1644	Coronary heart disease risk assessment in diabetes mellitus--a comparison of PROCAM and Framingham risk assessment functions. <i>Diabetic Medicine</i> , 2001, 18, 355-359.	1.2	40
1645	Coronary heart disease: pathophysiological events and risk factors. <i>Nutrition Bulletin</i> , 2001, 26, 213-218.	0.8	5
1646	Primary stroke prevention. <i>European Journal of Neurology</i> , 2001, 8, 1-15.	1.7	36
1647	Obstructive Sleep Apnea Syndrome. Effects of Therapy on Dyslipidemia. <i>Obstruktives Schlafapnoe Syndrom. Einfluss einer Therapie auf Fettstoffwechselstörungen. Somnologie</i> , 2001, 5, 97-102.	0.9	10
1648	Survey of UK dietetic departments: diet in secondary prevention of myocardial infarction. <i>Journal of Human Nutrition and Dietetics</i> , 2001, 14, 307-318.	1.3	9
1649	Use of lipid-lowering drugs during 1991-98 in Northern Jutland, Denmark. <i>British Journal of Clinical Pharmacology</i> , 2001, 52, 307-311.	1.1	27
1650	Dyslipidaemia and diabetes. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2001, 18, 201-207.	0.2	11
1651	Effects of a Novel Hydrophilic Phytostanol Analog on Plasma Lipid Concentrations in Gerbils. <i>Journal of Pharmaceutical Sciences</i> , 2001, 90, 1795-1799.	1.6	22
1652	FFR for all. <i>Catheterization and Cardiovascular Interventions</i> , 2001, 54, 435-436.	0.7	3
1653	High n-6 to n-3 ratio of dietary fatty acids rather than serum cholesterol as a major risk factor for coronary heart disease. <i>European Journal of Lipid Science and Technology</i> , 2001, 103, 418-422.	1.0	36
1654	Statins prevent endothelial cell activation induced by antiphospholipid (anti- $\beta$ 2-glycoprotein I) antibodies: Effect on the proadhesive and proinflammatory phenotype. <i>Arthritis and Rheumatism</i> , 2001, 44, 2870-2878.	6.7	250
1655	Lessons learned from statin trials. <i>Clinical Cardiology</i> , 2001, 24, 277-280.	0.7	14
1656	Low-dose combination therapy with colesvelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia. <i>Clinical Cardiology</i> , 2001, 24, 467-474.	0.7	95
1657	Current perspectives on lipid lowering with statins to decrease risk of cardiovascular disease. <i>Clinical Cardiology</i> , 2001, 24, 2-5.	0.7	46
1658	Treating mixed dyslipidemias: Why and how. <i>Clinical Cardiology</i> , 2001, 24, 6-9.	0.7	11

#	ARTICLE	IF	CITATIONS
1659	Coronary Heart Disease, Hypercholesterolemia, and Atherosclerosis II. Misrepresented Data. <i>Experimental and Molecular Pathology</i> , 2001, 70, 120-139.	0.9	22
1660	The effect of fluvastatin of hyperlipidemia in renal transplant recipients: a prospective, placebo-controlled study. <i>International Urology and Nephrology</i> , 2001, 32, 713-716.	0.6	11
1661	Prevention of coronary heart disease through treatment of infection with <i>Chlamydia pneumoniae</i> ? Estimation of possible effectiveness and costs. , 2001, 4, 269-279.		2
1662	Safety of HMG-CoA reductase inhibitors: focus on atorvastatin. <i>Cardiovascular Drugs and Therapy</i> , 2001, 15, 211-218.	1.3	69
1663	Rationale and design for the SARIS trial; effect of statin on atherosclerosis and vascular remodeling assessed with intravascular sonography. Effect of Statin on Atherosclerosis and vascular Remodeling assessed with Intravascular Sonography. <i>Cardiovascular Drugs and Therapy</i> , 2001, 15, 339-343.	1.3	11
1664	The impact of cholesterol lowering on patients' mood. <i>Journal of Behavioral Medicine</i> , 2001, 24, 517-536.	1.1	10
1665	Effects of simvastatin on the phospholipid composition of high-density lipoproteins in patients with hypercholesterolemia. <i>Bulletin of Experimental Biology and Medicine</i> , 2001, 132, 763-765.	0.3	4
1666	Short term effect of atorvastatin and vitamin E on serum levels of C3, a sensitive marker of the risk of myocardial infarction in men. <i>Cardiovascular Drugs and Therapy</i> , 2001, 15, 453-458.	1.3	22
1667	Pharmacotherapy of dyslipidemia. <i>Cardiovascular Drugs and Therapy</i> , 2001, 15, 413-422.	1.3	45
1668	Statins as immunosuppressive agents. <i>Liver Transplantation</i> , 2001, 7, 559-561.	1.3	21
1669	Long-term effect of simvastatin on the improvement of impaired myocardial flow reserve in patients with familial hypercholesterolemia without gender variance. <i>Journal of Nuclear Cardiology</i> , 2001, 8, 445-451.	1.4	29
1670	Beyond the cholesterol profile: Monitoring therapeutic effectiveness of statin therapy. <i>Journal of Nuclear Cardiology</i> , 2001, 8, 528-532.	1.4	7
1671	Coronary Revascularization: An Opportunity for Lipid Screening and Treatment. <i>Journal of Interventional Cardiology</i> , 2001, 14, 109-112.	0.5	0
1672	NK-104, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, reduces osteopontin expression by rat aortic smooth muscle cells. <i>British Journal of Pharmacology</i> , 2001, 133, 83-88.	2.7	25
1673	A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid. <i>British Journal of Pharmacology</i> , 2001, 133, 406-412.	2.7	180
1674	Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function. <i>British Journal of Pharmacology</i> , 2001, 134, 409-417.	2.7	187
1675	Pravastatin suppresses the interleukin-8 production induced by thrombin in human aortic endothelial cells cultured with high glucose by inhibiting the p44/42 mitogen activated protein kinase. <i>British Journal of Pharmacology</i> , 2001, 134, 753-762.	2.7	38
1676	Regression of atherosclerotic renal artery stenosis with aggressive lipid lowering therapy. <i>Journal of Human Hypertension</i> , 2001, 15, 431-433.	1.0	32

#	ARTICLE	IF	CITATIONS
1677	Ethnic variations in response to a statin (EVIREST). <i>Journal of Human Hypertension</i> , 2001, 15, S87-S89.	1.0	5
1678	Cardiology and AIDS—HAART and the Consequences. <i>Annals of the New York Academy of Sciences</i> , 2001, 946, 130-144.	1.8	24
1679	Solidarity and equity: new ethical frameworks for genetic databases. <i>Nature Reviews Genetics</i> , 2001, 2, 318-321.	7.7	202
1680	Evidence for Maximal Treatment of Atherosclerosis: Drastic Reduction of Cholesterol and Fibrinogen Restores Vascular Homeostasis. <i>Therapeutic Apheresis and Dialysis</i> , 2001, 5, 207-211.	0.6	10
1681	A Comparison of Continuous Combined Hormone Replacement Therapy, HMG-CoA Reductase Inhibitor and Combined Treatment for the Management of Hypercholesterolemia in Postmenopausal Women. <i>Journal of Obstetrics and Gynaecology Research</i> , 2001, 27, 353-358.	0.6	3
1682	Impact of preexisting statin use on adhesion molecule expression in patients presenting with acute coronary syndromes. <i>American Journal of Cardiology</i> , 2001, 87, 446-448.	0.7	43
1683	Effect of simvastatin in preventing progression of carotid artery stenosis. <i>American Journal of Cardiology</i> , 2001, 87, 643-645.	0.7	16
1684	Effect of concomitant or very early statin administration on in-hospital mortality and reinfarction in patients with acute myocardial infarction. <i>American Journal of Cardiology</i> , 2001, 87, 771-774.	0.7	49
1685	Pro and con: high-density lipoprotein, triglycerides, and other lipid subfractions are the future of lipid management—This article represents one side of a debate on the role of lipid subfractions in cardiovascular risk management; the opposing argument can be found in the accompanying article by Terje R. Pedersen, MD, PhD.. <i>American Journal of Cardiology</i> , 2001, 87, 2-7.	0.7	52
1686	Pro and con: low-density lipoprotein cholesterol lowering is and will be the key to the future of lipid management—This article represents one side of a debate regarding the role of lipid subfractions in cardiovascular risk management; the opposing argument can be found in the accompanying article by Gerd Assmann, MD.. <i>American Journal of Cardiology</i> , 2001, 87, 8-12.	0.7	50
1687	Statin therapy: where are we? where do we go next?. <i>American Journal of Cardiology</i> , 2001, 87, 13-18.	0.7	32
1688	Economics of lipid lowering in primary prevention: lessons from the West of Scotland Coronary Prevention Study. <i>American Journal of Cardiology</i> , 2001, 87, 19-22.	0.7	20
1689	Novel approaches to lipid lowering: what is on the horizon?. <i>American Journal of Cardiology</i> , 2001, 87, 23-27.	0.7	45
1690	Statin therapy and reductions in low-density lipoprotein cholesterol: initial clinical data on the potent new statin rosuvastatin11CRESTOR is a trademark, the property of AstraZeneca PLC. Research discussed in this article was supported by AstraZeneca.. <i>American Journal of Cardiology</i> , 2001, 87, 33-36.	0.7	37
1691	The Quinapril Ischemic Event Trial (QUIET): evaluation of chronic ace inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. <i>American Journal of Cardiology</i> , 2001, 87, 1058-1063.	0.7	222
1692	Air force/texas coronary atherosclerosis prevention study (afcaps/texcaps): Additional perspectives on tolerability of long-term treatment with lovastatin. <i>American Journal of Cardiology</i> , 2001, 87, 1074-1079.	0.7	127
1693	Using both “relative risk reduction” and “number needed to treat” in evaluating primary and secondary clinical trials of lipid reduction. <i>American Journal of Cardiology</i> , 2001, 87, 1206-1208.	0.7	10
1694	Effectiveness of the electronic medical record in cholesterol management in patients with coronary artery disease (Virtual Lipid Clinic). <i>American Journal of Cardiology</i> , 2001, 88, 163-165.	0.7	27

#	ARTICLE	IF	CITATIONS
1695	Endovascular and surgical revascularization for patients with intermittent claudication. American Journal of Cardiology, 2001, 87, 34-43.	0.7	241
1696	Statin therapy and the acute inflammatory response after coronary artery bypass grafting. American Journal of Cardiology, 2001, 88, 431-433.	0.7	60
1697	Coronary artery disease progression assessed by electron-beam computed tomography. American Journal of Cardiology, 2001, 88, 46-50.	0.7	95
1698	Development of tachyphylaxis on statin treatment. American Journal of Cardiology, 2001, 88, 936-937.	0.7	1
1699	Going from immutable to mutable atherosclerotic plaques. American Journal of Cardiology, 2001, 88, 2-9.	0.7	37
1700	Are we aggressive enough in lowering cholesterol?. American Journal of Cardiology, 2001, 88, 10-15.	0.7	13
1701	Making practical sense of clinical trial data in decreasing cardiovascular risk. American Journal of Cardiology, 2001, 88, 16-20.	0.7	4
1702	What are the priorities for managing cholesterol effectively?. American Journal of Cardiology, 2001, 88, 21-24.	0.7	5
1703	Developing a clinical strategy for cholesterol management in an era of unanswered questions. American Journal of Cardiology, 2001, 88, 25-30.	0.7	2
1704	Effectiveness of statins in acute coronary syndromes. American Journal of Cardiology, 2001, 88, 31-35.	0.7	8
1705	Ongoing clinical trials of statins. American Journal of Cardiology, 2001, 88, 36-40.	0.7	22
1706	Cerebrovascular disease and statins: a potential addition to the therapeutic armamentarium for stroke prevention. American Journal of Cardiology, 2001, 88, 33-37.	0.7	27
1707	Women and cardiovascular risk. American Journal of Cardiology, 2001, 88, 48-52.	0.7	30
1708	What is the role of intensive cholesterol lowering in the treatment of acute coronary syndromes?. American Journal of Cardiology, 2001, 88, 7-16.	0.7	17
1709	Postdischarge lipid management of coronary artery disease patients according to the new national cholesterol education program guidelines. American Journal of Cardiology, 2001, 88, 37-41.	0.7	13
1710	United states cholesterol guidelines 2001: expanded scope of intensive low-density lipoproteinâ€“lowering therapy. American Journal of Cardiology, 2001, 88, 23-27.	0.7	103
1711	Cholesterol lowering with statins reduces exercise-induced myocardial ischemia in hypercholesterolemic patients with coronary artery disease. American Journal of Cardiology, 2001, 88, 1134-1138.	0.7	6
1712	Effect of lipid-lowering agents, angiotensin-converting enzyme inhibitors, and calcium antagonists on coronary disease risk. American Journal of Cardiology, 2001, 88, 21-25.	0.7	8

#	ARTICLE	IF	CITATIONS
1713	Effectiveness of chart prompts to improve physician compliance with the National Cholesterol Education Program guidelines. <i>American Journal of Cardiology</i> , 2001, 88, 1420-1423.	0.7	25
1714	Managing the risk of atherosclerosis: the role of high-density lipoprotein. <i>American Journal of Cardiology</i> , 2001, 88, 3-8.	0.7	144
1715	Epidemiologic evidence for high-density lipoprotein cholesterol as a risk factor for coronary artery disease. <i>American Journal of Cardiology</i> , 2001, 88, 9-13.	0.7	137
1716	Targeting low high-density lipoprotein cholesterol for therapy: lessons from the Veterans Affairs High-density Lipoprotein Intervention Trial. <i>American Journal of Cardiology</i> , 2001, 88, 19-23.	0.7	68
1717	High-density lipoprotein cholesterol and treatment guidelines. <i>American Journal of Cardiology</i> , 2001, 88, 41-44.	0.7	6
1719	Rationale and Design of the St. Francis Heart Study. <i>Contemporary Clinical Trials</i> , 2001, 22, 553-572.	2.0	33
1720	Participant Recruitment in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). <i>Contemporary Clinical Trials</i> , 2001, 22, 674-686.	2.0	36
1721	Effect of atorvastatin, simvastatin, and lovastatin on the metabolism of cholesterol and triacylglycerides in HepG2 cells. <i>Biochemical Pharmacology</i> , 2001, 62, 1545-1555.	2.0	84
1722	Effect of simvastatin on vascular smooth muscle responsiveness: involvement of Ca <sup>2+</sup> homeostasis. <i>European Journal of Pharmacology</i> , 2001, 415, 217-224.	1.7	27
1723	The cholesterol absorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeys. <i>European Journal of Pharmacology</i> , 2001, 415, 79-84.	1.7	121
1724	Optimal medical management of patients with chronic ischemic heart disease. <i>Current Problems in Cardiology</i> , 2001, 26, 195-238.	1.1	0
1725	The expanding role of HMG-CoA reductase inhibitors (statins) in the prevention and treatment of ischemic heart disease. <i>Current Problems in Cardiology</i> , 2001, 26, 734-764.	1.1	6
1726	Temporal changes in cardiac function and cerebral blood flow during sequential postmenopausal hormone replacement. <i>American Journal of Obstetrics and Gynecology</i> , 2001, 184, 41-47.	0.7	13
1727	Treating dyslipidaemia in non-insulin-dependent diabetes mellitus – a special reference to statins. <i>Journal of Diabetes and Its Complications</i> , 2001, 15, 211-226.	1.2	27
1728	Management of hyperlipidemia in children. <i>Progress in Pediatric Cardiology</i> , 2001, 12, 205-213.	0.2	11
1729	Simulation of a putative susceptibility risk factor to explain the findings of the Heart and Estrogen/progestin Replacement Study (HERS). <i>GeneScreen</i> , 2001, 1, 169-171.	0.7	0
1730	Recent advances in myocardial perfusion imaging. <i>Current Problems in Cardiology</i> , 2001, 26, 8-140.	1.1	6
1731	The Lack of Cardiovascular Risk Factor Management in Patients with Critical Limb Ischaemia. <i>European Journal of Vascular and Endovascular Surgery</i> , 2001, 21, 143-146.	0.8	32

#	ARTICLE	IF	CITATIONS
1732	Pravastatin Attenuates Lower Torso Ischaemiaâ€“Reperfusion-induced Lung Injury by Upregulating Constitutive Endothelial Nitric Oxide Synthase. <i>European Journal of Vascular and Endovascular Surgery</i> , 2001, 21, 295-300.	0.8	34
1733	Four cases of tendinopathy in patients on statin therapy. <i>Joint Bone Spine</i> , 2001, 68, 430-433.	0.8	73
1734	Effects of yoghurt enriched with plant sterols on serum lipids in patients with moderate hypercholesterolaemia. <i>British Journal of Nutrition</i> , 2001, 86, 233-239.	1.2	108
1735	Time to look beyond just lowering the serum concentration of low density lipoprotein - high density lipoprotein levels are also important. <i>Perspectives in Public Health</i> , 2001, 121, 98-101.	0.5	2
1736	Pravastatin Treatment Increases Collagen Content and Decreases Lipid Content, Inflammation, Metalloproteinases, and Cell Death in Human Carotid Plaques. <i>Circulation</i> , 2001, 103, 926-933.	1.6	942
1737	Markers of Myocardial Damage and Inflammation in Unstable Coronary Artery Disease. <i>New England Journal of Medicine</i> , 2001, 344, 688-689.	13.9	3
1738	In-Hospital Initiation of Lipid-Lowering Therapy for Patients With Coronary Heart Disease. <i>Circulation</i> , 2001, 103, 2768-2770.	1.6	76
1739	Common Hepatic Lipase Gene Promoter Variant Determines Clinical Response to Intensive Lipid-Lowering Treatment. <i>Circulation</i> , 2001, 103, 792-798.	1.6	110
1740	Risk Reduction and the Program on the Surgical Control of the Hyperlipidemias. <i>Circulation</i> , 2001, 104, E47.	1.6	5
1741	The Relationship Between Low-Density Lipoprotein Cholesterol Goal Attainment and Prevention of Coronary Heart Disease-Related Events. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2001, 6, 129-135.	1.0	27
1742	Endothelial nitric oxide synthase is essential for the HMGâ€“CoA reductase inhibitor cerivastatin to promote collateral growth in response to ischemia. <i>FASEB Journal</i> , 2001, 15, 2530-2532.	0.2	112
1743	Diabetes Mellitus and Cardiovascular Disease. <i>The Diabetes Educator</i> , 2001, 27, 28-34.	2.6	2
1745	Rhabdomyolysis and HMG-CoA Reductase Inhibitors. <i>Annals of Pharmacotherapy</i> , 2001, 35, 1096-1107.	0.9	291
1746	3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibition Prevents Endothelial NO Synthase Downregulation by Atherogenic Levels of Native LDLs. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2001, 21, 804-809.	1.1	81
1747	Simvastatin Exerts Both Anti-inflammatory and Cardioprotective Effects in Apolipoprotein Eâ€“Deficient Mice. <i>Circulation</i> , 2001, 103, 2598-2603.	1.6	189
1748	Increase in Circulating Endothelial Progenitor Cells by Statin Therapy in Patients With Stable Coronary Artery Disease. <i>Circulation</i> , 2001, 103, 2885-2890.	1.6	968
1749	Comparison of Various Electrophoretic Characteristics of LDL Particles and Their Relationship to the Risk of Ischemic Heart Disease. <i>Circulation</i> , 2001, 104, 2295-2299.	1.6	241
1750	Raman Spectroscopic Evaluation of the Effects of Diet and Lipid-Lowering Therapy on Atherosclerotic Plaque Development in Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2001, 21, 1630-1635.	1.1	70

#	ARTICLE	IF	CITATIONS
1751	Invited Review: Cardioprotective Effects of $\omega$ -3 Fatty Acids. <i>Nutrition in Clinical Practice</i> , 2001, 16, 6-12.	1.1	1
1752	Statin status. <i>British Journal of Diabetes and Vascular Disease</i> , 2001, 1, 102-102.	0.6	1
1753	Blood Lipids and First-Ever Ischemic Stroke/Transient Ischemic Attack in the Bezafibrate Infarction Prevention (BIP) Registry. <i>Circulation</i> , 2001, 104, 2892-2897.	1.6	142
1754	Foundations for blockbuster drugs in federally sponsored research. <i>FASEB Journal</i> , 2001, 15, 1671-1676.	0.2	110
1755	Tamoxifen Effects on Endothelial Function and Cardiovascular Risk Factors in Men With Advanced Atherosclerosis. <i>Circulation</i> , 2001, 103, 1497-1502.	1.6	67
1756	Pretreatment With Simvastatin Attenuates Myocardial Dysfunction After Ischemia and Chronic Reperfusion. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2001, 21, 2059-2064.	1.1	84
1758	New Recommendations from the 1999 American College of Cardiology/American Heart Association Acute Myocardial Infarction Guidelines. <i>Annals of Pharmacotherapy</i> , 2001, 35, 589-617.	0.9	45
1759	Clinical Trials Update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001. <i>European Journal of Heart Failure</i> , 2001, 3, 381-387.	2.9	148
1760	Mevastatin, an HMG-CoA Reductase Inhibitor, Reduces Stroke Damage and Upregulates Endothelial Nitric Oxide Synthase in Mice. <i>Stroke</i> , 2001, 32, 980-986.	1.0	318
1761	Effect of Acute Myocardial Infarction on Cholesterol Ratios. <i>Chest</i> , 2001, 120, 1196-1199.	0.4	52
1762	Antioxidant Supplements Block the Response of HDL to Simvastatin-Niacin Therapy in Patients With Coronary Artery Disease and Low HDL. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2001, 21, 1320-1326.	1.1	193
1763	Lipid Disorders. <i>Chest</i> , 2001, 120, 979-988.	0.4	17
1764	Myocardial Infarction in Young Adults With Low-Density Lipoprotein Cholesterol Levels $\geq$ 100 mg/dL. <i>Chest</i> , 2001, 120, 1953-1958.	0.4	21
1765	Cholesteryl ester transfer protein inhibitors. <i>Expert Opinion on Therapeutic Patents</i> , 2001, 11, 739-745.	2.4	4
1766	The Role of Risk Factors in the Development of Atherosclerosis. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2001, 38, 401-440.	2.7	25
1767	Current approaches to therapy for vascular injury. <i>Expert Opinion on Pharmacotherapy</i> , 2001, 2, 753-764.	0.9	2
1768	Secondary prevention fallacy: pitfalls in comparing with primary. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2001, 1, 13-18.	0.7	0
1769	Simvastatin Has Anti-Inflammatory and Antiatherosclerotic Activities Independent of Plasma Cholesterol Lowering. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2001, 21, 115-121.	1.1	357

#	ARTICLE	IF	CITATIONS
1771	Simvastatin strongly reduces levels of Alzheimer's disease A $\beta$ -amyloid peptides A $\beta$ 42 and A $\beta$ 40 in vitro and in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 5856-5861.	3.3	1,050
1772	Alternate-Day Dosing of HMG-CoA Reductase Inhibitors for Cholesterol Reduction. Annals of Pharmacotherapy, 2001, 35, 496-500.	0.9	15
1773	Cerivastatin, a Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor, Improves Endothelial Function in Elderly Diabetic Patients Within 3 Days. Circulation, 2001, 104, 376-379.	1.6	261
1774	Prevention and Treatment of Coronary Heart Disease. Circulation, 2001, 104, 1688-1692.	1.6	25
1775	HMG-CoA Reductase Inhibitors Prevent Migration of Human Coronary Smooth Muscle Cells Through Suppression of Increase in Oxidative Stress. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 937-942.	1.1	66
1776	The in vitro Inhibitory Effect of Tannin Derivatives on 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase on Vero Cells. Pharmacology, 2001, 62, 224-228.	0.9	14
1777	Multiple Complex Coronary Plaques in Patients with Acute Myocardial Infarction. New England Journal of Medicine, 2001, 344, 527-528.	13.9	9
1778	Statins Alter Smooth Muscle Cell Accumulation and Collagen Content in Established Atheroma of Watanabe Heritable Hyperlipidemic Rabbits. Circulation, 2001, 103, 993-999.	1.6	366
1779	Downregulation of Angiotensin II Type 1 Receptor by Hydrophobic 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors in Vascular Smooth Muscle Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 1896-1901.	1.1	123
1780	BASELINE DIENE CONJUGATION IN LDL LIPIDS: AN INDICATOR OF CIRCULATING OXIDIZED LDL. , 2001, , 7-16.		0
1781	Reduction of Stroke Events With Pravastatin. Circulation, 2001, 103, 387-392.	1.6	258
1782	Guidelines accompanied by changes in reimbursement rules Effects on lipid-lowering drug prescribing. Scandinavian Journal of Primary Health Care, 2001, 19, 158-162.	0.6	11
1783	Do HMG-CoA Reductase Inhibitors Affect Fibrinogen?. Annals of Pharmacotherapy, 2001, 35, 236-241.	0.9	18
1784	The Year in Review: Cardiology. Journal of Pharmacy Practice, 2001, 14, 18-40.	0.5	0
1785	Cerivastatin Induces Carotid Artery Plaque Stabilization Independently of Cholesterol Lowering in Patients with Hypercholesterolaemia. Journal of International Medical Research, 2001, 29, 329-334.	0.4	12
1786	Low-Dose Metoprolol CR/XL and Fluvastatin Slow Progression of Carotid Intima-Media Thickness. Circulation, 2001, 103, 1721-1726.	1.6	309
1787	Effect of Statin Therapy on Remnant Lipoprotein Cholesterol Levels in Patients With Combined Hyperlipidemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 2026-2031.	1.1	70
1788	Coronary Heart Disease in the First 30 Years of the 21st Century: Challenges and Opportunities. Circulation, 2001, 103, 2428-2435.	1.6	38



#	ARTICLE	IF	CITATIONS
1789	Influence of Low High-Density Lipoprotein Cholesterol and Elevated Triglyceride on Coronary Heart Disease Events and Response to Simvastatin Therapy in 4S. <i>Circulation</i> , 2001, 104, 3046-3051.	1.6	390
1790	Use of Intravascular Ultrasound to Compare Effects of Different Strategies of Lipid-Lowering Therapy on Plaque Volume and Composition in Patients With Coronary Artery Disease. <i>Circulation</i> , 2001, 104, 387-392.	1.6	350
1791	A Comparison of Clinical Outcome Studies among Cholesterol-Lowering Agents. <i>Annals of Pharmacotherapy</i> , 2001, 35, 1599-1607.	0.9	18
1792	Primary Prevention of Ischemic Stroke. <i>Circulation</i> , 2001, 103, 163-182.	1.6	340
1793	HMG-CoA Reductase Inhibitors Improve Endothelial Dysfunction in Normocholesterolemic Hypertension via Reduced Production of Reactive Oxygen Species. <i>Hypertension</i> , 2001, 37, 1450-1457.	1.3	431
1794	Ezetimibe, a Potent Cholesterol Absorption Inhibitor, Inhibits the Development of Atherosclerosis in ApoE Knockout Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2001, 21, 2032-2038.	1.1	203
1795	Statins for Stroke: The Second Story?. <i>Circulation</i> , 2001, 103, 348-350.	1.6	23
1796	Pleiotropic Effects of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2001, 21, 1712-1719.	1.1	1,182
1797	Use of Lipid-Lowering Medications at Discharge in Patients With Acute Myocardial Infarction. <i>Circulation</i> , 2001, 103, 38-44.	1.6	220
1798	The Use of Numbers Needed to Treat Derived from Systematic Reviews and Meta-Analysis. <i>Evaluation and the Health Professions</i> , 2001, 24, 152-164.	0.9	22
1799	Effect of an Aggressive Lipid-Lowering Strategy on Progression of Atherosclerosis in the Left Main Coronary Artery From Patients in the Post Coronary Artery Bypass Graft Trial. <i>Circulation</i> , 2001, 104, 2660-2665.	1.6	51
1800	Reduction in Stroke With Gemfibrozil in Men With Coronary Heart Disease and Low HDL Cholesterol. <i>Circulation</i> , 2001, 103, 2828-2833.	1.6	254
1801	Colesevelam Hydrochloride: A Novel Bile Acid-Binding Resin. <i>Annals of Pharmacotherapy</i> , 2001, 35, 898-907.	0.9	81
1802	Facilitative interaction between angiotensin II and oxidised LDL in cultured human coronary artery endothelial cells. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2001, 2, S70-S76.	1.0	8
1803	The effect of HMG-CoA reductase inhibitors on chronic allograft rejection. <i>Expert Opinion on Emerging Drugs</i> , 2001, 6, 95-109.	1.1	3
1804	How Disturbing Is It to Be Approached for a Genetic Cascade Screening Programme for Familial Hypercholesterolaemia?. <i>Public Health Genomics</i> , 2001, 4, 244-252.	0.6	34
1805	Controversies in the Treatment of Hypercholesterolemia in the Elderly: Who Should Be Treated and How?. <i>The American Journal of Geriatric Cardiology</i> , 2001, 10, 152-158.	0.7	2
1806	Current practice in the treatment of hyperlipidaemias. <i>Expert Opinion on Pharmacotherapy</i> , 2001, 2, 1777-1794.	0.9	8

#	ARTICLE	IF	CITATIONS
1807	An Analysis of Nine Proprietary Chinese Red Yeast Rice Dietary Supplements: Implications of Variability in Chemical Profile and Contents. <i>Journal of Alternative and Complementary Medicine</i> , 2001, 7, 133-139.	2.1	127
1808	Elderly Patients at Risk for Coronary Heart Disease or Stroke: Selecting an Ideal Product for Lipid Lowering. <i>The American Journal of Geriatric Cardiology</i> , 2001, 10, 77-84.	0.7	6
1809	Ezetimibe, a Potent Cholesterol Absorption Inhibitor, Normalizes Combined Dyslipidemia in Obese Hyperinsulinemic Hamsters. <i>Diabetes</i> , 2001, 50, 1330-1335.	0.3	77
1810	Treatment of the Elderly Post-Myocardial Infarction Patient. <i>The American Journal of Geriatric Cardiology</i> , 2001, 10, 316-323.	0.7	4
1811	Physical exercise in dyslipoproteinemias: An update. <i>European Journal of Sport Science</i> , 2002, 2, 1-13.	1.4	3
1812	Pharmacology of 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitors (Statins), Including Rosuvastatin and Pitavastatin. <i>Journal of Clinical Pharmacology</i> , 2002, 42, 835-845.	1.0	81
1813	Rhabdomyolysis and Statin Therapy: Relevance to the Elderly. <i>The American Journal of Geriatric Cardiology</i> , 2002, 11, 48-55.	0.7	52
1814	Physical activity, body mass index, lipid lowering agents, and LDL cholesterol levels in secondary prevention of CHD. <i>European Journal of Sport Science</i> , 2002, 2, 1-10.	1.4	0
1815	Niacin extended-release/lovastatin: combination therapy for lipid disorders. <i>Expert Opinion on Pharmacotherapy</i> , 2002, 3, 1763-1771.	0.9	25
1816	Risk factor thresholds: their existence under scrutiny. <i>BMJ: British Medical Journal</i> , 2002, 324, 1570-1576.	2.4	207
1817	Immunomodulatory Effects of Statins: Mechanisms and Potential Impact on Arteriosclerosis. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 1673-1681.	3.0	109
1818	Early and Sustained Survival Benefit Associated With Statin Therapy at the Time of Percutaneous Coronary Intervention. <i>Circulation</i> , 2002, 105, 691-696.	1.6	237
1819	Statins: Powerful Drugs for Lowering Cholesterol. <i>Circulation</i> , 2002, 105, 1514-1516.	1.6	26
1820	The Effects of Combination Therapy with Niceritrol and Pravastatin on Hyperlipidaemia. <i>Journal of International Medical Research</i> , 2002, 30, 271-281.	0.4	4
1821	Development of a Pharmacist-Managed Lipid Clinic. <i>Annals of Pharmacotherapy</i> , 2002, 36, 892-904.	0.9	40
1822	Effect of 3 Months of Antimicrobial Treatment With Clarithromycin in Acute Non-Q-Wave Coronary Syndrome. <i>Circulation</i> , 2002, 105, 1555-1560.	1.6	120
1823	Statins and Renal Function. <i>Angiology</i> , 2002, 53, 493-502.	0.8	95
1824	Circulatory dynamics during dental extractions in normal, cardiac and transplant patients. <i>Journal of the American Dental Association</i> , 2002, 133, 468-472.	0.7	15

#	ARTICLE	IF	CITATIONS
1825	Five-year Mortality for Stable Angina in a Medical Practice Study and a Randomized Trial. <i>Scandinavian Cardiovascular Journal</i> , 2002, 36, 209-214.	0.4	1
1826	Inhibition of rat lipoprotein lipid peroxidation by the oral administration of D003, a mixture of very long-chain saturated fatty acids. <i>Canadian Journal of Physiology and Pharmacology</i> , 2002, 80, 13-21.	0.7	38
1827	Screening for traditional risk factors for cardiovascular disease. <i>Journal of the American Dental Association</i> , 2002, 133, 291-300.	0.7	18
1828	FDA Adverse Event Reports on Statin-Associated Rhabdomyolysis. <i>Annals of Pharmacotherapy</i> , 2002, 36, 288-295.	0.9	342
1829	Stroke Prevention Therapy Beyond Antithrombotics: Unifying Mechanisms in Ischemic Stroke Pathogenesis and Implications for Therapy. <i>Stroke</i> , 2002, 33, 862-875.	1.0	205
1830	Comparison of estimates and calculations of risk of coronary heart disease by doctors and nurses using different calculation tools in general practice: cross sectional study. <i>BMJ: British Medical Journal</i> , 2002, 324, 459-464.	2.4	58
1831	Cellular Antioxidant Effects of Atorvastatin In Vitro and In Vivo. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002, 22, 300-305.	1.1	546
1832	Statins: balancing benefits, efficacy and safety. <i>Expert Opinion on Pharmacotherapy</i> , 2002, 3, 469-477.	0.9	10
1833	Absorption of Colesevelam Hydrochloride in Healthy Volunteers. <i>Annals of Pharmacotherapy</i> , 2002, 36, 398-403.	0.9	40
1834	Bone Marrow-Derived Progenitor Cells Modulate Vascular Reendothelialization and Neointimal Formation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002, 22, 1567-1572.	1.1	415
1835	Medical Economics and the Assessment of Value in Cardiovascular Medicine: Part II. <i>Circulation</i> , 2002, 106, 626-630.	1.6	47
1836	Simvastatin Reduces Expression of Cytokines Interleukin-6, Interleukin-8, and Monocyte Chemoattractant Protein-1 in Circulating Monocytes From Hypercholesterolemic Patients. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002, 22, 1194-1199.	1.1	340
1837	Safety and Tolerability of Pravastatin in Long-Term Clinical Trials. <i>Circulation</i> , 2002, 105, 2341-2346.	1.6	233
1838	Reducing the Risk for Stroke in Patients With Myocardial Infarction. <i>Circulation</i> , 2002, 106, 1595-1598.	1.6	10
1839	Treating to goal: new strategies for initiating and optimizing lipid-lowering therapy in patients with atherosclerosis. <i>Vascular Medicine</i> , 2002, 7, 187-194.	0.8	9
1840	Statins Reduce Inflammation in Atheroma of Nonhuman Primates Independent of Effects on Serum Cholesterol. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002, 22, 1452-1458.	1.1	215
1841	Unraveling Pleiotropic Effects of Statins on Plaque Rupture. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002, 22, 1745-1750.	1.1	77
1842	Withdrawal of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Elicits Oxidative Stress and Induces Endothelial Dysfunction in Mice. <i>Circulation Research</i> , 2002, 91, 173-179.	2.0	158

#	ARTICLE	IF	CITATIONS
1843	Fluvastatin. Expert Opinion on Pharmacotherapy, 2002, 3, 1631-1641.	0.9	18
1844	A safety look at currently available statins. Expert Opinion on Drug Safety, 2002, 1, 269-274.	1.0	19
1845	Review: Renin-angiotensin system antagonism and lipid-lowering therapy in cardiovascular risk management. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2002, 3, 96-102.	1.0	4
1846	ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Stroke, 2002, 33, 2337-2341.	1.0	184
1847	High "population attributable fraction" for coronary heart disease mortality among relatives in monogenic familial hypercholesterolemia. Genetics in Medicine, 2002, 4, 275-278.	1.1	21
1848	Optimal treatment and current situation in reperfusion after thrombolysis for acute myocardial infarction. Annals of Medicine, 2002, 34, 514-522.	1.5	3
1849	Efficacy of case method learning in general practice for secondary prevention in patients with coronary artery disease: randomised controlled study. BMJ: British Medical Journal, 2002, 325, 877-880.	2.4	43
1850	Use of Statins and Aspirin to Reduce Risks of Cardiovascular Disease. Journal of Cardiovascular Pharmacology and Therapeutics, 2002, 7, 77-80.	1.0	22
1851	Statin enhances cytokine-mediated induction of nitric oxide synthesis in vascular smooth muscle cells. Cardiovascular Research, 2002, 54, 649-658.	1.8	61
1852	Ezetimibe. Expert Opinion on Investigational Drugs, 2002, 11, 1587-1604.	1.9	95
1853	Pleiotropic Effects of Statins: Lipid Reduction and Beyond. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 1451-1458.	1.8	282
1854	Impact of availability and use of coronary interventions on the prescription of aspirin and lipid lowering treatment after acute coronary syndromes. British Heart Journal, 2002, 88, 20-24.	2.2	26
1855	Simvastatin Promotes Atherosclerotic Plaque Stability in ApoE-Deficient Mice Independently of Lipid Lowering. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 1832-1837.	1.1	135
1856	Early Statin Therapy for Acute Coronary Syndromes. Annals of Pharmacotherapy, 2002, 36, 1749-1758.	0.9	16
1857	Statins as Potent Antiinflammatory Drugs. Circulation, 2002, 106, 2041-2042.	1.6	170
1858	The Anatomy of a Clinical Trial. Medical Principles and Practice, 2002, 11, 17-30.	1.1	3
1860	Effect of Atorvastatin on High-Density Lipoprotein Apolipoprotein A-I Production and Clearance in the New Zealand White Rabbit. Circulation, 2002, 106, 2955-2960.	1.6	37
1861	The fetal origins of atherosclerosis: maternal hypercholesterolemia, and cholesterol-lowering or antioxidant treatment during pregnancy influence in utero programming and postnatal susceptibility to atherogenesis. FASEB Journal, 2002, 16, 1348-1360.	0.2	237

#	ARTICLE	IF	CITATIONS
1862	Simvastatin Preserves the Structure of Coronary Adventitial Vasa Vasorum in Experimental Hypercholesterolemia Independent of Lipid Lowering. <i>Circulation</i> , 2002, 105, 415-418.	1.6	224
1863	Myopathy Due to Statin/Fibrate Use in the Netherlands. <i>Annals of Pharmacotherapy</i> , 2002, 36, 1957-1960.	0.9	10
1864	Fluvastatin, a 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor, Attenuates Left Ventricular Remodeling and Failure After Experimental Myocardial Infarction. <i>Circulation</i> , 2002, 105, 868-873.	1.6	298
1865	Use of secondary preventive drugs in patients with acute coronary syndromes treated medically or with coronary angioplasty: results from the nationwide French PREVENIR survey. <i>British Heart Journal</i> , 2002, 88, 159-162.	2.2	47
1866	RAGE Blockade Stabilizes Established Atherosclerosis in Diabetic Apolipoprotein E $\alpha$ -Null Mice. <i>Circulation</i> , 2002, 106, 2827-2835.	1.6	553
1867	Therapeutic Controversies; Lack of Therapeutic Interchangeability of HMG-CoA Reductase Inhibitors. <i>Annals of Pharmacotherapy</i> , 2002, 36, 1907-1917.	0.9	30
1868	Low prevalence of lipid lowering drug use in older men with established coronary heart disease. <i>British Heart Journal</i> , 2002, 88, 25-29.	2.2	64
1869	ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. <i>Circulation</i> , 2002, 106, 1024-1028.	1.6	657
1870	Improvements in total mortality and lipid levels after acute myocardial infarction in an English health district (1995-1999). <i>British Heart Journal</i> , 2002, 87, 428-431.	2.2	4
1871	Low-Density Lipoprotein Level Reduction by the 3-Hydroxy-3-Methylglutaryl Coenzyme-A Inhibitor Simvastatin Is Accompanied by a Related Reduction of F $2$ -Isoprostane Formation in Hypercholesterolemic Subjects. <i>Circulation</i> , 2002, 106, 2543-2549.	1.6	114
1872	Causal Structures for Evaluating Statin Class Effects. <i>Annals of Pharmacotherapy</i> , 2002, 36, 1961-1965.	0.9	1
1873	Undertreatment of dyslipidemia in peripheral arterial disease and other high-risk populations: an opportunity for cardiovascular disease reduction. <i>Vascular Medicine</i> , 2002, 7, 323-331.	0.8	36
1874	Coronary Heart Disease in Patients With Low LDL-Cholesterol. <i>Circulation</i> , 2002, 105, 1424-1428.	1.6	169
1875	Effect of Colesevelam on Lovastatin Pharmacokinetics. <i>Annals of Pharmacotherapy</i> , 2002, 36, 392-397.	0.9	25
1876	Lovastatin Enhances Ecto-5 $\alpha$ -Nucleotidase Activity and Cell Surface Expression in Endothelial Cells. <i>Circulation Research</i> , 2002, 90, 420-427.	2.0	55
1877	Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor Simvastatin Prevents Cardiac Hypertrophy Induced by Pressure Overload and Inhibits p21rasActivation. <i>Circulation</i> , 2002, 106, 2118-2124.	1.6	105
1878	Withdrawal of Statins Increases Event Rates in Patients With Acute Coronary Syndromes. <i>Circulation</i> , 2002, 105, 1446-1452.	1.6	472
1879	Use of statins in the secondary prevention of coronary heart disease: is treatment equitable?. <i>British Heart Journal</i> , 2002, 88, 15-19.	2.2	94

#	ARTICLE	IF	CITATIONS
1880	Statin Therapy, Cardiovascular Events, and Total Mortality in the Heart and Estrogen/Progestin Replacement Study (HERS). <i>Circulation</i> , 2002, 105, 2962-2967.	1.6	223
1881	Risk Factors Indicating Recurrent Myocardial Infarction After Recovery From Acute Myocardial Infarction.. <i>Circulation Journal</i> , 2002, 66, 877-880.	0.7	10
1882	Effect of Chlorella Tablet Ingestion on Mild Hypercholesterolemic Patients.. <i>Journal of the Japanese Society for Food Science and Technology</i> , 2002, 49, 395-400.	0.1	8
1883	Evaluation of Myopathy Risk for HMG-CoA Reductase Inhibitors by Urethane Infusion Method.. <i>Biological and Pharmaceutical Bulletin</i> , 2002, 25, 346-350.	0.6	21
1884	Medicalisation, limits to medicine, or never enough money to go around?. <i>BMJ: British Medical Journal</i> , 2002, 324, 864-865.	2.4	27
1885	Progress in the Search for Ideal Drugs. <i>Pharmacology</i> , 2002, 64, 1-7.	0.9	11
1886	Can statins be used in patients with hepatitis B?. <i>Postgraduate Medicine</i> , 2002, 111, 119-120.	0.9	1
1887	Statins in the Prevention and Treatment of Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2002, 16, 131-136.	0.6	80
1888	Prevalence of Lipid-lowering Therapy at Cardiac Rehabilitation Entry: 2000 Versus 1996. <i>Journal of Cardiopulmonary Rehabilitation and Prevention</i> , 2002, 22, 80-84.	0.5	2
1889	The Surveillance of Cholesterol Management in the Cardiac Rehabilitation Setting. <i>Journal of Cardiopulmonary Rehabilitation and Prevention</i> , 2002, 22, 245-250.	0.5	3
1890	The future direction of cholesterol-lowering therapy. <i>Current Opinion in Lipidology</i> , 2002, 13, 663-669.	1.2	24
1891	Simvastatin improves endothelial function in spontaneously hypertensive rats through a superoxide dismutase mediated antioxidant effect. <i>Journal of Hypertension</i> , 2002, 20, 429-437.	0.3	63
1892	Number Needed to Treat in Cardiac Rehabilitation. <i>Journal of Cardiopulmonary Rehabilitation and Prevention</i> , 2002, 22, 22-30.	0.5	29
1893	Hypertriglyceridemia: A Review Beyond Low-Density Lipoprotein. <i>Cardiology in Review</i> , 2002, 10, 163-172.	0.6	36
1894	Title is missing!. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2002, 9, 83-87.	1.5	4
1895	Strategies for the Prevention of Atherosclerotic Progression in Women. <i>Cardiology in Review</i> , 2002, 10, 119-125.	0.6	4
1897	Fluvastatin Enhances Apoptosis in Cytokine-Stimulated Vascular Smooth Muscle Cells. <i>Journal of Cardiovascular Pharmacology</i> , 2002, 39, 310-317.	0.8	19
1898	Microbial metabolites with inhibitory activity against lipid metabolism. <i>Proceedings of the Japan Academy Series B: Physical and Biological Sciences</i> , 2002, 78, 217-240.	1.6	19

#	ARTICLE	IF	CITATIONS
1899	High-Density Lipoprotein Cholesterol and the Role of Statins.. Circulation Journal, 2002, 66, 1037-1044.	0.7	27
1900	Cerivastatin, a HMG-CoA Reductase Inhibitor, Reduces Plasminogen Activator Inhibitor-1 (PAI-1) Expression in Endothelial Cells by Down-Regulation of Cellular Signaling and the Inhibition of PAI-1 Promoter Activity. The Japanese Journal of Pharmacology, 2002, 90, 337-344.	1.2	17
1901	Large Scale Cohort Study of the Relationship Between Serum Cholesterol Concentration and Coronary Events With Low-Dose Simvastatin Therapy in Japanese Patients With Hypercholesterolemia. Primary Prevention Cohort Study of the Japan Lipid Intervention Trial (J-LIT).. Circulation Journal, 2002, 66, 1087-1095.	0.7	243
1902	Large Scale Cohort Study of the Relationship Between Serum Cholesterol Concentration and Coronary Events With Low-Dose Simvastatin Therapy in Japanese Patients With Hypercholesterolemia and Coronary Heart Disease. Secondary Prevention Cohort Study of the Japan Lipid Intervention Trial (J-LIT).. Circulation Journal, 2002, 66, 1096-1100.	0.7	131
1903	Medication for Hypercholesterolemia and the Risk of Nonfatal Acute Myocardial Infarction. A Case-Control Study in Japan.. Circulation Journal, 2002, 66, 463-468.	0.7	6
1904	Effects of Pravastatin on Exercise Electrocardiography Test Performance and Cardiovascular Mortality and Morbidity in Patients With Hypercholesterolemia. Circulation Journal, 2002, 66, 47-52.	0.7	10
1905	Modification of Treatment Strategies Over a Period of 14 Years Has Markedly Reduced Cardiac Events Among Post-Myocardial Infarction Patients.. Circulation Journal, 2002, 66, 881-885.	0.7	17
1906	Plasminogen Activator Inhibitor-1: Physiologic Role, Regulation, and the Influence of Common Pharmacologic Agents. Journal of Clinical Pharmacology, 2002, 42, 1187-1199.	1.0	44
1907	Plant sterol esterâ€™enriched spread lowers plasma total and LDL cholesterol in children with familial hypercholesterolemia. American Journal of Clinical Nutrition, 2002, 76, 338-344.	2.2	127
1908	Follow up after a family based genetic screening programme for familial hypercholesterolaemia: is screening alone enough?. BMJ: British Medical Journal, 2002, 324, 1367-1368.	2.4	10
1909	Lipoproteins, nutrition, and heart disease. American Journal of Clinical Nutrition, 2002, 75, 191-212.	2.2	349
1910	New Advances in Lipid-Modifying Therapies for Reducing Cardiovascular Risk. Cardiology, 2002, 97, 59-66.	0.6	24
1911	Diabetic Dyslipidaemia in Kuwait. Medical Principles and Practice, 2002, 11, 47-55.	1.1	14
1912	An Internistâ€™s Update on Cholesterol Management. American Journal of the Medical Sciences, 2002, 324, 189-195.	0.4	0
1913	Further reduction in mortality following myocardial infarction. British Journal of Hospital Medicine, 2002, 63, 610-614.	0.3	1
1914	The Impact of Biomarkers and Surrogate End Points on Regulatory Approval of New Drugs. Cardiology, 2002, 2, 235-245.	0.3	3
1915	The Hypertension-Lipid Connection: Insights into the Relation between Angiotensin II and Cholesterol in Atherogenesis. American Journal of the Medical Sciences, 2002, 323, 17-24.	0.4	40
1916	Physiciansâ€™ Judgments of Survival After Medical Management and Mortality Risk Reduction Due to Revascularization Procedures for Patients With Coronary Artery Disease. Chest, 2002, 122, 122-133.	0.4	27

#	ARTICLE	IF	CITATIONS
1917	Columbia University's Informatics for Diabetes Education and Telemedicine (IDEATel) Project: Rationale and Design. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2002, 9, 49-62.	2.2	162
1918	Simvastatin normalizes QTc dispersion and reduces ventricular electrical instability in isolated hypercholesterolemia. <i>Journal of Endocrinological Investigation</i> , 2002, 25, RC16-RC18.	1.8	11
1919	Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia. <i>BMJ: British Medical Journal</i> , 2002, 324, 1303-1303.	2.4	190
1920	Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study. <i>British Heart Journal</i> , 2002, 88, 229-233.	2.2	242
1921	Rosuvastatin for the Treatment of Patients with Hypercholesterolemia. <i>Annals of Pharmacotherapy</i> , 2002, 36, 93-101.	0.9	24
1922	Congestive Heart Failure. <i>American Journal of Cardiovascular Drugs</i> , 2002, 2, 1-6.	1.0	26
1923	Randomized clinical trials on the effects of dietary fat and carbohydrate on plasma lipoproteins and cardiovascular disease. <i>American Journal of Medicine</i> , 2002, 113, 13-24.	0.6	416
1924	Current medical therapies for patients with peripheral arterial disease: a critical review. <i>American Journal of Medicine</i> , 2002, 112, 49-57.	0.6	131
1925	Limitations of a meta-analysis investigating the association between cancer and statin use. <i>American Journal of Medicine</i> , 2002, 112, 157.	0.6	5
1926	Effects of calcium supplementation on serum lipid concentrations in normal older women:. <i>American Journal of Medicine</i> , 2002, 112, 343-347.	0.6	213
1927	Does participation in a long-term clinical trial lead to survival gain for patients with coronary artery disease?. <i>American Journal of Medicine</i> , 2002, 112, 545-548.	0.6	4
1928	Introduction. <i>American Journal of Medicine</i> , 2002, 112, 1-2.	0.6	9
1929	Identification and treatment of individuals at high risk of coronary heart disease. <i>American Journal of Medicine</i> , 2002, 112, 3-9.	0.6	15
1930	Management of dyslipidemia. <i>American Journal of Medicine</i> , 2002, 112, 10-18.	0.6	48
1931	Lipid management in diabetic patients: lessons from prevention trials. <i>American Journal of Medicine</i> , 2002, 112, 19-26.	0.6	146
1932	A look to the future: new treatment guidelines and a perspective on statins. <i>American Journal of Medicine</i> , 2002, 112, 34-41.	0.6	10
1933	Statins do not meet expectations for lowering low-density lipoprotein cholesterol levels when used in clinical practice. <i>American Journal of Medicine</i> , 2002, 113, 625-629.	0.6	104
1934	The vulnerable plaque and acute coronary syndromes. <i>American Journal of Medicine</i> , 2002, 113, 668-680.	0.6	94



#	ARTICLE	IF	CITATIONS
1935	Adherence to statin therapy: why aren't we doing better?. American Journal of Medicine, 2002, 113, 685-686.	0.6	14
1936	Use of Lipid-Lowering Drugs and Blood Pressure Control in Patients With Arterial Hypertension. Journal of Clinical Hypertension, 2002, 4, 277-285.	1.0	35
1937	Prognostic Value of Coronary Vascular Endothelial Dysfunction. Circulation, 2002, 106, 653-658.	1.6	1,293
1939	Bedside quantification of atherosclerosis severity for cardiovascular risk stratification: a prospective cohort study. Journal of the American College of Cardiology, 2002, 39, 702-709.	1.2	10
1940	Statins and chronic heart failure: do we need a large-scale outcome trial?. Journal of the American College of Cardiology, 2002, 39, 1567-1573.	1.2	122
1941	Atorvastatin decreases vascular endothelial growth factor in patients with coronary artery disease. Journal of the American College of Cardiology, 2002, 39, 1951-1955.	1.2	55
1942	Physicians' interpretation of "class effects". Journal of the American College of Cardiology, 2002, 40, 19-26.	1.2	14
1943	Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia. Journal of the American College of Cardiology, 2002, 40, 220-227.	1.2	156
1945	Simvastatin preserves myocardial perfusion and coronary microvascular permeability in experimental hypercholesterolemia independent of lipid lowering. Journal of the American College of Cardiology, 2002, 40, 546-554.	1.2	59
1946	Medical treatment of myocardial ischemia in coronary artery disease: effect of drug regime and irregular dosing in the CAPE II trial. Journal of the American College of Cardiology, 2002, 40, 917-925.	1.2	22
1947	Statin treatment following coronary artery stenting and one-year survival. Journal of the American College of Cardiology, 2002, 40, 854-861.	1.2	51
1948	Task Force #4 adherence issues and behavior changes: achieving a long-term solution. Journal of the American College of Cardiology, 2002, 40, 630-640.	1.2	86
1949	Impact of hydroxymethylglutaryl coenzyme A reductase inhibition on left ventricular remodeling after myocardial infarction. Journal of the American College of Cardiology, 2002, 40, 1695-1700.	1.2	49
1950	Statin therapy is associated with reduced mortality across all age groups of individuals with significant coronary disease, including very elderly patients. Journal of the American College of Cardiology, 2002, 40, 1777-1785.	1.2	112
1953	Expression of tissue transglutaminase and elafin in human coronary artery. Atherosclerosis, 2002, 160, 31-39.	0.4	38
1954	Lipid-lowering therapy with fluvastatin inhibits oxidative modification of low density lipoprotein and improves vascular endothelial function in hypercholesterolemic patients. Atherosclerosis, 2002, 160, 369-376.	0.4	68
1955	Baseline intestinal absorption and synthesis of cholesterol regulate its response to hypolipidaemic treatments in coronary patients. Atherosclerosis, 2002, 160, 477-481.	0.4	59
1956	3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation. Atherosclerosis, 2002, 161, 17-26.	0.4	179

#	ARTICLE	IF	CITATIONS
1957	Genetic polymorphisms: importance for response to HMG-CoA reductase inhibitors. <i>Atherosclerosis</i> , 2002, 163, 213-222.	0.4	71
1958	Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates. <i>Atherosclerosis</i> , 2002, 164, 129-145.	0.4	81
1959	Ineffective decrease of serum cholesterol by simvastatin in a subgroup of hypercholesterolemic coronary patients. <i>Atherosclerosis</i> , 2002, 164, 147-152.	0.4	46
1960	1 The Discovery and Development of Atorvastatin, A Potent Novel Hypolipidemic Agent. <i>Progress in Medicinal Chemistry</i> , 2002, 40, 1-22.	4.1	195
1961	Prevention of heart failure. <i>Journal of Cardiac Failure</i> , 2002, 8, 333-346.	0.7	84
1962	Who Should Treat Patients with Peripheral Arterial Disease – the Vascular Specialist. <i>European Journal of Vascular and Endovascular Surgery</i> , 2002, 24, 1-5.	0.8	9
1963	Effects of HMG-CoA Reductase Inhibitors on Skeletal Muscle. <i>Drug Safety</i> , 2002, 25, 649-663.	1.4	184
1964	Pharmacokinetic-Pharmacodynamic Drug Interactions with HMG-CoA Reductase Inhibitors. <i>Clinical Pharmacokinetics</i> , 2002, 41, 343-370.	1.6	369
1965	Drugs Affecting Homocysteine Metabolism. <i>Drugs</i> , 2002, 62, 605-616.	4.9	108
1966	Who Should Receive HMG CoA Reductase Inhibitors?. <i>Drugs</i> , 2002, 62, 1707-1715.	4.9	15
1967	Micronised Fenofibrate. <i>Drugs</i> , 2002, 62, 1909-1944.	4.9	106
1968	Rosuvastatin. <i>Drugs</i> , 2002, 62, 2075-2085.	4.9	65
1969	Cholesterol Absorption Inhibitors for the Treatment of Hypercholesterolaemia. <i>Drugs</i> , 2002, 62, 2333-2347.	4.9	73
1970	Statins and Menopause. <i>Drugs</i> , 2002, 62, 2421-2431.	4.9	6
1971	Addressing a Treatment Gap. <i>Clinical Drug Investigation</i> , 2002, 22, 291-301.	1.1	3
1972	Lipoprotein metabolism and molecular pathogenesis of atherosclerosis. <i>Advances in Cell Aging and Gerontology</i> , 2002, 11, 23-77.	0.1	0
1973	Health-Related Quality of Life and Long-Term Therapy with Pravastatin and Tocopherol (Vitamin E) in Older Adults. <i>Drugs and Aging</i> , 2002, 19, 793-805.	1.3	33
1974	Management of Hypercholesterolaemia in Postmenopausal Women. <i>Drugs and Aging</i> , 2002, 19, 169-178.	1.3	31

#	ARTICLE	IF	CITATIONS
1977	Lipid-Lowering Drug Use and Cardiovascular Events after Myocardial Infarction. <i>Annals of Pharmacotherapy</i> , 2002, 36, 751-757.	0.9	20
1978	HYPOLIPEMIC AGENTS FOR STROKE PREVENTION. <i>Clinical and Experimental Hypertension</i> , 2002, 24, 573-594.	0.5	8
1979	COST-EFFECTIVENESS ANALYSIS IN THE REAL WORLD: THE CASE OF STATINS. <i>Clinical Research and Regulatory Affairs</i> , 2002, 19, 381-396.	2.1	0
1980	Design, Analysis and Presentation of Multinational Economic Studies. <i>Pharmacoeconomics</i> , 2002, 20, 75-90.	1.7	33
1981	Effects of Combined Treatment with Simvastatin and L-Carnitine on Triglyceride Levels in Diabetic Patients with Hyperlipidaemia. <i>Clinical Drug Investigation</i> , 2002, 22, 23-28.	1.1	12
1982	How Do HMG-CoA Reductase Inhibitors Prevent Stroke?. <i>American Journal of Cardiovascular Drugs</i> , 2002, 2, 7-14.	1.0	10
1983	Management of Co-Existing Diabetes Mellitus and Dyslipidemia. <i>American Journal of Cardiovascular Drugs</i> , 2002, 2, 15-21.	1.0	29
1984	Pharmacotherapy of Obesity. <i>American Journal of Cardiovascular Drugs</i> , 2002, 2, 245-253.	1.0	25
1985	Strategies for Minimizing Hyperlipidemia After Cardiac Transplantation. <i>American Journal of Cardiovascular Drugs</i> , 2002, 2, 377-387.	1.0	8
1986	Pharmacotherapeutic options for the management of myocardial infarction. <i>Expert Opinion on Pharmacotherapy</i> , 2002, 3, 1153-1168.	0.9	1
1987	Differing effects of low-dose estrogen+progestin therapy and pravastatin in postmenopausal hypercholesterolemic women. <i>Climacteric</i> , 2002, 5, 341-350.	1.1	16
1988	Effects of Picosanol on Older Patients with Hypertension and Type II Hypercholesterolaemia. <i>Drugs in R and D</i> , 2002, 3, 159-172.	1.1	28
1989	Assessment of the Effects of D-003, a New Antiplatelet and Lipid-Lowering Compound, in Healthy Volunteers. <i>Drugs in R and D</i> , 2002, 3, 337-348.	1.1	19
1990	Improved fibrinolysis after 1-year treatment with HMG CoA reductase inhibitors in patients with coronary heart disease. <i>Thrombosis Research</i> , 2002, 105, 285-290.	0.8	49
1991	Invasive and medical therapy for coronary artery disease. <i>Lancet, The</i> , 2002, 359, 354-355.	6.3	0
1992	Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. <i>Lancet, The</i> , 2002, 359, 1269-1275.	6.3	581
1993	Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. <i>Lancet, The</i> , 2002, 359, 1379-1387.	6.3	254
1994	Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls. <i>Lancet, The</i> , 2002, 359, 1686-1689.	6.3	410

#	ARTICLE	IF	CITATIONS
1995	Disparity between angiographic regression and clinical event rates with hydrophobic statins. <i>Lancet, The</i> , 2002, 359, 2195-2198.	6.3	64
1996	MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial. <i>Lancet, The</i> , 2002, 360, 7-22.	6.3	7,542
1997	MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20 536 high-risk individuals: a randomised placebo-controlled trial. <i>Lancet, The</i> , 2002, 360, 23-33.	6.3	1,413
1998	Two decades of progress in preventing vascular disease. <i>Lancet, The</i> , 2002, 360, 2-3.	6.3	344
1999	Diet and risk of coronary heart disease and type 2 diabetes. <i>Lancet, The</i> , 2002, 360, 783-789.	6.3	216
2000	Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. <i>Lancet, The</i> , 2002, 360, 1623-1630.	6.3	3,147
2001	High-risk elderly patients PROSPER from cholesterol-lowering therapy. <i>Lancet, The</i> , 2002, 360, 1618-1619.	6.3	35
2002	MRC/BHF Heart Protection Study. <i>Lancet, The</i> , 2002, 360, 1780-1781.	6.3	4
2003	Hospital readmission after coronary artery bypass grafting: are women doing worse?. <i>Annals of Thoracic Surgery</i> , 2002, 73, 1380-1386.	0.7	38
2004	Bilateral internal mammary artery grafting for coronary artery bypass grafting: why men versus women?. <i>Annals of Thoracic Surgery</i> , 2002, 74, 1435-1437.	0.7	5
2005	Screening for cardiovascular disease with cholesterol. <i>Clinica Chimica Acta</i> , 2002, 315, 49-60.	0.5	23
2006	A randomized, double-blind, placebo-controlled study of the efficacy and tolerability of policosanol in adolescents with type II hypercholesterolemia. <i>Current Therapeutic Research</i> , 2002, 63, 286-303.	0.5	11
2007	Antihypercholesterolemic effects of atorvastatin in patients previously receiving other 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors: an open-label study. <i>Current Therapeutic Research</i> , 2002, 63, 388-395.	0.5	0
2008	An open-label, uncontrolled, prospective study of the effects of atorvastatin 10 mg on low-density lipoprotein cholesterol levels in chinese adults with coronary artery disease and hypercholesterolemia. <i>Current Therapeutic Research</i> , 2002, 63, 399-408.	0.5	2
2009	Effects of orlistat, simvastatin, and orlistat + simvastatin in obese patients with hypercholesterolemia: a randomized, open-label trial. <i>Current Therapeutic Research</i> , 2002, 63, 621-633.	0.5	16
2010	Lipid-lowering long-term effects of six different statins in hypercholesterolemic renal transplant patients under cyclosporine immunosuppression. <i>Transplantation Proceedings</i> , 2002, 34, 398-400.	0.3	21
2011	Low-Density Lipoprotein Apheresis: Clinical Results with Different Methods. <i>Artificial Organs</i> , 2002, 26, 133-139.	1.0	20
2012	HMG-CoA reductase inhibitors improve heart rate variability in patients with a previous myocardial infarction. <i>Pharmacological Research</i> , 2002, 45, 479-483.	3.1	21

#	ARTICLE	IF	CITATIONS
2013	Lipid-lowering " translating evidence into benefits. <i>Atherosclerosis Supplements</i> , 2002, 2, 1-3.	1.2	3
2014	Efficacy and therapeutic potential of plant sterols. <i>Atherosclerosis Supplements</i> , 2002, 3, 11-15.	1.2	24
2015	HDL in risk prediction and its direct and indirect involvement in atherogenesis. <i>Atherosclerosis Supplements</i> , 2002, 3, 3-12.	1.2	19
2016	The management of familial hypercholesterolaemia in childhood. <i>Current Paediatrics</i> , 2002, 12, 104-109.	0.2	0
2017	Reduced frequency of high cholesterol levels among patients with intracerebral haemorrhage. <i>Journal of Clinical Neuroscience</i> , 2002, 9, 376-380.	0.8	15
2018	Are we asking too much of our trials?. <i>American Heart Journal</i> , 2002, 143, 1-3.	1.2	6
2019	Effect of very-low dose niacin on high-density lipoprotein in patients undergoing long-term statin therapy. <i>American Heart Journal</i> , 2002, 143, 514-518.	1.2	21
2020	Routine statin treatment after acute coronary syndromes?. <i>American Heart Journal</i> , 2002, 143, 940-942.	1.2	6
2021	Relationship between vascular dysfunction in peripheral arteries and ischemic episodes during daily life in patients with ischemic heart disease and hypercholesterolemia. <i>American Heart Journal</i> , 2002, 144, 108-114.	1.2	6
2022	Is alternate daily dose of atorvastatin effective in treating patients with hyperlipidemia? The Alternate Day Versus Daily Dosing of Atorvastatin Study (ADDAS). <i>American Heart Journal</i> , 2002, 144, 674-677.	1.2	28
2023	Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: A randomized, double-blind, 52-week trial. <i>American Heart Journal</i> , 2002, 144, 1036-1043.	1.2	148
2024	Management of dyslipidemia in the high-risk patient. <i>American Heart Journal</i> , 2002, 144, S43-S50.	1.2	24
2025	Introduction. <i>American Heart Journal</i> , 2002, 144, S19-S20.	1.2	0
2026	Acute myocardial infarction in the elderly with diabetes. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2002, 31, 327-339.	0.8	11
2027	Safety and efficacy of atorvastatin in heart transplant recipients. <i>Journal of Heart and Lung Transplantation</i> , 2002, 21, 204-210.	0.3	28
2028	Utilization of lipid-lowering drugs in men and women. <i>Journal of Clinical Epidemiology</i> , 2002, 55, 95-101.	2.4	31
2029	Is atherosclerotic vascular disease related to a high-fat diet?. <i>Journal of Clinical Epidemiology</i> , 2002, 55, 1064-1072.	2.4	7
2030	Self-report of high cholesterol. <i>American Journal of Preventive Medicine</i> , 2002, 23, 13-21.	1.6	41

#	ARTICLE	IF	CITATIONS
2031	Medical research. American Journal of Preventive Medicine, 2002, 23, 231-232.	1.6	6
2032	Distribution of microsomal triglyceride transfer protein within sub-endoplasmic reticulum regions in human hepatoma cells. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2002, 1581, 127-136.	1.2	12
2033	Cardiovascular risk factors in patients discharged from departments of internal medicine—the Italian FADOI-2 study. European Journal of Internal Medicine, 2002, 13, 44-51.	1.0	2
2034	Why do women fare worse than men after acute coronary syndromes?. European Journal of Internal Medicine, 2002, 13, 471-473.	1.0	2
2035	Efficacy and tolerability of a suprabioavailable formulation of fenofibrate in patients with dyslipidemia: a pooled analysis of two open-label trials. Clinical Therapeutics, 2002, 24, 1105-1116.	1.1	17
2036	Lipid effects of glyburide/metformin tablets in patients with type 2 diabetes mellitus with poor glycemic control and dyslipidemia in an open-label extension study. Clinical Therapeutics, 2002, 24, 1426-1438.	1.1	10
2037	Fenofibrate in the treatment of dyslipidemia: A review of the data as they relate to the new suprabioavailable tablet formulation. Clinical Therapeutics, 2002, 24, 2022-2050.	1.1	81
2038	A multiple-dose pharmacodynamic, safety, and pharmacokinetic comparison of extended- and immediate-release formulations of lovastatin. Clinical Therapeutics, 2002, 24, 112-125.	1.1	34
2039	Policosanol safely down-regulates HMG-CoA reductase potential as a component of the Esselstyn regimen. Medical Hypotheses, 2002, 59, 268-279.	0.8	46
2040	Statins as anti-inflammatory agents. Trends in Pharmacological Sciences, 2002, 23, 482-487.	4.0	305
2041	Are high-density lipoprotein and triglyceride levels important in secondary prevention: impressions from the BIP and VA-HIT trials. International Journal of Cardiology, 2002, 82, 199-207.	0.8	34
2042	Fighting restenosis after coronary angioplasty: contemporary and future treatment options. International Journal of Cardiology, 2002, 83, 199-205.	0.8	22
2043	Amlodipine for all undergoing PCI? The evidence is unconvincing. International Journal of Cardiology, 2002, 84, 30-32.	0.8	2
2044	Effects of short-term atorvastatin treatment on global fibrinolytic capacity, and sL-selectin and sFas levels in hyperlipidemic patients with coronary artery disease. International Journal of Cardiology, 2002, 84, 227-231.	0.8	32
2045	Beyond lipid lowering: the role of statins in vascular protection. International Journal of Cardiology, 2002, 86, 5-18.	0.8	241
2046	Effects of lipids on thrombotic mechanisms in atherosclerosis. International Journal of Cardiology, 2002, 86, 239-247.	0.8	13
2047	Estrogen and apoptosis in atherosclerosis. International Congress Series, 2002, 1229, 81-93.	0.2	1
2048	ACC/AHA/NHLBI clinical advisory on the use and safety of statins [When citing this document, the American College of Cardiology, American Heart Association, and National Heart, Lung and Blood Institute would appreciate the following citation format: Pasternak RC, Smith SC, Jr., Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI Advisory on the Use and Safety of Statins. J Am Coll Cardiol 2002;40:568-73.22This document is available on the Web sites of the ACC (www.acc.org), the		

#	ARTICLE	IF	CITATIONS
2049	Should Hypercholesterolemia Be Treated in Frail Elders?. Journal of the American Medical Directors Association, 2002, 3, 66-70.	1.2	1
2052	Statin Lipid-Lowering Therapy for Acute Myocardial Infarction and Unstable Angina: Efficacy and Mechanism of Benefit. Mayo Clinic Proceedings, 2002, 77, 1085-1092.	1.4	43
2053	Prevention of cardiovascular diseases. Clinics in Geriatric Medicine, 2002, 18, 463-483.	1.0	13
2054	Prevención secundaria del infarto de miocardio y calidad de vida relacionada con la salud. Medicina Clínica, 2002, 119, 9-12.	0.3	17
2055	La búsqueda de la mejor información para nuestro paciente y para nosotros. Tratamiento de un paciente tras el alta por infarto de miocardio. Semergen, 2002, 28, 305-306.	0.2	0
2057	Cardiovascular disease prevention. Primary Care - Clinics in Office Practice, 2002, 29, 667-696.	0.7	6
2061	Preventive health care for older patients. Primary Care - Clinics in Office Practice, 2002, 29, 599-614.	0.7	3
2063	Effect of HMG-CoA Reductase Inhibitors (Statins) on Bone Mineral Density. Journal of Clinical Densitometry, 2002, 5, 151-158.	0.5	38
2065	Differential Reactivity of Two Homogeneous LDL-Cholesterol Methods to LDL and VLDL Subfractions, as Demonstrated by Ultracentrifugation and HPLC. Clinical Chemistry, 2002, 48, 1946-1954.	1.5	38
2066	Methods for Measurement of LDL-Cholesterol: A Critical Assessment of Direct Measurement by Homogeneous Assays versus Calculation. Clinical Chemistry, 2002, 48, 236-254.	1.5	346
2067	Effect of Atorvastatin and Fish Oil on Plasma High-Sensitivity C-Reactive Protein Concentrations in Individuals with Visceral Obesity. Clinical Chemistry, 2002, 48, 877-883.	1.5	129
2068	Diabetic dyslipidaemia. British Journal of Diabetes and Vascular Disease, 2002, 2, S12-S17.	0.6	7
2069	Low-Density Lipoprotein Lowering and Atherosclerosis Progression. Circulation, 2002, 106, 2039-2040.	1.6	21
2070	Six years of treatment with the HELP system of a patient with familial hypercholesterolemia. Brazilian Journal of Medical and Biological Research, 2002, 35, 775-782.	0.7	3
2071	New Tools for Coronary Risk Assessment. Circulation, 2002, 105, 886-892.	1.6	184
2072	Native LDL Induces Proliferation of Human Vascular Smooth Muscle Cells via Redox-Mediated Activation of ERK 1/2 Mitogen-Activated Protein Kinases. Hypertension, 2002, 39, 645-650.	1.3	62
2073	Cholesterol-lowering therapy with pravastatin in patients with average cholesterol levels and established ischaemic heart disease: is it cost-effective?. Medical Journal of Australia, 2002, 177, 420-434.	0.8	20
2074	Simvastatin restores endothelial NO-mediated vasorelaxation in large arteries after myocardial infarction. American Journal of Physiology - Heart and Circulatory Physiology, 2002, 283, H768-H775.	1.5	41

#	ARTICLE	IF	CITATIONS
2075	Economical Aspects of High-Sensitivity C-Reactive Protein as Predictor of Coronary Heart Disease. <i>Cardiology</i> , 2002, 2, 61-68.	0.3	0
2076	The Current View on Hypercholesterolemia after the "Heart Protection Study" " Do We Need New Strategies?. <i>Cardiology</i> , 2002, 2, 201-203.	0.3	0
2077	Effect of Pravastatin-Induced LDL-Cholesterol Reduction on Coronary Heart Disease and Cerebrovascular Disease in Japanese: Hokuriku Lipid Coronary Heart Disease Study-Pravastatin Atherosclerosis Trial (Holicos-PAT). <i>Journal of Atherosclerosis and Thrombosis</i> , 2002, 9, 251-259.	0.9	14
2078	Acute Coronary Syndrome and Early Statin Therapy: What Is the Evidence?. <i>Cardiology</i> , 2002, 2, 246-250.	0.3	0
2079	How Well Are Hypertension, Hyperlipidemia, Diabetes, and Smoking Managed After a Stroke or Transient Ischemic Attack?. <i>Stroke</i> , 2002, 33, 1656-1659.	1.0	108
2080	Clinical Effects of Rosuvastatin, a New HMG-CoA Reductase Inhibitor, in Japanese Patients With Primary Hypercholesterolemia: an Early Phase II Study. <i>Journal of Atherosclerosis and Thrombosis</i> , 2002, 9, 48-56.	0.9	20
2081	Prognosis of Hypercholesterolemic Patients Taking Pravastatin for Five Years: The Chiba Lipid Intervention Program (CLIP) Study. <i>Journal of Atherosclerosis and Thrombosis</i> , 2002, 9, 99-108.	0.9	17
2082	Atorvastatin Reduces Plasma Levels of Factor VII Activity and Factor VII Antigen in Patients with Hyperlipidemia. <i>Journal of Atherosclerosis and Thrombosis</i> , 2002, 9, 72-77.	0.9	15
2083	Primary and Secondary Prevention of Coronary Heart Disease. <i>Medicine</i> , 2002, 30, 59-64.	0.2	1
2084	Daily Dosing versus Alternate-Day Dosing of Simvastatin in Patients with Hypercholesterolemia. <i>Pharmacotherapy</i> , 2002, 22, 1110-1116.	1.2	21
2085	Atherothrombosis: Plaque instability and thrombogenesis. <i>Progress in Cardiovascular Diseases</i> , 2002, 44, 381-394.	1.6	41
2086	Systemic and local inflammation in patients with unstable atherosclerotic plaques. <i>Progress in Cardiovascular Diseases</i> , 2002, 44, 469-478.	1.6	58
2087	Cerivastatin, a hydroxymethylglutaryl coenzyme A reductase inhibitor, inhibits cardiac myocyte hypertrophy induced by endothelin. <i>European Journal of Pharmacology</i> , 2002, 453, 175-181.	1.7	17
2088	Frequency of creatine kinase elevation during treatment with fluvastatin. <i>American Journal of Cardiology</i> , 2002, 89, 231-233.	0.7	35
2089	Tolerability of statin-fibrate and statin-niacin combination therapy in dyslipidemic patients at high risk for cardiovascular events. <i>American Journal of Cardiology</i> , 2002, 89, 390-394.	0.7	40
2090	Effects of simvastatin (40 and 80 mg) on highly sensitive C-reactive protein in patients with combined hyperlipidemia. <i>American Journal of Cardiology</i> , 2002, 89, 468-469.	0.7	9
2091	Need for a moratorium on percutaneous transluminal coronary angioplasty in stable coronary artery disease. <i>American Journal of Cardiology</i> , 2002, 89, 567-570.	0.7	2
2092	Cardiovascular risk management in clinical practice: the midwest heart specialists experience. <i>American Journal of Cardiology</i> , 2002, 89, 23-29.	0.7	11



#	ARTICLE	IF	CITATIONS
2093	Managing dyslipidemia in the high-risk patient. American Journal of Cardiology, 2002, 89, 50-57.	0.7	71
2094	Patient-reported frequency of taking aspirin in a population with coronary artery disease. American Journal of Cardiology, 2002, 89, 1042-1046.	0.7	16
2095	The liver and lovastatin. American Journal of Cardiology, 2002, 89, 1374-1380.	0.7	188
2096	Introduction: the role of hormone replacement therapy in prevention and treatment of cardiovascular disease in postmenopausal women. American Journal of Cardiology, 2002, 89, 1-4.	0.7	55
2097	Atherosclerosis imaging methods: assessing cardiovascular disease and evaluating the role of estrogen in the prevention of atherosclerosis. American Journal of Cardiology, 2002, 89, 19-27.	0.7	42
2098	Risk factors for coronary artery disease in women. American Journal of Cardiology, 2002, 89, 28-34.	0.7	71
2099	Antiatherosclerosis interventions in women. American Journal of Cardiology, 2002, 90, F17-F21.	0.7	11
2100	Benefits of cardiac rehabilitation in the ninth decade of life in patients with coronary heart disease. American Journal of Cardiology, 2002, 90, 645-648.	0.7	21
2101	Getting more people on statins. American Journal of Cardiology, 2002, 90, 683-685.	0.7	15
2102	Factors affecting low-density lipoprotein and high-density lipoprotein cholesterol response to pravastatin in the West Of Scotland Coronary Prevention Study (WOSCOPS). American Journal of Cardiology, 2002, 90, 731-736.	0.7	61
2103	Approach to lipoprotein management in 2001 National Cholesterol Guidelines. American Journal of Cardiology, 2002, 90, 11-21.	0.7	267
2104	Effects of simvastatin on C-reactive protein in mixed hyperlipidemic and hypertriglyceridemic patients. American Journal of Cardiology, 2002, 90, 942-946.	0.7	37
2105	Effects of atorvastatin 80 mg daily early after onset of unstable angina pectoris or non-Q-wave myocardial infarction. American Journal of Cardiology, 2002, 90, 872-874.	0.7	35
2106	Effectiveness of multiple antilipidemic agents on vertical auto profile ii guided treatment of dyslipoproteinemia. American Journal of Cardiology, 2002, 90, 887-890.	0.7	0
2107	Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. American Journal of Cardiology, 2002, 90, 1084-1091.	0.7	461
2108	Alternative approaches to cholesterol-lowering therapy. American Journal of Cardiology, 2002, 90, 1135-1138.	0.7	13
2109	The rationale for combination therapy. American Journal of Cardiology, 2002, 90, 2-7.	0.7	9
2110	Combination therapy for elevated low-density lipoprotein cholesterol: the key to coronary artery disease risk reduction. American Journal of Cardiology, 2002, 90, 8-20.	0.7	49

#	ARTICLE	IF	CITATIONS
2111	Use of combination therapy for dyslipidemia: a lipid clinic approach. <i>American Journal of Cardiology</i> , 2002, 90, 44-49.	0.7	10
2112	Peroxisome proliferator-activated receptor agonists, hyperlipidaemia, and atherosclerosis. , 2002, 95, 47-62.		95
2113	Measuring the cost-effectiveness of lipid-lowering drugs in the elderly.. <i>Contemporary Clinical Trials</i> , 2002, 23, 757-773.	2.0	8
2114	Reduction of bFGF-induced smooth muscle cell proliferation and endothelin receptor mRNA expression by mevastatin and atorvastatin. <i>Biochemical Pharmacology</i> , 2002, 64, 497-505.	2.0	31
2115	Diagnosis and Management of Lipoprotein Abnormalities. <i>Nutrition in Clinical Care: an Official Publication of Tufts University</i> , 2002, 5, 115-123.	0.2	11
2116	Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis. <i>American Journal of Kidney Diseases</i> , 2002, 39, 283-290.	2.1	79
2117	Management of Intermittent Claudication: the Importance of Secondary Prevention. <i>European Journal of Vascular and Endovascular Surgery</i> , 2002, 23, 100-107.	0.8	27
2118	Diabetes and macrovascular disease. <i>Journal of Diabetes and Its Complications</i> , 2002, 16, 235-245.	1.2	103
2119	Simvastatin reduces plasma concentration of high-sensitivity C-reactive protein in type 2 diabetic patients with hyperlipidemia. <i>Journal of Diabetes and Its Complications</i> , 2002, 16, 382-385.	1.2	19
2120	Overall mortality in the program on the surgical control of the hyperlipidemias <sup>1</sup> 1No competing interests declared.. <i>Journal of the American College of Surgeons</i> , 2002, 195, 327-331.	0.2	30
2121	Treatment of peripheral arterial disease. <i>Clinical Cornerstone</i> , 2002, 4, 26-37.	1.0	8
2122	Pharmaceutical initiatives to combat atherosclerosisâ€”What to do with the good, the bad, and the ugly lipoproteins. <i>Seminars in Vascular Surgery</i> , 2002, 15, 204-215.	1.1	2
2123	Estrogen, statins, and polyunsaturated fatty acids: similarities in their actions and benefitsâ€”is there a common link?. <i>Nutrition</i> , 2002, 18, 178-188.	1.1	46
2124	The Phytosterol Content of Some Cereal Foods Commonly Consumed in Sweden and in the Netherlands. <i>Journal of Food Composition and Analysis</i> , 2002, 15, 693-704.	1.9	95
2125	Direct adsorption of low-density lipoprotein and lipoprotein(a) from whole blood: Results of the first clinical long-term multicenter study using DALI apheresis. <i>Journal of Clinical Apheresis</i> , 2002, 17, 161-169.	0.7	39
2126	Future directions in lipid therapies. <i>Advances in Therapy</i> , 2002, 19, 61-72.	1.3	6
2127	Omega-3 fatty acids and cardiovascular disease: The epidemiological evidence. <i>Environmental Health and Preventive Medicine</i> , 2002, 6, 203-209.	1.4	64
2128	Increased cardiomyocyte apoptosis following ischemia and reperfusion in diet-induced hypercholesterolemia: Relation to Bcl-2 and bax proteins and caspase-3 activity. <i>Lipids</i> , 2002, 37, 385-394.	0.7	50

#	ARTICLE	IF	CITATIONS
2129	Antithrombotic secondary prevention after stroke. Current Treatment Options in Cardiovascular Medicine, 2002, 4, 429-440.	0.4	25
2130	ST-segment elevation myocardial infarction. Current Treatment Options in Cardiovascular Medicine, 2002, 4, 3-23.	0.4	1
2131	Management after myocardial infarction. Current Treatment Options in Cardiovascular Medicine, 2002, 4, 41-54.	0.4	0
2132	Conflicts of interest in drug development: The practices of Merck & Co., Inc.. Science and Engineering Ethics, 2002, 8, 429-442.	1.7	7
2133	Lipids and endothelium-dependent vasodilation—A review. Lipids, 2002, 37, 1-15.	0.7	35
2134	Lipoprotein-apolipoprotein changes in renal transplant recipients. Lipids, 2002, 37, 967-974.	0.7	6
2135	Treatment of lipid disorders after stroke. Current Atherosclerosis Reports, 2002, 4, A304-A310.	2.0	1
2137	Statin therapy after acute myocardial infarction: Are we adequately treating high-risk patients?. Current Atherosclerosis Reports, 2002, 4, 99-106.	2.0	12
2138	Lipoprotein changes with statins. Current Atherosclerosis Reports, 2002, 4, 14-18.	2.0	7
2139	Goals of statin therapy: Three viewpoints. Current Atherosclerosis Reports, 2002, 4, 26-33.	2.0	5
2140	A general assessment of the safety of HMG CoA reductase inhibitors (statins). Current Atherosclerosis Reports, 2002, 4, 34-41.	2.0	45
2141	Postmenopausal hormone replacement therapy as antiatherosclerotic therapy. Current Atherosclerosis Reports, 2002, 4, 52-58.	2.0	11
2142	Clinical implications of statin event trials. Current Atherosclerosis Reports, 2002, 4, 337-342.	2.0	4
2143	Noninvasive studies of coronary and peripheral arterial blood-flow. Current Atherosclerosis Reports, 2002, 4, 381-385.	2.0	3
2144	Prevention of ischemic stroke. Current Cardiology Reports, 2002, 4, 164-171.	1.3	4
2145	Early use of statins in acute coronary syndromes. Current Cardiology Reports, 2002, 4, 289-297.	1.3	2
2146	Lipid-lowering therapies in the management of acute coronary syndromes. Current Cardiology Reports, 2002, 4, 320-326.	1.3	2
2147	Prevention of ischemic stroke. Current Treatment Options in Cardiovascular Medicine, 2002, 4, 393-403.	0.4	5

#	ARTICLE	IF	CITATIONS
2148	LDL receptor mutation genotype and vascular disease phenotype in heterozygous familial hypercholesterolaemia. <i>Clinical Genetics</i> , 2002, 61, 408-415.	1.0	11
2149	Systematic review of antiplatelet therapy for the prevention of myocardial infarction, stroke or vascular death in patients with peripheral vascular disease. <i>British Journal of Surgery</i> , 2002, 88, 787-800.	0.1	156
2150	Thiourea-based gemfibrozil analogues as HDL-elevating agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2002, 12, 2439-2442.	1.0	11
2151	Statins and the assessment of endothelial function - reply to Lee et al.. <i>Journal of Internal Medicine</i> , 2002, 251, 453-454.	2.7	0
2152	HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. <i>Kidney International</i> , 2002, 61, 297-304.	2.6	263
2153	Use of cholesterol-lowering therapy and related beliefs among middle-aged adults after myocardial infarction. <i>Journal of General Internal Medicine</i> , 2002, 17, 95-102.	1.3	23
2154	Atherosclerotic risk factor reduction in peripheral arterial disease. <i>Journal of General Internal Medicine</i> , 2002, 17, 895-904.	1.3	122
2155	Meaning of Low-Density Lipoprotein Apheresis for Hypercholesterolemic Patients at High Risk for Recurrence of Coronary Heart Disease. <i>Therapeutic Apheresis and Dialysis</i> , 2002, 6, 372-380.	0.6	4
2156	Unanswered Questions: The Use of Statins in Older People to Prevent Cardiovascular Event Effects of Statins on Risk of Coronary Disease: A Meta-Analysis of Randomized Controlled Trials. <i>Journal of the American Geriatrics Society</i> , 2002, 50, 391-393.	1.3	2
2157	Effect of Statin (HMG-Co-A-Reductase Inhibitor) Use on 1-Year Mortality and Hospitalization Rates in Older Patients with Cardiovascular Disease Living in Nursing Homes. <i>Journal of the American Geriatrics Society</i> , 2002, 50, 1389-1395.	1.3	39
2158	Use of Lipid-Lowering Drugs in Older Adults With and Without Dementia: A Community-Based Epidemiological Study. <i>Journal of the American Geriatrics Society</i> , 2002, 50, 1852-1856.	1.3	93
2159	LDL-cholesterol lowering effect of a generic product of simvastatin compared to simvastatin (Zocor®) in Thai hypercholesterolemic subjects - a randomized crossover study, the first report from Thailand. <i>BMC Clinical Pharmacology</i> , 2002, 2, 1.	2.5	11
2160	Time trends in lipid lowering drug use in The Netherlands. Has the backlog of candidates for treatment been eliminated?. <i>British Journal of Clinical Pharmacology</i> , 2002, 53, 379-385.	1.1	22
2161	High persistence of statin use in a Danish population: Compliance study 1993-1998. <i>British Journal of Clinical Pharmacology</i> , 2002, 53, 375-378.	1.1	91
2162	Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. <i>British Journal of Clinical Pharmacology</i> , 2002, 54, 309-319.	1.1	103
2163	Direct in vivo evidence of a vascular statin: a single dose of cerivastatin rapidly increases vascular endothelial responsiveness in healthy normocholesterolaemic subjects. <i>British Journal of Clinical Pharmacology</i> , 2002, 54, 395-399.	1.1	85
2164	Allelic polymorphism $\epsilon$ 491A/T in apo E gene modulates the lipid-lowering response in combined hyperlipidemia treatment. <i>European Journal of Clinical Investigation</i> , 2002, 32, 421-428.	1.7	24
2165	Factorial study of the effects of atorvastatin and fish oil on dyslipidaemia in visceral obesity. <i>European Journal of Clinical Investigation</i> , 2002, 32, 429-436.	1.7	82

#	ARTICLE	IF	CITATIONS
2166	The Myocardial Ischemia Reduction with Acute Cholesterol Lowering trial: MIRACuLous or not, it's time to change current practice. <i>Current Controlled Trials in Cardiovascular Medicine</i> , 2002, 3, 3.	1.5	2
2167	A Prospective Study of Pravastatin in the Elderly at Risk (PROSPER): Screening Experience and Baseline Characteristics. <i>Current Controlled Trials in Cardiovascular Medicine</i> , 2002, 3, 8.	1.5	38
2168	Reducing the risk of stroke in diabetes: what have we learned that is new?. <i>Diabetes, Obesity and Metabolism</i> , 2002, 4, 27-34.	2.2	24
2169	Cardiovascular risk management in primary care. <i>Diabetes, Obesity and Metabolism</i> , 2002, 4, 362-367.	2.2	1
2170	Diabetes in the elderly: problems of care and service provision. <i>Diabetic Medicine</i> , 2002, 19, 66-72.	1.2	15
2171	Reproducibility of individualized coronary heart disease risk calculations in patients with diabetes mellitus. <i>Diabetic Medicine</i> , 2002, 19, 514-517.	1.2	3
2172	Old and new risk factors for atherosclerosis and development of treatment recommendations. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2002, 29, 838-842.	0.9	11
2173	Clinical trials in the new millennium. <i>Statistics in Medicine</i> , 2002, 21, 2779-2787.	0.8	14
2174	Policy developments in regulatory approval. <i>Statistics in Medicine</i> , 2002, 21, 2939-2948.	0.8	54
2175	Combined endpoints: can we use them?. <i>Statistics in Medicine</i> , 2002, 21, 2959-2970.	0.8	97
2176	Variability in abciximab (ReoPro®) prescribing: evidence based or budget driven?. <i>Pharmacoepidemiology and Drug Safety</i> , 2002, 11, 135-141.	0.9	3
2177	Determinants of non-compliance with lipid-lowering therapy in hyperlipidemic patients. <i>Pharmacoepidemiology and Drug Safety</i> , 2002, 11, 593-600.	0.9	44
2178	The role of serum lipids in exudative diabetic maculopathy: is there a place for lipid lowering therapy?. <i>Eye</i> , 2002, 16, 689-693.	1.1	90
2179	Lipid lowering: another method of reducing blood pressure?. <i>Journal of Human Hypertension</i> , 2002, 16, 753-760.	1.0	41
2180	Atherogenesis in perspective: Hypercholesterolemia and inflammation as partners in crime. <i>Nature Medicine</i> , 2002, 8, 1211-1217.	15.2	623
2181	HMG CoA reductase inhibitors affect the fibrinolytic system of human vascular cells in vitro : a comparative study using different statins. <i>British Journal of Pharmacology</i> , 2002, 135, 284-292.	2.7	105
2182	Shifting Statins from Clinic to Critical Care. <i>Journal of Interventional Cardiology</i> , 2002, 15, 431-434.	0.5	0
2183	Reducing global risk for cardiovascular disease: Using lifestyle changes and pharmacotherapy. <i>Clinical Cardiology</i> , 2002, 25, 205-212.	0.7	23

#	ARTICLE	IF	CITATIONS
2184	Inflammatory predictors of mortality in the scandinavian simvastatin survival study. <i>Clinical Cardiology</i> , 2002, 25, 461-466.	0.7	34
2185	Cholestin inhibits cholesterol synthesis and secretion in hepatic cells (HepG2). <i>Molecular and Cellular Biochemistry</i> , 2002, 233, 153-158.	1.4	39
2186	Novel statins: pharmacological and clinical results. <i>Cardiovascular Drugs and Therapy</i> , 2002, 16, 251-257.	1.3	30
2187	Antioxidative effects of fluvastatin on superoxide anion activated by angiotensin II in human aortic smooth muscle cells. <i>Cardiovascular Drugs and Therapy</i> , 2002, 16, 203-207.	1.3	10
2188	Use of discharge-worksheet enhances compliance with evidence-based myocardial infarction care. <i>Journal of Thrombosis and Thrombolysis</i> , 2002, 14, 43-49.	1.0	2
2189	Vitamins, antioxidants and endothelial function in coronary artery disease. <i>Cardiovascular Drugs and Therapy</i> , 2002, 16, 401-409.	1.3	11
2190	Serum lipid levels in an Iranian adults population: Tehran lipid and glucose study. <i>European Journal of Epidemiology</i> , 2002, 18, 311-319.	2.5	104
2191	Lipid-lowering therapy and cholesterol levels following acute myocardial infarction: A German study of 5361 patients. <i>European Journal of Epidemiology</i> , 2002, 18, 407-411.	2.5	4
2192	Serum Cholesterol Levels and Suicide: A Meta-Analysis. <i>Suicide and Life-Threatening Behavior</i> , 2002, 32, 333-346.	0.9	78
2193	Antiinflammatory and Immunomodulatory Properties of Statins. <i>Immunologic Research</i> , 2002, 25, 271-286.	1.3	65
2194	Fluvastatin Improves Insulin Resistance in Nondiabetic Dyslipidemic Patients. <i>Endocrine</i> , 2003, 22, 151-154.	2.2	44
2195	Illness representation and change in dietary habits in hypercholesterolemic patients. <i>Journal of Behavioral Medicine</i> , 2003, 26, 133-152.	1.1	15
2196	Title is missing!. <i>Molecular and Cellular Biochemistry</i> , 2003, 246, 45-50.	1.4	22
2197	HDL-C and triglyceride levels: relationship to coronary heart disease and treatment with statins. <i>Cardiovascular Drugs and Therapy</i> , 2003, 17, 53-62.	1.3	23
2198	Genetic polymorphisms in emerging cardiovascular risk factors and response to statin therapy. <i>Cardiovascular Drugs and Therapy</i> , 2003, 17, 75-82.	1.3	18
2199	Reduction of infarct size by short-term pretreatment with atorvastatin. <i>Cardiovascular Drugs and Therapy</i> , 2003, 17, 25-30.	1.3	38
2200	Plant sterols lower LDL cholesterol without improving endothelial function in prepubertal children with familial hypercholesterolaemia. <i>Journal of Inherited Metabolic Disease</i> , 2003, 26, 343-352.	1.7	81
2201	The safety of HMG-CoA reductase inhibitors in special populations at high cardiovascular risk. <i>Cardiovascular Drugs and Therapy</i> , 2003, 17, 265-285.	1.3	75

#	ARTICLE	IF	CITATIONS
2202	Impact of statins on novel risk markers. <i>Cardiovascular Drugs and Therapy</i> , 2003, 17, 361-366.	1.3	2
2203	The effects of raloxifene and simvastatin on plasma lipids and endothelium. <i>Cardiovascular Drugs and Therapy</i> , 2003, 17, 319-323.	1.3	32
2204	A Comprehensive Description of Muscle Symptoms Associated with Lipid-Lowering Drugs. <i>Cardiovascular Drugs and Therapy</i> , 2003, 17, 459-465.	1.3	106
2205	How Should Subgroup Analyses Affect Clinical Practice? Insights from the Metoprolol Succinate Controlled-Release/Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF). <i>Journal of Interventional Cardiac Electrophysiology</i> , 2003, 7, 264-275.	0.9	13
2206	Italian Drug Policy: Ethical Aims of Essential Assistance Levels. <i>Health Care Analysis</i> , 2003, 11, 279-286.	1.4	7
2207	Cholesterol changes in coronary patients after a short behavior modification program. <i>International Journal of Behavioral Medicine</i> , 2003, 10, 315-330.	0.8	10
2208	Cholesterol absorption inhibitors: Defining new options in lipid management. <i>Clinical Cardiology</i> , 2003, 26, 259-264.	0.7	20
2209	A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin. <i>Clinical Cardiology</i> , 2003, 26, 112-118.	0.7	55
2210	Differential effects of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I are consistent across hypercholesterolemic patient subgroups. <i>Clinical Cardiology</i> , 2003, 26, 509-514.	0.7	14
2211	LDL and beyond: New therapeutic approaches to hypercholesterolemia. <i>Clinical Cardiology</i> , 2003, 26, 1-2.	0.7	0
2212	Understanding risk in hypercholesterolemia. <i>Clinical Cardiology</i> , 2003, 26, 3-6.	0.7	16
2213	New dimension of statin action on apoB atherogenicity. <i>Clinical Cardiology</i> , 2003, 26, 7-10.	0.7	21
2214	Comparing HMG-CoA reductase inhibitors. <i>Clinical Cardiology</i> , 2003, 26, 15-20.	0.7	18
2215	Treating hypercholesterolemia: Looking forward. <i>Clinical Cardiology</i> , 2003, 26, 21-28.	0.7	27
2216	Reaching goal: Conquering the treatment gaps in dyslipidemia management. <i>Clinical Cardiology</i> , 2003, 26, 1-2.	0.7	3
2217	Risks and benefits of continued aggressive statin therapy. <i>Clinical Cardiology</i> , 2003, 26, 3-12.	0.7	27
2218	Benefits of statin therapy in patients with special risks: Coronary bypass surgery, stable coronary disease, and acute coronary syndromes. <i>Clinical Cardiology</i> , 2003, 26, 13-18.	0.7	10
2219	New features of the national cholesterol education program adult treatment panel III lipid-lowering guidelines. <i>Clinical Cardiology</i> , 2003, 26, 19-24.	0.7	29

#	ARTICLE	IF	CITATIONS
2220	The power of statins: Aggressive lipid lowering. <i>Clinical Cardiology</i> , 2003, 26, 25-31.	0.7	89
2221	Connecting the role of C-reactive protein and statins in cardiovascular disease. <i>Clinical Cardiology</i> , 2003, 26, 39-44.	0.7	43
2222	Effects of Policosanol and Lovastatin in Patients with Intermittent Claudication: A Double-Blind Comparative Pilot Study. <i>Angiology</i> , 2003, 54, 25-38.	0.8	54
2224	Use of statins for secondary prevention. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2003, 5, 63-73.	0.4	2
2225	Prevention of cardiovascular disease in women. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2003, 5, 287-298.	0.4	0
2226	Gender, hyperlipidemia, and coronary artery disease. <i>Comprehensive Therapy</i> , 2003, 29, 7-17.	0.2	2
2227	Implications of the heart protection study for reducing coronary events in high-risk patients. <i>Current Atherosclerosis Reports</i> , 2003, 5, 358-363.	2.0	0
2228	Isoprenoid metabolism and the pleiotropic effects of statins. <i>Current Atherosclerosis Reports</i> , 2003, 5, 372-378.	2.0	84
2229	In-hospital initiation of statin therapy in patients with acute coronary events. <i>Current Atherosclerosis Reports</i> , 2003, 5, 394-402.	2.0	2
2230	Toxicity of antilipidemic agents: Facts and fictions. <i>Current Atherosclerosis Reports</i> , 2003, 5, 403-410.	2.0	1
2232	Management of dyslipidemia: An update. <i>Current Atherosclerosis Reports</i> , 2003, 5, 284-290.	2.0	1
2233	Vascular pleiotropy of statins: Clinical evidence and biochemical mechanisms. <i>Current Atherosclerosis Reports</i> , 2003, 5, 33-37.	2.0	16
2234	Are cholesterol-lowering medications and antihypertensive agents preventing stroke in ways other than by controlling the risk factor?. <i>Current Atherosclerosis Reports</i> , 2003, 5, 38-43.	2.0	9
2235	Early use of statins in acute coronary syndromes. <i>Current Atherosclerosis Reports</i> , 2003, 5, 44-51.	2.0	10
2236	Clinical trials of vitamin E in coronary artery disease: Is it time to reconsider the low-density lipoprotein oxidation hypothesis?. <i>Current Atherosclerosis Reports</i> , 2003, 5, 83-87.	2.0	18
2237	Clinical trials report. <i>Current Atherosclerosis Reports</i> , 2003, 5, 93-95.	2.0	7
2238	Statins and myotoxicity. <i>Current Atherosclerosis Reports</i> , 2003, 5, 96-100.	2.0	27
2239	Lipid abnormalities in the metabolic syndrome. <i>Current Diabetes Reports</i> , 2003, 3, 65-72.	1.7	19



#	ARTICLE	IF	CITATIONS
2240	Reducing CVD risk in type 2 DM. <i>Current Diabetes Reports</i> , 2003, 3, 363-364.	1.7	0
2241	Potential mechanisms of impaired endothelial function in arterial hypertension and hypercholesterolemia. <i>Current Hypertension Reports</i> , 2003, 5, 199-207.	1.5	77
2242	Are cholesterol-lowering medications and antihypertensive agents preventing stroke in ways other than by controlling the risk factor?. <i>Current Neurology and Neuroscience Reports</i> , 2003, 3, 21-26.	2.0	8
2246	Under-prescribing of cardiovascular therapies for diabetes in primary care. <i>European Journal of Clinical Pharmacology</i> , 2003, 58, 835-841.	0.8	26
2247	Beyond lipid-lowering: effects of statins on endothelial nitric oxide. <i>European Journal of Clinical Pharmacology</i> , 2003, 58, 719-731.	0.8	157
2248	Statin compliance in the Umbrian population. <i>European Journal of Clinical Pharmacology</i> , 2003, 59, 659-661.	0.8	36
2249	The effect of low-dose simvastatin in children with familial hypercholesterolaemia: a 1-year observation. <i>European Journal of Pediatrics</i> , 2003, 162, 421-425.	1.3	41
2250	Managing the spectrum of dyslipidemia in primary care. <i>Journal of Vascular Nursing</i> , 2003, 21, 81-89.	0.2	4
2251	How many claudicants should be prescribed statins?. <i>European Journal of Vascular and Endovascular Surgery</i> , 2003, 25, 367-368.	0.8	6
2252	Lessons learned from recent lipid-lowering trials: Why physicians should change clinical practice. <i>Clinical Cornerstone</i> , 2003, 5, S11-S17.	1.0	1
2254	Erectile Dysfunction Is Associated with a High Prevalence of Hyperlipidemia and Coronary Heart Disease Risk. <i>European Urology</i> , 2003, 44, 355-359.	0.9	194
2255	Physiological Effects of Simvastatin and Diet on Hypercholesterolemic Men. <i>Progress in Cardiovascular Nursing</i> , 2003, 18, 160-161.	0.5	0
2256	Statin rebound effect?. <i>Translational Research</i> , 2003, 141, 235-236.	2.4	4
2257	Serum noncholesterol sterols during inhibition of cholesterol synthesis by statins. <i>Translational Research</i> , 2003, 141, 131-137.	2.4	104
2258	Treating patients with peripheral arterial disease and claudication. <i>Journal of Vascular Nursing</i> , 2003, 21, 5-16.	0.2	14
2259	Improving outcomes for women after coronary artery bypass grafting: A case for prevention. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2003, 126, 1704-1706.	0.4	2
2260	Home-based versus hospital-based cardiac rehabilitation after myocardial infarction or revascularisation: design and rationale of the Birmingham Rehabilitation Uptake Maximisation Study (BRUM): a randomised controlled trial [ISRCTN72884263]. <i>BMC Cardiovascular Disorders</i> , 2003, 3, 10.	0.7	46
2261	Adherence with statin therapy in secondary prevention of coronary heart disease in veterans administration male population. <i>American Journal of Cardiology</i> , 2003, 92, 1106-1108.	0.7	78

#	ARTICLE	IF	CITATIONS
2262	Effectiveness of lipid-lowering medications in outpatients with coronary heart disease in the Department of Veterans Affairs System**The views expressed in this work do not necessarily represent the views of the Department of Veterans Affairs.. American Journal of Cardiology, 2003, 92, 1177-1182.	0.7	12
2263	Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. American Journal of Cardiology, 2003, 92, 1379-1383.	0.7	277
2264	A propensity score-matched cohort study of the effect of statins, mainly fluvastatin, on the occurrence of acute myocardial infarction. American Journal of Cardiology, 2003, 92, 1447-1451.	0.7	60
2266	Predictors of cardiac and noncardiac mortality among 14,697 patients with coronary heart disease. American Journal of Cardiology, 2003, 91, 121-127.	0.7	45
2267	Mechanisms of plaque stabilization with statins. American Journal of Cardiology, 2003, 91, 4-8.	0.7	188
2268	Prevention of stroke and dementia with statins. American Journal of Cardiology, 2003, 91, 23-29.	0.7	119
2269	Introduction: rosuvastatinâ€”an efficacy assessment based on pooled trial data. American Journal of Cardiology, 2003, 91, 1-2.	0.7	5
2270	Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups. American Journal of Cardiology, 2003, 91, 3-10.	0.7	128
2271	Comparison of Once-Daily, niacin Extended-Release/lovastatin with standard doses of atorvastatin and simvastatin (the advicor versus other Cholesterol-Modulating agents trial evaluation) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50417 Td (		
2272	How cost-effective are new preventive strategies for cardiovascular disease?. American Journal of Cardiology, 2003, 91, 22-27.	0.7	49
2273	Antiatherosclerotic effects of Î²-blockers. American Journal of Cardiology, 2003, 91, 25-29.	0.7	52
2274	The Heart Protection Study: expanding the boundaries for high-risk coronary disease prevention. American Journal of Cardiology, 2003, 92, 3-9.	0.7	28
2275	Effective strategies for long-term statin use. American Journal of Cardiology, 2003, 92, 27-34.	0.7	28
2276	Increased use of lipid-lowering therapy in patients receiving human immunodeficiency virus protease inhibitors. American Journal of Cardiology, 2003, 92, 270-274.	0.7	19
2277	Current and future aims of lipid-lowering therapy: changing paradigms and lessons from the heart protection study on standards of efficacy and safety. American Journal of Cardiology, 2003, 92, 3-9.	0.7	105
2278	Clinical significance of High-Density lipoproteins and the development of atherosclerosis: focus on the role of the adenosine triphosphateâ€”Binding cassette protein A1 transporter. American Journal of Cardiology, 2003, 92, 10-16.	0.7	215
2279	Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients. American Journal of Cardiology, 2003, 92, 670-676.	0.7	164
2280	Statin safety: applying the results of randomized trials to clinical practice. American Journal of Cardiology, 2003, 92, 692-695.	0.7	12

#	ARTICLE	IF	CITATIONS
2281	Effect of simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at six months and at one year after treatment. <i>American Journal of Cardiology</i> , 2003, 92, 711-712.	0.7	178
2282	Current options in the management of coronary artery disease. <i>American Journal of Cardiology</i> , 2003, 92, 4-8.	0.7	17
2283	Atorvastatin inhibits expression of minichromosome maintenance proteins in vascular smooth muscle cells. <i>European Journal of Pharmacology</i> , 2003, 462, 15-23.	1.7	14
2284	Modern management of acute myocardial infarction. <i>Current Problems in Cardiology</i> , 2003, 28, 7-127.	1.1	0
2285	The lipid and non-lipid effects of statins. , 2003, 99, 95-112.		217
2286	A brief history of sudden cardiac death and its therapy. , 2003, 100, 89-99.		20
2287	Pitavastatin alters the expression of thrombotic and fibrinolytic proteins in human vascular cells. <i>Journal of Cellular Biochemistry</i> , 2003, 90, 23-32.	1.2	47
2288	Statin therapy for the treatment of diabetic dyslipidemia. <i>Diabetes/Metabolism Research and Reviews</i> , 2003, 19, 280-287.	1.7	14
2289	Risk perception of participants in a family-based genetic screening program on familial hypercholesterolemia. <i>American Journal of Medical Genetics Part A</i> , 2003, 116A, 136-143.	2.4	20
2290	Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model. <i>Arthritis and Rheumatism</i> , 2003, 48, 3272-3279.	6.7	138
2291	Effect of Statins on Mortality and Cardiovascular Events in Elderly High-Risk Persons. <i>Journal of the American Geriatrics Society</i> , 2003, 51, 717-718.	1.3	7
2292	Analytical methods for the quantitative determination of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in biological samples. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2003, 793, 193-205.	1.2	62
2293	Cardiac magnetic resonance imaging in small animal models of human heart failure. <i>Medical Image Analysis</i> , 2003, 7, 369-375.	7.0	72
2294	Statins in hypercholesterolaemia: A dose-specific meta-analysis of lipid changes in randomised, double blind trials. <i>BMC Family Practice</i> , 2003, 4, 18.	2.9	133
2295	Developing prevalence-based prescribing units for analysing variations in general practitioner prescribing: a case study using statins. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2003, 28, 23-29.	0.7	6
2296	Coronary artery disease - more disease, more patients, better treatment. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2003, 28, 1-4.	0.7	3
2297	Cholesterol Lowering for the Prevention of Stroke. <i>Practical Neurology</i> , 2003, 3, 224-233.	0.5	3
2298	Extracellular signal-regulated kinase inhibition by statins inhibits neutrophil activation by ANCA. <i>Kidney International</i> , 2003, 63, 96-106.	2.6	51

#	ARTICLE	IF	CITATIONS
2299	Blood pressure reduction with HMG-CoA reductase inhibitors in renal transplant recipients. <i>Kidney International</i> , 2003, 63, 360-364.	2.6	33
2300	Anti-inflammatory and immunomodulatory effects of statins. <i>Kidney International</i> , 2003, 63, 12-23.	2.6	279
2301	Why do we need a statin trial in hemodialysis patients?. <i>Kidney International</i> , 2003, 63, S204-S206.	2.6	43
2302	Treatment of hyperphosphatemia with sevelamer hydrochloride in hemodialysis patients: A comparison with calcium acetate. <i>Kidney International</i> , 2003, 63, S69-S72.	2.6	33
2303	THE CLINICAL EPIDEMIOLOGY OF CARDIOVASCULAR DISEASES IN CHRONIC KIDNEY DISEASE: Applying Multiple Interventions in Chronic Kidney Disease. <i>Seminars in Dialysis</i> , 2003, 16, 157-164.	0.7	16
2304	Editorials: Are HMG-CoA Reductase Inhibitors Underutilized in Dialysis Patients?. <i>Seminars in Dialysis</i> , 2003, 16, 179-185.	0.7	13
2305	Micro- and Macrocirculatory Effects of Apheresis in Patients with Familial Hyperlipidemia. <i>Therapeutic Apheresis and Dialysis</i> , 2003, 7, 115-118.	0.4	6
2306	Lipid Apheresis: The Only Therapeutic Option for a Very Small Group of Cardiovascular Patients with High Low-density Lipoprotein Cholesterol or Lipoprotein(a) Blood Concentrations. <i>Therapeutic Apheresis and Dialysis</i> , 2003, 7, 283-284.	0.4	1
2307	Indication of Low-density Lipoprotein Apheresis in Severe Hypercholesterolemia and its Atherosclerotic Vascular Complications: Dextran Sulfate Cellulose Low-density Lipoprotein Apheresis. <i>Therapeutic Apheresis and Dialysis</i> , 2003, 7, 345-349.	0.4	9
2308	Low-density Lipoprotein Apheresis: An Overview. <i>Therapeutic Apheresis and Dialysis</i> , 2003, 7, 382-390.	0.4	73
2309	Changes in C-reactive Protein Plasma Levels During Low-density Lipoprotein Apheresis. <i>Therapeutic Apheresis and Dialysis</i> , 2003, 7, 431-434.	0.4	32
2310	Use of Nonantiarrhythmic Drugs for Prevention of Sudden Cardiac Death. <i>Journal of Cardiovascular Electrophysiology</i> , 2003, 14, S87-S95.	0.8	61
2315	Myocardial Perfusion Imaging. <i>Imaging Decisions (Berlin, Germany)</i> , 2003, 7, 29-35.	0.2	0
2316	Cardiovascular risk in dialysis patients: A comparison of risk factors and cardioprotective therapy between 1996 and 2001. <i>Nephrology</i> , 2003, 8, 177-183.	0.7	19
2317	SUBOPTIMAL PREVENTIVE PRACTICES IN PATIENTS WITH CAROTID AND PERIPHERAL VASCULAR OCCLUSIVE DISEASE IN A TERTIARY REFERRAL SETTING. <i>ANZ Journal of Surgery</i> , 2003, 73, 932-937.	0.3	11
2318	Stroke prevention: what's new?. <i>Internal Medicine Journal</i> , 2003, 33, 177-181.	0.5	2
2319	Prediction of cardiovascular risk in people with diabetes. <i>Diabetic Medicine</i> , 2003, 20, 515-527.	1.2	29
2320	Effects of atorvastatin on glucose homeostasis, postprandial triglyceride response and C-reactive protein in subjects with impaired fasting glucose. <i>Diabetic Medicine</i> , 2003, 20, 743-745.	1.2	54

#	ARTICLE	IF	CITATIONS
2321	Who receives lipid-lowering drugs: the effects of comorbidities and patient characteristics on treatment initiation. <i>British Journal of Clinical Pharmacology</i> , 2003, 55, 288-298.	1.1	14
2322	Undertreatment of hypercholesterolaemia: a population-based study. <i>British Journal of Clinical Pharmacology</i> , 2003, 55, 389-397.	1.1	37
2323	Evidence for an age and gender bias in the secondary prevention of ischaemic heart disease in primary care. <i>British Journal of Clinical Pharmacology</i> , 2003, 55, 604-608.	1.1	87
2324	Discontinuation and switching of therapy after initiation of lipid-lowering drugs: the effects of comorbidities and patient characteristics. <i>British Journal of Clinical Pharmacology</i> , 2003, 56, 84-91.	1.1	38
2325	Differences between clinical trials and postmarketing use. <i>British Journal of Clinical Pharmacology</i> , 2003, 57, 86-92.	1.1	121
2326	<i>Chlamydia pneumoniae</i> and vascular disease. <i>British Journal of Surgery</i> , 2003, 85, 1191-1197.	0.1	41
2327	Hormone replacement therapy: current controversies. <i>Clinical Endocrinology</i> , 2003, 58, 249-261.	1.2	79
2328	Treatment with atorvastatin alters interleukin-12 and -10 gene expression. <i>European Journal of Clinical Investigation</i> , 2003, 33, 88-91.	1.7	7
2329	No acute impact of lipid apheresis treatment on free radical scavenging enzyme gene expression in white blood cells. <i>European Journal of Clinical Investigation</i> , 2003, 33, 134-140.	1.7	3
2330	Long-Term Prognostic Importance of Total Cholesterol in Elderly Survivors of an Acute Myocardial Infarction: The Cooperative Cardiovascular Pilot Project. <i>Journal of the American Geriatrics Society</i> , 2003, 51, 930-936.	1.3	14
2331	Continuous quality control in diabetes care - implications. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2003, 20, 85-88.	0.2	2
2332	Ensuring the quality of diabetes care: Use of the QUAD-CAT model and Alphabet Strategy in clinical practice. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2003, 20, 171-177.	0.2	2
2333	Development and validation of the hyperlipidemia. <i>Journal of General Internal Medicine</i> , 2003, 18, 984-990.	1.3	10
2334	Efficacy and Safety of a New Whole-blood Low-density Lipoprotein Apheresis System (Liposorber D) in Severe Hypercholesterolemia. <i>Artificial Organs</i> , 2003, 27, 1116-1122.	1.0	53
2335	Treatment Options for Patients With the Metabolic Syndrome. <i>Journal of the American Academy of Nurse Practitioners</i> , 2003, 15, 361-370.	1.4	8
2336	Diet and physical activity: a healthful binomial. <i>European Journal of Clinical Nutrition</i> , 2003, 57, S63-S65.	1.3	12
2337	Why not prescribe the best drugs for hypertension now?. <i>Journal of Human Hypertension</i> , 2003, 17, 505-511.	1.0	7
2338	Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. <i>Nature Reviews Drug Discovery</i> , 2003, 2, 517-526.	21.5	703

#	ARTICLE	IF	CITATIONS
2339	Clinical biomarkers in drug discovery and development. <i>Nature Reviews Drug Discovery</i> , 2003, 2, 566-580.	21.5	686
2340	Short-Term Statin Therapy Improves Cardiac Function and Symptoms in Patients With Idiopathic Dilated Cardiomyopathy. <i>Circulation</i> , 2003, 108, 839-843.	1.6	387
2341	Lipid Management: Case by Case. <i>Journal of Vascular and Interventional Radiology</i> , 2003, 14, P29-P30.	0.2	0
2342	Tratamiento farmacológico del riesgo cardiovascular metabólico. <i>Medicine</i> , 2003, 8, 6382-6395.	0.0	0
2344	Evolución de la dislipemia en pacientes intervenidos mediante derivación biliopancreática de Larrad. <i>Cirugía Española</i> , 2003, 73, 161-165.	0.1	2
2345	Management of dyslipidemias in the age of statins. <i>Primary Care - Clinics in Office Practice</i> , 2003, 30, 641-669.	0.7	3
2346	Eficiencia de los principales fármacos utilizados como tratamiento de la hipercolesterolemia en atención primaria. <i>Clínica e Investigación en Arteriosclerosis</i> , 2003, 15, 239-247.	0.4	0
2347	Putting prevention into daily practice. <i>Cardiology Clinics</i> , 2003, 21, 471-482.	0.9	3
2348	Guía del manejo de las dislipemias en los pacientes infectados por el VIH: recomendaciones farmacológicas. <i>Clínica e Investigación en Arteriosclerosis</i> , 2003, 15, 29-34.	0.4	0
2349	ACE inhibitors and ARBs in chronic heart failure: the established, the expected, and the pragmatic. <i>Medical Clinics of North America</i> , 2003, 87, 373-389.	1.1	17
2350	Cardiovascular risk in women with type 2 diabetes. <i>Medical Clinics of North America</i> , 2003, 87, 955-969.	1.1	11
2352	A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. <i>Atherosclerosis</i> , 2003, 168, 1-14.	0.4	490
2353	Simvastatin inhibits expression of tissue factor in advanced atherosclerotic lesions of apolipoprotein E deficient mice independently of lipid lowering: potential role of simvastatin-mediated inhibition of Egr-1 expression and activation. <i>Atherosclerosis</i> , 2003, 167, 187-194.	0.4	98
2354	Soluble intercellular adhesion molecule-1 and interleukin-6 levels reflect endothelial dysfunction in patients with primary hypercholesterolaemia treated with atorvastatin. <i>Atherosclerosis</i> , 2003, 169, 283-291.	0.4	86
2355	In the statin era, how important are intense lifestyle changes?. <i>Journal of the American College of Cardiology</i> , 2003, 41, 273-274.	1.2	6
2356	Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy. <i>Journal of the American College of Cardiology</i> , 2003, 41, 275-279.	1.2	88
2357	Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. <i>Journal of the American College of Cardiology</i> , 2003, 41, 508-515.	1.2	226
2358	ACC/AHA 2002 guideline update for the management of patients with chronic stable angina—summary article. <i>Journal of the American College of Cardiology</i> , 2003, 41, 159-168.	1.2	920

#	ARTICLE	IF	CITATIONS
2359	Antioxidants, statins, and atherosclerosis. <i>Journal of the American College of Cardiology</i> , 2003, 41, 1205-1210.	1.2	71
2360	Lipid-lowering therapy for prevention of ventricular tachyarrhythmias. <i>Journal of the American College of Cardiology</i> , 2003, 42, 88-92.	1.2	11
2361	Are lipid-lowering drugs also antiarrhythmic drugs?. <i>Journal of the American College of Cardiology</i> , 2003, 42, 81-87.	1.2	193
2362	Statins enhance postischemic hyperemia in the skin circulation of hypercholesterolemic patients. <i>Journal of the American College of Cardiology</i> , 2003, 42, 71-77.	1.2	162
2363	Clinical decision making on statin drug interactions. <i>Journal of the American College of Cardiology</i> , 2003, 42, 396-397.	1.2	1
2364	Prospective serial evaluation of myocardial perfusion and lipids during the first six months of pravastatin therapy. <i>Journal of the American College of Cardiology</i> , 2003, 42, 600-610.	1.2	71
2365	Changes in coronary plaque color and morphology by lipid-lowering therapy with atorvastatin: serial evaluation by coronary angiography. <i>Journal of the American College of Cardiology</i> , 2003, 42, 680-686.	1.2	406
2366	Effects of raloxifene on endothelium-dependent dilation, lipoproteins, and markers of vascular function in postmenopausal women with coronary artery disease. <i>Journal of the American College of Cardiology</i> , 2003, 42, 698-704.	1.2	43
2367	Long-term statin use and psychological well-being. <i>Journal of the American College of Cardiology</i> , 2003, 42, 690-697.	1.2	121
2368	Practical applications in stress echocardiography. <i>Journal of the American College of Cardiology</i> , 2003, 42, 1084-1090.	1.2	110
2369	Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy. <i>Journal of the American College of Cardiology</i> , 2003, 42, 1161-1170.	1.2	307
2370	Benefits and Risks of Simvastatin in Patients with Familial Hypercholesterolaemia. <i>Drug Safety</i> , 2003, 26, 769-786.	1.4	5
2371	Clinical Pharmacokinetics of Atorvastatin. <i>Clinical Pharmacokinetics</i> , 2003, 42, 1141-1160.	1.6	482
2372	Pharmacological Treatment of Patients with Peripheral Arterial Disease. <i>Drugs</i> , 2003, 63, 637-647.	4.9	10
2373	Lovastatin Extended Release. <i>Drugs</i> , 2003, 63, 685-699.	4.9	16
2374	Statin Treatment and Progression of Atherosclerotic Plaque Burden. <i>Drugs</i> , 2003, 63, 893-911.	4.9	25
2375	Effects of HMG-CoA Reductase Inhibitors on Coagulation and Fibrinolysis Processes. <i>Drugs</i> , 2003, 63, 1821-1854.	4.9	141
2376	Low High-Density Lipoprotein Cholesterol. <i>Drugs</i> , 2003, 63, 1907-1945.	4.9	59

#	ARTICLE	IF	CITATIONS
2377	Effects of D-003, a New Hypocholesterolaemic and Antiplatelet Compound, on Lipid Profile and Lipid Peroxidation in Healthy Volunteers. <i>Clinical Drug Investigation</i> , 2003, 23, 193-203.	1.1	19
2378	Comparison of the Effects of Policosanol and Atorvastatin on Lipid Profile and Platelet Aggregation in Patients with Dyslipidaemia and Type 2 Diabetes Mellitus. <i>Clinical Drug Investigation</i> , 2003, 23, 639-650.	1.1	29
2379	Effects of D-003 on the Lipid Profile of Patients with Type II Hypercholesterolaemia. <i>Clinical Drug Investigation</i> , 2003, 23, 789-802.	1.1	12
2380	Atorvastatin improves metabolic control and endothelial function in Type 2 diabetic patients: A placebo-controlled study. <i>Journal of Endocrinological Investigation</i> , 2003, 26, 73-78.	1.8	44
2381	Relation of Inflammation and Benefit of Statins After Percutaneous Coronary Interventions. <i>Circulation</i> , 2003, 107, 1750-1756.	1.6	195
2382	Ezetimibe for Management of Hypercholesterolemia. <i>Annals of Pharmacotherapy</i> , 2003, 37, 839-848.	0.9	32
2383	Agents that stabilise atherosclerotic plaque. <i>Expert Opinion on Investigational Drugs</i> , 2003, 12, 1681-1692.	1.9	2
2384	Role of lipid and lipoprotein profiles in risk assessment and therapy. <i>American Heart Journal</i> , 2003, 146, 227-233.	1.2	56
2385	Effect of dietary intervention and lipid-lowering treatment on brachial vasoreactivity in patients with ischemic heart disease and hypercholesterolemia. <i>American Heart Journal</i> , 2003, 145, 903.	1.2	51
2386	Role of single photon emission computed tomography imaging in the evaluation of therapy for angina pectoris. <i>American Heart Journal</i> , 2003, 145, 952-961.	1.2	4
2387	Comparison of the dose-response relationships of 2 lipid-lowering agents: A Bayesian meta-analysis. <i>American Heart Journal</i> , 2003, 145, 1036-1045.	1.2	22
2388	Antiarrhythmic effects of omega-3 fatty acids: from epidemiology to bedside. <i>American Heart Journal</i> , 2003, 146, 420-430.	1.2	61
2389	Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS). <i>American Heart Journal</i> , 2003, 146, 613-620.	1.2	103
2390	Screening for early detection of cardiovascular disease in asymptomatic individuals. <i>American Heart Journal</i> , 2003, 146, 679-685.	1.2	66
2391	Quality of care for secondary prevention for patients with coronary heart disease: results of the Hastening the Effective Application of Research through Technology (HEART) trial. <i>American Heart Journal</i> , 2003, 146, 1045-1051.	1.2	36
2392	Comparison of treatment and outcomes for patients with acute myocardial infarction in Minneapolis/St. Paul, Minnesota, and Gästeborg, Sweden. <i>American Heart Journal</i> , 2003, 146, 1023-1029.	1.2	14
2393	Lack of improvement in the treatment of hyperlipidemia among patients with type 2 diabetes. <i>American Journal of Medicine</i> , 2003, 114, 377-382.	0.6	17
2394	Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. <i>American Journal of Medicine</i> , 2003, 114, 359-364.	0.6	262



#	ARTICLE	IF	CITATIONS
2395	Evaluating the benefits of treating dyslipidemia: the importance of diabetes as a risk factor. American Journal of Medicine, 2003, 115, 122-128.	0.6	7
2396	Endothelial Dysfunction. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 168-175.	1.1	1,939
2397	AVID and COMET. Preventive Cardiology, 2003, 6, 218-220.	1.1	0
2398	Beyond the Mediterranean Diet: The Role of Omega-3 Fatty Acids in the Prevention of Coronary Heart Disease. Preventive Cardiology, 2003, 6, 136-146.	1.1	30
2399	Characteristics and Lipid Distribution of a Large, High-Risk, Hypertensive Population: The Lipid-Lowering Component of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Journal of Clinical Hypertension, 2003, 5, 377-384.	1.0	13
2400	Effects of policosanol on borderline to mildly elevated serum total cholesterol levels: a prospective, double-blind, placebo-controlled, parallel-group, comparative study. Current Therapeutic Research, 2003, 64, 522-537.	0.5	10
2402	Managing the high-risk patient: therapeutic approaches in 2002. Atherosclerosis Supplements, 2003, 4, 15-20.	1.2	3
2403	The next step in cardiovascular protection. Atherosclerosis Supplements, 2003, 4, 3-9.	1.2	6
2404	Long-term statin safety and efficacy in secondary prevention: can combination therapy improve outcomes?. Atherosclerosis Supplements, 2003, 4, 11-16.	1.2	10
2405	Preventing the next event in the elderly: the PROSPER perspective. Atherosclerosis Supplements, 2003, 4, 17-22.	1.2	11
2406	HMG CoA reductase inhibitor suppresses the expression of tissue factor and plasminogen activator inhibitor-1 induced by angiotensin II in cultured rat aortic endothelial cells. Thrombosis Research, 2003, 110, 227-234.	0.8	47
2407	Familial hypercholesterolaemia and quality of life in family members. Preventive Medicine, 2003, 36, 569-574.	1.6	13
2408	Contrast-enhanced MRI and routine single photon emission computed tomography (SPECT) perfusion imaging for detection of subendocardial myocardial infarcts: an imaging study. Lancet, The, 2003, 361, 374-379.	6.3	1,208
2409	Heart Protection Study. Lancet, The, 2003, 361, 528.	6.3	3
2410	Heart Protection Study. Lancet, The, 2003, 361, 529-530.	6.3	412
2411	More on the LIFE study. Lancet, The, 2003, 361, 533.	6.3	0
2412	Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet, The, 2003, 361, 1149-1158.	6.3	3,420
2413	Age and the treatment gap in the use of statins. Lancet, The, 2003, 361, 1925-1926.	6.3	8

#	ARTICLE	IF	CITATIONS
2414	MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. <i>Lancet, The</i> , 2003, 361, 2005-2016.	6.3	2,587
2415	Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. <i>Lancet, The</i> , 2003, 361, 2024-2031.	6.3	861
2416	Demographics and concomitant disorders in heart failure. <i>Lancet, The</i> , 2003, 362, 147-158.	6.3	127
2417	Ischemic heart disease in type 2 diabetes. <i>Metabolism: Clinical and Experimental</i> , 2003, 52, 6-12.	1.5	15
2418	The effect of combining plant sterols, soy protein, viscous fibers, and almonds in treating hypercholesterolemia. <i>Metabolism: Clinical and Experimental</i> , 2003, 52, 1478-1483.	1.5	127
2419	Effect of atorvastatin on apolipoprotein B48 metabolism and low-density lipoprotein receptor activity in normolipidemic patients with coronary artery disease. <i>Metabolism: Clinical and Experimental</i> , 2003, 52, 1279-1286.	1.5	29
2420	Effects of Fluvastatin on Plasma Levels of Low-Density Lipoprotein Subfractions, Oxidized Low-Density Lipoprotein, and Soluble Adhesion Molecules: A Twenty-Four-Week, Open-Label, Dose-Increasing Study. <i>Current Therapeutic Research</i> , 2003, 64, 236-247.	0.5	6
2421	A six-month, multicenter, open-label, noncomparative, prospective, observational study of the efficacy and tolerability of atorvastatin in the primary care setting (estudio del control de las Tj ETQq1 1 0.784314 rgBT / Overdock 10df 50 45	0.5	6
2422	Hypocholesterolemic activity of calcic and magnesic-sulphate-sulphurous spring mineral water in the rat. <i>Nutrition Research</i> , 2003, 23, 775-789.	1.3	9
2423	Effects of stable fish oil and simvastatin on plasma lipoproteins in patients with hyperlipidemia. <i>Nutrition Research</i> , 2003, 23, 1027-1034.	1.3	6
2424	Black tea consumption and serum lipid profiles in Saudi women: a cross-sectional study in Saudi Arabia. <i>Nutrition Research</i> , 2003, 23, 1515-1526.	1.3	5
2425	Focusing on changing clinical practice to enhance rational prescribing collaboration and networking enable comprehensive approaches. <i>Health Policy</i> , 2003, 66, 1-10.	1.4	11
2426	Comments on the MRC/BHF Heart Protection Study. <i>Lancet, The</i> , 2003, 362, 744.	6.3	0
2427	Dyslipidaemia. <i>Lancet, The</i> , 2003, 362, 717-731.	6.3	314
2428	Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). <i>Lancet, The</i> , 2003, 362, 782-788.	6.3	1,952
2429	Pharmacology and therapeutics of ezetimibe (SCH 58235), a cholesterol-absorption inhibitor. <i>Clinical Therapeutics</i> , 2003, 25, 2352-2387.	1.1	73
2430	A multicenter, randomized, double-blind clinical trial comparing the low-density lipoprotein cholesterol-lowering ability of lovastatin 10, 20, and 40 mg/d with fluvastatin 20 and 40 mg/d. <i>Clinical Therapeutics</i> , 2003, 25, 2738-2753.	1.1	16
2431	A retrospective cohort study of correlates of response to pharmacologic therapy for hyperlipidemia in members of a managed care organization. <i>Clinical Therapeutics</i> , 2003, 25, 2936-2957.	1.1	31

#	ARTICLE	IF	CITATIONS
2432	From cholesterol levels to risk analysis: the revolution of the Heart Protection Study. International Congress Series, 2003, 1253, 217-222.	0.2	0
2433	Ischemic optic neuropathy as the first manifestation of elevated cholesterol levels in young patients. Ophthalmology, 2003, 110, 1041-1046.	2.5	80
2434	Effects of statin on plaque stability and thrombogenicity in hypercholesterolemic patients with coronary artery disease. International Journal of Cardiology, 2003, 88, 77-82.	0.8	62
2435	Familial hypercholesterolemia—Improving treatment and meeting guidelines. International Journal of Cardiology, 2003, 89, 13-23.	0.8	64
2436	The effect of statin therapy on ventricular late potentials in acute myocardial infarction. International Journal of Cardiology, 2003, 90, 63-72.	0.8	44
2437	An open label crossover trial of effects of metronidazol on hyperlipidaemia. International Journal of Cardiology, 2003, 90, 141-145.	0.8	10
2438	A comparative study of the in vitro antioxidant activity of statins. International Journal of Cardiology, 2003, 90, 317-321.	0.8	145
2439	Determinants of appropriate lipid management in patients with ischaemic heart disease. Cracovian Program for Secondary Prevention of Ischaemic Heart Disease. International Journal of Cardiology, 2003, 91, 15-23.	0.8	12
2440	Effects of atorvastatin on in-stent stenosis in normo- and hypercholesterolemic rabbits. International Journal of Cardiology, 2003, 91, 59-69.	0.8	18
2441	Effect of atorvastatin on lipid parameters, LDL subtype distribution, hemorrheological parameters and adhesion molecule concentrations in patients with hypertriglyceridemia. Nutrition, Metabolism and Cardiovascular Diseases, 2003, 13, 87-92.	1.1	13
2442	Effects of statins on lipoprotein fractions. International Congress Series, 2003, 1253, 247-252.	0.2	4
2443	Patients' achievement of cholesterol targets. American Journal of Preventive Medicine, 2003, 25, 339-342.	1.6	11
2444	The potential benefits of dietary and/or supplemental calcium and vitamin D. Urologic Oncology: Seminars and Original Investigations, 2003, 21, 384-391.	0.8	8
2445	Life-years gained from coronary heart disease mortality reduction in Scotland. Journal of Clinical Epidemiology, 2003, 56, 583-590.	2.4	35
2446	Metformin and vascular protection: a cardiologist's view. Diabetes and Metabolism, 2003, 29, 6S117-6S120.	1.4	9
2447	What's in a risk factor? — who strikes the ball. Diabetes and Metabolism, 2003, 29, 6-13.	1.4	321
2448	Reverse cholesterol transport, high density lipoproteins and HDL cholesterol: recent data. Diabetes and Metabolism, 2003, 29, 201-205.	1.4	46
2449	Changes in serum HDL and LDL cholesterol in patients with paget's bone disease treated with pamidronate. Bone, 2003, 32, 15-19.	1.4	30

#	ARTICLE	IF	CITATIONS
2450	Effect of simvastatin treatment on bone mineral density and bone turnover in hypercholesterolemic postmenopausal women: a 1-year longitudinal study. <i>Bone</i> , 2003, 32, 427-433.	1.4	113
2451	Rosuvastatin in the Primary Prevention of Cardiovascular Disease Among Patients With Low Levels of Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein. <i>Circulation</i> , 2003, 108, 2292-2297.	1.6	412
2452	Hepatotoxicity of hypolipidemic drugs. <i>Clinics in Liver Disease</i> , 2003, 7, 415-433.	1.0	77
2453	Early Benefit from Structured Care with Atorvastatin in Patients with Coronary Heart Disease and Diabetes Mellitus. <i>Angiology</i> , 2003, 54, 679-690.	0.8	91
2454	Design and Baseline Characteristics of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study. <i>Cerebrovascular Diseases</i> , 2003, 16, 389-395.	0.8	170
2455	Ezetimibe: a novel option for lowering cholesterol. <i>Expert Review of Cardiovascular Therapy</i> , 2003, 1, 11-21.	0.6	35
2456	Dyslipidemia treatment: current considerations and unmet needs. <i>Expert Review of Cardiovascular Therapy</i> , 2003, 1, 121-134.	0.6	0
2457	Niacin as a Component of Combination Therapy for Dyslipidemia. <i>Mayo Clinic Proceedings</i> , 2003, 78, 735-742.	1.4	66
2458	RabdomiÃ³lisis asociada al uso de simvastatina. <i>Revista Clinica Espanola</i> , 2003, 203, 615.	0.2	0
2459	Benefits of Optimising Drug Treatment in Home-Dwelling Elderly Patients with Coronary Artery Disease. <i>Drugs and Aging</i> , 2003, 20, 585-595.	1.3	6
2460	HMG-CoA Reductase Inhibitors in Osteoporosis. <i>Drugs and Aging</i> , 2003, 20, 321-336.	1.3	11
2461	Statin Therapy in the Elderly. <i>Drugs and Aging</i> , 2003, 20, 263-275.	1.3	19
2462	Comparison of the Efficacy and Tolerability of Policosanol with Atorvastatin in Elderly Patients with Type II Hypercholesterolaemia. <i>Drugs and Aging</i> , 2003, 20, 153-163.	1.3	55
2463	Pharmacotherapy for dyslipidaemia â€“ current therapies and future agents. <i>Expert Opinion on Pharmacotherapy</i> , 2003, 4, 1901-1938.	0.9	154
2464	Comparison of the Cholesterol-Lowering Effects and Toxicity of D-003 and Lovastatin in Normocholesterolaemic Rabbits. <i>Drugs in R and D</i> , 2003, 4, 219-229.	1.1	10
2465	Cardiovascular disease and lipids. <i>European Journal of General Practice</i> , 2003, 9, 16-24.	0.9	5
2466	In light of ALLHAT and ASCOT: Are there benefits of statins as add-on treatment in hypertensives?. <i>Blood Pressure</i> , 2003, 12, 132-133.	0.7	0
2467	Behavioral Medicine in the Prevention and Treatment of Cardiovascular Disease. <i>Behavior Modification</i> , 2003, 27, 3-25.	1.1	37

#	ARTICLE	IF	CITATIONS
2468	Can antiarrhythmic drugs save lives in patients with congestive heart failure?. Expert Review of Cardiovascular Therapy, 2003, 1, 191-202.	0.6	2
2469	Expanding indications of statins; implications of the Heart Protection Study. Expert Opinion on Investigational Drugs, 2003, 12, 509-513.	1.9	5
2470	Atherosclerotic Plaque Rupture. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 2123-2130.	1.1	146
2471	The Multicentre Atorvastatin Plaque Stabilisation (MAPS) Study. High Blood Pressure and Cardiovascular Prevention, 2003, 10, 11-18.	1.0	0
2472	A Model to Assess the Cost Effectiveness of Statins in Achieving the UK National Service Framework Target Cholesterol Levels. Pharmacoeconomics, 2003, 21, 1-11.	1.7	18
2473	Stable Angina. American Journal of Cardiovascular Drugs, 2003, 3, 1-10.	1.0	7
2474	The Pursuit of Optimum Outcomes in Stable Angina. American Journal of Cardiovascular Drugs, 2003, 3, 11-20.	1.0	10
2475	Reduction of Serum LDL-C Levels. American Journal of Cardiovascular Drugs, 2003, 3, 271-281.	1.0	16
2476	Primary hypercholesterolemia: genetic causes and treatment of five monogenic disorders. Expert Review of Cardiovascular Therapy, 2003, 1, 107-119.	0.6	34
2477	Probing antiphospholipid-mediated thrombosis: the interplay between anticardiolipin antibodies and endothelial cells. Lupus, 2003, 12, 539-545.	0.8	46
2478	Clinical Trials: Evidence and Unanswered Questions " Hyperlipidaemia. Cerebrovascular Diseases, 2003, 16, 25-32.	0.8	13
2479	Simvastatin Initiated Early After Heart Transplantation. Circulation, 2003, 107, 93-97.	1.6	230
2480	Potential Nontraditional Applications of Statins. Annals of Pharmacotherapy, 2003, 37, 1063-1071.	0.9	15
2481	Statin Therapy Interacts With Cytomegalovirus Seropositivity and High C-Reactive Protein in Reducing Mortality Among Patients With Angiographically Significant Coronary Disease. Circulation, 2003, 107, 258-263.	1.6	48
2482	Noncholesterol-Lowering Effects of Statins. Vascular and Endovascular Surgery, 2003, 37, 301-313.	0.3	22
2483	Evolution of statin prescribing 1994-2001: a case of agism but not of sexism?. British Heart Journal, 2003, 89, 417-421.	2.2	130
2484	Review: The management of stable angina in diabetes. British Journal of Diabetes and Vascular Disease, 2003, 3, 18-25.	0.6	3
2485	3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Decrease Fas Ligand Expression and Cytotoxicity in Activated Human T Lymphocytes. Circulation, 2003, 108, 1506-1513.	1.6	64

#	ARTICLE	IF	CITATIONS
2486	The challenges of treating peripheral arterial disease. <i>Vascular Medicine</i> , 2003, 8, 109-114.	0.8	19
2487	Impact of Dyslipidemia in End-Stage Renal Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, S315-S320.	3.0	100
2488	Relation Between Progression and Regression of Atherosclerotic Left Main Coronary Artery Disease and Serum Cholesterol Levels as Assessed With Serial Long-Term (â‰¥12 Months) Follow-Up Intravascular Ultrasound. <i>Circulation</i> , 2003, 108, 2757-2762.	1.6	140
2489	Secondary Prevention of Coronary Heart Disease in the Elderly. <i>Annals of Pharmacotherapy</i> , 2003, 37, 1867-1876.	0.9	29
2490	Trends in blood pressure, lipids, lipoproteins and glucose metabolism in the Northern Sweden MONICA project 1986 - 99. <i>Scandinavian Journal of Public Health</i> , 2003, 31, 43-50.	1.2	16
2491	Patientsâ€™ Perspectives on Statin Therapy for Treatment of Hypercholesterolaemia: A Qualitative Study. <i>European Journal of Cardiovascular Nursing</i> , 2003, 2, 141-149.	0.4	38
2494	No Effect of Simvastatin Treatment on Insulin Sensitivity in Patients with Primary Hypercholesterolemia. <i>Endocrine Research</i> , 2003, 29, 265-275.	0.6	18
2495	Relationship of Peripheral Arterial Compliance and Standard Cardiovascular Risk Factors. <i>Vascular and Endovascular Surgery</i> , 2003, 37, 197-206.	0.3	25
2496	Prevention of Cardiovascular Ischemic Events. <i>Circulation</i> , 2003, 107, 2059-2065.	1.6	47
2497	Review: Diabetic dyslipidaemia â€” the case for using statins. <i>British Journal of Diabetes and Vascular Disease</i> , 2003, 3, 402-407.	0.6	0
2498	Rosuvastatin â€” A Highly Effective New 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor: Review of Clinical Trial Data at 10â€”40 mg Doses in Dyslipidemic Patients. <i>Cardiology</i> , 2003, 99, 126-139.	0.6	44
2499	Effect of an Oat Bran Enriched Diet on the Atherogenic Lipid Profile in Patients with an Increased Coronary Heart Disease Risk. <i>Annals of Nutrition and Metabolism</i> , 2003, 47, 306-311.	1.0	83
2500	New lipid-lowering agents. <i>Expert Opinion on Emerging Drugs</i> , 2003, 8, 365-376.	1.0	12
2502	Treatment with Simvastatin in Patients with Alzheimerâ€™s Disease Lowers Both $\text{A}\beta_{1-42}$ and $\text{A}\beta_{1-40}$ -Cleaved Amyloid Precursor Protein. <i>Dementia and Geriatric Cognitive Disorders</i> , 2003, 16, 25-30.	0.7	102
2503	Therapeutic Considerations for the Use of Statin Therapy in Chronic Renal Disease. <i>Nephron Clinical Practice</i> , 2003, 95, c107-c115.	2.3	6
2504	Simvastatin Reduces the Expression of Adhesion Molecules in Circulating Monocytes From Hypercholesterolemic Patients. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003, 23, 397-403.	1.1	138
2505	Statins in Threatened Stroke. <i>Stroke</i> , 2003, 34, 351-353.	1.0	7
2506	Simvastatin Attenuates Oxidant-Induced Mitochondrial Dysfunction in Cardiac Myocytes. <i>Circulation Research</i> , 2003, 93, 697-699.	2.0	114

#	ARTICLE	IF	CITATIONS
2507	Niacin-ER and Lovastatin Treatment of Hypercholesterolemia and Mixed Dyslipidemia. <i>Annals of Pharmacotherapy</i> , 2003, 37, 106-115.	0.9	14
2508	The impact of reimbursement criteria on the appropriateness of "statin"™ prescribing. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2003, 10, 456-462.	3.1	16
2510	Drug Therapy for Prevention of Recurrent Myocardial Infarction. <i>Annals of Pharmacotherapy</i> , 2003, 37, 1465-1477.	0.9	21
2511	CP-346086. <i>Journal of Lipid Research</i> , 2003, 44, 1887-1901.	2.0	166
2513	Short-Term Efficacy and Safety of Extended-Release Fluvastatin in a Large Cohort of Elderly Patients. <i>The American Journal of Geriatric Cardiology</i> , 2003, 12, 225-231.	0.7	33
2514	Statins and their potential targets in multiple sclerosis therapy. <i>Expert Opinion on Therapeutic Targets</i> , 2003, 7, 613-622.	1.5	20
2515	Statin Therapy in the Elderly—The Evidence Mounts. <i>The American Journal of Geriatric Cardiology</i> , 2003, 12, 65-67.	0.7	0
2516	Statins Promote Potent Systemic Antioxidant Effects Through Specific Inflammatory Pathways. <i>Circulation</i> , 2003, 108, 426-431.	1.6	380
2517	Simvastatin—Fluconazole Causing Rhabdomyolysis. <i>Annals of Pharmacotherapy</i> , 2003, 37, 1032-1035.	0.9	56
2518	Developing pharmaceutical treatments for peripheral artery disease. <i>Expert Opinion on Investigational Drugs</i> , 2003, 12, 101-108.	1.9	6
2519	New lipid-modifying therapies. <i>Expert Opinion on Investigational Drugs</i> , 2003, 12, 325-335.	1.9	10
2520	Combination lipid-lowering therapy with statins: safety issues in the postcerivastatin era. <i>Expert Opinion on Drug Safety</i> , 2003, 2, 269-286.	1.0	15
2521	Dual Roles for Lipolysis and Oxidation in Peroxisome Proliferation-Activator Receptor Responses to Electronegative Low Density Lipoprotein. <i>Journal of Biological Chemistry</i> , 2003, 278, 39874-39881.	1.6	58
2522	Inhibition of Hydroxymethylglutaryl-Coenzyme A Reductase Reduces Th1 Development and Promotes Th2 Development. <i>Circulation Research</i> , 2003, 93, 948-956.	2.0	176
2523	Rhabdomyolysis Due to Combined Therapy with Cerivastatin and Diclofenac. <i>Journal of Pharmacy Technology</i> , 2003, 19, 219-221.	0.5	3
2524	Rapid Effect of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibition on Coronary Endothelial Function. <i>Circulation Research</i> , 2003, 93, e98-103.	2.0	153
2525	Hemostatic Effects of Atorvastatin versus Simvastatin. <i>Annals of Pharmacotherapy</i> , 2003, 37, 478-484.	0.9	21
2526	Review: Reconsidering the value of fibrates: lessons from the trials. <i>British Journal of Diabetes and Vascular Disease</i> , 2003, 3, 162-167.	0.6	4

#	ARTICLE	IF	CITATIONS
2527	A prospective study of long term prognosis in young myocardial infarction survivors: the prognostic value of angiography and exercise testing. <i>British Heart Journal</i> , 2003, 89, 843-847.	2.2	22
2528	Mevastatin Can Cause G 1 Arrest and Induce Apoptosis in Pulmonary Artery Smooth Muscle Cells Through a p27 Kip1 -Independent Pathway. <i>Circulation Research</i> , 2003, 92, 501-509.	2.0	40
2529	Sympathetic Nerve Sprouting, Electrical Remodeling, and Increased Vulnerability to Ventricular Fibrillation in Hypercholesterolemic Rabbits. <i>Circulation Research</i> , 2003, 92, 1145-1152.	2.0	123
2530	Lifestyle changes after a health dialogue Results from the Live for Life health promotion programme. <i>Scandinavian Journal of Primary Health Care</i> , 2003, 21, 248-252.	0.6	27
2531	Cross sectional survey of effectiveness of lipid lowering drugs in reducing serum cholesterol concentration in patients in 17 general practices. <i>BMJ: British Medical Journal</i> , 2003, 326, 689-689.	2.4	23
2532	How can research ethics committees protect patients better?. <i>BMJ: British Medical Journal</i> , 2003, 326, 1199-1201.	2.4	39
2533	Electron-Beam Tomography Coronary Artery Calcium and Cardiac Events. <i>Circulation</i> , 2003, 107, 2571-2576.	1.6	722
2534	Possible Role of Parathyroid Hormone-Related Protein as a Proinflammatory Cytokine in Atherosclerosis. <i>Stroke</i> , 2003, 34, 1783-1789.	1.0	67
2535	Cholesterol and the Risk of Ischemic Stroke. <i>Stroke</i> , 2003, 34, 2930-2934.	1.0	131
2536	Statins Regulate $\alpha_2\beta_1$ -Integrin Expression and Collagen Dependent Functions in Human Vascular Smooth Muscle Cells. <i>Journal of Cardiovascular Pharmacology</i> , 2003, 41, 89-96.	0.8	16
2537	Comparison of Micronized Fenofibrate and Pravastatin in Patients With Primary Hyperlipidemia. <i>Journal of Cardiovascular Pharmacology</i> , 2003, 41, 60-67.	0.8	13
2538	Preservation of Endothelium-Dependent and Nitro-L-Arginine Methyl Ester- and Indomethacin-Resistant Arterial Relaxation in High-Cholesterol-Diet Fed Rabbits by Treatment with Fluvastatin, an HMG-CoA Reductase Inhibitor. <i>Journal of Cardiovascular Pharmacology</i> , 2003, 42, 55-62.	0.8	9
2539	Endothelium-Dependent Effects of Statins. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003, 23, 729-736.	1.1	372
2541	Care after Coronary-Artery Bypass Surgery. <i>New England Journal of Medicine</i> , 2003, 348, 1456-1463.	13.9	39
2542	Preservation of Endothelial Function by the HMG-CoA Reductase Inhibitor Fluvastatin through Its Lipid-Lowering Independent Antioxidant Properties in Atherosclerotic Rabbits. <i>Pharmacology</i> , 2003, 68, 121-130.	0.9	21
2543	Automating Complex Guidelines for Chronic Disease: Lessons Learned. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2003, 10, 154-165.	2.2	98
2544	Lovastatin, a 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase Inhibitor, Induces Apoptosis and Differentiation in Human Anaplastic Thyroid Carcinoma Cells. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 3021-3026.	1.8	65
2545	Smoking cessation for the secondary prevention of coronary heart disease. , 2003, , CD003041.		173



#	ARTICLE	IF	CITATIONS
2546	Melanoma Chemoprevention: A Role for Statins or Fibrates?. American Journal of Therapeutics, 2003, 10, 203-210.	0.5	42
2547	PROGRESS results: implementation in stroke guidelines. Journal of Hypertension, 2003, 21, S25-S28.	0.3	4
2548	Novel Cardiovascular Risk Factors. Journal of Cardiovascular Nursing, 2003, 18, 131-138.	0.6	13
2549	National Cholesterol Education Program. Journal of Cardiovascular Nursing, 2003, 18, 85-92.	0.6	5
2550	Therapeutic implications of recent ATP III guidelines and the important role of combination therapy in total dyslipidemia management. Current Opinion in Cardiology, 2003, 18, 278-285.	0.8	21
2551	Cholesterol-Lowering Drugs Bring Benefits to High-Risk Populations Even When LDL Is Normal. Journal of Cardiovascular Nursing, 2003, 18, 44-49.	0.6	9
2552	Critical Pathway for Cardiac Rehabilitation After Percutaneous Coronary Intervention. Critical Pathways in Cardiology, 2003, 2, 7-14.	0.2	0
2553	Review of Cardiovascular Disease in Women: Awareness, Prevention, and Psychosocial Characteristics. Cardiology, 2003, 3, 191-202.	0.3	2
2559	Statins and Stroke. Therapie, 2003, 58, 49-58.	0.6	3
2565	Reduction of myocardial infarct size by fluvastatin. American Journal of Physiology - Heart and Circulatory Physiology, 2003, 285, H59-H64.	1.5	66
2566	Combining Multiple Analyses. , 2003, , 359-378.		0
2567	The Lure and Complexity of Multiple Analyses. , 2003, , 75-103.		0
2568	Genetic evaluation for coronary artery disease. Genetics in Medicine, 2003, 5, 269-285.	1.1	59
2569	Cerebrovascular Disease in Italy and Europe: It Is Necessary to Prevent a "Pandemia"™. Gerontology, 2003, 49, 69-79.	1.4	8
2570	Association of HMG-CoA Reductase Inhibitors with Neuropathy. Annals of Pharmacotherapy, 2003, 37, 274-278.	0.9	52
2571	Sustained Reduction of Serum Cholesterol in Low-Dose 6-Year Simvastatin Treatment With Minimum Side Effects in 51,321 Japanese Hypercholesterolemic Patients. Implication of the J-LIT Study, a Large Scale Nationwide Cohort Study.. Circulation Journal, 2003, 67, 287-294.	0.7	75
2572	Reduction in Serum Total Cholesterol and Risks of Coronary Events and Cerebral Infarction in Japanese Men-The Kyushu Lipid Intervention Study-. Circulation Journal, 2003, 67, 473-478.	0.7	23
2573	Patterns of Coronary Artery Movement and the Development of Coronary Atherosclerosis. Circulation Journal, 2003, 67, 846-850.	0.7	23

#	ARTICLE	IF	CITATIONS
2574	Pravastatin Prevents Arrhythmias Induced by Coronary Artery Ischemia/Reperfusion in Anesthetized Normocholesterolemic Rats. <i>Journal of Pharmacological Sciences</i> , 2003, 93, 87-94.	1.1	45
2575	Withdrawal of Statin Treatment Abrogates Stroke Protection in Mice. <i>Stroke</i> , 2003, 34, 551-557.	1.0	153
2576	Aggressive Lipid Management for Cardiovascular Prevention: Evidence from Clinical Trials. <i>Experimental Biology and Medicine</i> , 2003, 228, 769-778.	1.1	11
2577	Contribution of Rho A and Rho Kinase to Platelet-Derived Growth Factor-BB-Induced Proliferation of Vascular Smooth Muscle Cells.. <i>Journal of Atherosclerosis and Thrombosis</i> , 2003, 10, 117-123.	0.9	54
2578	Statins in the Era of Evidence-Based Medicine " Who Will Not " Prosper". <i>Scottish Medical Journal</i> , 2003, 48, 64-68.	0.7	2
2579	Blood Pressure and Lipid Lowering in the Prevention of Stroke: A Note to Neurologists. <i>Cerebrovascular Diseases</i> , 2003, 16, 33-38.	0.8	4
2580	Food Products Containing Free Tall Oil-Based Phytosterols and Oat $\beta$ -Glucan Lower Serum Total and LDL Cholesterol in Hypercholesterolemic Adults. <i>Journal of Nutrition</i> , 2003, 133, 808-813.	1.3	39
2582	Potential Role of Statins in Inflammation and Atherosclerosis. <i>Journal of Atherosclerosis and Thrombosis</i> , 2003, 10, 140-144.	0.9	45
2583	Pravastatin Protection from Cold Stress in Myocardium of Rats.. <i>International Heart Journal</i> , 2003, 44, 243-255.	0.6	6
2584	Pravastatin Reduces the Incidence of Cardiac Events Among Patients With Myocardial Infarction.. <i>International Heart Journal</i> , 2003, 44, 873-887.	0.6	3
2585	Statins' role in reducing mortality. <i>Practice Nursing</i> , 2003, 14, 555-557.	0.1	0
2586	Life Style and Cardiovascular Risk Factors in the Japanese Population-From an Epidemiological Survey on Serum Lipid Levels in Japan 1990. Part 2: Association of Lipid Parameters with Hypertension. <i>Journal of Atherosclerosis and Thrombosis</i> , 2003, 10, 176-185.	0.9	13
2587	Fluvastatin Increases LDL Particle Size and Reduces Oxidative Stress in Patients with Hyperlipidemia. <i>Journal of Atherosclerosis and Thrombosis</i> , 2003, 10, 343-347.	0.9	10
2588	Rapid access chest pain clinics: are they clinically effective?. <i>British Journal of Hospital Medicine</i> , 2003, 64, 324-325.	0.3	1
2589	3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Protect Cortical Neurons from Excitotoxicity. <i>Journal of Neuroscience</i> , 2003, 23, 11104-11111.	1.7	236
2590	An update on cardiovascular risk of metabolic syndrome. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2003, 47, 220-227.	1.3	16
2592	Improvement in Japanese Clinical Laboratory Measurements of Total Cholesterol and HDL-cholesterol by the US Cholesterol Reference Method Laboratory Network. <i>Journal of Atherosclerosis and Thrombosis</i> , 2003, 10, 145-153.	0.9	159
2593	Cholesterol-independent Effects of Statins and New Therapeutic Targets: Ischemic Stroke and Dementia. <i>Journal of Atherosclerosis and Thrombosis</i> , 2004, 11, 253-264.	0.9	92

#	ARTICLE	IF	CITATIONS
2594	History and Biochemistry of Statins. , 2004, , 1-12.		0
2595	Statins in the Primary Prevention of Atherosclerosis-Related Events. , 2004, , 53-92.		1
2596	Secondary Prevention of Atherosclerosis and Related Events by Statins. , 2004, , 93-112.		0
2597	Statins and Reduction of Stroke: Cholesterol-Lowering versus Pleiotropic Effects. , 2004, , 113-141.		0
2598	Effects of Statins on C-Reactive Protein: Are All Statins Similar?. , 2004, , 189-201.		0
2599	Statins, Inflammation, and C-Reactive Protein. , 2004, , 219-232.		0
2600	Anticoagulant Effects of Statins. , 2004, , 233-256.		0
2601	Arresting cardiovascular disease progression. Postgraduate Medicine, 2004, 116, 45-48.	0.9	0
2603	Prevention of cardiovascular disease: an evidence-based clinical aid. Medical Journal of Australia, 2004, 180, 197-198.	0.8	0
2604	Global Analysis of RNA Expression Profile in Human Vascular Cells Treated with Statins. Journal of Atherosclerosis and Thrombosis, 2004, 11, 62-72.	0.9	64
2605	Statins for Primary Prevention: Strategic Options to Save Lives and Money. Journal of the Royal Society of Medicine, 2004, 97, 66-71.	1.1	2
2606	The Case for Statins: Has it Really been Made?. Journal of the Royal Society of Medicine, 2004, 97, 461-464.	1.1	10
2607	Justification-Based Pharmacy Benefits. Hospital Pharmacy, 2004, 39, 272-277.	0.4	0
2608	Prevention of coronary heart disease in women. , 2004, , 209-224.		1
2609	Milk, Blood Lipids and Coronary Heart Disease (CHD) - "The Myth and the Evidence"™. BSAP Occasional Publication, 2004, 29, 199-213.	0.0	0
2610	Medical management of chronic ischemic heart disease. Postgraduate Medicine, 2004, 115, 39-46.	0.9	2
2611	Effects of Fluvastatin in Type 2 Diabetic Patients with Hyperlipidemia: Reduction in Cholesterol Oxidation Products and VCAM-1. Journal of Atherosclerosis and Thrombosis, 2004, 11, 56-61.	0.9	21
2612	Meeting cholesterol targets in diabetes care. Practice Nursing, 2004, 15, 118-123.	0.1	0

#	ARTICLE	IF	CITATIONS
2613	Metabolic syndrome and effects of conjugated linoleic acid in obesity and lipoprotein disorders: the Quebec experience. <i>American Journal of Clinical Nutrition</i> , 2004, 79, 1149S-1152S.	2.2	21
2614	Statins and secondary prevention of coronary heart disease. <i>British Journal of Community Nursing</i> , 2004, 9, 160-165.	0.2	3
2615	Cytoskeletal Activation and Altered Gene Expression in Endothelial Barrier Regulation by Simvastatin. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2004, 30, 662-670.	1.4	144
2616	Effects of OxLDL on Number and Activity of Circulating Endothelial Progenitor Cells. <i>Drug and Chemical Toxicology</i> , 2004, 27, 243-255.	1.2	50
2617	Diet and the prevention of coronary heart disease. , 2004, , 21-55.		1
2618	Atorvastatin versus pravastatin: intensive versus moderate lipid lowering. <i>Expert Opinion on Pharmacotherapy</i> , 2004, 5, 2025-2028.	0.9	1
2619	Effects of an Inhibitor of Cholesteryl Ester Transfer Protein on HDL Cholesterol. <i>New England Journal of Medicine</i> , 2004, 350, 1505-1515.	13.9	743
2620	Glycosylated Hemoglobin, Cardiovascular, and Renal Outcomes in a Pharmacist-Managed Clinic. <i>Annals of Pharmacotherapy</i> , 2004, 38, 771-775.	0.9	56
2621	Cerivastatin Activates Endothelial Calcium-Activated Potassium Channels and Thereby Modulates Endothelial Nitric Oxide Production and Cell Proliferation. <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 868-875.	3.0	26
2622	Improving care for patients with acute coronary syndromes: initial results from the National Audit of Myocardial Infarction Project (MINAP). <i>Heart</i> , 2004, 90, 1004-1009.	1.2	92
2623	ATP binding cassette transporter G5 and G8 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin. <i>Journal of Lipid Research</i> , 2004, 45, 653-656.	2.0	84
2624	Effect of Pravastatin on Cardiovascular Events in People With Chronic Kidney Disease. <i>Circulation</i> , 2004, 110, 1557-1563.	1.6	351
2625	Thematic review series: Brain Lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. <i>Journal of Lipid Research</i> , 2004, 45, 1375-1397.	2.0	865
2626	A Rational Approach to Drug Development: The Exploratory Phase. <i>Clinical Research and Regulatory Affairs</i> , 2004, 21, 155-177.	2.1	1
2627	Endothelial Function and Oxidative Stress. <i>Endothelium: Journal of Endothelial Cell Research</i> , 2004, 11, 123-132.	1.7	145
2628	High-Density Lipoproteins: A New Potential Therapeutic Target for the Prevention of Cardiovascular Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004, 24, 387-391.	1.1	127
2629	Prevention of cardiac complications of non-cardiac surgery: stenosis and thrombosis. <i>British Journal of Anaesthesia</i> , 2004, 92, 628-632.	1.5	8
2630	Atorvastatin Prevents End-Organ Injury in Salt-Sensitive Hypertension. <i>Hypertension</i> , 2004, 44, 186-190.	1.3	114

#	ARTICLE	IF	CITATIONS
2631	Regression of Coronary Atherosclerosis by Simvastatin. <i>Circulation</i> , 2004, 110, 265-270.	1.6	183
2632	Review: Ezetimibe â€™ clinical and pharmacological profile. <i>British Journal of Diabetes and Vascular Disease</i> , 2004, 4, 163-171.	0.6	2
2633	Hypothesis: Atorvastatin Has Pleiotropic Effects that Translate into Early Clinical Benefits on Cardiovascular Disease. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2004, 9, 61-63.	1.0	17
2634	Chapter 2 Primary Prevention of Stroke by Modification of Selected Risk Factors. <i>Blue Books of Practical Neurology</i> , 2004, 29, 5-54.	0.1	0
2635	Impact of nicorandil in angina: subgroup analyses. <i>Heart</i> , 2004, 90, 1427-1430.	1.2	21
2636	Peroxisome Proliferatorâ€™ Activated Receptor Ligand Bezafibrate for Prevention of Type 2 Diabetes Mellitus in Patients With Coronary Artery Disease. <i>Circulation</i> , 2004, 109, 2197-2202.	1.6	157
2637	Statin-Induced Cholesterol Lowering and Plaque Regression After 6 Months of Magnetic Resonance Imagingâ€™ Monitored Therapy. <i>Circulation</i> , 2004, 110, 2336-2341.	1.6	191
2638	There Is No Evidence for an Increase in Acute Coronary Syndromes After Short-Term Abrupt Discontinuation of Statins in Stable Cardiac Patients. <i>Circulation</i> , 2004, 110, 2333-2335.	1.6	86
2639	Atorvastatin Lowers Plasma Matrix Metalloproteinase-9 in Patients with Acute Coronary Syndrome. <i>Clinical Chemistry</i> , 2004, 50, 750-753.	1.5	23
2640	Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. <i>Circulation</i> , 2004, 110, 227-239.	1.6	5,602
2641	Prior Statin Therapy Is Associated With a Decreased Rate of Severe Sepsis. <i>Circulation</i> , 2004, 110, 880-885.	1.6	366
2642	Stopping Statins. <i>Circulation</i> , 2004, 110, 2280-2282.	1.6	14
2643	Coronary Event Secondary Prevention with Statins Irrespective of LDL-Cholesterol. <i>Annals of Pharmacotherapy</i> , 2004, 38, 1060-1064.	0.9	6
2644	Cholesterol-Lowering Independent Regression and Stabilization of Atherosclerotic Lesions by Pravastatin and by Antimonocyte Chemoattractant Protein-1 Therapy in Nonhuman Primates. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004, 24, 1522-1528.	1.1	29
2645	Atherosclerotic Vascular Disease Conference. <i>Circulation</i> , 2004, 109, 2634-2642.	1.6	54
2646	Should Angiotensin II Receptor Blockers and Statins Be Combined?. <i>Circulation</i> , 2004, 110, 1013-1020.	1.6	86
2647	Statins but Not Angiotensin-Converting Enzyme Inhibitors Delay Progression of Aortic Stenosis. <i>Circulation</i> , 2004, 110, 1291-1295.	1.6	391
2648	High-Dose Atorvastatin Reduces Total Plasma Levels of Oxidized Phospholipids and Immune Complexes Present on Apolipoprotein B-100 in Patients With Acute Coronary Syndromes in the MIRACL Trial. <i>Circulation</i> , 2004, 110, 1406-1412.	1.6	209

#	ARTICLE	IF	CITATIONS
2649	Plasma Levels of Cholesteryl Ester Transfer Protein and the Risk of Future Coronary Artery Disease in Apparently Healthy Men and Women. <i>Circulation</i> , 2004, 110, 1418-1423.	1.6	210
2650	Optimal Windows of Statin Use for Immediate Infarct Limitation. <i>Circulation</i> , 2004, 110, 2143-2149.	1.6	81
2651	Amlodipine and atorvastatin in atherosclerosis: a review of the potential of combination therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2004, 5, 459-468.	0.9	42
2652	The absolute risk of recurrent myocardial infarction is similar amongst both sexes: MONICA Iceland Study 1981-1999. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2004, 11, 121-124.	3.1	1
2653	Single-center retrospective study of long-term use of low-dose acitretin (Soriatane®) for psoriasis. <i>Journal of Dermatological Treatment</i> , 2004, 15, 8-13.	1.1	29
2654	OTC Statins: Opportunity or Threat?. <i>Canadian Pharmacists Journal</i> , 2004, 137, 11-13.	0.4	0
2655	β-Blocker Underuse in Secondary Prevention of Myocardial Infarction. <i>Annals of Pharmacotherapy</i> , 2004, 38, 286-293.	0.9	48
2656	Design and Baseline Characteristics of a Study of Primary Prevention of Coronary Events With Pravastatin Among Japanese With Mildly Elevated Cholesterol Levels. <i>Circulation Journal</i> , 2004, 68, 860-867.	0.7	51
2657	Regulatory Decision-Making in the United States Based on a Single Pivotal Clinical Study: Principles and Precedents. <i>Clinical Research and Regulatory Affairs</i> , 2004, 21, 101-143.	2.1	2
2658	Effects of Simvastatin on Plasma Lipoproteins and Response to Arterial Injury in Wild-Type and Apolipoprotein-E-Deficient Mice. <i>Journal of Vascular Research</i> , 2004, 41, 75-83.	0.6	26
2659	Patients with Alzheimer's Disease May Be Particularly Susceptible to Adverse Effects of Statins. <i>Dementia and Geriatric Cognitive Disorders</i> , 2004, 17, 109-116.	0.7	24
2660	New Perspectives on the Pharmacotherapy of Ischemic Stroke. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2004, 44, S46-S56.	0.7	12
2661	Cerebral Ischemia: New Risk Factors. <i>Cerebrovascular Diseases</i> , 2004, 17, 43-50.	0.8	32
2662	Statins and Stroke Prevention. <i>Cerebrovascular Diseases</i> , 2004, 17, 81-88.	0.8	28
2663	A Review of the Treatment Guidelines on the Management of Low Levels of High-Density Lipoprotein Cholesterol. <i>Cardiology</i> , 2004, 102, 61-66.	0.6	14
2664	Chapter 10 Risk Factor Modification for Secondary Prevention. <i>Blue Books of Practical Neurology</i> , 2004, 29, 197-210.	0.1	0
2665	The case for statins: has it really been made?. <i>Journal of the Royal Society of Medicine</i> , 2004, 97, 461-464.	1.1	12
2666	Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy. <i>FASEB Journal</i> , 2004, 18, 805-815.	0.2	73

#	ARTICLE	IF	CITATIONS
2667	Statin therapy increases vascular sensitivity to angiotensin II in hypercholesterolaemic patients. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2004, 5, 109-113.	1.0	5
2668	Simvastatin Induces Heme Oxygenase-1. Circulation, 2004, 110, 1296-1302.	1.6	260
2669	The Metabolic Syndrome: Pathophysiology, Clinical Relevance, and Use of Niacin. Annals of Pharmacotherapy, 2004, 38, 277-285.	0.9	13
2670	Participatory learning: a Swedish perspective. British Heart Journal, 2004, 90, 113-116.	2.2	9
2671	Management and in-hospital outcome of patients with acute myocardial infarction admitted to intensive care units at the turn of the century: results from the French nationwide USIC 2000 registry. Heart, 2004, 90, 1404-1410.	1.2	103
2672	Actions of Statins on Ox-LDL-Mediated Signaling and Inflammation. , 2004, , 203-218.		0
2673	Randomized Trial of Atorvastatin for Reduction of Myocardial Damage During Coronary Intervention. Circulation, 2004, 110, 674-678.	1.6	451
2674	Cardiovascular risk and diabetes. Are the methods of risk prediction satisfactory?. European Journal of Cardiovascular Prevention and Rehabilitation, 2004, 11, 521-528.	3.1	42
2676	Statins: can the new generation make an impression?. Expert Opinion on Emerging Drugs, 2004, 9, 269-279.	1.0	26
2677	Immunomodulation and vaccination for atherosclerosis. Expert Opinion on Biological Therapy, 2004, 4, 599-612.	1.4	18
2678	Early Statin Treatment in Patients With Acute Coronary Syndrome. Circulation, 2004, 110, 1061-1068.	1.6	523
2679	Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, e149-61.	1.1	189
2680	Long-Term Outcome in Elderly Patients With Chronic Angina Managed Invasively Versus by Optimized Medical Therapy. Circulation, 2004, 110, 1213-1218.	1.6	183
2681	Progression of Coronary Artery Calcium and Risk of First Myocardial Infarction in Patients Receiving Cholesterol-Lowering Therapy. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 1272-1277.	1.1	298
2682	Effect of Genetic Polymorphism of OATP-C (SLCO1B1) on Lipid-Lowering Response to HMG-CoA Reductase Inhibitors. Drug Metabolism and Pharmacokinetics, 2004, 19, 375-380.	1.1	126
2683	Epidemiology of Stroke. , 2004, , 13-34.		76
2684	Statins and Inhibition of Atherosclerosis: Human Studies. , 2004, , 37-51.		0
2685	Effects of Statins on Endothelial Progenitor Cells: Mobilization, Differentiation, and Contribution to Adult Neovascularization. , 2004, , 257-269.		0

#	ARTICLE	IF	CITATIONS
2686	Current Medical Management of Chronic Stable Angina. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2004, 9, S11-S29.	1.0	35
2687	Tracking Progression of Heart Disease with Cardiac Computed Tomography. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2004, 9, 75-82.	1.0	9
2688	Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. <i>European Journal of Heart Failure</i> , 2004, 6, 635-641.	2.9	214
2689	Simvastatin Modulates Angiotensin II Signaling Pathway by Preventing Rac1-Mediated Upregulation of p27. <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 1711-1720.	3.0	28
2690	Simvastatin Prevents Vascular Hyporeactivity During Inflammation. <i>Circulation</i> , 2004, 110, 3349-3354.	1.6	117
2691	The use of statins in optimising reduction of cardiovascular risk: focus on fluvastatin. <i>International Journal of Clinical Practice</i> , 2004, 58, 494-503.	0.8	8
2692	Improving lipid management - to titrate, combine or switch. <i>International Journal of Clinical Practice</i> , 2004, 58, 689-694.	0.8	24
2693	Long-term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia. <i>International Journal of Clinical Practice</i> , 2004, 58, 653-658.	0.8	44
2694	The care gap: underuse of statin therapy in the elderly. <i>International Journal of Clinical Practice</i> , 2004, 58, 777-785.	0.8	22
2695	The influence of statin characteristics on their safety and tolerability. <i>International Journal of Clinical Practice</i> , 2004, 58, 945-955.	0.8	39
2696	A review of the efficacy of rosuvastatin in patients with type 2 diabetes. <i>International Journal of Clinical Practice</i> , 2004, 58, 30-40.	0.8	14
2697	Cardioprotective and other emerging effects of statins. <i>International Journal of Clinical Practice</i> , 2004, 58, 49-57.	0.8	10
2698	The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2004, 6, 133-156.	2.2	122
2699	ANTI-APOPTOTIC EFFECT OF ATORVASTATIN, A 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR, ON CARDIAC MYOCYTES THROUGH PROTEIN KINASE C ACTIVATION. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2004, 31, 360-364.	0.9	23
2700	EFFECTS OF FLUVASTATIN ON ENDOTHELIUM-DERIVED HYPERPOLARIZING FACTOR- AND NITRIC OXIDE-MEDIATED RELAXATIONS IN ARTERIES OF HYPERTENSIVE RATS. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2004, 31, 354-359.	0.9	20
2701	Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems. <i>British Journal of Clinical Pharmacology</i> , 2004, 57, 525-528.	1.1	205
2702	Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. <i>British Journal of Clinical Pharmacology</i> , 2004, 57, 640-651.	1.1	259
2703	Statins and newly diagnosed diabetes. <i>British Journal of Clinical Pharmacology</i> , 2004, 58, 303-309.	1.1	31



#	ARTICLE	IF	CITATIONS
2704	Association between adherence to statin therapy and lipid control in Hong Kong Chinese patients at high risk of coronary heart disease. <i>British Journal of Clinical Pharmacology</i> , 2004, 58, 528-535.	1.1	42
2705	Cholesterol lowering effect of dietary weight loss and orlistat treatment - efficacy and limitations. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 19, 1173-1179.	1.9	31
2706	Provider-perceived barriers and facilitators for ischaemic heart disease (IHD) guideline adherence. <i>Journal of Evaluation in Clinical Practice</i> , 2004, 10, 227-239.	0.9	28
2707	The doctor, his patient, and the computerized evidence-based guideline. <i>Journal of Evaluation in Clinical Practice</i> , 2004, 10, 163-176.	0.9	16
2708	Undertreatment and overtreatment with statins: the Oslo Health Study 2000-2001. <i>Journal of Internal Medicine</i> , 2004, 255, 494-502.	2.7	61
2709	Rationale, design and methods of the CASHMERE study+. <i>Fundamental and Clinical Pharmacology</i> , 2004, 18, 131-138.	1.0	19
2710	Do we care if statins prevent venous thromboembolism?. <i>Journal of Thrombosis and Haemostasis</i> , 2004, 2, 695-696.	1.9	5
2711	Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells. <i>Journal of Thrombosis and Haemostasis</i> , 2004, 2, 1558-1563.	1.9	121
2712	Cardiac medications and their association with cardiovascular events in incident dialysis patients: Cause or effect?. <i>Kidney International</i> , 2004, 65, 1017-1025.	2.6	42
2713	Improving Care to Patients with Ischemic Heart Disease: Experiences in a Single Network of the Veterans Health Administration. <i>Worldviews on Evidence-Based Nursing</i> , 2004, 1, S33-S40.	1.2	14
2714	Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. <i>Journal of General Internal Medicine</i> , 2004, 19, 638-645.	1.3	288
2715	Managing dyslipidemia in chronic kidney disease. <i>Journal of General Internal Medicine</i> , 2004, 19, 1045-1052.	1.3	70
2716	The Efficacy and Safety of the New Heparin-induced Extracorporeal Low-density Lipoprotein Precipitation System (Plasmat Futura) in Comparison with the Currently used System (Plasmat Secura). <i>Therapeutic Apheresis and Dialysis</i> , 2004, 8, 33-38.	0.4	18
2717	The Association Between Lipid Levels and the Risks of Incident Myocardial Infarction, Stroke, and Total Mortality: The Cardiovascular Health Study. <i>Journal of the American Geriatrics Society</i> , 2004, 52, 1639-1647.	1.3	186
2718	Primary Cardiovascular Events and Serum Lipid Levels in Elderly Japanese with Hypercholesterolemia Undergoing 6-Year Simvastatin Treatment: A Subanalysis of the Japan Lipid Intervention Trial. <i>Journal of the American Geriatrics Society</i> , 2004, 52, 1981-1987.	1.3	26
2719	A Qualitative Study to Identify Barriers and Facilitators to Implementation of Pilot Interventions in the Veterans Health Administration (VHA) Northwest Network. <i>Worldviews on Evidence-Based Nursing</i> , 2004, 1, 129-139.	1.2	39
2720	Lipid-altering agents: the future. <i>International Journal of Clinical Practice</i> , 2004, 58, 1063-1072.	0.8	22
2721	Clinical characteristics and methods of treatment of patients with stable coronary heart disease in the primary care settings - the results of the Polish, multicentre Angina Treatment Pattern (ATP) study. <i>International Journal of Clinical Practice</i> , 2004, 58, 1127-1133.	0.8	2

#	ARTICLE	IF	CITATIONS
2722	The case for blood pressure control in risk groups. <i>International Journal of Clinical Practice</i> , 2004, 58, 844-849.	0.8	4
2723	Cholesterol metabolism and its implications for therapeutic interventions in patients with hypercholesterolaemia. <i>International Journal of Clinical Practice</i> , 2004, 58, 859-866.	0.8	42
2724	The collaborative atorvastatin diabetes study: preliminary results*. <i>International Journal of Clinical Practice</i> , 2004, 59, 121-123.	0.8	4
2725	The FABP2 gene polymorphism in cerebrovascular disease. <i>Acta Neurologica Scandinavica</i> , 2004, 110, 355-360.	1.0	8
2726	A transferable programme of nutritional counselling for rehabilitation following myocardial infarction: a randomised controlled study. <i>European Journal of Clinical Nutrition</i> , 2004, 58, 778-786.	1.3	16
2727	Adeno-associated virus vector-mediated interleukin-10 gene transfer inhibits atherosclerosis in apolipoprotein E-deficient mice. <i>Gene Therapy</i> , 2004, 11, 1772-1779.	2.3	77
2728	Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004â€”BHS IV. <i>Journal of Human Hypertension</i> , 2004, 18, 139-185.	1.0	1,072
2729	Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease. <i>Journal of Human Hypertension</i> , 2004, 18, 781-788.	1.0	78
2730	Tamoxifen treatment reverses the adverse effects of chemotherapy-induced ovarian failure on serum lipids. <i>British Journal of Cancer</i> , 2004, 91, 476-481.	2.9	19
2731	Mutual amplification of apoptosis by statin-induced mitochondrial stress and doxorubicin toxicity in human rhabdomyosarcoma cells. <i>British Journal of Pharmacology</i> , 2004, 143, 715-724.	2.7	65
2732	Fluvastatin Prevents Cardiac Death and Myocardial Infarction in Renal Transplant Recipients: Post-Hoc Subgroup Analyses of the ALERT Study. <i>American Journal of Transplantation</i> , 2004, 4, 988-995.	2.6	116
2733	Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal myopathy in rats. <i>Toxicology and Applied Pharmacology</i> , 2004, 194, 10-23.	1.3	122
2734	Looking for prognostic information in the ST-T segmentâ€”is it really worth it?. <i>Journal of Electrocardiology</i> , 2004, 37, 209-213.	0.4	15
2735	Epidemiology of coronary heart disease in women. <i>Progress in Cardiovascular Diseases</i> , 2004, 46, 287-295.	1.6	157
2736	Update on statins. <i>Journal of Vascular Nursing</i> , 2004, 22, 49-50.	0.2	1
2737	Effects of diabetes on the vascular system: current research evidence and best practice recommendations. <i>Journal of Vascular Nursing</i> , 2004, 22, 2-11.	0.2	10
2738	Dialysis Outcomes and Practice Patterns Study (DOPPS) data on medications in hemodialysis patients. <i>American Journal of Kidney Diseases</i> , 2004, 44, 61-67.	2.1	32
2739	Rising statin use and effect on ischemic stroke outcome. <i>BMC Medicine</i> , 2004, 2, 4.	2.3	61

#	ARTICLE	IF	CITATIONS
2740	Viscous dietary fibre and metabolic effects. <i>Clinical Nutrition Supplements</i> , 2004, 1, 39-49.	0.0	40
2741	Treatment of type IIb familial combined hyperlipidemia with the combination pravastatin-piperazine sulfosilate. <i>European Journal of Pharmacology</i> , 2004, 496, 205-212.	1.7	5
2742	Hydroxy-Methylglutaryl-Coenzyme A Reductase Inhibition Improves Endothelial Dysfunction in Type-1 Diabetes. <i>European Journal of Vascular and Endovascular Surgery</i> , 2004, 27, 432-437.	0.8	13
2743	Effect of fluvastatin on long-term outcome after coronary revascularization with stent implantation. <i>American Journal of Cardiology</i> , 2004, 93, 92-95.	0.7	12
2744	The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). <i>American Journal of Cardiology</i> , 2004, 93, 136-141.	0.7	473
2745	Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?. <i>American Journal of Cardiology</i> , 2004, 93, 154-158.	0.7	182
2746	Superior short-term cholesterol control and achievement of the adult treatment panel III low-density lipoprotein goals with initiation of statin therapy by the time of hospital discharge following acute myocardial infarction. <i>American Journal of Cardiology</i> , 2004, 93, 776-779.	0.7	3
2747	Reappraisal of $\beta$ -blocker therapy in the acute and chronic post-myocardial infarction period. <i>American Journal of Cardiology</i> , 2004, 93, 21-29.	0.7	11
2748	Statin therapy is associated with lower mortality among patients with severe heart failure. <i>American Journal of Cardiology</i> , 2004, 93, 1124-1129.	0.7	166
2749	Emerging therapeutic strategies for the management of dyslipidemia in patients with the metabolic syndrome. <i>American Journal of Cardiology</i> , 2004, 93, 3-11.	0.7	28
2750	Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study. <i>American Journal of Cardiology</i> , 2004, 94, 720-724.	0.7	50
2751	Early effects of statins in patients with coronary artery disease and high C-reactive protein. <i>American Journal of Cardiology</i> , 2004, 94, 1107-1112.	0.7	25
2754	Update on statins. <i>Intensive and Critical Care Nursing</i> , 2004, 20, 53-55.	1.4	2
2755	Statins upregulate CD36 expression in human monocytes, an effect strengthened when combined with PPAR- $\beta$ ligands Putative contribution of Rho GTPases in statin-induced CD36 expression. <i>Biochemical Pharmacology</i> , 2004, 67, 303-313.	2.0	61
2756	The UCSD Statin Study: a randomized controlled trial assessing the impact of statins on selected noncardiac outcomes. <i>Contemporary Clinical Trials</i> , 2004, 25, 178-202.	2.0	50
2757	Multi-Bed Vascular Disease: Past, Present, and Future. <i>Journal of Thrombosis and Thrombolysis</i> , 2004, 17, 5-9.	1.0	0
2758	Fluvastatin Reduces Cardiac Mortality in Patients with Coronary Heart Disease. <i>Cardiovascular Drugs and Therapy</i> , 2004, 18, 67-75.	1.3	8
2759	Measuring Effects on Intima Media Thickness: An Evaluation of Rosuvastatin in Subclinical Atherosclerosis—The Rationale and Methodology of the METEOR Study. <i>Cardiovascular Drugs and Therapy</i> , 2004, 18, 231-238.	1.3	66

#	ARTICLE	IF	CITATIONS
2760	Peroxisome Proliferator-Activated Receptor (PPAR)- $\alpha$ : A Pharmacological Target with a Promising Future. <i>Pharmaceutical Research</i> , 2004, 21, 1531-1538.	1.7	241
2761	Health-related quality of life in cardiac patients with dyslipidemia and hypertension. <i>Quality of Life Research</i> , 2004, 13, 793-804.	1.5	30
2762	Lipids and the Elderly. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2004, 5, 359-364.	2.6	8
2763	Evolving targets for risk reduction in diabetes. <i>Clinical Cardiology</i> , 2004, 27, 125-128.	0.7	1
2764	Effects of conventional and aggressive statin treatment on markers of endothelial function and inflammation. <i>Clinical Cardiology</i> , 2004, 27, 199-203.	0.7	40
2765	Pathophysiology and therapeutic targets for ischemic stroke. <i>Clinical Cardiology</i> , 2004, 27, 12-24.	0.7	10
2766	Secondary stroke prevention: Review of clinical trials. <i>Clinical Cardiology</i> , 2004, 27, 25-35.	0.7	4
2767	Medical prevention of secondary stroke: A cardiologist's perspective. <i>Clinical Cardiology</i> , 2004, 27, 36-42.	0.7	1
2768	The importance of aggressive lipid management in patients at risk: Evidence from recent clinical trials. <i>Clinical Cardiology</i> , 2004, 27, 12-15.	0.7	14
2769	Optimizing lipid lowering in patients at risk. <i>Clinical Cardiology</i> , 2004, 27, 22-26.	0.7	2
2770	The Potential Role of HMG-CoA Reductase Inhibitors in Pediatric Nephrotic Syndrome. <i>Annals of Pharmacotherapy</i> , 2004, 38, 2105-2114.	0.9	35
2771	A pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes in Spain. <i>European Journal of Health Economics</i> , 2004, 5, 278-284.	1.4	14
2772	Synthesis and biological activity of a novel squalene epoxidase inhibitor, FR194738. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 633-637.	1.0	18
2773	Self-Reported Adherence to Cholesterol-Lowering Medication in Patients with Familial Hypercholesterolaemia: The Role of Illness Perceptions. <i>Cardiovascular Drugs and Therapy</i> , 2004, 18, 475-481.	1.3	93
2774	The Statin Breakthrough—Remembering to Involve the Patient. <i>Cardiovascular Drugs and Therapy</i> , 2004, 18, 343-344.	1.3	4
2775	Lipid-Lowering Therapy in Patients with Average Cholesterol and High Cardiovascular Risk, Insights from the Heart Protection Study. <i>Cardiovascular Drugs and Therapy</i> , 2004, 18, 387-389.	1.3	0
2776	Hopes, disillusion and more hopes from vitamin C. <i>Cellular and Molecular Life Sciences</i> , 2004, 61, 209-219.	2.4	69
2777	Whom are we treating with lipid-lowering drugs? Are we following the guidelines? Evidence from a population-based study: the Tromsø 1/2 study 2001. <i>European Journal of Clinical Pharmacology</i> , 2004, 60, 643-649.	0.8	18

#	ARTICLE	IF	CITATIONS
2778	Relation of coronary vasoreactivity and coronary calcification in asymptomatic subjects with a family history of premature coronary artery disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2004, 31, 663-670.	3.3	20
2779	Lessons learned from the prospective pravastatin pooling project. <i>Current Atherosclerosis Reports</i> , 2004, 6, 366-374.	2.0	4
2780	ALLHAT-LLT: Questions, questions, and more questions (and some answers). <i>Current Atherosclerosis Reports</i> , 2004, 6, 375-380.	2.0	3
2781	Evidence-based treatment of lipids in the elderly. <i>Current Atherosclerosis Reports</i> , 2004, 6, 388-397.	2.0	8
2782	Diet and low-density lipoprotein particle size. <i>Current Atherosclerosis Reports</i> , 2004, 6, 453-460.	2.0	17
2784	The role of fibrates in managing hyperlipidemia: Mechanisms of action and clinical efficacy. <i>Current Atherosclerosis Reports</i> , 2004, 6, 148-157.	2.0	106
2785	Multitasking of the 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor: Beyond cardiovascular diseases. <i>Current Atherosclerosis Reports</i> , 2004, 6, 36-41.	2.0	10
2786	The evaluation and management of dyslipidemia and impaired glucose metabolism during acute coronary syndromes. <i>Current Cardiology Reports</i> , 2004, 6, 300-307.	1.3	2
2787	Heart protection study: A focus on diabetic patients. <i>Current Diabetes Reports</i> , 2004, 4, 185-186.	1.7	1
2788	Do statins prevent heart failure in patients after myocardial infarction?. <i>Current Heart Failure Reports</i> , 2004, 1, 156-160.	1.3	2
2789	Combined antihypertensive and lipid-lowering treatment. <i>Current Hypertension Reports</i> , 2004, 6, 300-306.	1.5	5
2790	Statins as potential therapeutic agents in multiple sclerosis. <i>Current Neurology and Neuroscience Reports</i> , 2004, 4, 237-244.	2.0	11
2791	Cost-effectiveness in preventive cardiology. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2004, 6, 279-290.	0.4	0
2792	Evolving treatment strategies for carotid artery stenosis. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2004, 6, 105-112.	0.4	3
2793	The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. [ISRCTN64783481]. , 2004, 3, 9.		77
2794	HMG-CoA reductase inhibition causes neurite loss by interfering with geranylgeranylpyrophosphate synthesis. <i>Journal of Neurochemistry</i> , 2004, 89, 24-32.	2.1	93
2795	Community-based multiple screening model. <i>Cancer</i> , 2004, 100, 1734-1743.	2.0	150
2796	Improvement of endothelium-dependent coronary vasodilation after a single LDL apheresis in patients with hypercholesterolemia. <i>Journal of Clinical Apheresis</i> , 2004, 19, 11-16.	0.7	38

#	ARTICLE	IF	CITATIONS
2797	Use of statins prior to percutaneous coronary intervention reduces myonecrosis and improves clinical outcome. <i>Catheterization and Cardiovascular Interventions</i> , 2004, 62, 193-197.	0.7	45
2798	Risk of stroke in men is not associated with dietary fat intake. <i>Evidence-Based Healthcare and Public Health</i> , 2004, 8, 74-76.	0.0	0
2799	Novel therapies for the prevention of stroke. <i>Expert Opinion on Investigational Drugs</i> , 2004, 13, 1615-1630.	1.9	7
2800	Coenzyme Q10 and Adverse Effects of Statins. <i>Journal of Nutritional and Environmental Medicine</i> , 2004, 14, 17-28.	0.1	4
2801	Accelerated atherosclerosis in inflammatory rheumatic diseases. <i>Scandinavian Journal of Rheumatology</i> , 2004, 33, 281-292.	0.6	48
2802	Is the nocturnal fall in blood pressure reduced in essential hypertensive patients with metabolic syndrome?. <i>Blood Pressure</i> , 2004, 13, 230-235.	0.7	16
2803	Atazanavirâ€”A Once-daily HIV Protease Inhibitor That Does Not Cause Dyslipidemia in Newly Treated Patients: Results from Two Randomized Clinical Trials. <i>Journal of the International Association of Providers of AIDS Care</i> , 2004, 3, 92-98.	1.2	48
2804	Lipid-lowering therapies in development. <i>Expert Opinion on Investigational Drugs</i> , 2004, 13, 1405-1418.	1.9	6
2805	Secondary prevention after coronary artery bypass grafting â€” what do we know?. <i>Scandinavian Cardiovascular Journal</i> , 2004, 38, 69-74.	0.4	9
2806	Current lipid management and low cholesterol goal attainment in common daily practice in Spain. <i>Pharmacoeconomics</i> , 2004, 22, 1-12.	1.7	52
2807	Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy. <i>Pharmacoeconomics</i> , 2004, 22, 13-23.	1.7	104
2808	Cost of care for patients treated with lipid-lowering drugs. <i>Pharmacoeconomics</i> , 2004, 22, 25-35.	1.7	24
2809	Development and validation of a model to project the long-term benefit and cost of alternative lipid-lowering strategies in patients with hypercholesterolaemia. <i>Pharmacoeconomics</i> , 2004, 22, 37-48.	1.7	21
2810	Cost-effectiveness of ezetimibe coadministration in statin-treated patients not at cholesterol goal. <i>Pharmacoeconomics</i> , 2004, 22, 49-61.	1.7	26
2811	Rosuvastatin. <i>American Journal of Cardiovascular Drugs</i> , 2004, 4, 117-138.	1.0	63
2812	Therapeutic Potential of Anticytokine Therapy in Congestive Heart Failure. <i>American Journal of Cardiovascular Drugs</i> , 2004, 4, 169-177.	1.0	12
2813	Dyslipidemia in Visceral Obesity. <i>American Journal of Cardiovascular Drugs</i> , 2004, 4, 227-246.	1.0	94
2814	Genetic Polymorphisms in Cytochrome P450 Enzymes. <i>American Journal of Cardiovascular Drugs</i> , 2004, 4, 247-255.	1.0	35

#	ARTICLE	IF	CITATIONS
2815	Significance of High Density Lipoprotein-Cholesterol in Cardiovascular Risk Prevention. American Journal of Cardiovascular Drugs, 2004, 4, 299-314.	1.0	29
2816	Ezetimibe/Simvastatin. American Journal of Cardiovascular Drugs, 2004, 4, 405-422.	1.0	19
2817	Intensive Statin Therapy "A Sea Change in Cardiovascular Prevention. New England Journal of Medicine, 2004, 350, 1562-1564.	13.9	175
2818	Simvastatin: a review. Expert Opinion on Pharmacotherapy, 2004, 5, 2583-2596.	0.9	105
2819	Inflammation, Immunity, and HMG-CoA Reductase Inhibitors: Statins as Antiinflammatory Agents?. Circulation, 2004, 109, II-18-II-26.	1.6	417
2820	Simvastatin Does Not Have a Clinically Significant Pharmacokinetic Interaction With Fenofibrate in Humans. Journal of Clinical Pharmacology, 2004, 44, 1054-1062.	1.0	84
2821	Statin in Stroke Prevention and Carotid Atherosclerosis. Stroke, 2004, 35, 2902-2909.	1.0	686
2822	Albuminuria, a Therapeutic Target for Cardiovascular Protection in Type 2 Diabetic Patients With Nephropathy. Circulation, 2004, 110, 921-927.	1.6	679
2823	Rosuvastatin safety: lessons from the FDA review and post-approval surveillance. Expert Opinion on Drug Safety, 2004, 3, 547-557.	1.0	71
2824	Valoración terapéutica de las hipercolesterolemias. Revista Clínica Española, 2004, 204, 215-217.	0.2	0
2825	Preventive Health Care in the Elderly Population: A Guide for Practicing Physicians. Mayo Clinic Proceedings, 2004, 79, 416-427.	1.4	9
2827	Estatinas: potencia, relación coste-efectividad. Estudio comparativo. Semergen, 2004, 30, 142-146.	0.2	0
2828	Perfil de la expresión génica de los macrófagos humanos en cultivo en respuesta a atorvastatina. Clínica e Investigación en Arteriosclerosis, 2004, 16, 175-184.	0.4	1
2829	Importancia del colesterol ligado a lipoproteínas de alta densidad (cHDL) en la prevención del riesgo cardiovascular. Recomendaciones del Foro HDL. Clínica e Investigación en Arteriosclerosis, 2004, 16, 262-280.	0.4	0
2830	Management of atherogenic dyslipidemia of the metabolic syndrome: evolving rationale for combined drug therapy. Endocrinology and Metabolism Clinics of North America, 2004, 33, 525-544.	1.2	13
2831	Nefropatía diabética inicial y enfermedad cardiovascular en una población mediterránea: factores de riesgo y grado de tratamiento. Revista Clínica Española, 2004, 204, 255-259.	0.2	2
2833	Coronary artery disease and prevention of heart failure. Medical Clinics of North America, 2004, 88, 1209-1235.	1.1	23
2834	Guías para el tratamiento de las dislipemias en el adulto: Adult Treatment Panel III (ATP-III). Endocrinología Y Nutrición: Órgano De La Sociedad Española De Endocrinología Y Nutrición, 2004, 51, 254-265.	0.8	10

#	ARTICLE	IF	CITATIONS
2835	Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial. <i>Journal of Vascular Surgery</i> , 2004, 39, 967-975.	0.6	557
2836	Statin therapy is associated with improved patency of autogenous infrainguinal bypass grafts. <i>Journal of Vascular Surgery</i> , 2004, 39, 1178-1185.	0.6	168
2838	El papel del bloqueo de la absorción intestinal del colesterol en el tratamiento de la hipercolesterolemia. <i>Revista Clinica Espanola</i> , 2004, 204, 554-560.	0.2	0
2841	Tratamiento de la dislipemia diabética con fármacos hipolipemiantes. Nuevos conceptos. <i>Clínica E Investigación En Arteriosclerosis</i> , 2004, 16, 160-169.	0.4	4
2842	Impact of kidney transplantation on the progression of cardiovascular disease. <i>Advances in Chronic Kidney Disease</i> , 2004, 11, 274-293.	0.6	8
2844	Clinical application of genetic risk assessment strategies for coronary artery disease: genotypes, phenotypes, and family history. <i>Primary Care - Clinics in Office Practice</i> , 2004, 31, 711-737.	0.7	16
2845	HMG-coA reductase inhibitors: lipid-lowering and beyond. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2004, 1, 189-194.	0.5	4
2846	Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. <i>Journal of the American College of Cardiology</i> , 2004, 43, 642-648.	1.2	319
2847	The medicine, angioplasty, or surgery study (MASS-II): a randomized, controlled clinical trial of three therapeutic strategies for multivessel coronary artery disease. <i>Journal of the American College of Cardiology</i> , 2004, 43, 1743-1751.	1.2	347
2848	Prior convictions. <i>Journal of the American College of Cardiology</i> , 2004, 43, 1929-1939.	1.2	105
2849	The cardiologist's toolbox: improving care**Editorials published in the <i>Journal of the American College of Cardiology</i> reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.. <i>Journal of the American College of Cardiology</i> , 2004, 43, 2174-2176.	1.2	0
2850	Optimal low-density lipoprotein is 50 to 70 mg/dl. <i>Journal of the American College of Cardiology</i> , 2004, 43, 2142-2146.	1.2	444
2852	Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics. <i>Journal of the American College of Cardiology</i> , 2004, 44, 1772-1779.	1.2	130
2853	A pharmacological surveillance study of the tolerability of policosanol in the elderly population. <i>American Journal of Geriatric Pharmacotherapy</i> , 2004, 2, 219-229.	3.0	8
2854	Prevention of Coronary and Stroke Events with Atorvastatin in Hypertensive Patients who have Average or Lower-than-Average Cholesterol Concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial???Lipid Lowering Arm (ASCOT-LLA). <i>Drugs</i> , 2004, 64, 43-60.	4.9	189
2855	Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. <i>Atherosclerosis</i> , 2004, 173, 1-12.	0.4	233
2856	Effect of pretreatment with statins on the severity of acute ischemic cerebrovascular events. <i>Journal of the Neurological Sciences</i> , 2004, 221, 5-10.	0.3	103
2857	Management of Hyperlipidaemia Associated with Heart Transplantation. <i>Drugs</i> , 2004, 64, 1053-1068.	4.9	20



#	ARTICLE	IF	CITATIONS
2858	Medical Lipid-Regulating Therapy. <i>Drugs</i> , 2004, 64, 1181-1196.	4.9	68
2859	Fluvastatin. <i>Drugs</i> , 2004, 64, 1305-1323.	4.9	23
2860	Role of Fibrin Acid Derivatives in the Management of Risk Factors for Coronary Heart Disease. <i>Drugs</i> , 2004, 64, 2177-2198.	4.9	67
2861	Are Cardiovascular Disease and Osteoporosis Directly Linked?. <i>Sports Medicine</i> , 2004, 34, 779-807.	3.1	32
2862	Strategies to Increase HMG-CoA Reductase Inhibitor Use After Acute Myocardial Infarction. <i>Drugs and Aging</i> , 2004, 21, 583-595.	1.3	1
2863	Effects of Calcium Supplementation on Circulating Lipids. <i>Drugs and Aging</i> , 2004, 21, 7-17.	1.3	78
2864	Lipaemia, Inflammation and Atherosclerosis. <i>Drugs</i> , 2004, 64, 19-41.	4.9	59
2866	Metabolic abnormalities: high-density lipoproteins. <i>Endocrinology and Metabolism Clinics of North America</i> , 2004, 33, 393-403.	1.2	21
2867	The pivotal role of cholesterol absorption inhibitors in the management of dyslipidemia. <i>Lipids in Health and Disease</i> , 2004, 3, 22.	1.2	20
2868	Assessing compliance of cardiologists with the national cholesterol education program (NCEP) III guidelines in an ambulatory care setting. <i>Lipids in Health and Disease</i> , 2004, 3, 9.	1.2	12
2869	Extended-release niacin/lovastatin: the first combination product for dyslipidemia. <i>Expert Review of Cardiovascular Therapy</i> , 2004, 2, 485-501.	0.6	22
2870	Achieving lipid goals in Europe: how large is the treatment gap?. <i>Expert Review of Cardiovascular Therapy</i> , 2004, 2, 431-449.	0.6	20
2871	Hypolipidemic treatment of heterozygous familial hypercholesterolemia: a lifelong challenge. <i>Expert Review of Cardiovascular Therapy</i> , 2004, 2, 405-415.	0.6	6
2872	Fluvastatin and fluvastatin extended release: a clinical and safety profile. <i>Expert Review of Cardiovascular Therapy</i> , 2004, 2, 641-652.	0.6	15
2873	Recent advances in the secondary prevention of coronary heart disease. <i>Expert Review of Cardiovascular Therapy</i> , 2004, 2, 877-889.	0.6	6
2874	Influence of fibrate treatment on malondialdehyde-modified LDL concentration. <i>Clinica Chimica Acta</i> , 2004, 339, 97-103.	0.5	15
2875	Simvastatin reduces interleukin-1 $\beta$ secretion by peripheral blood mononuclear cells in patients with essential hypertension. <i>Clinica Chimica Acta</i> , 2004, 344, 195-200.	0.5	34
2876	Efficacy and safety of rosuvastatin alone and in combination with cholestyramine in patients with severe hypercholesterolemia: A randomized, open-label, multicenter trial. <i>Clinical Therapeutics</i> , 2004, 26, 1855-1864.	1.1	27

#	ARTICLE	IF	CITATIONS
2877	A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. <i>Clinical Therapeutics</i> , 2004, 26, 1758-1773.	1.1	171
2878	An open-label comparison of the effects of simvastatin and niacin alone and combined on the lipid profile and lipoprotein (a) level in an Indian population with dyslipidemia. <i>Current Therapeutic Research</i> , 2004, 65, 455-469.	0.5	2
2879	Pravastatin potentiates the anticoagulant effects of low molecular weight heparin. <i>Thrombosis Research</i> , 2004, 113, 407-410.	0.8	4
2880	Heparin-mediated extracorporeal low-density lipoprotein precipitation: rationale for a specific adjuvant therapy in cardiovascular disease. <i>Transfusion and Apheresis Science</i> , 2004, 30, 255-266.	0.5	13
2881	Cardiovascular disease in renal transplantation: Management by statins. <i>Transplantation Reviews</i> , 2004, 18, 122-128.	1.2	6
2882	Comparison of two methodologies to analyze exposure to statins in an observational study on effectiveness. <i>Journal of Clinical Epidemiology</i> , 2004, 57, 237-242.	2.4	5
2883	Drug prescriptions and referral to cardiac rehabilitation after acute coronary events: comparison between men and women in the French PREVENIR Survey. <i>International Journal of Cardiology</i> , 2004, 93, 217-223.	0.8	28
2884	Efficacy and safety of fluvastatin therapy for hypercholesterolemia after heart transplantation. <i>International Journal of Cardiology</i> , 2004, 94, 235-240.	0.8	29
2885	Effect of ramipril on postrevascularization prevalence of angina and quality of life. <i>International Journal of Cardiology</i> , 2004, 95, 159-165.	0.8	2
2886	The role of coronary endothelial function testing in patients suspected for angina pectoris. <i>International Journal of Cardiology</i> , 2004, 96, 123-129.	0.8	10
2887	An evaluation of the relationship between specialist training in cardiology and implementation of evidence-based care of patients following acute myocardial infarction. <i>International Journal of Cardiology</i> , 2004, 96, 335-340.	0.8	6
2888	Impaired left ventricular diastolic function during isometric exercise in asymptomatic patients with hyperlipidaemia. <i>International Journal of Cardiology</i> , 2004, 95, 275-280.	0.8	16
2889	A pharmaco-economic evaluation of aggressive cholesterol lowering in Sweden. <i>International Journal of Cardiology</i> , 2004, 96, 51-57.	0.8	12
2890	Optimal management of hyperlipidemia in primary prevention of cardiovascular disease. <i>International Journal of Cardiology</i> , 2004, 97, 355-366.	0.8	28
2891	Under-diagnosis of diabetes mellitus in patients with coronary artery disease. <i>International Journal of Cardiology</i> , 2004, 97, 77-82.	0.8	8
2892	Contemporary management of silent ischemia: the role of ambulatory monitoring. <i>International Journal of Cardiology</i> , 2004, 96, 311-319.	0.8	17
2893	Does aggressive statin therapy offer improved cholesterol-independent benefits compared to conventional statin treatment?. <i>International Journal of Cardiology</i> , 2004, 96, 131-139.	0.8	14
2894	Randomized, controlled trial of secondary prevention of coronary sclerosis in normocholesterolemic patients using pravastatin: final 5-year angiographic follow-up of the Prevention of Coronary Sclerosis (PCS) study. <i>International Journal of Cardiology</i> , 2004, 97, 107-114.	0.8	26

#	ARTICLE	IF	CITATIONS
2895	Atherosclerotic disease regression with statins: studies using vascular markers. <i>International Journal of Cardiology</i> , 2004, 96, 447-459.	0.8	33
2896	Reduced creatine kinase release with statin use at the time of myocardial infarction. <i>International Journal of Cardiology</i> , 2004, 96, 461-466.	0.8	14
2897	Ultrasound diagnosis of carotid artery lesions in a population of asymptomatic subjects presenting atherosclerosis risk factors. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2004, 13, 95-98.	0.7	7
2898	MCP-1-induced enhancement of THP-1 adhesion to vascular endothelium was modulated by HMG-CoA reductase inhibitor through RhoA GTPase-, but not ERK1/2-dependent pathway. <i>Life Sciences</i> , 2004, 75, 1333-1341.	2.0	38
2899	Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension. <i>Life Sciences</i> , 2004, 76, 281-292.	2.0	37
2901	Preprocedural inflammatory markers do not predict restenosis after successful coronary stenting. <i>American Heart Journal</i> , 2004, 147, 1071-1077.	1.2	39
2902	Effect of pravastatin compared with placebo initiated within 24 hours of onset of acute myocardial infarction or unstable angina: The Pravastatin in Acute Coronary Treatment (PACT) trial. <i>American Heart Journal</i> , 2004, 148, 91.	1.2	78
2903	Effect of age on the use of evidence-based therapies for acute myocardial infarction. <i>American Heart Journal</i> , 2004, 148, 834-841.	1.2	56
2904	Coronary heart disease and lipid-modifying treatment in african american patients. <i>American Heart Journal</i> , 2004, 147, 774-782.	1.2	30
2905	Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors. <i>American Heart Journal</i> , 2004, 147, 956-965.	1.2	105
2906	Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial. <i>American Heart Journal</i> , 2004, 148, 105.	1.2	42
2907	Introduction. <i>American Heart Journal</i> , 2004, 148, S1-S2.	1.2	2
2908	Economic evaluation of a compliance-enhancing intervention in patients with hypercholesterolemia: Design and baseline results of the Open Label Primary Care Study: Rosuvastatin Based Compliance Initiatives To Achievements of LDL Goals (ORBITAL) study. <i>American Heart Journal</i> , 2004, 148, 1060-1067.	1.2	11
2909	Effect of aggressive versus moderate lipid-lowering therapy on myocardial ischemia: The rationale, design, and baseline characteristics of the Study Assessing Goals in the Elderly (SAGE). <i>American Heart Journal</i> , 2004, 148, 1053-1059.	1.2	12
2910	Current overview of statin-induced myopathy. <i>American Journal of Medicine</i> , 2004, 116, 408-416.	0.6	259
2911	Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study. <i>American Journal of Medicine</i> , 2004, 117, 73-81.	0.6	198
2912	Introduction. <i>American Journal of Medicine</i> , 2004, 116, 1-2.	0.6	303
2913	Low-density lipoprotein cholesterol reduction and cardiovascular disease prevention: the search for superior treatment. <i>American Journal of Medicine</i> , 2004, 116, 17-25.	0.6	21

#	ARTICLE	IF	CITATIONS
2914	Effects of statins on stroke prevention in patients with and without coronary heart disease: A meta-analysis of randomized controlled trials. <i>American Journal of Medicine</i> , 2004, 117, 596-606.	0.6	132
2915	Effects of statins on vascular structure and function: A systematic review. <i>American Journal of Medicine</i> , 2004, 117, 775-790.	0.6	65
2916	A short course of cardiac rehabilitation program is highly cost effective in improving long-term quality of life in patients with recent myocardial infarction or percutaneous coronary intervention. <i>Archives of Physical Medicine and Rehabilitation</i> , 2004, 85, 1915-1922.	0.5	122
2917	Role of statin therapy in the coronary bypass patient. <i>Annals of Thoracic Surgery</i> , 2004, 78, 730-740.	0.7	48
2918	Should the National Cholesterol Education Program Guidelines Be Changed for Persons at High Risk for Cardiovascular Events?. <i>Preventive Cardiology</i> , 2004, 7, 71-72.	1.1	1
2920	Improving Outcomes in the Post-Myocardial Infarction Setting. <i>Journal of Clinical Hypertension</i> , 2004, 6, 34-41.	1.0	3
2921	Self-rated measures of physical activity and cardiovascular risk in a sample of Southern Italian male workers: The Olivetti Heart Study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2004, 14, 143-149.	1.1	11
2922	Diet for preventing cardiovascular diseases. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2004, 14, 52-57.	1.1	23
2924	Effects of simvastatin on blood pressure in hypercholesterolemic patients: An open-label study in patients with hypertension or normotension. <i>Current Therapeutic Research</i> , 2004, 65, 239-254.	0.5	2
2925	Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2004, 350, 1495-1504.	13.9	4,527
2926	Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. <i>Journal of the American College of Cardiology</i> , 2004, 44, 720-732.	1.2	1,207
2927	Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease management. <i>Atherosclerosis</i> , 2004, 177, 219-234.	0.4	84
2928	Stroke prevention, blood cholesterol, and statins. <i>Lancet Neurology</i> , The, 2004, 3, 271-278.	4.9	115
2929	Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. <i>Lancet</i> , The, 2004, 364, 849-857.	6.3	468
2930	Vital Exhaustion as a Risk Indicator for First Stroke. <i>Psychosomatics</i> , 2004, 45, 114-118.	2.5	44
2931	Cardiovascular disease and mortality in statin-treated patients with familial hypercholesterolemia. <i>Atherosclerosis</i> , 2004, 172, 329-335.	0.4	49
2932	Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. <i>Atherosclerosis</i> , 2004, 173, 55-68.	0.4	425
2933	A new HMG-CoA reductase inhibitor, pitavastatin remarkably retards the progression of high cholesterol induced atherosclerosis in rabbits. <i>Atherosclerosis</i> , 2004, 176, 255-263.	0.4	35

#	ARTICLE	IF	CITATIONS
2934	Simvastatin inhibits lymphocyte function in normal subjects and patients with cardiovascular disease. <i>Atherosclerosis</i> , 2004, 175, 305-313.	0.4	64
2935	Effects of statin therapy on the progression of carotid atherosclerosis: a systematic review and meta-analysis. <i>Atherosclerosis</i> , 2004, 177, 433-442.	0.4	124
2937	The importance of the emergence of statins to a lipidologistâ€”clinician: a personal perspective. <i>Atherosclerosis Supplements</i> , 2004, 5, 27-28.	1.2	2
2938	Statins have offered great benefits. <i>Atherosclerosis Supplements</i> , 2004, 5, 35-37.	1.2	0
2939	Mevastatin inhibits ovarian thecaâ€”interstitial cell proliferation and steroidogenesis. <i>Fertility and Sterility</i> , 2004, 82, 1193-1197.	0.5	82
2940	Clearance of a 3H-labeled chylomicron-like emulsion following the acute phase of myocardial infarction. <i>International Journal of Cardiology</i> , 2004, 93, 181-187.	0.8	3
2941	FÃ¡rmacos hipolipidemiantes. <i>Medicine</i> , 2004, 9, 1122-1130.	0.0	0
2942	Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20â€”536 people with cerebrovascular disease or other high-risk conditions. <i>Lancet, The</i> , 2004, 363, 757-767.	6.3	1,016
2943	Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). <i>Lancet, The</i> , 2004, 364, 771-777.	6.3	299
2944	Association of dyslipidemia and effects of statins on nonmacrovascular diseases. <i>Clinical Therapeutics</i> , 2004, 26, 337-351.	1.1	21
2945	A randomized, open-label, comparative study of simvastatin plus diet versus diet alone on angiographic retardation of coronary atherosclerosis in adult Japanese patients: Japanese utilization of simvastatin therapy (JUST) study. <i>Clinical Therapeutics</i> , 2004, 26, 878-888.	1.1	9
2946	Drotrecogin Alfa (Activated) for the Treatment of Severe Sepsis and Septic Shock. <i>American Journal of the Medical Sciences</i> , 2004, 328, 205-214.	0.4	11
2947	Dyslipidemia in the metabolic syndrome. <i>Journal of Drug Evaluation</i> , 2004, 2, 3-34.	0.0	5
2948	Recent insights into the expanding role of high-density lipoprotein cholesterol in dyslipidemia and disease. <i>Current Opinion in Cardiology</i> , 2004, 19, 363-365.	0.8	0
2949	Clinical Trials and Lipid Guidelines for Type II Diabetes. <i>Journal of Clinical Pharmacology</i> , 2004, 44, 423-430.	1.0	37
2950	Current and future concepts in stroke prevention. <i>Cmaj</i> , 2004, 170, 1123-1133.	0.9	32
2951	Is Lipid-Lowering Therapy Underused by African Americans at High Risk of Coronary Heart Disease Within the VA Health Care System?. <i>American Journal of Public Health</i> , 2004, 94, 2112-2117.	1.5	12
2952	Benefits of Individualized Counseling by the Pharmacist on the Treatment Outcomes of Hyperlipidemia in Hong Kong. <i>Journal of Clinical Pharmacology</i> , 2004, 44, 632-639.	1.0	28

#	ARTICLE	IF	CITATIONS
2953	Statins for primary prevention: strategic options to save lives and money. <i>Journal of the Royal Society of Medicine</i> , 2004, 97, 66-71.	1.1	3
2954	Genetically defined hyperlipidemia. <i>Pharmacogenomics</i> , 2004, 5, 295-304.	0.6	2
2955	Quality of Life After Coronary Artery Bypass Graft. <i>Chest</i> , 2004, 126, 487-495.	0.4	10
2956	Answering important questions reliably-GISSI Heart Failure, a factorially designed trial with composite (co)primary outcome measures. <i>European Journal of Heart Failure</i> , 2004, 6, 531-533.	2.9	2
2957	Preventing a Second Stroke in the Young. <i>Topics in Stroke Rehabilitation</i> , 2004, 11, 40-50.	1.0	1
2958	Isolated soya protein with standardised levels of isoflavones, cotyledon soya fibres and soya phospholipids improves plasma lipids in hypercholesterolaemia: a double-blind, placebo-controlled trial of a yoghurt formulation. <i>British Journal of Nutrition</i> , 2004, 91, 393-401.	1.2	17
2959	A substitution model of dietary manipulation is an effective means of optimising lipid profile, reducing C-reactive protein and increasing insulin-like growth factor-1. <i>British Journal of Nutrition</i> , 2004, 92, 809-818.	1.2	12
2960	Progress in Clinical Neurosciences: Pharmacotherapies for the Secondar Prevention of Stroke. <i>Canadian Journal of Neurological Sciences</i> , 2004, 31, 295-303.	0.3	1
2961	Statin therapy in kidney disease populations: potential benefits beyond lipid lowering and the need for clinical trials. <i>Current Opinion in Nephrology and Hypertension</i> , 2004, 13, 601-605.	1.0	15
2962	Therapy and clinical trials. <i>Current Opinion in Lipidology</i> , 2004, 15, 627-629.	1.2	0
2963	The Meaning of Quality of Life Among Patients With Familial Hypercholesterolemia. <i>Journal of Cardiovascular Nursing</i> , 2004, 19, 243-250.	0.6	12
2964	Conceptual Foundations of the UCSD Statin Study. <i>Archives of Internal Medicine</i> , 2004, 164, 153.	4.3	47
2965	Interventions to improve adherence to lipid lowering medication. , 2004, , CD004371.		41
2966	Lipids in health and disease. <i>Biochemical Society Transactions</i> , 2004, 32, 1051-1056.	1.6	11
2967	Lipoprotein transport in the metabolic syndrome: pathophysiological and interventional studies employing stable isotopy and modelling methods. <i>Clinical Science</i> , 2004, 107, 233-249.	1.8	42
2968	The Novel HMG-CoA Reductase Inhibitor, Pitavastatin, Induces a Protective Action in Vascular Endothelial Cells through the Production of Nitric Oxide (NO). <i>Yakugaku Zasshi</i> , 2004, 124, 121-126.	0.0	11
2969	Contribution of Vascular NAD(P)H Oxidase to Endothelial Dysfunction in Heart Failure and the Therapeutic Effects of HMG-CoA Reductase Inhibitor. <i>Circulation Journal</i> , 2004, 68, 1067-1075.	0.7	39
2970	Relation of Serum Total Cholesterol and Other Risk Factors to Risk of Coronary Events in Middle-Aged and Elderly Japanese Men With Hypercholesterolemia-The Kyushu Lipid Intervention Study-. <i>Circulation Journal</i> , 2004, 68, 405-409.	0.7	13

#	ARTICLE	IF	CITATIONS
2971	ACE inhibitors and target organ protection. <i>Postgraduate Medicine</i> , 2004, 116, 11-48.	0.9	11
2972	Clinical Practice Guidelines and Performance Indicators as Relatedâ€”But Often Misunderstoodâ€”Tools. <i>Joint Commission Journal on Quality and Safety</i> , 2004, 30, 48-56.	1.3	0
2973	Clinical Practice Guidelines and Performance Indicators as Relatedâ€”But Often Misunderstoodâ€”Tools. <i>Joint Commission Journal on Quality and Safety</i> , 2004, 30, 163-171.	1.3	21
2975	More Western Hypercholesterolemic Patients Achieve Japan Atherosclerosis Society LDL-C Goals With Rosuvastatin Therapy Than With Atorvastatin, Pravastatin, or Simvastatin Therapy. <i>Circulation Journal</i> , 2004, 68, 107-113.	0.7	10
2976	Difference in the Risk Factors for Coronary, Renal and Other Peripheral Arteriosclerosis in Heterozygous Familial Hypercholesterolemia. <i>Circulation Journal</i> , 2004, 68, 623-627.	0.7	21
2978	Non-Attendance at Secondary Prevention Clinics: The Effect on Lipid Management. <i>Scottish Medical Journal</i> , 2005, 50, 54-56.	0.7	5
2979	Addressing the Global Cardiovascular Risk of Hypertension, Dyslipidemia, Diabetes Mellitus, and the Metabolic Syndrome in the Southeastern United States, Part II: Treatment Recommendations for Management of the Global Cardiovascular Risk of Hypertension, Dyslipidemia, Diabetes Mellitus, and the Metabolic Syndrome. <i>American Journal of the Medical Sciences</i> , 2005, 329, 292-305.	0.4	69
2980	Preventing Cardiovascular Outcome in Patients with Renal Impairment. <i>American Journal of Cardiovascular Drugs</i> , 2005, 5, 255-269.	1.0	8
2981	Are Statins Being Underdosed in Clinical Practice?. <i>Critical Pathways in Cardiology</i> , 2005, 4, 169-173.	0.2	8
2983	Hypercholesterolemia and LDL Apheresis. <i>International Journal of Artificial Organs</i> , 2005, 28, 1025-1031.	0.7	14
2984	Statin Initiation Following Coronary Artery Bypass Grafting. <i>Chest</i> , 2005, 127, 455-463.	0.4	18
2985	Tamoxifen for the Prevention of Myocardial Infarction in Humans: Preclinical and Early Clinical Evidence. <i>Circulation</i> , 2005, 112, 3018-3024.	1.6	62
2986	Direct comparison of a dietary portfolio of cholesterol-lowering foods with a statin in hypercholesterolemic participants1â€”3. <i>American Journal of Clinical Nutrition</i> , 2005, 81, 380-387.	2.2	224
2988	Time to Benefit. <i>Critical Pathways in Cardiology</i> , 2005, 4, 43-45.	0.2	8
2989	Opportunity for Intervention to Achieve American Heart Association Guidelines for Optimal Lipid Levels in High-Risk Women in a Managed Care Setting. <i>Circulation</i> , 2005, 111, 488-493.	1.6	91
2991	Anti-oxidative Effect of Fluvastatin in Hyperlipidemic Type 2 Diabetic Patients. <i>Endocrine Journal</i> , 2005, 52, 259-264.	0.7	20
2993	Emerging Topics in Atherosclerosis: HDL Raising Therapies. <i>Annual Reports in Medicinal Chemistry</i> , 2005, , 71-83.	0.5	4
2994	Atorvastatin and Myocardial Reperfusion Injury. <i>Journal of Cardiovascular Pharmacology</i> , 2005, 45, 247-252.	0.8	70

#	ARTICLE	IF	CITATIONS
2995	Torcetrapib/atorvastatin combination therapy. <i>Expert Review of Cardiovascular Therapy</i> , 2005, 3, 789-820.	0.6	27
2996	Independent Effect of Cardiac Rehabilitation on Lipids in Coronary Artery Disease. <i>Journal of Cardiopulmonary Rehabilitation and Prevention</i> , 2005, 25, 257-261.	0.5	4
2997	New Guidelines in Statin Therapy. <i>Plastic Surgical Nursing</i> , 2005, 25, 109-110.	0.3	0
2998	Beneficial effect of simvastatin and pravastatin treatment on adverse cardiac remodelling and glomeruli loss in spontaneously hypertensive rats. <i>Clinical Science</i> , 2005, 108, 349-355.	1.8	43
2999	Inhibitory effect of pitavastatin (NK-104) on the C-reactive-protein-induced interleukin-8 production in human aortic endothelial cells. <i>Clinical Science</i> , 2005, 108, 515-521.	1.8	51
3001	Large-Scale Cohort Study on the Relationship Between Serum Lipid Concentrations and Risk of Cerebrovascular Disease Under Low-Dose Simvastatin in Japanese Patients With Hypercholesterolemia Sub-Analysis of the Japan Lipid Intervention Trial (J-LIT). <i>Circulation Journal</i> , 2005, 69, 1016-1021.	0.7	42
3002	Biphasic Effect of HMG-CoA Reductase Inhibitor, Pitavastatin, on Vascular Endothelial Cells and Angiogenesis. <i>Circulation Journal</i> , 2005, 69, 1547-1555.	0.7	58
3003	Fluvastatin Ameliorates the Hyperhomocysteinemia-Induced Endothelial Dysfunction-The Antioxidative Properties of Fluvastatin-. <i>Circulation Journal</i> , 2005, 69, 475-480.	0.7	17
3004	Efficacy of Colestimide Coadministered With Atorvastatin in Japanese Patients With Heterozygous Familial Hypercholesterolemia (FH). <i>Circulation Journal</i> , 2005, 69, 515-520.	0.7	14
3005	Morbidity of Myocardial Infarction Multicenter Study in Japan (3M Study). <i>Circulation Journal</i> , 2005, 69, 767-773.	0.7	21
3006	Three-Year Follow-up Results of Angiographic Intervention Trial Using an HMG-CoA Reductase Inhibitor to Evaluate Retardation of Obstructive Multiple Atheroma (ATHEROMA) Study. <i>Circulation Journal</i> , 2005, 69, 875-883.	0.7	25
3007	Acute Onset and Worsening of Diabetes Concurrent with Administration of Statins. <i>Endocrine Journal</i> , 2005, 52, 369-372.	0.7	27
3008	Elevated Preprocedural High-Sensitivity C-Reactive Protein Levels are Associated With Neointimal Hyperplasia and Restenosis Development After Successful Coronary Artery Stenting. <i>Circulation Journal</i> , 2005, 69, 1477-1483.	0.7	34
3009	Effect of Pravastatin on Progression of Coronary Atherosclerosis in Patients After Coronary Artery Bypass Surgery Pravastatin Coronary Artery Bypass Graft Study. <i>Circulation Journal</i> , 2005, 69, 636-643.	0.7	27
3010	Effect of statin therapy on serum trace element status in dyslipidaemic subjects. <i>Journal of Trace Elements in Medicine and Biology</i> , 2005, 19, 61-67.	1.5	33
3011	Combination of dietary phytosterols plus niacin or fenofibrate: effects on lipid profile and atherosclerosis in apo E-KO mice. <i>Journal of Nutritional Biochemistry</i> , 2005, 16, 222-228.	1.9	28
3012	Evaluation of apoptosis and necrosis induced by statins using fluorescence-enhanced flow cytometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2005, 39, 712-717.	1.4	22
3013	Effect of preexisting statin use on expression of C-reactive protein, adhesion molecules, interleukin-6, and antioxidantized low-density lipoprotein antibody in patients with unstable angina undergoing coronary stenting. <i>Clinical Cardiology</i> , 2005, 28, 72-76.	0.7	16



#	ARTICLE	IF	CITATIONS
3014	The benefits of statin therapy-what questions remain?. <i>Clinical Cardiology</i> , 2005, 28, 499-503.	0.7	11
3015	Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. <i>Fundamental and Clinical Pharmacology</i> , 2005, 19, 117-125.	1.0	920
3016	Atorvastatin affects leukocyte gene expression in dyslipidemia patients: in vivo regulation of hemostasis, inflammation and apoptosis. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 677-685.	1.9	36
3017	Stromelysin-1 promoter 5A/6A polymorphism is an independent genetic prognostic risk factor and interacts with smoking cessation after index premature myocardial infarction. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 1998-2005.	1.9	9
3018	A novel nitric oxide-releasing statin derivative exerts an antiplatelet/antithrombotic activity and inhibits tissue factor expression1. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 2554-2562.	1.9	51
3019	Management of dyslipidemia in women in the post-hormone therapy era. <i>Journal of General Internal Medicine</i> , 2005, 20, 297-305.	1.3	10
3020	Cardiovascular Risk Factors Predictive for Survival and Morbidity-Free Survival in the Oldest-Old Framingham Heart Study Participants. <i>Journal of the American Geriatrics Society</i> , 2005, 53, 1944-1950.	1.3	122
3021	Low-Density Lipoprotein Cholesterol and Mortality in Older People. <i>Journal of the American Geriatrics Society</i> , 2005, 53, 2159-2164.	1.3	66
3022	Establishing the Cost-Effectiveness of New Pharmaceuticals under Conditions of Uncertaintyâ€”When Is There Sufficient Evidence?. <i>Value in Health</i> , 2005, 8, 433-446.	0.1	93
3023	Cost-Effectiveness of Rosuvastatin Compared with Other Statins from a Managed Care Perspective. <i>Value in Health</i> , 2005, 8, 618-628.	0.1	21
3024	Insulin resistance, diabetes and cardiovascular risk: approaches to treatment. <i>Diabetes, Obesity and Metabolism</i> , 2005, 7, 642-653.	2.2	50
3025	Predicting vascular risk in Type 1 diabetes: stratification in a hospital based population in Scotland. <i>Diabetic Medicine</i> , 2005, 22, 164-171.	1.2	15
3026	Atherothrombosis: management of patients at risk. <i>International Journal of Clinical Practice</i> , 2005, 59, 407-414.	0.8	8
3027	Achievement of English National Service Framework lipid-lowering goals: pooled data from recent comparative treatment trials of statins at starting doses. <i>International Journal of Clinical Practice</i> , 2005, 59, 1171-1177.	0.8	8
3028	Lipid-altering efficacy of switching from atorvastatin 10â€”mg/day to ezetimibe/simvastatin 10/20â€”mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease. <i>International Journal of Clinical Practice</i> , 2005, 59, 1377-1386.	0.8	38
3029	Ezetimibe/simvastatin (INEGYâ„¢) in the treatment of hyperlipidaemia. <i>International Journal of Clinical Practice</i> , 2005, 59, 1464-1471.	0.8	14
3030	The Heart Protection Study and bias in the interpretation of RCTs. <i>Journal of Evaluation in Clinical Practice</i> , 2005, 11, 405-407.	0.9	2
3031	Low utilization and wide interhospital variation in investigation of patients after acute myocardial infarction: inadequate resources or insufficient evidence?. <i>Journal of Evaluation in Clinical Practice</i> , 2005, 11, 388-396.	0.9	0

#	ARTICLE	IF	CITATIONS
3032	Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes - CORALL study. <i>Journal of Internal Medicine</i> , 2005, 257, 531-539.	2.7	66
3033	Pharmacokinetics of pitavastatin in subjects with Child-Pugh A and B cirrhosis. <i>British Journal of Clinical Pharmacology</i> , 2005, 59, 291-297.	1.1	40
3034	Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention. <i>British Journal of Clinical Pharmacology</i> , 2005, 59, 564-573.	1.1	125
3035	Statin use after acute myocardial infarction: a nationwide study in Denmark. <i>British Journal of Clinical Pharmacology</i> , 2005, 60, 150-158.	1.1	33
3036	Socioeconomic gradient in use of statins among Danish patients: population-based cross-sectional study. <i>British Journal of Clinical Pharmacology</i> , 2005, 60, 534-542.	1.1	77
3037	Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2005, 30, 189-192.	0.7	14
3038	Review article: hyperlipidaemia and cardiovascular risk. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 22, 28-30.	1.9	14
3039	Anti-Inflammatory Effects of Statins: Clinical Evidence and Basic Mechanisms. <i>Nature Reviews Drug Discovery</i> , 2005, 4, 977-987.	21.5	760
3040	Effects of soy supplementation on blood lipids and arterial function in hypercholesterolaemic subjects. <i>European Journal of Clinical Nutrition</i> , 2005, 59, 843-850.	1.3	72
3041	Direct comparison of dietary portfolio vs statin on C-reactive protein. <i>European Journal of Clinical Nutrition</i> , 2005, 59, 851-860.	1.3	64
3042	Statins and Stroke. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2005, 25, 1093-1110.	2.4	170
3043	Improved Cerebral Vasoreactivity After Statin Administration in Healthy Adults. <i>Journal of Neuroimaging</i> , 2005, 15, 266-270.	1.0	29
3044	Acute myocardial infarction - are women different?. <i>International Journal of Clinical Practice</i> , 2005, 59, 2-5.	0.8	8
3045	Review of efficacy of rosuvastatin 5â€ƒmg. <i>International Journal of Clinical Practice</i> , 2005, 59, 92-101.	0.8	11
3046	Pitavastatin. <i>International Journal of Clinical Practice</i> , 2005, 59, 239-252.	0.8	148
3047	Physical activity and stroke risk. <i>International Journal of Clinical Practice</i> , 2005, 59, 922-930.	0.8	44
3048	Early Initiation of Statin Therapy in Acute Coronary Syndromes: A Review of the Evidence. <i>Journal of Interventional Cardiology</i> , 2005, 18, 55-63.	0.5	7
3049	Effects of simvastatin on cardiac performance and expression of sarco-plasmic reticular calcium regulatory proteins in rat heart. <i>Acta Pharmacologica Sinica</i> , 2005, 26, 696-704.	2.8	23

#	ARTICLE	IF	CITATIONS
3050	Improving Compliance in Your Dyslipidemic Patient: An Evidence-Based Approach. <i>Journal of the American Academy of Nurse Practitioners</i> , 2001, 13, 200-207.	1.4	13
3051	Discussion on "Statistical Issues Arising in the Women's Health Initiative". <i>Biometrics</i> , 2005, 61, 914-918.	0.8	1
3052	Long-term protective effect of atorvastatin in permanent focal cerebral ischemia. <i>Brain Research</i> , 2005, 1052, 174-179.	1.1	40
3053	Statin use and risks of death or fatal rejection in the Heart Transplant Lipid Registry. <i>American Journal of Cardiology</i> , 2005, 95, 367-372.	0.7	43
3054	Effect of statin therapy on risk of ventricular arrhythmia among patients with coronary artery disease and an implantable cardioverter-defibrillator. <i>American Journal of Cardiology</i> , 2005, 95, 490-491.	0.7	72
3055	Impact of dyslipidemia associated with Highly Active Antiretroviral Therapy (HAART) on cardiovascular risk and life expectancy**The sponsor provided the principal investigator with the results of study AI 424-008 before the study's subsequent publication but did not participate in the data analysis presented in this report. A draft of the manuscript was submitted to the sponsor before submission with the understanding that the final manuscript remained under the complete control of the principal investigator. <i>American Journal of Cardiology</i> , 2005, 95, 586-591.	0.7	84
3056	Do Statins Increase the Risk of Idiopathic Polyneuropathy?. <i>American Journal of Cardiology</i> , 2005, 95, 1097-1099.	0.7	26
3057	Cost Effectiveness of Rosuvastatin in Treating Patients to Low-Density Lipoprotein Cholesterol Goals Compared With Atorvastatin, Pravastatin, and Simvastatin (a US Analysis of the STELLAR Trial). <i>American Journal of Cardiology</i> , 2005, 95, 1314-1319.	0.7	23
3058	Use of Combination Evidence-Based Medical Therapy Prior to Acute Myocardial Infarction (from the) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.7	8
3059	Pharmacologic Options for Aggressive Low-Density Lipoprotein Cholesterol Lowering: Benefits Versus Risks. <i>American Journal of Cardiology</i> , 2005, 96, 60-66.	0.7	66
3060	Review of Primary and Secondary Prevention Trials with Lovastatin, Pravastatin, and Simvastatin. <i>American Journal of Cardiology</i> , 2005, 96, 34-38.	0.7	38
3061	Role of Low-Density Lipoprotein Apheresis. <i>American Journal of Cardiology</i> , 2005, 96, 67-69.	0.7	17
3062	Different Time Course for Prevention of Coronary and Stroke Events by Atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm (ASCOT-LLA). <i>American Journal of Cardiology</i> , 2005, 96, 39-44.	0.7	54
3063	The Case for Intensive Statin Therapy After Acute Coronary Syndromes. <i>American Journal of Cardiology</i> , 2005, 96, 45-53.	0.7	26
3064	Early Time to Benefit with Intensive Statin Treatment: Could It Be the Pleiotropic Effects?. <i>American Journal of Cardiology</i> , 2005, 96, 54-60.	0.7	70
3065	Safety of High-Dose Atorvastatin Therapy. <i>American Journal of Cardiology</i> , 2005, 96, 69-75.	0.7	67
3066	Comparison of Efficacy and Safety Assessment of Fluvastatin in Patients <65 Years Versus ≥65 Years of Age. <i>American Journal of Cardiology</i> , 2005, 96, 1142-1148.	0.7	9
3067	Lipid Management in Patients with Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2005, 96, 26-32.	0.7	23

#	ARTICLE	IF	CITATIONS
3068	Effect of Intensive Lipid Lowering on Progression of Coronary Atherosclerosis: Evidence for an Early Benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Trial. American Journal of Cardiology, 2005, 96, 61-68.	0.7	103
3069	Pharmacogenomics of Statin Responsiveness. American Journal of Cardiology, 2005, 96, 65-70.	0.7	52
3071	Protective Effect of Policosanol on Atherosclerotic Plaque on Aortas in Monkeys. Archives of Medical Research, 2005, 36, 441-447.	1.5	15
3072	HMG-coenzyme a reductase inhibitor use is associated with mortality reduction in hemodialysis patients. American Journal of Kidney Diseases, 2005, 45, 119-126.	2.1	144
3073	First United Kingdom Heart and Renal Protection (UK-HARP-I) study: Biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. American Journal of Kidney Diseases, 2005, 45, 473-484.	2.1	184
3074	Cardiovascular Risk and Renal Transplantation: Post Hoc Analyses of the Assessment of Lescol in Renal Transplantation (ALERT) Study. American Journal of Kidney Diseases, 2005, 46, 529-536.	2.1	119
3075	Long-term Cardiac Outcomes in Renal Transplant Recipients Receiving Fluvastatin: The ALERT Extension Study. American Journal of Transplantation, 2005, 5, 2929-2936.	2.6	299
3076	Pharmacological basis of different targets for the treatment of atherosclerosis. Journal of Cellular and Molecular Medicine, 2005, 9, 818-839.	1.6	23
3077	Toward Immunomodulatory and Anti-Inflammatory Properties of Statins. Trends in Cardiovascular Medicine, 2005, 15, 202-206.	2.3	102
3078	A cluster randomized trial to assess the impact of opinion leader endorsed evidence summaries on improving quality of prescribing for patients with chronic cardiovascular disease: rationale and design [ISRCTN26365328]. BMC Cardiovascular Disorders, 2005, 5, 17.	0.7	7
3079	The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393]. BMC Medicine, 2005, 3, 6.	2.3	99
3080	Statins and Osteoporosis: A Clinical Review. Pharmacotherapy, 2005, 25, 228-243.	1.2	27
3081	Achieving Cholesterol Target in a Managed Care Organization (ACTION) Trial. Pharmacotherapy, 2005, 25, 360-371.	1.2	30
3082	Time as a Variable With Niacin Extendedâ€Release/Lovastatin vs. Atorvastatin and Simvastatin. Preventive Cardiology, 2005, 8, 226-233.	1.1	3
3083	Decreasing LDL Cholesterol and Medication Cost With Everyâ€Otherâ€Day Statin Therapy. Preventive Cardiology, 2005, 8, 197-199.	1.1	37
3084	Hydroxymethylglutaryl co-enzyme A reductase inhibition attenuates endotoxin-mediated inflammatory responses. British Journal of Surgery, 2005, 92, 1034-1040.	0.1	2
3085	Effects of atorvastatin on serum lipids, lipoproteins, and hemostasis. American Journal of Hematology, 2005, 78, 1-6.	2.0	9
3086	Statins in nephrotic syndrome: A new weapon against tissue injury. Medicinal Research Reviews, 2005, 25, 587-609.	5.0	17

#	ARTICLE	IF	CITATIONS
3087	Underuse of lipid-lowering drugs and factors associated with poor adherence: a real practice analysis in Italy. <i>European Journal of Clinical Pharmacology</i> , 2005, 61, 225-230.	0.8	24
3088	Persistence and determinants of statin therapy among middle-aged patients free of cardiovascular disease. <i>European Journal of Clinical Pharmacology</i> , 2005, 61, 667-674.	0.8	59
3089	Changes in myocardial perfusion due to physical exercise in patients with stable coronary artery disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2005, 32, 813-819.	3.3	30
3090	Efficacy and safety of statins in hypercholesterolemia with emphasis on lipoproteins. <i>Heart and Vessels</i> , 2005, 20, 217-223.	0.5	12
3093	Cellular cholesterol efflux to plasma from moderately hypercholesterolaemic type 1 diabetic patients is enhanced, and is unaffected by simvastatin treatment. <i>Diabetologia</i> , 2005, 48, 1105-1113.	2.9	49
3094	Interaction between simvastatin and metoprolol with respect to cardiac $\beta_2$ -adrenoceptor density, catecholamine levels and perioperative catecholamine requirements in cardiac surgery patients. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2005, 372, 115-124.	1.4	19
3095	Short-term reduction in bone markers with high-dose simvastatin. <i>Osteoporosis International</i> , 2005, 16, 1272-1276.	1.3	37
3096	Comparison of apolipoprotein B and plasma lipids as targets for lipid lowering treatment. <i>Clinical Biochemistry</i> , 2005, 38, 509-513.	0.8	6
3097	Simvastatin and Preparation of Polyunsaturated Phospholipids Produce Similar Changes in the Phospholipid Composition of High-Density Lipoproteins during Hypercholesterolemia. <i>Bulletin of Experimental Biology and Medicine</i> , 2005, 139, 210-212.	0.3	2
3098	Interindividual Differences of Response to Statin Treatment Cannot Be Explained by Variations of the Human Gene for RhoA. <i>Biochemical Genetics</i> , 2005, 43, 143-148.	0.8	3
3099	Heart failure and statinsâ€”Why do we need a clinical trial?. <i>Clinical Research in Cardiology</i> , 2005, 94, 223-230.	1.2	23
3101	Secondary prevention after ischemic stroke. <i>Journal of Neurology</i> , 2005, 252, 14-20.	1.8	40
3102	Women and cardiovascular diseaseâ€”Prevention of heart disease. <i>International Journal of Angiology</i> , 2005, 14, 218-224.	0.2	2
3103	Medication adherence trends with statins. <i>Advances in Therapy</i> , 2005, 22, 163-171.	1.3	81
3104	Comparison of two methods of estimation of low density lipoprotein cholesterol, the direct versus friedewald estimation. <i>Indian Journal of Clinical Biochemistry</i> , 2005, 20, 54-61.	0.9	38
3107	Plasma kinetics of free and esterified cholesterol in familial hypercholesterolemia: Effects of simvastatin. <i>Lipids</i> , 2005, 40, 737-743.	0.7	18
3108	Pharmacogenetics of response to statins: Where do we stand?. <i>Current Atherosclerosis Reports</i> , 2005, 7, 204-208.	2.0	23
3109	Statins and stroke prevention. <i>Current Atherosclerosis Reports</i> , 2005, 7, 313-318.	2.0	7

#	ARTICLE	IF	CITATIONS
3111	The role of statins in the prevention of ischemic stroke. <i>Current Atherosclerosis Reports</i> , 2005, 7, 364-368.	2.0	12
3112	Extending the cardiovascular benefits of omega-3 fatty acids. <i>Current Atherosclerosis Reports</i> , 2005, 7, 375-380.	2.0	36
3113	Statin use in the metabolic syndrome. <i>Current Atherosclerosis Reports</i> , 2005, 7, 17-21.	2.0	11
3114	Pleiotropic effects of statins: Moving beyond cholesterol control. <i>Current Atherosclerosis Reports</i> , 2005, 7, 34-39.	2.0	19
3115	How aggressive should lipid lowering be among patients with acute coronary syndromes?. <i>Current Cardiology Reports</i> , 2005, 7, 283-287.	1.3	0
3116	Effective use of combination lipid therapy. <i>Current Cardiology Reports</i> , 2005, 7, 471-479.	1.3	9
3117	Characteristics Associated with Differences in Reported Versus Measured Total Cholesterol Among Male Physicians. <i>Journal of Primary Prevention</i> , 2005, 26, 51-61.	0.8	3
3118	Immediate Effects of Fluvastatin on Circulating Soluble Endothelial Protein C and Free Tissue Factor Pathway Inhibitor in Acute Coronary Syndromes. <i>Cardiovascular Drugs and Therapy</i> , 2005, 19, 177-181.	1.3	8
3119	Short-Term Adjuvant Atorvastatin Improves Frequency Domain Indices of Heart Rate Variability in Stable Systolic Heart Failure. <i>Cardiovascular Drugs and Therapy</i> , 2005, 19, 183-187.	1.3	35
3120	Mild to Moderate Muscular Symptoms with High-Dosage Statin Therapy in Hyperlipidemic Patients â€”The PRIMO Study. <i>Cardiovascular Drugs and Therapy</i> , 2005, 19, 403-414.	1.3	1,039
3121	Multidisciplinary Vascular Screening Program Modestly Improves the Medical Treatment of Vascular Risk Factors. <i>Cardiovascular Drugs and Therapy</i> , 2005, 19, 429-435.	1.3	8
3122	Simvastatin Regulates Myocardial Cytokine Expression and Improves Ventricular Remodeling in Rats after Acute Myocardial Infarction. <i>Cardiovascular Drugs and Therapy</i> , 2005, 19, 13-21.	1.3	52
3123	Fluvastatin in the therapy of acute coronary syndrome: Rationale and design of a multicenter, randomized, double-blind, placebo-controlled trial (The FACS Trial) [ISRCTN81331696]. <i>Current Controlled Trials in Cardiovascular Medicine</i> , 2005, 6, 4.	1.5	17
3124	Effect of rosuvastatin on outcomes in chronic haemodialysis patients â€” design and rationale of the AURORA study. <i>Current Controlled Trials in Cardiovascular Medicine</i> , 2005, 6, 9.	1.5	71
3125	Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]. , 2005, 4, 13.		84
3126	Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study. <i>Cardiovascular Diabetology</i> , 2005, 4, 7.	2.7	50
3127	Statins research unfinished saga: desirability versus feasibility. <i>Cardiovascular Diabetology</i> , 2005, 4, 8.	2.7	9
3128	Statin therapy should be considered routinely for people with diabetes mellitus. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2005, 22, 233-236.	0.2	0

#	ARTICLE	IF	CITATIONS
3129	An application of propensity score matching using claims data. <i>Pharmacoepidemiology and Drug Safety</i> , 2005, 14, 465-476.	0.9	183
3130	Exploring unexplained twofold differences in sales of cardiovascular drugs between two neighbouring Swedish municipalities. <i>Pharmacoepidemiology and Drug Safety</i> , 2005, 14, 349-355.	0.9	5
3131	Modulating T cell signaling cascades by HMG-CoA reductase inhibitors. <i>Signal Transduction</i> , 2005, 5, 231-244.	0.7	3
3132	The Association Between Cholesterol and Mortality in Heart Failure Comparison Between Patients With and Without Coronary Artery Disease. <i>International Heart Journal</i> , 2005, 46, 619-629.	0.5	48
3133	Ten-year Follow-up of Familial Hypercholesterolemia Patients After Intensive Cholesterol-lowering Therapy. <i>International Heart Journal</i> , 2005, 46, 833-843.	0.5	33
3134	Reduction of Soluble E-Selectin after Combined Treatment with Simvastatin and Vitamins C and E. <i>Cardiology</i> , 2005, 5, 75-80.	0.3	0
3135	Modern intervention strategies for managing dyslipidaemia: the case for combination therapy. <i>British Journal of Diabetes and Vascular Disease</i> , 2005, 5, S17-S23.	0.6	0
3136	Rationale and Design of the OACIS-LIPID Study That Evaluates Early Use of Pravastatin in Acute Myocardial Infarction. <i>Cardiology</i> , 2005, 5, 193-196.	0.3	3
3137	Assessing adherence to statin therapy using patient report, pill count, and an electronic monitoring device. <i>American Journal of Health-System Pharmacy</i> , 2005, 62, 411-415.	0.5	9
3138	Efficacy and safety of rosuvastatin in treatment of dyslipidemia. <i>American Journal of Health-System Pharmacy</i> , 2005, 62, 1033-1047.	0.5	72
3139	The management of hyperlipidaemia. <i>Practice Nursing</i> , 2005, 16, 382-387.	0.1	0
3140	Decreased Heart Rate Recovery in Patients With Heart Failure Effect of Fluvastatin Therapy. <i>International Heart Journal</i> , 2005, 46, 845-854.	0.5	13
3141	Assessing adherence to statin therapy using patient report, pill count, and an electronic monitoring device. <i>American Journal of Health-System Pharmacy</i> , 2005, 62, 411-415.	0.5	15
3142	Cost of lipid lowering in patients with coronary artery disease by Case Method Learning. <i>International Journal of Technology Assessment in Health Care</i> , 2005, 21, 180-186.	0.2	6
3143	Role of nicotinic acid in raising high-density lipoprotein cholesterol (HDL-C) to reduce cardiovascular risk: an Asian/Pacific consensus. <i>British Journal of Diabetes and Vascular Disease</i> , 2005, 5, S1-S15.	0.6	0
3144	The Era of Statins – Is There Still a Place for Other Classes of Lipid-Lowering Drugs?. <i>Cardiology</i> , 2005, 5, 34-38.	0.3	1
3145	Antiatherogenic Effects of Dietary Plant Sterols Are Associated with Inhibition of Proinflammatory Cytokine Production in Apo E-KO Mice. <i>Journal of Nutrition</i> , 2005, 135, 2438-2444.	1.3	96
3146	Aspirin and Cardiovascular Prevention in the Guidelines and in the Real World. , 2005, , 63-74.		0

#	ARTICLE	IF	CITATIONS
3147	Diagnosis and Prevention of Atherosclerotic Cerebral Infarction. <i>CNS Spectrums</i> , 2005, 10, 553-566.	0.7	12
3148	Reduction of Serum Ubiquinol-10 and Ubiquinone-10 Levels by Atorvastatin in Hypercholesterolemic Patients. <i>Journal of Atherosclerosis and Thrombosis</i> , 2005, 12, 111-119.	0.9	107
3149	Number needed to treat: A descriptor for weighing therapeutic options. <i>American Journal of Health-System Pharmacy</i> , 2005, 62, 2031-2036.	0.5	47
3150	Modulation of High-Density Lipoprotein Cholesterol Metabolism and Reverse Cholesterol Transport. <i>Handbook of Experimental Pharmacology</i> , 2005, , 537-561.	0.9	17
3151	Fluvastatin Prevents Vascular Hyperplasia by Inhibiting Phenotype Modulation and Proliferation Through Extracellular Signal-Regulated Kinase 1 and 2 and p38 Mitogen-Activated Protein Kinase Inactivation in Organ-Cultured Artery. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 327-333.	1.1	37
3152	Effect of statins on the mortality of patients with ischaemic heart disease: population based cohort study with nested case-control analysis. <i>Heart</i> , 2005, 92, 752-758.	1.2	35
3153	Clinical Progression of Incidental, Asymptomatic Lesions Discovered During Culprit Vessel Coronary Intervention. <i>Circulation</i> , 2005, 111, 143-149.	1.6	258
3154	Guggulipid use in hyperlipidemia: Case report and review of the literature. <i>American Journal of Health-System Pharmacy</i> , 2005, 62, 1690-1692.	0.5	16
3155	Reduction of high cholesterol levels associated with younger age and longer education in a primary health care programme for cardiovascular prevention. <i>Scandinavian Journal of Primary Health Care</i> , 2005, 23, 75-81.	0.6	10
3156	Can statin therapy alter the natural history of bicuspid aortic valves?. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2005, 288, H2547-H2549.	1.5	17
3158	Optimizing Percutaneous Coronary Intervention Outcomes. <i>Circulation</i> , 2005, 111, 125-126.	1.6	5
3159	Simvastatin Blunts Endotoxin-Induced Tissue Factor In Vivo. <i>Circulation</i> , 2005, 111, 1841-1846.	1.6	136
3160	Should Treatment of Sepsis Include Statins?. <i>Circulation</i> , 2005, 111, 1735-1737.	1.6	17
3161	Simvastatin Versus Ezetimibe. <i>Circulation</i> , 2005, 111, 2356-2363.	1.6	416
3162	The effect of intensive lipid lowering on coronary atheroma and clinical outcome. <i>Heart</i> , 2005, 93, 149-151.	1.2	4
3163	Safety and efficacy of atorvastatin in patients with severe renal dysfunction. <i>Scandinavian Journal of Urology and Nephrology</i> , 2005, 39, 503-510.	1.4	26
3164	Improving secondary prevention in coronary bypass patients: closing the audit loop. <i>Heart</i> , 2005, 91, 456-459.	1.2	7
3165	Increased ApoB in Small Dense LDL Particles Predicts Premature Coronary Artery Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 474-475.	1.1	31



#	ARTICLE	IF	CITATIONS
3166	HMG-CoA Reductase Inhibitors Inhibit Endothelial Exocytosis and Decrease Myocardial Infarct Size. <i>Circulation Research</i> , 2005, 96, 1185-1192.	2.0	75
3167	Rho GTPases, Statins, and Nitric Oxide. <i>Circulation Research</i> , 2005, 97, 1232-1235.	2.0	434
3168	Effects of atorvastatin on reactive hyperaemia and the thrombosis-fibrinolysis system in patients with heart failure. <i>Heart</i> , 2005, 91, 27-31.	1.2	56
3169	Effect of Antihypertensive Treatment on Plasma Fibrinogen and Serum HDL Levels in Patients with Essential Hypertension. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2005, 11, 139-146.	0.7	17
3170	Low-dose atorvastatin in severe chronic kidney disease patients: A randomized, controlled endpoint study. <i>Scandinavian Journal of Urology and Nephrology</i> , 2005, 39, 489-497.	1.4	42
3171	Impact of Short-Term Administration of High-Density Lipoproteins and Atorvastatin on Atherosclerosis in Rabbits. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 2416-2421.	1.1	146
3172	Treatment With Simvastatin Suppresses the Development of Experimental Abdominal Aortic Aneurysms in Normal and Hypercholesterolemic Mice. <i>Annals of Surgery</i> , 2005, 241, 92-101.	2.1	152
3173	Intrusion and Confusion – The Impact of Medication and Health Professionals after Acute Myocardial Infarction. <i>European Journal of Cardiovascular Nursing</i> , 2005, 4, 153-159.	0.4	23
3174	Plaque Rupture After Short Periods of Fat Feeding in the Apolipoprotein E – Knockout Mouse. <i>Circulation</i> , 2005, 111, 1422-1430.	1.6	235
3175	Effect of Simvastatin, an Established Lipid-Lowering Drug, on Pulmonary Chlamydia pneumoniae Infection in Mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 3959-3962.	1.4	53
3176	Lipids and Stroke: The Opportunity of Lipid-Lowering Treatment. <i>Cerebrovascular Diseases</i> , 2005, 20, 53-67.	0.8	19
3177	Physician Perceptions of Enhanced Community Pharmacist Care in Cholesterol Management. <i>Canadian Pharmacists Journal</i> , 2005, 138, 33-39.	0.4	4
3178	Gene transfer for ischemic cardiovascular disease: is this the end of the beginning or the beginning of the end?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2005, 2, 138-144.	3.3	10
3179	Cost offset of lipid-lowering drugs for primary and secondary prevention of cardiovascular disease. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2005, 5, 193-205.	0.7	5
3180	Rosuvastatin: achieving cholesterol targets. <i>Future Cardiology</i> , 2005, 1, 289-297.	0.5	0
3181	Prevention of perioperative cardiovascular complications in non-cardiac surgery: the future role of statins. <i>Future Cardiology</i> , 2005, 1, 701-704.	0.5	0
3182	Implications of statin adverse effects in the elderly. <i>Expert Opinion on Drug Safety</i> , 2005, 4, 389-397.	1.0	34
3183	Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect. <i>Cmaj</i> , 2005, 172, 1187-1194.	0.9	49

#	ARTICLE	IF	CITATIONS
3184	Differences in Physician Compliance with Guideline on Lipid Profile Determination within 24 h after Acute Myocardial Infarction. <i>Medical Principles and Practice</i> , 2005, 14, 41-45.	1.1	3
3185	Socioeconomic relevance of selected treatment strategies in patients with chronic heart failure. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2005, 5, 277-286.	0.7	0
3187	Drug Insight: using statins to treat neuroinflammatory disease. <i>Nature Clinical Practice Neurology</i> , 2005, 1, 106-112.	2.7	27
3188	Lipoprotein-associated phospholipase A2: a novel marker of cardiovascular risk and potential therapeutic target. <i>Expert Opinion on Investigational Drugs</i> , 2005, 14, 671-679.	1.9	20
3189	Managing Abnormal Blood Lipids. <i>Circulation</i> , 2005, 112, 3184-3209.	1.6	199
3190	The contrOL of dYslipideMia in outPatlent clinics in GreeCe (Olympic) Study. <i>Angiology</i> , 2005, 56, 731-741.	0.8	19
3191	Treatment of dyslipidaemia in HIV-infected persons. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 1619-1645.	0.9	11
3193	Statin response and pharmacokinetics variants. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 1291-1297.	0.9	12
3194	Rosuvastatin: a risk-benefit assessment for intensive lipid lowering. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 1897-1910.	0.9	10
3195	Thematic Review Series: The Immune System and Atherogenesis. Molecular mechanisms regulating monocyte recruitment in atherosclerosis. <i>Journal of Lipid Research</i> , 2005, 46, 1582-1590.	2.0	60
3196	Long-Term Benefits and Limitations of Combined Antianginal Drug Therapy in Elderly Patients with Symptomatic Chronic Coronary Artery Disease. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2005, 10, 29-37.	1.0	5
3197	Over the counter statins – a good idea?. <i>British Journal of Diabetes and Vascular Disease</i> , 2005, 5, 51-53.	0.6	2
3198	When to Measure Lipid Profile after Stroke?. <i>Cerebrovascular Diseases</i> , 2005, 19, 234-238.	0.8	20
3199	Erythrocyte Plasma Membrane Perturbations in Rats Fed a Cholesterol-Rich Diet: Effect of Drinking Sulphurous Mineral Water. <i>Annals of Nutrition and Metabolism</i> , 2005, 49, 9-15.	1.0	6
3200	Effects of Diet and Simvastatin on Fatty Acid Composition in Hypercholesterolemic Men. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 1952-1959.	1.1	71
3201	Short-Term Treatment With Atorvastatin Reduces Platelet CD40 Ligand and Thrombin Generation in Hypercholesterolemic Patients. <i>Circulation</i> , 2005, 111, 412-419.	1.6	159
3202	Therapy of Stable Angina Pectoris. <i>Circulation</i> , 2005, 112, e255-9.	1.6	24
3203	Plasma Lipoproteins and Apolipoproteins as Predictors of Cardiovascular Risk and Treatment Benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). <i>Circulation</i> , 2005, 112, 3058-3065.	1.6	113

#	ARTICLE	IF	CITATIONS
3204	Treating Diastolic Heart Failure With Statins. <i>Circulation</i> , 2005, 112, 300-303.	1.6	24
3205	APOE genotypes and dyslipidemias in a sample of the Portuguese population. <i>Clinical Chemistry and Laboratory Medicine</i> , 2005, 43, 907-12.	1.4	11
3206	Lipid and Non-lipid Effects of Statins. <i>Handbook of Experimental Pharmacology</i> , 2005, , 365-388.	0.9	13
3208	Statin Therapy May Be Associated With Lower Mortality in Patients With Diastolic Heart Failure. <i>Circulation</i> , 2005, 112, 357-363.	1.6	282
3209	Effect of mild endurance exercise training and pravastatin on peripheral vasodilatation of forearm resistance vessels in patients with coronary artery disease. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2005, 12, 332-340.	3.1	10
3210	Effect of Combined Treatment With an Angiotensin II Receptor Antagonist and an HMG-CoA Reductase Inhibitor on Atherosclerosis in Genetically Hyperlipidemic Rabbits. <i>Journal of Cardiovascular Pharmacology</i> , 2005, 46, 556-562.	0.8	22
3211	Benefits and risks assessment of simvastatin in familial hypercholesterolaemia. <i>Expert Opinion on Drug Safety</i> , 2005, 4, 171-181.	1.0	8
3212	In-Hospital Initiation of Statin Therapy in Acute Coronary Syndromes. <i>Chest</i> , 2005, 128, 3641-3651.	0.4	16
3213	Total risk factor management in patients with type 2 diabetes. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2005, 66, 529-533.	0.2	0
3214	Regulation of Vascular Tone from Spontaneously Hypertensive Rats by the HMG-CoA Reductase Inhibitor, Simvastatin. <i>Pharmacology</i> , 2005, 74, 209-215.	0.9	15
3215	Rate of Admission and Long-Term Prognosis among Patients with Acute Chest Pain in the 1990s Compared with the 1980s. <i>Cardiology</i> , 2005, 104, 51-56.	0.6	1
3216	Uric Acid, Microalbuminuria and Cardiovascular Events in High-Risk Patients. <i>American Journal of Nephrology</i> , 2005, 25, 36-44.	1.4	45
3217	Plasma C-Reactive Protein and Lipoprotein Levels, and Progression of Coronary Artery Disease after Myocardial Infarction Treated with Thrombolysis. <i>Cardiology</i> , 2005, 104, 65-71.	0.6	2
3218	Statins, Ventricular Arrhythmias and Heart Rate Variability in Patients with Implantable Cardioverter Defibrillators and Coronary Heart Disease. <i>Cardiology</i> , 2005, 104, 210-214.	0.6	16
3219	Effect of combinations of drugs on all cause mortality in patients with ischaemic heart disease: nested case-control analysis. <i>BMJ: British Medical Journal</i> , 2005, 330, 1059-1063.	2.4	118
3220	Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. <i>BMJ: British Medical Journal</i> , 2005, 331, 1310-1316.	2.4	201
3221	Statin use in the secondary prevention of coronary heart disease in primary care: cohort study and comparison of inclusion and outcome with patients in randomised trials. <i>BMJ: British Medical Journal</i> , 2005, 330, 821.	2.4	78
3222	Estimating the high risk group for cardiovascular disease in the Norwegian HUNT 2 population according to the 2003 European guidelines: modelling study. <i>BMJ: British Medical Journal</i> , 2005, 331, 551.	2.4	79

#	ARTICLE	IF	CITATIONS
3223	Sensitivity and Specificity of the Ankle-Brachial Index to Predict Future Cardiovascular Outcomes. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 1463-1469.	1.1	306
3224	Veterans Affairs/Department of Defense Clinical Practice Guideline for the Management of Adult Stroke Rehabilitation Care. Stroke, 2005, 36, 2049-2056.	1.0	124
3225	Inhibition of Rho Kinase (ROCK) Leads to Increased Cerebral Blood Flow and Stroke Protection. Stroke, 2005, 36, 2251-2257.	1.0	351
3226	Statins Are Associated With Better Outcomes After Carotid Endarterectomy in Symptomatic Patients. Stroke, 2005, 36, 2072-2076.	1.0	188
3227	HMG-CoA Reductase Inhibitors Improve Acute Ischemic Stroke Outcome. Stroke, 2005, 36, 2344-2344.	1.0	15
3228	Management and outcome of patients with established coronary artery disease: the Euro Heart Survey on coronary revascularization. European Heart Journal, 2005, 26, 1169-1179.	1.0	161
3229	Impact of statins in microalbuminuric subjects with the metabolic syndrome: a substudy of the PREVENT Intervention Trial. European Heart Journal, 2005, 26, 1314-1320.	1.0	51
3230	Can a Marker Be a Surrogate for Development of Cancer, and Would We Know It if It Exists?. , 2005, 166, 99-112.		4
3231	Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet, The, 2005, 366, 1267-1278.	6.3	6,113
3233	¿Hasta dónde hay que reducir el colesterol en el paciente de alto riesgo cardiovascular?. Hipertension, 2005, 22, 318-331.	0.0	0
3234	Interaction between Amlodipine and Simvastatin in Patients with Hypercholesterolemia and Hypertension. Hypertension Research, 2005, 28, 223-227.	1.5	74
3235	Management of dyslipidemia in elderly diabetic patients. Diabetes and Metabolism, 2005, 31, 5S74-5S81.	1.4	6
3236	Editorial. Current Therapeutic Research, 2005, 66, 46-47.	0.5	0
3237	Effects of increasing doses of simvastatin on fasting lipoprotein subfractions, and the effect of high-dose simvastatin on postprandial chylomicron remnant clearance in normotriglyceridemic patients with premature coronary sclerosis. Atherosclerosis, 2005, 178, 147-155.	0.4	25
3238	Lipid transfer proteins (LTP) and atherosclerosis. Atherosclerosis, 2005, 178, 217-230.	0.4	82
3239	Endothelium-ameliorating effects of statin therapy and coenzyme Q10 reductions in chronic heart failure. Atherosclerosis, 2005, 179, 201-206.	0.4	90
3240	What causes acute coronary syndromes? Applying Koch's postulates. Atherosclerosis, 2005, 179, 1-15.	0.4	29
3241	Atheroma stabilizing effects of simvastatin due to depression of macrophages or lipid accumulation in the atheromatous plaques of coronary plaque-prone WHHL rabbits. Atherosclerosis, 2005, 178, 287-294.	0.4	42

#	ARTICLE	IF	CITATIONS
3242	Projected coronary heart disease risk benefit with ezetimibe. <i>Atherosclerosis</i> , 2005, 179, 375-378.	0.4	10
3243	Tracking atherosclerosis regression: a clinical tool in preventive cardiology. <i>Atherosclerosis</i> , 2005, 180, 1-10.	0.4	41
3244	Enhanced oxidative stress in neutrophils from hyperlipidemic guinea pig. <i>Atherosclerosis</i> , 2005, 181, 87-92.	0.4	30
3245	High-density lipoprotein cholesterol in the cardiovascular equation: Does the "œgood" still count?. <i>Atherosclerosis</i> , 2005, 180, 217-223.	0.4	21
3246	The inflammation: Lipoprotein cycle. <i>Atherosclerosis Supplements</i> , 2005, 6, 15-20.	1.2	44
3247	Is dyslipidaemia important if we control glycaemia?. <i>Atherosclerosis Supplements</i> , 2005, 6, 3-10.	1.2	4
3248	What is the consequence of an abnormal lipid profile in patients with type 2 diabetes or the metabolic syndrome?. <i>Atherosclerosis Supplements</i> , 2005, 6, 11-14.	1.2	23
3249	What is the most effective strategy for managing diabetic dyslipidaemia?. <i>Atherosclerosis Supplements</i> , 2005, 6, 21-27.	1.2	7
3251	Preoperative Statin Therapy Does Not Reduce Cognitive Dysfunction After Cardiopulmonary Bypass. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2005, 19, 294-299.	0.6	34
3252	Chronic Stable Angina. <i>New England Journal of Medicine</i> , 2005, 352, 2524-2533.	13.9	195
3253	Rosuvastatin: A High-Potency HMG-CoA Reductase Inhibitor. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2005, 45, 503-513.	0.7	11
3254	HMG-CoA Reductase Inhibitors Improve Acute Ischemic Stroke Outcome. <i>Stroke</i> , 2005, 36, 1298-1300.	1.0	129
3255	A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): Study design and baseline characteristics. <i>European Journal of Heart Failure</i> , 2005, 7, 1059-1069.	2.9	127
3256	Role of Neurohormonal Modulators in Heart Failure with Relatively Preserved Systolic Function. <i>Heart Failure Clinics</i> , 2005, 1, 77-93.	1.0	3
3258	The Cardiovascular Outcomes with Renal Atherosclerotic Lesions (CORAL) Study: Rationale and Methods. <i>Journal of Vascular and Interventional Radiology</i> , 2005, 16, 1295-1300.	0.2	84
3259	Hyperlipidemia. <i>Primary Care - Clinics in Office Practice</i> , 2005, 32, 1027-1055.	0.7	35
3261	The role of lipid management in diabetes. <i>Cardiology Clinics</i> , 2005, 23, 153-164.	0.9	0
3262	Conversion to Atorvastatin in Patients Intolerant or Refractory to Simvastatin Therapy: The CAPISH Study. <i>Mayo Clinic Proceedings</i> , 2005, 80, 1163-1168.	1.4	22

#	ARTICLE	IF	CITATIONS
3264	Risk factors, medical therapies and perioperative events in limb salvage surgery: Observations from the PREVENT III multicenter trial. <i>Journal of Vascular Surgery</i> , 2005, 42, 456-464.	0.6	149
3265	A pharmacoeconomic evaluation of statins in the treatment of hypercholesterolaemia in the primary care setting in Spain. <i>Pharmacoeconomics</i> , 2005, 23, 275-287.	1.7	13
3266	Effects of Concurrent Therapy with Policosanol and Omega-3 Fatty Acids on Lipid Profile and Platelet Aggregation in Rabbits. <i>Drugs in R and D</i> , 2005, 6, 11-19.	1.1	13
3267	Effects of Addition of Policosanol to??Omega-3 Fatty Acid Therapy on the??Lipid Profile of Patients with Type??II Hypercholesterolaemia. <i>Drugs in R and D</i> , 2005, 6, 207-219.	1.1	20
3268	Dieci anni di utilizzo delle statine: adesione alla terapia e costi del trattamento farmacologico. <i>Pharmacoeconomics Italian Research Articles</i> , 2005, 7, 187-194.	0.2	4
3269	A review of acitretin, a systemic retinoid for the treatment of psoriasis. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 1725-1734.	0.9	63
3270	Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. <i>BMJ: British Medical Journal</i> , 2005, 330, 1366.	2.4	487
3271	Critical appraisal of revised cholesterol guidelines for the very high-risk patient. <i>Expert Review of Cardiovascular Therapy</i> , 2005, 3, 173-178.	0.6	7
3272	Statin Therapy Helps to Control Blood Pressure Levels in Hypertensive Dyslipidemic Patients. <i>Renal Failure</i> , 2005, 27, 297-303.	0.8	29
3273	Cardiac Rehabilitation and Secondary Prevention of Coronary Heart Disease. <i>Circulation</i> , 2005, 111, 369-376.	1.6	879
3274	Myeloperoxidase and Cardiovascular Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 1102-1111.	1.1	653
3275	Simvastatin plus ezetimibe: combination therapy for the management of dyslipidaemia. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 131-139.	0.9	32
3276	Drug Insight: statins and stroke. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2005, 2, 576-584.	3.3	25
3277	Costâ€ effectiveness of HMG-CoA reductase inhibitors in the treatment of dyslipidemia and prevention of CHD. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2005, 5, 603-623.	0.7	0
3278	Inflammatory and anti-inflammatory cytokines in chronic heart failure: Potential therapeutic implications. <i>Annals of Medicine</i> , 2005, 37, 74-85.	1.5	140
3279	The link between cholesterol and Alzheimer's disease. <i>World Journal of Biological Psychiatry</i> , 2005, 6, 85-97.	1.3	54
3280	Pharmacoeconomic Impact of Non-Compliance with Statins. <i>Pharmacoeconomics</i> , 2005, 23, 13-25.	1.7	27
3281	Place of Drug Therapy in the Treatment of Carotid Stenosis. <i>CNS Drugs</i> , 2005, 19, 597-622.	2.7	5

#	ARTICLE	IF	CITATIONS
3282	Progress in the Identification of Stroke-Related Genes. <i>CNS Drugs</i> , 2005, 19, 821-832.	2.7	10
3283	Statins and the Response to Myocardial Injury. <i>American Journal of Cardiovascular Drugs</i> , 2005, 5, 163-170.	1.0	13
3284	Modified-Release Formulation of Trimetazidine for Exceptional Control of Angina Pectoris. <i>American Journal of Cardiovascular Drugs</i> , 2005, 5, 331-334.	1.0	8
3285	Global Cardiovascular Risk. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2005, 12, 125-133.	1.0	0
3286	Adverse Effects of Statins. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2005, 12, 141-148.	1.0	1
3287	Atorvastatin. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 1191-1203.	0.9	18
3288	Statins and fibrates for preventing melanoma. <i>The Cochrane Library</i> , 2005, , CD003697.	1.5	30
3289	ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult. <i>Circulation</i> , 2005, 112, e154-235.	1.6	2,179
3290	The Role of Statins in Preventing Stroke. <i>Preventive Cardiology</i> , 2005, 8, 98-101.	1.1	7
3291	Women's Health Study (Aspirin) and TNT. <i>Preventive Cardiology</i> , 2005, 8, 181-185.	1.1	0
3292	Stroke in Patients With Diabetes and Hypertension. <i>Journal of Clinical Hypertension</i> , 2005, 7, 286-294.	1.0	32
3293	Baseline levels of low-density lipoprotein cholesterol and lipoprotein (a) and the A polymorphism of the low-density lipoprotein receptor gene influence the response of low-density lipoprotein cholesterol to pravastatin treatment. <i>Metabolism: Clinical and Experimental</i> , 2005, 54, 741-747.	1.5	19
3294	Gp78, a Membrane-Anchored Ubiquitin Ligase, Associates with Insig-1 and Couples Sterol-Regulated Ubiquitination to Degradation of HMG CoA Reductase. <i>Molecular Cell</i> , 2005, 19, 829-840.	4.5	317
3295	Effects of atorvastatin on the Th1/Th2 polarization of ongoing experimental autoimmune myocarditis in Lewis rats. <i>Journal of Autoimmunity</i> , 2005, 25, 258-263.	3.0	65
3296	Both clinical epidemiology and population health perspectives can define the role of health care in reducing health disparities. <i>Journal of Clinical Epidemiology</i> , 2005, 58, 757-762.	2.4	28
3297	Influence of withdrawal of statin treatment on proinflammatory response and fibrinolytic activity in humans: an effect independent on cholesterol elevation. <i>International Journal of Cardiology</i> , 2005, 98, 459-464.	0.8	38
3298	Fluvastatin reduces the 4-year cardiac risk in patients with multivessel disease. <i>International Journal of Cardiology</i> , 2005, 98, 479-486.	0.8	12
3299	Electrocardiographic events and cholesterol reduction with pravastatin in patients with hypercholesterolemia: the Hokuriku Lipid Coronary Heart Disease Study-Pravastatin Atherosclerosis Trial. <i>International Journal of Cardiology</i> , 2005, 99, 395-401.	0.8	11

#	ARTICLE	IF	CITATIONS
3300	The benefit of fibrates in the treatment of "bad HDL-C responders to statins"™. <i>International Journal of Cardiology</i> , 2005, 101, 231-235.	0.8	9
3301	Association between plasma lipids, and apolipoproteins and coronary artery disease: a cross-sectional study in a low-risk Korean population. <i>International Journal of Cardiology</i> , 2005, 101, 435-440.	0.8	35
3302	Regional variation in medication following coronary events in Germany. <i>International Journal of Cardiology</i> , 2005, 102, 47-53.	0.8	8
3303	Prognostic value of lipoproteins and their relation to inflammatory markers among patients with coronary artery disease. <i>International Journal of Cardiology</i> , 2005, 102, 477-485.	0.8	25
3304	Preoperative statin use and outcomes following cardiac surgery. <i>International Journal of Cardiology</i> , 2005, 103, 12-18.	0.8	57
3305	Cholesterol levels after 3 days of high-dose simvastatin in patients at moderate to high risk for coronary events. <i>International Journal of Cardiology</i> , 2005, 101, 111-114.	0.8	10
3306	Rosuvastatin is cost-effective compared with atorvastatin in reaching cholesterol goals. <i>International Journal of Cardiology</i> , 2005, 104, 251-256.	0.8	18
3307	Statins reduce connexin40 and connexin43 expression in atherosclerotic aorta of rabbits. <i>International Journal of Cardiology</i> , 2005, 100, 467-475.	0.8	32
3308	Pravastatin suppresses the increase in matrix metalloproteinase-2 levels after acute myocardial infarction. <i>International Journal of Cardiology</i> , 2005, 105, 67-73.	0.8	43
3309	Long-term follow-up after invasive approach of coronary artery disease in daily practice. <i>International Journal of Cardiology</i> , 2005, 105, 186-191.	0.8	4
3310	Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin. <i>International Journal of Cardiology</i> , 2005, 104, 338-345.	0.8	24
3311	Effect of co-administering ezetimibe with on-going simvastatin treatment on LDL-C goal attainment in hypercholesterolemic patients with coronary heart disease. <i>International Journal of Cardiology</i> , 2005, 102, 327-332.	0.8	47
3312	The role of fat tissue in the cholesterol lowering and the pleiotropic effects of statins " statins activate the generation of metabolically more capable adipocytes. <i>Medical Hypotheses</i> , 2005, 64, 69-73.	0.8	15
3313	Blockade of geranylgeranylation by rosuvastatin upregulates eNOS expression in human venous endothelial cells. <i>Biochemical and Biophysical Research Communications</i> , 2005, 336, 1005-1009.	1.0	13
3314	Conversion From Cyclosporine Microemulsion to Tacrolimus-Based Immunoprophylaxis Improves Cholesterol Profile in Heart Transplant Recipients With Treated but Persistent Dyslipidemia: The Canadian Multicentre Randomized Trial of Tacrolimus vs Cyclosporine Microemulsion. <i>Journal of Heart and Lung Transplantation</i> , 2005, 24, 798-809.	0.3	35
3315	Safety and Efficacy of Rosuvastatin Therapy for the Prevention of Hyperlipidemia in Adult Cardiac Transplant Recipients. <i>Journal of Heart and Lung Transplantation</i> , 2005, 24, 1008-1013.	0.3	18
3316	Sample sizes for clinical trials with time-to-event endpoints and competing risks. <i>Contemporary Clinical Trials</i> , 2005, 26, 386-396.	0.8	42
3317	A randomized, open-label study to evaluate the efficacy and safety of pitavastatin compared with simvastatin in Korean patients with hypercholesterolemia. <i>Clinical Therapeutics</i> , 2005, 27, 1074-1082.	1.1	49



#	ARTICLE	IF	CITATIONS
3318	The long-term course of low-density lipoprotein cholesterol after initiation of statin treatment: Retrospective database analysis over 3 years in health maintenance organization enrollees. <i>Clinical Therapeutics</i> , 2005, 27, 1622-1628.	1.1	1
3319	Compliance with a statin treatment in a usual-care setting: Retrospective database analysis over 3 years after treatment initiation in health maintenance organization enrollees with dyslipidemia. <i>Clinical Therapeutics</i> , 2005, 27, 1639-1646.	1.1	81
3320	Preventive drug use in patients with a history of nonfatal myocardial infarction during 12-year follow-up in The Netherlands: A retrospective analysis. <i>Clinical Therapeutics</i> , 2005, 27, 1806-1814.	1.1	17
3321	Insig-mediated degradation of HMG CoA reductase stimulated by lanosterol, an intermediate in the synthesis of cholesterol. <i>Cell Metabolism</i> , 2005, 1, 179-189.	7.2	236
3322	Increased risk for cardiovascular outcomes and effect of cholesterol-lowering pravastatin therapy in patients with diabetes mellitus in the pravastatin anti-atherosclerosis trial in the elderly (PATE). <i>Current Therapeutic Research</i> , 2005, 66, 48-65.	0.5	2
3323	Status of lipid-lowering therapy prescribed based on recommendations in the 2002 report of the Japan Atherosclerosis Society Guideline for Diagnosis and Treatment of Hyperlipidemia in Japanese Adults: A study of the Japan Lipid Assessment Program (J-LAP). <i>Current Therapeutic Research</i> , 2005, 66, 80-95.	0.5	43
3324	Effects of simvastatin 20 mg/d on serum lipid profiles in Japanese hyperlipidemic patients: A prospective, open-label pilot study. <i>Current Therapeutic Research</i> , 2005, 66, 613-629.	0.5	3
3325	Impact of simvastatin on hemostatic and fibrinolytic regulators in Type 2 diabetes mellitus. <i>Diabetes Research and Clinical Practice</i> , 2005, 70, 110-118.	1.1	34
3326	Clinical usage of hypolipidemic and antidiabetic drugs in the prevention and treatment of cancer. <i>Cancer Letters</i> , 2005, 224, 203-212.	3.2	57
3327	Statins, cholesterol, Co-enzyme Q10, and Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2005, 11, 81-84.	1.1	37
3328	HMG CoA Reductase Inhibitors (Statins): Do They Have a Role in Age-related Macular Degeneration?. <i>Survey of Ophthalmology</i> , 2005, 50, 194-206.	1.7	52
3329	Atorvastatin reduces thrombin generation after percutaneous coronary intervention independent of soluble tissue factor. <i>Thrombosis Research</i> , 2005, 115, 469-474.	0.8	9
3330	Statins and cholesterol lowering after a cancer diagnosis: Why not?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2005, 23, 49-55.	0.8	16
3331	Improved posthypoxic recovery in vitro on treatment with drugs used for secondary stroke prevention. <i>Neuropharmacology</i> , 2005, 48, 558-565.	2.0	4
3332	Post-ischemic delivery of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor rosuvastatin protects against focal cerebral ischemia in mice via inhibition of extracellular-regulated kinase-1/-2. <i>Neuroscience</i> , 2005, 134, 901-906.	1.1	35
3334	Rate and adequacy of cholesterol screening in patients admitted to a large rehabilitation unit after stroke. <i>Archives of Physical Medicine and Rehabilitation</i> , 2005, 86, 69-72.	0.5	6
3335	Fluvastatin reduces the impact of diabetes on long-term outcome after coronary intervention—A Lescol Intervention Prevention Study (LIPS) substudy. <i>American Heart Journal</i> , 2005, 149, 329-335.	1.2	28
3336	Early initiation of lipid-lowering therapy for acute coronary syndromes improves compliance with guideline recommendations: Observations from the Orbofiban in Patients with Unstable Coronary Syndromes (OPUS—TIMI 16) trial. <i>American Heart Journal</i> , 2005, 149, 444-450.	1.2	30

#	ARTICLE	IF	CITATIONS
3337	Diabetes and progression of coronary calcium under the influence of statin therapy. American Heart Journal, 2005, 149, 695-700.	1.2	77
3338	Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: Results of a randomized, double-blind, placebo-controlled study. American Heart Journal, 2005, 149, 451-457.	1.2	94
3339	The benefit of cholesterol-lowering medications after coronary revascularization: A population study. American Heart Journal, 2005, 150, 282-286.	1.2	8
3341	Statins in acute coronary syndromes: The sooner, the better?. American Heart Journal, 2005, 149, 377-380.	1.2	3
3342	Association between lipid testing and statin therapy in acute myocardial infarction patients. American Heart Journal, 2005, 150, 419-425.	1.2	16
3343	A prospective evaluation of the effect of simvastatin on heart rate variability in non-ischemic cardiomyopathy. American Heart Journal, 2005, 150, 478-483.	1.2	25
3344	Atrial fibrillation in heart failure: High mortality risk even if ventricular function is preserved. American Heart Journal, 2005, 150, 701-706.	1.2	55
3345	The biology, utilization, and attenuation of C-reactive protein in cardiovascular disease: Part II. American Heart Journal, 2005, 149, 977-983.	1.2	22
3346	Impact of combined secondary prevention therapy after myocardial infarction: Data from a nationwide French registry. American Heart Journal, 2005, 150, 1147-1153.	1.2	52
3347	Genetic variation in the hepatic lipase gene is associated with combined hyperlipidemia, plasma lipid concentrations, and lipid-lowering drug response. American Heart Journal, 2005, 150, 1154-1162.	1.2	15
3348	Early effects of statin therapy on endothelial function and microvascular reactivity in patients with coronary artery disease. American Heart Journal, 2005, 149, 1137.e9-1137.e16.	1.2	32
3349	Determinants of coronary events in patients with stable angina: Results from the Impact of Nicorandil in Angina Study. American Heart Journal, 2005, 150, 689.e1-689.e9.	1.2	17
3350	Plasma low-density lipoprotein reduction and structural effects on coronary atherosclerotic plaques by atorvastatin as clinically assessed with intravascular ultrasound radio-frequency signal analysis: A randomized prospective study. American Heart Journal, 2005, 150, 287.e1-287.e7.	1.2	47
3351	Evaluation of cases of severe statin-related transaminitis within a large health maintenance organization. American Journal of Medicine, 2005, 118, 618-624.	0.6	67
3352	Lipid-lowering therapy and the patient with multiple risk factors: what have we learned from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)?. American Journal of Medicine, 2005, 118, 3-9.	0.6	14
3353	Statin use in a "real-world" clinical setting: aggressive lipid lowering compared with usual care in the Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE) trial. American Journal of Medicine, 2005, 118, 16-21.	0.6	26
3354	Barriers to effective implementation of guideline recommendations. American Journal of Medicine, 2005, 118, 36-41.	0.6	59
3355	What impact will current trial data have on future guideline recommendations?. American Journal of Medicine, 2005, 118, 42-47.	0.6	5

#	ARTICLE	IF	CITATIONS
3356	Statin therapy in the treatment of Alzheimer disease: what is the rationale?. American Journal of Medicine, 2005, 118, 48-53.	0.6	41
3357	Benefits of lipid-lowering therapy in patients with type 2 diabetes mellitus. American Journal of Medicine, 2005, 118, 10-15.	0.6	15
3358	Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: results from the Pravastatin or Atorvastatin Evaluation and Infection Therapyâ€“Thrombolysis in Myocardial Infarction 22 (PROVE ITâ€“TIMI 22) trial. American Journal of Medicine, 2005, 118, 28-35.	0.6	60
3359	Halting the progression of atherosclerosis with intensive lipid lowering: results from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial. American Journal of Medicine, 2005, 118, 22-27.	0.6	38
3362	Atorvastatin reduces lipopolysaccharide-induced expression of cyclooxygenase-2 in human pulmonary epithelial cells. Respiratory Research, 2005, 6, 27.	1.4	17
3363	Ezetimibe. Clinical Pharmacokinetics, 2005, 44, 467-494.	1.6	374
3364	High Prevalence and Undertreatment of Hypercholesterolaemia in Participants in a Public Stroke Prevention Programme in Austria. Clinical Drug Investigation, 2005, 25, 709-717.	1.1	8
3365	Dyslipidemias. , 2005, , 145-172.		0
3366	Effect of Maximum Dose of Atorvastatin on Inflammation, Thrombogenesis, and Fibrinolysis in High-Risk Patients With Ischemic Heart Disease. Revista Espanola De Cardiologia (English Ed ), 2005, 58, 934-940.	0.4	4
3369	The influence of physicians' guideline compliance on patients' statin adherence: A retrospective cohort study. American Journal of Geriatric Pharmacotherapy, 2005, 3, 229-239.	3.0	17
3370	Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: Subanalyses of data from a randomized, double-blind, placebo-controlled trial. American Journal of Geriatric Pharmacotherapy, 2005, 3, 218-228.	3.0	20
3371	Statin Therapy Is Associated With Improved Cardiovascular Outcomes and Levels of Inflammatory Markers in Patients With Heart Failure. Journal of Cardiac Failure, 2005, 11, 607-612.	0.7	62
3372	CD40 ligand enhances monocyte tissue factor expression and thrombin generation via oxidative stress in patients with hypercholesterolemia. Journal of the American College of Cardiology, 2005, 45, 35-42.	1.2	56
3373	Cardiac medical therapy in patients after undergoing coronary artery bypass graft surgery. Journal of the American College of Cardiology, 2005, 45, 177-184.	1.2	54
3374	Statins decrease perioperative cardiac complications in patients undergoing noncardiac vascular surgery. Journal of the American College of Cardiology, 2005, 45, 336-342.	1.2	262
3375	Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment. Journal of the American College of Cardiology, 2005, 45, 1287-1291.	1.2	136
3376	Treatment of Asymptomatic Adults With Elevated Coronary Calcium Scores With Atorvastatin, Vitamin C, and Vitamin E. Journal of the American College of Cardiology, 2005, 46, 166-172.	1.2	380
3377	Different Effects of a High-Cholesterol Diet on Ischemic Cardiac Dysfunction and Remodeling Induced by Coronary Stenosis and Coronary Occlusion. Journal of the American College of Cardiology, 2005, 45, 2078-2087.	1.2	22

#	ARTICLE	IF	CITATIONS
3378	Early and Late Benefits of High-Dose Atorvastatin in Patients With Acute Coronary Syndromes. Journal of the American College of Cardiology, 2005, 46, 1405-1410.	1.2	313
3379	Can Low-Density Lipoprotein Be Too Low? The Safety and Efficacy of Achieving Very Low Low-Density Lipoprotein With Intensive Statin Therapy. Journal of the American College of Cardiology, 2005, 46, 1411-1416.	1.2	306
3380	The Changing Face of Cardiovascular Risk**Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.. Journal of the American College of Cardiology, 2005, 46, 173-175.	1.2	41
3381	Pleiotropic Effects of Statins: Benefit Beyond Cholesterol Reduction?. Journal of the American College of Cardiology, 2005, 46, 1855-1862.	1.2	397
3382	Evolving Concepts of Dyslipidemia, Atherosclerosis, and Cardiovascular Disease. Journal of the American College of Cardiology, 2005, 46, 1219-1224.	1.2	48
3383	The Year in Epidemiology, Health Services, and Outcomes Research. Journal of the American College of Cardiology, 2005, 46, 1362-1370.	1.2	8
3384	The Forgotten Majority. Journal of the American College of Cardiology, 2005, 46, 1225-1228.	1.2	345
3385	ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult. Journal of the American College of Cardiology, 2005, 46, e1-e82.	1.2	1,860
3386	Ã©pidÃ©miologie de l'infarctus du myocarde. EMC - Cardiologie-AngÃ©iologie, 2005, 2, 375-387.	0.9	5
3387	National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand. Heart Lung and Circulation, 2005, 14, 275-291.	0.2	115
3388	Effects of raloxifene and low-dose simvastatin coadministration on plasma lipids in postmenopausal women with primary hypercholesterolemia. Metabolism: Clinical and Experimental, 2005, 54, 939-946.	1.5	14
3389	PLEIOTROPIC EFFECTS OF STATINS. Annual Review of Pharmacology and Toxicology, 2005, 45, 89-118.	4.2	1,574
3390	Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease. New England Journal of Medicine, 2005, 352, 1425-1435.	13.9	3,152
3391	Atherosclerotic risk factor control in patients with peripheral arterial disease. Journal of Vascular Surgery, 2005, 41, 816-822.	0.6	88
3392	HYPERLIPIDEMIA   Overview. , 2005, , 479-491.		0
3393	Cardiovascular Drug Therapy in Elderly Patients. Drugs and Aging, 2005, 22, 913-941.	1.3	35
3394	Prevention of Cardiovascular Events in Elderly People. Drugs and Aging, 2005, 22, 859-876.	1.3	65
3395	Lipid-modified proteins as biomarkers for cardiovascular disease: a review. Biomarkers, 2005, 10, 219-237.	0.9	29

#	ARTICLE	IF	CITATIONS
3396	Impact of Coaching Patients on Coronary Risk Factors. Disease Management and Health Outcomes, 2005, 13, 225-244.	0.3	13
3397	The Performance Gap between Clinical Trials and Patient Treatment for Dyslipidemia. Disease Management and Health Outcomes, 2005, 13, 255-265.	0.3	3
3398	Effectiveness of Interventions to Increase Adherence to Statin Therapy. Disease Management and Health Outcomes, 2005, 13, 73-82.	0.3	2
3399	Do the pleiotropic effects of statins in the vasculature predict a role in inflammatory diseases?. Arthritis Research, 2005, 7, 55.	2.0	36
3401	Managing Hyperlipidaemia in the Elderly. Drugs and Aging, 2006, 23, 181-189.	1.3	13
3402	Effectiveness of Ezetimibe Added to Ongoing Statin Therapy in Modifying Lipid Profiles and Low-Density Lipoprotein Cholesterol Goal Attainment in Patients of Different Races and Ethnicities: A Substudy of the Ezetimibe Add-On to Statin for Effectiveness Trial. Mayo Clinic Proceedings, 2006, 81, 1177-1185.	1.4	28
3403	Papel de la atorvastatina en la prevención del ictus. ¿Puede estar relacionado con su acción sobre la activación plaquetaria? Consideraciones basadas en nuestra propia experiencia. Hipertension Y Riesgo Vascular, 2006, 23, 260-265.	0.3	1
3404	New therapies for familial hypercholesterolemia. Expert Opinion on Therapeutic Patents, 2006, 16, 349-361.	2.4	0
3405	Assessment and Management of Lipid Disorders in Men. Primary Care - Clinics in Office Practice, 2006, 33, 93-114.	0.7	1
3406	Established and evolving medical therapies for claudication in patients with peripheral arterial disease. Nature Clinical Practice Cardiovascular Medicine, 2006, 3, 604-610.	3.3	28
3407	Primary and secondary prevention of heart failure with statins. Expert Review of Cardiovascular Therapy, 2006, 4, 917-926.	0.6	13
3408	The Impact of Therapeutic Reference Pricing on Innovation in Cardiovascular Medicine. Pharmacoeconomics, 2006, 24, 35-54.	1.7	10
3409	Impact of Medicaid Preferred Drug Lists on Therapeutic Adherence. Pharmacoeconomics, 2006, 24, 65-78.	1.7	25
3410	Cost Effectiveness of Adding Ezetimibe to Atorvastatin Therapy in Patients Not at Cholesterol Treatment Goal in Canada. Pharmacoeconomics, 2006, 24, 815-830.	1.7	18
3411	Lipid Management and Cholesterol Goal Attainment in Norway. American Journal of Cardiovascular Drugs, 2006, 6, 121-128.	1.0	16
3412	Different Effects of Simvastatin and Losartan on Cytokine Levels in Coronary Artery Disease. American Journal of Cardiovascular Drugs, 2006, 6, 169-175.	1.0	3
3413	Cost-Effectiveness Analysis of Cholesterol-Lowering Therapies in Spain. American Journal of Cardiovascular Drugs, 2006, 6, 177-188.	1.0	12
3414	Medical Treatment of Patients with Heart Failure or Left Ventricular Dysfunction Undergoing Percutaneous Coronary Intervention. American Journal of Cardiovascular Drugs, 2006, 6, 313-325.	1.0	1


#	ARTICLE	IF	CITATIONS
3415	The A-SACT (Achievement in Singapore of Cholesterol Targets) Study in Patients with Coronary Heart Disease. <i>American Journal of Cardiovascular Drugs</i> , 2006, 6, 383-391.	1.0	23
3416	The Role of Cardiac Rehabilitation in the Treatment and Secondary Prevention of Cardiovascular Disease. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2006, 13, 21-27.	1.0	1
3418	Recent developments in the treatment of atherosclerosis. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2006, 21, 1-15.	2.5	13
3419	Development of an Evaluation of Medical Student Competence in Evidence-Based Medicine Using a Computer-Based OSCE Station. <i>Teaching and Learning in Medicine</i> , 2006, 18, 267-272.	1.3	20
3420	Uno studio di drug utilisation delle statine nella recente prassi terapeutica italiana. <i>Pharmacoeconomics Italian Research Articles</i> , 2006, 8, 3-17.	0.2	5
3421	Effects of statins on experimental colitis in normocholesterolemic rats. <i>Scandinavian Journal of Gastroenterology</i> , 2006, 41, 954-962.	0.6	29
3422	Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack. <i>Stroke</i> , 2006, 37, 577-617.	1.0	1,510
3423	Statins: panacea for sepsis?. <i>Lancet Infectious Diseases</i> , The, 2006, 6, 242-248.	4.6	114
3424	Dyslipidemia is Associated with Ventricular Tachyarrhythmia in Patients with Acute ST-Segment Elevation Myocardial Infarction. <i>Journal of the Formosan Medical Association</i> , 2006, 105, 17-24.	0.8	23
3426	Statin wars following coronary revascularization â€“ Evidence-based clinical practice?. <i>Canadian Journal of Cardiology</i> , 2006, 22, 54-58.	0.8	8
3427	Cardioprotective medication use in hemodialysis patients. <i>Canadian Journal of Cardiology</i> , 2006, 22, 755-760.	0.8	39
3428	Surveillance and treatment of dyslipidemia in the post-infarct patient: Can a nurse-led management approach make a difference?. <i>Canadian Journal of Cardiology</i> , 2006, 22, 761-767.	0.8	18
3429	Lower is better: Implications of the Treating to New Targets (TNT) study for Canadian patients. <i>Canadian Journal of Cardiology</i> , 2006, 22, 835-839.	0.8	9
3430	Combination of statin and ezetimibe for the treatment of dyslipidemias and the prevention of coronary artery disease. <i>Canadian Journal of Cardiology</i> , 2006, 22, 863-868.	0.8	19
3431	The clinical effect and tolerability of ezetimibe in high-risk patients managed in a specialty cardiovascular risk reduction clinic. <i>Canadian Journal of Cardiology</i> , 2006, 22, 939-945.	0.8	8
3432	A comparison of Canadian and American guidelines for lipid management using data from the National Cholesterol Education Program Evaluation Project Utilizing Novel E-technology (NEPTUNE) II survey. <i>Canadian Journal of Cardiology</i> , 2006, 22, 315-322.	0.8	6
3433	The use of lipid-lowering therapy for secondary prevention in patients undergoing percutaneous coronary intervention. <i>Canadian Journal of Cardiology</i> , 2006, 22, 419-423.	0.8	2
3434	Profound regression of coronary atherosclerosis with statins. <i>Canadian Journal of Cardiology</i> , 2006, 22, 709.	0.8	1

#	ARTICLE	IF	CITATIONS
3435	PROVE-IT proved it: Lower is better – Pro. Canadian Journal of Cardiology, 2006, 22, 91B-94B.	0.8	1
3436	Prevention challenges: The era of atherosclerosis regression. Canadian Journal of Cardiology, 2006, 22, 27C-30C.	0.8	4
3437	Papel de la atorvastatina en la prevención del ictus. ¿Puede estar relacionado con su acción sobre la activación plaquetaria? Consideraciones basadas en nuestra propia experiencia. Hipertension, 2006, 23, 260-265.	0.0	2
3440	Importancia de la prevención cardiovascular en la diabetes mellitus: un reto pendiente. Clínica E Investigación En Arteriosclerosis, 2006, 18, 139-145.	0.4	0
3441	Efectividad de la combinación de atorvastatina 10 mg más ezetimiba en el control de la hipercolesterolemia en atención primaria. Clínica E Investigación En Arteriosclerosis, 2006, 18, 211-217.	0.4	0
3443	Controversia terapéutica: clopidogrel y estatinas. Clínica E Investigación En Arteriosclerosis, 2006, 18, 34-48.	0.4	0
3444	Statins: a preventive strike against sepsis in patients with cardiovascular disease?. Lancet, The, 2006, 367, 372-373.	6.3	18
3445	Are statins analogues of vitamin D?. Lancet, The, 2006, 368, 83-86.	6.3	82
3446	Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet, The, 2006, 368, 919-928.	6.3	369
3447	Japan: are statins still good for everybody?. Lancet, The, 2006, 368, 1135-1136.	6.3	10
3448	Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet, The, 2006, 368, 1155-1163.	6.3	856
3449	ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Journal of the American College of Cardiology, 2006, 48, e247-e346.	1.2	1,280
3450	Risks Associated With Statin Therapy. Circulation, 2006, 114, 2788-2797.	1.6	444
3451	Factores de riesgo en la enfermedad cardiovascular y la rehabilitación. Rehabilitación, 2006, 40, 282-289.	0.2	2
3452	Which progestogen is more likely to increase the risk of fatal myocardial infarction: A combination of epidemiological and trial evidence. Maturitas, 2006, 54, 154-163.	1.0	6
3454	Commentary on ‘‘Cytoskeletal modulators and pleiotropic strategies for Alzheimer drug discovery.’’ Atorvastatin’s effect in Alzheimer’s dementia (LEADe) study. , 2006, 2, 282-283.		1
3455	Plasma lipid, lipoprotein and apolipoprotein levels in a random population sample of 2875 Hong Kong Chinese adults and their implications (NCEP ATP-III, 2001 guidelines) on cardiovascular risk assessment. Atherosclerosis, 2006, 184, 438-445.	0.4	16
3456	Neither plasma coenzyme Q10 concentration, nor its decline during pravastatin therapy, is linked to recurrent cardiovascular disease events: A prospective case-control study from the LIPID study. Atherosclerosis, 2006, 187, 198-204.	0.4	22

#	ARTICLE	IF	CITATIONS
3457	Association of TNF- $\alpha$ serum levels and TNFA promoter polymorphisms with risk of myocardial infarction. <i>Atherosclerosis</i> , 2006, 187, 408-414.	0.4	84
3458	LDL-cholesterol lowering or HDL-cholesterol raising for cardiovascular prevention. <i>Atherosclerosis</i> , 2006, 186, 1-11.	0.4	43
3459	Phytosterols and vascular disease. <i>Atherosclerosis</i> , 2006, 186, 12-19.	0.4	178
3460	A triumvirate of targets in the prevention and treatment paradigm for cardiovascular disease. <i>Atherosclerosis Supplements</i> , 2006, 7, 21-29.	1.2	6
3461	Serum markers of vascular inflammation in dyslipemia. <i>Clinica Chimica Acta</i> , 2006, 369, 1-16.	0.5	47
3462	Effect of a clinical pharmacy service on lipid control in patients with peripheral arterial disease. <i>Journal of Vascular Surgery</i> , 2006, 43, 1205-1210.	0.6	20
3463	Statins and myotoxicity: a therapeutic limitation. <i>Expert Opinion on Drug Safety</i> , 2006, 5, 651-666.	1.0	70
3464	Role of Statins in Aortic Valve Disease. <i>Heart Failure Clinics</i> , 2006, 2, 395-413.	1.0	6
3465	Angina Pectoris: Evaluation in the Office. <i>Medical Clinics of North America</i> , 2006, 90, 391-416.	1.1	3
3466	Is There Evidence for the Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women?. <i>Gender Medicine</i> , 2006, 3, 5-12.	1.4	0
3467	Assessment of Progression and Regression of Coronary Atherosclerosis by Intravascular Ultrasound. A New Paradigm Shift?. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2006, 59, 57-66.	0.4	1
3468	HMG CoA Reductase Inhibitors and Impotence. <i>Drug Safety</i> , 2006, 29, 143-149.	1.4	30
3469	Overcoming ???Ageism??? Bias in the Treatment of Hypercholesterolaemia. <i>Drug Safety</i> , 2006, 29, 421-448.	1.4	48
3470	HMG-CoA Reductase Inhibitors in Chronic Heart Failure. <i>Drugs</i> , 2006, 66, 145-154.	4.9	25
3473	Atorvastatin Improves Left Ventricular Systolic Function and Serum Markers of Inflammation in Nonischemic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2006, 47, 332-337.	1.2	310
3474	Reduction in Ventricular Tachyarrhythmias With Statins in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. <i>Journal of the American College of Cardiology</i> , 2006, 47, 769-773.	1.2	169
3475	Number of Yellow Plaques Detected in a Coronary Artery Is Associated With Future Risk of Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2006, 47, 2194-2200.	1.2	398
3476	Efficacy and Safety in Clinical Trials in Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2006, 48, 430-433.	1.2	17



# ACC/AHA 2005 Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower) Tj ETQq0 0 0 rgBT /Overl...  
3477 Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular  
Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional



#	ARTICLE	IF	CITATIONS
3495	Persistence and adherence to cholesterol lowering agents: Evidence from R��gion de l'Assurance Maladie du Qu��bec data. <i>American Heart Journal</i> , 2006, 152, 164-169.	1.2	34
3496	Intravascular ultrasound assessment of novel antiatherosclerotic therapies: Rationale and design of the Acyl-CoA:Cholesterol Acyltransferase Intravascular Atherosclerosis Treatment Evaluation (ACTIVATE) Study. <i>American Heart Journal</i> , 2006, 152, 67-74.	1.2	27
3497	Intranasal continuous combined 17��-estradiol/norethisterone therapy improves the lipid profile in healthy postmenopausal women. <i>Fertility and Sterility</i> , 2006, 85, 979-988.	0.5	11
3498	The effect of different doses of fluvastatin on inflammatory markers in the early phase of acute coronary syndrome. <i>Clinica Chimica Acta</i> , 2006, 368, 183-187.	0.5	15
3499	Atorvastatin reduces plasminogen activator inhibitor-1 expression in adipose tissue of atherosclerotic rabbits. <i>Clinica Chimica Acta</i> , 2006, 370, 57-62.	0.5	22
3500	Statin-related adverse events: A meta-analysis. <i>Clinical Therapeutics</i> , 2006, 28, 26-35.	1.1	243
3501	Impact of rosuvastatin use on costs and outcomes in patients at high risk for cardiovascular disease in US managed care and medicare populations: A data analysis. <i>Clinical Therapeutics</i> , 2006, 28, 1425-1442.	1.1	7
3502	Expanding options with a wider range of rosuvastatin doses. <i>Clinical Therapeutics</i> , 2006, 28, 1747-1763.	1.1	6
3503	Effects of atorvastatin 10 mg/d on insulin resistance: A 12-week, open-label study in hyperlipidemic patients. <i>Current Therapeutic Research</i> , 2006, 67, 44-54.	0.5	2
3504	Effects of combination treatment with policosanol and omega-3 fatty acids on platelet aggregation: A randomized, double-blind clinical study. <i>Current Therapeutic Research</i> , 2006, 67, 174-192.	0.5	16
3505	Influences of age, sex, and LDL-C change on cardiovascular risk reduction with pravastatin treatment in elderly Japanese patients: A post hoc analysis of data from the Pravastatin Anti-atherosclerosis Trial in the Elderly (PATE). <i>Current Therapeutic Research</i> , 2006, 67, 241-256.	0.5	1
3506	Alteration in risk factor accumulations of acute myocardial infarction during the last one decade: Analysis of patients admitted in Coronary Care Unit. <i>Diabetes Research and Clinical Practice</i> , 2006, 71, 339-344.	1.1	2
3507	Determinants of the Differences in Ldl-Cholesterol After Initiation of Statin Treatment. <i>Annals of Pharmacotherapy</i> , 2006, 40, 21-26.	0.9	7
3508	PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS: How Their Effects on Macrophages Can Lead to the Development of a New Drug Therapy Against Atherosclerosis. <i>Annual Review of Pharmacology and Toxicology</i> , 2006, 46, 1-39.	4.2	67
3509	Lower Is Better-The Contemporary Concept of Low-Density Lipoprotein Lowering in the Preventive Management of Cardiovascular Risk: Does This Apply to All Patients?. <i>Preventive Cardiology</i> , 2006, 9, 219-227.	1.1	0
3510	Gender Differences in Adhering to National Guidelines in a Community Lipid Clinic. <i>Preventive Cardiology</i> , 2006, 9, 215-218.	1.1	3
3511	IDEAL and FIELD. <i>Preventive Cardiology</i> , 2006, 9, 115-120.	1.1	0
3512	Niacin-ER/Statin Combination for the Treatment of Dyslipidemia: Focus on Low High-Density Lipoprotein Cholesterol. <i>Journal of Clinical Hypertension</i> , 2006, 8, 493-501.	1.0	9

#	ARTICLE	IF	CITATIONS
3513	Behaviour of some indicators of oxidative stress in postmenopausal and fertile women. <i>Maturitas</i> , 2006, 53, 77-82.	1.0	123
3514	Effects of early administration of atorvastatin treatment on thrombotic process in normocholesterolemic patients with unstable angina. <i>International Journal of Cardiology</i> , 2006, 106, 333-337.	0.8	23
3515	Short- and long-term influence of diet and simvastatin on brachial artery endothelial function. <i>International Journal of Cardiology</i> , 2006, 107, 101-106.	0.8	8
3516	The impact of early administration of low-dose atorvastatin treatment on inflammatory process, in patients with unstable angina and low cholesterol level. <i>International Journal of Cardiology</i> , 2006, 109, 48-52.	0.8	38
3517	Effects of statins beyond lipid lowering: Potential for clinical benefits. <i>International Journal of Cardiology</i> , 2006, 109, 7-15.	0.8	121
3518	Key factors associated with the under-prescription of statins in elderly coronary heart disease patients: Results from the ELIAGE and ELICOEUR surveys. <i>International Journal of Cardiology</i> , 2006, 111, 12-18.	0.8	29
3519	The effect of atorvastatin on heart rate variability and lipoproteins in patients treated with coronary bypass surgery. <i>International Journal of Cardiology</i> , 2006, 111, 436-441.	0.8	14
3520	Coronary risk factors and inflammation in patients with coronary artery disease and internal cardioverter defibrillator implants. <i>International Journal of Cardiology</i> , 2006, 112, 72-79.	0.8	4
3521	Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an international, open-label program to assess the effectiveness of a single pill (amlodipine/atorvastatin) to attain recommended target levels for blood pressure and lipids (The JEWEL Program). <i>International Journal of Cardiology</i> , 2006, 110, 242-250.	0.8	25
3522	Immunomodulatory effects of statins and autoimmune rheumatic diseases: Novel intracellular mechanism involved. <i>International Immunopharmacology</i> , 2006, 6, 1833-1846.	1.7	24
3523	Plant stanols do not restore endothelial function in pre-pubertal children with familial hypercholesterolemia despite reduction of low-density lipoprotein cholesterol levels. <i>Journal of Pediatrics</i> , 2006, 148, 495-500.	0.9	64
3524	Childhood Obesity and the Metabolic Syndrome. <i>Advances in Pediatrics</i> , 2006, 53, 23-53.	0.5	19
3525	Impact of LDL-C lowering on recurrent cardiovascular events and hospitalization in secondary prevention in German clinical practice. <i>Prevention and Control: the Official Journal of the World Heart Federation</i> , 2006, 2, 5-14.	0.3	1
3526	Cholesterol lowering and mortality: Time for a new paradigm?. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2006, 16, 387-390.	1.1	14
3527	Red yeast rice stimulates bone formation in rats. <i>Nutrition Research</i> , 2006, 26, 124-129.	1.3	20
3528	Simvastatin and supplementation with $\omega$ -3 polyunsaturated fatty acids and vitamins improves claudication distance in a randomized PILOT study in patients with peripheral vascular disease. <i>Nutrition Research</i> , 2006, 26, 637-643.	1.3	11
3529	Spray-dried milk supplemented with $\gamma$ -linolenic acid or eicosapentaenoic acid and docosahexaenoic acid decreases HMG Co A reductase activity and increases biliary secretion of lipids in rats. <i>Steroids</i> , 2006, 71, 409-415.	0.8	32
3530	Applying pharmacogenomics to enhance the use of biomarkers for drug effect and drug safety. <i>Trends in Pharmacological Sciences</i> , 2006, 27, 498-502.	4.0	16

#	ARTICLE	IF	CITATIONS
3531	Dyslipidemia. , 2006, , 321-326.		0
3532	The Anti-Atherosclerotic Effects of Lipid Lowering with Atorvastatin in Patients with Hypercholesterolemia. <i>Journal of Atherosclerosis and Thrombosis</i> , 2006, 13, 216-219.	0.9	48
3533	Influence of 3-hydroxy-3-methylglutaryl Coenzyme A Reductase Inhibitors on Ubiquinone Levels in Rat Skeletal Muscle and Heart: Relationship to Cytotoxicity and Inhibitory Activity for Cholesterol Synthesis in Human Skeletal Muscle Cells. <i>Journal of Atherosclerosis and Thrombosis</i> , 2006, 13, 295-307.	0.9	19
3534	Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack. <i>Circulation</i> , 2006, 113, .	1.6	416
3535	Distinct Effects of Pravastatin, Atorvastatin, and Simvastatin on Insulin Secretion from a $\beta$ -cell Line, MIN6 Cells. <i>Journal of Atherosclerosis and Thrombosis</i> , 2006, 13, 329-335.	0.9	70
3536	Influences of Statins on Glucose Tolerance in Patients with Type 2 Diabetes Mellitus. <i>Journal of Atherosclerosis and Thrombosis</i> , 2006, 13, 95-100.	0.9	53
3537	Assessment of the longer-term effects of a dietary portfolio of cholesterol-lowering foods in hypercholesterolemia. <i>American Journal of Clinical Nutrition</i> , 2006, 83, 582-591.	2.2	160
3538	Treatment of Hyperlipidemia from Japanese Evidence. <i>Journal of Atherosclerosis and Thrombosis</i> , 2006, 13, 267-280.	0.9	20
3539	Statins: Beneficial or Adverse for Glucose Metabolism. <i>Journal of Atherosclerosis and Thrombosis</i> , 2006, 13, 123-129.	0.9	79
3540	Kaiser Permanente Colorado Region Pharmacy Department: Innovative Leader in Pharmacy Practice. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2006, 46, 67-76.	0.7	38
3541	Effect of Cardiac Rehabilitation and Statin Treatment on Anti-HSP Antibody Titers in Patients With Coronary Artery Disease After Percutaneous Coronary Intervention. <i>International Heart Journal</i> , 2006, 47, 671-682.	0.5	24
3542	Cholesterol-Years Score is Associated with Development of Senile Degenerative Aortic Stenosis in Heterozygous Familial Hypercholesterolemia. <i>Journal of Atherosclerosis and Thrombosis</i> , 2006, 13, 323-328.	0.9	12
3543	Physician Practice in the Discontinuation of Statins among Patients with Advanced Lung Cancer. <i>Journal of Palliative Care</i> , 2006, 22, 281-285.	0.4	18
3544	The challenge of tackling cardiovascular outcomes. <i>British Journal of Diabetes and Vascular Disease</i> , 2006, 6, S12-S16.	0.6	0
3545	Monitoring pharmaceutical interventions with IVUS. , 2006, , 451-463.		0
3546	A dual approach to cholesterol targets. <i>Practice Nursing</i> , 2006, 17, 144-148.	0.1	0
3548	Statins for Treatment of Dyslipidemia in Chronic Kidney Disease. <i>Peritoneal Dialysis International</i> , 2006, 26, 523-539.	1.1	65
3550	Effect of Combination Therapy With Simvastatin and Carvedilol in Patients With Left Ventricular Dysfunction Complicated With Acute Myocardial Infarction Who Underwent Percutaneous Coronary Intervention. <i>Circulation Journal</i> , 2006, 70, 1269-1274.	0.7	9

#	ARTICLE	IF	CITATIONS
3551	Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome (JAPAN-ACS) Rationale and Design. <i>Circulation Journal</i> , 2006, 70, 1624-1628.	0.7	33
3552	Pravastatin Use and the Five-year Incidence of Cancer in Coronary Heart Disease Patients: from the Prevention of Coronary Sclerosis Study. <i>Journal of Epidemiology</i> , 2006, 16, 201-206.	1.1	45
3553	Synthetic Peptide (P-21) Derived from Asp-Hemolysin Inhibits the Induction of Apoptosis on HUVECs by Lysophosphatidylcholine. <i>Biological and Pharmaceutical Bulletin</i> , 2006, 29, 907-910.	0.6	19
3554	Up-Coming Drugs. <i>Practice Nursing</i> , 2006, 17, 114-114.	0.1	0
3555	Statin therapy in cardiovascular disease. <i>British Journal of Cardiac Nursing</i> , 2006, 1, 270-277.	0.0	2
3556	Atorvastatin normalizes endothelial function in healthy smokers. <i>Clinical Science</i> , 2006, 111, 87-91.	1.8	25
3557	Multiple risk factor interventions for primary prevention of coronary heart disease. , 2006, , CD001561.		77
3558	Effect of Lipid Levels and Lipid-Lowering Therapy on Restenosis after Coronary Artery Stenting. <i>American Journal of the Medical Sciences</i> , 2006, 331, 270-273.	0.4	11
3560	Nutrition and Stroke Prevention. <i>Stroke</i> , 2006, 37, 2430-2435.	1.0	92
3561	The gap between theory and practice: what do the trials tell us?. <i>Country Review Ukraine</i> , 2006, 8, F10-F16.	0.8	0
3565	Simvastatin Versus Ezetimibe: Pleiotropic and Lipid-Lowering Effects on Endothelial Function in Humans. <i>Yearbook of Cardiology</i> , 2006, 2006, 343-345.	0.0	0
3566	Increased Introduction, Advertising, and Sales of Preventive Drugs During 1986-2002 in Sweden. <i>Journal of Ambulatory Care Management</i> , 2006, 29, 238-249.	0.5	5
3567	A Projection of the Impact of Lipid-Lowering Therapy on High-Risk Employee Disability and Medical Costs. <i>Journal of Occupational and Environmental Medicine</i> , 2006, 48, 1014-1022.	0.9	7
3568	Statin therapy for prevention and treatment of acute and chronic cardiovascular disease: update on recent trials and metaanalyses. <i>Current Opinion in Internal Medicine</i> , 2006, 5, 29-33.	1.5	9
3569	Pretreatment with Simvastatin Reduces Lung Injury Related to Intestinal Ischemia-Reperfusion in Rats. <i>Anesthesia and Analgesia</i> , 2006, 102, 225-232.	1.1	604
3570	Statins: are any questions unanswered?. <i>Current Opinion in Lipidology</i> , 2006, 17, 418-425.	1.2	10
3573	A randomized trial to assess the impact of opinion leader endorsed evidence summaries on the use of secondary prevention strategies in patients with coronary artery disease: the ESP-CAD trial protocol [NCT00175240]. <i>Implementation Science</i> , 2006, 1, 11.	2.5	17
3574	Lipid treatment strategies for metabolic syndrome in established cardiovascular disease: a consensus guideline. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2006, 23, 78-85.	0.2	1

#	ARTICLE	IF	CITATIONS
3575	A dietitian-led lipid clinic is effective. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2006, 23, 221-226.	0.2	5
3576	Treatment with statins after acute myocardial infarction in patients $\geq 80$ years: underuse despite general acceptance of drug therapy for secondary prevention. <i>Pharmacoepidemiology and Drug Safety</i> , 2006, 15, 261-267.	0.9	21
3577	Effect of intervention through a pharmaceutical care program on patient adherence with prescribed once-daily atorvastatin. <i>Pharmacoepidemiology and Drug Safety</i> , 2006, 15, 115-121.	0.9	72
3578	CHRONIC FLUVASTATIN TREATMENT ALTERS VASCULAR CONTRACTION BY INHIBITING THE RHO/RHO KINASE PATHWAY. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2006, 33, 673-678.	0.9	9
3579	Statins and the acute coronary syndrome: "the early bird catches the worm". <i>International Journal of Clinical Practice</i> , 2006, 60, 716-727.	0.8	4
3580	What's in the CARDS?. <i>Diabetic Medicine</i> , 2006, 23, 711-714.	1.2	2
3581	Proton pump inhibitors and acute interstitial nephritis: Report and analysis of 15 cases. <i>Nephrology</i> , 2006, 11, 381-385.	0.7	121
3582	Bringing Health Economic Modeling to the 21st Century. <i>Value in Health</i> , 2006, 9, 168-178.	0.1	16
3583	Endocrinology and Dialysis: Management of Lipid Abnormalities Associated with End-Stage Renal Disease. <i>Seminars in Dialysis</i> , 2006, 19, 391-401.	0.7	2
3584	Fluvastatin, HMG CoA Reductase Inhibitor: Antiatherogenic Profiles Through Its Lipid Lowering Dependent and Independent Actions. <i>Cardiovascular Drug Reviews</i> , 2000, 18, 284-303.	4.4	6
3585	Rosuvastatin: A Highly Effective New HMG CoA Reductase Inhibitor. <i>Cardiovascular Drug Reviews</i> , 2002, 20, 303-328.	4.4	160
3586	Development of Novel Water Soluble Phytostanol Analogs: Disodium Ascorbyl Phytostanyl Phosphates (FMVP4): Preclinical Pharmacology, Pharmacokinetics and Toxicology. <i>Cardiovascular Drug Reviews</i> , 2003, 21, 151-168.	4.4	11
3587	Pitavastatin: Efficacy and Safety Profiles of A Novel Synthetic HMG CoA Reductase Inhibitor. <i>Cardiovascular Drug Reviews</i> , 2003, 21, 199-215.	4.4	108
3588	Ezetimibe: A First Class, Novel Cholesterol Absorption Inhibitor. <i>Cardiovascular Drug Reviews</i> , 2003, 21, 293-312.	4.4	30
3589	Colesevelam: Potential Uses for the Newest Bile Resin. <i>Cardiovascular Drug Reviews</i> , 2005, 23, 15-30.	4.4	21
3590	Statins, Nitric Oxide and Neovascularization. <i>Cardiovascular Drug Reviews</i> , 2006, 23, 281-292.	4.4	21
3591	Hydroxymethylglutaryl-CoA Reductase Inhibitors in Older Persons with Acute Myocardial Infarction: Evidence for an Age-Related "Statin Interaction". <i>Journal of the American Geriatrics Society</i> , 2006, 54, 421-430.	1.3	71
3592	Lipid Lowering Reduces Proteolytic and Prothrombotic Potential in Rabbit Atheroma. <i>Annals of the New York Academy of Sciences</i> , 2000, 902, 140-152.	1.8	38

#	ARTICLE	IF	CITATIONS
3593	Human Acyl-CoA:cholesterol Acyltransferase (ACAT) and its Potential as a Target for Pharmaceutical Intervention against Atherosclerosis. <i>Acta Biochimica Et Biophysica Sinica</i> , 2006, 38, 151-156.	0.9	45
3594	Effects of simvastatin withdrawal on serum matrix metalloproteinases in hypercholesterolaemic patients. <i>European Journal of Clinical Investigation</i> , 2006, 36, 76-84.	1.7	21
3595	Statin therapy in patients with chronic kidney disease: to use or not to use. <i>European Journal of Clinical Investigation</i> , 2006, 36, 519-527.	1.7	10
3596	Composition of coronary plaques obtained by directional atherectomy in stable angina: its relation to serum lipids and statin treatment. <i>Journal of Internal Medicine</i> , 2006, 259, 267-275.	2.7	19
3597	Genetically determined apo B levels and peak LDL density predict angiographic response to intensive lipid-lowering therapy. <i>Journal of Internal Medicine</i> , 2006, 259, 401-409.	2.7	13
3598	Who should receive a statin these days? Lessons from recent clinical trials. <i>Journal of Internal Medicine</i> , 2006, 260, 305-319.	2.7	46
3599	The implications of a growing evidence base for drug use in elderly patients. Part 1. Statins for primary and secondary cardiovascular prevention. <i>British Journal of Clinical Pharmacology</i> , 2006, 61, 494-501.	1.1	19
3600	Prescribing behaviour according to Dutch and European guidelines on the management of hypercholesterolaemia (1992-1999). <i>British Journal of Clinical Pharmacology</i> , 2006, 61, 592-600.	1.1	8
3601	Use of hydroxy-methyl-glutaryl coenzyme A reductase inhibitors is associated with risk of lymphoid malignancies. <i>Cancer Science</i> , 2006, 97, 133-138.	1.7	36
3602	Proton NMR analysis of plasma is a weak predictor of coronary artery disease. <i>Nature Medicine</i> , 2006, 12, 705-710.	15.2	155
3603	Application of intravascular ultrasound in anti-atherosclerotic drug development. <i>Nature Reviews Drug Discovery</i> , 2006, 5, 485-492.	21.5	43
3604	The immune response in atherosclerosis: a double-edged sword. <i>Nature Reviews Immunology</i> , 2006, 6, 508-519.	10.6	1,890
3605	Pretreatment with simvastatin reduces myocardial no-reflow by opening mitochondrial KATP channel. <i>British Journal of Pharmacology</i> , 2006, 149, 243-249.	2.7	43
3606	High-density lipoproteins: an emerging target in the prevention of cardiovascular disease. <i>Cell Research</i> , 2006, 16, 799-808.	5.7	19
3607	Statins: another class of antihypertensive agents?. <i>Journal of Human Hypertension</i> , 2006, 20, 320-335.	1.0	55
3608	Redefinition of uremic cardiomyopathy by contrast-enhanced cardiac magnetic resonance imaging. <i>Kidney International</i> , 2006, 69, 1839-1845.	2.6	220
3609	Management of hyperlipidemia in patients on peritoneal dialysis: Current approaches. <i>Kidney International</i> , 2006, 70, S115-S117.	2.6	20
3610	Effect of statins and white blood cell count on mortality in patients with ischemic left ventricular dysfunction undergoing percutaneous coronary intervention. <i>Clinical Cardiology</i> , 2006, 29, 36-41.	0.7	9

#	ARTICLE	IF	CITATIONS
3611	Insufficient treatment of hypercholesterolemia among patients hospitalized with chest pain. <i>Clinical Cardiology</i> , 2006, 29, 259-262.	0.7	6
3612	The effects of atorvastatin on coronary endothelial function in patients with recent myocardial infarction. <i>Clinical Cardiology</i> , 2006, 29, 357-362.	0.7	11
3613	Effect of atorvastatin withdrawal on circulating coenzyme Q <sub>10</sub> concentration in patients with hypercholesterolemia. <i>BioFactors</i> , 2006, 28, 177-184.	2.6	22
3614	A review of health care models for coronary heart disease interventions. <i>Health Care Management Science</i> , 2006, 9, 311-324.	1.5	27
3615	Arterial wall cholesterol content is a predictor of development and severity of arterial thrombosis. <i>Journal of Thrombosis and Thrombolysis</i> , 2006, 22, 5-11.	1.0	13
3616	Cholesterol, C-reactive protein, and cerebrovascular events following intensive and moderate statin therapy. <i>Journal of Thrombosis and Thrombolysis</i> , 2006, 22, 71-76.	1.0	24
3617	Safety of Nifedipine GITS in Stable Angina: The ACTION Trial. <i>Cardiovascular Drugs and Therapy</i> , 2006, 20, 45-54.	1.3	25
3618	Prognosis at 6 Months for Coronary and Cerebrovascular Patients: Impact of Antiplatelet Agents and Statins: Results from the Prevenir III Study. <i>Cardiovascular Drugs and Therapy</i> , 2006, 20, 55-61.	1.3	6
3619	Correlation Between Inflammation and Oxidative Stress in Normocholesterolemic Coronary Artery Disease Patients on <sup>TM</sup> and off <sup>TM</sup> Atorvastatin for Short Time Intervals. <i>Cardiovascular Drugs and Therapy</i> , 2006, 20, 37-44.	1.3	16
3620	Pravastatin Prevents Myocardium from Ischemia-Induced Fibrosis by Protecting Vascular Endothelial Cells Exposed to Oxidative Stress. <i>Cardiovascular Drugs and Therapy</i> , 2006, 20, 273-280.	1.3	14
3621	Low density lipoprotein cholesterol, statins and cardiovascular events: a meta-analysis. <i>Clinical Research in Cardiology</i> , 2006, 95, 393-404.	1.5	57
3623	Statins: the next step in adjuvant therapy for sepsis?. <i>Intensive Care Medicine</i> , 2006, 32, 11-14.	3.9	26
3624	Effects of simvastatin on cardiohemodynamic responses to ischemia-reperfusion in isolated rat hearts. <i>Heart and Vessels</i> , 2006, 21, 116-123.	0.5	13
3625	Preprocedural statin therapy reduces the risk and extent of cardiac biomarker release following percutaneous coronary intervention. <i>Heart and Vessels</i> , 2006, 21, 146-151.	0.5	27
3626	The effect of early statin treatment on inflammation and cardiac events in acute coronary syndrome patients with low-density lipoprotein cholesterol. <i>Heart and Vessels</i> , 2006, 21, 291-297.	0.5	24
3627	Effect of pravastatin on plasma sterols and oxysterols in men. <i>European Journal of Clinical Pharmacology</i> , 2006, 62, 9-14.	0.8	29
3628	Concomitant Detection of Systemic Atherosclerotic Disease while Screening for Abdominal Aortic Aneurysm. <i>World Journal of Surgery</i> , 2006, 30, 1350-1359.	0.8	9
3629	Digami too?. <i>Diabetologia</i> , 2006, 49, 1134-1137.	2.9	6



#	ARTICLE	IF	CITATIONS
3631	Low-density lipoprotein cholesterol lowering in the prevention of CHD: How low should we go?. Current Treatment Options in Cardiovascular Medicine, 2006, 8, 289-297.	0.4	7
3632	Implications of changing national cholesterol education program goals for the treatment and control of hypercholesterolemia. Journal of General Internal Medicine, 2006, 21, 171-176.	1.3	24
3633	Statin therapy for coronary heart disease and its effect on stroke. Current Atherosclerosis Reports, 2006, 8, 337-342.	2.0	3
3634	Are lower levels of low-density lipoprotein cholesterol beneficial? A review of recent data. Current Atherosclerosis Reports, 2006, 8, 382-389.	2.0	1
3635	Optimal low-density lipoprotein levels: Evidence from epidemiology and clinical trials. Current Atherosclerosis Reports, 2006, 8, 157-162.	2.0	3
3637	Effective use of combination lipid therapy. Current Atherosclerosis Reports, 2006, 8, 76-84.	2.0	12
3638	Diabetes and stroke: Part one—Risk factors and pathophysiology. Current Cardiology Reports, 2006, 8, 23-28.	1.3	27
3639	Reduction of cardiovascular risk and mortality: A population-based approach. Advances in Therapy, 2006, 23, 905-920.	1.3	8
3640	Advance in basic and clinical research of Xuezhikang Capsule. Chinese Journal of Integrative Medicine, 2006, 12, 85-93.	0.7	5
3641	Review article: The role of statins in reducing perioperative cardiac risk: physiologic and clinical perspectives. Canadian Journal of Anaesthesia, 2006, 53, 1126-1147.	0.7	17
3642	Pharmacogenetics of multigenic disease: Heart disease as an example. Vascular Pharmacology, 2006, 44, 66-74.	1.0	11
3643	Pharmacogenomics of cholesterol-lowering therapy. Vascular Pharmacology, 2006, 44, 75-89.	1.0	75
3644	Statins in rheumatology. Joint Bone Spine, 2006, 73, 159-168.	0.8	12
3645	Pharmacological characterization in vitro of EP2306 and EP2302, potent inhibitors of squalene synthase and lipid biosynthesis. European Journal of Pharmacology, 2006, 535, 34-42.	1.7	27
3646	Pactimibe stabilizes atherosclerotic plaque through macrophage acyl-CoA:cholesterol acyltransferase inhibition in WHHL rabbits. European Journal of Pharmacology, 2006, 539, 81-88.	1.7	15
3647	Multiple mechanisms of hypocholesterolemic action of pactimibe, a novel acyl-coenzyme A:cholesterol acyltransferase inhibitor. European Journal of Pharmacology, 2006, 543, 123-132.	1.7	9
3648	Managing Risk Factors for Atherosclerosis in Critical Limb Ischaemia. European Journal of Vascular and Endovascular Surgery, 2006, 32, 478-483.	0.8	27
3649	Comparative Safety of Atorvastatin 80 mg Versus 10 mg Derived from Analysis of 49 Completed Trials in 14,236 Patients. American Journal of Cardiology, 2006, 97, 61-67.	0.7	203

#	ARTICLE	IF	CITATIONS
3650	Potential Impact on Cardiovascular Public Health of Over-the-Counter Statin Availability. American Journal of Cardiology, 2006, 97, 851-856.	0.7	15
3651	Statins, Cardiovascular Disease, and Drug Safety. American Journal of Cardiology, 2006, 97, S3-S5.	0.7	50
3652	Statin Safety: An Overview and Assessment of the Data—2005. American Journal of Cardiology, 2006, 97, S6-S26.	0.7	226
3653	Statin Safety: Lessons from New Drug Applications for Marketed Statins. American Journal of Cardiology, 2006, 97, S44-S51.	0.7	122
3654	Statin Safety: An Assessment Using an Administrative Claims Database. American Journal of Cardiology, 2006, 97, S61-S68.	0.7	111
3655	Benefit versus Risk in Statin Treatment. American Journal of Cardiology, 2006, 97, S95-S97.	0.7	63
3656	An Assessment of Statin Safety by Neurologists. American Journal of Cardiology, 2006, 97, S86-S88.	0.7	38
3657	What the Statin Trials Have Taught Us. American Journal of Cardiology, 2006, 98, 129-134.	0.7	29
3658	Rationale for the Revascularization Arm of the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. American Journal of Cardiology, 2006, 97, 31-40.	0.7	25
3659	Impact of Low High-Density Lipoproteins on In-Hospital Events and One-Year Clinical Outcomes in Patients With Non-ST-Elevation Myocardial Infarction Acute Coronary Syndrome Treated With Drug-Eluting Stent Implantation. American Journal of Cardiology, 2006, 98, 711-717.	0.7	72
3660	Identifying Patients for Aggressive Cholesterol Lowering: The Risk Curve Concept. American Journal of Cardiology, 2006, 98, 1405-1408.	0.7	43
3661	Relation Between Plaque Progression and Low-Density Lipoprotein Cholesterol During Aging as Assessed With Serial Long-Term (≈12 Months) Follow-Up Intravascular Ultrasound of the Left Main Coronary Artery. American Journal of Cardiology, 2006, 98, 1419-1423.	0.7	19
3663	Pathophysiology, Diagnosis, and Management of Dyslipidemia. Current Problems in Cardiology, 2006, 31, 445-486.	1.1	29
3664	Statins and the vasculopathy of systemic sclerosis: Potential therapeutic agents?. Autoimmunity Reviews, 2006, 5, 25-32.	2.5	35
3665	Fundamentos del tratamiento farmacológico actual de la cardiopatía isquémica. Revista Espanola De Cardiologia Suplementos, 2006, 6, 31A-40A.	0.2	0
3667	Poor Short-Term Survival and Low Use of Cardiovascular Medications in Elderly Dialysis Patients After Acute Myocardial Infarction. American Journal of Kidney Diseases, 2006, 47, 301-308.	2.1	59
3668	The Second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: A Randomized Controlled Study of the Biochemical Safety and Efficacy of Adding Ezetimibe to Simvastatin as Initial Therapy Among Patients With CKD. American Journal of Kidney Diseases, 2006, 47, 385-395.	2.1	104
3669	The Nonlipid Effects of Statins on Endothelial Function. Trends in Cardiovascular Medicine, 2006, 16, 156-162.	2.3	59

#	ARTICLE	IF	CITATIONS
3670	Statins in the treatment of central nervous system autoimmune disease. <i>Journal of Neuroimmunology</i> , 2006, 178, 140-148.	1.1	59
3671	Preoperative statin treatment is associated with reduced postoperative mortality and morbidity in patients undergoing cardiac surgery: An 8-year retrospective cohort study. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2006, 131, 679-685.	0.4	97
3672	Dose-dependent cholesterol-lowering effect of a mayonnaise-type product with a main component of diacylglycerol-containing plant sterol esters. <i>Nutrition</i> , 2006, 22, 174-178.	1.1	22
3673	Pharmacological regulation of low density lipoprotein receptor expression: Current status and future developments. , 2006, 111, 424-433.		14
3674	Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: Drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. , 2006, 112, 71-105.		501
3675	Secretory phospholipase A2 of group IIA: Is it an offensive or a defensive player during atherosclerosis and other inflammatory diseases?. <i>Prostaglandins and Other Lipid Mediators</i> , 2006, 79, 1-33.	1.0	114
3676	Revascularization and cardioprotective drug treatment in myocardial infarction patients: how do they impact on patients' survival when delivered as usual care. <i>BMC Cardiovascular Disorders</i> , 2006, 6, 21.	0.7	4
3677	Management of acute myocardial infarction. <i>Medicine</i> , 2006, 34, 188-194.	0.2	2
3678	Analysis of five HMG-CoA reductase inhibitors— atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies. <i>Biomedical Chromatography</i> , 2006, 20, 282-293.	0.8	91
3679	Statins as antiinflammatory and immunomodulatory agents: A future in rheumatologic therapy?. <i>Arthritis and Rheumatism</i> , 2006, 54, 393-407.	6.7	127
3680	Inhibition of systemic sclerosis dermal fibroblast type I collagen production and gene expression by simvastatin. <i>Arthritis and Rheumatism</i> , 2006, 54, 1298-1308.	6.7	45
3681	In vivo and in vitro characterization of skeletal muscle metabolism in patients with statin-induced adverse effects. <i>Arthritis and Rheumatism</i> , 2006, 55, 551-557.	6.7	59
3682	Plasma cholesterol is hyperresponsive to statin in ABCG5/ABCG8 transgenic mice. <i>Hepatology</i> , 2006, 44, 1259-1266.	3.6	23
3683	Update on lipid-lowering therapy and LDL-cholesterol targets. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2006, 3, 424-436.	3.3	8
3684	The Power of Pharmacological Sciences: The Example of Proton Pump Inhibitors. <i>Pharmacology</i> , 2006, 76, 148-156.	0.9	7
3685	The Heart of Drug Discovery and Development: Rational Target Selection. <i>Pharmacology</i> , 2006, 77, 85-92.	0.9	8
3686	Low-Density Lipoprotein-Lowering Medication and Platelet Function. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2006, 35, 346-354.	0.5	23
3687	Statin Use and Sex-Specific Stroke Outcomes in Patients With Vascular Disease. <i>Stroke</i> , 2006, 37, 1427-1431.	1.0	45

#	ARTICLE	IF	CITATIONS
3688	Statin Treatment Is Not Associated With Consistent Alterations in Inflammatory Status of Carotid Atherosclerotic Plaques. <i>Stroke</i> , 2006, 37, 2054-2060.	1.0	54
3689	Intensive statin therapy for treating acute coronary syndromes. <i>Expert Opinion on Investigational Drugs</i> , 2006, 15, 1151-1159.	1.9	3
3690	Pharmacoeconomic considerations with statin therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 1291-1304.	0.9	6
3691	Does statin therapy improve cardiovascular outcomes in patients with type 2 diabetes receiving hemodialysis?. <i>Nature Clinical Practice Nephrology</i> , 2006, 2, 76-77.	2.0	8
3692	Lipid-lowering effects of statins: a comparative review. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 1701-1714.	0.9	47
3693	Adjunctive Pharmacologic Use in Carotid Endarterectomy: A Review. <i>Vascular</i> , 2006, 14, 93-102.	0.4	2
3694	Management of Dyslipidemia in Special Populations. <i>Journal of Pharmacy Practice</i> , 2006, 19, 63-78.	0.5	1
3695	Thematic review series: The Pathogenesis of Atherosclerosis. An interpretive history of the cholesterol controversy, part V: The discovery of the statins and the end of the controversy. <i>Journal of Lipid Research</i> , 2006, 47, 1339-1351.	2.0	172
3696	Drug Insight: immunomodulatory effects of statinsâ€™ potential benefits for renal patients?. <i>Nature Clinical Practice Nephrology</i> , 2006, 2, 378-387.	2.0	31
3697	Low-dose simvastatin improves survival and ventricular function via eNOS in congestive heart failure. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2006, 291, H2743-H2751.	1.5	30
3698	The Argument Against the Appropriateness of Over-the-Counter Statins. <i>Circulation</i> , 2006, 114, 1315-1320.	1.6	9
3699	Does CPAP delay the development of cardiovascular disease in patients with obstructive sleep apnoea hypopnoea?. <i>Thorax</i> , 2006, 61, 459-460.	2.7	7
3700	Potent Reduction of Apolipoprotein B and Low-Density Lipoprotein Cholesterol by Short-Term Administration of an Antisense Inhibitor of Apolipoprotein B. <i>Circulation</i> , 2006, 114, 1729-1735.	1.6	335
3701	Fluvastatin Ameliorates Podocyte Injury in Proteinuric Rats via Modulation of Excessive Rho Signaling. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 754-764.	3.0	108
3702	Potential therapeutic role for statins in respiratory disease. <i>Thorax</i> , 2006, 61, 729-734.	2.7	162
3703	Cholesterol Primes Vascular Smooth Muscle to Induce Ca <sup>2+</sup> Sensitization Mediated by a Sphingosylphosphorylcholineâ€™Rho-Kinase Pathway. <i>Circulation Research</i> , 2006, 99, 299-306.	2.0	56
3704	Statins in the Treatment of Chronic Heart Failure: A Systematic Review. <i>PLoS Medicine</i> , 2006, 3, e333.	3.9	44
3705	Antiatherosclerotic Effect of <i>Caparis decidua</i> . Fruit Extract in Cholesterol-fed Rabbits. <i>Pharmaceutical Biology</i> , 2006, 44, 172-177.	1.3	20

#	ARTICLE	IF	CITATIONS
3706	A Systems Biology Strategy Reveals Biological Pathways and Plasma Biomarker Candidates for Potentially Toxic Statin-Induced Changes in Muscle. <i>PLoS ONE</i> , 2006, 1, e97.	1.1	202
3707	Pharmacology and Statistics: Recommendations to Strengthen a Productive Partnership. <i>Pharmacology</i> , 2006, 78, 113-122.	0.9	13
3708	New anti-inflammatory agents to reduce atherosclerosis. <i>Archives of Physiology and Biochemistry</i> , 2006, 112, 130-137.	1.0	3
3709	Lipid Testing and Lipid-Lowering Therapy in Hospitalized Ischemic Stroke and Transient Ischemic Attack Patients. <i>Stroke</i> , 2006, 37, 44-49.	1.0	32
3710	Stroke Prevention and Statin Treatment. <i>Clinical and Experimental Hypertension</i> , 2006, 28, 335-344.	0.5	7
3711	Evidence-Based Prescribing of Statins: A Developing World Perspective. <i>PLoS Medicine</i> , 2006, 3, e50.	3.9	10
3713	The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes. <i>Circulation</i> , 2006, 114, 2871-2891.	1.6	109
3714	Noninvasive Screening for Coronary Artery Disease With Computed Tomography Is Useful. <i>Circulation</i> , 2006, 113, 125-146.	1.6	47
3715	Lipid-lowering therapy in type 2 diabetes: a review of the evidence. <i>Diabetes and Vascular Disease Research</i> , 2006, 3, S10-S15.	0.9	0
3716	Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine. <i>Journal of Lipid Research</i> , 2006, 47, 1281-1288.	2.0	290
3717	Review: PROactive O3: Pioglitazone, type 2 diabetes and reducing macrovascular events – economic implications?. <i>British Journal of Diabetes and Vascular Disease</i> , 2006, 6, 63-70.	0.6	7
3718	Protecting the Heart with Cardiac Medication in Patients with Left Ventricular Dysfunction Undergoing Major Noncardiac Vascular Surgery. <i>Seminars in Cardiothoracic and Vascular Anesthesia</i> , 2006, 10, 25-31.	0.4	28
3719	Oxidative Stress and Vascular Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 689-695.	1.1	180
3720	Statins Activate AMP-Activated Protein Kinase In Vitro and In Vivo. <i>Circulation</i> , 2006, 114, 2655-2662.	1.6	234
3721	What do lupus specialists believe about managing conventional cardiovascular risk factors in patients with systemic lupus erythematosus?. <i>Lupus</i> , 2006, 15, 697-699.	0.8	4
3722	Navigating the Crossroads of Coronary Artery Disease and Heart Failure. <i>Circulation</i> , 2006, 114, 1202-1213.	1.6	320
3723	Review: Comparing cardiovascular outcomes in diabetes studies. <i>British Journal of Diabetes and Vascular Disease</i> , 2006, 6, 111-118.	0.6	4
3724	Simvastatin–Amiodarone Interaction Resulting in Rhabdomyolysis, Azotemia, and Possible Hepatotoxicity. <i>Annals of Pharmacotherapy</i> , 2006, 40, 753-757.	0.9	62

#	ARTICLE	IF	CITATIONS
3725	ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. <i>Circulation</i> , 2006, 114, e385-484.	1.6	1,031
3726	Ezetimibe added to ongoing statin therapy improves LDL-C goal attainment and lipid profile in patients with diabetes or metabolic syndrome. <i>Diabetes and Vascular Disease Research</i> , 2006, 3, 93-102.	0.9	65
3727	Polypill Strategy vs. Prevention Clinics for Stroke Prevention. <i>Cerebrovascular Diseases</i> , 2006, 21, 35-40.	0.8	13
3728	Clinical Trials in the Wake of Vioxx. <i>Circulation</i> , 2006, 113, 2253-2259.	1.6	25
3729	Gap between guidelines and practice: attainment of treatment targets in patients with primary hypercholesterolemia starting statin therapy. Results of the 4E-Registry (Efficacy Calculation and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	3.1	33
3730	What's New? Guidelines and Goals. <i>Journal of Pharmacy Practice</i> , 2006, 19, 103-112.	0.5	0
3731	The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes. <i>Circulation</i> , 2006, 114, 2850-2870.	1.6	346
3732	Statin Use and Cancer Risk: An Epidemiologic Review. <i>Cancer Investigation</i> , 2006, 24, 413-424.	0.6	24
3733	Investigating the association between influenza vaccination and reduced stroke risk. <i>Expert Review of Vaccines</i> , 2006, 5, 535-540.	2.0	6
3734	Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: metaanalysis of randomised controlled trials. <i>BMJ: British Medical Journal</i> , 2006, 332, 1115-1124.	2.4	270
3735	Drug Insight: statin use in the elderly. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2006, 3, 318-328.	3.3	13
3736	Statin-Induced Myopathy: The Two Faces of Janus. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2006, 11, 105-112.	1.0	41
3737	The importance of total cardiovascular risk assessment in clinical practice. <i>European Journal of General Practice</i> , 2006, 12, 148-155.	0.9	26
3738	Simvastatin Treatment Ameliorates Autoimmune Disease Associated with Accelerated Atherosclerosis in a Murine Lupus Model. <i>Journal of Immunology</i> , 2006, 177, 3028-3034.	0.4	88
3739	Effectiveness calculation in economic analysis: the case of statins for cardiovascular disease prevention. <i>Journal of Epidemiology and Community Health</i> , 2006, 60, 839-845.	2.0	9
3740	Statins in stroke: prevention, protection and recovery. <i>Expert Review of Neurotherapeutics</i> , 2006, 6, 195-202.	1.4	22
3741	Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. <i>European Heart Journal</i> , 2006, 27, 1153-1158.	1.0	268
3743	Evaluation of patient and provider satisfaction with a pharmacist-managed lipid clinic in a Veterans Affairs medical center. <i>American Journal of Health-System Pharmacy</i> , 2006, 63, 1723-1727.	0.5	29

#	ARTICLE	IF	CITATIONS
3744	Statins and the Risk of Lung, Breast, and Colorectal Cancer in the Elderly. <i>Circulation</i> , 2007, 115, 27-33.	1.6	145
3745	ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction. <i>Circulation</i> , 2007, 116, e148-304.	1.6	1,247
3746	Effectiveness of rosuvastatin versus atorvastatin in reducing lipid levels and achieving low-density-lipoprotein cholesterol goals in a usual care setting. <i>American Journal of Health-System Pharmacy</i> , 2007, 64, 276-284.	0.5	16
3747	Potential of non-antiarrhythmic drugs to provide an innovative upstream approach to the pharmacological prevention of sudden cardiac death. <i>Expert Opinion on Investigational Drugs</i> , 2007, 16, 605-623.	1.9	16
3748	Exploring the natural history of atherosclerosis with intravascular ultrasound. <i>Expert Review of Cardiovascular Therapy</i> , 2007, 5, 295-306.	0.6	7
3749	Inhibition of Cholesterol Biosynthesis, the Discovery of the Statins, and a Revolution in Preventive Cardiology. , 2007, , 171-193.		2
3750	Improvement of myocardial blood flow by lipid-lowering therapy with pravastatin is modulated by apolipoprotein E genotype. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2007, 67, 723-734.	0.6	10
3751	Risk of Myocardial Infarction or Vascular Death After First Ischemic Stroke. <i>Stroke</i> , 2007, 38, 1752-1758.	1.0	120
3752	Inequalities in the primary care of patients with coronary heart disease and serious mental health problems: a cross-sectional study. <i>Heart</i> , 2007, 93, 1256-1262.	1.2	85
3753	Coronary heart disease and the management of risk: Patient perspectives of outcomes associated with the clinical implementation of the National Service Framework targets. <i>Health, Risk and Society</i> , 2007, 9, 359-373.	0.9	9
3754	Effect of pravastatin on sympathetic reinnervation in postinfarcted rats. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2007, 293, H3617-H3626.	1.5	23
3755	Preprocedural Statin Therapy in Percutaneous Coronary Intervention. <i>Annals of Pharmacotherapy</i> , 2007, 41, 1687-1693.	0.9	12
3756	Statins prevent cholinesterase inhibitor blockade of sympathetic $\alpha_7$ -nAChR-mediated currents in rat superior cervical ganglion neurons. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2007, 293, H1737-H1744.	1.5	24
3757	The development of heart failure in patients with stable angina pectoris. <i>European Journal of Heart Failure</i> , 2007, 9, 234-242.	2.9	3
3758	Early changes in coronary artery wall structure detected by microcomputed tomography in experimental hypercholesterolemia. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2007, 293, H1997-H2003.	1.5	19
3760	Should women be offered cholesterol lowering drugs to prevent cardiovascular disease? No. <i>BMJ: British Medical Journal</i> , 2007, 334, 983-983.	2.4	24
3761	Should women be offered cholesterol lowering drugs to prevent cardiovascular disease? Yes. <i>BMJ: British Medical Journal</i> , 2007, 334, 982-982.	2.4	16
3762	Is it Time for a Cardiovascular Primary Prevention Trial in the Elderly?. <i>Stroke</i> , 2007, 38, 441-450.	1.0	55

#	ARTICLE	IF	CITATIONS
3763	Revascularization Compared to Medical Treatment in Patients with Silent vs. Symptomatic Residual Ischemia after Thrombolyzed Myocardial Infarction – The DANAMI Study. <i>Cardiology</i> , 2007, 108, 243-251.	0.6	15
3764	Effects of Pitavastatin on Adiponectin in Patients with Hyperlipidemia. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2007, 36, 1-8.	0.5	39
3765	Diabetes and residual risk of coronary heart disease. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2007, 3, 71-71.	2.9	2
3766	Mechanisms of action of statins in stroke. <i>Expert Opinion on Therapeutic Targets</i> , 2007, 11, 273-278.	1.5	14
3767	Clinical efficacy and cost-effectiveness of rosuvastatin. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2007, 7, 31-39.	0.7	0
3768	Endothelial nitric oxide synthase gene: prospects for treatment of heart disease. <i>Pharmacogenomics</i> , 2007, 8, 1723-1734.	0.6	48
3770	Pitavastatin: efficacy and safety in intensive lipid lowering. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 2315-2327.	0.9	54
3771	Mendelian randomization as an instrumental variable approach to causal inference. <i>Statistical Methods in Medical Research</i> , 2007, 16, 309-330.	0.7	670
3772	Statin therapy in South-Asian patients: clinical implications beyond lipid lowering?. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 1235-1243.	0.9	8
3773	Drug Insight: statins for nonischemic heart failure—evidence and potential mechanisms. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2007, 4, 196-205.	3.3	25
3774	ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: Executive Summary. <i>Circulation</i> , 2007, 116, 803-877.	1.6	177
3775	Use of Lipid-Lowering Agents for the Prevention of Age-Related Macular Degeneration: A Meta-Analysis of Observational Studies. <i>Ophthalmic Epidemiology</i> , 2007, 14, 367-374.	0.8	33
3776	Acute Coronary Care in the Elderly, Part II. <i>Circulation</i> , 2007, 115, 2570-2589.	1.6	489
3777	Statins and Children. <i>Circulation</i> , 2007, 116, 594-595.	1.6	21
3778	Adherence to Statin Therapy Under Drug Cost Sharing in Patients With and Without Acute Myocardial Infarction. <i>Circulation</i> , 2007, 115, 2128-2135.	1.6	112
3779	The Unique Character of Cardiovascular Disease in Chronic Kidney Disease and Its Implications for Treatment with Lipid-Lowering Drugs. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2007, 2, 766-785.	2.2	30
3780	Impact of Statins on Risk of Stroke: A Meta-Analysis. <i>Annals of Pharmacotherapy</i> , 2007, 41, 1937-1945.	0.9	18
3781	Statin Therapy for Secondary Stroke Prevention: Evidence Catches Up to Practice. <i>Journal of Pharmacy Practice</i> , 2007, 20, 117-122.	0.5	0



#	ARTICLE	IF	CITATIONS
3782	To what extent do patients in general practice reach guideline lipid-lowering treatment goals?. European Journal of Cardiovascular Prevention and Rehabilitation, 2007, 14, 149-151.	3.1	3
3783	Clinical pharmacy cardiac risk service for managing patients with coronary artery disease in a health maintenance organization. American Journal of Health-System Pharmacy, 2007, 64, 77-84.	0.5	28
3784	Pravastatin Enhances Beneficial Effects of Olmesartan on Vascular Injury of Salt-Sensitive Hypertensive Rats, via Pleiotropic Effects. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 556-563.	1.1	70
3785	Effect of Rosuvastatin on Outcomes in Chronic Haemodialysis Patients: Baseline Data from the AURORA Study. Kidney and Blood Pressure Research, 2007, 30, 314-322.	0.9	56
3786	A comprehensive view of sex-specific issues related to cardiovascular disease. Cmaj, 2007, 176, S1-S44.	0.9	348
3787	Rosiglitazone and cardiovascular disease: an epidemiologist's perspective. Diabetes and Vascular Disease Research, 2007, 4, 77-79.	0.9	4
3788	Comparison of intensive and low-dose atorvastatin therapy in the reduction of carotid intimal-medial thickness in patients with coronary heart disease. Heart, 2007, 93, 933-939.	1.2	62
3789	Statins in elderly patients with acute coronary syndrome: an analysis of dose and class effects in typical practice. Heart, 2007, 93, 945-951.	1.2	23
3790	The Immune Response Is Involved in Atherosclerotic Plaque Calcification: Could the RANKL/RANK/OPG System Be a Marker of Plaque Instability?. Clinical and Developmental Immunology, 2007, 2007, 1-8.	3.3	50
3791	Action on Vascular Risk Factors: Importance of Blood Pressure and Lipid Lowering in Stroke Secondary Prevention. Cerebrovascular Diseases, 2007, 24, 96-106.	0.8	8
3792	Fluvastatin Alters Platelet Aggregability in Patients With Hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 1471-1477.	1.1	65
3793	Usefulness of Hydrophilic vs Lipophilic Statins After Acute Myocardial Infarction Subanalysis of MUSASHI-AMI. Circulation Journal, 2007, 71, 1348-1353.	0.7	50
3794	Rationale and Design of a Study to Examine Lower Targets for Low-Density Lipoprotein-Cholesterol and Blood Pressure in Coronary Artery Disease Patients The Japanese Coronary Artery Disease Study II (JCADII). Circulation Journal, 2007, 72, 515-520.	0.7	4
3796	Dyslipidaemia: Focus shifts from LDL-C to HDL-C. Journal of Commercial Biotechnology, 2007, 13, 120-124.	0.2	0
3797	Randomized Evaluation of Atorvastatin in Patients With Coronary Heart Disease A Serial Intravascular Ultrasound Study. Circulation Journal, 2007, 71, 1845-1850.	0.7	23
3798	Difference in Early Effects of Statin Therapy on Coronary and Forearm Flow Reserve in Postmenopausal Hypercholesterolemic Women. Circulation Journal, 2007, 71, 954-961.	0.7	7
3799	Pravastatin Inhibits Arrhythmias Induced by Coronary Artery Ischemia in Anesthetized Rats. Journal of Pharmacological Sciences, 2007, 103, 317-322.	1.1	19
3800	Pravastatin Reduces Myocardial Infarct Size Via Increasing Protein Kinase C-Dependent Nitric Oxide, Decreasing Oxyradicals and Opening the Mitochondrial Adenosine Triphosphate-Sensitive Potassium Channels in Rabbits. Circulation Journal, 2007, 71, 1622-1628.	0.7	33

#	ARTICLE	IF	CITATIONS
3801	Impact of Lipid-Lowering Therapy With Pitavastatin, a New HMG-CoA Reductase Inhibitor, on Regression of Coronary Atherosclerotic Plaque A 3-Dimensional Intravascular Ultrasound Study. <i>Circulation Journal</i> , 2007, 71, 1678-1684.	0.7	36
3802	Impact of Newly Diagnosed Abnormal Glucose Tolerance on Long-Term Prognosis in Patients With Acute Myocardial Infarction. <i>Circulation Journal</i> , 2007, 71, 834-841.	0.7	49
3803	Impact of Statin Therapy on Left Ventricular Function and Carotid Arterial Stiffness in Patients With Hypercholesterolemia. <i>Circulation Journal</i> , 2007, 72, 538-544.	0.7	58
3804	Preferable Effect of Pravastatin Compared to Atorvastatin on Beta Cell Function in Japanese Early-state Type 2 Diabetes with Hypercholesterolemia. <i>Endocrine Journal</i> , 2007, 54, 441-447.	0.7	41
3805	Fluvastatin inhibits regulated secretion of endothelial cell von Willebrand factor in response to diverse secretagogues. <i>Biochemical Journal</i> , 2007, 405, 597-604.	1.7	23
3806	Statins and clinical outcomes in heart failure. <i>Clinical Science</i> , 2007, 113, 119-127.	1.8	23
3807	Attitudes and interests of pharmacists regarding independent pharmacy ownership. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2007, 47, 140-146.	0.7	5
3809	Nonuse of statins—A new risk factor for infectious death in cardiovascular patients?*. <i>Critical Care Medicine</i> , 2007, 35, 631-632.	0.4	6
3810	Pitavastatin Restores Vascular Dysfunction in Insulin-Resistant State by Inhibiting NAD(P)H Oxidase Activity and Uncoupled Endothelial Nitric Oxide Synthase-Dependent Superoxide Production. <i>Journal of Cardiovascular Pharmacology</i> , 2007, 49, 122-130.	0.8	34
3811	Effects of Initiation and Acute Withdrawal of Statins on the Neurovascular Coupling Mechanism in Healthy, Normocholesterolemic Humans. <i>Stroke</i> , 2007, 38, 3193-3197.	1.0	21
3812	Phytosterols and vascular disease. <i>Current Opinion in Lipidology</i> , 2007, 18, 35-40.	1.2	66
3815	Pitavastatin Suppresses Acute and Chronic Rejection in Murine Cardiac Allografts. <i>Transplantation</i> , 2007, 83, 1093-1097.	0.5	15
3816	Use of Propensity Score Technique to Account for Exposure-Related Covariates. <i>Medical Care</i> , 2007, 45, S143-S148.	1.1	81
3817	The Use of Statins and Lung Function in Current and Former Smokers. <i>Chest</i> , 2007, 132, 1764-1771.	0.4	103
3818	Effect of Polymorphic CYP3A5 Genotype on the Single-Dose Simvastatin Pharmacokinetics in Healthy Subjects. <i>Journal of Clinical Pharmacology</i> , 2007, 47, 87-93.	1.0	90
3819	Statins Reduce the Risk of Lung Cancer in Humans. <i>Chest</i> , 2007, 131, 1282-1288.	0.4	198
3820	Comparison of a dietary portfolio diet of cholesterol-lowering foods and a statin on LDL particle size phenotype in hypercholesterolaemic participants. <i>British Journal of Nutrition</i> , 2007, 98, 1229-1236.	1.2	26
3821	Can drug treatment prevent disease in common practice?. <i>Zeitschrift Für Ärztliche Fortbildung Und Qualitätssicherung</i> , 2007, 101, 326-332.	0.2	0

#	ARTICLE	IF	CITATIONS
3822	The under-use of statin in type 2 diabetic patients attending diabetic clinics in Italy. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2007, 17, 32-40.	1.1	16
3823	Statins for women, elderly: Malpractice?. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2007, 17, e19-e20.	1.1	2
3824	Statins and Blood Pressure: Is There an Effect or Not?. <i>Journal of Clinical Hypertension</i> , 2007, 9, 460-467.	1.0	10
3825	Statins and C-reactive Protein Levels. <i>Journal of Clinical Hypertension</i> , 2007, 9, 622-628.	1.0	46
3826	Absence of an interaction between the angiotensin-converting enzyme insertion-deletion polymorphism and pravastatin on cardiovascular disease in high-risk hypertensive patients: The Genetics of Hypertension-Associated Treatment (GenHAT) study. <i>American Heart Journal</i> , 2007, 153, 54-58.	1.2	25
3827	Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia. <i>American Heart Journal</i> , 2007, 153, 335.e1-335.e8.	1.2	69
3828	The effects of initiation or continuation of statin therapy on cholesterol level and all-cause mortality after the diagnosis of left ventricular systolic dysfunction. <i>American Heart Journal</i> , 2007, 153, 537-544.	1.2	19
3829	Study of the effectiveness of additional reductions in cholesterol and homocysteine (SEARCH): Characteristics of a randomized trial among 12064 myocardial infarction survivors. <i>American Heart Journal</i> , 2007, 154, 815-823.e6.	1.2	88
3830	The role of fibrates in the prevention of cardiovascular disease—a pooled meta-analysis of long-term randomized placebo-controlled clinical trials. <i>American Heart Journal</i> , 2007, 154, 943-953.	1.2	116
3831	Statins and Age-related Macular Degeneration: Time for a Randomized Controlled Trial?. <i>American Journal of Ophthalmology</i> , 2007, 144, 117-119.	1.7	18
3832	Management of Post-Myocardial Infarction Patients with Left Ventricular Systolic Dysfunction. <i>American Journal of Medicine</i> , 2007, 120, 109-120.	0.6	16
3833	Lifetime Risk for Developing Dyslipidemia: The Framingham Offspring Study. <i>American Journal of Medicine</i> , 2007, 120, 623-630.e1.	0.6	14
3834	Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice. <i>American Journal of Geriatric Pharmacotherapy</i> , 2007, 5, 185-194.	3.0	22
3835	Body Mass Index and Coronary Heart Disease Risk Score: The TromsÅ Study, 1979 to 2001. <i>Annals of Epidemiology</i> , 2007, 17, 100-105.	0.9	21
3836	Interventional Cardiology: Delivered with a Fork. <i>Explore: the Journal of Science and Healing</i> , 2007, 3, 514-516.	0.4	0
3837	Determination of pitavastatin in human plasma via HPLC-ESI-MS/MS and subsequent application to a clinical study in healthy Chinese volunteers. <i>Clinica Chimica Acta</i> , 2007, 386, 25-30.	0.5	28
3838	Achievement of optimal combined lipid values in a managed care setting: Is a new treatment paradigm needed?. <i>Clinical Therapeutics</i> , 2007, 29, 196-209.	1.1	11
3839	A dose-specific meta-analysis of lipid changes in randomized controlled trials of atorvastatin and simvastatin. <i>Clinical Therapeutics</i> , 2007, 29, 242-252.	1.1	32

#	ARTICLE	IF	CITATIONS
3840	Cholesterol reduction yields clinical benefits: meta-analysis including recent trials. <i>Clinical Therapeutics</i> , 2007, 29, 778-794.	1.1	116
3841	Mixed Dyslipidemia Among Patients Using Lipid-Lowering Therapy in French General Practice: An Observational Study. <i>Clinical Therapeutics</i> , 2007, 29, 1671-1681.	1.1	27
3842	Does Statin Therapy Initiation Increase the Risk for Myopathy? An Observational Study of 32,225 Diabetic and Nondiabetic Patients. <i>Clinical Therapeutics</i> , 2007, 29, 1761-1770.	1.1	158
3843	Simvastatin and fluvastatin reduce interleukin-6 and interleukin-8 lipopolysaccharide (LPS) stimulated production by isolated human monocytes from chronic kidney disease patients. <i>Biomedicine and Pharmacotherapy</i> , 2007, 61, 360-365.	2.5	28
3844	Double-Blind, Randomized, Placebo-Controlled Study of High-Dose HMG CoA Reductase Inhibitor Therapy on Ventricular Remodeling, Pro-Inflammatory Cytokines and Neurohormonal Parameters in Patients With Chronic Systolic Heart Failure. <i>Journal of Cardiac Failure</i> , 2007, 13, 1-7.	0.7	104
3845	Statin Pre-Treatment Protects Brain Against Focal Cerebral Ischemia in Diabetic Mice. <i>Journal of Surgical Research</i> , 2007, 138, 254-258.	0.8	25
3846	Statin and statin+“fibrate use was significantly associated with increased myositis risk in a managed care population. <i>Journal of Clinical Epidemiology</i> , 2007, 60, 812-818.	2.4	63
3847	Simvastatin inhibits NF- $\kappa$ B signaling in intestinal epithelial cells and ameliorates acute murine colitis. <i>International Immunopharmacology</i> , 2007, 7, 241-248.	1.7	79
3848	The effect of statin on the aortic gene expression profiling. <i>International Journal of Cardiology</i> , 2007, 114, 71-77.	0.8	16
3849	Long-term (11-year) statin therapy following percutaneous coronary intervention improves clinical outcome and is not associated with increased malignancy. <i>International Journal of Cardiology</i> , 2007, 114, 210-217.	0.8	19
3850	Atorvastatin reduces tissue factor expression in adipose tissue of atherosclerotic rabbits. <i>International Journal of Cardiology</i> , 2007, 115, 229-234.	0.8	19
3851	Statins in heart failure. Beyond the lipid lowering effect. <i>International Journal of Cardiology</i> , 2007, 115, 144-150.	0.8	60
3852	Impact of neurohormonal blockade on association between body mass index and mortality. <i>International Journal of Cardiology</i> , 2007, 119, 33-40.	0.8	5
3853	Current questions regarding the use of statins in patients with coronary heart disease. <i>International Journal of Cardiology</i> , 2007, 122, 188-194.	0.8	16
3854	Risk of coronary events in Japanese patients with both hypercholesterolemia and type 2 diabetes mellitus on low-dose simvastatin therapy: Implication from Japan Lipid Intervention Trial (J-LIT). <i>Atherosclerosis</i> , 2007, 191, 440-446.	0.4	34
3855	Statins inhibit NK cell cytotoxicity by membrane raft depletion rather than inhibition of isoprenylation. <i>Atherosclerosis</i> , 2007, 191, 319-325.	0.4	40
3856	A 1,3-diacylglycerol-rich oil induces less atherosclerosis and lowers plasma cholesterol in diabetic apoE-deficient mice. <i>Atherosclerosis</i> , 2007, 193, 55-61.	0.4	19
3857	To statin or to non-statin in coronary disease+“considering absolute risk is the answer. <i>Atherosclerosis</i> , 2007, 195, 1-6.	0.4	38

#	ARTICLE	IF	CITATIONS
3858	Statin-associated adverse effects beyond muscle and liver toxicity. <i>Atherosclerosis</i> , 2007, 195, 7-16.	0.4	107
3859	Statin treated patients have reduced intraplaque angiogenesis in carotid endarterectomy specimens. <i>Atherosclerosis</i> , 2007, 192, 457-463.	0.4	64
3860	European guidelines on cardiovascular disease prevention in clinical practice: Executive summary. <i>Atherosclerosis</i> , 2007, 194, 1-45.	0.4	292
3861	Low density lipoprotein triglycerides and lipoprotein(a) are risk factors for retinal vascular occlusion. <i>Clinica Chimica Acta</i> , 2007, 382, 77-81.	0.5	30
3862	Cholesterol lowering in patients with CHD and metabolic syndrome – Authors' reply. <i>Lancet</i> , The, 2007, 369, 26-27.	6.3	2
3863	Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. <i>Lancet</i> , The, 2007, 369, 1090-1098.	6.3	2,172
3864	The safety of statins in clinical practice. <i>Lancet</i> , The, 2007, 370, 1781-1790.	6.3	705
3865	Guías de práctica clínica sobre diabetes, prediabetes y enfermedades cardiovasculares: versión resumida. <i>Revista Espanola De Cardiologia</i> , 2007, 60, 525.e1-525.e64.	0.6	13
3866	Dislipemia del síndrome metabólico. Documento sumario del Foro-HDL. <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2007, 19, 252-263.	0.4	1
3867	Endothelial dysfunction, lipid peroxidation and cholesterol level in rabbit arteries: relationship to progressive hypercholesterolemia. <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2007, 19, 293-299.	0.4	3
3868	Outcomes Associated With the Use of Secondary Prevention Medications After Coronary Artery Bypass Graft Surgery. <i>Annals of Thoracic Surgery</i> , 2007, 83, 993-1001.	0.7	86
3869	Effects of an enhanced secondary prevention program for patients with heart disease: A prospective randomized trial. <i>Canadian Journal of Cardiology</i> , 2007, 23, 1066-1072.	0.8	13
3870	Central Nervous System Ischemia. , 2007, , 657-683.		1
3871	Reducing cardiovascular risk by targeting high-density lipoprotein cholesterol. <i>Current Atherosclerosis Reports</i> , 2007, 9, 81-88.	2.0	10
3872	Cytochrome P450 – physiological key factor against cholesterol accumulation and the atherosclerotic vascular process. <i>Annals of Medicine</i> , 2007, 39, 359-370.	1.5	25
3873	Effects of Atorvastatin on Ventricular Late Potentials and Repolarization Dispersion in Patients with Hypercholesterolemia. <i>Kaohsiung Journal of Medical Sciences</i> , 2007, 23, 217-224.	0.8	11
3874	Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease. <i>New England Journal of Medicine</i> , 2007, 356, 775-789.	13.9	2,963
3875	Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. <i>Journal of Vascular Surgery</i> , 2007, 45, 645-654.e1.	0.6	353

#	ARTICLE	IF	CITATIONS
3876	The course of vascular risk factors and the occurrence of vascular events in patients with symptomatic peripheral arterial disease. <i>Journal of Vascular Surgery</i> , 2007, 45, 47-54.	0.6	35
3877	Acute ST-Segment Elevation Myocardial Infarction: Critical Care Perspective. <i>Critical Care Clinics</i> , 2007, 23, 685-707.	1.0	1
3878	Rosuvastatin in Elderly Patients. <i>Drugs and Aging</i> , 2007, 24, 933-944.	1.3	7
3879	Atorvastatin. <i>Drugs</i> , 2007, 67, 3-15.	4.9	61
3880	Effects of Atorvastatin on the Different Phases of Atherogenesis. <i>Drugs</i> , 2007, 67, 17-27.	4.9	27
3881	Atorvastatin Efficacy in the Primary and Secondary Prevention of Cardiovascular Events. <i>Drugs</i> , 2007, 67, 29-42.	4.9	41
3882	Atorvastatin. <i>Drugs</i> , 2007, 67, 55-62.	4.9	15
3883	Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited) Tj ETQq1 1 0.784314 38 BT /Over	0.784314	38
3884	Optimal Medical Therapy with or without PCI for Stable Coronary Disease. <i>New England Journal of Medicine</i> , 2007, 356, 1503-1516.	13.9	4,022
3885	Atorvastatin. <i>Pharmacoeconomics</i> , 2007, 25, 1031-1053.	1.7	22
3886	Evidence-Based Medical Therapy of Patients with Acute Coronary Syndromes. <i>American Journal of Cardiovascular Drugs</i> , 2007, 7, 95-116.	1.0	15
3887	Long-Term Benefit of Statin Therapy Initiated during Hospitalization for an Acute Coronary Syndrome. <i>American Journal of Cardiovascular Drugs</i> , 2007, 7, 135-141.	1.0	44
3888	Underuse of American College of Cardiology/American Heart Association Guidelines in Hemodialysis Patients. <i>Renal Failure</i> , 2007, 29, 559-565.	0.8	16
3889	Comparative efficacy of daily versus alternate-day dosing of atorvastatin in Type 2 diabetic patients. <i>Therapy: Open Access in Clinical Medicine</i> , 2007, 4, 541-545.	0.2	3
3890	Effects of treatment with a commercially available St John's Wort product (Movina®) on cholesterol levels in patients with hypercholesterolemia treated with simvastatin. <i>Scandinavian Journal of Primary Health Care</i> , 2007, 25, 154-159.	0.6	24
3891	Pitavastatin: Protection against Neuronal Retinal Damage Induced by Ischemia-Reperfusion Injury in Rats. <i>Current Eye Research</i> , 2007, 32, 991-997.	0.7	19
3892	ACE inhibitors: back to prime time?. <i>Heart</i> , 2007, 93, 1015-1016.	1.2	1
3893	Valutazione economica di rosuvastatina nel trattamento di prevenzione delle malattie cardiovascolari: una revisione sistematica della letteratura. <i>Pharmacoeconomics Italian Research Articles</i> , 2007, 9, 45-58.	0.2	0

#	ARTICLE	IF	CITATIONS
3895	Lipid-lowering for peripheral arterial disease of the lower limb. The Cochrane Library, 2007, , CD000123.	1.5	105
3896	The safety of rosuvastatin: effects on renal and hepatic function. Expert Opinion on Drug Safety, 2007, 6, 573-581.	1.0	15
3897	Predictors of acute myocardial infarction mortality in hypertensive patients treated in primary care. Scandinavian Journal of Primary Health Care, 2007, 25, 237-243.	0.6	8
3898	Simvastatin: present and future perspectives. Expert Opinion on Pharmacotherapy, 2007, 8, 2159-2127.	0.9	20
3899	Risk of cardiovascular events in patients at optimal values for combined lipid parameters. Current Medical Research and Opinion, 2007, 23, 553-563.	0.9	45
3900	Short-term effect of simvastatin treatment on inflammatory parameters in peritoneal dialysis patients. Scandinavian Journal of Urology and Nephrology, 2007, 41, 436-441.	1.4	14
3901	Role of statins for the primary prevention of cardiovascular disease in patients with type 2 diabetes mellitus. American Journal of Health-System Pharmacy, 2007, 64, 1603-1610.	0.5	11
3902	Rational approach to the treatment for heterozygous familial hypercholesterolemia in childhood and adolescence: A review. Journal of Endocrinological Investigation, 2007, 30, 700-719.	1.8	23
3903	Discontinuation of Statin Therapy and Clinical Outcome After Ischemic Stroke. Stroke, 2007, 38, 2652-2657.	1.0	150
3904	Biomarkers of Atherosclerotic Plaque Instability and Rupture. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 15-26.	1.1	354
3905	Acute Coronary Syndromes in the Elderly. Clinics in Geriatric Medicine, 2007, 23, 425-440.	1.0	13
3907	Angioplasty and Stenting for Atherosclerotic Intracranial Stenosis: Rationale for a Randomized Clinical Trial. Neuroimaging Clinics of North America, 2007, 17, 355-363.	0.5	70
3909	Simvastatin pretreatment reduces the severity of limb ischemia in an experimental diabetes model. Journal of Vascular Surgery, 2007, 45, 590-596.	0.6	18
3910	Lovastatin specifically prevents focal ischemic ventricular tachycardia due to triggered activity. Heart Rhythm, 2007, 4, 629-637.	0.3	11
3911	Statins: An essential component in the management of carotid artery disease. Journal of Vascular Surgery, 2007, 46, 373-386.e9.	0.6	79
3912	Effect of Statin Therapy on Early Return of Potency After Nerve Sparing Radical Retropubic Prostatectomy. Journal of Urology, 2007, 178, 613-616.	0.2	41
3913	Implication of the New Low-Density Lipoprotein Goals in Dyslipidemia Management of Patients With Acute Coronary Syndrome. Mayo Clinic Proceedings, 2007, 82, 551-555.	1.4	7
3914	Gastric bypass reduces biochemical cardiac risk factors. Surgery for Obesity and Related Diseases, 2007, 3, 8-13.	1.0	61

#	ARTICLE	IF	CITATIONS
3918	Guía de Práctica Clínica para el diagnóstico y tratamiento del síndrome coronario agudo sin elevación del segmento ST. Revista Española De Cardiología, 2007, 60, 1070.e1-1070.e80.	0.6	29
3919	Factors Predictive of Cardiovascular Disease in Patients With Type-2 Diabetes and Hypercholesterolemia. ESODIAH Study. Revista Española De Cardiología (English Ed ), 2007, 60, 251-258.	0.4	4
3920	Thrombosis and Thrombolysis: Platelet Membrane Glycoproteins. Heart Lung and Circulation, 2007, 16, 176-179.	0.2	7
3921	Inhibition of synthesis and absorption of cholesterol: A new option in managing hypercholesterolemia. International Congress Series, 2007, 1303, 121-128.	0.2	1
3922	Screen Testing. Journal of the American College of Cardiology, 2007, 49, 1915-1917.	1.2	42
3923	Safety of Aggressive Lipid Management. Journal of the American College of Cardiology, 2007, 49, 1753-1762.	1.2	144
3924	Low-Density Lipoprotein-Dependent and -Independent Effects of Cholesterol-Lowering Therapies on C-Reactive Protein. Journal of the American College of Cardiology, 2007, 49, 2003-2009.	1.2	161
3925	ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2007, 50, e1-e157.	1.2	1,587
3926	Atorvastatin Pretreatment Improves Outcomes in Patients With Acute Coronary Syndromes Undergoing Early Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2007, 49, 1272-1278.	1.2	435
3927	ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction Executive Summary. Journal of the American College of Cardiology, 2007, 50, 652-726.	1.2	252
3928	Effect of the Magnitude of Lipid Lowering on Risk of Elevated Liver Enzymes, Rhabdomyolysis, and Cancer. Journal of the American College of Cardiology, 2007, 50, 409-418.	1.2	224
3930	Ezetimibe and Simvastatin Reduce Inflammation, Disease Activity, and Aortic Stiffness and Improve Endothelial Function in Rheumatoid Arthritis. Journal of the American College of Cardiology, 2007, 50, 852-858.	1.2	225
3931	Simvastatin does not exhibit therapeutic anti-inflammatory effects in asthma. Journal of Allergy and Clinical Immunology, 2007, 119, 328-335.	1.5	114
3932	Primary care physician treatment of low HDL: Rational approach or Pandora's Box?. Journal of Clinical Lipidology, 2007, 1, 198-202.	0.6	0
3933	Implications of recent statin trials for primary care practice. Journal of Clinical Lipidology, 2007, 1, 182-190.	0.6	5
3934	Plant sterols added to combination statin and colesvelam hydrochloride therapy failed to lower low-density lipoprotein cholesterol concentrations. Journal of Clinical Lipidology, 2007, 1, 626-633.	0.6	8
3935	Statins and Stroke Prevention. Cerebrovascular Diseases, 2007, 24, 170-182.	0.8	61
3936	An Improved Manufacturing Process for Fluvastatin. Organic Process Research and Development, 2007, 11, 13-18.	1.3	34



#	ARTICLE	IF	CITATIONS
3938	The Effect of Biliary Sphincterotomy on Serum Cholesterol Levels in Postcholecystectomy Patients: A Pilot Study. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2007, 21, 81-84.	1.8	5
3940	Primary Prevention of Ischemic Heart Disease. , 2007, , 178-220.		1
3941	Coronary fat content evaluated by morphometry in patients with severe atherosclerosis has no relation with serum lipid levels. <i>Brazilian Journal of Medical and Biological Research</i> , 2007, 40, 467-473.	0.7	4
3942	Are the beneficial cardiovascular effects of simvastatin and metformin also associated with a hormone-dependent mechanism improving insulin sensitivity?. <i>Brazilian Journal of Medical and Biological Research</i> , 2007, 40, 229-235.	0.7	11
3943	Atherothrombosis and Coronary Artery Disease. , 2007, , 629-655.		9
3944	The 1984 Coronary Primary Prevention Trial. , 2007, , 143-170.		0
3945	Effect of Early Versus Late In-Hospital Initiation of Statin Therapy on the Clinical Outcomes of Patients With Acute Coronary Syndrome. <i>International Heart Journal</i> , 2007, 48, 677-688.	0.5	15
3946	Lipid-Lowering Therapy. , 2007, , 1087-1099.		1
3947	Goals of Dyslipidemia Management Executive Summary of Japan Atherosclerosis Society (JAS) Guideline for Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases for Japanese. <i>Journal of Atherosclerosis and Thrombosis</i> , 2007, 14, 209-212.	0.9	26
3949	Relationship between Metabolic Syndrome and Early Stage Coronary Atherosclerosis. <i>Journal of Atherosclerosis and Thrombosis</i> , 2007, 14, 294-302.	0.9	36
3950	Nitric Oxide and Cardiovascular Risk Factors. <i>Heart International</i> , 2007, 3, 182618680700300.	0.4	8
3952	Factors affecting long-term survival following renal artery stenting. <i>Catheterization and Cardiovascular Interventions</i> , 2007, 69, 1037-1043.	0.7	46
3953	Is survival of patients with atherosclerotic renal artery stenosis affected by different predictors compared to other atherosclerosis manifestations?. <i>Catheterization and Cardiovascular Interventions</i> , 2007, 69, 1046-1047.	0.7	0
3954	Alimentary hyperlipemia of rabbits is affected by exposure to low-intensity pulsed magnetic fields. <i>Bioelectromagnetics</i> , 2007, 28, 608-614.	0.9	11
3955	Fluvastatin reverses endothelial dysfunction and increased vascular oxidative stress in rat adjuvant-induced arthritis. <i>Arthritis and Rheumatism</i> , 2007, 56, 1827-1835.	6.7	64
3956	Effects of two whole blood systems (DALI and Liposorber D) for LDL apheresis on lipids and cardiovascular risk markers in severe hypercholesterolemia. <i>Journal of Clinical Apheresis</i> , 2007, 22, 301-305.	0.7	25
3957	Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid. <i>Hepatology</i> , 2007, 46, 776-784.	3.6	77
3958	Chromatography-mass spectrometry methods for the quantitation of statins in biological samples. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2007, 44, 379-387.	1.4	80

#	ARTICLE	IF	CITATIONS
3959	How equitable are GP practice prescribing rates for statins?: an ecological study in four primary care trusts in North West England. <i>International Journal for Equity in Health</i> , 2007, 6, 2.	1.5	18
3960	HMG-CoA-Reduktase Hemmer. <i>Pharmazie in Unserer Zeit</i> , 1999, 28, 147-152.	0.0	5
3961	Systematic review and meta-analysis of clinically relevant adverse events from HMG CoA reductase inhibitor trials worldwide from 1982 to present. <i>Pharmacoepidemiology and Drug Safety</i> , 2007, 16, 132-143.	0.9	50
3962	Statins and fracture risk. A systematic review. <i>Pharmacoepidemiology and Drug Safety</i> , 2007, 16, 627-640.	0.9	75
3963	The impact of pharmaceuticals on the decline of cardiovascular mortality in Germany. <i>Pharmacoepidemiology and Drug Safety</i> , 2007, 16, 1167-1176.	0.9	7
3964	Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. <i>Nature Reviews Drug Discovery</i> , 2007, 6, 904-916.	21.5	351
3965	Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 82, 726-733.	2.3	381
3966	Effect on hematologic risk factors for coronary heart disease of a cholesterol reducing diet. <i>European Journal of Clinical Nutrition</i> , 2007, 61, 483-492.	1.3	20
3967	No Effect of Low-Dose Statins Treatment on Cerebral Blood Flow in Humans with Atherosclerotic Cerebrovascular Disease. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2007, 27, 1643-1648.	2.4	8
3968	Cardiovascular risk in chronic obstructive pulmonary disease. <i>Respirology</i> , 2007, 12, 634-641.	1.3	142
3969	An evaluation of two Rapid Access Chest Pain Clinics in central Lancashire, UK. <i>Journal of Evaluation in Clinical Practice</i> , 2007, 13, 326-336.	0.9	8
3970	Co-administration of ezetimibe and simvastatin in acute myocardial infarction. <i>European Journal of Clinical Investigation</i> , 2007, 37, 357-363.	1.7	15
3971	A perioperative statin update for non-cardiac surgery. Part I: The effects of statin therapy on atherosclerotic disease and lessons learnt from statin therapy in medical (non-surgical) patients. <i>Anaesthesia</i> , 2008, 63, 52-64.	1.8	22
3972	Adherence to chronic cardiovascular therapies: persistence over the years and dose coverage. <i>British Journal of Clinical Pharmacology</i> , 2007, 63, 346-355.	1.1	30
3973	Impact of adherence to statins on coronary artery disease in primary prevention. <i>British Journal of Clinical Pharmacology</i> , 2007, 63, 698-708.	1.1	86
3974	Switching statins in Norway after new reimbursement policy ? a nationwide prescription study. <i>British Journal of Clinical Pharmacology</i> , 2007, 64, 476-481.	1.1	74
3975	Reduced Mortality Rates after Intensive Statin Therapy in Managed-Care Patients. <i>Value in Health</i> , 2007, 10, 161-169.	0.1	18
3976	The pharmacologic elegance of inhibiting cholesterol absorption and synthesis while providing a homeostatic balance. <i>Fundamental and Clinical Pharmacology</i> , 2007, 21, 21-26.	1.0	6

#	ARTICLE	IF	CITATIONS
3977	Statin utilisation - recognising the role of the invisible hand. <i>International Journal of Clinical Practice</i> , 2007, 61, 3-6.	0.8	9
3978	Role of imaging end points in atherosclerosis trials: focus on intravascular ultrasound. <i>International Journal of Clinical Practice</i> , 2007, 61, 951-962.	0.8	5
3979	A multi-centre, randomised, double-blind 14-week extension study examining the long-term safety and efficacy profile of the ezetimibe/simvastatin combination tablet*. <i>International Journal of Clinical Practice</i> , 2007, 61, 1469-1480.	0.8	11
3980	Recent trials of lipid lowering. <i>International Journal of Clinical Practice</i> , 2007, 61, 1145-1159.	0.8	13
3981	LDL-apheresis: indications and clinical experience in a tertiary cardiac centre. <i>International Journal of Clinical Practice</i> , 2007, 61, 1834-1842.	0.8	9
3982	Effectiveness of statins in Medicare-eligible patients and patients &lt;€65&gt;years using clinical practice data*. <i>International Journal of Clinical Practice</i> , 2007, 61, 1634-1642.	0.8	5
3983	Absence of policy on how to use statins in England and Wales: do not let JBS2 fill the void. <i>International Journal of Clinical Practice</i> , 2007, 61, 1967-1970.	0.8	1
3984	Health Promotion Practices of the Old-Old. <i>Journal of the American Academy of Nurse Practitioners</i> , 2007, 10, 147-153.	1.4	0
3985	Can postponement of an adverse outcome be used to present risk reductions to a lay audience? A population survey. <i>BMC Medical Informatics and Decision Making</i> , 2007, 7, 8.	1.5	27
3986	Effectiveness of Statins in Reducing the Rate of Severe Sepsis: A Retrospective Evaluation. <i>Pharmacotherapy</i> , 2007, 27, 20-26.	1.2	59
3987	Effects of long-term administration of HMG-CoA reductase inhibitor, atorvastatin, on stroke events and local cerebral blood flow in stroke-prone spontaneously hypertensive rats. <i>Brain Research</i> , 2007, 1169, 125-132.	1.1	35
3988	The Rationale for Using HMG-CoA Reductase Inhibitors (â€˜Statinsâ€™™) in Peripheral Arterial Disease. <i>European Journal of Vascular and Endovascular Surgery</i> , 2007, 33, 192-201.	0.8	22
3989	The Impact of Hormone Replacement Therapy on the Pathophysiology of Peripheral Arterial Disease. <i>European Journal of Vascular and Endovascular Surgery</i> , 2007, 34, 569-575.	0.8	12
3991	Efficacy and Safety of Rosuvastatin 40 mg Alone or in Combination With Ezetimibe in Patients at High Risk of Cardiovascular Disease (Results from the EXPLORER Study). <i>American Journal of Cardiology</i> , 2007, 99, 673-680.	0.7	168
3992	Role of C-Reactive Protein in Coronary Risk Reduction: Focus on Primary Prevention. <i>American Journal of Cardiology</i> , 2007, 99, 718-725.	0.7	38
3993	The Things to Come of SHAPE: Cost and Effectiveness of Cardiovascular Prevention. <i>American Journal of Cardiology</i> , 2007, 99, 1013-1015.	0.7	28
3994	Efficacy of Drug Therapy in the Secondary Prevention of Cardiovascular Disease and Stroke. <i>American Journal of Cardiology</i> , 2007, 99, S1-S35.	0.7	20
3995	Prevention of Cardiovascular Disease in Persons with Type 2 Diabetes Mellitus: Current Knowledge and Rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. <i>American Journal of Cardiology</i> , 2007, 99, S4-S20.	0.7	189

#	ARTICLE	IF	CITATIONS
3996	Evolution of the Lipid Trial Protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. American Journal of Cardiology, 2007, 99, S56-S67.	0.7	87
3997	Prevention of Stroke in Patients with Hypertension. American Journal of Cardiology, 2007, 100, S17-S24.	0.7	59
3998	Meta-Analysis of Effect of Statin Treatment on Risk of Sudden Death. American Journal of Cardiology, 2007, 100, 1644-1650.	0.7	41
3999	Statins and Peripheral Arterial Disease: Effects on Claudication, Disease Progression, and Prevention of Cardiovascular Events. Archives of Medical Research, 2007, 38, 479-488.	1.5	36
4000	Towards a "new beginning": dietary fat restrictions in infancy?. Acta Paediatrica, International Journal of Paediatrics, 2000, 89, 2-4.	0.7	0
4001	Low-Density Lipoprotein Cholesterol in High-Risk Asymptomatic Individuals. Journal of the Cardiometabolic Syndrome, 2007, 2, 49-52.	1.7	1
4002	Prevention of stroke and dementia by statin therapy: Experimental and clinical evidence of their pleiotropic effects. , 2007, 113, 378-393.		65
4003	Lipid-lowering therapy with statins, a new approach to antiarrhythmic therapy. , 2007, 114, 107-126.		40
4004	Protective effects of a squalene synthase inhibitor, lapaquistat acetate (TAK-475), on statin-induced myotoxicity in guinea pigs. Toxicology and Applied Pharmacology, 2007, 223, 39-45.	1.3	33
4005	Simvastatin for Secondary Prevention of All-Cause Mortality and Major Coronary Events in Patients With Mild Chronic Renal Insufficiency. American Journal of Kidney Diseases, 2007, 49, 373-382.	2.1	73
4006	The Effect of Statin Medications on Perioperative and Long-Term Outcomes Following Carotid Endarterectomy or Stenting. Seminars in Vascular Surgery, 2007, 20, 252-258.	1.1	70
4007	Rosuvastatin: a highly potent statin for the prevention and management of coronary artery disease. Expert Review of Cardiovascular Therapy, 2007, 5, 161-175.	0.6	25
4008	Trials and tribulations associated with angina and traditional therapeutic approaches. Clinical Cardiology, 2007, 30, 116-124.	0.7	31
4009	Effects of Atorvastatin on Coronary Flow Reserve in Patients with Slow Coronary Flow. Clinical Cardiology, 2007, 30, 475-479.	0.7	77
4010	Evolution of Anticoagulant and Antiplatelet Therapy: Benefits and Risks of Contemporary Pharmacologic Agents and Their Implications for Myonecrosis and Bleeding in Percutaneous Coronary Intervention. Clinical Cardiology, 2007, 30, 114-115.	0.7	3
4011	Does the prevalence of nasal polyps increase in patients using statins?. Advances in Therapy, 2007, 24, 1330-1339.	1.3	5
4012	Aggressive statin therapy for acute coronary syndromes. Current Cardiology Reports, 2007, 9, 298-302.	1.3	0
4013	HDL metabolism and the role of HDL in the treatment of high-risk patients with cardiovascular disease. Current Cardiology Reports, 2007, 9, 486-492.	1.3	40

#	ARTICLE	IF	CITATIONS
4014	Residual risk in statin-treated patients: Future therapeutic options. <i>Current Cardiology Reports</i> , 2007, 9, 499-505.	1.3	23
4015	Statin therapy: Is the percent reduction or the attained low-density lipoprotein cholesterol level more important?. <i>Current Atherosclerosis Reports</i> , 2007, 9, 10-17.	2.0	4
4016	Statin therapy in cardiovascular diseases other than atherosclerosis. <i>Current Atherosclerosis Reports</i> , 2007, 9, 25-32.	2.0	6
4017	Statins and biomarkers of inflammation. <i>Current Atherosclerosis Reports</i> , 2007, 9, 33-41.	2.0	62
4018	One-Month Therapy with Simvastatin Restores Endothelial Function in Hypercholesterolemic Children and Adolescents. <i>Pediatric Cardiology</i> , 2007, 28, 8-13.	0.6	31
4020	Role of Biomarkers in Developing New Therapies for Vascular Disease. <i>World Journal of Surgery</i> , 2007, 31, 676-681.	0.8	14
4021	Immediate effect of fluvastatin on lipid levels in acute coronary syndrome. <i>Molecular and Cellular Biochemistry</i> , 2007, 306, 19-23.	1.4	5
4022	The Mechanism Underlying Vascular Smooth Muscle Cell Apoptosis Induced by Atorvastatin may be Mainly Associated with Down-regulation of Survivin Expression. <i>Cardiovascular Drugs and Therapy</i> , 2007, 21, 145-153.	1.3	10
4023	Beyond Lipid Lowering: The Anti-Hypertensive Role of Statins. <i>Cardiovascular Drugs and Therapy</i> , 2007, 21, 161-169.	1.3	28
4024	The Importance of Managing Hypertension and Dyslipidemia to Decrease Cardiovascular Disease. <i>Cardiovascular Drugs and Therapy</i> , 2007, 21, 297-309.	1.3	49
4025	Statin Therapy for Vascular Failure. <i>Cardiovascular Drugs and Therapy</i> , 2007, 21, 281-295.	1.3	27
4027	A Green Tea Catechin Extract Upregulates the Hepatic Low-Density Lipoprotein Receptor in Rats. <i>Lipids</i> , 2007, 42, 621-627.	0.7	54
4032	Atherosclerosis regression: Is low-density lipoprotein or high-density lipoprotein the answer?. <i>Current Atherosclerosis Reports</i> , 2007, 9, 266-273.	2.0	11
4033	Statins for stroke prevention. <i>Current Atherosclerosis Reports</i> , 2007, 9, 305-311.	2.0	7
4034	SPARCL: The glimmer of statins for stroke risk reduction. <i>Current Atherosclerosis Reports</i> , 2007, 9, 347-351.	2.0	4
4035	Intensive management of risk factors for accelerated atherosclerosis: the role of multiple interventions. <i>Current Neurology and Neuroscience Reports</i> , 2007, 7, 42-48.	2.0	31
4037	Intensive lipid lowering in the cardiovascular patient: Who, how low, and for how long?. <i>Current Cardiovascular Risk Reports</i> , 2007, 1, 290-295.	0.8	0
4038	Mevalonate pathway: A review of clinical and therapeutical implications. <i>Clinical Biochemistry</i> , 2007, 40, 575-584.	0.8	471

#	ARTICLE	IF	CITATIONS
4039	Statinsâ€™ Treatment Option for Central Nervous System Autoimmune Disease?. <i>Neurotherapeutics</i> , 2007, 4, 693-700.	2.1	21
4040	Interest in healthy lifestyle and adherence to medications: Impact on mortality among elderly cardiovascular patients in the DEBATE Study. <i>Patient Education and Counseling</i> , 2007, 67, 44-49.	1.0	13
4041	Simvastatin attenuates cisplatin-induced kidney and liver damage in rats. <i>Toxicology</i> , 2007, 230, 256-264.	2.0	156
4042	Glucoseâ€™phosphate dehydrogenase deficiency protects against coronary heart disease. <i>Journal of Inherited Metabolic Disease</i> , 2008, 31, 412-417.	1.7	54
4043	Effects of Statins on High-Density Lipoproteins: A Potential Contribution to Cardiovascular Benefit. <i>Cardiovascular Drugs and Therapy</i> , 2008, 22, 321-338.	1.3	134
4044	Effect of an Educational Program (PEGASE) on Cardiovascular Risk in Hypercholesterolaemic Patients. <i>Cardiovascular Drugs and Therapy</i> , 2008, 22, 495-505.	1.3	16
4045	Anemia treatment in chronic kidney disease: shifting uncertainty. <i>Heart Failure Reviews</i> , 2008, 13, 425-430.	1.7	6
4046	Do we learn the right things from clinical trials?. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 115-125.	0.8	3
4047	Efficacy and safety of disodium ascorbyl phytostanol phosphates in men with moderate dyslipidemia. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 651-661.	0.8	15
4048	Cholesterol in women at high cardiovascular risk is less successfully treated than in corresponding men. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 815-820.	0.8	9
4049	Therapy with statins and aspirin enhances long-term outcome of percutaneous coronary intervention. <i>Heart and Vessels</i> , 2008, 23, 35-39.	0.5	18
4050	Cholestin ( <i>Monascus purpureus</i> rice) inhibits homocysteine-induced reactive oxygen species generation, nuclear factor-Î²B activation, and vascular cell adhesion molecule-1 expression in human aortic endothelial cells. <i>Journal of Biomedical Science</i> , 2008, 15, 183-196.	2.6	27
4051	Recognizing and improving patient nonadherence to statin therapy. <i>Current Atherosclerosis Reports</i> , 2008, 10, 19-24.	2.0	28
4052	What is the evidence in favor of low-dose statin therapy in 2008?. <i>Current Atherosclerosis Reports</i> , 2008, 10, 33-38.	2.0	2
4053	Adjunctive interventions in myocardial infarction: The role of statin therapy. <i>Current Atherosclerosis Reports</i> , 2008, 10, 142-148.	2.0	8
4054	Intensive statin therapy in acute coronary syndromes. <i>Current Atherosclerosis Reports</i> , 2008, 10, 158-163.	2.0	5
4056	Statins and congestive heart failure. <i>Current Atherosclerosis Reports</i> , 2008, 10, 369-376.	2.0	1
4057	Optimal treatment of the diabetic patient with multivessel disease. <i>Current Cardiology Reports</i> , 2008, 10, 272-284.	1.3	1

#	ARTICLE	IF	CITATIONS
4058	Lipid management: Considerations in acute coronary syndrome. <i>Current Cardiology Reports</i> , 2008, 10, 334-341.	1.3	0
4059	Why Don't Diabetes Patients Achieve Recommended Risk Factor Targets? Poor Adherence versus Lack of Treatment Intensification. <i>Journal of General Internal Medicine</i> , 2008, 23, 588-594.	1.3	214
4060	Treatment options for patients with coronary artery disease identified as high risk by T-wave alternans testing. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2008, 10, 39-48.	0.4	7
4061	Atherosclerosis regression. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2008, 10, 187-194.	0.4	1
4062	Pitavastatin may Reduce Risk of Steroid-induced Osteonecrosis in Rabbits: A Preliminary Histological Study. <i>Clinical Orthopaedics and Related Research</i> , 2008, 466, 1054-1058.	0.7	44
4063	Prevalence of dyslipidemia and associated risk factors among Turkish adults: Trabzon lipid study. <i>Endocrine</i> , 2008, 34, 36-51.	1.1	100
4064	Prior Statin Use Reduces Mortality in Intracerebral Hemorrhage. <i>Neurocritical Care</i> , 2008, 8, 6-12.	1.2	73
4065	Plant sterol-enriched fermented milk enhances the attainment of LDL-cholesterol goal in hypercholesterolemic subjects. <i>European Journal of Nutrition</i> , 2008, 47, 32-39.	1.8	69
4066	Statin use is associated with fewer periodontal lesions: A retrospective study. <i>BMC Oral Health</i> , 2008, 8, 16.	0.8	114
4067	Dyslipidemia in primary care – prevalence, recognition, treatment and control: data from the German Metabolic and Cardiovascular Risk Project (GEMCAS). <i>Cardiovascular Diabetology</i> , 2008, 7, 31.	2.7	49
4068	Implementing electronic clinical reminders for lipid management in patients with ischemic heart disease in the veterans health administration: QUERI Series. <i>Implementation Science</i> , 2008, 3, 28.	2.5	16
4069	Replication of the Scandinavian Simvastatin Survival Study using a primary care medical record database prompted exploration of a new method to address unmeasured confounding. <i>Pharmacoepidemiology and Drug Safety</i> , 2008, 17, 661-670.	0.9	38
4070	Chronic statin therapy and the risk of colorectal cancer. <i>Pharmacoepidemiology and Drug Safety</i> , 2008, 17, 869-876.	0.9	50
4071	The demand for statin: the effect of copay on utilization and compliance. <i>Health Economics (United Kingdom)</i> 2008, 23, 1111-1123.	0.8	33
4072	Tendinous disorders attributed to statins: A study on ninety-six spontaneous reports in the period 1990-2005 and review of the literature. <i>Arthritis and Rheumatism</i> , 2008, 59, 367-372.	6.7	158
4073	Effect of statins on proteolytic activity in the wall of abdominal aortic aneurysms. <i>British Journal of Surgery</i> , 2008, 95, 333-337.	0.1	47
4074	Atorvastatin Administration after Percutaneous Coronary Intervention in Patients with Coronary Artery Disease and Normal Lipid Profiles: Impact on Plasma Adiponectin Level. <i>Clinical Cardiology</i> , 2008, 31, 253-258.	0.7	23
4075	Rosuvastatin and progression of atherosclerosis. <i>Expert Review of Cardiovascular Therapy</i> , 2008, 6, 925-933.	0.6	8

#	ARTICLE	IF	CITATIONS
4076	Pravastatin improves renal ischemiaâ€“reperfusion injury by inhibiting the mevalonate pathway. <i>Kidney International</i> , 2008, 74, 577-584.	2.6	54
4077	The cholesterol lowering properties of the complex compound simvastatin with glycyrrhizic acid (simvaglyzin) in experimental models. <i>Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry</i> , 2008, 2, 373-380.	0.2	13
4078	Lipid changes occurring in the course of hematological cancers. <i>Cellular and Molecular Biology Letters</i> , 2008, 13, 465-74.	2.7	46
4079	Stroke and atherothrombosis: An Update on the Role of Antiplatelet Therapy. <i>International Journal of Stroke</i> , 2008, 3, 175-181.	2.9	10
4080	Lipid-altering efficacy of ezetimibe/simvastatin 10/40â€“mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study. <i>International Journal of Clinical Practice</i> , 2008, 62, 539-554.	0.8	29
4081	Evaluation Cardioprotective Effects of Atorvastatin in Rats by Real Time Myocardial Contrast Echocardiography. <i>Echocardiography</i> , 2008, 25, 974-981.	0.3	8
4082	Effect of APOE Genotype on Lipid Levels in Patients With Coronary Heart Disease During a 3-Week Inpatient Rehabilitation Program. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 84, 222-227.	2.3	2
4083	Torcetrapibâ€“induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. <i>British Journal of Pharmacology</i> , 2008, 154, 1465-1473.	2.7	258
4084	Form to function: current and future roles for atherosclerosis imaging in drug development. <i>Nature Reviews Drug Discovery</i> , 2008, 7, 517-529.	21.5	68
4085	Cholesterolâ€“When Is Lower Better?. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 83, 777-780.	2.3	8
4086	Benefit/Risk Ratio of Statins in Primary Prevention. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 83, 498-500.	2.3	5
4087	Comparison of Effects of Pitavastatin and Atorvastatin on Plasma Coenzyme Q10 in Heterozygous Familial Hypercholesterolemia: Results From a Crossover Study. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 83, 731-739.	2.3	32
4088	Probiotic capsules do not lower plasma lipids in young women and men. <i>European Journal of Clinical Nutrition</i> , 2008, 62, 232-237.	1.3	71
4089	Inflammatory Biomarkers and Risks of Myocardial Infarction, Stroke, Diabetes, and Total Mortality: Implications for Longevity. <i>Nutrition Reviews</i> , 2007, 65, S253-S259.	2.6	117
4090	Atorvastatin induces apoptosis by a caspaseâ€“dependent pathway: an <i>in vitro</i> study on activated rat hepatic stellate cells. <i>Liver International</i> , 2008, 28, 546-557.	1.9	45
4091	Cost-Effectiveness of Rosuvastatin in the Prevention of Ischemic Heart Disease in Portugal. <i>Value in Health</i> , 2008, 11, 154-159.	0.1	12
4092	Lipid Metabolism in Dialysis Patientsâ€“The Story Gets More Complicated. <i>Seminars in Dialysis</i> , 2008, 21, 390-394.	0.7	5
4093	Longâ€“term adherence to statin treatment in diabetes. <i>Diabetic Medicine</i> , 2008, 25, 850-855.	1.2	74



#	ARTICLE	IF	CITATIONS
4094	Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study. <i>Clinical Genetics</i> , 1997, 52, 254-261.	1.0	121
4095	Potential immunosuppressive effects of statins*. <i>Pediatric Transplantation</i> , 2008, 12, 381-384.	0.5	5
4096	Review article: improving adherence to medication in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 27, 9-14.	1.9	58
4097	Reduced thyroid volume and nodularity in dyslipidaemic patients on statin treatment. <i>Clinical Endocrinology</i> , 2008, 68, 16-21.	1.2	34
4098	Using paper chart based clinical reminders to improve guideline adherence to lipid management. <i>Journal of Evaluation in Clinical Practice</i> , 2008, 14, 861-866.	0.9	9
4099	Prevention of cardiovascular disease and diabetes: lessons from the MalmÅr Preventive Project. <i>Journal of Internal Medicine</i> , 2000, 248, 455-462.	2.7	1
4100	â€œReal-lifeâ€™ reduction in cholesterol with statins, 1993 to 2002. <i>British Journal of Clinical Pharmacology</i> , 2008, 65, 587-592.	1.1	16
4101	Shift of statin use towards the elderly in 1995âˆ’2005: a nationâ€™wide register study in Finland. <i>British Journal of Clinical Pharmacology</i> , 2008, 66, 405-410.	1.1	30
4102	Impact of adherence to statins on chronic heart failure in primary prevention. <i>British Journal of Clinical Pharmacology</i> , 2008, 66, 706-716.	1.1	24
4103	Cholesterol complacency in Australia: time to revisit the basics of cardiovascular disease prevention. <i>Journal of Clinical Nursing</i> , 2009, 18, 678-686.	1.4	5
4104	EPOC y acontecimientos cardiovasculares. <i>Archivos De Bronconeumologia</i> , 2008, 44, 152-159.	0.4	4
4105	Effect of Statin Therapy Before Q-Wave Myocardial Infarction on Myocardial Perfusion. <i>American Journal of Cardiology</i> , 2008, 101, 139-143.	0.7	19
4106	Impact of Systemic Hypertension on the Cardiovascular Benefits of Statin Therapyâ€™A Meta-Analysis. <i>American Journal of Cardiology</i> , 2008, 101, 319-325.	0.7	31
4107	Prognostic Value of Early Exercise Testing After Coronary Stent Implantation. <i>American Journal of Cardiology</i> , 2008, 101, 807-811.	0.7	6
4108	Reducing the Residual Risk of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor Therapy With Combination Therapy. <i>American Journal of Cardiology</i> , 2008, 101, S27-S35.	0.7	16
4109	Effect of Xuezhikang, an Extract From Red Yeast Chinese Rice, on Coronary Events in a Chinese Population With Previous Myocardial Infarction. <i>American Journal of Cardiology</i> , 2008, 101, 1689-1693.	0.7	276
4110	Controlled Rosuvastatin Multinational Trial in Heart Failure (The Positive Negative Trial). <i>American Journal of Cardiology</i> , 2008, 101, 1808-1809.	0.7	2
4111	Consensus Panel Recommendation for Incorporating Lipoprotein-Associated Phospholipase A2 Testing into Cardiovascular Disease Risk Assessment Guidelines. <i>American Journal of Cardiology</i> , 2008, 101, S51-S57.	0.7	133

#	ARTICLE	IF	CITATIONS
4112	The Residual Risk Reduction Initiative: A Call to Action to Reduce Residual Vascular Risk in Patients with Dyslipidemia. <i>American Journal of Cardiology</i> , 2008, 102, 1K-34K.	0.7	371
4114	A description of the characteristics of patients with non-ST elevation acute coronary syndromes admitted to different settings in the 1990s. <i>Intensive and Critical Care Nursing</i> , 2008, 24, 286-294.	1.4	1
4115	Decreased plasma and cardiac matrix metalloproteinase activities in patients with coronary artery disease and treated with pravastatin. <i>European Journal of Pharmacology</i> , 2008, 594, 146-151.	1.7	16
4116	Critical Missing Data on Erythropoiesis-Stimulating Agents in CKD: First Beat Placebo. <i>American Journal of Kidney Diseases</i> , 2008, 51, 366-369.	2.1	13
4117	The Benefits of Intensive Lipid Lowering in Patients With Stable Coronary Heart Disease With Normal or High Systolic Blood Pressure: An Analysis of the Treating to New Targets (TNT) Study. <i>Journal of Clinical Hypertension</i> , 2008, 10, 367-376.	1.0	13
4118	Atherogenic Lipoprotein Particle Size and Concentrations and the Effect of Pravastatin in Children with Familial Hypercholesterolemia. <i>Journal of Pediatrics</i> , 2008, 152, 873-878.	0.9	18
4119	Effect of preoperative statins in patients without coronary artery disease who undergo cardiac surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2008, 136, 1510-1513.	0.4	29
4120	A Review of Therapeutic Strategies for Risk Reduction of Recurrent Stroke. <i>Progress in Cardiovascular Diseases</i> , 2008, 50, 264-273.	1.6	13
4121	NADPH oxidases in the vasculature: Molecular features, roles in disease and pharmacological inhibition. , 2008, 120, 254-291.		221
4122	Long-term effects of early statin therapy for patients with acute myocardial infarction treated with stent implantation. <i>Journal of Cardiology</i> , 2008, 51, 171-178.	0.8	13
4123	Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality. <i>Expert Opinion on Drug Safety</i> , 2008, 7, 717-725.	1.0	63
4124	Pharmacologic risk factor management in peripheral arterial disease: A vade mecum for vascular surgeons. <i>Journal of Vascular Surgery</i> , 2008, 47, 1108-1115.	0.6	11
4125	Suboptimal use of statin therapy in elderly patients with atherosclerosis: A population-based study. <i>Journal of Vascular Surgery</i> , 2008, 48, 607-612.e1.	0.6	27
4126	Assessment and management of acute coronary syndrome. <i>Foundation Years</i> , 2008, 4, 99-105.	0.0	0
4127	Short- and long-term effect of simvastatin therapy on the heterogeneity of cardiac repolarization in diabetic patients. <i>Pharmacological Research</i> , 2008, 57, 393-397.	3.1	17
4128	Hepatic Effects of Lovastatin Exposure in Patients with Liver Disease. <i>Drug Safety</i> , 2008, 31, 325-334.	1.4	31
4129	Pharmacokinetic Comparison of the Potential Over-the-Counter Statins Simvastatin, Lovastatin, Fluvastatin and Pravastatin. <i>Clinical Pharmacokinetics</i> , 2008, 47, 463-474.	1.6	177
4130	HMG-CoA Reductase Inhibitors. <i>Drugs</i> , 2008, 68, 1771-1785.	4.9	24

#	ARTICLE	IF	CITATIONS
4131	Cuñas de práctica clínica sobre prevención de la enfermedad cardiovascular: versión resumida. Revista Española De Cardiología, 2008, 61, 82.e1-82.e49.	0.6	19
4134	Chronic Obstructive Pulmonary Disease and Cardiovascular Events. Archivos De Bronconeumología, 2008, 44, 152-159.	0.4	4
4135	Statins for Secondary Prevention in Elderly Patients. Journal of the American College of Cardiology, 2008, 51, 37-45.	1.2	326
4137	Statins, Low-Density Lipoprotein Cholesterol, and Risk of Cancer. Journal of the American College of Cardiology, 2008, 52, 1141-1147.	1.2	99
4138	ACC/AHA 2008 Performance Measures for Adults With ST-Elevation and Non-ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2008, 52, 2046-2099.	1.2	172
4139	Efficacy of simvastatin therapy in attainment of LDL-C and TG goal levels in patients with type 2 diabetic dyslipidemia. Journal of Clinical Lipidology, 2008, 2, 12-18.	0.6	3
4140	A pilot study in the efficacy and safety of gemfibrozil in a pediatric population. Journal of Clinical Lipidology, 2008, 2, 106-111.	0.6	14
4141	Comparison of the efficacy and safety of a combination tablet of niacin extended-release and simvastatin with simvastatin 80 mg monotherapy: the SEACOAST II (high-dose) study. Journal of Clinical Lipidology, 2008, 2, 79-90.	0.6	37
4142	Point: Statins, plant sterol absorption, and increased coronary risk. Journal of Clinical Lipidology, 2008, 2, 304-305.	0.6	5
4143	Counterpoint: Lipoproteins and dementia: Is there compelling evidence to treat Alzheimer's patients with statins?. Journal of Clinical Lipidology, 2008, 2, 394-396.	0.6	1
4144	Diabetic dyslipidemia and the metabolic syndrome. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2008, 2, 208-222.	1.8	6
4145	Essential fatty acids and their metabolites could function as endogenous HMG-CoA reductase and ACE enzyme inhibitors, anti-arrhythmic, anti-hypertensive, anti-atherosclerotic, anti-inflammatory, cytoprotective, and cardioprotective molecules. Lipids in Health and Disease, 2008, 7, 37.	1.2	195
4146	Nitric oxide and cardiovascular effects: new insights in the role of nitric oxide for the management of osteoarthritis. Arthritis Research and Therapy, 2008, 10, S3.	1.6	25
4147	Clinical Aspects of Coenzyme Q10 in Relationship with Its Bioenergetic and Antioxidant Properties. , 2008, , 303-321.		2
4148	Efficacy and Tolerability of Rosuvastatin and Atorvastatin when Force-Titrated in Patients with Primary Hypercholesterolemia. Cardiology, 2008, 111, 219-228.	0.6	32
4149	Quantitative 3T MR Imaging of the Descending Thoracic Aorta: Patients with Familial Hypercholesterolemia Have an Increased Aortic Plaque Burden Despite Long-Term Lipid-lowering Therapy. Journal of Vascular and Interventional Radiology, 2008, 19, 1403-1408.	0.2	13
4151	Secondary Prevention of Coronary Heart Disease in Elderly Patients Following Myocardial Infarction. Drugs and Aging, 2008, 25, 649-664.	1.3	21
4152	The effects of short term statin treatment on left ventricular function and inflammatory markers in patients with chronic heart failure. International Journal of Cardiology, 2008, 123, 102-107.	0.8	61

#	ARTICLE	IF	CITATIONS
4153	Can dysfunctional HDL explain high coronary artery disease risk in South Asians?. International Journal of Cardiology, 2008, 129, 125-132.	0.8	57
4154	Effect of intensive vs standard statin therapy on endothelial progenitor cells and left ventricular function in patients with acute myocardial infarction: Statins for regeneration after acute myocardial infarction and PCI (STRAP) trial. International Journal of Cardiology, 2008, 130, 457-462.	0.8	69
4155	Low-dose of Statin Treatment Improves Cerebrovascular Reactivity in Patients With Ischemic Stroke: Single Photon Emission Computed Tomography Analysis. Journal of Stroke and Cerebrovascular Diseases, 2008, 17, 16-22.	0.7	17
4156	Simvastatin prevents cardiac hypertrophy in vitro and in vivo via JAK/STAT pathway. Life Sciences, 2008, 82, 991-996.	2.0	28
4158	Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends in Molecular Medicine, 2008, 14, 37-44.	3.5	522
4160	Statin Therapy Improves Outcomes After Valvular Heart Surgery. Annals of Thoracic Surgery, 2008, 85, 1521-1526.	0.7	45
4161	Simple adaptation of current abdominal aortic aneurysm screening programs may address all-cause cardiovascular mortality. American Heart Journal, 2008, 155, 938-945.	1.2	2
4162	Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International) outcomes in patients with acute coronary syndromes. American Heart Journal, 2008, 156, 826-832.	0.784314	280
4163	Statin Therapy in Stroke Prevention: A Meta-analysis Involving 121,000 Patients. American Journal of Medicine, 2008, 121, 24-33.	0.6	198
4164	Lowering LDL Cholesterol in Adults: A Prospective, Community-Based Practice Initiative. American Journal of Medicine, 2008, 121, 604-610.	0.6	14
4165	Phytosterols dissolved in diacylglycerol oil reinforce the cholesterol-lowering effect of low-dose pravastatin treatment. Nutrition, Metabolism and Cardiovascular Diseases, 2008, 18, 483-491.	1.1	21
4166	Differential mechanisms of angiotensin II and PDGF-BB on migration and proliferation of coronary artery smooth muscle cells. Journal of Molecular and Cellular Cardiology, 2008, 45, 198-208.	0.9	10
4167	Correlation between adiponectin and reduction of cell adhesion molecules after pitavastatin treatment in hyperlipidemic patients with type 2 diabetes mellitus. Thrombosis Research, 2008, 122, 39-45.	0.8	40
4168	Simvastatin induces apoptosis in human breast cancer cells in a NF $\kappa$ B-dependent manner and abolishes the anti-apoptotic signaling of TF/FVIIa and TF/FVIIa/FXa. Thrombosis Research, 2008, 122, 191-202.	0.8	34
4169	Lifestyle or Life-Saving Medicines? A Primary Healthcare Professional and Consumer Opinion Survey on Over-the-Counter Statins. Annals of Pharmacotherapy, 2008, 42, 413-420.	0.9	10
4170	Emerging antidyplipidemic drugs. Expert Opinion on Emerging Drugs, 2008, 13, 363-381.	1.0	14
4171	Mevalonate independent effects of atorvastatin on angiogenesis: Relevance to cancer. Bioscience Hypotheses, 2008, 1, 67-69.	0.2	0
4172	Statins and cancer: A systematic review and meta-analysis. European Journal of Cancer, 2008, 44, 2122-2132.	1.3	257

#	ARTICLE	IF	CITATIONS
4173	Statins in stroke prevention: What an internist should know. <i>European Journal of Internal Medicine</i> , 2008, 19, 8-14.	1.0	25
4174	Simvastatin enhances endothelial differentiation of peripheral blood mononuclear cells in hypercholesterolemic patients and induces pro-angiogenic cytokine IL-8 secretion from monocytes. <i>Clinica Chimica Acta</i> , 2008, 388, 156-166.	0.5	31
4175	The Discovery of Statins. <i>Cell</i> , 2008, 134, 903-905.	13.5	78
4176	Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: A large database analysis of managed care plans in the United States. <i>Clinical Therapeutics</i> , 2008, 30, 195-205.	1.1	33
4177	Delay in filling the initial prescription for a statin: A potential early indicator of medication nonpersistence. <i>Clinical Therapeutics</i> , 2008, 30, 761-774.	1.1	21
4178	A 52-Week, Randomized, Open-Label, Parallel-Group Comparison of the Tolerability and Effects of Pitavastatin and Atorvastatin on High-Density Lipoprotein Cholesterol Levels and Glucose Metabolism in Japanese Patients with Elevated Levels of Low-Density Lipoprotein Cholesterol and Glucose Intolerance. <i>Clinical Therapeutics</i> , 2008, 30, 1089-1101.	1.1	93
4179	Long-term persistence with statin treatment in a not-for-profit health maintenance organization: A population-based retrospective cohort study in Israel. <i>Clinical Therapeutics</i> , 2008, 30, 2167-2179.	1.1	134
4180	Effects of D-003, a mixture of high-molecular-weight sugar cane wax acids, on lipid peroxidation markers in older individuals: A randomized, double-blind, placebo-controlled study. <i>Current Therapeutic Research</i> , 2008, 69, 36-48.	0.5	3
4181	Effects of xuezhikang on proliferation and adhesion capacity of cultured endothelial progenitor cells: An in vitro study. <i>Current Therapeutic Research</i> , 2008, 69, 252-259.	0.5	3
4182	Controlling the ABCs of diabetes in clinical practice: A community-based endocrinology practice experience. <i>Diabetes Research and Clinical Practice</i> , 2008, 80, 89-95.	1.1	24
4183	Dislipidemias en pacientes muy ancianos. <i>EMC - Tratado De Medicina</i> , 2008, 12, 1-10.	0.0	0
4184	Dyslipidaemia and cardiorenal disease: mechanisms, therapeutic opportunities and clinical trials. <i>Atherosclerosis</i> , 2008, 196, 823-834.	0.4	57
4185	Effect of pravastatin on the development of diabetes and adiponectin production. <i>Atherosclerosis</i> , 2008, 196, 114-121.	0.4	82
4186	Treatment potential for cholesterol management in patients with coronary heart disease in 15 European countries: Findings from the EUROASPIRE II survey. <i>Atherosclerosis</i> , 2008, 197, 710-717.	0.4	63
4187	Early changes in arterial structure and function following statin initiation: Quantification by magnetic resonance imaging. <i>Atherosclerosis</i> , 2008, 197, 951-958.	0.4	54
4188	Plasma remnant-like lipoprotein particles or LDL-C as major pathologic factors in sudden cardiac death cases. <i>Atherosclerosis</i> , 2008, 198, 237-246.	0.4	27
4189	Berberine decreases PCSK9 expression in HepG2 cells. <i>Atherosclerosis</i> , 2008, 201, 266-273.	0.4	183
4190	Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients. <i>Atherosclerosis</i> , 2008, 201, 345-352.	0.4	91

#	ARTICLE	IF	CITATIONS
4191	LDL induces parathyroid hormone-related protein expression in vascular smooth muscle cells: Modulation by simvastatin. <i>Atherosclerosis</i> , 2008, 198, 264-271.	0.4	7
4194	Ictus y estatinas: más allá de la reducción de los valores de colesterol. <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2008, 20, 239-246.	0.4	0
4195	Statins for people with diabetes. <i>Lancet, The</i> , 2008, 371, 94-95.	6.3	14
4196	Efficacy of cholesterol-lowering therapy in 18686 people with diabetes in 14 randomised trials of statins: a meta-analysis. <i>Lancet, The</i> , 2008, 371, 117-125.	6.3	1,735
4197	Clinical and public health assessment of benefits and risks of statins in primary prevention of coronary events: Resolved and unresolved issues. <i>Canadian Journal of Cardiology</i> , 2008, 24, 293-300.	0.8	15
4198	Preventing cardiovascular disease among Canadians: Is the treatment of hypertension or dyslipidemia cost-effective?. <i>Canadian Journal of Cardiology</i> , 2008, 24, 891-898.	0.8	18
4199	Treatment of low high-density lipoprotein cholesterol. <i>Canadian Journal of Cardiology</i> , 2008, 24, 27C-31C.	0.8	7
4200	Insulin Resistance and Atherosclerosis. <i>Endocrinology and Metabolism Clinics of North America</i> , 2008, 37, 603-621.	1.2	82
4201	Anticoagulants, Antiplatelets, and Statins in Heart Failure. <i>Cardiology Clinics</i> , 2008, 26, 49-58.	0.9	12
4202	Observational Studies of Statins in Heart Failure with Preserved Systolic Function. <i>Heart Failure Clinics</i> , 2008, 4, 209-216.	1.0	15
4203	Toward "Pain-Free" Statin Prescribing: Clinical Algorithm for Diagnosis and Management of Myalgia. <i>Mayo Clinic Proceedings</i> , 2008, 83, 687-700.	1.4	83
4204	Homocysteine: The Rubik's Cube of Cardiovascular Risk Factors. <i>Mayo Clinic Proceedings</i> , 2008, 83, 1200-1202.	1.4	22
4205	Antiarrhythmic Effects of Statins in Heart Failure. <i>Heart Failure Clinics</i> , 2008, 4, 187-200.	1.0	2
4206	Role of Neurohormonal Modulators in Heart Failure with Relatively Preserved Systolic Function. <i>Cardiology Clinics</i> , 2008, 26, 23-40.	0.9	8
4207	Clinical Update on Nursing Home Medicine: 2008. <i>Journal of the American Medical Directors Association</i> , 2008, 9, 460-475.	1.2	16
4208	Aldosterone Receptor Blockade in Patients with Left Ventricular Systolic Dysfunction Following Acute Myocardial Infarction. <i>Cardiology Clinics</i> , 2008, 26, 91-105.	0.9	7
4209	Comparison of Cardiovascular Event Rates in Patients Without Cardiovascular Disease in Whom Atorvastatin or Simvastatin Was Newly Initiated. <i>Mayo Clinic Proceedings</i> , 2008, 83, 1316-1325.	1.4	22
4210	Cardiovascular Risk Assessment and Hyperlipidemia. <i>Critical Care Nursing Clinics of North America</i> , 2008, 20, 277-285.	0.4	2

#	ARTICLE	IF	CITATIONS
4211	Cholesterol lowering, sudden cardiac death and mortality. <i>Scandinavian Cardiovascular Journal</i> , 2008, 42, 264-267.	0.4	2
4212	Secondary Stroke Prevention. <i>CNS Drugs</i> , 2008, 22, 113-121.	2.7	0
4213	Current and Future Pharmacologic Options for the Management of Patients Unable to Achieve Low-Density Lipoprotein-Cholesterol Goals with Statins. <i>American Journal of Cardiovascular Drugs</i> , 2008, 8, 233-242.	1.0	23
4214	Candidate Mechanisms for Regression of Coronary Atherosclerosis with High-Dose Statins. <i>American Journal of Cardiovascular Drugs</i> , 2008, 8, 365-371.	1.0	11
4215	Statin Adverse Effects. <i>American Journal of Cardiovascular Drugs</i> , 2008, 8, 373-418.	1.0	564
4216	Achieving Vascular Risk Factor Targets: A Survey of a London General Practice. <i>Angiology</i> , 2008, 59, 36-46.	0.8	9
4217	Clinical trials update from European Society of Cardiology meeting 2008: TIMEâ€œCHF, BACH, BEAUTIFUL, GISSIâ€œCHF, and HOMEâ€œCHF. <i>European Journal of Heart Failure</i> , 2008, 10, 1264-1267.	2.9	13
4218	Review of the Effect of Dairy Products on Non-Lipid Risk Factors for Cardiovascular Disease. <i>Journal of the American College of Nutrition</i> , 2008, 27, 741S-746S.	1.1	43
4219	Lâ€™utilizzo delle DDD reference based per la valutazione della compliance terapeutica nel trattamento con statine. <i>Pharmacoeconomics Italian Research Articles</i> , 2008, 10, 77-88.	0.2	1
4220	Valutazione di un risultato del trattamento con statine: il caso dellâ€™ASL di Foligno (PG). <i>Pharmacoeconomics Italian Research Articles</i> , 2008, 10, 123-136.	0.2	1
4221	Atorvastatin Reduces Oxidative Stress in the Rostral Ventrolateral Medulla of Stroke-Prone Spontaneously Hypertensive Rats. <i>Clinical and Experimental Hypertension</i> , 2008, 30, 3-11.	0.5	41
4222	Antiinflammatory and Antiatherogenic Effects of the NF-Î²B Inhibitor Acetyl-11-Keto-Î²-Boswellic Acid in LPS-Challenged ApoE <sup>0/0</sup> Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 272-277.	1.1	157
4223	Mortality in COPD: Inevitable or Preventable? Insights from the Cardiovascular Arena. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2008, 5, 187-200.	0.7	17
4224	Chapter 11 A cerebrovascular perspective of atherosclerosis. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2008, 92, 215-238.	1.0	1
4225	Preventing Heart Disease in the 21st Century. <i>Circulation</i> , 2008, 117, 1216-1227.	1.6	441
4226	Statins in Heart Failure. <i>Cardiology Clinics</i> , 2008, 26, 573-587.	0.9	4
4227	Effect of very low LDL-cholesterol on cortisol synthesis. <i>Journal of Endocrinological Investigation</i> , 2008, 31, 1075-1078.	1.8	9
4228	Risk factors for first-ever stroke in the EPIC-Norfolk prospective population-based study. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2008, 15, 663-669.	3.1	32

#	ARTICLE	IF	CITATIONS
4229	Calcium supplementation and vascular disease. <i>Climacteric</i> , 2008, 11, 280-286.	1.1	22
4230	Effects of Cerivastatin Withdrawal on Statin Persistence. <i>Annals of Pharmacotherapy</i> , 2008, 42, 956-961.	0.9	7
4231	Challenges to Evidence-Based Prescribing in Clinical Practice. <i>Annals of Pharmacotherapy</i> , 2008, 42, 704-707.	0.9	16
4232	The Possibility of Simvastatin as a Chemotherapeutic Agent for All-trans Retinoic Acid-Resistant Promyelocytic Leukemia. <i>Biological and Pharmaceutical Bulletin</i> , 2008, 31, 369-374.	0.6	20
4233	Stroke and visual loss. <i>Expert Review of Ophthalmology</i> , 2008, 3, 529-541.	0.3	0
4234	Risk Factor Profile and Management of Cerebrovascular Patients in the REACH Registry. <i>Cerebrovascular Diseases</i> , 2008, 25, 366-374.	0.8	59
4235	Pitavastatin, an HMG-CoA Reductase Inhibitor, Exerts eNOS-Independent Protective Actions Against Angiotensin II-Induced Cardiovascular Remodeling and Renal Insufficiency. <i>Circulation Research</i> , 2008, 102, 68-76.	2.0	77
4236	Statin Potentiates Human Platelet eNOS Activity without Enhancing eNOS mRNA and Protein Levels. <i>Cerebrovascular Diseases</i> , 2008, 26, 190-198.	0.8	16
4237	Strategies for prescribing statins. <i>BMJ: British Medical Journal</i> , 2008, 336, 288-289.	2.4	8
4238	Is chronic diabetic foot ulcer an indicator of cardiac disease?. <i>Journal of Wound Care</i> , 2008, 17, 12-16.	0.5	19
4239	Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial. <i>BMJ: British Medical Journal</i> , 2008, 336, 262-266.	2.4	585
4240	Impact on mortality following first acute myocardial infarction of distance between home and hospital: cohort study. <i>Heart</i> , 2008, 94, 1141-1146.	1.2	41
4241	Clinical significance of carotid bruits: an innocent finding or a useful warning sign?. <i>Neurological Research</i> , 2008, 30, 523-530.	0.6	16
4242	The Effect of Statin Pretreatment on Infarct Volume in Ischemic Stroke. <i>Neuroepidemiology</i> , 2008, 31, 48-56.	1.1	21
4243	Non-Cardiovascular Mortality, Low-Density Lipoprotein Cholesterol and Statins: A Meta-Regression Analysis. <i>Cardiology</i> , 2008, 109, 110-116.	0.6	6
4244	Approaches to dyslipidemia treatment in children and adolescents. <i>Expert Review of Endocrinology and Metabolism</i> , 2008, 3, 615-633.	1.2	2
4245	Ezetimibe plus simvastatin cardiovascular outcomes study program. <i>Expert Review of Cardiovascular Therapy</i> , 2008, 6, 17-25.	0.6	3
4246	Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. <i>BMJ: British Medical Journal</i> , 2008, 336, 645-651.	2.4	382



#	ARTICLE	IF	CITATIONS
4247	Advances in the management of hyperlipidemia-induced atherosclerosis. Expert Review of Cardiovascular Therapy, 2008, 6, 369-383.	0.6	18
4248	Renoprotection by statins is linked to a decrease in renal oxidative stress, TGF- $\beta$ <sup>2</sup> , and fibronectin with concomitant increase in nitric oxide bioavailability. American Journal of Physiology - Renal Physiology, 2008, 295, F53-F59.	1.3	89
4249	Effects of Statins on Adipose Tissue Inflammation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 871-877.	1.1	94
4250	Infusion of Reconstituted High-Density Lipoprotein Leads to Acute Changes in Human Atherosclerotic Plaque. Circulation Research, 2008, 103, 1084-1091.	2.0	251
4251	Best Practices for Lowering the Risk of Cardiovascular Disease in Diabetes. Diabetes Spectrum, 2008, 21, 177-189.	0.4	11
4252	Re: The Association Between Statins and Cancer Incidence in a Veterans Population. Journal of the National Cancer Institute, 2008, 100, 972-973.	3.0	9
4253	Review: Percutaneous coronary interventions and statins therapy. Therapeutic Advances in Cardiovascular Disease, 2008, 2, 101-107.	1.0	4
4254	The Role of Statin Drugs in the Management of the Peripheral Vascular Patient. Vascular and Endovascular Surgery, 2008, 42, 352-366.	0.3	16
4255	Statins in the Treatment of Polycystic Ovary Syndrome. Seminars in Reproductive Medicine, 2008, 26, 127-138.	0.5	34
4256	ACC/AHA 2008 Performance Measures for Adults With ST-Elevation and Non- $\sigma$ ST-Elevation Myocardial Infarction. Circulation, 2008, 118, 2596-2648.	1.6	188
4257	Statin Therapy for Stroke Prevention. Stroke, 2008, 39, 1042-1048.	1.0	64
4258	Myriocin slows the progression of established atherosclerotic lesions in apolipoprotein E gene knockout mice. Journal of Lipid Research, 2008, 49, 324-331.	2.0	51
4259	Gene-Nutrient Interactions in G6PD-Deficient Subjects $\sigma$ Implications for Cardiovascular Disease Susceptibility. Journal of Nutrigenetics and Nutrigenomics, 2008, 1, 49-54.	1.8	9
4260	Recurrence of Cardiovascular Events in Patients With Type 2 Diabetes. Diabetes Care, 2008, 31, 2154-2159.	4.3	71
4262	Clinical trials update from the American Heart Association 2007: CORONA, RethinQ, MASCOT, AF $\sigma$ CHF, HART, MASTER, POISE and stem cell therapy. European Journal of Heart Failure, 2008, 10, 102-108.	2.9	23
4263	Evidence Mandating Earlier and More Aggressive Treatment of Hypercholesterolemia. Circulation, 2008, 118, 672-677.	1.6	90
4264	Usefulness of Pravastatin in Primary Prevention of Cardiovascular Events in Women. Circulation, 2008, 117, 494-502.	1.6	105
4265	Lipid-Lowering Therapy is Related to Inflammatory Markers and 3-Year Mortality in Patients With Critical Limb Ischemia. Angiology, 2008, 59, 542-548.	0.8	17

#	ARTICLE	IF	CITATIONS
4266	Statin Use Is Associated with Prolonged Survival of Renal Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2008, 19, 2211-2218.	3.0	52
4267	Patients Prefer Pictures to Numbers to Express Cardiovascular Benefit From Treatment. <i>Annals of Family Medicine</i> , 2008, 6, 213-217.	0.9	87
4268	Should All Patients With Asymptomatic but Significant (>50%) Left Main Coronary Artery Stenosis Undergo Surgical Revascularization?. <i>Circulation</i> , 2008, 118, 422-425.	1.6	15
4269	Treatment of Vascular Dementia: The Route of Prevention. <i>European Neurology</i> , 2008, 60, 217-223.	0.6	26
4270	Applications of statins in cardiothoracic surgery: more than just lipid-lowering. <i>European Journal of Cardio-thoracic Surgery</i> , 2008, 33, 377-390.	0.6	28
4271	Targeted versus global approaches to the management of hypercholesterolaemia. <i>Perspectives in Public Health</i> , 2008, 128, 248-254.	0.5	6
4272	Preliminary Observations From Preliminary Trial Results. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2008, 1, 54-57.	0.9	13
4273	Fate of Incidental, Asymptomatic Lesions Discovered During Percutaneous Coronary Intervention. <i>Angiology</i> , 2008, 59, 193-197.	0.8	1
4274	Inhibition of Lipoprotein-Associated Phospholipase Activity by Darapladib. <i>Circulation</i> , 2008, 118, 1120-1122.	1.6	14
4275	Primary Prevention of Cardiovascular Disease and Type 2 Diabetes in Patients at Metabolic Risk: An Endocrine Society Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 3671-3689.	1.8	164
4276	Pravastatin: an evidence-based statin?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2008, 4, 821-825.	1.5	8
4277	Fixed-dose combination of extended-release niacin plus simvastatin for lipid disorders. <i>Expert Review of Cardiovascular Therapy</i> , 2008, 6, 1303-1310.	0.6	3
4278	Current and emerging paradigms in the therapeutic management of atherosclerosis. <i>Expert Opinion on Therapeutic Targets</i> , 2008, 12, 1523-1546.	1.5	1
4279	Drug Insight: translating evidence on statin therapy into clinical benefits. <i>Nature Clinical Practice Neurology</i> , 2008, 4, 43-49.	2.7	18
4280	A viewpoint on statin effects – benefits and problems. <i>International Journal of Angiology</i> , 2008, 17, 178-180.	0.2	2
4281	Atorvastatin Reduces the Risk of Cardiovascular Events in Patients With Carotid Atherosclerosis. <i>Stroke</i> , 2008, 39, 3297-3302.	1.0	243
4282	Cardiovascular Disease in Older Women: A Challenge in Diagnosis and Treatment. <i>Women's Health</i> , 2008, 4, 449-464.	0.7	9
4283	Cholesteryl Ester Transfer Protein Inhibition, High-Density Lipoprotein Raising, and Progression of Coronary Atherosclerosis. <i>Circulation</i> , 2008, 118, 2506-2514.	1.6	200

#	ARTICLE	IF	CITATIONS
4284	Pravastatin increases the expression of the tissue inhibitor of matrix metalloproteinase-1 and the oncogeneBaxin human aortic abdominal aneurysms. Canadian Journal of Physiology and Pharmacology, 2008, 86, 431-437.	0.7	13
4285	A Neuromuscular Approach to Statin-Related Myotoxicity. Canadian Journal of Neurological Sciences, 2008, 35, 8-21.	0.3	37
4286	Relationship Between Coronary Events and Serum Cholesterol During 10 Years of Low-Dose Simvastatin Therapy Long-Term Efficacy and Safety in Japanese Patients With Hypercholesterolemia in the Japan Lipid Intervention Trial (J-LIT) Extension 10 Study, a Prospective Large-Scale Observational Cohort Study. Circulation Journal, 2008, 72, 1218-1224.	0.7	20
4287	Effect of Early Use of Low-Dose Pravastatin on Major Adverse Cardiac Events in Patients With Acute Myocardial Infarction. Circulation Journal, 2008, 72, 17-22.	0.7	49
4288	Importance of Lipid Levels in Elderly Diabetic Individuals Baseline Characteristics and 1-Year Survey of Cardiovascular Events. Circulation Journal, 2008, 72, 218-225.	0.7	12
4289	Better Survival With Statin Administration After Revascularization Therapy in Japanese Patients With Coronary Artery Disease Perspectives From the CREDO-Kyoto Registry. Circulation Journal, 2008, 72, 1937-1945.	0.7	27
4292	The Relationship Between the Effect of Pravastatin and Risk Factors for Coronary Heart Disease in Japanese Patients With Hypercholesterolemia. Circulation Journal, 2008, 72, 1576-1582.	0.7	18
4293	Investigation of Blood Lipid Levels and Statin Interventions in Outpatients With Coronary Heart Disease in China The China Cholesterol Education Program (CCEP). Circulation Journal, 2008, 72, 2040-2045.	0.7	15
4294	Effects of Rosuvastatin and Pitavastatin on Ischemia-Induced Myocardial Stunning in Dogs. Journal of Pharmacological Sciences, 2008, 106, 593-599.	1.1	16
4295	Possible Involvement of Akt Activity in Endothelial Dysfunction in Type 2 Diabetic Mice. Journal of Pharmacological Sciences, 2008, 106, 600-608.	1.1	21
4296	Statins and the Risk of Lung, Breast, and Colorectal Cancer in the Elderly. Yearbook of Cardiology, 2008, 2008, 288-290.	0.0	0
4297	Toward "Pain-Free" Statin Prescribing: Clinical Algorithm for Diagnosis and Management of Myalgia. Mayo Clinic Proceedings, 2008, 83, 687-700.	1.4	136
4298	A Macadamia Nut-Rich Diet Reduces Total and LDL-Cholesterol in Mildly Hypercholesterolemic Men and Women. Journal of Nutrition, 2008, 138, 761-767.	1.3	121
4299	Interactions between the single nucleotide polymorphisms in the homocysteine pathway (MTHFR) Tj ETQq1 1 0.784314 rgBT /Overlook preventing cardiovascular disease in high-risk patients of hypertension: the GenHAT study. Pharmacogenetics and Genomics. 2008, 18, 651-656.	0.7	34
4300	Patient-Centered Modular Secondary Prevention Following Acute Coronary Syndrome. Journal of Cardiopulmonary Rehabilitation and Prevention, 2008, 28, 107-115.	1.2	35
4301	Response to Letter by Paraskevas. Stroke, 2008, 39, .	1.0	0
4302	Exploring the gap between National Cholesterol Education Program guidelines and clinical practice in secondary care: results of a cross-sectional study involving over 10 000 patients followed in different specialty settings across Italy. Journal of Cardiovascular Medicine, 2008, 9, 878-887.	0.6	14
4303	Association of statin therapy with reduced coronary plaque rupture: an optical coherence tomography study. Coronary Artery Disease, 2008, 19, 237-242.	0.3	40

#	ARTICLE	IF	CITATIONS
4305	HMG-CoA Reductase Inhibitor, Simvastatin Improves Reverse Cholesterol Transport in Type 2 Diabetic Patients with Hyperlipidemia. <i>Journal of Atherosclerosis and Thrombosis</i> , 2008, 15, 20-25.	0.9	30
4307	Mechanisms of atherothrombosis in chronic obstructive pulmonary disease. <i>International Journal of COPD</i> , 2008, Volume 3, 89-96.	0.9	56
4308	Targeting multiple dyslipidemias with fixed combinations &ndash; focus on extended release niacin and simvastatin. <i>Vascular Health and Risk Management</i> , 2008, Volume 4, 1001-1009.	1.0	12
4309	Combination therapy in cholesterol reduction: focus on ezetimibe and statins. <i>Vascular Health and Risk Management</i> , 2008, Volume 4, 267-278.	1.0	21
4310	Acute Coronary Syndromes and Acute Myocardial Infarction. , 2008, , 589-646.		0
4312	Atorvastatin and cardiovascular risk in the elderly &ndash; patient considerations. <i>Clinical Interventions in Aging</i> , 2008, Volume 3, 299-314.	1.3	15
4313	Beneficial Effects of Pitavastatin, a 3-Hydroxy-3-Methylglutaryl Coenzyme a Reductase Inhibitor, on Cardiac Function in Ischemic and Nonischemic Heart Failure. <i>International Heart Journal</i> , 2008, 49, 49-58.	0.5	14
4314	Superior Benefit of Aggressive Lipid-Lowering Therapy for High- Risk Patients Using Statins: the SUBARU Study -More Hypercholesterolemic Patients Achieve Japan Atherosclerosis Society LDL-C Goals with Rosuvastatin Therapy than with Atorvastatin Therapy. <i>Journal of Atherosclerosis and Thrombosis</i> . 2008. 15. 314-323.	0.9	33
4315	Clinical efficacy and safety of statins in managing cardiovascular risk. <i>Vascular Health and Risk Management</i> , 2008, Volume 4, 341-353.	1.0	106
4316	Therapies to Increase High-Density Lipoprotein Cholesterol and Their Effect on Cardiovascular Outcomes and Regression of Atherosclerosis. <i>American Journal of the Medical Sciences</i> , 2008, 336, 64-68.	0.4	10
4317	Influence of Pitavastatin on Glucose Tolerance in Patients with Type 2 Diabetes Mellitus. <i>Journal of Atherosclerosis and Thrombosis</i> , 2008, 15, 269-275.	0.9	92
4318	Recent Epidemiological Trends of Stroke. <i>Journal of Korean Neurosurgical Society</i> , 2008, 43, 16.	0.5	25
4319	DIABETES MELLITUS: OLD ASSUMPTIONS AND NEW REALITIES. , 2008, , 23-32.		0
4320	Excess coronary artery disease risk in South Asian immigrants: Can dysfunctional high-density lipoprotein explain increased risk?. <i>Vascular Health and Risk Management</i> , 2008, Volume 4, 953-961.	1.0	43
4321	Pleiotropic vasoprotective effects of statins: The chicken or the egg?. <i>Drug Design, Development and Therapy</i> , 2009, 3, 191.	2.0	9
4322	Low Incidence of Cardiac Events in Statin-Administered Patients in CAG Study. <i>Journal of Atherosclerosis and Thrombosis</i> , 2009, 16, 172-178.	0.9	6
4323	Lipid management in secondary prevention. <i>Practice Nursing</i> , 2009, 20, 592-595.	0.1	0
4324	Reducing morbidity and mortality in high risk patients with statins. <i>Vascular Health and Risk Management</i> , 2009, 5, 495.	1.0	6

#	ARTICLE	IF	CITATIONS
4325	Supporting vulnerable adults. <i>Practice Nursing</i> , 2009, 20, 511-515.	0.1	1
4326	Lipid-Modifying and Antiatherosclerotic Drugs. , 2009, , 341-372.		2
4327	Hypertension and stroke. , 0, , 307-318.		0
4328	Therapeutic interventions and oxidative stress in diabetes. <i>Frontiers in Bioscience - Landmark</i> , 2009, Volume, 192.	3.0	24
4329	Thinking beyond low-density lipoprotein cholesterol: strategies to further reduce cardiovascular risk. <i>Vascular Health and Risk Management</i> , 2009, 5, 793.	1.0	38
4330	Modern Drug Discovery and Development. , 2009, , 361-380.		3
4331	Long-term use of rosuvastatin: a critical risk benefit appraisal and comparison with other antihyperlipidemics. <i>Drug, Healthcare and Patient Safety</i> , 2009, 1, 25.	1.0	12
4332	Efficacy, effectiveness and real life goal attainment of statins in managing cardiovascular risk. <i>Vascular Health and Risk Management</i> , 2009, 5, 369.	1.0	23
4333	Simvastatin and Amiodarone: Emergence of a Potentially Toxic Interaction. <i>Hospital Pharmacy</i> , 2009, 44, 221-225.	0.4	0
4334	A Randomized Controlled Study to Compare the Effects of Rosuvastatin 2.5mg and Pravastatin 10mg on the Plasma Lipid Profile in Japanese Patients with Hypercholesterolemia (ASTRO-1). <i>Annals of Vascular Diseases</i> , 2009, 2, 148-158.	0.2	1
4335	A Randomized Controlled Study to Compare the Effects of Rosuvastatin 5mg and Atorvastatin 10mg on the Plasma Lipid Profile in Japanese Patients with Hypercholesterolemia (ASTRO-2). <i>Annals of Vascular Diseases</i> , 2009, 2, 159-173.	0.2	9
4336	Secondary Stroke Prevention, and the Role of Antiplatelet Therapies. <i>Clinical Medicine Therapeutics</i> , 2009, 1, CMT.S2208.	0.1	0
4337	Pitavastatin in the Management of Hypercholesterolemia. <i>Clinical Medicine Therapeutics</i> , 2009, 1, CMT.S2690.	0.1	1
4338	Use of primary care electronic medical record database in drug efficacy research on cardiovascular outcomes: comparison of database and randomised controlled trial findings. <i>BMJ: British Medical Journal</i> , 2009, 338, b81-b81.	2.4	117
4339	Effects of Pitavastatin (LIVALO Tablet) on High Density Lipoprotein Cholesterol (HDL-C) in Hypercholesterolemia Sub-Analysis of LIVALO Effectiveness and Safety (LIVES) Study. <i>Journal of Atherosclerosis and Thrombosis</i> , 2009, 16, 654-661.	0.9	60
4340	Clinical Significance of Serum 7-Ketocholesterol Concentrations in the Progression of Coronary Atherosclerosis. <i>Journal of Atherosclerosis and Thrombosis</i> , 2009, 16, 363-370.	0.9	29
4341	The JUPITER and AURORA clinical trials for rosuvastatin in special primary prevention populations: perspectives, outcomes, and consequences. <i>Vascular Health and Risk Management</i> , 2009, 5, 1033.	1.0	16
4342	Lipid-Lowering Drugs in Ischemic Stroke Prevention and Their Influence on Acute Stroke Outcome. <i>Cerebrovascular Diseases</i> , 2009, 27, 126-133.	0.8	50

#	ARTICLE	IF	CITATIONS
4343	Number Needed to Treat With Rosuvastatin to Prevent First Cardiovascular Events and Death Among Men and Women With Low Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2009, 2, 616-623.	0.9	128
4344	Statins in Endothelial Signaling and Activation. <i>Antioxidants and Redox Signaling</i> , 2009, 11, 811-821.	2.5	30
4345	Effects of Statins on the Pharmacokinetics of Midazolam in Healthy Volunteers. <i>Journal of Clinical Pharmacology</i> , 2009, 49, 568-573.	1.0	15
4346	Association between prescription burden and medication adherence in patients initiating antihypertensive and lipid-lowering therapy. <i>American Journal of Health-System Pharmacy</i> , 2009, 66, 1471-1477.	0.5	81
4347	Cholesterol Was Healthy in the End. <i>World Review of Nutrition and Dietetics</i> , 2009, 100, 90-109.	0.1	5
4348	High-density lipoprotein is superior to B-type natriuretic peptide as a marker of systolic dysfunction in an elderly general population. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2009, 69, 865-872.	0.6	7
4349	From 4S to IDEAL: the health economics of the statin trials. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2009, 16, 138-143.	3.1	6
4350	Early Atorvastatin Reduces Hemorrhage after Acute Cerebral Ischemia in Diabetic Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009, 330, 532-540.	1.3	44
4351	Associations Between Statin Treatment and Markers of Inflammation, Vasoconstriction, and Coagulation in Patients With Abdominal Aortic Aneurysm. <i>Vascular and Endovascular Surgery</i> , 2009, 42, 567-573.	0.3	9
4352	Statins for Asymptomatic Middle Cerebral Artery Stenosis: The Regression of Cerebral Artery Stenosis Study. <i>Cerebrovascular Diseases</i> , 2009, 28, 18-25.	0.8	27
4353	2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults. <i>Circulation</i> , 2009, 119, e391-479.	1.6	2,001
4354	Management of Hyperlipidemia in Older Adults. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2009, 14, 49-58.	1.0	34
4355	Statins. , 2009, , 253-280.		5
4356	A randomized, controlled trial of simvastatin versus rosuvastatin in patients with acute myocardial infarction: the Secondary Prevention of Acute Coronary Events "Reduction of Cholesterol to Key European Targets Trial. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2009, 16, 712-721.	3.1	17
4357	A Review of Lifetime Risk Factors for Mortality. <i>British Actuarial Journal</i> , 2009, 15, 17-64.	0.2	14
4358	Beneficial effects of statins after percutaneous coronary intervention. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2009, 16, 445-450.	3.1	17
4359	Statins Do Not Affect Mineral Metabolism in Chronic Kidney Disease: A Retrospective Analysis. <i>Nephron Clinical Practice</i> , 2009, 111, c236-c239.	2.3	3
4361	Simvastatin Reduces OX40 and OX40 Ligand Expression in Human Peripheral Blood Mononuclear Cells and in Patients with Atherosclerotic Cerebral Infarction. <i>Journal of International Medical Research</i> , 2009, 37, 601-610.	0.4	8

#	ARTICLE	IF	CITATIONS
4362	Intensive Lowering of Low-Density Lipoprotein Cholesterol Levels for Primary Prevention of Coronary Artery Disease. <i>Mayo Clinic Proceedings</i> , 2009, 84, 345-352.	1.4	37
4363	Quality-adjusted life-years as decisionmaker tools to address limitations inherent in number-needed-to-treat/harm values. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2009, 9, 99-102.	0.7	4
4364	Low-Density Lipoprotein Cholesterol Reduction and Prevention of Cardiovascular Disease. <i>Mayo Clinic Proceedings</i> , 2009, 84, 307-309.	1.4	11
4365	Cardiovascular clinical trials in Japan and controversies regarding prospective randomized open-label blinded end-point design. <i>Hypertension Research</i> , 2009, 32, 109-114.	1.5	13
4366	Placebo-Controlled Trial of High-Dose Atorvastatin in Patients With Severe Cerebral Small Vessel Disease. <i>Stroke</i> , 2009, 40, e542.	1.0	1
4367	Hypercholesterolaemia. <i>InnovAiT</i> , 2009, 2, 721-731.	0.0	0
4368	The effect of dyslipidemic drugs on mortality: A meta-analysis. <i>Indian Journal of Pharmacology</i> , 2009, 41, 4.	0.4	4
4369	The Jupiter trialâ€”new territory for statins?*. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 2036-2037.	0.4	2
4370	Blood Pressure and Lipid Control Status in Japanese Hypertensive Patients. <i>Clinical and Experimental Hypertension</i> , 2009, 31, 298-305.	0.5	3
4371	High-density Lipoprotein Cholesterol: Current Perspective for Clinicians. <i>Angiology</i> , 2009, 60, 644-649.	0.8	3
4372	Atherosclerosis and Physical Activity. <i>Oman Medical Journal</i> , 2009, 24, 173-8.	0.3	11
4373	The Vytorin on Carotidâ€”Media Thickness and Overall Arterial Rigidity (VYCTOR) study. <i>Expert Review of Cardiovascular Therapy</i> , 2009, 7, 1057-1060.	0.6	1
4374	Ten-Year Survival in 75-Year-Old Men and Women: Predictive Ability of Total Cholesterol, HDL-C, and LDL-C. <i>Current Gerontology and Geriatrics Research</i> , 2009, 2009, 1-7.	1.6	18
4375	Evidence for Statin Pleiotropy in Humans. <i>Circulation</i> , 2009, 119, 131-138.	1.6	208
4376	Yearsâ€”neededâ€”toâ€”treat to add 1 year of life: a new metric to estimate treatment effects in randomized trials. <i>European Journal of Heart Failure</i> , 2009, 11, 256-263.	2.9	11
4377	When to stop?. <i>Scandinavian Journal of Primary Health Care</i> , 2009, 27, 1-3.	0.6	5
4378	Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. <i>BMJ: British Medical Journal</i> , 2009, 338, b92-b92.	2.4	401
4379	Results of a randomized controlled trial on statin use in dialysis patients had no influence on statin prescription. <i>Kidney International</i> , 2009, 76, 1172-1179.	2.6	14

#	ARTICLE	IF	CITATIONS
4380	Pravastatin for Cardiovascular Event Primary Prevention in Patients With Mild-to-Moderate Hypertension in the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study. <i>Hypertension</i> , 2009, 53, 135-141.	1.3	32
4381	Small Dense Low-Density Lipoprotein Concentration and Oxidative Susceptibility Changes after Consumption of Soybean Oil, Rice Bran Oil, Palm Oil and Mixed Rice Bran/Palm Oil in Hypercholesterolaemic Women. <i>Journal of International Medical Research</i> , 2009, 37, 96-104.	0.4	34
4382	Alterations in cholesterol absorption/synthesis markers characterize Framingham Offspring Study participants with CHD. <i>Journal of Lipid Research</i> , 2009, 50, 1927-1935.	2.0	149
4383	Rosuvastatin Increases Extracellular Adenosine Formation in Humans In Vivo. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 963-968.	1.1	37
4384	Aggressive statin therapy in multicenter and effectiveness for the reduction of intra-myocardial damage caused by non-ST elevation acute coronary syndrome: AMERICA study. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2009, 3, 357-365.	1.0	11
4385	Response to Letter of Mascitelli L, Ravnskov U, Pezzetta F, and Goldstein M. <i>Angiology</i> , 2009, 60, 129-130.	0.8	1
4386	Issues to consider in the pharmaceutical development of a cardiovascular polypill. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2009, 6, 112-119.	3.3	31
4387	Cardiovascular Benefit of Magnitude of Low-Density Lipoprotein Cholesterol Reduction. <i>Circulation</i> , 2009, 120, 1491-1497.	1.6	29
4388	Is Calcitriol Life-Protective for Patients with Chronic Kidney Disease?. <i>Journal of the American Society of Nephrology: JASN</i> , 2009, 20, 2285-2290.	3.0	14
4389	Adding exercise training to rosuvastatin treatment: influence on serum lipids and biomarkers of muscle and liver damage. <i>Metabolism: Clinical and Experimental</i> , 2009, 58, 1030-1038.	1.5	31
4390	Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and disease. , 2009, 122, 246-263.		127
4391	Cardiac fibroblasts: At the heart of myocardial remodeling. , 2009, 123, 255-278.		864
4392	Simvastatin reduces myocardial infarct size via increased nitric oxide production in normocholesterolemic rabbits. <i>Journal of Cardiology</i> , 2009, 53, 102-107.	0.8	16
4393	The impact of statins on health services utilization and mortality in older adults discharged from hospital with ischemic heart disease: a cohort study. <i>BMC Health Services Research</i> , 2009, 9, 198.	0.9	12
4394	Low-Density Lipoprotein Reduction and Magnitude of Cardiovascular Risk Reduction. <i>Preventive Cardiology</i> , 2009, 12, 80-87.	1.1	9
4395	Safety and Feasibility of Achieving Lower Systolic Blood Pressure Goals in Persons With Type 2 Diabetes: The SANDS Trial. <i>Journal of Clinical Hypertension</i> , 2009, 11, 540-548.	1.0	18
4396	Homocysteine-An Atherogenic and a Thrombogenic Factor?. <i>Nutrition Reviews</i> , 2009, 53, 323-325.	2.6	19
4397	Anticholesterol Antibodies and Plaque Formation. <i>Nutrition Reviews</i> , 2009, 54, 124-127.	2.6	1



#	ARTICLE	IF	CITATIONS
4398	Will an Increased Dietary Folate Intake Reduce the Incidence of Cardiovascular Disease?. Nutrition Reviews, 2009, 54, 213-216.	2.6	9
4399	The Obesity, Metabolic Syndrome, and Type 2 Diabetes Mellitus Pandemic: II. Therapeutic Management of Atherogenic Dyslipidemia. Journal of Clinical Hypertension, 2009, 11, 520-527.	1.0	20
4400	Statin Use Is Associated With Improved Survival in Patients With Advanced Heart Failure Receiving Resynchronization Therapy. Congestive Heart Failure, 2009, 15, 159-164.	2.0	7
4401	The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: An updated meta-analysis. Clinical Therapeutics, 2009, 31, 236-244.	1.1	144
4402	Effects of pitavastatin on cerebral blood flow. Clinical Therapeutics, 2009, 31, 575-579.	1.1	5
4403	Relation of High-Density Lipoprotein Cholesterol to Mortality After Percutaneous Coronary Interventions in Patients With Low-Density Lipoprotein <70 mg/dl. American Journal of Cardiology, 2009, 103, 350-354.	0.7	9
4404	Rate of Acute ST-Elevation Myocardial Infarction in the United States from 1988 to 2004 (from the) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.7	26
4405	Effect of Atorvastatin on Platelet Thromboxane A2 Synthesis in Aspirin-Treated Patients With Acute Myocardial Infarction. American Journal of Cardiology, 2009, 104, 1618-1623.	0.7	50
4406	Meta-Analysis of Randomized Controlled Trials of Statins Versus Placebo in Patients With Heart Failure. American Journal of Cardiology, 2009, 104, 1708-1716.	0.7	93
4407	Low High-Density Lipoprotein Cholesterol and Increased Cardiovascular Disease Risk: An Analysis of Statin Clinical Trials. American Journal of Cardiology, 2009, 104, 3E-9E.	0.7	18
4408	High-Density Lipoprotein and Progression Rate of Atherosclerosis in Intravascular Ultrasound Trials. American Journal of Cardiology, 2009, 104, 16E-21E.	0.7	7
4409	Defining and measuring physicians'™ responses to clinical reminders. Journal of Biomedical Informatics, 2009, 42, 317-326.	2.5	41
4410	Making the Case for Cardiovascular Screening in Irish Males: Detection of Abdominal Aortic Aneurysms, and Assessment of Cardiovascular Risk Factors. European Journal of Vascular and Endovascular Surgery, 2009, 37, 300-304.	0.8	3
4411	Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurology, The, 2009, 8, 453-463.	4.9	537
4412	Hepatitis C virus infection and its clearance alter circulating lipids: Implications for long-term follow-up. Hepatology, 2009, 50, 1030-1037.	3.6	169
4413	Unusual sterolic mixture, and 24-isoopropylcholesterol, from the sponge <i>Ciocalypta</i> sp. reduce cholesterol uptake and basolateral secretion in Caco-2 cells. Journal of Cellular Biochemistry, 2009, 106, 659-665.	1.2	8
4414	Prospective, double blind, randomized, controlled trial of simvastatin in human fracture healing. Journal of Orthopaedic Research, 2009, 27, 281-285.	1.2	35
4415	Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets study. European Journal of Health Economics, 2009, 10, 255-265.	1.4	27

#	ARTICLE	IF	CITATIONS
4416	The therapeutic modulation of atherogenic dyslipidemia and inflammatory markers in the metabolic syndrome: what is the clinical relevance?. <i>Acta Diabetologica</i> , 2009, 46, 1-11.	1.2	27
4418	Effects of statins on the progression of cerebral white matter lesion. <i>Journal of Neurology</i> , 2009, 256, 750-757.	1.8	91
4419	Can we use statins to prevent stroke in Fabry disease?. <i>Journal of Inherited Metabolic Disease</i> , 2009, 32, 481-487.	1.7	19
4420	Increased Levels of 25 Hydroxyvitamin D and 1,25-Dihydroxyvitamin D After Rosuvastatin Treatment: A Novel Pleiotropic Effect of Statins?. <i>Cardiovascular Drugs and Therapy</i> , 2009, 23, 295-299.	1.3	98
4421	Statins and Vitamin D. <i>Cardiovascular Drugs and Therapy</i> , 2009, 23, 261-262.	1.3	20
4422	Benefits and Difficulties in Measuring HDL Subfractions and Human Paraoxonase-1 Activity During Statin Treatment. <i>Cardiovascular Drugs and Therapy</i> , 2009, 23, 501-510.	1.3	19
4423	Coronary Artery Diseases in South Asian Immigrants: An Update on High Density Lipoprotein Role in Disease Prevention. <i>Journal of Immigrant and Minority Health</i> , 2009, 11, 415-421.	0.8	7
4424	Low-density lipoprotein apheresis as a treatment option for hyperlipidemia. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2009, 11, 279-288.	0.4	24
4425	Justification for the use of statins in primary prevention: An intervention trial evaluating rosuvastatin (the JUPITER trial). <i>Current Cardiovascular Risk Reports</i> , 2009, 3, 83-85.	0.8	2
4426	Evolving concepts of cardiovascular disease prevention in older adults. <i>Current Cardiovascular Risk Reports</i> , 2009, 3, 366-373.	0.8	0
4427	An intensive nurse-led, multi-interventional clinic is more successful in achieving vascular risk reduction targets than standard diabetes care. <i>Irish Journal of Medical Science</i> , 2009, 178, 179-186.	0.8	14
4428	Should we treat all patients with coronary heart disease or the equivalent with statins?. <i>Current Atherosclerosis Reports</i> , 2009, 11, 28-35.	2.0	1
4429	High-density lipoprotein/apolipoprotein A-I infusion therapy. <i>Current Atherosclerosis Reports</i> , 2009, 11, 58-63.	2.0	43
4430	Lipid management: Considerations in acute coronary syndrome. <i>Current Atherosclerosis Reports</i> , 2009, 11, 149-156.	2.0	1
4431	Review of the SPARCL trial and its subanalyses. <i>Current Atherosclerosis Reports</i> , 2009, 11, 315-321.	2.0	8
4432	Lipid-lowering drugs and risk for cancer. <i>Current Atherosclerosis Reports</i> , 2009, 11, 350-357.	2.0	7
4433	The role of cholesterol and statins in stroke. <i>Current Cardiology Reports</i> , 2009, 11, 4-11.	1.3	14
4434	AURORA and JUPITER trials: Recognizing the limitations and expanding the benefits of statin treatment. <i>Current Cardiology Reports</i> , 2009, 11, 401-403.	1.3	1

#	ARTICLE	IF	CITATIONS
4435	Role of cardiac resynchronization therapy in asymptomatic and mildly symptomatic heart failure. <i>Current Heart Failure Reports</i> , 2009, 6, 44-48.	1.3	1
4436	The Association Between the Receipt of Lipid Lowering Therapy and HIV Status Among Veterans Who Met NCEP/ATP III Criteria for the Receipt of Lipid Lowering Medication. <i>Journal of General Internal Medicine</i> , 2009, 24, 334-340.	1.3	43
4437	Five-Year Follow-up after Laparoscopic Roux-en-Y Gastric and Partial Ileal Bypass for Treatment of Morbid Obesity and Uncontrolled Hyperlipidemia. <i>Obesity Surgery</i> , 2009, 19, 121-124.	1.1	6
4438	Cardiovascular risk reduction: What do recent trials with rosuvastatin tell us?. <i>Advances in Therapy</i> , 2009, 26, 469-487.	1.3	13
4439	Cardiovascular residual risk assessment in patients undergoing therapy: A combined structural and functional approach. <i>Current Cardiovascular Imaging Reports</i> , 2009, 2, 405-409.	0.4	2
4442	Selective prescribing of simvastatin and atorvastatin by patient characteristics at treatment initiation over a 7-year period in Finland. <i>European Journal of Clinical Pharmacology</i> , 2009, 65, 927-933.	0.8	8
4443	Update on statin-mediated anti-inflammatory activities in atherosclerosis. <i>Seminars in Immunopathology</i> , 2009, 31, 127-142.	2.8	79
4444	Atorvastatin modifies the protein profile of circulating human monocytes after an acute coronary syndrome. <i>Proteomics</i> , 2009, 9, 1982-1993.	1.3	23
4445	Effects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people. <i>BMC Clinical Pharmacology</i> , 2009, 9, 6.	2.5	60
4446	Low plasma HDL, a vascular risk factor in high risk patients independent of LDL. <i>European Journal of Clinical Investigation</i> , 2009, 39, 680-688.	1.7	9
4447	Intensive lipid lowering may reduce progression of carotid atherosclerosis within 12 months of treatment: the METEOR study. <i>Journal of Internal Medicine</i> , 2009, 265, 698-707.	2.7	39
4448	Statin treatment in a cohort of 20,212 men and women in Norway according to cardiovascular risk factors and level of education. <i>British Journal of Clinical Pharmacology</i> , 2009, 67, 355-362.	1.1	26
4449	The Value, Qualification, and Regulatory Use of Surrogate End Points in Drug Development. <i>Clinical Pharmacology and Therapeutics</i> , 2009, 86, 32-43.	2.3	60
4450	Biologic Effects of Simvastatin in Patients with Aneurysmal Subarachnoid Hemorrhage: A Double-Blind, Placebo-Controlled Randomized Trial. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2009, 29, 1444-1453.	2.4	118
4451	Is There a Role for Statins in Atrial Fibrillation?. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2009, 32, 1063-1072.	0.5	9
4452	Potential roles of melatonin and chronotherapy among the new trends in hypertension treatment. <i>Journal of Pineal Research</i> , 2009, 47, 127-133.	3.4	64
4453	Preventing coronary heart disease and stroke with aggressive statin therapy in older adults using a team management model. <i>Journal of the American Academy of Nurse Practitioners</i> , 2009, 21, 47-53.	1.4	9
4454	Identification of patients at risk of ischemic events for long-term secondary prevention. <i>Journal of the American Academy of Nurse Practitioners</i> , 2009, 21, 677-689.	1.4	5

#	ARTICLE	IF	CITATIONS
4455	Statin treatment after a recent TIA or stroke: is effectiveness shown in randomized clinical trials also observed in everyday clinical practice?. <i>Acta Neurologica Scandinavica</i> , 2010, 122, 15-20.	1.0	9
4456	Prevalence of low HDL cholesterol, and relationship between serum HDL and cardiovascular disease in elderly Spanish population: the PREV-ICTUS study. <i>International Journal of Clinical Practice</i> , 2009, 63, 71-81.	0.8	17
4457	Simvastatin and Indomethacin Have Similar Anti-inflammatory Activity in a Rat Model of Acute Local Inflammation. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2009, 104, 185-191.	1.2	25
4458	(TTA)n Polymorphism in 3-hydroxy-methylglutaryl-Coenzyme A and Response to Atorvastatin in Coronary Artery Disease Patients. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2009, 104, 211-215.	1.2	7
4459	Rosuvastatin Attenuates Heart Failure and Cardiac Remodelling in the Ageing Spontaneously Hypertensive Rat. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2009, 105, 262-270.	1.2	10
4460	Beneficial effect of atorvastatin on erythropoietin responsiveness in maintenance haemodialysis patients. <i>Nephrology</i> , 2009, 14, 560-564.	0.7	7
4461	Atorvastatin enhances humoral immune responses but does not alter renal injury in experimental crescentic glomerulonephritis. <i>Nephrology</i> , 2009, 14, 650-657.	0.7	1
4462	Statin therapy and carotid endarterectomy: a review of trends in New South Wales, 1990-2004. <i>ANZ Journal of Surgery</i> , 2009, 79, 456-461.	0.3	1
4463	Do plant sterol concentrations correlate with coronary artery disease in type 1 diabetes? A report from the Pittsburgh Epidemiology of Diabetes Complications Study. <i>Journal of Diabetes</i> , 2009, 1, 112-117.	0.8	7
4464	HMG-CoA reductase inhibitors, other lipid-lowering medication, antiplatelet therapy, and the risk of venous thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 514-520.	1.9	94
4465	Diabetes-Related Risk Factors Across Hispanic Subgroups in the Hispanic Health and Nutritional Examination Survey (1982-1984). <i>Public Health Nursing</i> , 2009, 26, 23-38.	0.7	19
4466	Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?. <i>British Journal of Pharmacology</i> , 2009, 157, 1340-1351.	2.7	112
4467	Ethical considerations in cardiovascular prevention. <i>Fundamental and Clinical Pharmacology</i> , 2009, 23, 669-673.	1.0	4
4468	Statins for sepsis: a critical and updated review. <i>Clinical Microbiology and Infection</i> , 2009, 15, 325-334.	2.8	97
4469	Therapeutic approach against intimal hyperplasia of vein grafts through endothelial nitric oxide synthase/nitric oxide (eNOS/NO) and the Rho/Rho-kinase pathway. <i>Surgery Today</i> , 2009, 39, 459-465.	0.7	31
4470	Determination of Pitavastatin in Human Plasma by LC-MS. <i>Chromatographia</i> , 2009, 69, 1041-1047.	0.7	11
4471	Effect of n-3 polyunsaturated fatty acids and rosuvastatin in patients with heart failure: results of the GISSI-HF trial. <i>Expert Review of Cardiovascular Therapy</i> , 2009, 7, 735-748.	0.6	37
4472	Effects of Statins on Endothelial Function in Patients with Coronary Artery Disease. <i>Clinical Cardiology</i> , 2009, 32, 193-198.	0.7	7

#	ARTICLE	IF	CITATIONS
4473	The Gender Differences in Baseline Characteristics and Statin Intervention Among Outpatients with Coronary Heart Disease in China: The China Cholesterol Education Program. <i>Clinical Cardiology</i> , 2009, 32, 308-314.	0.7	15
4474	Hypercholesterolemia Paradox in Relation to Mortality in Acute Coronary Syndrome. <i>Clinical Cardiology</i> , 2009, 32, E22-8.	0.7	66
4475	Statin Therapy in Patients with Diastolic Heart Failure. <i>Clinical Cardiology</i> , 2010, 33, E1-5.	0.7	15
4476	Statin therapy in the new millennium: Is there room for improvement?. <i>Clinical Cardiology</i> , 2009, 24, 1-2.	0.7	0
4477	What do the statin trials tell us?. <i>Clinical Cardiology</i> , 2009, 24, 3-7.	0.7	8
4478	How do we achieve optimal cardiovascular risk reduction?. <i>Clinical Cardiology</i> , 2001, 24, 8-12.	0.7	2
4479	A new statin: A new standard. <i>Clinical Cardiology</i> , 2009, 24, 18-23.	0.7	3
4480	Reducing the risks of sudden death and heart failure post myocardial infarction: Utility of optimized pharmacotherapy. <i>Clinical Cardiology</i> , 2005, 28, 19-27.	0.7	7
4481	Morbilidad y mortalidad secundaria a complicaciones cardiológicas despu�s de la revascularizaci�n de extremidad por isquemia cr�nica. <i>Annals of Vascular Surgery</i> , 2009, 23, 642-657.	0.0	0
4483	The monocyte/macrophage as a therapeutic target in atherosclerosis. <i>Current Opinion in Pharmacology</i> , 2009, 9, 109-118.	1.7	73
4484	Hypercholesterolaemia and risk of coronary heart disease in the elderly: Impact of age. <i>European Journal of Internal Medicine</i> , 2009, 20, 139-144.	1.0	29
4485	Statin Therapy and Clinical Outcomes in Heart Failure: A Propensity-Matched Analysis. <i>Journal of Cardiac Failure</i> , 2009, 15, 241-248.	0.7	22
4486	Mobile diabetes intervention study: Testing a personalized treatment/behavioral communication intervention for blood glucose control. <i>Contemporary Clinical Trials</i> , 2009, 30, 334-346.	0.8	65
4487	Effects of a phytosterol-enriched dairy product on lipids, sterols and 8-isoprostane in hypercholesterolemic patients: A multicenter Italian study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2009, 19, 84-90.	1.1	68
4488	Simvastatin as a Novel Strategy To Alleviate Periapical Lesions. <i>Journal of Endodontics</i> , 2009, 35, 657-662.	1.4	49
4489	Has the association between saturated fatty acids, serum cholesterol and coronary heart disease been over emphasized?. <i>International Dairy Journal</i> , 2009, 19, 345-361.	1.5	70
4490	Statins in the treatment of heart failure. <i>International Journal of Cardiology</i> , 2009, 132, 124-126.	0.8	1
4491	Changing trends (1986�2003) in the use of lipid lowering medication in patients hospitalized with acute myocardial infarction: A community-based perspective. <i>International Journal of Cardiology</i> , 2009, 132, 66-74.	0.8	5

#	ARTICLE	IF	CITATIONS
4492	Primary percutaneous coronary intervention for ST-elevation myocardial infarction: From clinical trial to clinical practice. <i>International Journal of Cardiology</i> , 2009, 134, 104-109.	0.8	8
4494	LDL-cholesterol differences predicted survival benefit in statin trials by the surrogate threshold effect (STE). <i>Journal of Clinical Epidemiology</i> , 2009, 62, 328-336.	2.4	13
4495	Late effect of treatment for reducing cardiovascular risk – A hypothesis on cardiometabolic therapeutic memory. <i>Medical Hypotheses</i> , 2009, 73, 73-79.	0.8	6
4496	Rationale and design of the Study Assessing the Effect of Cardiovascular Medications Provided as Low-cost, Evidence-based Generic Samples (SAMPLES) trial. <i>American Heart Journal</i> , 2009, 157, 613-619.	1.2	7
4497	Rationale and design of China intensive lipid lowering with statins in acute coronary syndrome: The CHILLAS study. <i>American Heart Journal</i> , 2009, 158, 509-512.e1.	1.2	8
4498	Effect of Statin Adherence on Cerebrovascular Disease in Primary Prevention. <i>American Journal of Medicine</i> , 2009, 122, 647-655.	0.6	56
4499	Outcomes After Stroke: Risk of Recurrent Ischemic Stroke and Other Events. <i>American Journal of Medicine</i> , 2009, 122, S7-S13.	0.6	47
4500	Low Levels of Low-Density Lipoprotein Cholesterol and Blood Pressure and Progression of Coronary Atherosclerosis. <i>Journal of the American College of Cardiology</i> , 2009, 53, 1110-1115.	1.2	63
4501	Meta-Analysis of the Relationship Between Non-High-Density Lipoprotein Cholesterol Reduction and Coronary Heart Disease Risk. <i>Journal of the American College of Cardiology</i> , 2009, 53, 316-322.	1.2	327
4502	Effect of Intensive Statin Therapy on Regression of Coronary Atherosclerosis in Patients With Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2009, 54, 293-302.	1.2	332
4503	Early Statin Therapy in Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2009, 54, 1434-1437.	1.2	24
4504	Effects of High-Dose Modified-Release Nicotinic Acid on Atherosclerosis and Vascular Function. <i>Journal of the American College of Cardiology</i> , 2009, 54, 1787-1794.	1.2	237
4506	Beyond Low-Density Lipoprotein Cholesterol. <i>Journal of the American College of Cardiology</i> , 2009, 55, 35-41.	1.2	268
4507	Not so choppy SEAS. <i>Journal of Clinical Lipidology</i> , 2009, 3, 11-13.	0.6	1
4508	Is HDL function as important as HDL quantity in the coronary artery disease risk assessment?. <i>Journal of Clinical Lipidology</i> , 2009, 3, 70-77.	0.6	23
4509	Benefits of the MEDPED treatment support program for patients with familial hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2009, 3, 94-100.	0.6	13
4510	Efficacy and safety of combination therapy with niacin extended-release and simvastatin versus atorvastatin in patients with dyslipidemia: The SUPREME Study. <i>Journal of Clinical Lipidology</i> , 2009, 3, 109-118.	0.6	26
4511	The benefit of statins in non-cardiac vascular surgery patients. <i>Journal of Vascular Surgery</i> , 2009, 49, 260-265.	0.6	41

#	ARTICLE	IF	CITATIONS
4512	Statins and Erectile Dysfunction. <i>Drug Safety</i> , 2009, 32, 591-597.	1.4	41
4513	Androgenic Anabolic Steroid Abuse and the Cardiovascular System. <i>Handbook of Experimental Pharmacology</i> , 2009, , 411-457.	0.9	94
4514	Statins and stroke prevention. <i>Expert Review of Cardiovascular Therapy</i> , 2009, 7, 1231-1243.	0.6	20
4515	Lowering Low-Density Lipoprotein Cholesterol: Statins, Ezetimibe, Bile Acid Sequestrants, and Combinations: Comparative Efficacy and Safety. <i>Endocrinology and Metabolism Clinics of North America</i> , 2009, 38, 79-97.	1.2	84
4516	Non-Atheroprotective Effects of Statins. <i>American Journal of Cardiovascular Drugs</i> , 2009, 9, 361-370.	1.0	40
4517	Statins for the Treatment of Antiphospholipid Syndrome?. <i>Annals of the New York Academy of Sciences</i> , 2009, 1173, 736-745.	1.8	49
4518	Lipid-Lowering Therapy for the Primary Prevention of Cardiovascular Disease in the Elderly. <i>Drugs and Aging</i> , 2009, 26, 917-931.	1.3	14
4519	Secondary Stroke Prevention Strategies for the Oldest Patients. <i>Drugs and Aging</i> , 2009, 26, 209-230.	1.3	18
4520	Variability in the Prescription of Cardiovascular Medications in Older Patients. <i>Drugs and Aging</i> , 2009, 26, 41-51.	1.3	10
4521	Morbidity and Mortality Caused by Cardiac Adverse Events after Revascularization for Critical Limb Ischemia. <i>Annals of Vascular Surgery</i> , 2009, 23, 583-597.	0.4	16
4522	Lipid Management in the Geriatric Patient. <i>Endocrinology and Metabolism Clinics of North America</i> , 2009, 38, 185-206.	1.2	5
4523	HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. , 2009, , CD007784.		84
4524	Hypolipidemic effect of MeOH extract of <i>Bambusae Caulis</i> in <i>Taeniam</i> in hyperlipidemia induced by Triton WR-1339 and high cholesterol diet in rats. <i>Immunopharmacology and Immunotoxicology</i> , 2009, 31, 439-445.	1.1	4
4525	Pharmacologic therapy for coronary atherosclerosis in patients with Type 2 diabetes mellitus. <i>Expert Review of Cardiovascular Therapy</i> , 2009, 7, 85-93.	0.6	2
4526	Targeting eNOS and beyond: emerging heterogeneity of the role of endothelial Rho proteins in stroke protection. <i>Expert Review of Neurotherapeutics</i> , 2009, 9, 1171-1186.	1.4	30
4527	Statins and the risk of Parkinson disease: an update on the controversy. <i>Expert Opinion on Drug Safety</i> , 2009, 8, 261-271.	1.0	17
4528	Treatment strategies to prevent stroke: focus on optimal lipid and blood pressure control. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 955-966.	0.9	3
4529	Careful individualized therapy improves the therapeutic efficacy of statins in patients with coronary heart disease. <i>Drugs and Therapy Perspectives</i> , 2009, 25, 12-15.	0.3	0

#	ARTICLE	IF	CITATIONS
4530	Effect of lipid-modifying therapies on the functional quality of high-density lipoproteins: implications for drug development. <i>Expert Opinion on Drug Discovery</i> , 2009, 4, 753-761.	2.5	2
4531	Ezetimibe/simvastatin. <i>Expert Opinion on Drug Safety</i> , 2009, 8, 715-725.	1.0	8
4532	Statin Effects on LDL and HDL Cholesterol in South Asian and White Populations. <i>Journal of Clinical Pharmacology</i> , 2009, 49, 831-837.	1.0	25
4533	Ezetimibe potently reduces vascular inflammation and arteriosclerosis in eNOS-deficient ApoE ko mice. <i>Atherosclerosis</i> , 2009, 202, 48-57.	0.4	39
4534	Effect of simvastatin on kidney function loss in patients with coronary heart disease. <i>Atherosclerosis</i> , 2009, 205, 202-206.	0.4	41
4535	Flow-mediated dilation in patients with coronary artery disease is enhanced by high dose atorvastatin compared to combined low dose atorvastatin and ezetimibe: Results of the CEZAR study. <i>Atherosclerosis</i> , 2009, 205, 227-232.	0.4	70
4536	Statin prevents plaque disruption in apoE-knockout mouse model through pleiotropic effect on acute inflammation. <i>Atherosclerosis</i> , 2009, 206, 355-361.	0.4	56
4537	Pravastatin and cardiovascular risk in moderate chronic kidney disease. <i>Atherosclerosis</i> , 2009, 206, 512-517.	0.4	76
4538	Multimodality imaging of atherosclerotic plaque activity and composition using FDG-PET/CT and MRI in carotid and femoral arteries. <i>Atherosclerosis</i> , 2009, 207, 139-143.	0.4	142
4539	The Triad of Endothelial Dysfunction, Cardiovascular Disease, and Erectile Dysfunction: Clinical Implications. <i>European Urology Supplements</i> , 2009, 8, 58-66.	0.1	17
4540	Novel uses for statins in surgical patients. <i>International Journal of Surgery</i> , 2009, 7, 285-290.	1.1	10
4541	Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretinâ€”based therapies. <i>Journal of the American Society of Hypertension</i> , 2009, 3, 245-259.	2.3	63
4542	Current Strategies and Recent Advances in the Therapy of Hypercholesterolemia. <i>Atherosclerosis Supplements</i> , 2009, 10, 1-4.	1.2	4
4543	Perioperative Statin Therapy Is Associated With a Significant and Dose-Dependent Reduction of Adverse Cardiovascular Outcomes After Coronary Artery Bypass Graft Surgery. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2009, 23, 633-638.	0.6	39
4544	A winterâ€™s tale: Report from the First Annual Canadian Biomarkers and Surrogate Endpoints Symposium. <i>Canadian Journal of Cardiology</i> , 2009, 25, 527-532.	0.8	2
4545	Efficacy of alternate day versus daily dosing of rosuvastatin. <i>Canadian Journal of Cardiology</i> , 2009, 25, e28-e31.	0.8	18
4546	Prasugrel STEMI subgroup analysis. <i>Lancet, The</i> , 2009, 373, 1846.	6.3	3
4548	The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. <i>BMJ: British Medical Journal</i> , 2009, 338, b2376-b2376.	2.4	650



#	ARTICLE	IF	CITATIONS
4549	Non-adherence to statin therapy: a major challenge for preventive cardiology. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 2973-2985.	0.9	114
4550	2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults. <i>Journal of the American College of Cardiology</i> , 2009, 53, e1-e90.	1.2	1,386
4551	Low-Density Lipoprotein Cholesterol Reduction and Prevention of Cardiovascular Disease. <i>Mayo Clinic Proceedings</i> , 2009, 84, 307-309.	1.4	5
4552	Morbidit� et mortalit� d'origine cardiaque apr�s revascularisation pour isch�mie critique. <i>Annales De Chirurgie Vasculaire</i> , 2009, 23, 632-646.	0.0	0
4553	Managing Statin Myopathy. <i>Endocrinology and Metabolism Clinics of North America</i> , 2009, 38, 121-136.	1.2	59
4554	Other Therapies for Reducing Low-Density Lipoprotein Cholesterol: Medications in Development. <i>Endocrinology and Metabolism Clinics of North America</i> , 2009, 38, 99-119.	1.2	31
4555	Diabetes and Cardiovascular Disease Prevention in Older Adults. <i>Clinics in Geriatric Medicine</i> , 2009, 25, 607-641.	1.0	44
4556	Hyperlipidemia in Older Adults. <i>Clinics in Geriatric Medicine</i> , 2009, 25, 591-606.	1.0	23
4557	Is Intermittent Vasculogenic Claudication Still a Nonsurgical Disease?. <i>Advances in Surgery</i> , 2009, 43, 53-72.	0.6	0
4558	Intensive Lowering of Low-Density Lipoprotein Cholesterol Levels for Primary Prevention of Coronary Artery Disease. <i>Mayo Clinic Proceedings</i> , 2009, 84, 345-352.	1.4	28
4559	Primary and Secondary Prevention of Cardiovascular Disease in Older Adults: A Status Report. <i>Clinics in Geriatric Medicine</i> , 2009, 25, 745-755.	1.0	13
4560	Nicotinic acid and the prevention of coronary artery disease. <i>Current Opinion in Lipidology</i> , 2009, 20, 321-326.	1.2	38
4561	Nonproportional Hazards and the Power of Sequential Trials. <i>Statistics in Biopharmaceutical Research</i> , 2009, 1, 66-73.	0.6	3
4562	Myalgia in Patients on High-Dose and Low-to-Moderate Dose Statin Therapy. <i>Journal of Pharmacy Practice and Research</i> , 2009, 39, 202-206.	0.5	1
4563	Effect of Chronic Statin Pretreatment on Hospital Outcome in Patients With Acute Non-ST-Elevation Myocardial Infarction. <i>Journal of Cardiovascular Pharmacology</i> , 2009, 53, 132-136.	0.8	17
4564	An Elective Course on Landmark Trials to Improve Pharmacy Students' Literature Evaluation and Therapeutic Application Skills. <i>American Journal of Pharmaceutical Education</i> , 2009, 73, 31.	0.7	11
4565	Marked Aortic Valve Stenosis Progression After Receiving Long-Term Aggressive Cholesterol-Lowering Therapy Using Low-Density Lipoprotein Apheresis in a Patient With Familial Hypercholesterolemia. <i>Circulation Journal</i> , 2009, 73, 963-966.	0.7	112
4566		0.0	0

#	ARTICLE	IF	CITATIONS
4567	1. Pathophysiology and Treatment of Acute Coronary Syndrome. The Journal of the Japanese Society of Internal Medicine, 2009, 98, 595-600.	0.0	0
4568	Expression of HMGR and corresponding cholesterol content in tissues of two pig breeds. Animal, 2009, 3, 1436-1441.	1.3	4
4569	Early Effect of Lipid-Lowering Therapy With Pitavastatin on Regression of Coronary Atherosclerotic Plaque Comparison With Atorvastatin. Circulation Journal, 2009, 73, 1466-1472.	0.7	74
4570	Rationale and Design of the Carotid Plaque in Human for All Evaluations With Aggressive Rosuvastatin Therapy (CHALLENGER Trial) Evaluation by Magnetic Resonance Imaging. Circulation Journal, 2009, 73, 111-115.	0.7	18
4571	Treatment With Statin on Atheroma Regression Evaluated by Intravascular Ultrasound With Virtual Histology (TRUTH Study) Rationale and Design. Circulation Journal, 2009, 73, 352-355.	0.7	21
4572	Effects of Pitavastatin on Fasting and Postprandial Endothelial Function and Blood Rheology in Patients With Stable Coronary Artery Disease. Circulation Journal, 2009, 73, 1523-1530.	0.7	30
4573	Coronary Risk Factor Profile and Prognostic Factors for Young Japanese Patients Undergoing Coronary Revascularization. Circulation Journal, 2009, 73, 1459-1465.	0.7	26
4574	Computed Tomographic Coronary Angiography for Diagnosing Stable Coronary Artery Disease A Cost-Utility and Cost-Effectiveness Analysis. Circulation Journal, 2009, 73, 1263-1270.	0.7	17
4575	The Impact of Pravastatin Therapy on Long-Term Outcome in Patients With Metabolic Syndrome Undergoing Complete Coronary Revascularization. Circulation Journal, 2009, 73, 2104-2109.	0.7	12
4576	Variation in the Net Benefit of Aggressive Cardiovascular Risk Factor Control Across the US Population of Patients With Diabetes Mellitus. Archives of Internal Medicine, 2010, 170, 1037.	4.3	52
4577	Effects of Statins on Regeneration of Olfactory Epithelium. American Journal of Rhinology and Allergy, 2010, 24, 121-125.	1.0	7
4579	Interventions to improve adherence to lipid lowering medication. , 2010, , CD004371.		95
4580	Markers of Cholesterol Absorption and Synthesis Predict the Low-density Lipoprotein Cholesterol Response to Atorvastatin. Journal of Cardiovascular Pharmacology, 2010, 56, 396-401.	0.8	8
4581	Submaximal exercise coronary artery flow increases in postmenopausal women without coronary artery disease after estrogen and atorvastatin. Menopause, 2010, 17, 114-120.	0.8	4
4582	Should we change our lipid management strategies to focus on non-high-density lipoprotein cholesterol?. Current Opinion in Cardiology, 2010, 25, 622-626.	0.8	8
4583	Simultaneous Determination of Prazosin, Atorvastatin, Rosuvastatin and Simvastatin in API, Dosage Formulations and Human Serum by RP-HPLC. Journal of the Chinese Chemical Society, 2010, 57, 1286-1292.	0.8	16
4584	Traditional Chinese herbal products for stable angina. The Cochrane Library, 2010, , CD004468.	1.5	7
4585		0.0	0

#	ARTICLE	IF	CITATIONS
4586	99, 473-479.	0.0	0
4588	Deeply discounted medications: Implications of generic prescription drug wars. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2010, 50, 752-757.	0.7	17
4589	Hepatotoxicity Fears Contribute to Underutilization of Statin Medications by Primary Care Physicians. <i>American Journal of the Medical Sciences</i> , 2010, 340, 89-93.	0.4	88
4591	Statins have beneficial effects on platelet free radical activity and intracellular distribution of GTPases in hyperlipidaemia. <i>Clinical Science</i> , 2010, 118, 359-366.	1.8	12
4592	Attainment of combined optimal lipid values: a paradigm shift in the management of dyslipidemia. <i>Clinical Lipidology</i> , 2010, 5, 527-541.	0.4	2
4593	Japan Expects Decrements in Both the Incidence and Mortality of Acute Myocardial Infarction in the Modern Era:. <i>Circulation Journal</i> , 2010, 74, 43-44.	0.7	4
4594	"Just Make It Lower" Is an Alternative Strategy of Lipid-Lowering Therapy With Statins in Japanese Patients - LDL-Cholesterol: The Lower, the Better; Is It True for Asians? (Con) -. <i>Circulation Journal</i> , 2010, 74, 1731-1741.	0.7	30
4595	A historical perspective on the discovery of statins. <i>Proceedings of the Japan Academy Series B: Physical and Biological Sciences</i> , 2010, 86, 484-493.	1.6	368
4596	Clinical Significance of Intensive Lipid-Lowering Therapy Using Statins in Patients With Coronary Artery Disease. <i>Circulation Journal</i> , 2010, 74, 1718-1730.	0.7	26
4598	Post-stroke atorvastatin treatment reduces neurological deficits and mortality rate in the stroke-prone spontaneously hypertensive rat. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 56, 893-898.	1.2	6
4599	High-density lipoproteins and cardiovascular disease: 2010 update. <i>Expert Review of Cardiovascular Therapy</i> , 2010, 8, 413-423.	0.6	31
4600	Genome-Wide Association Studies Identify New Targets in Cardiovascular Disease. <i>Science Translational Medicine</i> , 2010, 2, 48ps46.	5.8	18
4601	Influence of statin treatment on coronary atherosclerosis visualised using multidetector computed tomography. <i>European Radiology</i> , 2010, 20, 2824-2833.	2.3	49
4604	Intensified glucose lowering in type 2 diabetes: time for a reappraisal. <i>Diabetologia</i> , 2010, 53, 2079-2085.	2.9	131
4605	Trends in age-standardised and age-specific mortality from ischaemic heart disease in Germany. <i>Clinical Research in Cardiology</i> , 2010, 99, 545-551.	1.5	12
4606	Saving lives, money and resources: drug and CABG/PCI use after myocardial infarction in a Swedish record-linkage study. <i>European Journal of Health Economics</i> , 2010, 11, 177-184.	1.4	3
4607	Systematic review on evidence of the effectiveness of cholesterol-lowering drugs. <i>Advances in Therapy</i> , 2010, 27, 348-364.	1.3	20
4608	High-Density Lipoprotein Therapy: Is There Hope?. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2010, 12, 315-328.	0.4	10

#	ARTICLE	IF	CITATIONS
4609	Pitavastatin Reduces Lectin-Like Oxidized Low-Density Lipoprotein Receptor Ligands in Hypercholesterolemic Humans. <i>Lipids</i> , 2010, 45, 329-335.	0.7	19
4610	Hyperlipidemia and Primary Prevention of Stroke: Does Risk Factor Identification and Reduction Really Work?. <i>Current Atherosclerosis Reports</i> , 2010, 12, 225-229.	2.0	23
4611	Statins and Their Role in Pre-Percutaneous Coronary Intervention. <i>Current Cardiology Reports</i> , 2010, 12, 295-301.	1.3	8
4612	Secondary prevention strategies for coronary heart disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2010, 29, 8-24.	1.0	24
4613	Statins and vitamin D: a friendly association in pre-dialysis patients. <i>International Urology and Nephrology</i> , 2010, 42, 173-179.	0.6	8
4614	Statin prescribing in Northern Ireland and England pre and post introduction of the quality and outcomes framework. <i>International Journal of Clinical Pharmacy</i> , 2010, 32, 43-51.	1.4	4
4615	Can statin therapy reduce the risk of melanoma? A meta-analysis of randomized controlled trials. <i>European Journal of Epidemiology</i> , 2010, 25, 29-35.	2.5	43
4617	Exploring new indications for statins beyond atherosclerosis: Successes and setbacks. <i>Journal of Cardiology</i> , 2010, 55, 155-162.	0.8	29
4619	Low-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio as a useful marker for early-stage carotid atherosclerosis. <i>Metabolism: Clinical and Experimental</i> , 2010, 59, 653-657.	1.5	29
4620	Ischaemic heart disease: stable angina. <i>Medicine</i> , 2010, 38, 414-420.	0.2	0
4621	Diagnosis and Treatment of Heart Disease: Are Women Different From Men?. <i>Progress in Cardiovascular Diseases</i> , 2010, 53, 227-236.	1.6	71
4622	Niacin and fibrates in atherogenic dyslipidemia: Pharmacotherapy to reduce cardiovascular risk. , 2010, 126, 314-345.		196
4623	Prevalence of lipid abnormalities before and after introduction of lipid modifying therapy among Swedish patients with dyslipidemia (PRIMUM). <i>BMC Public Health</i> , 2010, 10, 737.	1.2	10
4624	Synergistic effect of simvastatin and ezetimibe on lipid and pro-inflammatory profiles in pre-diabetic subjects. <i>Diabetology and Metabolic Syndrome</i> , 2010, 2, 34.	1.2	18
4625	Statin-Associated Muscle-Related Adverse Effects: A Case Series of 354 Patients. <i>Pharmacotherapy</i> , 2010, 30, 541-553.	1.2	95
4626	Distribution of Traditional and Novel Risk Factors and Their Relation to Subsequent Cardiovascular Events in Patients With Acute Coronary Syndromes (from the PROVE IT-TIMI 22 Trial). <i>American Journal of Cardiology</i> , 2010, 105, 619-623.	0.7	12
4627	Relation of Different Measures of Low-Density Lipoprotein Cholesterol to Risk of Coronary Artery Disease and Death in a Meta-Regression Analysis of Large-Scale Trials of Statin Therapy. <i>American Journal of Cardiology</i> , 2010, 105, 1289-1296.	0.7	46
4628	Problems of Nonadherence in Cardiology and Proposals to Improve Outcomes. <i>American Journal of Cardiology</i> , 2010, 105, 1495-1501.	0.7	47

#	ARTICLE	IF	CITATIONS
4629	Low-Density Lipoprotein Cholesterol Level in Patients With Acute Myocardial Infarction Having Percutaneous Coronary Intervention (the Cholesterol Paradox). <i>American Journal of Cardiology</i> , 2010, 106, 1061-1068.	0.7	62
4630	Statin Therapy in Primary Prevention: New Insights Regarding Women and the Elderly. <i>American Journal of Cardiology</i> , 2010, 106, 1357-1359.	0.7	3
4631	Effect of Preoperative Statin Therapy on Patients Undergoing Isolated and Combined Valvular Heart Surgery. <i>Annals of Thoracic Surgery</i> , 2010, 89, 773-780.	0.7	27
4632	Pharmacokinetic comparison of controlled-release and immediate-release oral formulations of simvastatin in healthy Korean subjects: A randomized, open-label, parallel-group, single- and multiple-dose study. <i>Clinical Therapeutics</i> , 2010, 32, 206-216.	1.1	18
4633	Results of a retrospective database analysis of adherence to statin therapy and risk of nonfatal ischemic heart disease in daily clinical practice in Italy. <i>Clinical Therapeutics</i> , 2010, 32, 300-310.	1.1	76
4634	Effect of simvastatin on cholesterol metabolism in C2C12 myotubes and HepG2 cells, and consequences for statin-induced myopathy. <i>Biochemical Pharmacology</i> , 2010, 79, 1200-1209.	2.0	70
4635	Statins: A Potential Therapeutic Addition to Treatment for Aneurysmal Subarachnoid Hemorrhage?. <i>World Neurosurgery</i> , 2010, 73, 646-653.	0.7	27
4636	Do Statins Improve Heart Failure Outcome in Post-Myocardial Infarction Patients With Moderate to Severe Left Ventricular Dysfunction?. <i>Congestive Heart Failure</i> , 2010, 16, 181-186.	2.0	6
4637	Statins for Primary Prevention of Cardiovascular Mortality in Women: A Systematic Review and Meta-Analysis. <i>Preventive Cardiology</i> , 2010, 13, 84-90.	1.1	40
4638	A Randomized Clinical Trial to Assess the Effect of Statins on Skeletal Muscle Function and Performance: Rationale and Study Design. <i>Preventive Cardiology</i> , 2010, 13, 104-111.	1.1	30
4639	Short-Term Treatment with High-Dose Atorvastatin Reduces LDL Cholesterol but Shows no Anti-Inflammatory Effects in Normolipidemic Subjects with Normal CRP Levels. <i>Clinical and Translational Science</i> , 2010, 3, 140-146.	1.5	14
4640	Prevalence of risk factors for statin-induced myopathy in rheumatoid arthritis patients. <i>Musculoskeletal Care</i> , 2010, 8, 2-9.	0.6	13
4641	Association between DNA repair gene ATM polymorphisms and oral cancer susceptibility. <i>Laryngoscope</i> , 2010, 120, 2417-2422.	1.1	42
4642	Statin therapy in the elderly: A review. <i>Archives of Gerontology and Geriatrics</i> , 2010, 50, 114-118.	1.4	47
4643	Carotid Artery Stent Placement. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 467-474.	1.1	24
4644	Post-load hyperglycemia as an important predictor of long-term adverse cardiac events after acute myocardial infarction: a scientific study. <i>Cardiovascular Diabetology</i> , 2010, 9, 75.	2.7	25
4645	Statins and clinical outcome of acute ischemic stroke: a systematic review. <i>International Archive of Medicine</i> , 2010, 3, 22.	1.2	26
4646	Influence of genetic variation in <i>CYP3A4</i> and <i>ABCB1</i> on dose decrease or switching during simvastatin and atorvastatin therapy. <i>Pharmacoepidemiology and Drug Safety</i> , 2010, 19, 75-81.	0.9	46

#	ARTICLE	IF	CITATIONS
4647	Statin use and depressive symptoms in a prospective study of community-living older persons. <i>Pharmacoepidemiology and Drug Safety</i> , 2010, 19, 942-948.	0.9	23
4648	Prior use of statins and outcome in patients with intracerebral haemorrhage. <i>European Journal of Neurology</i> , 2010, 17, 78-83.	1.7	41
4649	Atherosclerosis induced by chronic inhibition of the synthesis of nitric oxide in moderately hypercholesterolaemic rabbits is suppressed by pitavastatin. <i>British Journal of Pharmacology</i> , 2010, 159, 1418-1428.	2.7	16
4650	Acute activation of eNOS by statins involves scavenger receptor-B1, G protein subunit Gi, phospholipase C and calcium influx. <i>British Journal of Pharmacology</i> , 2010, 160, 1765-1772.	2.7	31
4651	Projected Cost-Effectiveness of Ezetimibe/Simvastatin Compared with Doubling the Statin Dose in the United Kingdom: Findings from the INFORCE Study. <i>Value in Health</i> , 2010, 13, 726-734.	0.1	20
4652	Transportability of Comparative Effectiveness and Cost-Effectiveness between Countries. <i>Value in Health</i> , 2010, 13, S22-S25.	0.1	14
4653	Gender differences in the treatment of chronic ischemic heart disease: prognostic implications. <i>Fundamental and Clinical Pharmacology</i> , 2010, 24, 707-710.	1.0	6
4654	Role of drugs and devices in patients at risk of sudden cardiac death. <i>Fundamental and Clinical Pharmacology</i> , 2010, 24, 575-594.	1.0	15
4655	The economic consequences of non-adherence to lipid-lowering therapy: results from the Anglo-Scandinavian-Cardiac Outcomes Trial. <i>International Journal of Clinical Practice</i> , 2010, 64, 1228-1234.	0.8	10
4656	Is there an anti-inflammatory effect of statins in rheumatoid arthritis? Analysis of a large routinely collected claims database. <i>British Journal of Clinical Pharmacology</i> , 2010, 69, 85-94.	1.1	27
4657	Immune regulatory effects of simvastatin on regulatory T cell-mediated tumour immune tolerance. <i>Clinical and Experimental Immunology</i> , 2010, 161, 298-305.	1.1	28
4658	ACE Inhibition Reduces Infarction in Normotensive but Not Hypertensive Rats: Correlation with Cortical ACE Activity. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2010, 30, 1520-1526.	2.4	21
4659	Severe statin-induced rhabdomyolysis mimicking Guillain-Barré syndrome in four patients with diabetes mellitus treated with fusidic acid. <i>Diabetic Medicine</i> , 2010, 27, 696-700.	1.2	19
4660	Systematic review of statins for the prevention of vascular dementia or dementia. <i>Geriatrics and Gerontology International</i> , 2010, 10, 199-208.	0.7	25
4661	3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors prevent the progression of renal dysfunction in Japanese hypertensive patients. <i>Geriatrics and Gerontology International</i> , 2010, 10, 219-224.	0.7	2
4662	Inhibition of the renal renin-angiotensin system and renoprotection by pitavastatin in type 1 diabetes. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2010, 37, 1064-1070.	0.9	14
4663	Prevalence of modifiable cardiovascular risk factors in long-term renal transplant patients. <i>International Journal of Nephrology and Renovascular Disease</i> , 2010, 3, 175.	0.8	3
4664	A guide to lipid modification. <i>British Journal of Cardiac Nursing</i> , 2010, 5, 410-416.	0.0	0

#	ARTICLE	IF	CITATIONS
4665	Atorvastatin in stroke: a review of SPARCL and subgroup analysis. <i>Vascular Health and Risk Management</i> , 2010, 6, 229.	1.0	34
4666	Impact of Statin Treatment on the Clinical Fate of Heterozygous Familial Hypercholesterolemia. <i>Journal of Atherosclerosis and Thrombosis</i> , 2010, 17, 667-674.	0.9	60
4667	Myocardial Blood Flow Measurement. , 2010, , 506-527.		2
4668	The Effects of Ezetimibe on Surrogate Markers of Cholesterol Absorption and Synthesis in Japanese Patients with Dyslipidemia. <i>Journal of Atherosclerosis and Thrombosis</i> , 2010, 17, 106-114.	0.9	41
4669	Benefits of statin therapy and compliance in high risk cardiovascular patients. <i>Vascular Health and Risk Management</i> , 2010, 6, 843.	1.0	48
4670	Clinical utility of rosuvastatin and other statins for cardiovascular risk reduction among the elderly. <i>Clinical Interventions in Aging</i> , 2011, 6, 27.	1.3	16
4672	Current status and future directions in lipid management: emphasizing low-density lipoproteins, high-density lipoproteins, and triglycerides as targets for therapy. <i>Vascular Health and Risk Management</i> , 2010, 6, 73.	1.0	20
4673	Role of bile acid sequestrants in the treatment of type 2 diabetes. <i>World Journal of Diabetes</i> , 2010, 1, 146.	1.3	14
4674	Statin therapy reduces inflammatory markers in hypercholesterolemic patients with high baseline levels. <i>Journal of Atherosclerosis and Thrombosis</i> , 2010, 17, 722-729.	0.9	33
4675	Can Intensive Lipid-Lowering Therapy with Statins Ameliorate Atherosclerosis in Japanese Patients?. <i>Journal of Atherosclerosis and Thrombosis</i> , 2010, 17, 416-422.	0.9	6
4676	Pitavastatin approved for treatment of primary hypercholesterolemia and combined dyslipidemia. <i>Vascular Health and Risk Management</i> , 2010, 6, 997.	1.0	6
4677	Post-Prandial Lipid Levels for Assessing Target Goal Achievement in Type 2 Diabetic Patients Taking Statin. <i>Journal of Korean Medical Science</i> , 2010, 25, 387.	1.1	5
4678	Residual risk for secondary ischemic events in patients with atherothrombotic disease: Opportunity for future improvements in patient care. <i>Annals of Medicine</i> , 2010, 42, 19-35.	1.5	23
4679	New evidence on pitavastatin: efficacy and safety in clinical studies. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 817-828.	0.9	49
4680	Pleiotropic effects of statins in atherosclerotic disease. <i>Expert Review of Cardiovascular Therapy</i> , 2010, 8, 1235-1237.	0.6	26
4681	Effects of Statins on Progression of Carotid Atherosclerosis as Measured By Carotid Intimal Medial Thickness: A Meta-Analysis of Randomized Controlled Trials. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2010, 15, 268-273.	1.0	52
4682	Effects of Statins on Progression of Subclinical Brain Infarct. <i>Cerebrovascular Diseases</i> , 2010, 30, 51-56.	0.8	31
4683	Age-related change in endothelial and microvessel function and therapeutic consequences. <i>Reviews in Clinical Gerontology</i> , 2010, 20, 161-170.	0.5	3

#	ARTICLE	IF	CITATIONS
4684	Monitoring and treatment for cardiovascular risk. Primary Health Care Research and Development, 2010, 11, 29.	0.5	0
4685	Current cardiovascular risk management patterns with special focus on lipid lowering in daily practice in Switzerland. European Journal of Cardiovascular Prevention and Rehabilitation, 2010, 17, 363-372.	3.1	11
4686	Prevalence of modifiable cardiovascular risk factors in German adolescents. European Journal of Cardiovascular Prevention and Rehabilitation, 2010, 17, 204-210.	3.1	21
4687	Effects of Simvastatin on Cholesterol Metabolism and Alzheimer Disease Biomarkers. Alzheimer Disease and Associated Disorders, 2010, 24, 220-226.	0.6	57
4688	Basic Science Review Section: Statin Therapy—Part II: Clinical Considerations for Cardiovascular Disease. Vascular and Endovascular Surgery, 2010, 44, 421-433.	0.3	19
4689	Use of Statin Therapy to Reduce Cardiovascular Risk in Older Patients. Current Gerontology and Geriatrics Research, 2010, 2010, 1-9.	1.6	10
4690	Niacin or Ezetimibe for Patients with, or at Risk of Coronary Heart Disease. Clinical Medicine Insights: Cardiology, 2010, 4, CMC.S5970.	0.6	3
4691	Control of cholesterol synthesis through regulated ER-associated degradation of HMG CoA reductase. Critical Reviews in Biochemistry and Molecular Biology, 2010, 45, 185-198.	2.3	134
4692	Rosuvastatin in the Prevention of Stroke Among Men and Women With Elevated Levels of C-Reactive Protein. Circulation, 2010, 121, 143-150.	1.6	157
4693	Medication therapy management and condition care services in a community-based employer setting. American Journal of Health-System Pharmacy, 2010, 67, 1362-1367.	0.5	15
4695	Association of Higher Levels of High-Density Lipoprotein Cholesterol in Elderly Individuals and Lower Risk of Late-Onset Alzheimer Disease. Archives of Neurology, 2010, 67, 1491-7.	4.9	193
4696	Pharmacotherapy of dyslipidemias in the adult population. Expert Opinion on Pharmacotherapy, 2010, 11, 3041-3052.	0.9	8
4697	Lipid lowering goals: back to nature?. Therapeutic Advances in Cardiovascular Disease, 2010, 4, 185-191.	1.0	13
4698	Diabetic dyslipidemia: extending the target beyond LDL cholesterol. European Journal of Cardiovascular Prevention and Rehabilitation, 2010, 17, s20-s24.	3.1	11
4699	A gene score of nine LDL and HDL regulating genes is associated with fluvastatin-induced cholesterol changes in women. Journal of Lipid Research, 2010, 51, 625-634.	2.0	19
4700	Darapladib: an emerging therapy for atherosclerosis. Therapeutic Advances in Cardiovascular Disease, 2010, 4, 241-248.	1.0	14
4701	Statins in the Treatment of Heart Failure. Circulation: Heart Failure, 2010, 3, 462-464.	1.6	8
4702	Manejo poblacional de las dislipidemias primarias. Revista Médica Clínica Las Condes, 2010, 21, 705-713.	0.2	1



#	ARTICLE	IF	CITATIONS
4703	The application of biomarkers in clinical trials for motor neuron disease. <i>Biomarkers in Medicine</i> , 2010, 4, 281-297.	0.6	26
4704	A Review of Perioperative Statin Therapy for Noncardiac Surgery. <i>Seminars in Cardiothoracic and Vascular Anesthesia</i> , 2010, 14, 283-290.	0.4	15
4705	Modeling the 4D Study. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 856-866.	2.2	19
4706	The underutilization of adjunctive pharmacotherapy in treating acute coronary syndrome patients admitted to a tertiary care hospital in Southwest region, Saudi Arabia. <i>Heart Views</i> , 2010, 11, 99.	0.1	2
4707	Stents and statins: history, clinical outcomes and mechanisms. <i>Expert Review of Cardiovascular Therapy</i> , 2010, 8, 1283-1295.	0.6	9
4708	Perspective: Beyond Storytelling in Medicine: An Encounter-Based Curriculum. <i>Academic Medicine</i> , 2010, 85, 794-798.	0.8	8
4709	Associations Between Peripheral Artery Disease and Ischemic Stroke. <i>Stroke</i> , 2010, 41, 2102-2107.	1.0	81
4710	Optimizing lipid-lowering therapy in the prevention of coronary heart disease. <i>Expert Review of Clinical Pharmacology</i> , 2010, 3, 649-661.	1.3	0
4711	Metabolic syndrome, peripheral vascular disease and coronary artery disease: A concise review. <i>International Journal of Angiology</i> , 2010, 19, e96-e99.	0.2	13
4712	An IV for the RCT: using instrumental variables to adjust for treatment contamination in randomised controlled trials. <i>BMJ: British Medical Journal</i> , 2010, 340, c2073-c2073.	2.4	151
4713	Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implications. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2010, 10, 73-85.	0.7	63
4714	Simvastatin reduces sympathetic activity in men with hypertension and hypercholesterolemia. <i>Hypertension Research</i> , 2010, 33, 1038-1043.	1.5	37
4715	Guideline-recommended secondary prevention drug therapy after acute myocardial infarction: predictors and outcomes of nonadherence. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2010, 17, 576-581.	3.1	43
4716	Hereâ€™s to You, Baby! A Step Forward in Support of Universal Screening of Thyroid Function during Pregnancy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 1575-1577.	1.8	18
4717	Atherosclerosis regression and high-density lipoproteins. <i>Expert Review of Cardiovascular Therapy</i> , 2010, 8, 1325-1334.	0.6	14
4718	Does the blood pressure-lowering effect of statins contribute to their beneficial cardiovascular effects?. <i>Expert Review of Cardiovascular Therapy</i> , 2010, 8, 775-779.	0.6	10
4719	Management of Cardiovascular Risk Associated with Insulin Resistance, Diabetes, and the Metabolic Syndrome. <i>Postgraduate Medicine</i> , 2010, 122, 61-70.	0.9	11
4720	The Utility of Observational Studies in Clinical Decision Making: Lessons Learned from Statin Trials. <i>Postgraduate Medicine</i> , 2010, 122, 222-229.	0.9	9

#	ARTICLE	IF	CITATIONS
4721	Improving Cardiovascular Risk Reduction for Primary Prevention—Utility of Lifetime Risk Assessment. <i>Postgraduate Medicine</i> , 2010, 122, 192-199.	0.9	13
4722	The epidemic of nonmelanoma skin cancer and the widespread use of statins. <i>Dermato-Endocrinology</i> , 2010, 2, 37-38.	1.9	8
4723	Raising highly desirable lipoprotein versus lowering deleterious lipoprotein. <i>Expert Review of Clinical Pharmacology</i> , 2010, 3, 173-176.	1.3	0
4724	Statin use and cancer risk: a comprehensive review. <i>Expert Opinion on Drug Safety</i> , 2010, 9, 603-621.	1.0	235
4725	Perioperative Statin Use: An Update. <i>Anesthesiology Clinics</i> , 2010, 28, 739-751.	0.6	15
4726	Statins in the Treatment of Dyslipidemia in the Presence of Elevated Liver Aminotransferase Levels: A Therapeutic Dilemma. <i>Mayo Clinic Proceedings</i> , 2010, 85, 349-356.	1.4	130
4727	Pharmacotherapy to Improve Outcomes in Infrainguinal Bypass Graft Surgery: A Review of Current Treatment Strategies. <i>Annals of Vascular Surgery</i> , 2010, 24, 562-572.	0.4	4
4728	Peripheral Artery Disease: Current Insight Into the Disease and Its Diagnosis and Management. <i>Mayo Clinic Proceedings</i> , 2010, 85, 678-692.	1.4	244
4731	La pharmacoth�rapie pour am�liorer les r�sultats des pontages sous-inguinaux : Examen des strat�gies actuelles de traitement. <i>Annales De Chirurgie Vasculaire</i> , 2010, 24, 612-624.	0.0	0
4732	Pleiotropic Effects of Statins. <i>American Journal of Cardiovascular Drugs</i> , 2010, 10, 10-17.	1.0	49
4733	Pleiotropic Effects of Statins. <i>American Journal of Cardiovascular Drugs</i> , 2010, 10, 3-9.	1.0	52
4734	Issues in Data Analysis. , 2010, , 345-398.		5
4735	Elevated total cholesterol in severely depressed patients: Role in cardiovascular risk?. <i>World Journal of Biological Psychiatry</i> , 2010, 11, 321-328.	1.3	12
4736	Cholesterol-Lowering Interventions and Stroke. <i>Journal of the American College of Cardiology</i> , 2010, 55, 198-211.	1.2	88
4737	A First-in-Man, Randomized, Placebo-Controlled Study to Evaluate the Safety and Feasibility of Autologous Delipidated High-Density Lipoprotein Plasma Infusions in Patients With Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2010, 55, 2727-2735.	1.2	202
4738	Baseline and On-Treatment High-Density Lipoprotein Cholesterol and the Risk of Cancer in Randomized Controlled Trials of Lipid-Altering Therapy. <i>Journal of the American College of Cardiology</i> , 2010, 55, 2846-2854.	1.2	145
4739	Clinical Predictors of Plaque Progression Despite Very Low Levels of Low-Density Lipoprotein Cholesterol. <i>Journal of the American College of Cardiology</i> , 2010, 55, 2736-2742.	1.2	143
4740	Evaluation of a pharmacist-managed lipid clinic that uses point-of-care lipid testing. <i>Journal of Clinical Lipidology</i> , 2010, 4, 120-125.	0.6	12

#	ARTICLE	IF	CITATIONS
4741	Attainment of low-density lipoprotein cholesterol goals in coronary artery disease. <i>Journal of Clinical Lipidology</i> , 2010, 4, 173-180.	0.6	33
4742	Cholesterol crystals piercing the arterial plaque and intima trigger local and systemic inflammation. <i>Journal of Clinical Lipidology</i> , 2010, 4, 156-164.	0.6	158
4743	Cardiac PET Imaging for the Detection and Monitoring of Coronary Artery Disease and Microvascular Health. <i>JACC: Cardiovascular Imaging</i> , 2010, 3, 623-640.	2.3	338
4744	Serial Coronary CT Angiography—Verified Changes in Plaque Characteristics as an End Point. <i>JACC: Cardiovascular Imaging</i> , 2010, 3, 691-698.	2.3	156
4745	Efficacy of simvastatin or ezetimibe on tissue factor, von Willebrand's factor and C-reactive protein in patients with hypercholesterolaemia. <i>Archives of Cardiovascular Diseases</i> , 2010, 103, 26-32.	0.7	13
4746	Uninsured South Florida vascular surgery patients are less likely to receive optimal medical management than their insured counterparts. <i>Journal of Vascular Surgery</i> , 2010, 51, S4-S8.	0.6	12
4747	Drug Treatment of Hyperlipidaemia. <i>Drugs</i> , 2010, 70, 1363-1379.	4.9	42
4748	Emerging drugs for hyperlipidemia. <i>Expert Opinion on Emerging Drugs</i> , 2010, 15, 433-451.	1.0	16
4749	Nanotechnology for synthetic high-density lipoproteins. <i>Trends in Molecular Medicine</i> , 2010, 16, 553-560.	3.5	27
4750	Up-regulating PPAR- $\beta$ expression and NO concentration, and down-regulating PAI-1 concentration in a rabbit atherosclerotic model: The possible antiatherogenic and antithrombotic effects of atorvastatin. <i>International Journal of Cardiology</i> , 2010, 139, 213-217.	0.8	3
4751	Mortality and morbidity of newly diagnosed heart failure treated with statins. <i>International Journal of Cardiology</i> , 2010, 140, 210-218.	0.8	12
4752	A hydroxymethylglutaryl coenzyme a reductase inhibitor improves endothelial function within 7 days in patients with chronic hemodialysis. <i>International Journal of Cardiology</i> , 2010, 145, 21-26.	0.8	17
4754	Effects of statins vs. non-statin lipid-lowering therapy on bone formation and bone mineral density biomarkers in patients with hyperlipidemia. <i>Bone</i> , 2010, 46, 1011-1015.	1.4	69
4755	A cluster randomised controlled trial of pharmacist led Statin Outreach Support (SOS) in primary care: Design and baseline characteristics. <i>Contemporary Clinical Trials</i> , 2010, 31, 303-311.	0.8	7
4756	Why statin therapy may increase the risk for posttransplantation squamous cell carcinoma. <i>Transplant Immunology</i> , 2010, 23, 224-225.	0.6	4
4757	Thrombus Aspiration in ST-Elevation myocardial infarction in Scandinavia (TASTE trial). A multicenter, prospective, randomized, controlled clinical registry trial based on the Swedish angiography and angioplasty registry (SCAAR) platform. Study design and rationale. <i>American Heart Journal</i> , 2010, 160, 1042-1048.	1.2	150
4758	Lipid-lowering intensification and low-density lipoprotein cholesterol achievement from hospital admission to 1-year follow-up after an acute coronary syndrome event: Results from the Medications Applied and Sustained Over Time (MAINTAIN) registry. <i>American Heart Journal</i> , 2010, 160, 1121-1129.e1.	1.2	38
4759	Introduction. <i>Atherosclerosis Supplements</i> , 2010, 11, 1-2.	1.2	7

#	ARTICLE	IF	CITATIONS
4760	Statins Decrease Adverse Outcomes in Coronary Artery Bypass for Extensive Coronary Artery Disease as well as Left Main Coronary Stenosis. <i>Cardiovascular Therapeutics</i> , 2010, 28, 70-79.	1.1	28
4761	Statins—Is There Potential for Uncovering New Benefits (or Detriments)? <i>Cardiovascular Therapeutics</i> , 2010, 28, 67-69.	1.1	2
4762	CARDIOVASCULAR DISEASE IN RENAL TRANSPLANT RECIPIENTS. <i>Journal of Renal Care</i> , 2010, 36, 136-145.	0.6	7
4763	Pitavastatin — from clinical trials to clinical practice. <i>Atherosclerosis Supplements</i> , 2010, 11, 15-22.	1.2	19
4764	Genetic variation in the ABCA1 gene, HDL cholesterol, and risk of ischemic heart disease in the general population. <i>Atherosclerosis</i> , 2010, 208, 305-316.	0.4	82
4765	The role of apoptosis in LDL transport through cultured endothelial cell monolayers. <i>Atherosclerosis</i> , 2010, 208, 335-341.	0.4	44
4766	Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. <i>Atherosclerosis</i> , 2010, 210, 353-361.	0.4	250
4767	Relationship between cholesterol synthesis and intestinal absorption is associated with cardiovascular risk. <i>Atherosclerosis</i> , 2010, 210, 362-365.	0.4	50
4768	Reduced LDL-cholesterol levels in patients with coronary artery disease are paralleled by improved endothelial function: An observational study in patients from 2003 and 2007. <i>Atherosclerosis</i> , 2010, 211, 271-277.	0.4	18
4769	The effect of statins on carotid plaque morphology: A LDL-associated action or one more pleiotropic effect of statins?. <i>Atherosclerosis</i> , 2010, 213, 8-20.	0.4	53
4770	Patients' self-estimated likelihood of taking a statin as prescribed after different types of prognostic information. <i>Atherosclerosis</i> , 2010, 212, 586-588.	0.4	3
4771	Impact of statin pretreatment on the incidence of plaque rupture in ST-elevation acute myocardial infarction. <i>Atherosclerosis</i> , 2010, 213, 505-511.	0.4	23
4772	The Health Impact Fund: incentives for improving access to medicines. <i>Lancet, The</i> , 2010, 375, 166-169.	6.3	72
4773	Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. <i>Lancet, The</i> , 2010, 375, 735-742.	6.3	2,064
4774	Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2010, 375, 998-1006.	6.3	813
4775	Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial. <i>Lancet, The</i> , 2010, 376, 1658-1669.	6.3	501
4776	HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. <i>Lancet, The</i> , 2010, 376, 333-339.	6.3	221
4777	Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. <i>Lancet, The</i> , 2010, 376, 517-523.	6.3	222

#	ARTICLE	IF	CITATIONS
4778	Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170â€™000 participants in 26 randomised trials. <i>Lancet, The</i> , 2010, 376, 1670-1681.	6.3	5,162
4779	Is intensive LDL-cholesterol lowering beneficial and safe?. <i>Lancet, The</i> , 2010, 376, 1622-1624.	6.3	13
4780	Statins and Cardiac Surgery. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2010, 24, 909-912.	0.6	9
4781	Achieving cholesterol targets by individualizing starting doses of statin according to baseline low-density lipoprotein cholesterol and coronary artery disease risk category: The CANadians Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (CanACTFAST) study. <i>Canadian Journal of Cardiology</i> , 2010, 26, 80-86.	0.8	27
4782	Basic Science Review: Statin Therapy-Part I: The Pleiotropic Effects of Statins in Cardiovascular Disease. <i>Vascular and Endovascular Surgery</i> , 2010, 44, 241-251.	0.3	121
4783	Population Trends in the Incidence and Outcomes of Acute Myocardial Infarction. <i>New England Journal of Medicine</i> , 2010, 362, 2155-2165.	13.9	1,444
4784	Statins and the Reduction of Sudden Cardiac Death. <i>American Journal of Cardiovascular Drugs</i> , 2010, 10, 155-164.	1.0	22
4785	Long-Term Results of Eversion Carotid Endarterectomy. <i>Annals of Vascular Surgery</i> , 2010, 24, 92-99.	0.4	19
4786	Rosuvastatin-Associated Adverse Effects and Drug-Drug Interactions in the Clinical Setting of Dyslipidemia. <i>American Journal of Cardiovascular Drugs</i> , 2010, 10, 11-28.	1.0	78
4787	Evaluation of different formulas for LDL-C calculation. <i>Lipids in Health and Disease</i> , 2010, 9, 27.	1.2	78
4788	Rheumatoid arthritis patients receive less frequent acute reperfusion and secondary prevention therapy after myocardial infarction compared with the general population. <i>Arthritis Research and Therapy</i> , 2010, 12, R183.	1.6	37
4789	Adjunctive Pharmacologic Therapies in Acute Myocardial Infarction. , 2010, , 145-182.		1
4790	Efficacia clinica e costo-efficacia di atorvastatina a elevati dosaggi nella prevenzione degli eventi cardiocerebrovascolari. <i>Giornale Italiano Di Health Technology Assessment</i> , 2011, 4, 17-31.	0.1	0
4791	Quinazolin-4(3H)-ones capable of upregulating the expression of endogenous apolipoprotein A-1. <i>Expert Opinion on Therapeutic Patents</i> , 2011, 21, 431-435.	2.4	0
4792	Epidemiological link between low cholesterol and suicidality: A puzzle never finished. <i>Nutritional Neuroscience</i> , 2011, 14, 268-287.	1.5	27
4793	Simvastatin pretreatment prevents ambient particle-induced lung injury in mice. <i>Inhalation Toxicology</i> , 2011, 23, 889-896.	0.8	27
4794	ETC-216 for coronary artery disease. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 387-394.	1.4	25
4795	Peripheral artery disease. Part 2: medical and endovascular treatment. <i>Nature Reviews Cardiology</i> , 2011, 8, 429-441.	6.1	32

#	ARTICLE	IF	CITATIONS
4796	Reduced or modified dietary fat for preventing cardiovascular disease. , 2011, , CD002137.		71
4797	Medication Adherence: Hope for Improvement?. Mayo Clinic Proceedings, 2011, 86, 268-270.	1.4	20
4798	Comparison of Effects of Morning Versus Evening Administration of Ezetimibe/Simvastatin on Serum Cholesterol in Patients with Primary Hypercholesterolemia. Annals of Pharmacotherapy, 2011, 45, 841-849.	0.9	20
4799	LDL cholesterol goals and cardiovascular risk during statin treatment: the IDEAL study. European Journal of Cardiovascular Prevention and Rehabilitation, 2011, 18, 262-269.	3.1	10
4800	Lipid-Lowering Therapy with Statins for the Primary and Secondary Prevention of Cardiovascular Disease. Cardiology Clinics, 2011, 29, 87-103.	0.9	37
4801	The Complex Interplay Between Cholesterol and Prostate Malignancy. Urologic Clinics of North America, 2011, 38, 243-259.	0.8	61
4802	Opening a New Lipid "Apo-theary": Incorporating Apolipoproteins as Potential Risk Factors and Treatment Targets to Reduce Cardiovascular Risk. Mayo Clinic Proceedings, 2011, 86, 762-780.	1.4	32
4803	The REALIST (REsiduAl risk, Lipids and Standard Therapies) study: an analysis of residual risk attributable to lipid profile in acute coronary syndrome. EndocrinologĀ Y NutriciĀn (English) Tj ETQq1 1 0.784310.8BT /Overlock 10T		
4804	Therapeutic approach to dyslipidemia and goal achievement in a Spanish population with type 2 diabetes without cardiovascular disease. EndocrinologĀ Y NutriciĀn (English Edition), 2011, 58, 283-290.	0.5	2
4805	Coadministration of Atorvastatin Prevents Nitroglycerin-Induced Endothelial Dysfunction and Nitrate Tolerance in Healthy Humans. Journal of the American College of Cardiology, 2011, 57, 93-98.	1.2	32
4807	2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non"ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2011, 57, e215-e367.	1.2	420
4808	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2011, 58, e44-e122.	1.2	2,027
4809	Continuation of mortality reduction after the end of randomized therapy in clinical trials of lipid-lowering therapy. Journal of Clinical Lipidology, 2011, 5, 97-104.	0.6	20
4810	Treatment of adults with Familial Hypercholesterolemia and evidence for treatment: Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. Journal of Clinical Lipidology, 2011, 5, S18-S29.	0.6	107
4811	Efficacy and tolerability of once-weekly rosuvastatin in patients with previous statin intolerance. Journal of Clinical Lipidology, 2011, 5, 308-315.	0.6	44
4812	Management of Familial Hypercholesterolemias in adult patients: Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. Journal of Clinical Lipidology, 2011, 5, S38-S45.	0.6	120
4813	MR Imaging-Verified Plaque Delipidation With Lipid-Lowering Therapy. JACC: Cardiovascular Imaging, 2011, 4, 987-989.	2.3	6
4815	Statins and myocardial remodelling: cell and molecular pathways. Expert Reviews in Molecular Medicine, 2011, 13, e22.	1.6	44

#	ARTICLE	IF	CITATIONS
4816	Imaging of Atherosclerosis. <i>Annual Review of Medicine</i> , 2011, 62, 25-40.	5.0	101
4817	Multiple risk factor interventions for primary prevention of coronary heart disease. <i>The Cochrane Library</i> , 2011, , CD001561.	1.5	278
4818	The effect of simvastatin in penile erection: a randomized, double-blind, placebo-controlled clinical trial (Simvastatin treatment for erectile dysfunctionâ€”STED TRIAL). <i>International Journal of Impotence Research</i> , 2011, 23, 242-248.	1.0	15
4819	Statins for acute coronary syndrome. , 2011, , CD006870.		16
4820	Will apoA-I-based therapies step up to cure coronary artery disease?. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 1367-1370.	0.6	0
4821	Antiatherogenic Effect of Antioxidant Polyphenols from <i>Phellinus baumii</i> in Apolipoprotein E-Deficient Mice. <i>Annals of Nutrition and Metabolism</i> , 2011, 59, 145-153.	1.0	8
4822	Statins for women with polycystic ovary syndrome not actively trying to conceive. <i>The Cochrane Library</i> , 2011, , CD008565.	1.5	35
4823	Clinical experience with rosuvastatin in the management of hyperlipidemia and the reduction of cardiovascular risk. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 1383-1390.	0.6	7
4824	Low-Dose Pravastatin and Age-Related Differences in Risk Factors for Cardiovascular Disease in Hypercholesterolaemic Japanese. <i>Drugs and Aging</i> , 2011, 28, 681-692.	1.3	31
4825	Lipid control in patients with diabetes mellitus. <i>Nature Reviews Cardiology</i> , 2011, 8, 278-290.	6.1	38
4826	Modifiers of Symptomatic Embolic Risk in Infective Endocarditis. <i>Mayo Clinic Proceedings</i> , 2011, 86, 1068-1074.	1.4	27
4828	The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol. <i>American Heart Journal</i> , 2011, 161, 471-477.e2.	1.2	80
4829	The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: Baseline characteristics of study participants. <i>The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH) trial. American Heart Journal</i> , 2011, 161, 538-543.	1.2	132
4830	Medical Therapy Versus Myocardial Revascularization in Chronic Coronary Syndrome and Stable Angina. <i>American Journal of Medicine</i> , 2011, 124, 681-688.	0.6	14
4831	Secondary Prevention of Stroke in the Elderly: A Review of the Evidence. <i>American Journal of Geriatric Pharmacotherapy</i> , 2011, 9, 143-152.	3.0	24
4832	COACH trial: A randomized controlled trial of nurse practitioner/community health worker cardiovascular disease risk reduction in urban community health centers: Rationale and design. <i>Contemporary Clinical Trials</i> , 2011, 32, 403-411.	0.8	39
4833	Rationale and design of STOP DVT study: Rosuvastatin for the prevention of deep vein thrombosis in patients undergoing total knee replacement arthroplasty â€” A prospective randomized open-label controlled trial. <i>Contemporary Clinical Trials</i> , 2011, 32, 779-782.	0.8	1
4834	Estimating the Benefits of Patient and Physician Adherence to Cardiovascular Prevention Guidelines: The MyHealthCheckup Survey. <i>Canadian Journal of Cardiology</i> , 2011, 27, 159-166.	0.8	17

#	ARTICLE	IF	CITATIONS
4835	Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Proceedings of a Canadian Working Group Consensus Conference. <i>Canadian Journal of Cardiology</i> , 2011, 27, 635-662.	0.8	160
4836	Current developments in lipid-lowering therapy for the patient with chronic kidney disease. <i>Clinical Lipidology</i> , 2011, 6, 693-702.	0.4	0
4837	Hypercholesterolemia and hypoadiponectinemia are associated with necrotic core-rich coronary plaque. <i>International Journal of Cardiology</i> , 2011, 147, 371-376.	0.8	28
4838	Effects of statin therapy on non-calcified coronary plaque assessed by 64-slice computed tomography. <i>International Journal of Cardiology</i> , 2011, 150, 146-150.	0.8	20
4839	Local persistent hypercoagulability after sirolimus-eluting stent implantation in patients with stable angina. <i>International Journal of Cardiology</i> , 2011, 153, 272-276.	0.8	1
4840	The complex interplay of cardiovascular system and cognition: How to predict dementia in the elderly?. <i>International Journal of Cardiology</i> , 2011, 150, 123-129.	0.8	34
4841	The large clinical statin trials. <i>International Journal of Cardiology</i> , 2011, 150, 108-111.	0.8	2
4842	Lovastatin Inhibits Thrombospondin-1-Induced Smooth Muscle Cell Chemotaxis. <i>Journal of Surgical Research</i> , 2011, 168, 149-154.	0.8	10
4843	Impacto de la apertura de un nuevo laboratorio de hemodinámica sobre la supervivencia a 30 días y a 2 años en los pacientes con infarto de miocardio. <i>Revista Espanola De Cardiología</i> , 2011, 64, 96-104.	0.6	16
4844	Papel de un nuevo laboratorio de cateterismo cardiaco en la mejora de la asistencia cardiovascular y sus resultados en pacientes con infarto de miocardio. <i>Revista Espanola De Cardiología</i> , 2011, 64, 87-88.	0.6	0
4846	Management of Elevated Cholesterol in the primary prevention Group of Adult Japanese (MEGA) Study assists the view that a fasting plasma glucose level $\geq 100$ mg/dL increases cardiovascular risk. <i>Journal of Diabetes Investigation</i> , 2011, 2, 399-405.	1.1	0
4847	Professional perspectives on a feasibility study of GP-pharmacist collaboration in the management of angina. <i>International Journal of Pharmacy Practice</i> , 2011, 8, 275-284.	0.3	3
4848	Development of a pharmacist-led cholesterol screening and lipid-lowering medication review service in coronary artery bypass graft patients. <i>International Journal of Pharmacy Practice</i> , 2011, 9, 275-281.	0.3	3
4849	Statins utilisation pattern: a retrospective evaluation in a tertiary care hospital in Thailand. <i>International Journal of Pharmacy Practice</i> , 2011, 19, 129-135.	0.3	8
4850	STATIN-D Study: Comparison of the Influences of Rosuvastatin and Fluvastatin Treatment on the Levels of 25 Hydroxyvitamin D. <i>Cardiovascular Therapeutics</i> , 2011, 29, 146-152.	1.1	66
4851	Targeting Inflammation as a Therapeutic Strategy in Accelerated Atherosclerosis in Rheumatoid Arthritis. <i>Cardiovascular Therapeutics</i> , 2011, 29, 231-242.	1.1	21
4852	Therapeutic Strategies in Patients with Chronic Stable Coronary Artery Disease. <i>Cardiovascular Therapeutics</i> , 2011, 29, e23-e30.	1.1	5
4853	Introduction. <i>Atherosclerosis Supplements</i> , 2011, 12, 265-266.	1.2	8



#	ARTICLE	IF	CITATIONS
4854	Pitavastatin: Novel effects on lipid parameters. <i>Atherosclerosis Supplements</i> , 2011, 12, 277-284.	1.2	17
4855	Drug safety evaluation of rosuvastatin. <i>Expert Opinion on Drug Safety</i> , 2011, 10, 969-986.	1.0	27
4856	Effect of Opening a New Catheterization Laboratory on 30-Day and 2-Year Survival Rates in Myocardial Infarction Patients. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2011, 64, 96-104.	0.4	2
4857	The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. <i>Atherosclerosis</i> , 2011, 218, 156-162.	0.4	74
4858	ESC/EAS Guidelines for the management of dyslipidaemias. <i>Atherosclerosis</i> , 2011, 217, 1-44.	0.4	180
4859	ESC/EAS Guidelines for the management of dyslipidaemias. <i>Atherosclerosis</i> , 2011, 217, 3-46.	0.4	561
4860	HMG-CoA reductase inhibitors enhance phagocytosis by upregulating ATP-binding cassette transporter A7. <i>Atherosclerosis</i> , 2011, 217, 407-414.	0.4	42
4861	Association of lower total bilirubin level with statin usage: The United States National Health and Nutrition Examination Survey 1999-2008. <i>Atherosclerosis</i> , 2011, 219, 728-733.	0.4	26
4862	Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. <i>Lancet, The</i> , 2011, 378, 1547-1559.	6.3	479
4863	The Effects of Statin and Niacin on Plaque Stability, Plaque Regression, Inflammation and Oxidative Stress in Patients With Mild to Moderate Coronary Artery Stenosis. <i>Korean Circulation Journal</i> , 2011, 41, 641.	0.7	17
4864	Prescription Prevalence and Continuing Medication Use for Secondary Prevention After Myocardial Infarction. <i>Deutsches A&amp;#x0308;rztblatt International</i> , 2011, 108, 856-62.	0.6	43
4865	Rhabdomyolysis with simvastatin. <i>BMJ Case Reports</i> , 2011, 2011, bcr1220092552-bcr1220092552.	0.2	2
4866	Effective CVD prevention strategies in the young. <i>British Journal of Health Care Management</i> , 2011, 17, 477-479.	0.1	0
4867	Protective role of heme oxygenase-1 against inflammation in atherosclerosis. <i>Frontiers in Bioscience - Landmark</i> , 2011, 16, 2372.	3.0	57
4868	Statins in multiple sclerosis. , 0, , 465-471.		0
4869	Effect of Previous Statin Therapy in Patients With Acute Coronary Syndrome and Percutaneous Coronary Intervention. <i>Korean Circulation Journal</i> , 2011, 41, 458.	0.7	15
4870	Efficacy and safety of gonadotropin-releasing hormone agonists used in the treatment of prostate cancer. <i>Drug, Healthcare and Patient Safety</i> , 2011, 3, 107.	1.0	14
4871	ACE up the sleeve &ndash; are vascular patients medically optimized. <i>Vascular Health and Risk Management</i> , 2011, 7, 15.	1.0	14

#	ARTICLE	IF	CITATIONS
4872	Quality evaluation of simvastatin compounded capsules. Brazilian Journal of Pharmaceutical Sciences, 2011, 47, 495-502.	1.2	5
4873	Aspectos clínicos e socioeconômicos das dislipidemias em portadores de doenças cardiovasculares. Physis, 2011, 21, 417-436.	0.1	2
4874	Vascular Biology and Atherosclerosis of Cerebral Arteries. , 2011, , 3-15.		0
4875	Reducing CVD Risk with Lipid Management This article was first published in British Journal of Cardiac Nursing Vol. 5 No. 9, pp. 410-416. Practice Nursing, 2011, 22, 93-97.	0.1	0
4876	Total lipid management and residual risk: beyond statin therapy. British Journal of Hospital Medicine (London, England: 2005), 2011, 72, 132-136.	0.2	3
4877	CHALLENGES IN ATHEROSCLEROSIS. , 0, , 62-88.		0
4878	Differential Effects of Pravastatin and Simvastatin on the Growth of Tumor Cells from Different Organ Sites. PLoS ONE, 2011, 6, e28813.	1.1	71
4879	Association of High-Density Lipoprotein Cholesterol With Coronary Heart Disease Risk Across Categories of Low-Density Lipoprotein Cholesterol: The Atherosclerosis Risk in Communities Study. American Journal of the Medical Sciences, 2011, 341, 173-180.	0.4	15
4880	Influence of Predictive Modeling in Implementing Optimal Heart Failure Therapy. American Journal of the Medical Sciences, 2011, 341, 185-190.	0.4	9
4881	Are statins diabetogenic?. Current Opinion in Cardiology, 2011, 26, 342-347.	0.8	94
4882	Understanding the potential role of statins in pneumonia and sepsis*. Critical Care Medicine, 2011, 39, 1871-1878.	0.4	118
4883	Haem oxygenase-1 and cardiovascular disease: mechanisms and therapeutic potential. Clinical Science, 2011, 120, 493-504.	1.8	51
4884	Cardioprotective Effects of Pravastatin Against Lethal Ventricular Arrhythmias Induced by Reperfusion in the Rat Heart. Circulation Journal, 2011, 75, 1601-1608.	0.7	14
4885	Clinical Usefulness of Additional Treatment With Ezetimibe in Patients With Coronary Artery Disease on Statin Therapy - From the Viewpoint of Cholesterol Metabolism -. Circulation Journal, 2011, 75, 2496-2504.	0.7	20
4886	Intensively Lowering Both Low-Density Lipoprotein Cholesterol and Blood Pressure Does Not Reduce Cardiovascular Risk in Japanese Coronary Artery Disease Patients. Circulation Journal, 2011, 75, 2062-2070.	0.7	8
4887	The rise of cholesterol testing: how much is unnecessary. British Journal of General Practice, 2011, 61, e81-e88.	0.7	22
4888	Impact of Low-Density Lipoprotein Cholesterol/High-Density Lipoprotein Cholesterol Ratio on Long-Term Outcome in Patients Undergoing Percutaneous Coronary Intervention. Circulation Journal, 2011, 75, 905-910.	0.7	28
4889	Early Intervention With Rosuvastatin Decreases the Lipid Components of the Plaque in Acute Coronary Syndrome - Analysis Using Integrated Backscatter IVUS (ELAN Study) -. Circulation Journal, 2011, 75, 633-641.	0.7	42

#	ARTICLE	IF	CITATIONS
4891	Managing statin-induced muscle toxicity in a lipid clinic. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2011, 36, 336-341.	0.7	10
4892	Statin adherence and the risk of major coronary events in patients with diabetes: a nested case-control study. <i>British Journal of Clinical Pharmacology</i> , 2011, 71, 766-776.	1.1	32
4893	Review article: drug-induced liver injury - its pathophysiology and evolving diagnostic tools. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 11-20.	1.9	98
4894	Statin use in patients with asthma - a nationwide population-based study. <i>European Journal of Clinical Investigation</i> , 2011, 41, 507-512.	1.7	80
4895	How do prescribing doctors anticipate the effect of statins?. <i>Journal of Evaluation in Clinical Practice</i> , 2011, 17, 420-428.	0.9	6
4896	Effects of a healthy Nordic diet on cardiovascular risk factors in hypercholesterolaemic subjects: a randomized controlled trial (NORDIET). <i>Journal of Internal Medicine</i> , 2011, 269, 150-159.	2.7	202
4897	Nonfasting cholesterol and triglycerides and association with risk of myocardial infarction and total mortality: the Copenhagen City Heart Study with 31 years of follow-up. <i>Journal of Internal Medicine</i> , 2011, 270, 65-75.	2.7	163
4898	Use of principal component analysis in the evaluation of adherence to statin treatment: a method to determine a potential target population for public health intervention. <i>Fundamental and Clinical Pharmacology</i> , 2011, 25, 528-533.	1.0	6
4899	Trig-onometry™: non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia. <i>International Journal of Clinical Practice</i> , 2011, 65, 82-101.	0.8	17
4900	Anti-inflammatory and Monocyte Suppressing Effects of Simvastatin in Patients with Impaired Fasting Glucose. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2011, 108, 131-137.	1.2	10
4901	A Population Pharmacokinetic-Pharmacodynamic Model for Simvastatin that Predicts Low-Density Lipoprotein Cholesterol Reduction in Patients with Primary Hyperlipidaemia. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2011, 109, 156-163.	1.2	35
4902	Impact of Lipid Apheresis on Egr1, Jun, Fos, and Hsp70 Gene Expression in White Blood Cells. <i>Therapeutic Apheresis and Dialysis</i> , 2011, 15, 105-112.	0.4	8
4903	Meta-analysis of the cardiovascular benefits of intensive lipid lowering with statins. <i>Acta Neurologica Scandinavica</i> , 2011, 124, 188-195.	1.0	24
4904	Single nucleotide polymorphisms in genes that are associated with a modified response to statin therapy: the Rotterdam Study. <i>Pharmacogenomics Journal</i> , 2011, 11, 72-80.	0.9	16
4905	Small leucine-rich proteoglycans in atherosclerotic lesions: novel targets of chronic statin treatment?. <i>Journal of Cellular and Molecular Medicine</i> , 2011, 15, 232-243.	1.6	18
4906	Atherosclerosis induced by arsenic in drinking water in rats through altering lipid metabolism. <i>Toxicology and Applied Pharmacology</i> , 2011, 256, 146-153.	1.3	47
4907	Long-term event monitoring study of fluvastatin in Japanese patients with hypercholesterolemia: Efficacy and incidence of cardiac and other events in elderly patients (≥65 years old). <i>Journal of Cardiology</i> , 2011, 57, 77-88.	0.8	13
4908	Impact of early statin initiation on secondary prevention in Japanese patients with coronary artery disease. <i>Journal of Cardiology</i> , 2011, 57, 172-180.	0.8	17

#	ARTICLE	IF	CITATIONS
4909	Rosuvastatin Lowers Coenzyme Q10 Levels, but not Mitochondrial Adenosine Triphosphate Synthesis, in Children with Familial Hypercholesterolemia. <i>Journal of Pediatrics</i> , 2011, 158, 458-462.	0.9	25
4910	Chapter III: Management of Cardiovascular Risk Factors and Medical Therapy. <i>European Journal of Vascular and Endovascular Surgery</i> , 2011, 42, S33-S42.	0.8	27
4911	Beneficio cl�nico de las estatinas: �hemos cubierto todo el espectro?. <i>Revista Espanola De Cardiologia Suplementos</i> , 2011, 11, 3-13.	0.2	2
4912	Exposure to statins and risk of common cancers: a series of nested case-control studies. <i>BMC Cancer</i> , 2011, 11, 409.	1.1	108
4913	Combination Therapy With Ezetimibe/Simvastatin Versus Statin Monotherapy for Low-Density Lipoprotein Cholesterol Reduction and Goal Attainment in a Real-World Clinical Setting. <i>Clinical Therapeutics</i> , 2011, 33, 212-224.	1.1	23
4914	Measuring Clinical Relevance and Impact in Journal Publishing: A Proposed Model and Publisher's Perspective. <i>Clinical Therapeutics</i> , 2011, 33, B11-B15.	1.1	3
4915	Simvastatin Exerts Favourable Effects on Neointimal Formation in a Mouse Model of Vein Graft. <i>European Journal of Vascular and Endovascular Surgery</i> , 2011, 42, 393-399.	0.8	9
4916	The Editor's Roundtable: Closing the Clinical Practice Gap� Using Evidence-Based Treatments for Managing Lipids. <i>American Journal of Cardiology</i> , 2011, 107, 230-242.	0.7	1
4917	Effect of Lipid-Lowering Treatment on Natural History of Heterozygous Familial Hypercholesterolemia in Past Three Decades. <i>American Journal of Cardiology</i> , 2011, 108, 223-226.	0.7	58
4918	Susceptibility to simvastatin-induced toxicity is partly determined by mitochondrial respiration and phosphorylation state of Akt. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2011, 1813, 2079-2087.	1.9	67
4919	Developing predictive CSF biomarkers� A challenge critical to success in Alzheimer's disease and neuropsychiatric translational medicine. <i>Biochemical Pharmacology</i> , 2011, 81, 1422-1434.	2.0	41
4920	Effects of short-term anti-inflammatory therapy on endothelial function in patients with non-ST-segment elevation acute coronary syndrome. <i>Cardiovascular Revascularization Medicine</i> , 2011, 12, 2-9.	0.3	7
4921	The Effects of Statin Monotherapy and Low�Dose Statin/Ezetimibe on Lipoprotein�Associated Phospholipase A <sub>2</sub> . <i>Clinical Cardiology</i> , 2011, 34, 108-112.	0.7	18
4922	Drug metabolome of the Simvastatin formed by human intestinal microbiota in vitro. <i>Molecular BioSystems</i> , 2011, 7, 437-446.	2.9	44
4923	2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 82, E266-355.	0.7	97
4924	The Effects of Potential Neuroprotective Agents on Rat Facial Function Recovery Following Facial Nerve Injury. <i>Otolaryngology - Head and Neck Surgery</i> , 2011, 144, 53-59.	1.1	11
4925	Personalized vascular medicine: Individualizing drug therapy. <i>Vascular Medicine</i> , 2011, 16, 391-404.	0.8	16
4926	Statins and Intracerebral Hemorrhage. <i>Circulation</i> , 2011, 124, 2233-2242.	1.6	164

#	ARTICLE	IF	CITATIONS
4927	Statins in Heart Failure—Where Do We Stand?. <i>Cardiovascular Drugs and Therapy</i> , 2011, 25, 99-104.	1.3	4
4928	Fluvastatin modulates renal water reabsorption in vivo through increased AQP2 availability at the apical plasma membrane of collecting duct cells. <i>Pflugers Archiv European Journal of Physiology</i> , 2011, 462, 753-766.	1.3	56
4929	Suboptimal use of statins at treatment initiation. <i>European Journal of Clinical Pharmacology</i> , 2011, 67, 971-973.	0.8	9
4930	The Impact of Pravastatin Pre-Treatment on Periprocedural Microcirculatory Damage in Patients Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 513-520.	1.1	42
4932	Carotid Artery Disease and Stenting: Insights From Recent Clinical Trials. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2011, 13, 129-145.	0.4	1
4933	Systems Biology Approaches for Investigating the Relationship Between Lipids and Cardiovascular Disease. <i>Current Cardiovascular Risk Reports</i> , 2011, 5, 52-61.	0.8	2
4934	Phytosterols and phytosterolemia: gene—diet interactions. <i>Genes and Nutrition</i> , 2011, 6, 17-26.	1.2	55
4935	Pitavastatin: a New 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor for the treatment of hyperlipidemia. <i>Advances in Therapy</i> , 2011, 28, 13-27.	1.3	10
4936	Long-term efficacy of pitavastatin versus simvastatin. <i>Advances in Therapy</i> , 2011, 28, 799-810.	1.3	29
4937	A practical approach to lipid management in the elderly. <i>Journal of Nutrition, Health and Aging</i> , 2011, 15, 65-70.	1.5	1
4938	Translational research: Lessons from past research, growing up nowadays, and development goal in future. <i>Science China Life Sciences</i> , 2011, 54, 1085-1088.	2.3	7
4939	Statin Rebound or Withdrawal Syndrome: Does It Exist?. <i>Current Atherosclerosis Reports</i> , 2011, 13, 23-30.	2.0	46
4940	Are Cardiovascular Benefits in Statin Lipid Effects Dependent on Baseline Lipid Levels?. <i>Current Atherosclerosis Reports</i> , 2011, 13, 64-72.	2.0	5
4941	The Role of Atherosclerosis Imaging in Redefining Normal and Abnormal Cholesterol Values, and Risk Reduction in Primary Prevention Statin Trials. <i>Current Atherosclerosis Reports</i> , 2011, 13, 422-430.	2.0	6
4942	Coronary Artery Calcium: Utilization for Primary Prevention of CHD. <i>Current Cardiology Reports</i> , 2011, 13, 465-474.	1.3	7
4943	Predictors of Statin Adherence. <i>Current Cardiology Reports</i> , 2011, 13, 553-558.	1.3	47
4944	Adherence with statins in a real-life setting is better when associated cardiovascular risk factors increase: a cohort study. <i>BMC Cardiovascular Disorders</i> , 2011, 11, 46.	0.7	42
4945	Cardiac medication prescribing and adherence after acute myocardial infarction in Chinese and South Asian Canadian patients. <i>BMC Cardiovascular Disorders</i> , 2011, 11, 56.	0.7	40

#	ARTICLE	IF	CITATIONS
4946	Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2011, 10, 22.	2.7	137
4947	Effects of simvastatin on apolipoprotein M in vivo and in vitro. <i>Lipids in Health and Disease</i> , 2011, 10, 112.	1.2	7
4948	Modelling approach to simulate reductions in LDL cholesterol levels after combined intake of statins and phytosterols/-stanols in humans. <i>Lipids in Health and Disease</i> , 2011, 10, 187.	1.2	15
4949	No connection between the level of exposition to statins in the population and the incidence/mortality of acute myocardial infarction: An ecological study based on Sweden's municipalities. <i>Journal of Negative Results in BioMedicine</i> , 2011, 10, 6.	1.4	10
4950	Carotid plaque regression following 6-month statin therapy assessed by 3T cardiovascular magnetic resonance: comparison with ultrasound intima media thickness. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2011, 13, 37.	1.6	46
4951	Accounting for the mortality benefit of drug-eluting stents in percutaneous coronary intervention: a comparison of methods in a retrospective cohort study. <i>BMC Medicine</i> , 2011, 9, 78.	2.3	17
4952	The effect of incident antidiabetic regimens on lipid profiles in veterans with type 2 diabetes: a retrospective cohort. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 36-44.	0.9	13
4953	Inhibition of endothelial adhesion molecule expression by <i>Monascus purpureus</i> -fermented rice metabolites, monacolin K, ankaflavin, and monascin. <i>Journal of the Science of Food and Agriculture</i> , 2011, 91, 1751-1758.	1.7	59
4954	Continuous Positive Airway Pressure Reduces Postprandial Lipidemia in Obstructive Sleep Apnea. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 184, 355-361.	2.5	133
4955	Event reduction: revisiting why we treat with statins and harnessing current evidence towards optimal therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 99-117.	0.9	5
4956	The Role of Statins in Chronic Kidney Disease. <i>American Journal of Nephrology</i> , 2011, 34, 195-202.	1.4	37
4957	Xanthelasmata, arcus corneae, and ischaemic vascular disease and death in general population: prospective cohort study. <i>BMJ: British Medical Journal</i> , 2011, 343, d5497-d5497.	2.4	75
4958	Atherosclerosis: Current Status of Prevention and Treatment. <i>International Journal of Angiology</i> , 2011, 20, 213-222.	0.2	25
4959	Decreasing trends in the incidence of heart failure after acute myocardial infarction from 1993 to 2004: a study of 175 216 patients with a first acute myocardial infarction in Sweden. <i>European Journal of Heart Failure</i> , 2011, 13, 135-141.	2.9	49
4960	Effects of fluvastatin on insulin resistance and cardiac morphology in hypertensive patients. <i>Journal of Human Hypertension</i> , 2011, 25, 492-499.	1.0	10
4961	Oxidative stress and endothelial dysfunction: Therapeutic implications. <i>Annals of Medicine</i> , 2011, 43, 259-272.	1.5	104
4962	Secondary Prevention and Mortality in Peripheral Artery Disease. <i>Circulation</i> , 2011, 124, 17-23.	1.6	348
4963	Effects of statins on coronary and peripheral endothelial function in humans: a systematic review and meta-analysis of randomized controlled trials. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2011, 18, 704-716.	3.1	110

#	ARTICLE	IF	CITATIONS
4964	Egg consumption as part of an energy-restricted high-protein diet improves blood lipid and blood glucose profiles in individuals with type 2 diabetes. <i>British Journal of Nutrition</i> , 2011, 105, 584-592.	1.2	90
4965	Clustering of Risk Factors: A Simple Method of Detecting Cardiovascular Disease in Youth. <i>Pediatrics</i> , 2011, 127, e312-e318.	1.0	26
4966	Does Pay for Performance Improve Cardiovascular Care in a "Real-World" Setting?. <i>American Journal of Medical Quality</i> , 2011, 26, 340-348.	0.2	8
4967	Health aspects of saturated fatty acids. , 2011, , 77-97.		5
4968	Utility of genetic determinants of lipids and cardiovascular events in assessing risk. <i>Nature Reviews Cardiology</i> , 2011, 8, 207-221.	6.1	39
4969	Benefit of Intensive Statin Therapy in Women. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2011, 4, 328-336.	0.9	61
4970	Estimates of Statin Discontinuation Rates are Influenced by Exposure and Outcome Definitions. <i>Annals of Pharmacotherapy</i> , 2011, 45, 576-581.	0.9	20
4971	Cholesterol: An Inflammatory Compound. <i>European Journal of Inflammation</i> , 2011, 9, 209-217.	0.2	0
4972	Case-Based Training of Evidence-Based Clinical Practice in Primary Care and Decreased Mortality in Patients With Coronary Heart Disease. <i>Annals of Family Medicine</i> , 2011, 9, 211-218.	0.9	32
4973	Optimizing secondary prevention: Statin prescribing across East and West London in accordance with NICE guidelines. <i>JRSM Short Reports</i> , 2011, 2, 1-6.	0.6	2
4974	ISSFAL 2010 Dinner Debate: Healthy Fats for Healthy Hearts " Annotated Report of a Scientific Discussion. <i>Annals of Nutrition and Metabolism</i> , 2011, 58, 59-65.	1.0	4
4975	Recent Advances in the Treatment of Atherogenic Dyslipidemia in Type 2 Diabetes Mellitus. <i>Kidney and Blood Pressure Research</i> , 2011, 34, 209-217.	0.9	15
4976	Coffee consumption and mortality in women with cardiovascular disease. <i>American Journal of Clinical Nutrition</i> , 2011, 94, 218-224.	2.2	29
4977	Age-Related White Matter Changes. <i>Journal of Aging Research</i> , 2011, 2011, 1-13.	0.4	103
4978	The Efficacy and Safety of the 3-Hydroxy-3-methylglutaryl-CoA Reductase Inhibitors in Chronic Kidney Disease, Dialysis, and Transplant Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 664-678.	2.2	25
4979	Renal Association Clinical Practice Guideline on Post-operative Care of the Kidney Transplant Recipient. <i>Nephron Clinical Practice</i> , 2011, 118, c311-c347.	2.3	37
4980	Statins for Secondary Prevention of Cardiovascular Disease: The Right Dose. <i>Pharmacology</i> , 2011, 87, 63-69.	0.9	26
4981	Proteomic Approach to the Study of Statin Pleiotropy in Kidney Transplant Patients. <i>Pharmacology</i> , 2011, 87, 161-168.	0.9	10

#	ARTICLE	IF	CITATIONS
4982	Racial and Geographic Differences in Prevalence, Awareness, Treatment and Control of Dyslipidemia: The Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. <i>Neuroepidemiology</i> , 2011, 37, 39-44.	1.1	32
4983	Endotoxin-induced cardiovascular dysfunction in mice: effect of simvastatin. <i>Journal of Applied Physiology</i> , 2011, 111, 1118-1124.	1.2	16
4984	Statin Use Associates with a Lower Incidence of Acute Kidney Injury after Major Elective Surgery. <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 939-946.	3.0	105
4985	The facts behind niacin. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2011, 5, 227-240.	1.0	20
4986	HMG CoA Reduction in Patients with Average Cholesterol Concentrations. <i>Clinical Chemistry</i> , 2011, 57, 1072-1073.	1.5	2
4987	Statin Myopathy: Significant Problem With Minimal Awareness by Clinicians and no Emphasis by Clinical Investigators. <i>Angiology</i> , 2011, 62, 415-421.	0.8	19
4988	2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non- $\sigma$ ST-Elevation Myocardial Infarction. <i>Circulation</i> , 2011, 123, e426-579.	1.6	658
4989	Lipid-lowering effects of ezetimibe and simvastatin in combination. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 131-145.	0.6	14
4990	High-density lipoprotein (HDL) cholesterol: leveraging practice-based biobank cohorts to characterize clinical and genetic predictors of treatment outcome. <i>Pharmacogenomics Journal</i> , 2011, 11, 162-173.	0.9	8
4991	Lipid parameters for measuring risk of cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2011, 8, 197-206.	6.1	177
4992	Statins in hemorrhagic stroke. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 1141-1149.	1.4	10
4993	fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 1945-1958.	0.9	24
4994	Efficacy and safety of pitavastatin in Japanese patients with hypercholesterolemia: LIVES study and subanalysis. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 555-562.	0.6	36
4995	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. <i>Circulation</i> , 2011, 124, e574-651.	1.6	1,946
4996	Acute simvastatin increases endothelial nitric oxide synthase phosphorylation via AMP-activated protein kinase and reduces contractility of isolated rat mesenteric resistance arteries. <i>Clinical Science</i> , 2011, 121, 449-458.	1.8	52
4997	Medical angioplasty - Hope and expectations: An optimistic overview. <i>Journal of Family and Community Medicine</i> , 2011, 18, 101.	0.5	0
4998	Paradoxical decrease in HDL-cholesterol and apolipoprotein A1 with simvastatin and atorvastatin in a patient with type 2 diabetes. <i>Annals of Clinical Biochemistry</i> , 2011, 48, 75-78.	0.8	8
4999	Pitavastatin: finding its place in therapy. <i>Therapeutic Advances in Chronic Disease</i> , 2011, 2, 101-117.	1.1	13



#	ARTICLE	IF	CITATIONS
5000	A comparative clinical study of hypolipidemic efficacy of Amla ( <i>Emblica officinalis</i> ) with 3-hydroxy-3-methylglutaryl-coenzyme-A reductase inhibitor simvastatin. <i>Indian Journal of Pharmacology</i> , 2012, 44, 238.	0.4	45
5001	Loss of the preconditioning effect of rosuvastatin during sustained therapy: a human in vivo study. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2012, 302, H153-H158.	1.5	12
5002	Stroke Prevention: Managing Modifiable Risk Factors. <i>Stroke Research and Treatment</i> , 2012, 2012, 1-15.	0.5	22
5003	Strategies to preserve the use of statins in patients with previous muscular adverse effects. <i>American Journal of Health-System Pharmacy</i> , 2012, 69, 291-300.	0.5	16
5004	Clinical Neuroprotective Drugs for Treatment and Prevention of Stroke. <i>International Journal of Molecular Sciences</i> , 2012, 13, 7739-7761.	1.8	22
5005	Novel incentive-based approaches to adherence. <i>Clinical Trials</i> , 2012, 9, 689-695.	0.7	16
5006	Inclusion of Stroke in Cardiovascular Risk Prediction Instruments. <i>Stroke</i> , 2012, 43, 1998-2027.	1.0	125
5007	Sub-optimal achievement of guideline-derived lipid goals in management of diabetes patients with atherosclerotic cardiovascular disease, despite high use of evidence-based therapies. <i>Diabetes and Vascular Disease Research</i> , 2012, 9, 138-145.	0.9	7
5008	Multivessel Coronary Artery Bypass Grafting Versus Percutaneous Coronary Intervention in ESRD. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 2042-2049.	3.0	128
5010	High-capacity selective uptake of cholesteryl ester from native LDL during macrophage foam cell formation. <i>Journal of Lipid Research</i> , 2012, 53, 2081-2091.	2.0	12
5011	LDL lowering in peripheral arterial disease: are there benefits beyond reducing cardiovascular morbidity and mortality?. <i>Clinical Lipidology</i> , 2012, 7, 141-149.	0.4	9
5012	Annual review for housebound patients with coronary heart disease. <i>British Journal of Nursing</i> , 2012, 21, 1194-1198.	0.3	2
5013	Novel Strategies for Managing Dyslipidemia: Treatment beyond Statins. <i>Postgraduate Medicine</i> , 2012, 124, 43-54.	0.9	13
5014	Screening for Coronary Artery Disease in Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 1434-1442.	1.8	22
5015	Coronary artery calcium scanning in asymptomatic patients with diabetes mellitus: A paradigm shift. <i>Journal of Diabetes</i> , 2012, 4, 342-350.	0.8	24
5016	The rise of cardiovascular medicine. <i>European Heart Journal</i> , 2012, 33, 838-845.	1.0	59
5017	Puesta al día en el manejo de las dislipidemias. <i>Revista Médica Clínica Las Condes</i> , 2012, 23, 681-687.	0.2	1
5018	Using Stress Testing to Guide Primary Prevention of Coronary Heart Disease Among Intermediate-Risk Patients. <i>Circulation</i> , 2012, 125, 260-270.	1.6	22

#	ARTICLE	IF	CITATIONS
5019	Primary prevention of cardiovascular disease using validated risk scores: A systematic review. <i>Journal of the Royal Society of Medicine</i> , 2012, 105, 348-356.	1.1	31
5020	Statin-Induced Low Cholesterol is Not Associated With Poor Outcome in Chronic Heart Failure. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2012, 17, 284-290.	1.0	10
5021	Another Telescope for Examining Statins: the SATURN Trial. <i>Clinical Diabetes</i> , 2012, 30, 115-119.	1.2	0
5022	Statins as a Novel Therapeutic Strategy in Acute Lung Injury. <i>Pulmonary Circulation</i> , 2012, 2, 397-406.	0.8	24
5023	Rosuvastatin: A Review of the Pharmacology and Clinical Effectiveness in Cardiovascular Disease. <i>Clinical Medicine Insights: Cardiology</i> , 2012, 6, CMC.S4324.	0.6	94
5024	Rosuvastatin and Atorvastatin: Comparative Effects on Glucose Metabolism in Non-Diabetic Patients with Dyslipidaemia. <i>Clinical Medicine Insights: Endocrinology and Diabetes</i> , 2012, 5, CMED.S7591.	1.0	15
5025	Established and Emerging Approaches for the Management of Dyslipidaemia. <i>Scientifica</i> , 2012, 2012, 1-14.	0.6	2
5026	Screening for Ischemic Heart Disease with Cardiac CT: Current Recommendations. <i>Scientifica</i> , 2012, 2012, 1-12.	0.6	7
5027	A Randomized Trial Assessing the Effectiveness of Ezetimibe in South Asian Canadians with Coronary Artery Disease or Diabetes: The INFINITY Study. <i>Advances in Preventive Medicine</i> , 2012, 2012, 1-11.	1.1	8
5028	Effects of Statins on Cardiorenal Syndrome. <i>International Journal of Vascular Medicine</i> , 2012, 2012, 1-7.	0.4	9
5029	Lipid Disorders in Elderly Hypertensive Patients. <i>International Journal of Hypertension</i> , 2012, 2012, 1-3.	0.5	1
5030	CKD and Sudden Cardiac Death. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 1929-1939.	3.0	113
5031	BENEFITS OF PHARMACEUTICAL INNOVATION: THE CASE OF SIMVASTATIN IN CANADA. <i>International Journal of Technology Assessment in Health Care</i> , 2012, 28, 390-397.	0.2	2
5032	Association between preoperative statin therapy and postoperative change in glomerular filtration rate in endovascular aortic surgery. <i>British Journal of Anaesthesia</i> , 2012, 109, 161-167.	1.5	9
5033	Effect of Statins on Skeletal Muscle. <i>Exercise and Sport Sciences Reviews</i> , 2012, 40, 188-194.	1.6	104
5035	2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease. <i>Circulation</i> , 2012, 126, e354-471.	1.6	675
5036	Statin Therapy and the Risk of Intracerebral Hemorrhage. <i>Stroke</i> , 2012, 43, 2149-2156.	1.0	266
5037	Plant sterols and cardiovascular disease: a systematic review and meta-analysis. <i>European Heart Journal</i> , 2012, 33, 444-451.	1.0	180

#	ARTICLE	IF	CITATIONS
5038	Effects of n-3 fatty acids on major cardiovascular events in statin users and non-users with a history of myocardial infarction. <i>European Heart Journal</i> , 2012, 33, 1582-1588.	1.0	78
5039	Smoking cessation for the secondary prevention of coronary heart disease. <i>The Cochrane Library</i> , 2012, 2012, CD003041.	1.5	15
5040	Effects of Statins on the Recovery of Olfactory Function in a 3-Methylindole-Induced Anosmia Mouse Model. <i>American Journal of Rhinology and Allergy</i> , 2012, 26, e81-e84.	1.0	18
5041	Toll-Like Receptors and Human Disease: Lessons from Single Nucleotide Polymorphisms. <i>Current Genomics</i> , 2012, 13, 633-645.	0.7	59
5042	Module 15. Statins and their role in the prevention of cardiovascular disease. <i>NursePrescribing</i> , 2012, 10, 1-11.	0.1	0
5043	Attainment of combined optimal lipid values with the use of niacin: has AIM-HIGH closed the book on this debate?. <i>Clinical Lipidology</i> , 2012, 7, 389-396.	0.4	0
5046	Fibrates for primary prevention of cardiovascular disease events. , 2012, , .		8
5047	Who Benefits From Statins? Patient or Focal Plaque?. <i>Circulation Journal</i> , 2012, 76, 2744-2745.	0.7	0
5049	Sex differences in endothelial function of aged hypertriglyceridemic rats – effect of atorvastatin treatment. <i>Interdisciplinary Toxicology</i> , 2012, 5, 155-158.	1.0	4
5051	Effects of Pitavastatin on Pressure Overload-Induced Heart Failure in Mice. <i>Circulation Journal</i> , 2012, 76, 1159-1168.	0.7	20
5052	Low-Density Lipoprotein Cholesterol Lowering Therapy and Established Atherosclerosis. <i>Circulation Journal</i> , 2012, 76, 49-50.	0.7	2
5053	Intensity of Statin Therapy, Achieved Low-Density Lipoprotein Cholesterol Levels and Cardiovascular Outcomes in Japanese Patients After Coronary Revascularization. <i>Circulation Journal</i> , 2012, 76, 1369-1379.	0.7	49
5054	Effect of Intensive Lipid-Lowering Therapy With Rosuvastatin on Progression of Carotid Intima-Media Thickness in Japanese Patients. <i>Circulation Journal</i> , 2012, 76, 221-229.	0.7	51
5055	Effect of Spinally Administered Simvastatin on the Formalin-Induced Nociceptive Response in Mice. <i>Journal of Pharmacological Sciences</i> , 2012, 119, 102-106.	1.1	10
5056	The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. <i>Lancet</i> , The, 2012, 380, 581-590.	6.3	2,250
5057	Targeting tumor cell metabolism with statins. <i>Oncogene</i> , 2012, 31, 4967-4978.	2.6	193
5058	Effect of statins on chronic inflammation and nutrition status in renal dialysis patients: A systematic review and meta-analysis. <i>Nephrology</i> , 2012, 17, 545-551.	0.7	30
5059	Management of Dyslipidemias in the Presence of the Metabolic Syndrome or Type 2 Diabetes. <i>Current Cardiology Reports</i> , 2012, 14, 721-731.	1.3	20

#	ARTICLE	IF	CITATIONS
5060	2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease. <i>Journal of the American College of Cardiology</i> , 2012, 60, e44-e164.	1.2	1,423
5061	Associations among 25-year trends in diet, cholesterol and BMI from 140,000 observations in men and women in Northern Sweden. <i>Nutrition Journal</i> , 2012, 11, 40.	1.5	77
5062	Prevalence of lipid abnormalities in the United States: The National Health and Nutrition Examination Survey 2003-2006. <i>Journal of Clinical Lipidology</i> , 2012, 6, 325-330.	0.6	206
5063	Physiological and Laboratory Markers of Drug Effect. , 2012, , 309-325.		0
5064	Adverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta-analysis. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2012, 105, 145-157.	0.2	60
5065	Blinded assessment of treatment effects for survival endpoint in an ongoing trial. <i>Pharmaceutical Statistics</i> , 2012, 11, 204-213.	0.7	2
5066	Inhibition of Cholesterol Absorption: Targeting the Intestine. <i>Pharmaceutical Research</i> , 2012, 29, 3235-3250.	1.7	15
5067	Effect of Statins and Anticoagulants on Prostate Cancer Aggressiveness. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 1149-1153.	0.4	13
5068	Risk of coronary heart disease is associated with triglycerides and high-density lipoprotein cholesterol in women and non-high-density lipoprotein cholesterol in men. <i>Journal of Clinical Lipidology</i> , 2012, 6, 374-381.	0.6	29
5069	Statins, Risk of Dementia, and Cognitive Function: Secondary Analysis of the Ginkgo Evaluation of Memory Study. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2012, 21, 436-444.	0.7	108
5070	Statins in Heart Failure: The Paradox Between Large Randomized Clinical Trials and Real Life. <i>Mayo Clinic Proceedings</i> , 2012, 87, 555-560.	1.4	55
5071	Pharmacologic Prevention of Microvascular and Macrovascular Complications in Diabetes Mellitus. <i>American Journal of Cardiovascular Drugs</i> , 2012, 12, 7-22.	1.0	65
5072	Statins and Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 185, 547-556.	2.5	133
5073	Perioperative cardiovascular evaluation: heads or tails?. <i>Revista Da Associação Médica Brasileira</i> , 2012, 58, 505-512.	0.3	5
5074	Estatinas en pacientes sin enfermedad cardiovascular: una revisión crítica. <i>Farmaceuticos De Atencion Primaria</i> , 2012, 10, 36-43.	0.0	1
5075	Perioperative cardiovascular evaluation: heads or tails?. <i>Revista Da Associação Médica Brasileira (English Edition)</i> , 2012, 58, 505-512.	0.1	0
5076	Leptin in congenital or HIV-associated lipodystrophy and metabolic syndrome: A need for more mechanistic studies and large, randomized, placebo-controlled trials. <i>Metabolism: Clinical and Experimental</i> , 2012, 61, 1331-1336.	1.5	16
5079	Caso clínico 2: paciente con angina crónica estable y varios factores de riesgo. Diagnóstico, estratificación pronóstica y tratamiento. <i>Revista Espanola De Cardiologia Suplementos</i> , 2012, 12, 30-36.	0.2	2

#	ARTICLE	IF	CITATIONS
5080	Improving Compliance with Statins in Patients with Peripheral Arterial Disease: A Quality Improvement Study. <i>Annals of Medicine and Surgery</i> , 2012, 1, 30-33.	0.5	4
5081	Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Lowering With Atorvastatin in Patients of South Asian Compared With European Origin: Insights From the Achieve Cholesterol Targets Fast With Atorvastatin Stratified Titration (ACTFAST) Study. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 850-858.	1.0	15
5082	Significant Increase in High-Density Lipoprotein Cholesterol with Fibrates Is Associated with Low Pretreatment High-Density Lipoprotein Cholesterol: Findings from an Outpatient Clinic Setting. <i>Metabolic Syndrome and Related Disorders</i> , 2012, 10, 189-194.	0.5	8
5083	Extended-release niacin with laropiprant: a review on efficacy, clinical effectiveness and safety. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 1345-1362.	0.9	24
5084	Risk factor levels, risk factor combinations, and residual coronary risk: population-based estimates for secondary prevention patients using statins. <i>European Journal of Preventive Cardiology</i> , 2012, 19, 109-117.	0.8	6
5085	Nutrition and the healthy heart with an exercise boost. <i>Canadian Journal of Physiology and Pharmacology</i> , 2012, 90, 967-976.	0.7	17
5086	The emerging role of plasma lipidomics in cardiovascular drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2012, 7, 63-72.	2.5	20
5087	A proposal for an additional clinical trial outcome measure assessing preventive effect as delay of events. <i>European Journal of Epidemiology</i> , 2012, 27, 903-909.	2.5	12
5088	The effects of old, new and emerging medicines on metabolic aberrations in PCOS. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2012, 3, 27-47.	1.4	91
5089	Statin use after first myocardial infarction in UK men and women from 1997 to 2006: Who started and who continued treatment?. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2012, 22, 400-408.	1.1	24
5090	Medical management of metabolic dysfunction in PCOS. <i>Steroids</i> , 2012, 77, 306-311.	0.8	46
5091	Bias in Observational Studies of Prevalent Users: Lessons for Comparative Effectiveness Research From a Meta-Analysis of Statins. <i>American Journal of Epidemiology</i> , 2012, 175, 250-262.	1.6	205
5092	The effect of ezetimibe and simvastatin on hemostasis in patients with isolated hypercholesterolemia. <i>Fundamental and Clinical Pharmacology</i> , 2012, 26, 424-431.	1.0	18
5093	Diagnosing the decline in pharmaceutical R&D efficiency. <i>Nature Reviews Drug Discovery</i> , 2012, 11, 191-200.	21.5	1,520
5095	Assessment of the use of hypolipidemic agents (HAs), mainly statins, in elderly subjects aged 80 years and more in Burgundy: Analysis of 13,211 patients. <i>Archives of Gerontology and Geriatrics</i> , 2012, 55, 101-105.	1.4	4
5097	Hepatotoxicity associated with statins: Reports of idiosyncratic liver injury post-marketing. <i>Journal of Hepatology</i> , 2012, 56, 374-380.	1.8	264
5098	Statin therapy is associated with superior clinical outcomes after endovascular treatment of critical limb ischemia. <i>Journal of Vascular Surgery</i> , 2012, 55, 371-380.	0.6	72
5099	Nutrition in the primary and secondary prevention of stroke. <i>Maturitas</i> , 2012, 72, 29-34.	1.0	16

#	ARTICLE	IF	CITATIONS
5100	Endothelial FAK as a therapeutic target in disease. <i>Microvascular Research</i> , 2012, 83, 89-96.	1.1	49
5101	Risk stratification in patients with chronic heart failure based on metabolic-immunological, functional and haemodynamic parameters. <i>International Journal of Cardiology</i> , 2012, 156, 62-68.	0.8	17
5102	Updated evidence on early statin therapy for acute coronary syndromes: Meta-analysis of 18 randomized trials involving over 14,000 patients. <i>International Journal of Cardiology</i> , 2012, 158, 93-100.	0.8	23
5103	Effect of intensive lipid-lowering treatment compared to moderate lipid-lowering treatment with rosuvastatin on endothelial function in high risk patients. <i>International Journal of Cardiology</i> , 2012, 158, 376-379.	0.8	12
5104	Managing the underestimated risk of statin-associated myopathy. <i>International Journal of Cardiology</i> , 2012, 159, 169-176.	0.8	84
5105	The anti-carcinogenic effect of statins in a rat model correlates with levels and synthesis of ubiquinone. <i>Biochemical and Biophysical Research Communications</i> , 2012, 425, 348-352.	1.0	9
5106	Cross-Sectional Survey to Assess the Status of Lipid Management in High-Risk Patients With Dyslipidemia: Clinical Impact of Combination Therapy With Ezetimibe. <i>Current Therapeutic Research</i> , 2012, 73, 1-15.	0.5	18
5107	Comparative reactivity of remnant-like lipoprotein particles (RLP) and low-density lipoprotein (LDL) to LDL receptor and VLDL receptor: Effect of a high-dose statin on VLDL receptor expression. <i>Clinica Chimica Acta</i> , 2012, 413, 441-447.	0.5	14
5108	Mortality Rate Increases Steeply With Nonadherence to Statin Therapy in Patients With Acute Coronary Syndrome. <i>Clinical Cardiology</i> , 2012, 35, E22-7.	0.7	29
5109	Nutritional genomics for the characterization of the effect of bioactive molecules in lipid metabolism and related pathways. <i>Electrophoresis</i> , 2012, 33, 2266-2289.	1.3	23
5110	Is the high-risk strategy to prevent cardiovascular disease equitable? A pharmacoepidemiological cohort study. <i>BMC Public Health</i> , 2012, 12, 610.	1.2	15
5111	Improving treatment intensification to reduce cardiovascular disease risk: a cluster randomized trial. <i>BMC Health Services Research</i> , 2012, 12, 183.	0.9	10
5112	Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?. <i>Cardiovascular Diabetology</i> , 2012, 11, 140.	2.7	86
5113	Vascular memory: can we broaden the concept of the metabolic memory?. <i>Cardiovascular Diabetology</i> , 2012, 11, 44.	2.7	27
5114	2-h postchallenge plasma glucose predicts cardiovascular events in patients with myocardial infarction without known diabetes mellitus. <i>Cardiovascular Diabetology</i> , 2012, 11, 93.	2.7	11
5115	Assessing the effectiveness and cost-effectiveness of audit and feedback on physician's prescribing indicators: study protocol of a randomized controlled trial with economic evaluation. <i>DARU, Journal of Pharmaceutical Sciences</i> , 2012, 20, 88.	0.9	18
5116	Diagnosis and treatment of coronary artery disease in hemodialysis patients evaluated for transplant. <i>Transplantation Research</i> , 2012, 1, 3.	1.5	5
5117	The clofibrate saga: a retrospective commentary. <i>British Journal of Clinical Pharmacology</i> , 2012, 74, 907-910.	1.1	26

#	ARTICLE	IF	CITATIONS
5118	Relationships between HMG-CoA reductase inhibitors (statin) use and strength, balance and falls in older people. <i>Internal Medicine Journal</i> , 2012, 42, 1329-1334.	0.5	27
5120	The 50th Anniversary of the Kefauver-Harris Amendments: Efficacy Assessment and the Randomized Clinical Trial. <i>Journal of Clinical Hypertension</i> , 2012, 14, 810-815.	1.0	14
5121	LDL Cholesterol: The Lower the Better. <i>Medical Clinics of North America</i> , 2012, 96, 13-26.	1.1	73
5122	Statin Use and the Risk of Incident Diabetes Mellitus: A Review of the Literature. <i>Canadian Journal of Cardiology</i> , 2012, 28, 581-589.	0.8	26
5123	Association of Statin Use with Risk and Outcome of Acute Kidney Injury in Community-Acquired Pneumonia. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 895-905.	2.2	34
5124	Reduction in Life-Threatening Ventricular Tachyarrhythmias in Statin-Treated Patients With Nonischemic Cardiomyopathy Enrolled in the MADIT-CRT (Multicenter Automatic Defibrillator) Trial. <i>Journal of the American College of Cardiology</i> , 2012, 60, 749-755.	1.2	39
5125	Inclusion of the birth cohort dimension improved description and explanation of trends in statin use. <i>Journal of Clinical Epidemiology</i> , 2012, 65, 1052-1060.	2.4	8
5126	Impact of Statin Therapy on Plaque Characteristics as Assessed by Serial OCT, Grayscale and Integrated Backscatter-IVUS. <i>JACC: Cardiovascular Imaging</i> , 2012, 5, 169-177.	2.3	162
5127	Asymptomatic Individuals With a Positive Family History for Premature Coronary Artery Disease and Elevated Coronary Calcium Scores Benefit From Statin Treatment. <i>JACC: Cardiovascular Imaging</i> , 2012, 5, 252-260.	2.3	33
5128	Effect of atorvastatin on dynamic parameters of myocardial repolarization in healthy subjects. <i>Journal of Electrocardiology</i> , 2012, 45, 752-757.	0.4	1
5129	Meta-Analysis of Comparison of Effectiveness of Lowering Apolipoprotein B Versus Low-Density Lipoprotein Cholesterol and Nonhigh-Density Lipoprotein Cholesterol for Cardiovascular Risk Reduction in Randomized Trials. <i>American Journal of Cardiology</i> , 2012, 110, 1468-1476.	0.7	108
5130	Renal Function and Effect of Statin Therapy on Cardiovascular Outcomes in Patients Undergoing Coronary Revascularization (from the CREDO-Kyoto PCI/CABG Registry Cohort-2). <i>American Journal of Cardiology</i> , 2012, 110, 1568-1577.	0.7	33
5131	The Effect of Statins on Acute and Long-Term Outcome After Ischemic Stroke in the Elderly. <i>American Journal of Geriatric Pharmacotherapy</i> , 2012, 10, 313-322.	3.0	15
5132	Statins and New-Onset Diabetes: A Retrospective Longitudinal Cohort Study. <i>Clinical Therapeutics</i> , 2012, 34, 1977-1983.	1.1	41
5133	Statin utilization according to indication and age: A Danish cohort study on changing prescribing and purchasing behaviour. <i>Health Policy</i> , 2012, 108, 216-227.	1.4	35
5134	Atorvastatin improves sodium handling and decreases blood pressure in salt-loaded rats with chronic renal insufficiency. <i>Nutrition</i> , 2012, 28, e23-e28.	1.1	6
5135	Impact of Secondary Cardiovascular Events on Health Status. <i>Value in Health</i> , 2012, 15, 175-182.	0.1	7
5136	Translating the effects of statins: From redox regulation to suppression of vascular wall inflammation. <i>Thrombosis and Haemostasis</i> , 2012, 108, 840-848.	1.8	61

#	ARTICLE	IF	CITATIONS
5137	Reduced or modified dietary fat for preventing cardiovascular disease. The Cochrane Library, 2012, , CD002137.	1.5	174
5138	Isoprenoids and Related Pharmacological Interventions: Potential Application in Alzheimer's Disease. Molecular Neurobiology, 2012, 46, 64-77.	1.9	43
5139	Cardiovascular risk management of hypertension and hypercholesterolaemia in the Netherlands: from unifactorial to multifactorial approach. Netherlands Heart Journal, 2012, 20, 320-325.	0.3	15
5140	Drugs Targeting High-Density Lipoprotein Cholesterol for Coronary Artery Disease Management. Canadian Journal of Cardiology, 2012, 28, 667-677.	0.8	6
5141	Treatment With Simvastatin Inhibits the Formation of Abdominal Aortic Aneurysms in Rabbits. Annals of Vascular Surgery, 2012, 26, 250-258.	0.4	16
5143	Glucose and Low-Density Lipoprotein Cholesterol Lowering in Elderly Patients with Type 2 Diabetes. Drugs and Aging, 2012, 29, e1-e12.	1.3	7
5144	The Long-Term Effect of Statins on the Risk of New-Onset Diabetes Mellitus in Elderly Taiwanese Patients with Hypertension and Dyslipidaemia. Drugs and Aging, 2012, 29, 45-51.	1.3	21
5145	The Role of Diet in Prevention and Management of Type 2 Diabetes: Implications for Public Health. Critical Reviews in Food Science and Nutrition, 2012, 52, 382-389.	5.4	40
5146	Update on guidelines for management of hypercholesterolemia. Expert Review of Cardiovascular Therapy, 2012, 10, 1239-1249.	0.6	5
5147	Lymphocyte-suppressing and systemic anti-inflammatory effects of high-dose metformin in simvastatin-treated patients with impaired fasting glucose. Atherosclerosis, 2012, 225, 403-407.	0.4	29
5148	Clinical Value of Drugs Targeting Inflammation for the Management of Coronary Artery Disease. Canadian Journal of Cardiology, 2012, 28, 678-686.	0.8	15
5149	Statin-Induced Muscle Toxicity. , 2012, , 945-954.		0
5150	Anacetrapib, a Novel CETP Inhibitor: Pursuing a New Approach to Cardiovascular Risk Reduction. Clinical Pharmacology and Therapeutics, 2012, 91, 109-122.	2.3	62
5151	Statins in the critically ill. Annals of Intensive Care, 2012, 2, 19.	2.2	33
5152	The impact of statins on psychological wellbeing: a systematic review and meta-analysis. BMC Medicine, 2012, 10, 154.	2.3	67
5153	The 'Mevalonate hypothesis' a cholesterol-independent alternative for the etiology of atherosclerosis. Lipids in Health and Disease, 2012, 11, 149.	1.2	12
5154	Factors explaining the gender disparity in lipid-lowering treatment goal attainment rate in Chinese patients with statin therapy. Lipids in Health and Disease, 2012, 11, 59.	1.2	21
5155	Proteomic Analysis of Aortae from Human Lipoprotein(a) Transgenic Mice Shows an Early Metabolic Response Independent of Atherosclerosis. PLoS ONE, 2012, 7, e30383.	1.1	7



#	ARTICLE	IF	CITATIONS
5156	Acute Coronary Syndrome in Patients with Prior Coronary Artery Bypass Surgery: Observations from a 20-Year Registry in a Middle-Eastern Country. <i>PLoS ONE</i> , 2012, 7, e40571.	1.1	16
5157	Association of Chronic Kidney Disease and Peripheral Artery Disease with Inappropriate Left Ventricular Mass. <i>PLoS ONE</i> , 2012, 7, e48422.	1.1	3
5158	Differences in Statin Usage and Target-Goal Achievement between Departments at the Same Hospital. <i>PLoS ONE</i> , 2012, 7, e50466.	1.1	0
5159	Ezetimibe therapy: mechanism of action and clinical update. <i>Vascular Health and Risk Management</i> , 2012, 8, 415.	1.0	169
5160	Treatment of dyslipidemia in chronic kidney disease: Effectiveness and safety of statins. <i>World Journal of Nephrology</i> , 2012, 1, 184.	0.8	25
5161	The impact of initial statin treatment decisions on cardiovascular outcomes in clinical care settings: estimates using the Archimedes Model. <i>ClinicoEconomics and Outcomes Research</i> , 2012, 4, 337.	0.7	11
5162	Optimal Range of Triglyceride Values to Estimate Serum Low Density Lipoprotein Cholesterol Concentration in Korean Adults: the Korea National Health and Nutrition Examination Survey, 2009. <i>Journal of Korean Medical Science</i> , 2012, 27, 1530.	1.1	11
5163	Challenge of Surrogate Endpoints. <i>Southern Medical Journal</i> , 2012, 105, 156-160.	0.3	4
5164	Statins as Anti-Inflammatory Agents in Atherogenesis: Molecular Mechanisms and Lessons from the Recent Clinical Trials. <i>Current Pharmaceutical Design</i> , 2012, 18, 1519-1530.	0.9	349
5165	Usefulness of LDL-C-Related Parameters to Predict Cardiovascular Risk and Effect of Pravastatin in Mild-to-Moderate Hypercholesterolemia. <i>Journal of Atherosclerosis and Thrombosis</i> , 2012, 19, 176-185.	0.9	11
5166	Effects of Weight Change on Clinical Outcomes in Overweight and Obese Patients with Acute Myocardial Infarction Who Underwent Successful Percutaneous Coronary Intervention. <i>Chonnam Medical Journal</i> , 2012, 48, 32.	0.5	8
5167	Simvastatin Modulates Remodeling of Kv4.3 Expression in Rat Hypertrophied Cardiomyocytes. <i>International Journal of Biological Sciences</i> , 2012, 8, 236-248.	2.6	8
5168	Effects of pitavastatin on plasminogen activator inhibitor-1 in hyperlipidemic patients. <i>International Journal of General Medicine</i> , 2012, 5, 535.	0.8	7
5169	LDL-Apheresis: Technical and Clinical Aspects. <i>Scientific World Journal</i> , The, 2012, 2012, 1-19.	0.8	61
5170	The ezetimibe controversy “can this be resolved by comparing the clinical trials with simvastatin and ezetimibe alone and together?”. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 1469-1480.	0.9	10
5171	Drug utilization according to reason for prescribing: a pharmacoepidemiologic method based on an indication hierarchy. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 1027-1035.	0.9	24
5172	Role of disease risk scores in comparative effectiveness research with emerging therapies. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 138-147.	0.9	87
5173	Prior event rate ratio adjustment: numerical studies of a statistical method to address unrecognized confounding in observational studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 60-68.	0.9	28

#	ARTICLE	IF	CITATIONS
5174	Prospective analysis of association between use of statins and melanoma risk in the Women's Health Initiative. <i>Cancer</i> , 2012, 118, 5124-5131.	2.0	27
5175	Is Statin-Associated Cognitive Impairment Clinically Relevant? A Narrative Review and Clinical Recommendations. <i>Annals of Pharmacotherapy</i> , 2012, 46, 549-557.	0.9	100
5176	Jaundice Due to Suspected Statin Hepatotoxicity: A Case Series. <i>Digestive Diseases and Sciences</i> , 2012, 57, 1959-1964.	1.1	17
5177	Fluvastatin suppresses native and recombinant human P2X4 receptor function. <i>Purinergic Signalling</i> , 2012, 8, 311-316.	1.1	18
5179	The Role of Non-HDL Cholesterol in Risk Stratification for Coronary Artery Disease. <i>Current Atherosclerosis Reports</i> , 2012, 14, 130-134.	2.0	56
5180	Role of Antithrombotic Agents in Heart Failure. <i>Current Cardiology Reports</i> , 2012, 14, 314-325.	1.3	9
5181	Diabetes-Specific Nutrition Algorithm: A Transcultural Program to Optimize Diabetes and Prediabetes Care. <i>Current Diabetes Reports</i> , 2012, 12, 180-194.	1.7	49
5182	Approach to Lipid Therapy in the Patient With Atherosclerotic Vascular Disease. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2012, 14, 177-183.	0.4	1
5183	Neuroprotective Effects of Statins: Evidence from Preclinical and Clinical Studies. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2012, 14, 252-259.	0.4	21
5184	Diabetic Cardiovascular Disease: Getting to the Heart of the Matter. <i>Journal of Cardiovascular Translational Research</i> , 2012, 5, 436-445.	1.1	23
5185	Does LDL-C Estimation Using Anandaraja's Formula Give a Better Agreement with Direct LDL-C Estimation than the Friedewald's Formula?. <i>Indian Journal of Clinical Biochemistry</i> , 2012, 27, 127-133.	0.9	26
5187	Reduction of serum lipids by the intake of the extract of garlic fermented with <i>Monascus pilosus</i> : A randomized, double-blind, placebo-controlled clinical trial. <i>Clinical Nutrition</i> , 2012, 31, 261-266.	2.3	19
5188	Protection against osteoporosis by statins is linked to a reduction of oxidative stress and restoration of nitric oxide formation in aged and ovariectomized rats. <i>European Journal of Pharmacology</i> , 2012, 674, 200-206.	1.7	49
5189	Meta-analysis of the comparative efficacy and safety of pitavastatin and atorvastatin in patients with dyslipidaemia. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2012, 37, 166-172.	0.7	14
5190	Predictors of Statin-Induced Regression of Left Anterior Descending Coronary Artery Wall Thickness as Measured by High-Resolution Transthoracic Echocardiography. <i>Echocardiography</i> , 2012, 29, 641-646.	0.3	2
5191	Investigation of the effects of <i>Chlorella vulgaris</i> as an adjunctive therapy for dyslipidemia: Results of a randomised open-label clinical trial. <i>Nutrition and Dietetics</i> , 2012, 69, 13-19.	0.9	38
5192	Muscle mitochondrial metabolism and calcium signaling impairment in patients treated with statins. <i>Toxicology and Applied Pharmacology</i> , 2012, 259, 263-268.	1.3	78
5193	Concomitant use of clopidogrel and statins and risk of major adverse cardiovascular events following coronary stent implantation. <i>British Journal of Clinical Pharmacology</i> , 2012, 74, 161-170.	1.1	14

#	ARTICLE	IF	CITATIONS
5194	Statin use and the risk of renal cell carcinoma in 2 prospective US cohorts. <i>Cancer</i> , 2012, 118, 797-803.	2.0	27
5195	Residual Cardiovascular Risk Despite Optimal LDL Cholesterol Reduction with Statins: The Evidence, Etiology, and Therapeutic Challenges. <i>Current Atherosclerosis Reports</i> , 2012, 14, 1-10.	2.0	304
5196	FDG-PET-CT as a Biomarker for Aortic Valve Inflammation. <i>Current Cardiovascular Imaging Reports</i> , 2012, 5, 1-10.	0.4	2
5197	Simvastatin Attenuates Intestinal Fibrosis Independent of the Anti-Inflammatory Effect by Promoting Fibroblast/Myofibroblast Apoptosis in the Regeneration/Healing Process from TNBS-Induced Colitis. <i>Digestive Diseases and Sciences</i> , 2012, 57, 335-344.	1.1	45
5198	Statins in dermatology: is nonmelanoma skin cancer the dark side of the moon?. <i>International Journal of Dermatology</i> , 2013, 52, 899-900.	0.5	5
5199	Adherence to preventive statin therapy according to socioeconomic position. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 1553-1563.	0.8	60
5200	Social stratification in the dissemination of statins after stroke in Sweden. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 1173-1180.	0.8	19
5201	Effect of treatment with pravastatin or ezetimibe on endothelial function in patients with moderate hypercholesterolemia. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 341-346.	0.8	23
5202	Regulatory and Scientific Issues Regarding Use of Foreign Data in Support of New Drug Applications in the United States: An FDA Perspective. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 94, 230-242.	2.3	35
5203	Statins in the primary prevention of cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2013, 10, 453-464.	6.1	156
5204	Protocolo terapéutico hospitalario del infarto de miocardio. <i>Medicine</i> , 2013, 11, 2275-2278.	0.0	0
5205	Discontinuation of Statins in Routine Care Settings. <i>Annals of Internal Medicine</i> , 2013, 158, 526.	2.0	480
5206	Identification of Inflammatory Mediators and Their Modulation by Strategies for the Management of the Systemic Inflammatory Response During Cardiac Surgery. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2013, 27, 983-1033.	0.6	70
5207	Recent findings on the health effects of omega-3 fatty acids and statins, and their interactions: do statins inhibit omega-3?. <i>BMC Medicine</i> , 2013, 11, 5.	2.3	43
5208	Coronary CT angiography and high-risk plaque morphology. <i>Cardiovascular Intervention and Therapeutics</i> , 2013, 28, 1-8.	1.2	46
5209	Statins in cardiometabolic disease: what makes pitavastatin different?. <i>Cardiovascular Diabetology</i> , 2013, 12, S1.	2.7	17
5210	When Clinical Trials Fail to Address Treatment Gaps: The Failure of Niacin-Laropiprant to Reduce Cardiovascular Events. <i>Current Atherosclerosis Reports</i> , 2013, 15, 332.	2.0	4
5211	Medical Management of Stable Coronary Atherosclerosis. <i>Current Atherosclerosis Reports</i> , 2013, 15, 313.	2.0	6

#	ARTICLE	IF	CITATIONS
5212	Statin use and lower extremity amputation risk in nonelderly diabetic patients. <i>Journal of Vascular Surgery</i> , 2013, 58, 1578-1585.e1.	0.6	42
5213	Statin therapy in patients with atypical chest pain and mild-to-moderate coronary stenosis on 64-slice multidetector coronary computed tomography; a retrospective propensity score matching analysis. <i>European Radiology</i> , 2013, 23, 2954-2960.	2.3	2
5214	Effects of lipid-lowering therapy with strong statin on serum polyunsaturated fatty acid levels in patients with coronary artery disease. <i>Heart and Vessels</i> , 2013, 28, 34-38.	0.5	28
5215	25-Hydroxyvitamin D insufficiency is associated with impaired renal endothelial function and both are improved with rosuvastatin treatment. <i>Clinical Research in Cardiology</i> , 2013, 102, 299-304.	1.5	14
5216	Role of Colesevelam in Combination Lipid-Lowering Therapy. <i>American Journal of Cardiovascular Drugs</i> , 2013, 13, 315-323.	1.0	26
5217	Drug-Drug Interactions Between HMG-CoA Reductase Inhibitors (Statins) and Antiviral Protease Inhibitors. <i>Clinical Pharmacokinetics</i> , 2013, 52, 815-831.	1.6	116
5218	Acute vascular effects of atorvastatin in hypertensive men: a pilot study. <i>Scandinavian Cardiovascular Journal</i> , 2013, 47, 275-280.	0.4	4
5219	Acute coronary syndrome and stable coronary artery disease: Are they so different? Long-term outcomes in a contemporary PCI cohort. <i>International Journal of Cardiology</i> , 2013, 167, 1343-1346.	0.8	32
5220	Effect of Equivalent On-Treatment Apolipoprotein Levels on Outcomes (from the AIM-HIGH and Tj ETQq0 0 0 rgBT /Qverlock 10 Tf 50 4	0.7	11
5221	Changes in serum cholesterol levels determine future risk of cardiovascular events in patients with acute coronary syndrome in the Japanese Coronary Artery Disease (JCAD) Study. <i>Journal of Cardiology</i> , 2013, 61, 387-392.	0.8	4
5222	The Shortfall in Long-term Survival of Patients with Repaired Thoracic or Abdominal Aortic Aneurysms: Retrospective Case-Control Analysis of Hospital Episode Statistics. <i>European Journal of Vascular and Endovascular Surgery</i> , 2013, 46, 533-541.	0.8	55
5223	Discontinuation of statin therapy due to muscular side effects: A survey in real life. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2013, 23, 871-875.	1.1	89
5224	Lipid-Lowering Agents and Hepatotoxicity. <i>Clinics in Liver Disease</i> , 2013, 17, 699-714.	1.0	24
5225	Statin Therapy in the Reduction of Cardiovascular Events in Patients Undergoing Intermediate-Risk Noncardiac, Nonvascular Surgery. <i>Clinical Cardiology</i> , 2013, 36, 456-461.	0.7	29
5226	Traditional Heart Failure Medications and Sudden Cardiac Death Prevention. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2013, 18, 412-426.	1.0	20
5227	Lymphocyte-suppressing action of simvastatin in patients with isolated hypertriglyceridemia. <i>Pharmacological Reports</i> , 2013, 65, 756-760.	1.5	3
5228	The lower the better: Target values after LDL-Apheresis and semi-selective LDL-elimination therapies. <i>Transfusion and Apheresis Science</i> , 2013, 48, 203-206.	0.5	3
5229	Management of Risk Factors Among Ambulatory Patients at High Cardiovascular Risk in Canada: A Follow-up Study. <i>Canadian Journal of Cardiology</i> , 2013, 29, 1586-1592.	0.8	5

#	ARTICLE	IF	CITATIONS
5230	Comparison of long-term outcomes in STEMI and NSTEMI-ACS after coronary stent placement: an analysis in a real world BMS and DES population. <i>International Journal of Cardiology</i> , 2013, 167, 2082-2087.	0.8	11
5231	Hydroxycholesterol improves HDL function and inhibits atherosclerotic lesion formation in LDLR <sup>-/-</sup> mice. <i>FASEB Journal</i> , 2013, 27, 3805-3817.	0.2	41
5232	Coronary and carotid atherosclerosis: How useful is the imaging?. <i>Atherosclerosis</i> , 2013, 231, 323-333.	0.4	45
5233	Myeloperoxidase in Cardiovascular Disease. <i>Advances in Clinical Chemistry</i> , 2013, 62, 1-32.	1.8	23
5234	Evolution and involution of atherosclerosis and its relationship with vascular reactivity in hypercholesterolemic rabbits. <i>Experimental and Toxicologic Pathology</i> , 2013, 65, 297-304.	2.1	12
5235	Assessment of Low-Density Lipoprotein Targets. <i>Angiology</i> , 2013, 64, 411-416.	0.8	11
5237	Impact of Cholesterol Metabolism on Coronary Plaque Vulnerability of Target Vessels. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 746-755.	1.1	41
5238	Levels and Changes of HDL Cholesterol and Apolipoprotein A-I in Relation to Risk of Cardiovascular Events Among Statin-Treated Patients. <i>Circulation</i> , 2013, 128, 1504-1512.	1.6	162
5239	Natural History of Mild and of Moderate Aortic Stenosis: New Insights From a Large Prospective European Study. <i>Current Problems in Cardiology</i> , 2013, 38, 365-409.	1.1	28
5240	Comparison of pitavastatin with atorvastatin in increasing HDL-cholesterol and adiponectin in patients with dyslipidemia and coronary artery disease: The COMPACT-CAD study. <i>Journal of Cardiology</i> , 2013, 62, 87-94.	0.8	33
5241	Coronary Artery Disease. <i>Primary Care - Clinics in Office Practice</i> , 2013, 40, 1-16.	0.7	50
5242	Abdominal obesity, insulin resistance, metabolic syndrome and cholesterol homeostasis. <i>PharmaNutrition</i> , 2013, 1, 130-136.	0.8	12
5243	Current Ways of Treating Dyslipidemias to Prevent Atherosclerosis. <i>Therapeutic Apheresis and Dialysis</i> , 2013, 17, 125-129.	0.4	1
5244	Endoscopic ulcers as a surrogate marker of NSAID-induced mucosal damage. <i>Arthritis Research and Therapy</i> , 2013, 15, S4.	1.6	10
5245	Two apolipoprotein E mimetic peptides with similar cholesterol reducing properties exhibit differential atheroprotective effects in LDL-R null mice. <i>Atherosclerosis</i> , 2013, 227, 58-64.	0.4	37
5246	2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2013, 61, e78-e140.	1.2	2,612
5247	High fat diets and pathology in the guinea pig. Atherosclerosis or liver damage?. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2013, 1832, 355-364.	1.8	32
5248	Statins and percutaneous coronary intervention: A complementary synergy. <i>Clinica E Investigaci3n En Arteriosclerosis</i> , 2013, 25, 112-122.	0.4	2

#	ARTICLE	IF	CITATIONS
5249	Impact of statin dose on major cardiovascular events: A mixed treatment comparison meta-analysis involving more than 175,000 patients. <i>International Journal of Cardiology</i> , 2013, 166, 431-439.	0.8	31
5250	Head-to-head comparison of fibrates versus statins for elevation of circulating adiponectin concentrations: a systematic review and meta-analysis. <i>Metabolism: Clinical and Experimental</i> , 2013, 62, 1876-1885.	1.5	14
5251	The effect of metformin on monocyte secretory function in simvastatin-treated patients with impaired fasting glucose. <i>Metabolism: Clinical and Experimental</i> , 2013, 62, 39-43.	1.5	30
5252	Niacin Therapy Lives for Another Day—Maybe?. <i>Journal of the American College of Cardiology</i> , 2013, 61, 2197-2198.	1.2	8
5253	2012 ACCF/AHA Focused Update Incorporated Into the ACCF/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non- $\text{ST}$ -Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2013, 61, e179-e347.	1.2	370
5254	Effect of oral administration with pravastatin and atorvastatin on airway hyperresponsiveness and allergic reactions in asthmatic mice. <i>Annals of Allergy, Asthma and Immunology</i> , 2013, 110, 11-17.	0.5	14
5255	Differences in interaction and subgroup-specific effects were observed between randomized and nonrandomized studies in three empirical examples. <i>Journal of Clinical Epidemiology</i> , 2013, 66, 599-607.	2.4	14
5256	High-Potency Statins and Acute Kidney Injury—Associated Hospitalizations. <i>American Journal of Kidney Diseases</i> , 2013, 62, 877-879.	2.1	2
5257	Risk reductions for cardiovascular disease with pravastatin treatment by dyslipidemia phenotype: A post hoc analysis of the MEGA Study. <i>Journal of Cardiology</i> , 2013, 61, 196-200.	0.8	6
5258	Observational research—opportunities and limitations. <i>Journal of Diabetes and Its Complications</i> , 2013, 27, 642-648.	1.2	161
5259	Obesity paradox in Japanese patients after percutaneous coronary intervention: An observation cohort study. <i>Journal of Cardiology</i> , 2013, 62, 18-24.	0.8	50
5260	Effect of Ezetimibe on Major Atherosclerotic Disease Events and All-Cause Mortality. <i>American Journal of Cardiology</i> , 2013, 111, 532-539.	0.7	15
5261	Low-density lipoprotein-dependent and independent effects of statins on prevention of major coronary events: Meta-regression of randomized placebo-controlled trials. <i>International Journal of Cardiology</i> , 2013, 168, 4850-4853.	0.8	3
5262	The prognostic value of very low admission LDL-cholesterol levels in ST-segment elevation myocardial infarction compared in statin-pretreated and statin-naïve patients undergoing primary percutaneous coronary intervention. <i>International Journal of Cardiology</i> , 2013, 167, 458-463.	0.8	20
5263	Low HDL-C predicts risk and PCI outcomes in the Han Chinese population. <i>Atherosclerosis</i> , 2013, 226, 193-197.	0.4	15
5264	Evidence based policy decisions through a Bayesian approach: The case of a statin appraisal in the Netherlands. <i>Health Policy</i> , 2013, 112, 234-240.	1.4	6
5265	Low Levels of High-Density Lipoprotein Cholesterol and Increased Risk of Cardiovascular Events in Stable Ischemic Heart Disease Patients. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1826-1833.	1.2	84
5266	Pharmacologic manipulation of coronary vascular physiology for the evaluation of coronary artery disease. , 2013, 140, 121-132.		12

#	ARTICLE	IF	CITATIONS
5267	Distribution, frequency and clinical implications of napkin-ring sign assessed by multidetector computed tomography. <i>Journal of Cardiology</i> , 2013, 61, 399-403.	0.8	24
5268	High dose atorvastatin therapy and QTc interval in patients treated with coronary bypass surgery. <i>International Journal of Cardiology</i> , 2013, 168, 1526-1528.	0.8	2
5269	Relationship between low-density lipoprotein levels on admission and 1-year outcome in patients with acute ST-segment-elevation myocardial infarction. <i>Kaohsiung Journal of Medical Sciences</i> , 2013, 29, 206-213.	0.8	4
5270	Nondaily Statin Dosing: Mechanisms of a Potentially Important Approach to Dealing With Statin Intolerance. <i>Canadian Journal of Cardiology</i> , 2013, 29, 895-898.	0.8	2
5271	Treatment Differences by Health Insurance Among Outpatients With Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2013, 61, 1069-1075.	1.2	39
5272	Does it Make Sense to Combine Statins with Other Lipid-Altering Agents Following AIM-HIGH, SHARP and ACCORD?. <i>Current Atherosclerosis Reports</i> , 2013, 15, 290.	2.0	3
5273	How Do We Improve Patient Compliance and Adherence to Long-Term Statin Therapy?. <i>Current Atherosclerosis Reports</i> , 2013, 15, 291.	2.0	159
5274	Is Atherosclerosis Regression a Realistic Goal of Statin Therapy and What Does That Mean?. <i>Current Atherosclerosis Reports</i> , 2013, 15, 294.	2.0	20
5275	Statins and Diabetes: The Good, the Bad, and the Unknown. <i>Current Atherosclerosis Reports</i> , 2013, 15, 299.	2.0	25
5276	Is the Future of Statins Aligned with New Novel Lipid Modulation Therapies?. <i>Current Atherosclerosis Reports</i> , 2013, 15, 300.	2.0	5
5277	Lipidomics: Opportunities to Identify New Causal Mechanisms and Therapeutics for Atherosclerosis. <i>Current Cardiovascular Risk Reports</i> , 2013, 7, 60-65.	0.8	0
5278	Lipoprotein apheresis in isolated hyperlipoproteinemia(a): a validated treatment or an illusion of validity?. <i>European Journal of Clinical Investigation</i> , 2013, 43, 108-112.	1.7	4
5279	Lipid management in the prevention of stroke: a meta-analysis of fibrates for stroke prevention. <i>BMC Neurology</i> , 2013, 13, 1.	0.8	87
5280	Central Nervous System Ischemia. , 2013, , 669-697.		0
5281	Meta-Analysis of Impact of Different Types and Doses of Statins on New-Onset Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2013, 111, 1123-1130.	0.7	239
5282	Safety and Effect of Very Low Levels of Low-Density Lipoprotein Cholesterol on Cardiovascular Events. <i>American Journal of Cardiology</i> , 2013, 111, 1221-1229.	0.7	35
5283	Metabolomics and ischaemic heart disease. <i>Clinical Science</i> , 2013, 124, 289-306.	1.8	43
5284	HMG-CoA reductase inhibitors (statins) and bone mineral density: A meta-analysis. <i>Bone</i> , 2013, 54, 151-156.	1.4	43

#	ARTICLE	IF	CITATIONS
5285	Changes in adherence to statins and subsequent lipid profiles during and following breast cancer treatment. <i>Breast Cancer Research and Treatment</i> , 2013, 138, 225-233.	1.1	34
5286	Homocysteine-lowering interventions for preventing cardiovascular events. , 2013, , CD006612.		53
5288	Beyond Statins: Lipid Management to Reduce Cardiovascular Risk. <i>Pharmacotherapy</i> , 2013, 33, 754-764.	1.2	13
5290	Genetics of HDL-C: A Causal Link to Atherosclerosis?. <i>Current Atherosclerosis Reports</i> , 2013, 15, 326.	2.0	23
5291	Pharmacokinetic interaction studies of co-administration of ticagrelor and atorvastatin or simvastatin in healthy volunteers. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 477-487.	0.8	52
5292	Association of statin use with risk of dementia: A meta-analysis of prospective cohort studies. <i>Geriatrics and Gerontology International</i> , 2013, 13, 817-824.	0.7	47
5293	Potential role for statins in sickle cell disease. <i>Pediatric Blood and Cancer</i> , 2013, 60, 550-557.	0.8	12
5294	A Reappraisal of the Risks and Benefits of Treating to Target with Cholesterol Lowering Drugs. <i>Drugs</i> , 2013, 73, 1025-1054.	4.9	30
5295	Genetic variation in the ABCC2 gene is associated with dose decreases or switches to other cholesterol-lowering drugs during simvastatin and atorvastatin therapy. <i>Pharmacogenomics Journal</i> , 2013, 13, 251-256.	0.9	35
5296	Emerging anti-inflammatory drugs for atherosclerosis. <i>Expert Opinion on Emerging Drugs</i> , 2013, 18, 193-205.	1.0	30
5297	GPCR responses in vascular smooth muscle can occur predominantly through dual transactivation of kinase receptors and not classical G1±q protein signalling pathways. <i>Life Sciences</i> , 2013, 92, 951-956.	2.0	19
5298	Characterization of polysaccharides with marked inhibitory effect on lipid accumulation in <i>Pleurotus eryngii</i> . <i>Carbohydrate Polymers</i> , 2013, 97, 604-613.	5.1	52
5299	Lipid-lowering and anti-inflammatory effect of ezetimibe in hyperlipidemic patients with coronary artery disease. <i>Heart and Vessels</i> , 2013, 28, 39-45.	0.5	19
5300	HDL particle functionality as a primary pharmacological target for HDL-based therapies. <i>Biochemical Pharmacology</i> , 2013, 85, 1575-1578.	2.0	27
5301	Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy—a meta-analysis of 11 randomized controlled trials involving 21,295 participants. <i>Pharmacological Research</i> , 2013, 72, 35-44.	3.1	90
5303	Stable Angina. , 2013, , 419-438.		0
5304	Rosuvastatin calcium in acute coronary syndromes. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 1215-1227.	0.9	17
5306	Cardiovascular event rates in atorvastatin patients versus patients switching from atorvastatin to simvastatin. <i>Current Medical Research and Opinion</i> , 2013, 29, 773-781.	0.9	2



#	ARTICLE	IF	CITATIONS
5307	Effect of a Single High Loading Dose of Rosuvastatin on Percutaneous Coronary Intervention for Acute Coronary Syndromes. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2013, 18, 327-333.	1.0	27
5308	Impact of Coronary Artery Calcium Progression and Statin Therapy on Clinical Outcome in Subjects With and Without Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2013, 111, 356-361.	0.7	43
5309	Lipid management: maximising reduction of cardiac risk. <i>Clinical Medicine</i> , 2013, 13, 618-620.	0.8	3
5310	Statin therapy and clinical outcomes in myocardial infarction patients complicated by acute heart failure: insights from the EPHEBUS trial. <i>European Journal of Heart Failure</i> , 2013, 15, 221-227.	2.9	10
5311	Can Statins Improve Outcomes After Isolated Cardiac Valve Surgery? A Systematic Literature Review. <i>Clinical Cardiology</i> , 2013, 36, 448-455.	0.7	3
5312	Twenty-Year Trends in Long-Term Mortality Risk in 17 149 Survivors of Ischemic Stroke Less Than 55 Years of Age. <i>Stroke</i> , 2013, 44, 3338-3343.	1.0	23
5313	Medical Management and Strategies to Prevent Coronary Artery Disease in Patients with Type 2 Diabetes Mellitus. <i>Postgraduate Medicine</i> , 2013, 125, 17-33.	0.9	11
5314	Medical Treatment of Peripheral Artery Disease. , 2013, , 242-258.		6
5315	Problems and Possible Solutions for Therapy with Statins. <i>International Journal of Angiology</i> , 2013, 22, 075-082.	0.2	12
5316	Lipid disorders. , 2013, , 68-77.		1
5317	2012 ACCF/AHA Focused Update Incorporated Into the ACCF/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-â€œST-Elevation Myocardial Infarction. <i>Circulation</i> , 2013, 127, e663-828.	1.6	219
5318	Role of diuretics, Æ blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study. <i>BMJ, The</i> , 2013, 347, f6745-f6745.	3.0	72
5319	Use of Lipid-lowering Agents in Rheumatoid Arthritis: A Population-based Cohort Study. <i>Journal of Rheumatology</i> , 2013, 40, 1082-1088.	1.0	26
5320	Lipoprotein(a): A Promising Marker for Residual Cardiovascular Risk Assessment. <i>Disease Markers</i> , 2013, 35, 551-559.	0.6	39
5321	A Clinical Review of Statin-Associated Myopathy. <i>Journal of Pharmacy Technology</i> , 2013, 29, 219-230.	0.5	10
5322	Unique and Varied Contributions of Traditional CVD Risk Factors: A Systematic Literature Review of CAD Risk Factors in China. <i>Clinical Medicine Insights: Cardiology</i> , 2013, 7, CMC.S10225.	0.6	20
5323	Dyslipidemic drugs in metabolic syndrome. <i>Indian Journal of Endocrinology and Metabolism</i> , 2013, 17, 472.	0.2	7
5325	Outcomes After Acute Myocardial Infarction in HIV-Infected Patients. <i>Circulation</i> , 2013, 127, 1767-1774.	1.6	122

#	ARTICLE	IF	CITATIONS
5326	Sex-Specific Differences in the Predictive Value of Cholesterol Homeostasis Markers and 10-Year Cardiovascular Disease Event Rate in Framingham Offspring Study Participants. <i>Journal of the American Heart Association</i> , 2013, 2, e005066.	1.6	48
5327	Lipoprotein Kinetics in Male Hemodialysis Patients Treated with Atorvastatin. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1319-1326.	2.2	2
5328	Statins and beyond: Concurrent strategies for prevention of cardiovascular disease in patients with type 2 diabetes. <i>Diabetes and Vascular Disease Research</i> , 2013, 10, 99-114.	0.9	7
5329	Impact of Statin Use Before the Onset of Acute Myocardial Infarction on Coronary Plaque Morphology of the Culprit Lesion. <i>Angiology</i> , 2013, 64, 375-378.	0.8	8
5330	Statins Exert the Pleiotropic Effects Through Small GTP-Binding Protein Dissociation Stimulator Upregulation With a Resultant Rac1 Degradation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, 1591-1600.	1.1	73
5331	Low-Density Lipoprotein Cholesterol, Apolipoprotein B, and Risk of Coronary Heart Disease. <i>Biological Research for Nursing</i> , 2013, 15, 292-308.	1.0	37
5332	Dyslipidemia in Patients with Chronic and End-Stage Kidney Disease. <i>CardioRenal Medicine</i> , 2013, 3, 165-177.	0.7	26
5333	Assessing Appropriateness of Lipid Management Among Patients With Diabetes Mellitus. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2013, 6, 66-74.	0.9	24
5334	Prevalence and Management of Dyslipidemia in Korea: Korea National Health and Nutrition Examination Survey during 1998 to 2010. <i>Diabetes and Metabolism Journal</i> , 2013, 37, 433.	1.8	78
5335	Stable Ischemic Heart Disease/Chronic Stable Angina. , 2013, , 131-152.		0
5336	Peripheral Artery Disease. , 2013, , 539-552.		1
5337	Relationship between Adiponectin and Leptin, and Blood Lipids in Hyperlipidemia Patients Treated with Red Yeast Rice. <i>Research in Complementary Medicine</i> , 2013, 20, 197-203.	2.2	13
5338	Niacin, an old drug with a new twist. <i>Journal of Lipid Research</i> , 2013, 54, 2586-2594.	2.0	44
5339	Is Lipid Management Effective for All Stages of CKD. <i>Blood Purification</i> , 2013, 35, 26-30.	0.9	12
5340	Association of Copayment and Statin Adherence Stratified by Socioeconomic Status. <i>Annals of Pharmacotherapy</i> , 2013, 47, 1463-1470.	0.9	14
5341	2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. <i>Circulation</i> , 2013, 127, e362-425.	1.6	2,639
5342	Statins and primary liver cancer. <i>European Journal of Cancer Prevention</i> , 2013, 22, 229-234.	0.6	70
5343	Statins and succinylcholine interaction: A cause of concern for serious muscular damage in anesthesiology practice!. <i>Saudi Journal of Anaesthesia</i> , 2013, 7, 442.	0.2	2

#	ARTICLE	IF	CITATIONS
5344	The Role of Simvastatin in the Therapeutic Approach of Rheumatoid Arthritis. <i>Autoimmune Diseases</i> , 2013, 2013, 1-7.	2.7	25
5345	Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin-Receptor Blockers (ARBs) in Patients at High Risk of Cardiovascular Events: A Meta-Analysis of 10 Randomised Placebo-Controlled Trials. <i>ISRN Cardiology</i> , 2013, 2013, 1-8.	1.6	28
5346	Association Between Statin Adherence and Cholesterol Level Reduction from Baseline in a Veteran Population. <i>Pharmacotherapy</i> , 2013, 33, 1044-1052.	1.2	12
5347	Non-HDL cholesterol vs. Apo B for risk of coronary heart disease in healthy individuals: the EPIC-Norfolk prospective population study. <i>European Journal of Clinical Investigation</i> , 2013, 43, 1009-1015.	1.7	27
5348	Syntheses of deuterium labeled prenyldiphosphate and prenylcysteine analogues for <i>in vivo</i> mass spectrometric quantification. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2013, 56, 370-375.	0.5	4
5349	Doubling up: maximising statin therapy as opposed to adding other drugs for cardiovascular disease prevention. <i>International Journal of Clinical Practice</i> , 2013, 67, 391-393.	0.8	0
5350	Effectiveness of a Pharmacy Care Management Program for Veterans with Dyslipidemia. <i>Pharmacotherapy</i> , 2013, 33, 736-743.	1.2	18
5351	Preoperative Statins and Limb Salvage After Lower Extremity Revascularization in the Medicare Population. <i>Circulation: Cardiovascular Interventions</i> , 2013, 6, 694-700.	1.4	47
5352	Attenuation by Statins of Membrane Raft-Redox Signaling in Coronary Arterial Endothelium. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 345, 170-179.	1.3	34
5353	Long-Term Use of Lipid-Lowering Drugs Slows Progression of Carotid Atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, 858-862.	1.1	23
5354	Use of statins and risk of glioma: a nationwide case-control study in Denmark. <i>British Journal of Cancer</i> , 2013, 108, 715-720.	2.9	44
5355	A Clinician's Guide to the ABCs of Cardiovascular Disease Prevention: The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease and American College of Cardiology Cardiosource Approach to the Million Hearts Initiative. <i>Clinical Cardiology</i> , 2013, 36, 383-393.	0.7	45
5356	Targeted lipid treatment: decades of failure suggest new targets are in order. <i>International Journal of Clinical Practice</i> , 2013, 67, 1214-1216.	0.8	0
5357	The Role of Statins in Diabetes Treatment. <i>Diabetes Spectrum</i> , 2013, 26, 156-164.	0.4	8
5358	Housebound patients with coronary heart disease. <i>British Journal of Cardiac Nursing</i> , 2013, 8, 146-152.	0.0	1
5359	High-Density Lipoprotein Cholesterol Level Is Associated With Fibrous Cap Thickness in Acute Coronary Syndrome. <i>Circulation Journal</i> , 2013, 77, 2982-2989.	0.7	23
5360	Lack of Goal Attainment Regarding the Low-density Lipoprotein Cholesterol Level in the Management of Type 2 Diabetes Mellitus. <i>Internal Medicine</i> , 2013, 52, 2409-2415.	0.3	4
5361	Status of Dyslipidemia Treatment in Japanese Adults: An Analysis of the 2009 Japan Society of Ningen Dock Database. <i>Internal Medicine</i> , 2013, 52, 295-301.	0.3	11

#	ARTICLE	IF	CITATIONS
5362	Status of Lipid Management Using Lifestyle Modification in Japanese Adults: An Analysis of the 2009 Japan Society of Ningen Dock Database. <i>Internal Medicine</i> , 2013, 52, 1681-1686.	0.3	4
5364	Lipid-lowering agents for nephrotic syndrome. <i>The Cochrane Library</i> , 2013, , CD005425.	1.5	21
5365	Evidence of Lifestyle Modification in the Management of Hypercholesterolemia. <i>Current Cardiology Reviews</i> , 2013, 9, 2-14.	0.6	53
5366	Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes. <i>Vascular Health and Risk Management</i> , 2013, 9, 617.	1.0	71
5367	Association between triglycerides and cardiovascular events in primary populations: a meta-regression analysis and synthesis of evidence. <i>Vascular Health and Risk Management</i> , 2013, 9, 671.	1.0	28
5368	Does Combination Therapy with Statins and Fibrates Prevent Cardiovascular Disease in Diabetic Patients with Atherogenic Mixed Dyslipidemia?. <i>Review of Diabetic Studies</i> , 2013, 10, 171-190.	0.5	31
5369	Reassessing the Benefits of Statins in the Prevention of Cardiovascular Disease in Diabetic Patients - A Systematic Review and Meta-Analysis. <i>Review of Diabetic Studies</i> , 2013, 10, 157-170.	0.5	14
5370	Very rapid effect of pitavastatin on microvascular function in comparison to rosuvastatin: reactive hyperemia peripheral arterial tonometric study. <i>Drug Design, Development and Therapy</i> , 2013, 7, 369.	2.0	2
5371	Pleiotropic effects of simvastatin in physically trained ovariectomized rats. <i>Brazilian Journal of Medical and Biological Research</i> , 2013, 46, 447-453.	0.7	3
5372	Effects of Ezetimibe on Serum Polyunsaturated Fatty Acids in Patients With Coronary Artery Disease. <i>International Heart Journal</i> , 2013, 54, 254-257.	0.5	6
5373	Management of dyslipidemia and hyperglycemia with a fixed-dose combination of sitagliptin and simvastatin. <i>Vascular Health and Risk Management</i> , 2013, 9, 273.	1.0	7
5374	High Density Lipoprotein Cholesterol in Coronary Artery Disease: When Higher Means Later. <i>Journal of Atherosclerosis and Thrombosis</i> , 2013, 20, 23-31.	0.9	5
5375	Reverse evidence based medicine. <i>Pan African Medical Journal</i> , 2013, 16, 89.	0.3	1
5376	Early Differential Changes in Coronary Plaque Composition According to Plaque Stability Following Statin Initiation in Acute Coronary Syndrome: Classification and Analysis by Intravascular Ultrasound-Virtual Histology. <i>Yonsei Medical Journal</i> , 2013, 54, 336.	0.9	18
5377	Effects of Low Dose versus High Dose Statin Therapy on the Changes of Endothelial Function and Carotid Intima-Media Thickness in Patients with Variant Angina. <i>Journal of Cardiovascular Imaging</i> , 2013, 21, 58.	0.8	11
5378	Statins in heart failure: do we need another trial?. <i>Vascular Health and Risk Management</i> , 2013, 9, 303.	1.0	25
5379	Effects of the <i>Cynanchum wilfordii</i> Ethanol Extract on the Serum Lipid Profile in Hypercholesterolemic Rats. <i>Preventive Nutrition and Food Science</i> , 2013, 18, 157-162.	0.7	25
5380	Intensive Lipid-Lowering Therapy for Slowing Progression as Well as Inducing Regression of Atherosclerosis in Japanese Patients. <i>International Heart Journal</i> , 2013, 54, 33-39.	0.5	27

#	ARTICLE	IF	CITATIONS
5381	Facts and Principles Learned at the 39th Annual Williamsburg Conference on Heart Disease. Baylor University Medical Center Proceedings, 2013, 26, 124-136.	0.2	2
5382	Trends in Low-Density Lipoprotein Cholesterol Goal Achievement in High Risk United States Adults: Longitudinal Findings from the 1999-2008 National Health and Nutrition Examination Surveys. PLoS ONE, 2013, 8, e59309.	1.1	17
5383	Adherence to Drug Label Recommendations for Avoiding Drug Interactions Causing Statin-Induced Myopathy—A Nationwide Register Study. PLoS ONE, 2013, 8, e69545.	1.1	14
5384	Pitavastatin and Atorvastatin Double-Blind Randomized Comparative Study among High-Risk Patients, Including Those with Type 2 Diabetes Mellitus, in Taiwan (PAPAGO-T Study). PLoS ONE, 2013, 8, e76298.	1.1	28
5385	Role of Statins in Coronary Artery Disease. Chonnam Medical Journal, 2013, 49, 1.	0.5	30
5386	Statin Use in Patients with Diabetes and Kidney Disease: The Japanese Experience. Journal of Atherosclerosis and Thrombosis, 2013, 20, 407-424.	0.9	15
5388	The role of pharmaceutical marketing. , 2013, , 303-317.		0
5389	Recent Characteristics and Outcomes of Japanese Stable Angina Pectoris After Percutaneous Coronary Intervention. International Heart Journal, 2013, 54, 335-340.	0.5	11
5390	Effects of Pravastatin and Atorvastatin on HDL Cholesterol and Glucose Metabolism in Patients with Dyslipidemia and Glucose Intolerance: The PRAT Study. Journal of Atherosclerosis and Thrombosis, 2013, 20, 368-379.	0.9	14
5391	Role of Traditional Heart Failure Medications on Sudden Cardiac Death Prevention in Patients with Cardiomyopathy. , 2013, , .		0
5392	Lowering cholesterol naturally alongside prescribed medication. NursePrescribing, 2013, 11, 609-614.	0.1	1
5393	Coronary Artery Disease. Journal of Atherosclerosis and Thrombosis, 2014, 21, 86-92.	0.9	11
5394	Can cholesterol be defined as just "good" or "bad"? British Journal of Cardiac Nursing, 2014, 9, 515-516.	0	0
5395	Simvastatin Inhibits Glucose Metabolism and Legumain Activity in Human Myotubes. PLoS ONE, 2014, 9, e85721.	1.1	24
5396	The Effect of Rosuvastatin on Inflammation, Matrix Turnover and Left Ventricular Remodeling in Dilated Cardiomyopathy: A Randomized, Controlled Trial. PLoS ONE, 2014, 9, e89732.	1.1	9
5398	Protective Effects of Panax Notoginseng Saponins on Cardiovascular Diseases: A Comprehensive Overview of Experimental Studies. Evidence-based Complementary and Alternative Medicine, 2014, 2014, 1-13.	0.5	112
5399	The Relationship Between Low-Density Lipoprotein Cholesterol Levels and the Incidence of Cardiovascular Disease in High-Risk Patients Treated With Pravastatin. International Heart Journal, 2014, 55, 39-47.	0.5	11
5400	Dyslipidemia in women: etiology and management. International Journal of Women's Health, 2014, 6, 185.	1.1	57

#	ARTICLE	IF	CITATIONS
5401	Current and emerging treatment options for the elderly patient with chronic kidney disease. <i>Clinical Interventions in Aging</i> , 2014, 9, 191.	1.3	33
5402	Pantethine, a derivative of vitamin B5, favorably alters total, LDL and non-HDL cholesterol in low to moderate cardiovascular risk subjects eligible for statin therapy: a triple-blinded placebo and diet-controlled investigation. <i>Vascular Health and Risk Management</i> , 2014, 10, 89.	1.0	32
5403	HEART AND LUNG FAILURE, TRANSPLANTOLOGY The role of statins in chronic heart failure. <i>Kardiochirurgia I Torakochirurgia Polska</i> , 2014, 3, 301-305.	0.1	3
5404	Stage B: What is the Evidence for Treatment of Asymptomatic Left Ventricular Dysfunction?. <i>Current Cardiology Reviews</i> , 2014, 11, 18-22.	0.6	12
5405	Effect of High Dose Rosuvastatin Loading before Primary Percutaneous Coronary Intervention on Infarct Size in Patients with ST-Segment Elevation Myocardial Infarction. <i>Korean Circulation Journal</i> , 2014, 44, 76.	0.7	29
5406	Statins and the risk of colorectal cancer: An updated systematic review and meta-analysis of 40 studies. <i>World Journal of Gastroenterology</i> , 2014, 20, 1858.	1.4	94
5407	Statins: Definitive Translational Research. <i>Molecular Medicine</i> , 2014, 20, S20-S23.	1.9	7
5410	Carotid atherosclerotic plaque stenosis: the stabilizing role of statins. <i>European Journal of Clinical Investigation</i> , 2014, 44, 1122-1134.	1.7	33
5411	Statin initiation and treatment non-adherence following a first acute myocardial infarction in patients with inflammatory rheumatic disease versus the general population. <i>Arthritis Research and Therapy</i> , 2014, 16, 443.	1.6	4
5412	Centralized Pan-Middle East Survey on the Under-Treatment of Hypercholesterolemia: Results from the CEPHEUS Study in Egypt. <i>Cardiology and Therapy</i> , 2014, 3, 27-40.	1.1	9
5413	High-Density Lipoproteins and Coronary Artery Disease. <i>Angiology</i> , 2014, 65, 696-702.	0.8	11
5414	Consensus statement on management of dyslipidemia in Indian subjects. <i>Indian Heart Journal</i> , 2014, 66, S1-S51.	0.2	47
5415	Trends in Cause of Death After Percutaneous Coronary Intervention. <i>Circulation</i> , 2014, 129, 1286-1294.	1.6	149
5416	Cholesteryl Ester Transfer Protein (CETP) Deficiency and CETP Inhibitors. <i>Molecules and Cells</i> , 2014, 37, 777-784.	1.0	46
5417	MicroRNAs Involved in the Lipid Metabolism and Their Possible Implications for Atherosclerosis Development and Treatment. <i>Mediators of Inflammation</i> , 2014, 2014, 1-14.	1.4	42
5418	Low level of inflammatory marker in hyperhomocysteinemic patients on statin therapy. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2014, 74, 1-7.	0.6	6
5419	New cholesterol guidelines and the secondary prevention of cardiovascular disease – A commentary on epistemic aspects. <i>Preventive Medicine</i> , 2014, 69, 314-316.	1.6	4
5420	Can analyses of electronic patient records be independently and externally validated? The effect of statins on the mortality of patients with ischaemic heart disease: a cohort study with nested case-control analysis. <i>BMJ Open</i> , 2014, 4, e004952.	0.8	29

#	ARTICLE	IF	CITATIONS
5421	Statins and the autonomic nervous system. <i>Clinical Science</i> , 2014, 126, 401-415.	1.8	55
5422	Lipid Parameters " Significance in Patients with Endogenous Depression. <i>Journal of Clinical and Diagnostic Research JCDR</i> , 2014, 8, 17-9.	0.8	13
5423	Genomics and Pharmacogenomics of Lipid-Lowering Therapies. , 2014, , 715-746.		0
5424	A Multicenter, Prospective, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared to Pioglitazone 45 mg in Diabetic Dyslipidemia (PRESS V). <i>Journal of Diabetes Science and Technology</i> , 2014, 8, 132-141.	1.3	76
5425	Clinician's Guide to the Updated ABCs of Cardiovascular Disease Prevention. <i>Journal of the American Heart Association</i> , 2014, 3, e001098.	1.6	24
5426	Pharmacology of statins: A brief overview. <i>NursePrescribing</i> , 2014, 12, 451-456.	0.1	2
5427	Imaging of atherosclerotic plaques in obesity: excessive fat accumulation, plaque progression and vulnerability. <i>Expert Review of Cardiovascular Therapy</i> , 2014, 12, 1471-1489.	0.6	6
5428	Statins and long-term survival after isolated valve surgery: the importance of valve type, position and procedure". <i>European Journal of Cardio-thoracic Surgery</i> , 2014, 45, 419-425.	0.6	10
5429	Impact of the JUPITER Trial on Statin Prescribing for Primary Prevention. <i>Pharmacotherapy</i> , 2014, 34, 9-18.	1.2	5
5430	Changes in Low-Density Lipoprotein Cholesterol Levels After Discharge for Acute Myocardial Infarction in a Real-World Patient Population. <i>American Journal of Epidemiology</i> , 2014, 179, 1293-1300.	1.6	7
5431	Coronary Artery Calcium Scanning. <i>Endocrinology and Metabolism Clinics of North America</i> , 2014, 43, 893-911.	1.2	9
5432	Statin treatment reduces the risk of hepatocellular carcinoma but not colon cancer-results from a nationwide case-control study in Sweden. <i>Pharmacoepidemiology and Drug Safety</i> , 2014, 23, 1101-1106.	0.9	31
5433	The 2013 American College of Cardiology/American Heart Association Guidelines on Treating Blood Cholesterol and Assessing Cardiovascular Risk. <i>Endocrinology and Metabolism Clinics of North America</i> , 2014, 43, 869-892.	1.2	5
5434	Nationwide trends in development of heart failure and mortality after first-time myocardial infarction 1997"2010: A Danish cohort study. <i>European Journal of Internal Medicine</i> , 2014, 25, 731-738.	1.0	33
5435	Combination Therapy with Statins. <i>Endocrinology and Metabolism Clinics of North America</i> , 2014, 43, 993-1006.	1.2	1
5436	A comprehensive analysis of dyslipidaemia management in a large health care system. <i>Journal of Evaluation in Clinical Practice</i> , 2014, 20, 81-87.	0.9	2
5437	Sigmoidal Maximal Effect Modeling of Low"Density Lipoprotein Cholesterol Concentration and Annual Incidence of Coronary Heart Disease Events in Secondary Prevention Trials. <i>Pharmacotherapy</i> , 2014, 34, 452-463.	1.2	6
5438	Statin use and survival following glioblastoma multiforme. <i>Cancer Epidemiology</i> , 2014, 38, 722-727.	0.8	57

#	ARTICLE	IF	CITATIONS
5439	Bayesian network meta-analysis for unordered categorical outcomes with incomplete data. <i>Research Synthesis Methods</i> , 2014, 5, 162-185.	4.2	14
5440	Atorvastatin plus omega-3 fatty acid ethyl ester decreases very-low-density lipoprotein triglyceride production in insulin resistant obese men. <i>Diabetes, Obesity and Metabolism</i> , 2014, 16, 519-526.	2.2	11
5441	HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. <i>The Cochrane Library</i> , 2014, , CD007784.	1.5	141
5442	Why do statins reduce cardiovascular disease more than other lipid modulating therapies?. <i>European Journal of Clinical Investigation</i> , 2014, 44, 1135-1140.	1.7	16
5443	National Lipid Association Annual Summary of Clinical Lipidology 2015. <i>Journal of Clinical Lipidology</i> , 2014, 8, S1-S36.	0.6	64
5444	Genotoxicity evaluation of HMG CoA reductase inhibitor rosuvastatin. <i>Drug and Chemical Toxicology</i> , 2014, 37, 316-321.	1.2	7
5445	Critical Review of High-Sensitivity C-Reactive Protein and Coronary Artery Calcium for the Guidance of Statin Allocation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 315-322.	0.9	13
5446	Evidence of Sample Use Among New Users of Statins. <i>Medical Care</i> , 2014, 52, 773-780.	1.1	33
5447	Statin-Mediated Low-Density Lipoprotein Lowering in Chronic Congestive Heart Failure. <i>American Journal of the Medical Sciences</i> , 2014, 347, 14-22.	0.4	4
5448	Effects of Rosuvastatin on Fibrinolytic System of Human Umbilical Vein Endothelial Cells In Vitro. <i>American Journal of the Medical Sciences</i> , 2014, 348, 319-323.	0.4	0
5450	Association of a reduction in low-density lipoprotein cholesterol with incident cardiovascular and cerebrovascular events among people with type 2 diabetes mellitus. <i>European Journal of Preventive Cardiology</i> , 2014, 21, 855-865.	0.8	7
5451	Ezetimibe-Mediated Protection of Vascular Smooth Muscle Cells from Cholesterol Accumulation through the Regulation of Lipid Metabolism-Related Gene Expression. <i>Pharmacology</i> , 2014, 94, 214-222.	0.9	4
5452	Maintenance of statin use over 3+ years following acute coronary syndromes: a national data linkage study (ANZACS-QI-2). <i>Heart</i> , 2014, 100, 770-774.	1.2	19
5453	Low-density lipoprotein cholesterol levels in adults with type 2 diabetes: An alternative equation for accurate estimation and improved cardiovascular risk classification. <i>Diabetes and Vascular Disease Research</i> , 2014, 11, 431-439.	0.9	8
5454	LC-MS/MS assay for pitavastatin in human plasma and subsequent application to a clinical study in healthy Chinese volunteers. <i>Asian Journal of Pharmaceutical Sciences</i> , 2014, 9, 348-355.	4.3	9
5455	Tackling inequalities: are secondary prevention therapies for reducing post-infarction mortality used without disparities?. <i>European Journal of Preventive Cardiology</i> , 2014, 21, 222-230.	0.8	15
5456	Assessing Uncertainties Surrounding Combined Endpoints for Use in Economic Models. <i>Medical Decision Making</i> , 2014, 34, 300-310.	1.2	2
5457	Centralized Pan-Middle East Survey on the Undertreatment of Hypercholesterolemia. <i>Angiology</i> , 2014, 65, 919-926.	0.8	27



#	ARTICLE	IF	CITATIONS
5458	Systematic study of the effects of lowering low-density lipoprotein-cholesterol on regression of coronary atherosclerotic plaques using intravascular ultrasound. <i>BMC Cardiovascular Disorders</i> , 2014, 14, 60.	0.7	31
5459	Identification of the Effect of Multiple Polymorphisms on the Pharmacokinetics of Simvastatin and Simvastatin Acid Using a Population-Modeling Approach. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 96, 90-100.	2.3	55
5460	Peripheral microvascular dysfunction predicts residual risk in coronary artery disease patients on statin therapy. <i>Atherosclerosis</i> , 2014, 232, 186-190.	0.4	27
5461	Lipid-Lowering Therapy in Patients 75 Years and Older: Clinical Priority or Superfluous Therapy?. <i>Progress in Cardiovascular Diseases</i> , 2014, 57, 187-196.	1.6	10
5462	Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: A critical reappraisal. <i>Diabetes and Metabolism</i> , 2014, 40, 176-185.	1.4	61
5463	High-potency statins increase the risk of acute kidney injury: Evidence from a large population-based study. <i>Atherosclerosis</i> , 2014, 234, 224-229.	0.4	19
5464	Is Myopathy the Achilles' Heel of Statins?. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2300-2301.	1.2	2
5465	Intensified insulin-based glycaemic control after myocardial infarction: mortality during 20 year follow-up of the randomised Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI 1) trial. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 627-633.	5.5	73
5466	Which statin worked best to achieve lipid level targets in a European registry? A post-hoc analysis of the EUROASPIRE III for coronary heart disease patients. <i>Journal of the Saudi Heart Association</i> , 2014, 26, 183-191.	0.2	12
5467	<i>Hypericum perforatum</i> : Pharmacokinetic, Mechanism of Action, Tolerability, and Clinical Drug-Drug Interactions. <i>Phytotherapy Research</i> , 2014, 28, 643-655.	2.8	138
5468	Blood pressure-lowering effect of simvastatin: a placebo-controlled randomized clinical trial with 24-h ambulatory blood pressure monitoring. <i>Journal of Human Hypertension</i> , 2014, 28, 62-67.	1.0	13
5469	Impact of aging on the clinical outcomes of Japanese patients with coronary artery disease after percutaneous coronary intervention. <i>Heart and Vessels</i> , 2014, 29, 156-164.	0.5	34
5470	Use of secondary prevention pharmacotherapy after first myocardial infarction in patients with diabetes mellitus. <i>BMC Cardiovascular Disorders</i> , 2014, 14, 4.	0.7	12
5471	Effect of fibrate treatment on liver function tests in patients with the metabolic syndrome. <i>SpringerPlus</i> , 2014, 3, 14.	1.2	15
5472	The impact of Regional co-payment and National reimbursement criteria on statins use in Italy: an interrupted time-series analysis. <i>BMC Health Services Research</i> , 2014, 14, 6.	0.9	18
5473	The pharmacology of statins. <i>Pharmacological Research</i> , 2014, 88, 3-11.	3.1	458
5474	Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease. , 2014, 143, 87-110.		131
5475	Meta-Analysis of the Effect of Statins on Mortality in Patients With Preserved Ejection Fraction. <i>American Journal of Cardiology</i> , 2014, 113, 1198-1204.	0.7	56

#	ARTICLE	IF	CITATIONS
5476	Association Between Statin Medications and Mortality, Major Adverse Cardiovascular Event, and Amputation-Free Survival in Patients With Critical Limb Ischemia. <i>Journal of the American College of Cardiology</i> , 2014, 63, 682-690.	1.2	142
5477	Trends in statin therapy initiation during the period 2000–2010 in Israel. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 557-564.	0.8	3
5478	Statins and Risk of New-Onset Diabetes Mellitus: is there a Rationale for Individualized Statin Therapy?. <i>American Journal of Cardiovascular Drugs</i> , 2014, 14, 79-87.	1.0	29
5479	Screening and management for ischemic heart disease in patients undergoing emergency surgery for a type A acute aortic dissection. <i>Surgery Today</i> , 2014, 44, 1669-1673.	0.7	0
5480	Association of Low-Frequency and Rare Coding-Sequence Variants with Blood Lipids and Coronary Heart Disease in 56,000 Whites and Blacks. <i>American Journal of Human Genetics</i> , 2014, 94, 223-232.	2.6	287
5481	About Randomised Clinical Trials Related to Lipoproteins in Diabetes Mellitus. <i>Contemporary Diabetes</i> , 2014, , 329-346.	0.0	0
5482	Fibrate Therapy: Impact on Dyslipidemia and Cardiovascular Events in Diabetic Patients. <i>Contemporary Diabetes</i> , 2014, , 373-398.	0.0	0
5483	HDL Hypothesis: Where Do We Stand Now?. <i>Current Atherosclerosis Reports</i> , 2014, 16, 398.	2.0	24
5484	Long-term efficacy and safety of statin treatment beyond six years: A meta-analysis of randomized controlled trials with extended follow-up. <i>Pharmacological Research</i> , 2014, 81, 64-73.	3.1	23
5485	Advances in the Understanding of Plaque Composition and Treatment Options. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1604-1616.	1.2	45
5486	An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia-Full report. <i>Journal of Clinical Lipidology</i> , 2014, 8, 29-60.	0.6	289
5487	Innate and Adaptive Inflammation as a Therapeutic Target in Vascular Disease. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2491-2502.	1.2	155
5488	New AHA and ACC guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk. <i>Wiener Klinische Wochenschrift</i> , 2014, 126, 169-175.	1.0	17
5489	Nanoparticle-Mediated Delivery of Pitavastatin Inhibits Atherosclerotic Plaque Destabilization/Rupture in Mice by Regulating the Recruitment of Inflammatory Monocytes. <i>Circulation</i> , 2014, 129, 896-906.	1.6	137
5490	Use and misuse of statins after ACS: analysis of a prescription database of a community setting of 2,042,968 subjects. <i>European Journal of Preventive Cardiology</i> , 2014, 21, 1109-1116.	0.8	8
5491	Statins and skeletal muscles toxicity: From clinical trials to everyday practice. <i>Pharmacological Research</i> , 2014, 88, 107-113.	3.1	48
5492	Simvastatin for the Prevention of Exacerbations in Moderate-to-Severe COPD. <i>New England Journal of Medicine</i> , 2014, 370, 2201-2210.	13.9	281
5493	Dietary fats and cardiovascular disease: Putting together the pieces of a complicated puzzle. <i>Atherosclerosis</i> , 2014, 234, 320-328.	0.4	158

#	ARTICLE	IF	CITATIONS
5494	The Severe Hypercholesterolemia Phenotype. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1935-1947.	1.2	153
5495	Simvastatin dose and risk of rhabdomyolysis: Nested case-control study based on national health and drug dispensing data. <i>International Journal of Cardiology</i> , 2014, 174, 83-89.	0.8	9
5496	Targeting LDL: Is lower better and is it safe?. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2014, 28, 309-324.	2.2	27
5497	Development and validation of a reversed-phase HPLC method for simultaneous analysis of butylhydroxyanisol, simvastatin and its impurities in tablet dosage forms. <i>Annales Pharmaceutiques Francaises</i> , 2014, 72, 244-255.	0.4	5
5498	2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2889-2934.	1.2	3,414
5499	Target-Attainment Rates of Low-Density Lipoprotein Cholesterol Using Lipid-Lowering Drugs One Year After Acute Myocardial Infarction in Sweden. <i>American Journal of Cardiology</i> , 2014, 113, 17-22.	0.7	10
5500	Are statins really wonder drugs?. <i>Journal of the Formosan Medical Association</i> , 2014, 113, 892-898.	0.8	22
5501	Statins use and risk of depression: A systematic review and meta-analysis. <i>Journal of Affective Disorders</i> , 2014, 160, 62-67.	2.0	81
5502	Targeting Cholesterol Crystal-Induced Inflammation for the Secondary Prevention of Cardiovascular Disease. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2014, 19, 45-52.	1.0	38
5503	Statin Therapy in Heart Failure: For Good, for Bad, or Indifferent?. <i>Current Atherosclerosis Reports</i> , 2014, 16, 377.	2.0	12
5504	The Mediterranean-style dietary pattern and mortality among men and women with cardiovascular disease. <i>American Journal of Clinical Nutrition</i> , 2014, 99, 172-180.	2.2	155
5505	Sudden Cardiac Death From the Perspective of Coronary Artery Disease. <i>Mayo Clinic Proceedings</i> , 2014, 89, 1685-1698.	1.4	36
5506	Effect of statin therapy on cardiovascular outcomes after coronary revascularization in patients ≥80 years of age: Observations from the CREDO-Kyoto Registry Cohort-2. <i>Atherosclerosis</i> , 2014, 237, 821-828.	0.4	10
5507	The Evolution of Preclinical Alzheimer's Disease: Implications for Prevention Trials. <i>Neuron</i> , 2014, 84, 608-622.	3.8	568
5508	Strategia di gestione delle sindromi coronariche acute. <i>EMC - Urgenze</i> , 2014, 18, 1-14.	0.0	0
5509	Comparative effectiveness of rosuvastatin versus simvastatin in primary prevention among new users: a cohort study in the French national health insurance database. <i>Pharmacoepidemiology and Drug Safety</i> , 2014, 23, 240-250.	0.9	24
5510	Efficacy and Safety of Pitavastatin Versus Simvastatin: A Meta-Analysis of Randomized Controlled Trials. <i>Clinical Drug Investigation</i> , 2014, 34, 599-608.	1.1	8
5511	Control of cholesterol homeostasis by entero-hepatic bile transport - the role of feedback mechanisms. <i>RSC Advances</i> , 2014, 4, 58964-58975.	1.7	14

#	ARTICLE	IF	CITATIONS
5512	Statins in Heart Failure. <i>Heart Lung and Circulation</i> , 2014, 23, 895-896.	0.2	0
5513	Statin therapy in lower limb peripheral arterial disease: Systematic review and meta-analysis. <i>Vascular Pharmacology</i> , 2014, 63, 79-87.	1.0	49
5514	Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 684-698.	1.1	215
5515	Prolonged combination lipid therapy is associated with reduced carotid intima-media thickness: A case-control study of the 20-year Familial Atherosclerosis Treatment - Observational Study (FATS-OS). <i>Journal of Clinical Lipidology</i> , 2014, 8, 489-493.	0.6	7
5516	Statins in oncological research: From experimental studies to clinical practice. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 92, 296-311.	2.0	43
5517	The Therapeutic Role of Niacin in Dyslipidemia Management. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2014, 19, 141-158.	1.0	52
5518	Cardiovascular Disease and Transgenerational Epigenetic Effects. , 2014, , 321-341.		0
5519	Toll-like receptor 4 activation promotes cardiac arrhythmias by decreasing the transient outward potassium current (I <sub>to</sub> ) through an IRF3-dependent and MyD88-independent pathway. <i>Journal of Molecular and Cellular Cardiology</i> , 2014, 76, 116-125.	0.9	42
5520	Secondary Prevention of Stroke in the Elderly: Focus on Drug Therapy. <i>Drugs and Aging</i> , 2014, 31, 721-730.	1.3	16
5521	Statins for acute coronary syndrome. <i>The Cochrane Library</i> , 2014, , CD006870.	1.5	32
5522	How to balance cardiorenometabolic benefits and risks of statins. <i>Atherosclerosis</i> , 2014, 235, 644-648.	0.4	26
5523	Effect of Rosuvastatin on Coronary Flow Reserve in Patients With Systemic Hypertension. <i>American Journal of Cardiology</i> , 2014, 114, 1234-1237.	0.7	18
5524	LDL-Cholesterol Targets After the ACC/AHA 2013 Guidelines. <i>Journal of the American College of Cardiology</i> , 2014, 64, 495-497.	1.2	8
5525	Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events. <i>Journal of the American College of Cardiology</i> , 2014, 64, 485-494.	1.2	512
5526	Global Perspective on Acute Coronary Syndrome. <i>Circulation Research</i> , 2014, 114, 1959-1975.	2.0	187
5527	Dyslipidaemia in perspective. <i>Lancet, The</i> , 2014, 384, 566-568.	6.3	4
5528	Triglycerides and cardiovascular disease. <i>Lancet, The</i> , 2014, 384, 626-635.	6.3	1,005
5529	Recent advances in pharmacotherapy for hypertriglyceridemia. <i>Progress in Lipid Research</i> , 2014, 56, 47-66.	5.3	128

#	ARTICLE	IF	CITATIONS
5530	Principles of Primary and Secondary Prevention of Cardiovascular Disease. , 2014, , 1-44.		0
5531	Non-cardiovascular effects associated with statins. <i>BMJ, The</i> , 2014, 349, g3743-g3743.	3.0	137
5532	Statins: Do They Have a Potential Role in Cancer Prevention and Modifying Cancer-Related Outcomes?. <i>Drugs</i> , 2014, 74, 1841-1848.	4.9	25
5534	Why training and specialization is needed for peer review: a case study of peer review for randomized controlled trials. <i>BMC Medicine</i> , 2014, 12, 128.	2.3	53
5535	Do statins reduce the cardiovascular risk in patients with rheumatoid arthritis?. <i>International Journal of Rheumatic Diseases</i> , 2014, 17, 606-611.	0.9	32
5536	A Summary and Critical Assessment of the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Disease Risk in Adults: Filling the Gaps. <i>Mayo Clinic Proceedings</i> , 2014, 89, 1257-1278.	1.4	35
5538	Standard and intensive lipid-lowering therapy with statins for the primary prevention of vascular diseases: a population-based study. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 99-108.	0.8	13
5539	Graft Vessel Disease Following Heart Transplantation: A Systematic Review of the Role of Statin Therapy. <i>World Journal of Surgery</i> , 2014, 38, 2324-2334.	0.8	9
5540	Inappropriate prescribing in patients accessing specialist palliative day care services. <i>International Journal of Clinical Pharmacy</i> , 2014, 36, 535-543.	1.0	29
5541	LDL-cholesterol versus non-HDL-to-HDL-cholesterol ratio and risk for coronary heart disease in type 2 diabetes. <i>European Journal of Preventive Cardiology</i> , 2014, 21, 1420-1428.	0.8	39
5542	The Effect of Laparoscopic Gastric Bypass on Dyslipidemia in Severely Obese Patients: a 5-Year Follow-up Analysis. <i>Obesity Surgery</i> , 2014, 24, 549-553.	1.1	10
5543	HDL: To Treat or Not To Treat?. <i>Current Atherosclerosis Reports</i> , 2014, 16, 429.	2.0	12
5544	Is there Sufficient Enhancement of the Reduction in CVD Rates after a Decade of Statin Therapy to Justify Continuation?. <i>Current Atherosclerosis Reports</i> , 2014, 16, 432.	2.0	1
5545	Does Friedewald Formula Underestimate the Risk of Ischemic Heart Disease?. <i>Indian Journal of Clinical Biochemistry</i> , 2014, 29, 496-500.	0.9	15
5546	Hyperglycemia, Acute Ischemic Stroke, and Thrombolytic Therapy. <i>Translational Stroke Research</i> , 2014, 5, 442-453.	2.3	102
5547	Add-on Ezetimibe Reduces Small Dense Low-Density Lipoprotein Cholesterol Levels Without Affecting Absorption of Eicosapentaenoic Acid in Patients with Coronary Artery Disease: A Pilot Study. <i>American Journal of Cardiovascular Drugs</i> , 2014, 14, 387-392.	1.0	5
5548	Benefitâ€“Risk Assessment of Rosuvastatin in the Treatment of Atherosclerosis and Related Diseases. <i>Drug Safety</i> , 2014, 37, 481-500.	1.4	4
5549	The 2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol. <i>Circulation Research</i> , 2014, 114, 761-764.	2.0	17

#	ARTICLE	IF	CITATIONS
5550	2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. <i>Circulation</i> , 2014, 129, S1-45.	1.6	4,842
5551	Comparison of the Efficacy and Safety Profile of Morning Administration of Controlled-release Simvastatin Versus Evening Administration of Immediate-release Simvastatin in Chronic Kidney Disease Patients With Dyslipidemia. <i>Clinical Therapeutics</i> , 2014, 36, 1182-1190.	1.1	12
5552	Ischaemic heart disease: stable angina. <i>Medicine</i> , 2014, 42, 495-501.	0.2	1
5553	Comparison of cardiovascular disease risk associated with 3 lipid measures in Japanese adults. <i>Journal of Clinical Lipidology</i> , 2014, 8, 501-509.	0.6	11
5554	Impact on Optical Coherence Tomographic Coronary Findings of Fluvastatin Alone Versus Fluvastatin+ Ezetimibe. <i>American Journal of Cardiology</i> , 2014, 113, 580-587.	0.7	49
5555	The effect of acute simvastatin administration on the severity of arrhythmias resulting from ischaemia and reperfusion in the canine: Is there a role for nitric oxide?. <i>European Journal of Pharmacology</i> , 2014, 732, 96-104.	1.7	6
5556	Impact of Cardiac Rehabilitation on Angiographic Outcomes After Drug-Eluting Stents in Patients With De Novo Long Coronary Artery Lesions. <i>American Journal of Cardiology</i> , 2014, 113, 1977-1985.	0.7	9
5557	Subjects with familial hypercholesterolemia are characterized by an inflammatory phenotype despite long-term intensive cholesterol lowering treatment. <i>Atherosclerosis</i> , 2014, 233, 561-567.	0.4	48
5558	Serum myeloperoxidase/paraoxonase 1 ratio as potential indicator of dysfunctional high-density lipoprotein and risk stratification in coronary artery disease. <i>Atherosclerosis</i> , 2014, 234, 288-294.	0.4	65
5560	Combination therapy of eicosapentaenoic acid and pitavastatin for coronary plaque regression evaluated by integrated backscatter intravascular ultrasonography (CHERRY study)â€”Rationale and design. <i>Journal of Cardiology</i> , 2014, 64, 236-239.	0.8	9
5561	Statin therapy is associated with a reduced risk of non-alcoholic fatty liver in overweight individuals. <i>Digestive and Liver Disease</i> , 2014, 46, 720-725.	0.4	32
5562	Statins: Can we advocate them for primary prevention of heart disease?. <i>Medical Journal Armed Forces India</i> , 2014, 70, 270-273.	0.3	8
5563	Effects of statin treatment in patients with coronary artery disease and chronic kidney disease. <i>Heart and Vessels</i> , 2014, 29, 21-28.	0.5	28
5564	Relationships between the Serum Cholesterol Levels, Production of Monocyte Proinflammatory Cytokines and Long-term Prognosis in Patients with Chronic Heart Failure. <i>Internal Medicine</i> , 2014, 53, 2415-2424.	0.3	24
5565	Contributors to Newly Developed Coronary Artery Disease in Patients with a Previous History of Percutaneous Coronary Intervention beyond the Early Phase of Restenosis. <i>Internal Medicine</i> , 2014, 53, 819-828.	0.3	8
5567	Prescription medication burden in patients with newly diagnosed diabetes: A SURveillance, PREvention, and ManagEment of Diabetes Mellitus (SUPREME-DM) study. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2014, 54, 374-382.	0.7	24
5569	Estimating Mortality in Survivors of the Acute Coronary Syndrome by the 4-Drug Score. <i>Cardiology</i> , 2014, 127, 83-89.	0.6	3
5570	New statin guidelines: The rift between the medical profession. <i>NursePrescribing</i> , 2014, 12, 214-216.	0.1	1

#	ARTICLE	IF	CITATIONS
5572	Is High-Intensity Statin Therapy Associated With Lower Statin Adherence Compared With Low- to Moderate-Intensity Statin Therapy? Implications of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guidelines. <i>Clinical Cardiology</i> , 2014, 37, 653-659.	0.7	53
5573	The Potential Effects of Implementing the 2013 ACC/AHA Cholesterol Guidelines on the Use of Statins in a Large Health Maintenance Organization in Israel. <i>Value in Health Regional Issues</i> , 2015, 7, 22-26.	0.5	1
5574	Altered microRNA Profiling in Statin-Induced HepG2 Cells: A Pilot Study Identifying Potential new Biomarkers Involved in Lipid-Lowering Treatment. <i>Cardiovascular Drugs and Therapy</i> , 2015, 29, 509-518.	1.3	17
5575	Does African American Race Impact Statin Efficacy in Renal Transplant Outcomes?. <i>Medicine (United States)</i> 2015, 94, 1474-1481.	0.4	4
5576	Lipids, blood pressure and kidney update 2015. <i>Lipids in Health and Disease</i> , 2015, 14, 167.	1.2	49
5577	Lipid Interventions in Aortic Valvular Disease. <i>American Journal of the Medical Sciences</i> , 2015, 350, 313-319.	0.4	4
5578	Reduction in saturated fat intake for cardiovascular disease. <i>The Cochrane Library</i> , 2015, , CD011737.	1.5	329
5579	Myopathy in older people receiving statin therapy: a systematic review and meta-analysis. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 363-371.	1.1	78
5580	Simvastatin may induce insulin resistance through a novel fatty acid mediated cholesterol independent mechanism. <i>Scientific Reports</i> , 2015, 5, 13823.	1.6	49
5582	A review of the clinical evidence related to early treatment of elevated LDL for cardiovascular primary prevention: Table 1. <i>Evidence-Based Medicine</i> , 2015, 20, 162-169.	0.6	7
5583	Alterações eletrocardiográficas na população adulta de cidade do sul do Brasil: estudo populacional. <i>Revista Portuguesa De Cardiologia</i> , 2015, 34, 745-751.	0.2	7
5584	How low should we target the LDL goal to improve survival for acute coronary syndrome patients in Hong Kong?. <i>BMC Cardiovascular Disorders</i> , 2015, 15, 117.	0.7	11
5585	Baseline diabetes as a way to predict CV outcomes in a lipid-modifying trial: a meta-analysis of 330,376 patients from 47 landmark studies. <i>Cardiovascular Diabetology</i> , 2015, 14, 60.	2.7	3
5586	Recent Advances in Targeted, Self-Assembling Nanoparticles to Address Vascular Damage Due to Atherosclerosis. <i>Advanced Healthcare Materials</i> , 2015, 4, 2408-2422.	3.9	40
5587	Statin-Induced Myopathy and Ubiquinone Levels in Serum – Results from a Prospective, Observational Study. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2015, 117, 133-136.	1.2	8
5588	Statin effects on atherosclerotic plaques: regression or healing?. <i>BMC Medicine</i> , 2015, 13, 260.	2.3	43
5589	PCSK9 inhibition: the way forward in the treatment of dyslipidemia. <i>BMC Medicine</i> , 2015, 13, 258.	2.3	32
5590	Association of Treatment for Hyperlipidemia with Decreased Total Mortality in Japanese Individuals: the Yamagata (Takahata) Study. <i>Journal of Atherosclerosis and Thrombosis</i> , 2015, 22, 1030-1039.	0.9	11

#	ARTICLE	IF	CITATIONS
5591	Effect of Statin Therapy on Fibrous Cap Thickness in Coronary Plaques Using Optical Coherence Tomography: A Systematic Review and Meta-Analysis. <i>Journal of Interventional Cardiology</i> , 2015, 28, 514-522.	0.5	21
5592	Common statin side effects explain poor compliance. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 170-171.	1.1	4
5593	Therapeutic Management of Familial Hypercholesterolemia: Current and Emerging Drug Therapies. <i>Pharmacotherapy</i> , 2015, 35, 1189-1203.	1.2	17
5594	Excessive range of statin dose in Western Australian primary care. <i>Internal Medicine Journal</i> , 2015, 45, 860-863.	0.5	3
5595	Impact of Cognitive Dysfunction on Survival in Patients With and Without Statin Use Following Carotid Endarterectomy. <i>Neurosurgery</i> , 2015, 77, 880-887.	0.6	17
5596	Statins in Type 2 Diabetes. , 2015, , .		0
5597	Adherence to statin treatment following a myocardial infarction: an Italian population-based survey. <i>ClinicoEconomics and Outcomes Research</i> , 2015, 7, 273.	0.7	6
5598	Cholesterol confusion and statin controversy. <i>World Journal of Cardiology</i> , 2015, 7, 404.	0.5	51
5599	State of the art paper Lipid-lowering therapy in older persons. <i>Archives of Medical Science</i> , 2015, 1, 43-56.	0.4	18
5600	Statin-Associated Adverse Events. <i>Clinical Medicine Insights Therapeutics</i> , 2015, 7, CMT.S18865.	0.4	2
5601	Differential Effects of Atorvastatin and Pitavastatin on Inflammation, Insulin Resistance, and the Carotid Intima-Media Thickness in Patients with Dyslipidemia. <i>Journal of Atherosclerosis and Thrombosis</i> , 2015, 22, 1158-1171.	0.9	29
5602	Edible bird's nest attenuates procoagulation effects of high-fat diet in rats. <i>Drug Design, Development and Therapy</i> , 2015, 9, 3951.	2.0	7
5603	Statin therapy in patients with cirrhosis. <i>Frontline Gastroenterology</i> , 2015, 6, 255-261.	0.9	13
5604	Structural and functional changes in HDL with low grade and chronic inflammation. <i>International Journal of Cardiology</i> , 2015, 188, 111-116.	0.8	60
5605	PCOS Therapy. , 2015, , 89-137.		3
5606	Heart health: diets and lifestyle. <i>Transactions of the Royal Society of South Africa</i> , 2015, 70, 79-82.	0.8	0
5607	Niacin Therapy, HDL Cholesterol, and Cardiovascular Disease: Is the HDL Hypothesis Defunct?. <i>Current Atherosclerosis Reports</i> , 2015, 17, 43.	2.0	27
5608	Protein Intake in Infancy and Carotid Intima Media Thickness at 5 Years - A Secondary Analysis from a Randomized Trial. <i>Annals of Nutrition and Metabolism</i> , 2015, 66, 51-59.	1.0	8



#	ARTICLE	IF	CITATIONS
5609	Atheroma Progression in Hyporesponders to Statin Therapy. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 990-995.	1.1	58
5610	Pharmacological Treatment and Current Management of Peripheral Artery Disease. <i>Circulation Research</i> , 2015, 116, 1579-1598.	2.0	87
5611	Using a Systems Pharmacology Approach to Study the Effect of Statins on the Early Stage of Atherosclerosis in Humans. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2015, 4, 41-50.	1.3	8
5612	Near-infrared spectroscopy for intracoronary detection of lipid-rich plaques to understand atherosclerotic plaque biology in man and guide clinical therapy. <i>Journal of Internal Medicine</i> , 2015, 278, 110-125.	2.7	24
5613	Homocysteine-lowering interventions for preventing cardiovascular events. , 2015, 1, CD006612.		94
5614	Initiation rates of statin therapy for the primary prevention of cardiovascular disease: an assessment of differences between countries of the UK and between regions within England. <i>BMJ Open</i> , 2015, 5, e007207-e007207.	0.8	12
5615	Rho-GTPase and Atherosclerosis: Pleiotropic Effects of Statins. <i>Journal of the American Heart Association</i> , 2015, 4, .	1.6	50
5616	Contemporary and Novel Therapeutic Options for Hypertriglyceridemia. <i>Clinical Therapeutics</i> , 2015, 37, 2732-2750.	1.1	7
5617	Non-statin Treatments for Managing LDL Cholesterol and Their Outcomes. <i>Clinical Therapeutics</i> , 2015, 37, 2751-2769.	1.1	27
5618	Pharmacokinetic Properties of Single- and Multiple-Dose Pitavastatin Calcium Tablets in Healthy Chinese Volunteers. <i>Current Therapeutic Research</i> , 2015, 77, 52-57.	0.5	18
5619	Comparison of the effects of low-dose rosuvastatin on plasma levels of cholesterol and oxidized low-density lipoprotein in 3Åultracentrifugally separated low-density lipoprotein subfractions. <i>Journal of Clinical Lipidology</i> , 2015, 9, 751-757.	0.6	4
5620	The past, present and future of lipid-lowering therapy. <i>Clinical Lipidology</i> , 2015, 10, 481-498.	0.4	6
5621	Electrocardiographic changes in adults living in a southern Brazilian city: A population-based study. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2015, 34, 745-751.	0.2	3
5622	Cerivastatin represses atherogenic gene expression through the induction of KLF2 via isoprenoid metabolic pathways. <i>Cellular and Molecular Biology Letters</i> , 2015, 20, 825-39.	2.7	7
5623	Association Between Use of Statins and Outcomes in Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2015, 8, 252-260.	1.6	37
5624	Statin therapy lowers the risk of new-onset atrial fibrillation in patients with end-stage renal disease. <i>International Journal of Cardiology</i> , 2015, 201, 538-543.	0.8	8
5625	How statistical deception created the appearance that statins are safe and effective in primary and secondary prevention of cardiovascular disease. <i>Expert Review of Clinical Pharmacology</i> , 2015, 8, 201-210.	1.3	56
5626	No effects of atorvastatin (10mg/d or 80mg/d) on nitric oxide, prostacyclin, thromboxane and oxidative stress in type 2 diabetes mellitus patients of the DALI study. <i>Pharmacological Research</i> , 2015, 94, 1-8.	3.1	11

#	ARTICLE	IF	CITATIONS
5627	Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial. <i>Lancet HIV</i> , 2015, 2, e52-e63.	2.1	188
5628	Translation of acute coronary syndrome therapies: From evidence to routine clinical practice. <i>American Heart Journal</i> , 2015, 169, 266-273.	1.2	14
5629	Low-density lipoprotein cholesterol was inversely associated with 3-year all-cause mortality among Chinese oldest old: Data from the Chinese Longitudinal Healthy Longevity Survey. <i>Atherosclerosis</i> , 2015, 239, 137-142.	0.4	52
5630	Anti-hyperlipidemic effect of methanol bark extract of <i>Terminalia chebula</i> in male albino Wistar rats. <i>Pharmaceutical Biology</i> , 2015, 53, 1133-1140.	1.3	20
5631	The Role of Antisense Oligonucleotide Therapy in Patients with Familial Hypercholesterolemia: Risks, Benefits, and Management Recommendations. <i>Current Atherosclerosis Reports</i> , 2015, 17, 467.	2.0	27
5632	Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: Management of asymptomatic disease and claudication. <i>Journal of Vascular Surgery</i> , 2015, 61, 2S-41S.e1.	0.6	624
5633	Statin Treatment for Older Adults: The Impact of the 2013 ACC/AHA Cholesterol Guidelines. <i>Drugs and Aging</i> , 2015, 32, 87-93.	1.3	5
5634	A novel therapeutic effect of statins on nephrogenic diabetes insipidus. <i>Journal of Cellular and Molecular Medicine</i> , 2015, 19, 265-282.	1.6	29
5635	Present status of statin therapy. <i>Trends in Cardiovascular Medicine</i> , 2015, 25, 216-225.	2.3	17
5636	Red Yeast Rice for the Treatment of Dyslipidemia. <i>Current Atherosclerosis Reports</i> , 2015, 17, 495.	2.0	60
5637	Low-Density Lipoprotein Cholesterol Levels and Statin Treatment by HIV Status Among Multicenter AIDS Cohort Study Men. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 593-602.	0.5	18
5638	Central Retinal Artery Occlusion. , 2015, , 239-305.		2
5639	Clinical benefit of long-term lipoprotein apheresis in patients with severe hypercholesterolemia or Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease. <i>Clinical Research in Cardiology Supplements</i> , 2015, 10, 8-13.	2.0	14
5640	Generating Evidence From Computerized Healthcare Utilization Databases. <i>Hypertension</i> , 2015, 65, 490-498.	1.3	70
5641	Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2015, 66, 495-507.	1.2	352
5642	Fenofibrate effects on arterial endothelial function in adults with type 2 diabetes mellitus: A FIELD substudy. <i>Atherosclerosis</i> , 2015, 242, 295-302.	0.4	19
5643	The low-density lipoprotein hypothesis: Proven again with the Improved Reduction of Outcomes: Vytorin Efficacy International Trial. <i>Journal of Clinical Lipidology</i> , 2015, 9, 496-497.	0.6	1
5644	Efficacy, safety, and tolerability of long-term lipoprotein apheresis in patients with LDL- or Lp(a) hyperlipoproteinemia: Findings gathered from more than 36,000 treatments at one center in Germany. <i>Atherosclerosis Supplements</i> , 2015, 18, 154-162.	1.2	50

#	ARTICLE	IF	CITATIONS
5645	Lipid-Induced Epigenomic Changes in Human Macrophages Identify a Coronary Artery Disease-Associated Variant that Regulates PPAP2B Expression through Altered C/EBP-Beta Binding. <i>PLoS Genetics</i> , 2015, 11, e1005061.	1.5	56
5646	Safety considerations with fenofibrate/simvastatin combination. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 1481-1493.	1.0	21
5647	Cardiovascular Risk Factors and In-hospital Mortality in Acute Coronary Syndromes: Insights From the Canadian Global Registry of Acute Coronary Events. <i>Canadian Journal of Cardiology</i> , 2015, 31, 1455-1461.	0.8	37
5648	Utilization of and Adherence to Guideline-Recommended Lipid-Lowering Therapy After Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2015, 66, 184-192.	1.2	91
5649	Antidiabetic and cardiovascular drug utilisation in patients diagnosed with type 2 diabetes mellitus over the age of 80 years: a population-based cohort study. <i>Age and Ageing</i> , 2015, 44, 566-573.	0.7	17
5650	Patient adherence to generic versus brand statin therapy after acute myocardial infarction: Insights from the Can Rapid Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the American College of Cardiology/American Heart Association Guidelines Registry. <i>American Heart Journal</i> , 2015, 170, 55-61.	1.2	16
5651	High-intensity statin therapy in patients with chronic kidney disease: a systematic review and meta-analysis. <i>BMJ Open</i> , 2015, 5, e006886-e006886.	0.8	36
5652	Should CMR Become the New Darling of Noninvasive Imaging for the Monitoring of Progression and Regression of Coronary Heart Disease? <i>Journal of the American College of Cardiology</i> , 2015, 66, 257-260.	1.2	2
5653	A paradigm shift in the treatment of atherosclerosis. <i>Archives of Cardiovascular Diseases</i> , 2015, 108, 337-339.	0.7	1
5655	Effects of intensive lipid-lowering therapy on coronary plaques composition in patients with acute myocardial infarction: Assessment with serial coronary CT angiography. <i>Atherosclerosis</i> , 2015, 241, 579-587.	0.4	54
5656	Do statins reduce the risk of myocardial infarction in patients with heart failure? A pooled individual-level reanalysis of CORONA and GISSI-HF. <i>European Journal of Heart Failure</i> , 2015, 17, 434-441.	2.9	39
5657	Dyslipidemia testing: Why, for whom and when. <i>Maturitas</i> , 2015, 81, 442-445.	1.0	4
5658	Prognostic and Therapeutic Implications of Statin and Aspirin Therapy in Individuals With Nonobstructive Coronary Artery Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 981-989.	1.1	147
5660	Future Translational Applications From the Contemporary Genomics Era. <i>Circulation</i> , 2015, 131, 1715-1736.	1.6	38
5662	Dyslipidemia in Dialysis Patients. <i>Seminars in Dialysis</i> , 2015, 28, 345-353.	0.7	20
5663	Rosuvastatin improves endothelial dysfunction in ankylosing spondylitis. <i>Clinical Rheumatology</i> , 2015, 34, 1065-1071.	1.0	28
5665	Cardiac Rehabilitation after an Acute Coronary Syndrome: The Impact in Elderly Patients. <i>Cardiology</i> , 2015, 131, 177-185.	0.6	19
5666	Cellular and molecular mechanisms of statins: an update on pleiotropic effects. <i>Clinical Science</i> , 2015, 129, 93-105.	1.8	74

#	ARTICLE	IF	CITATIONS
5667	Statin Use Following Hospitalization Among Medicare Beneficiaries With a Secondary Discharge Diagnosis of Acute Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2015, 4, .	1.6	11
5668	A Century of Cholesterol and Coronaries: From Plaques to Genes to Statins. <i>Cell</i> , 2015, 161, 161-172.	13.5	827
5669	Effect of Statins on Early and Late Clinical Outcomes of Carotid Endarterectomy and the Rate of Post-Carotid Endarterectomy Restenosis. <i>Journal of the American College of Surgeons</i> , 2015, 220, 481-487.	0.2	25
5670	Impact of the Mediterranean Diet on Features of Metabolic Syndrome. , 2015, , 325-335.		0
5671	Statins use and the risk of all and subtype hematological malignancies: a meta-analysis of observational studies. <i>Cancer Medicine</i> , 2015, 4, 770-780.	1.3	28
5672	Gender-related lipid and/or lipoprotein responses to statins in subjects in primary and secondary prevention. <i>Journal of Clinical Lipidology</i> , 2015, 9, 226-233.	0.6	22
5673	The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. <i>European Heart Journal</i> , 2015, 36, 1536-1546.	1.0	126
5674	National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1—Full Report. <i>Journal of Clinical Lipidology</i> , 2015, 9, 129-169.	0.6	632
5675	Medical Management of Serum Lipids and Coronary Heart Disease. <i>Cardiovascular Medicine</i> , 2015, , 39-55.	0.0	0
5676	Is lipid lowering therapy an independent risk factor for venous thromboembolism? A population-based case-control study. <i>Thrombosis Research</i> , 2015, 135, 1110-1116.	0.8	16
5677	Statin Treatment by Low-Density Lipoprotein Cholesterol Levels in Patients With Non-ST-Segment Elevation Myocardial Infarction/Unstable Angina Pectoris (from the CRUSADE Registry). <i>American Journal of Cardiology</i> , 2015, 115, 1655-1660.	0.7	7
5678	Cardiovascular Risk Factors and Disease in Women. <i>Medical Clinics of North America</i> , 2015, 99, 535-552.	1.1	17
5679	Should we use statins in all patients with chronic kidney disease without dialysis therapy? The current state of knowledge. <i>International Urology and Nephrology</i> , 2015, 47, 805-813.	0.6	14
5680	Apolipoprotein C-III. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2015, 22, 119-125.	1.2	87
5681	Statins and Aspirin: Do They Really Work in Women?. <i>American Journal of Cardiovascular Drugs</i> , 2015, 15, 151-162.	1.0	1
5682	Increased plant sterol deposition in vascular tissue characterizes patients with severe aortic stenosis and concomitant coronary artery disease. <i>Steroids</i> , 2015, 99, 272-280.	0.8	27
5683	Impact of Combined C-Reactive Protein and High-Density Lipoprotein Cholesterol Levels on Long-Term Outcomes in Patients With Coronary Artery Disease After a First Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2015, 116, 999-1002.	0.7	14
5684	Lipid-Lowering Drug Therapy for CVD Prevention: Looking into the Future. <i>Current Cardiology Reports</i> , 2015, 17, 104.	1.3	24

#	ARTICLE	IF	CITATIONS
5685	Nonstatin Low-Density Lipoproteinâ€“Lowering Therapy and Cardiovascular Risk Reductionâ€”Statement From <i>ATVB</i> Council. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 2269-2280.	1.1	58
5686	The Association of Statin Use with Age-Related Macular Degeneration Progression. <i>Ophthalmology</i> , 2015, 122, 2490-2496.	2.5	25
5687	The IMPROVE-IT study and ezetimibe. <i>British Journal of Community Nursing</i> , 2015, 20, 243-244.	0.2	2
5688	Role of Ezetimibe in Lipid-Lowering and Cardiovascular Disease Prevention. <i>Current Atherosclerosis Reports</i> , 2015, 17, 72.	2.0	11
5689	Sociodemographic and diagnostic characteristics of prescribing a second-line lipid-lowering medication: ezetimibe used as initial medication, switch from statins, or add-on medication. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 1245-1254.	0.8	6
5690	Plaque microstructures in patients with coronary artery disease who achieved very low low-density lipoprotein cholesterol levels. <i>Atherosclerosis</i> , 2015, 242, 490-495.	0.4	43
5691	The effect of statins on average survival in randomised trials, an analysis of end point postponement: TableÂ1. <i>BMJ Open</i> , 2015, 5, e007118.	0.8	45
5692	Meta-Analyses of Statin Therapy for Primary Prevention Do Not Answer Key Questions: An Empirical Appraisal of 5ÂYears of Statin Meta-Analyses. <i>American Journal of Cardiovascular Drugs</i> , 2015, 15, 379-386.	1.0	1
5693	Perspectives on Cholesterol Guidelines. <i>Contemporary Endocrinology</i> , 2015, , 313-327.	0.3	0
5694	Safety and efficacy of ezetimibe: A meta-analysis. <i>International Journal of Cardiology</i> , 2015, 201, 247-252.	0.8	70
5695	Population-Based Study of Incidence, Risk Factors, Outcome, and Prognosis of Ischemic Peripheral Arterial Events. <i>Circulation</i> , 2015, 132, 1805-1815.	1.6	148
5696	Long-Term Use of Cardiovascular Drugs. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1273-1285.	1.2	111
5697	Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT. <i>Circulation</i> , 2015, 132, 1224-1233.	1.6	267
5698	Clinical imaging in anti-atherosclerosis drug development. <i>Drug Discovery Today</i> , 2015, 20, 1317-1327.	3.2	4
5699	Artworldsâ€”and Scienceworlds?. <i>Clinical Chemistry</i> , 2015, 61, 1219-1221.	1.5	1
5700	Antilipidemic Drug Therapy Today and in the Future. <i>Handbook of Experimental Pharmacology</i> , 2015, 233, 373-435.	0.9	5
5701	The Effects of Publicity on Demand: The Case of Anti-Cholesterol Drugs. <i>Marketing Science</i> , 2016, 35, 158-181.	2.7	38
5702	One Small Step for Empagliflozin, One Giant Leap for Diabetology. <i>Diabetes Therapy</i> , 2015, 6, 405-409.	1.2	7

#	ARTICLE	IF	CITATIONS
5703	The potential role of an expert computer system to augment the opportunistic detection of individuals with familial hypercholesterolaemia from a community laboratory. <i>Clinica Chimica Acta</i> , 2015, 448, 18-21.	0.5	13
5704	Levels of perfluoroalkyl substances and risk of coronary heart disease: Findings from a population-based longitudinal study. <i>Environmental Research</i> , 2015, 142, 148-154.	3.7	45
5705	Statin therapy and plasma vitamin E concentrations: A systematic review and meta-analysis of randomized placebo-controlled trials. <i>Atherosclerosis</i> , 2015, 243, 579-588.	0.4	5
5706	Rosuvastatin treatment in stable chronic obstructive pulmonary disease (<scp>RODEO</scp>): a randomized controlled trial. <i>Journal of Internal Medicine</i> , 2015, 278, 59-67.	2.7	41
5707	Meta-analysis of the effects of statins on perioperative outcomes in vascular and endovascular surgery. <i>Journal of Vascular Surgery</i> , 2015, 61, 519-532.e1.	0.6	70
5708	Changes in ultracentrifugally separated plasma lipoprotein subfractions in patients with polygenic hypercholesterolemia, familial combined hyperlipoproteinemia, and familial hypercholesterolemia after treatment with atorvastatin. <i>Journal of Clinical Lipidology</i> , 2015, 9, 210-216.	0.6	3
5709	Gender Disparities in Evidence-Based Statin Therapy in Patients With Cardiovascular Disease. <i>American Journal of Cardiology</i> , 2015, 115, 21-26.	0.7	134
5710	Pharmacists Role in Cholesterol Management. <i>Journal of Pharmacy Practice</i> , 2015, 28, 35-43.	0.5	1
5711	Effects of HDL-modifiers on cardiovascular outcomes: A meta-analysis of randomized trials. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2015, 25, 9-23.	1.1	29
5712	Statins and alveolar bone resorption: a narrative review of preclinical and clinical studies. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2015, 119, 65-73.	0.2	9
5713	Statin use and risk for ovarian cancer: a Danish nationwide caseâ€“control study. <i>British Journal of Cancer</i> , 2015, 112, 157-161.	2.9	39
5714	Implications of reverse cholesterol transport: Recent studies. <i>Clinica Chimica Acta</i> , 2015, 439, 154-161.	0.5	30
5715	Cardiovascular morbidity and mortality after kidney transplantation. <i>Transplant International</i> , 2015, 28, 10-21.	0.8	162
5716	Use of fibrates in the metabolic syndrome: A review. <i>World Journal of Diabetes</i> , 2016, 7, 74.	1.3	47
5717	Lipoprotein abnormalities in South Asians and its association with cardiovascular disease: Current state and future directions. <i>World Journal of Cardiology</i> , 2016, 8, 247.	0.5	79
5718	The Relationship between Serum Levels of Hs-CRP and Coronary Lesion Severity. <i>Medicine and Pharmacy Reports</i> , 2016, 89, 352-364.	0.2	9
5719	Inducing apolipoprotein A-I synthesis to reduce cardiovascular risk: from ASSERT to SUSTAIN and beyond. <i>Archives of Medical Science</i> , 2016, 6, 1302-1307.	0.4	14
5720	Time trends in the prescription of statins for the primary prevention of cardiovascular disease in the United Kingdom: a cohort study using The Health Improvement Network primary care data. <i>Clinical Epidemiology</i> , 2016, 8, 123.	1.5	70

#	ARTICLE	IF	CITATIONS
5721	Omega-3 carboxylic acids monotherapy and combination with statins in the management of dyslipidemia. <i>Vascular Health and Risk Management</i> , 2016, Volume 12, 481-490.	1.0	9
5722	Developing food products, which help consumers to lower their cholesterol level. , 2016, , 173-199.		0
5723	Non-HDL Cholesterol is a More Superior Predictor of Small-Dense LDL Cholesterol than LDL Cholesterol in Japanese Subjects with TG Levels $\geq 400$ mg/dL. <i>Journal of Atherosclerosis and Thrombosis</i> , 2016, 23, 1126-1137.	0.9	34
5724	Antioxidative Activity after Rosuvastatin Treatment in Patients with Stable Ischemic Heart Disease and Decreased High Density Lipoprotein Cholesterol. <i>Korean Circulation Journal</i> , 2016, 46, 309.	0.7	2
5725	Progression of coronary artery calcification at the crossroads: sign of progression or stabilization of coronary atherosclerosis?. <i>Cardiovascular Diagnosis and Therapy</i> , 2016, 6, 250-258.	0.7	29
5726	Statin-associated rhabdomyolysis triggered by drug-drug interaction with itraconazole. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016216457.	0.2	15
5727	Paraoxonase-1 and Simvastatin Treatment in Patients with Stable Coronary Artery Disease. <i>International Journal of Vascular Medicine</i> , 2016, 2016, 1-10.	0.4	2
5728	MediterrAsian Diet Products That Could Raise HDL-Cholesterol: A Systematic Review. <i>BioMed Research International</i> , 2016, 2016, 1-15.	0.9	27
5729	Residual Dyslipidemia Leads to Unfavorable Outcomes in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention. <i>Stem Cells International</i> , 2016, 2016, 1-5.	1.2	1
5730	Rationale and Design of the PROSPECTIVE Trial: Probuco Trial for Secondary Prevention of Atherosclerotic Events in Patients with Prior Coronary Heart Disease. <i>Journal of Atherosclerosis and Thrombosis</i> , 2016, 23, 746-756.	0.9	15
5731	Disorders of Lipid Metabolism. , 2016, , 1660-1700.		7
5732	Early Effects of Intensive Lipid-Lowering Treatment on Plaque Characteristics Assessed by Virtual Histology Intravascular Ultrasound. <i>Yonsei Medical Journal</i> , 2016, 57, 1087.	0.9	8
5733	Impact of statins on risk of new onset diabetes mellitus: a population-based cohort study using the Korean National Health Insurance claims database. <i>Therapeutics and Clinical Risk Management</i> , 2016, Volume 12, 1533-1543.	0.9	23
5734	Antianginal drugs. , 2016, , 530-532.		0
5735	Update on Inflammatory Biomarkers and Treatments in Ischemic Stroke. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1967.	1.8	121
5736	Prompt impact of first prospective statin mega-trials on postoperative lipid management of CABG patients: a 20-year follow-up in a single hospital. <i>Lipids in Health and Disease</i> , 2016, 15, 124.	1.2	3
5737	Efficacy of Statin Therapy in Inducing Coronary Plaque Regression in Patients with Low Baseline Cholesterol Levels. <i>Journal of Atherosclerosis and Thrombosis</i> , 2016, 23, 1055-1066.	0.9	15
5738	Simvastatin Ameliorates Matrix Stiffness-Mediated Endothelial Monolayer Disruption. <i>PLoS ONE</i> , 2016, 11, e0147033.	1.1	39

#	ARTICLE	IF	CITATIONS
5739	Survival Benefits of Statins for Primary Prevention: A Cohort Study. <i>PLoS ONE</i> , 2016, 11, e0166847.	1.1	10
5740	Do statins really cause diabetes?. <i>Journal of King Abdulaziz University, Islamic Economics</i> , 2016, 37, 1051-1060.	0.5	13
5741	Statin use and the risk of developing diabetes: a network meta-analysis. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 1131-1149.	0.9	97
5742	Drug-induced Diabetes Mellitus: Evidence for Statins and Other Drugs Affecting Glucose Metabolism. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 99, 390-400.	2.3	30
5743	Downregulation of miR-146a, cyclooxygenase-2 and advanced glycation end-products in simvastatin-treated older patients with hyperlipidemia. <i>Geriatrics and Gerontology International</i> , 2016, 16, 322-328.	0.7	8
5744	Inaccurate risk perceptions contribute to treatment gaps in secondary prevention of cardiovascular disease. <i>Internal Medicine Journal</i> , 2016, 46, 339-346.	0.5	24
5745	Role of pharmacist in cardiovascular disease-related health promotion and in hypertension and dyslipidemia management: a cross-sectional study in the state of Qatar. <i>Journal of Evaluation in Clinical Practice</i> , 2016, 22, 329-340.	0.9	20
5747	Statin prescribing according to gender, age and indication: what about the benefit-risk balance?. <i>Journal of Evaluation in Clinical Practice</i> , 2016, 22, 235-246.	0.9	24
5748	Relation of statin use with non-melanoma skin cancer: Prospective results from the Women's Health Initiative. <i>Women's Health</i> , 2016, 12, 453-455.	0.7	6
5749	Influenza vaccine as a coronary intervention for prevention of myocardial infarction. <i>Heart</i> , 2016, 102, 1953-1956.	1.2	117
5750	Statins in prevention and treatment of ischemic stroke. <i>Human Physiology</i> , 2016, 42, 858-864.	0.1	0
5752	Interventions to improve adherence to lipid-lowering medication. <i>The Cochrane Library</i> , 2021, 2021, CD004371.	1.5	131
5754	Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV). <i>American Heart Journal</i> , 2016, 176, 83-92.	1.2	45
5755	All cholesterol-lowering interventions are expected to reduce stroke: Confirmatory data from IMPROVE-IT. <i>Data in Brief</i> , 2016, 7, 1541-1550.	0.5	1
5756	Falling cholesterol trend at acute coronary syndrome presentation is strongly related to statin use for secondary prevention. <i>International Journal of Cardiology</i> , 2016, 212, 192-197.	0.8	3
5757	Low-carbohydrate diets increase LDL-cholesterol, and thereby indicate increased risk of CVD. <i>British Journal of Nutrition</i> , 2016, 115, 2264-2266.	1.2	5
5758	Detection and interpretation of shared genetic influences on 42 human traits. <i>Nature Genetics</i> , 2016, 48, 709-717.	9.4	990
5759	The role of pharmacotherapy in the prevention of sudden cardiac death in patients with heart failure. <i>Heart Failure Reviews</i> , 2016, 21, 415-431.	1.7	6



#	ARTICLE	IF	CITATIONS
5760	AMI in very young (aged <math>\leq 35</math> years) Bangladeshi patients: Risk factors & coronary angiographic profile. <i>Clinical Trials and Regulatory Science in Cardiology</i> , 2016, 13, 1-5.	1.0	12
5761	Viejos y nuevos hipolipemiantes. <i>FMC Formacion Medica Continuada En Atencion Primaria</i> , 2016, 23, 172-184.	0.0	0
5762	Controversies Regarding Lipid Management and Statin Use for Cardiovascular Risk Reduction in Patients With CKD. <i>American Journal of Kidney Diseases</i> , 2016, 67, 965-977.	2.1	16
5763	Use of Statins to Augment Progenitor Cell Function in Preclinical and Clinical Studies of Regenerative Therapy: a Systematic Review. <i>Stem Cell Reviews and Reports</i> , 2016, 12, 327-339.	5.6	27
5764	Biochemistry of Statins. <i>Advances in Clinical Chemistry</i> , 2016, 73, 127-168.	1.8	38
5765	Two Randomized Controlled Pilot Trials of Social Forces to Improve Statin Adherence among Patients with Diabetes. <i>Journal of General Internal Medicine</i> , 2016, 31, 402-410.	1.3	22
5766	The effect of statins on mortality in heart failure with preserved ejection fraction: a meta-analysis of propensity score analyses. <i>International Journal of Cardiology</i> , 2016, 214, 301-306.	0.8	50
5767	Statin therapy in cardiac allograft vasculopathy progression in heart transplant patients: Does potency matter?. <i>Transplantation Reviews</i> , 2016, 30, 178-186.	1.2	15
5768	The role of gonadotrophin-releasing hormone antagonists in the treatment of patients with advanced hormone-dependent prostate cancer in the UK. <i>World Journal of Urology</i> , 2016, 34, 1601-1609.	1.2	37
5769	Associations between patients' risk attitude and their adherence to statin treatment – a population based questionnaire and register study. <i>BMC Family Practice</i> , 2016, 17, 28.	2.9	12
5770	Cardiovascular Outcome Studies in Diabetes: How Do We Make Sense of These New Data?. <i>Diabetes Therapy</i> , 2016, 7, 175-185.	1.2	9
5771	Use of Coronary Computed Tomographic Angiography to Guide Management of Patients With Coronary Disease. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1759-1768.	1.2	274
5772	Statin Utilization and Recommendations Among HIV- and HCV-infected Veterans: A Cohort Study. <i>Clinical Infectious Diseases</i> , 2016, 63, 407-413.	2.9	49
5773	Comparative Effectiveness of Generic Atorvastatin and Lipitor <sup>®</sup> in Patients Hospitalized with an Acute Coronary Syndrome. <i>Journal of the American Heart Association</i> , 2016, 5, e003350.	1.6	29
5774	Diagnosis and Management of Individuals With Heterozygous Familial Hypercholesterolemia. <i>Circulation</i> , 2016, 134, 710-712.	1.6	15
5775	Statin Medications and Development and Progression of Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms. <i>Current Bladder Dysfunction Reports</i> , 2016, 11, 146-152.	0.2	0
5776	Cardiovascular Disease Risk Associated With the Long-term Use of Depot Medroxyprogesterone Acetate. <i>American Journal of the Medical Sciences</i> , 2016, 352, 487-492.	0.4	8
5777	Lactobacillus casei-fermented milk improves serum and hepatic lipid profiles in diet-induced hypercholesterolaemic hamsters. <i>Journal of Functional Foods</i> , 2016, 26, 691-697.	1.6	8

#	ARTICLE	IF	CITATIONS
5778	Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. <i>Journal of Lipid Research</i> , 2016, 57, 1953-1975.	2.0	365
5779	Different cardiometabolic effects of atorvastatin in men with normal vitamin D status and vitamin D insufficiency. <i>Clinical Cardiology</i> , 2016, 39, 715-720.	0.7	12
5780	Treatment effect expressed as the novel Delay of Event measure is associated with high willingness to initiate preventive treatment – A randomized survey experiment comparing effect measures. <i>Patient Education and Counseling</i> , 2016, 99, 2005-2011.	1.0	6
5781	Anti-arthritis and cardioprotective action of hesperidin and daidzein in collagen-induced rheumatoid arthritis. <i>Molecular and Cellular Biochemistry</i> , 2016, 423, 115-127.	1.4	34
5782	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1659-1724.	6.3	4,203
5783	Are elderly and women under-represented in cardiovascular clinical trials? Implication for treatment. <i>Wiener Klinische Wochenschrift</i> , 2016, 128, 433-438.	1.0	14
5784	Lipid disorders in patients with renal failure: Role in cardiovascular events and progression of chronic kidney disease. <i>Journal of Clinical and Translational Endocrinology</i> , 2016, 6, 8-14.	1.0	34
5785	Prevention is better than cure: the new ESC Guidelines. <i>European Heart Journal</i> , 2016, 37, 2291-2293.	1.0	10
5786	Statins worsen glycemic control of T2DM in target LDL-c level and LDL-c reduction dependent manners: a meta-analysis. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1839-1849.	0.9	21
5787	Therapeutic efficacy of PCSK9 monoclonal antibodies in statin-nonresponsive patients with hypercholesterolemia and dyslipidemia: A systematic review and meta-analysis. <i>International Journal of Cardiology</i> , 2016, 222, 119-129.	0.8	23
5788	Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. <i>Genetic Epidemiology</i> , 2016, 40, 304-314.	0.6	4,142
5789	Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 829-839.	5.5	234
5790	Treatment of diabetes: Crossing to the other side. <i>Hellenic Journal of Cardiology</i> , 2016, 57, 304-310.	0.4	16
5791	Insulin-like growth factors and their potential role in cardiac epigenetics. <i>Journal of Cellular and Molecular Medicine</i> , 2016, 20, 1589-1602.	1.6	7
5792	Lipid-lowering treatment patterns in patients with new cardiovascular events – estimates from population-based register data in Sweden. <i>International Journal of Clinical Practice</i> , 2016, 70, 222-228.	0.8	1
5793	Differing predictive relationships between baseline LDL-C, systolic blood pressure, and cardiovascular outcomes. <i>International Journal of Cardiology</i> , 2016, 222, 548-556.	0.8	19
5794	Safety of atorvastatin in Asian patients within clinical trials. <i>Cardiovascular Therapeutics</i> , 2016, 34, 431-440.	1.1	15
5795	Long-Term Visit-to-Visit Blood Pressure Variability and Renal Function Decline in Patients With Hypertension Over 15 Years. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	38

#	ARTICLE	IF	CITATIONS
5796	Effects of the Addition of Eicosapentaenoic Acid to Strong Statin Therapy on Inflammatory Cytokines and Coronary Plaque Components Assessed by Integrated Backscatter Intravascular Ultrasound. <i>Circulation Journal</i> , 2016, 80, 450-460.	0.7	69
5797	Effect of Statin Treatment and Low-Density Lipoprotein-Cholesterol on Short-Term Mortality in Acute Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention—“Multicenter Registry From Tokyo CCU Network Database”. <i>Circulation Journal</i> , 2016, 80, 461-468.	0.7	17
5798	Simvastatin rescues homocysteine-induced apoptosis of osteocytic MLO-Y4 cells by decreasing the expressions of NADPH oxidase 1 and 2. <i>Endocrine Journal</i> , 2016, 63, 389-395.	0.7	15
5799	Statins and their role in the secondary prevention of coronary heart disease. <i>British Journal of Cardiac Nursing</i> , 2016, 11, 446-452.	0.0	0
5800	Management of Stable Angina “Current Guidelines: A Critical Appraisal. <i>Cardiovascular Drugs and Therapy</i> , 2016, 30, 419-426.	1.3	37
5801	Resection of hepatocellular carcinoma in elderly patients and the role of energy balance. <i>International Journal of Surgery</i> , 2016, 33, S119-S125.	1.1	6
5802	Adipose-Derived Mesenchymal Stem Cells Ameliorate Lipid Metabolic Disturbance in Mice. <i>Stem Cells Translational Medicine</i> , 2016, 5, 1162-1170.	1.6	31
5803	Moderate-intensity statin therapy seems ineffective in primary cardiovascular prevention in patients with type 2 diabetes complicated by nephropathy. A multicenter prospective 8-years follow up study. <i>Cardiovascular Diabetology</i> , 2016, 15, 147.	2.7	6
5804	Fibrates for primary prevention of cardiovascular disease events. <i>The Cochrane Library</i> , 2017, 2017, CD009753.	1.5	78
5805	The idea of uniform change: is it time to revisit a central tenet of Rose’s “Strategy of Preventive Medicine”? <i>American Journal of Clinical Nutrition</i> , 2016, 104, 1497-1507.	2.2	21
5806	Episomal Nonviral Gene Therapy Vectors Slow Progression of Atherosclerosis in a Model of Familial Hypercholesterolemia. <i>Molecular Therapy - Nucleic Acids</i> , 2016, 5, e383.	2.3	11
5807	Epidemiology of Cardiovascular Disease. , 2016, , 45-64.		1
5808	Statins and their role in the secondary prevention of coronary heart disease. <i>NursePrescribing</i> , 2016, 14, 496-501.	0.1	0
5809	Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2016, 134, e468-e495.	1.6	203
5810	Protective Effects of Statins in Cancer: Should They Be Prescribed for High-Risk Patients?. <i>Current Atherosclerosis Reports</i> , 2016, 18, 72.	2.0	14
5811	The NHS Health Check in England: an evaluation of the first 4...years. <i>BMJ Open</i> , 2016, 6, e008840.	0.8	134
5813	Neighborhood socioeconomic characteristics and statin medication in patients with myocardial infarction: a Swedish nationwide follow-up study. <i>BMC Cardiovascular Disorders</i> , 2016, 16, 146.	0.7	7
5814	Low use of statins for secondary prevention in primary care: a survey in a northern Swedish population. <i>BMC Family Practice</i> , 2016, 17, 110.	2.9	12

#	ARTICLE	IF	CITATIONS
5815	The importance of proteinuria and prior cardiovascular disease in all major clinical outcomes of atherosclerotic renovascular disease – a single-center observational study. <i>BMC Nephrology</i> , 2016, 17, 198.	0.8	4
5817	Statin-induced myopathy in a usual care setting – a prospective observational study of gender differences. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 1171-1176.	0.8	15
5818	Roles of High-Density Lipoprotein Cholesterol in Patients With Acute Myocardial Infarction. <i>Medicine (United States)</i> , 2016, 95, e3319.	0.4	6
5819	Age-Dependent Impact of Medication Underuse and Strategies for Improvement. <i>Gerontology</i> , 2016, 62, 491-499.	1.4	6
5820	Bezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trial. <i>Cardiovascular Diabetology</i> , 2016, 15, 11.	2.7	28
5822	Triple Combination Therapy for Global Cardiovascular Risk: Atorvastatin, Perindopril, and Amlodipine. <i>American Journal of Cardiovascular Drugs</i> , 2016, 16, 241-253.	1.0	12
5823	Apoprotein C-III: A review of its clinical implications. <i>Clinica Chimica Acta</i> , 2016, 460, 50-54.	0.5	18
5824	Early High-dosage Atorvastatin Treatment Improved Serum Immune-inflammatory Markers and Functional Outcome in Acute Ischemic Strokes Classified as Large Artery Atherosclerotic Stroke. <i>Medicine (United States)</i> , 2016, 95, e3186.	0.4	66
5825	Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: Subanalysis of PRECISE-IVUS trial. <i>Atherosclerosis</i> , 2016, 251, 367-372.	0.4	22
5826	Safety and effectiveness of combined antihypertensive and cholesterol-lowering therapy in high-/very high-risk patients. <i>Journal of Comparative Effectiveness Research</i> , 2016, 5, 355-364.	0.6	6
5827	Statins and Their Effect on PCSK9 – Impact and Clinical Relevance. <i>Current Atherosclerosis Reports</i> , 2016, 18, 46.	2.0	40
5828	In vitro and in vivo investigation of the gastrointestinal behavior of simvastatin. <i>International Journal of Pharmaceutics</i> , 2016, 510, 296-303.	2.6	18
5830	Comparison of lipid parameters to predict cardiovascular events in Japanese mild-to-moderate hypercholesterolemic patients with and without type 2 diabetes: Subanalysis of the MEGA study. <i>Diabetes Research and Clinical Practice</i> , 2016, 113, 14-22.	1.1	25
5831	Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis. <i>Diabetes Care</i> , 2016, 39, 1115-1122.	4.3	474
5832	A framework for quantifying the influence of adherence and dose individualization. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 99, 452-459.	2.3	12
5833	Cholesterol trials and mortality. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 168-177.	1.1	17
5834	Serum testosterone, testosterone replacement therapy and all-cause mortality in men with type 2 diabetes: retrospective consideration of the impact of PDE5 inhibitors and statins. <i>International Journal of Clinical Practice</i> , 2016, 70, 244-253.	0.8	76
5835	Simvastatin induces mitochondrial dysfunction and increased atrogin-1 expression in H9c2 cardiomyocytes and mice in vivo. <i>Archives of Toxicology</i> , 2016, 90, 203-215.	1.9	40

#	ARTICLE	IF	CITATIONS
5836	Outcome of patients with high-risk Duke treadmill score and normal myocardial perfusion imaging on spect. <i>Journal of Nuclear Cardiology</i> , 2016, 23, 1291-1300.	1.4	14
5837	Attainment of low-density lipoprotein cholesterol goal after endovascular treatment is associated with reduced cardiovascular events in patients with peripheral arterial disease. <i>Journal of Vascular Surgery</i> , 2016, 63, 756-763.	0.6	12
5838	Acute Myocardial Infarction in Women. <i>Circulation</i> , 2016, 133, 916-947.	1.6	858
5839	Update on PCSK9 therapies for the treatment of dyslipidemia. <i>Expert Review of Endocrinology and Metabolism</i> , 2016, 11, 87-95.	1.2	2
5840	A randomized study of coconut oil versus sunflower oil on cardiovascular risk factors in patients with stable coronary heart disease. <i>Indian Heart Journal</i> , 2016, 68, 498-506.	0.2	54
5841	Prevalence, awareness, treatment, and control of high low-density lipoprotein cholesterol in Brazil: Baseline of the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). <i>Journal of Clinical Lipidology</i> , 2016, 10, 568-576.	0.6	30
5842	Does IMPROVE-IT prove it?. <i>Preventive Medicine</i> , 2016, 85, 32-35.	1.6	2
5843	The diabetogenic action of statins – mechanisms and clinical implications. <i>Nature Reviews Endocrinology</i> , 2016, 12, 99-110.	4.3	122
5844	Statin Intolerance From a Clinician’s Perspective. <i>Angiology</i> , 2016, 67, 205-207.	0.8	0
5845	No evidence to support high-intensity statin in Chinese patients with coronary heart disease. <i>International Journal of Cardiology</i> , 2016, 204, 57-58.	0.8	19
5846	Association of Serum Lipids and Coronary Heart Disease in Contemporary Observational Studies. <i>Circulation</i> , 2016, 133, 256-264.	1.6	80
5847	Dabigatran etexilate and reduction in serum apolipoprotein B. <i>Heart</i> , 2016, 102, 57-62.	1.2	34
5848	Longer duration of statin therapy is associated with decreased carotid plaque vascularity by magnetic resonance imaging. <i>Atherosclerosis</i> , 2016, 245, 74-81.	0.4	23
5849	Heart Failure Prevention: Special Considerations for Women. <i>Current Cardiovascular Risk Reports</i> , 2016, 10, 1.	0.8	0
5850	Statin therapy/lipid lowering therapy among Indian adults with first acute coronary event: The dyslipidemia Residual and Mixed Abnormalities IN spite of Statin therapy (REMAINS) study. <i>Indian Heart Journal</i> , 2016, 68, 646-654.	0.2	6
5851	Dyslipidemia Part 2. <i>Vascular and Endovascular Surgery</i> , 2016, 50, 119-135.	0.3	4
5852	New Era of Lipid-Lowering Drugs. <i>Pharmacological Reviews</i> , 2016, 68, 458-475.	7.1	45
5853	Engineering Nanomaterials to Address Cell-Mediated Inflammation in Atherosclerosis. <i>Regenerative Engineering and Translational Medicine</i> , 2016, 2, 37-50.	1.6	39

#	ARTICLE	IF	CITATIONS
5854	The Success Story of LDL Cholesterol Lowering. <i>Circulation Research</i> , 2016, 118, 721-731.	2.0	48
5855	A lipidologist perspective of global lipid guidelines and recommendations, part 2: Lipid treatment goals. <i>Journal of Clinical Lipidology</i> , 2016, 10, 240-264.	0.6	3
5856	Association between statin treatment and LDL-cholesterol levels on the rate of ST-elevation myocardial infarction among patients with acute coronary syndromes: ACS Israeli Survey (ACSIS) 2002-2010. <i>International Journal of Cardiology</i> , 2016, 210, 133-138.	0.8	6
5857	Guidelines for Management of Hyperlipidemia: Implications for Treatment of Patients with Stroke Secondary to Atherosclerotic Disease. <i>Current Neurology and Neuroscience Reports</i> , 2016, 16, 24.	2.0	12
5858	The pharmacokinetic characters of simvastatin after co-administration with Shexiang Baoxin Pill in healthy volunteers' plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016, 1026, 162-167.	1.2	4
5859	ESSENS dyslipidemia: A placebo-controlled, randomized study of a nutritional supplement containing red yeast rice in subjects with newly diagnosed dyslipidemia. <i>Nutrition</i> , 2016, 32, 767-776.	1.1	15
5860	Mammogram Tribulations. <i>Academic Radiology</i> , 2016, 23, 126-127.	1.3	0
5861	Statins: the Panacea of Cirrhosis?. <i>Current Hepatology Reports</i> , 2016, 15, 1-7.	0.4	8
5862	The effects of chromium picolinate and simvastatin on pig serum cholesterol contents in swine muscular and adipose tissues. <i>Livestock Science</i> , 2016, 185, 74-78.	0.6	2
5863	Cochrane corner: early statin therapy in acute coronary syndromes-what is the clinical benefit?. <i>Heart</i> , 2016, 102, 653-654.	1.2	10
5864	Lipoprotein apheresis to treat elevated lipoprotein (a). <i>Journal of Lipid Research</i> , 2016, 57, 1751-1757.	2.0	78
5865	Lipid Control and Beyond: Current and Future Indications for Statin Therapy in Stroke. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2016, 18, 27.	0.4	7
5866	The safety of ezetimibe and simvastatin combination for the treatment of hypercholesterolemia. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 559-569.	1.0	14
5867	Survival in Patients with Degenerative Mitral Stenosis: Results from a Large Retrospective Cohort Study. <i>Journal of the American Society of Echocardiography</i> , 2016, 29, 461-469.	1.2	50
5868	National Lipid Association Annual Summary of Clinical Lipidology 2016. <i>Journal of Clinical Lipidology</i> , 2016, 10, S1-S43.	0.6	99
5869	LIFESTAT - Living with statins: An interdisciplinary project on the use of statins as a cholesterol-lowering treatment and for cardiovascular risk reduction. <i>Scandinavian Journal of Public Health</i> , 2016, 44, 534-539.	1.2	14
5870	Current Controversies With Recent Cholesterol Treatment Guidelines. <i>Journal of Pharmacy Practice</i> , 2016, 29, 15-25.	0.5	6
5871	Protocol for the China PEACE (Patient-centered Evaluative Assessment of Cardiac Events) Million Persons Project pilot. <i>BMJ Open</i> , 2016, 6, e010200.	0.8	69

#	ARTICLE	IF	CITATIONS
5872	Relation of statin use with non-melanoma skin cancer: prospective results from the Women's Health Initiative. <i>British Journal of Cancer</i> , 2016, 114, 314-320.	2.9	17
5873	Time to Replace Assessment of Liver Histology With MR-Based Imaging Tests to Assess Efficacy of Interventions for Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2016, 150, 7-10.	0.6	36
5874	Beyond Mendelian randomization: how to interpret evidence of shared genetic predictors. <i>Journal of Clinical Epidemiology</i> , 2016, 69, 208-216.	2.4	77
5875	Mortality benefit of statin use in traumatic spinal cord injury: a retrospective analysis. <i>Spinal Cord</i> , 2016, 54, 298-302.	0.9	9
5876	Allopurinol in Vascular Disease: Is There a New Role for an Old Drug?. <i>Canadian Journal of Cardiology</i> , 2016, 32, 145-147.	0.8	0
5877	Effects of Chios mastic gum on cholesterol and glucose levels of healthy volunteers: A prospective, randomized, placebo-controlled, pilot study (CHIOS-MASTIHA). <i>European Journal of Preventive Cardiology</i> , 2016, 23, 722-729.	0.8	27
5878	Making progress in the ethical treatment of medical trainees. <i>Advances in Health Sciences Education</i> , 2016, 21, 711-718.	1.7	6
5879	Statin use and mortality in rheumatoid arthritis: a general population-based cohort study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1315-1320.	0.5	53
5880	Lipoprotein Metabolism and the Treatment of Lipid Disorders. , 2016, , 715-736.e7.		5
5881	Long-term outcomes and factors influencing late survival following elective abdominal aortic aneurysm repair: A 24-year experience. <i>Vascular</i> , 2016, 24, 115-125.	0.4	19
5882	Depression and anxiety symptoms as predictors of mortality in PCI patients at 10 years of follow-up. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 552-558.	0.8	57
5883	Guideline Confusion for the Clinician. <i>Angiology</i> , 2016, 67, 5-9.	0.8	4
5884	Individualized lipid-lowering therapy to further reduce residual cardiovascular risk. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2017, 169, 198-201.	1.2	8
5885	Evaluating bempedoic acid for the treatment of hyperlipidaemia. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 251-259.	1.9	40
5886	NHS Health Check comorbidity and management: an observational matched study in primary care. <i>British Journal of General Practice</i> , 2017, 67, e86-e93.	0.7	26
5887	Pleiotropic Effects of Statins on the Cardiovascular System. <i>Circulation Research</i> , 2017, 120, 229-243.	2.0	808
5888	Relation between resting amygdalar activity and cardiovascular events: a longitudinal and cohort study. <i>Lancet, The</i> , 2017, 389, 834-845.	6.3	442
5889	Is There an Ideal Low-Density Lipoprotein Cholesterol Level? Confusion regarding Lipid Guidelines, Low-Density Lipoprotein Cholesterol Targets, and Medical Management. <i>International Journal of Angiology</i> , 2017, 26, 073-077.	0.2	4

#	ARTICLE	IF	CITATIONS
5890	Under-representation of elderly and women in clinical trials. <i>International Journal of Cardiology</i> , 2017, 232, 216-221.	0.8	105
5891	Simvastatin ameliorates graft-vs-host disease by regulating angiotensin-1 and angiotensin-2 in a murine model. <i>Leukemia Research</i> , 2017, 55, 49-54.	0.4	6
5892	Effectiveness of a combination of ezetimibe and statins in patients with acute coronary syndrome and multiple comorbidities: A 6-year population-based cohort study. <i>International Journal of Cardiology</i> , 2017, 233, 43-51.	0.8	10
5893	Effects of preoperative statin use on perioperative outcomes of carotid endarterectomy. <i>Brain and Behavior</i> , 2017, 7, e00597.	1.0	7
5894	Comment on "Statin use and all-cancer survival: prospective results from the Women's Health Initiative". <i>British Journal of Cancer</i> , 2017, 116, e9-e9.	2.9	2
5895	Genetics of coronary artery disease: discovery, biology and clinical translation. <i>Nature Reviews Genetics</i> , 2017, 18, 331-344.	7.7	448
5896	Atorvastatin-induced dermatomyositis. <i>Rheumatology International</i> , 2017, 37, 1217-1219.	1.5	9
5897	2017 Taiwan lipid guidelines for high risk patients. <i>Journal of the Formosan Medical Association</i> , 2017, 116, 217-248.	0.8	123
5898	Association between reductions in low-density lipoprotein cholesterol with statin therapy and the risk of new-onset diabetes: a meta-analysis. <i>Scientific Reports</i> , 2017, 7, 39982.	1.6	44
5899	Pathophysiology and treatment of atherosclerosis. <i>Netherlands Heart Journal</i> , 2017, 25, 231-242.	0.3	186
5900	When less is more " efficacy with less toxicity at the ED50. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1365-1368.	1.1	32
5901	Targeting LDL Cholesterol: Beyond Absolute Goals Toward Personalized Risk. <i>Current Cardiology Reports</i> , 2017, 19, 52.	1.3	13
5902	Should a statin be given to all hypertensive patients?. <i>Artery Research</i> , 2017, 18, 66.	0.3	0
5903	Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HJ-PROPER study, a prospective, open-label, randomized trial. <i>European Heart Journal</i> , 2017, 38, 2264-2276.	1.0	94
5904	A Genomic DNA Reporter Screen Identifies Squalene Synthase Inhibitors That Act Cooperatively with Statins to Upregulate the Low-Density Lipoprotein Receptor. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2017, 361, 417-428.	1.3	5
5905	Statins and Lower Gastrointestinal Conditions: A Retrospective Cohort Study. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 1053-1063.	1.0	7
5906	Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial. <i>Atherosclerosis</i> , 2017, 261, 12-18.	0.4	32
5907	Moderate statin treatment reduces prebeta-1 high-density lipoprotein levels in dyslipidemic patients. <i>Journal of Clinical Lipidology</i> , 2017, 11, 908-914.	0.6	8



#	ARTICLE	IF	CITATIONS
5908	Mendelian Randomization Implicates High-Density Lipoprotein Cholesterol-Associated Mechanisms in Etiology of Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2017, 124, 1165-1174.	2.5	109
5909	Statin Treatment and Clinical Outcomes of Heart Failure Among Africans: An Inverse Probability Treatment Weighted Analysis. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	9
5910	Benefits of Statin Therapy in Patients With Acute Myocardial Infarction With Serum Low-Density Lipoprotein Cholesterol $\geq 50$ mg/dl. <i>American Journal of Cardiology</i> , 2017, 120, 174-180.	0.7	6
5911	A study in high-risk, maximally pretreated patients to determine the potential use of PCSK9 inhibitors at various thresholds of total and LDL cholesterol levels. <i>Postgraduate Medical Journal</i> , 2017, 93, 205-208.	0.9	1
5912	Effects of morning vs evening statin administration on lipid profile: A systematic review and meta-analysis. <i>Journal of Clinical Lipidology</i> , 2017, 11, 972-985.e9.	0.6	40
5913	Niacin for primary and secondary prevention of cardiovascular events. <i>The Cochrane Library</i> , 2017, 2017, CD009744.	1.5	43
5914	Coronary artery disease: Risk stratification and patient selection for more aggressive secondary prevention. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 88-100.	0.8	45
5915	Cardiovascular pleiotropic effects of statins and new onset diabetes: is there a common link: do we need to evaluate the role of KATP channels?. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 823-831.	1.0	10
5916	Left ventricular ejection fraction as therapeutic target: is it the ideal marker?. <i>Heart Failure Reviews</i> , 2017, 22, 641-655.	1.7	19
5917	Novel Diabetes Drugs and the Cardiovascular Specialist. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2646-2656.	1.2	75
5918	Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 534-543.	5.5	84
5919	Interventions in type 2 diabetes mellitus and cardiovascular mortality—An overview of clinical trials. <i>European Journal of Internal Medicine</i> , 2017, 42, 1-15.	1.0	11
5920	Prescribing statins in general practice: who decides?. <i>British Journal of General Practice</i> , 2017, 67, 246-247.	0.7	0
5921	The effect of statins on cardiovascular outcomes by smoking status: A systematic review and meta-analysis of randomized controlled trials. <i>Pharmacological Research</i> , 2017, 122, 105-117.	3.1	21
5922	Mendelian randomisation in cardiovascular research: an introduction for clinicians. <i>Heart</i> , 2017, 103, 1400-1407.	1.2	126
5923	Has cost inhibited the uptake of more potent statins in England?. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 984-991.	0.9	6
5924	Meta-analysis of Placebo-Controlled Randomized Controlled Trials on the Prevalence of Statin Intolerance. <i>American Journal of Cardiology</i> , 2017, 120, 774-781.	0.7	40
5925	High-density lipoprotein cholesterol levels are associated with coronary severity but not with outcomes in new-onset patients with stable coronary artery disease. <i>Atherosclerosis</i> , 2017, 263, 104-111.	0.4	7

#	ARTICLE	IF	CITATIONS
5926	Effects of obesity treatment on female reproduction: results do not match expectations. <i>Fertility and Sterility</i> , 2017, 107, 860-867.	0.5	32
5927	T cell metabolism in metabolic disease-associated autoimmunity. <i>Immunobiology</i> , 2017, 222, 925-936.	0.8	12
5928	Rosuvastatin Pharmacokinetics in Asian and White Subjects Wild Type for Both OATP1B1 and BCRP Under Control and Inhibited Conditions. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 2751-2757.	1.6	64
5929	Is regression of atherosclerotic plaque possible?. <i>Cl�nica E Investigaci�n En Arteriosclerosis (English)</i> Tj ETQq1 1 0,784314 rgBT /Overd... 0,1	0.1	0
5930	From the Editor: Preventing cardiovascular death. <i>Journal of Clinical Lipidology</i> , 2017, 11, 313-314.	0.6	0
5931	Antiplatelet activity of drugs used in hypertension, dyslipidemia and diabetes: Additional benefit in cardiovascular diseases prevention. <i>Vascular Pharmacology</i> , 2017, 91, 10-17.	1.0	7
5932	Redefining the role of biomarkers in heart failure trials: expert consensus document. <i>Heart Failure Reviews</i> , 2017, 22, 263-277.	1.7	18
5933	Triglycerides: A reappraisal. <i>Trends in Cardiovascular Medicine</i> , 2017, 27, 428-432.	2.3	12
5934	Variations in Echogenicity in Carotid and Femoral Atherosclerotic Plaques with Pycnogenol�+�Centella Asiatica Supplementation. <i>International Journal of Angiology</i> , 2017, 26, 095-101.	0.2	16
5935	Health Benefits and Cost-Effectiveness of Asymptomatic Screening for Hypertension and High Cholesterol and Aspirin Counseling for Primary Prevention. <i>Annals of Family Medicine</i> , 2017, 15, 23-36.	0.9	42
5936	Statin Intolerance and Risk of Coronary Heart Events and All-Cause Mortality Following Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1386-1395.	1.2	258
5937	Effects of dyslipidaemia on monocyte production and function in cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2017, 14, 387-400.	6.1	66
5938	Do Statins Have Antidepressant Effects?. <i>CNS Drugs</i> , 2017, 31, 335-343.	2.7	22
5939	Empa's New Clothes: The Untold Story of the Empa-Reg Outcome Trial. <i>Diabetes Technology and Therapeutics</i> , 2017, 19, 324-327.	2.4	5
5940	Effect of Dose and Timing of Preoperative Statins on Mortality After Coronary Artery Bypass Surgery. <i>Annals of Thoracic Surgery</i> , 2017, 104, 782-789.	0.7	17
5941	Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis. <i>Expert Opinion on Emerging Drugs</i> , 2017, 22, 1-26.	1.0	45
5942	Statin treatment in dialysis patients after acute myocardial infarction improves overall mortality. <i>Atherosclerosis</i> , 2017, 267, 156-157.	0.4	5
5943	2017 AHA/ACC Clinical Performance and Quality Measures for Adults With ST-Elevation and Non�ST-Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2048-2090.	1.2	146

#	ARTICLE	IF	CITATIONS
5944	Statin Prescribing in the Elderly: Special Considerations. <i>Current Atherosclerosis Reports</i> , 2017, 19, 47.	2.0	19
5945	Nonadherence in the Learning Healthcare System. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017, 10, .	0.9	0
5946	From Eisenhower's heart attack to modern management: a true success story!. <i>European Heart Journal</i> , 2017, 38, 3066-3069.	1.0	37
5947	Saturated fat "a never ending story?. <i>Food and Nutrition Research</i> , 2017, 61, 1377572.	1.2	7
5948	The sirtuin family members SIRT1, SIRT3 and SIRT6: Their role in vascular biology and atherogenesis. <i>Atherosclerosis</i> , 2017, 265, 275-282.	0.4	144
5949	Evaluation of the impact of statin therapy on the obesity paradox in patients with acute myocardial infarction. <i>Medicine (United States)</i> , 2017, 96, e7180.	0.4	8
5950	Characterization of simvastatin acid uptake by organic anion transporting polypeptide 3A1 (OATP3A1) and influence of drug-drug interaction. <i>Toxicology in Vitro</i> , 2017, 45, 158-165.	1.1	12
5951	Statins for Primary Prevention of Cardiovascular Events and Mortality in Older Men. <i>Journal of the American Geriatrics Society</i> , 2017, 65, 2362-2368.	1.3	37
5952	Preventative Cardiology. <i>Physician Assistant Clinics</i> , 2017, 2, 743-758.	0.1	0
5953	Human electronegative low-density lipoprotein modulates cardiac repolarization via LOX-1-mediated alteration of sarcolemmal ion channels. <i>Scientific Reports</i> , 2017, 7, 10889.	1.6	5
5954	2017 AHA/ACC Clinical Performance and Quality Measures for Adults With ST-Elevation and Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017, 10, .	0.9	71
5955	High glucose-induced endothelial progenitor cell dysfunction. <i>Diabetes and Vascular Disease Research</i> , 2017, 14, 381-394.	0.9	50
5957	Residual atherosclerotic cardiovascular disease risk in statin-treated adults: The Multi-Ethnic Study of Atherosclerosis. <i>Journal of Clinical Lipidology</i> , 2017, 11, 1223-1233.	0.6	61
5958	Cardiopatia isquémica: concepto, clasificación, epidemiología, factores de riesgo, pronóstico y prevención. <i>Medicine</i> , 2017, 12, 2145-2152.	0.0	4
5959	Residual Risk After Treatment of Patients With Atherosclerotic Cardiovascular Disease With Proprotein Convertase Subtilisin-Kexin Type 9 Monoclonal Antibody Therapy (from the Further) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 18 <i>American Journal of Cardiology</i> , 2017, 120, 1220-1222.	0.7	3
5960	Trans fatty acids and plaque vulnerability: Research continues. <i>Atherosclerosis</i> , 2017, 265, 244-245.	0.4	0
5961	Utilization of cardiovascular medicines and cardiovascular mortality in Lithuania, Sweden and Norway in 2003-2012. <i>Medicina (Lithuania)</i> , 2017, 53, 259-267.	0.8	7
5962	Factors associated with unattained LDL-cholesterol goals in Chinese patients with acute coronary syndrome one year after percutaneous coronary intervention. <i>Medicine (United States)</i> , 2017, 96, e5469.	0.4	15

#	ARTICLE	IF	CITATIONS
5963	Homocysteine-lowering interventions for preventing cardiovascular events. The Cochrane Library, 2021, 2021, CD006612.	1.5	117
5964	Target achievement with maximal statin-based lipid-lowering therapy in Korean patients with familial hypercholesterolemia: A study supported by the Korean Society of Lipid and Atherosclerosis. Clinical Cardiology, 2017, 40, 1291-1296.	0.7	10
5965	ApoCIII as a Cardiovascular Risk Factor and Modulation by the Novel Lipid-Lowering Agent Volanesorsen. Current Atherosclerosis Reports, 2017, 19, 62.	2.0	41
5966	Lipid Management After First Diagnosis of Coronary Artery Disease: Contemporary Results From an Observational Cohort Study. Clinical Therapeutics, 2017, 39, 2311-2320.e2.	1.1	10
5967	Predictors of incident heart failure in patients after an acute coronary syndrome: The LIPID heart failure risk-prediction model. International Journal of Cardiology, 2017, 248, 361-368.	0.8	17
5968	Considerations and treatment options for patients with comorbid atrial fibrillation and diabetes mellitus. Expert Opinion on Pharmacotherapy, 2017, 18, 1101-1114.	0.9	12
5969	Inception and deprescribing of statins in people aged over 80 years: cohort study. Age and Ageing, 2017, 46, 1001-1005.	0.7	35
5970	Dyslipidemias and Cardiovascular Prevention: Tailoring Treatment According to Lipid Phenotype. Current Cardiology Reports, 2017, 19, 61.	1.3	12
5971	Acute coronary syndrome patients admitted to a cardiology vs non-cardiology service: variations in treatment & outcome. BMC Health Services Research, 2017, 17, 354.	0.9	10
5972	Effects of simvastatin on serum adiponectin: a meta-analysis of randomized controlled trials. Lipids in Health and Disease, 2017, 16, 53.	1.2	5
5973	The Effect of PCSK9 Loss-of-Function Variants on the Postprandial Lipid and ApoB-Lipoprotein Response. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3452-3460.	1.8	32
5974	Hypercholesterolaemia and vascular dementia. Clinical Science, 2017, 131, 1561-1578.	1.8	94
5975	Atherosclerosis. Advances in Experimental Medicine and Biology, 2017, 1003, 121-144.	0.8	61
5976	Comparative evaluation of a heparin-citrate anticoagulation for LDL-apheresis in two primary apheresis systems. Journal of Clinical Apheresis, 2017, 32, 319-328.	0.7	5
5977	Hepatotoxicity of statins and other lipid-lowering agents. Liver International, 2017, 37, 173-178.	1.9	108
5978	Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus. Diabetes Therapy, 2017, 8, 33-53.	1.2	14
5979	Renal Tubular Toxicity Associated With Rosuvastatin Therapy. American Journal of Kidney Diseases, 2017, 69, 473-476.	2.1	8
5980	Adverse Drug Reactions. Clinics in Liver Disease, 2017, 21, 73-87.	1.0	38

#	ARTICLE	IF	CITATIONS
5981	Plaque imaging to refine indications for emerging lipid-lowering drugs. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2017, 3, 58-67.	1.4	26
5982	No additional cholesterol-lowering effect observed in the combined treatment of red yeast rice and <i>Lactobacillus casei</i> in hyperlipidemic patients: A double-blind randomized controlled clinical trial. <i>Chinese Journal of Integrative Medicine</i> , 2017, 23, 581-588.	0.7	3
5983	Impact of Intensive LDL Cholesterol Lowering on Coronary Artery Atherosclerosis Progression. <i>JACC: Cardiovascular Imaging</i> , 2017, 10, 437-446.	2.3	73
5984	Intracoronary Imaging, Cholesterol Efflux, and Transcriptomes After Intensive Statin Treatment. <i>Journal of the American College of Cardiology</i> , 2017, 69, 628-640.	1.2	56
5985	Rationale, design features, and baseline characteristics: The Heart Institute of Japan-PROper level of lipid lowering with Pitavastatin and Ezetimibe in acute coronary syndrome (HIJ-PROPER). <i>Journal of Cardiology</i> , 2017, 69, 536-541.	0.8	9
5986	Treat-to-target lipid control is effective but highlighted poor prognosis without indication of statin following percutaneous coronary intervention. <i>Cardiovascular Intervention and Therapeutics</i> , 2017, 32, 358-364.	1.2	4
5987	Effect of statins on coronary blood flow after percutaneous coronary intervention in patients with stable coronary artery disease. <i>Netherlands Heart Journal</i> , 2017, 25, 258-263.	0.3	6
5988	Pleiotropic effects of statins on acute kidney injury: involvement of KrÄ¼ppel-like factor 4. <i>Clinical and Experimental Nephrology</i> , 2017, 21, 175-181.	0.7	9
5990	A Systematic Review of Cardiovascular Outcomes-Based Cost-Effectiveness Analyses of Lipid-Lowering Therapies. <i>Pharmacoeconomics</i> , 2017, 35, 297-318.	1.7	15
5991	Pharmacological management of diabetic dyslipidemia. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 187-200.	1.3	23
5992	Statins and the cholesterol mortality paradox. <i>Scottish Medical Journal</i> , 2017, 62, 19-23.	0.7	10
5993	The Yin-Yang Dynamics of DNA Methylation Is the Key Regulator for Smooth Muscle Cell Phenotype Switch and Vascular Remodeling. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 84-97.	1.1	70
5994	Impact of age and sex on left ventricular function determined by coronary computed tomographic angiography: results from the prospective multicentre CONFIRM study. <i>European Heart Journal Cardiovascular Imaging</i> , 2017, 18, 990-1000.	0.5	23
5995	Simvastatin attenuates renal ischemia/reperfusion injury from oxidative stress via targeting Nrf2/HOÄ¹ pathway. <i>Experimental and Therapeutic Medicine</i> , 2017, 14, 4460-4466.	0.8	20
5996	Metabolic profiles of adipose-derived and bone marrow-derived stromal cells from elderly coronary heart disease patients by capillary liquid chromatography quadrupole time-of-flight mass spectrometry. <i>International Journal of Molecular Medicine</i> , 2018, 41, 184-194.	1.8	5
5997	Frontiers of lipid research: cholesterol variability, HDL biogenesis, genetics of myalgia, and lipoprotein(a). <i>European Heart Journal</i> , 2017, 38, 3541-3544.	1.0	1
5998	Laboratory Medicine is Faced with the Evolution of Medical Practice. <i>Journal of Medical Biochemistry</i> , 2017, 36, 211-215.	0.7	28
5999	Dyslipidaemia is associated with an increased risk of rotator cuff disease: a systematic review. <i>Journal of ISAKOS</i> , 2017, 2, 241-246.	1.1	2

#	ARTICLE	IF	CITATIONS
6000	Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. <i>Lancet, The</i> , 2017, 390, 1962-1971.	6.3	487
6001	Una historia resumida. Impacto de los avances en el control lipídico. <i>Revista Espanola De Cardiologia Suplementos</i> , 2017, 17, 7-9.	0.2	0
6002	Secondary prevention of major cerebrovascular events with seven different statins: a multi-treatment meta-analysis. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 2517-2526.	2.0	14
6003	Investigating the long-term legacy of statin therapy. <i>Journal of Thoracic Disease</i> , 2017, 9, 936-939.	0.6	5
6004	Diabetes and dyslipidemia: characterizing lipoprotein metabolism. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2017, Volume 10, 333-343.	1.1	34
6005	Homogeneous Assays for LDL-C and HDL-C are Reliable in Both the Postprandial and Fasting State. <i>Journal of Atherosclerosis and Thrombosis</i> , 2017, 24, 583-599.	0.9	39
6006	Statins, Muscle Disease and Mitochondria. <i>Journal of Clinical Medicine</i> , 2017, 6, 75.	1.0	61
6007	Anti-inflammatory Nanomedicine for Cardiovascular Disease. <i>Frontiers in Cardiovascular Medicine</i> , 2017, 4, 87.	1.1	70
6008	The Therapeutic Potential of Anti-Inflammatory Exerkines in the Treatment of Atherosclerosis. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1260.	1.8	28
6009	Pattern of statin use changes following media coverage of its side effects. <i>Patient Preference and Adherence</i> , 2017, Volume 11, 1151-1157.	0.8	13
6010	Recent advances in preventing stroke recurrence. <i>F1000Research</i> , 2017, 6, 1017.	0.8	8
6011	Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy. <i>Vascular Health and Risk Management</i> , 2017, Volume 13, 29-41.	1.0	20
6012	Ventricular Arrhythmia after Acute Myocardial Infarction: ‘The Perfect Storm’. <i>Arrhythmia and Electrophysiology Review</i> , 2017, 6, 134.	1.3	81
6013	Atorvastatin reduces $\beta^2$ -Adrenergic dysfunction in rats with diabetic cardiomyopathy. <i>PLoS ONE</i> , 2017, 12, e0180103.	1.1	14
6014	Lipid lowering therapy in patients with atherosclerotic cardiovascular diseases: Which matters in the real world? Statin intensity or low-density lipoprotein cholesterol level? ‘Data from a multicenter registry cohort study in Taiwan. <i>PLoS ONE</i> , 2017, 12, e0186861.	1.1	20
6015	Impact of Lipoprotein (a) on Long-Term Outcomes in Patients with Coronary Artery Disease Treated with Statin After a First Percutaneous Coronary Intervention. <i>Journal of Atherosclerosis and Thrombosis</i> , 2017, 24, 1125-1131.	0.9	28
6016	Systematic tissue-specific functional annotation of the human genome highlights immune-related DNA elements for late-onset Alzheimer’s disease. <i>PLoS Genetics</i> , 2017, 13, e1006933.	1.5	96
6017	Risk prediction for Korean shift workers in Y power plant to prevent cardiovascular disease. <i>Toxicology and Environmental Health Sciences</i> , 2017, 9, 222-228.	1.1	0

#	ARTICLE	IF	CITATIONS
6018	Racial Differences in the Cholesterol-Lowering Effect of Statin. <i>Journal of Atherosclerosis and Thrombosis</i> , 2017, 24, 19-25.	0.9	78
6019	Lipid Lowering Therapy to Modify Plaque Microstructures:. <i>Journal of Atherosclerosis and Thrombosis</i> , 2017, 24, 360-372.	0.9	7
6020	Incremental Prognostic Value of Coronary Computed Tomography Angiography: High-Risk Plaque Characteristics in Asymptomatic Patients. <i>Journal of Atherosclerosis and Thrombosis</i> , 2017, 24, 1174-1185.	0.9	20
6021	A Method of Decision Analysis Quantifying the Effects of Age and Comorbidities on the Probability of Deriving Significant Benefit from Medical Treatments. <i>Journal of Comorbidity</i> , 2017, 7, 50-63.	3.9	2
6022	Diabetes mellitus and stroke: A clinical update. <i>World Journal of Diabetes</i> , 2017, 8, 235.	1.3	105
6023	Infusional high-density lipoproteins therapies as a novel strategy for treating atherosclerosis. <i>Archives of Medical Science</i> , 2017, 1, 210-214.	0.4	4
6024	Marketed drugs used for the management of hypercholesterolemia as anticancer armament. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 4393-4411.	1.0	9
6025	Re-Evaluation of Efficacy of Moderate-Intensity Statins in Korean Patients with Type 2 Diabetes Mellitus. <i>Diabetes and Metabolism Journal</i> , 2017, 41, 20.	1.8	2
6026	Efficacy and safety of pitavastatins in patients with acute myocardial infarction: Livalo in Acute Myocardial Infarction Study (LAMIS) II. <i>Korean Journal of Internal Medicine</i> , 2017, 32, 656-667.	0.7	5
6027	Anti-inflammatory and Antioxidant Effects of Sesame Oil on Atherosclerosis: A Descriptive Literature Review. <i>Cureus</i> , 2017, 9, e1438.	0.2	33
6028	Fasting or Non-fasting Lipids for Atherosclerotic Cardiovascular Disease Risk Assessment and Treatment?. <i>Current Atherosclerosis Reports</i> , 2018, 20, 14.	2.0	11
6029	PCSK9 inhibitor valuation: A science-based review of the two recent models. <i>Clinical Cardiology</i> , 2018, 41, 544-550.	0.7	7
6030	Statin use is associated with carotid plaque composition: The Rotterdam Study. <i>International Journal of Cardiology</i> , 2018, 260, 213-218.	0.8	35
6031	Diminished bile acids excretion is a risk factor for coronary artery disease: 20-year follow up and long-term outcome. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 1756283X1774342.	1.4	39
6032	The Role of PCSK9 Inhibitors in the Treatment of Hypercholesterolemia. <i>Annals of Pharmacotherapy</i> , 2018, 52, 1000-1018.	0.9	21
6033	Evaluation of the cost-effectiveness of evolocumab in the FOURIER study: a Canadian analysis. <i>CMAJ Open</i> , 2018, 6, E162-E167.	1.1	7
6034	Low-density lipoprotein cholesterol and risk of type 2 diabetes: The Isfahan diabetes prevention study. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2018, 12, 715-719.	1.8	11
6035	Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 1566.	3.8	339

#	ARTICLE	IF	CITATIONS
6036	Why all randomised controlled trials produce biased results. <i>Annals of Medicine</i> , 2018, 50, 312-322.	1.5	89
6037	Lipids and lipid lowering: current management with statins and PCSK9 inhibitors. <i>European Heart Journal</i> , 2018, 39, 1117-1120.	1.0	0
6038	Lower Limb Claudication Due to Iliac Artery Occlusive Disease. , 2018, , 201-213.		0
6039	Varied origins of promising hypotheses in cardiovascular medicine. <i>European Heart Journal Supplements</i> , 2018, 20, C8-C10.	0.0	0
6040	Temporal changes in statin prescription and intensity at discharge and impact on outcomes in patients with newly diagnosed atherosclerotic cardiovascular disease—Real-world experience within a large integrated health care system: The IMPRES study. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1008-1018.e1.	0.6	8
6041	Documented coronary atherothrombosis as the cause of death in post-discharge patients after coronary revascularization. <i>Cardiovascular Revascularization Medicine</i> , 2018, 19, 597-606.	0.3	0
6042	Clinical and pathophysiological evidence supporting the safety of extremely low LDL levels—the zero-LDL hypothesis. <i>Journal of Clinical Lipidology</i> , 2018, 12, 292-299.e3.	0.6	51
6043	The pharmacodynamic and clinical trial evidence for statin dose. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1128-1135.	1.1	17
6044	Postoperative Myocardial Injury and Inflammation Is Not Blunted by a Trial of Atorvastatin in Orthopedic Surgery Patients. <i>HSS Journal</i> , 2018, 14, 67-76.	0.7	4
6045	Recent Developments in Sex-Related Differences in Presentation, Prognosis, and Management of Coronary Artery Disease. <i>Canadian Journal of Cardiology</i> , 2018, 34, 390-399.	0.8	28
6046	Perioperative Management of Cardiovascular Medications. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2018, 32, 2289-2302.	0.6	6
6047	Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other) Trial. <i>Journal of the American Heart Association</i> , 2018, 7, e011414.	1.6	51
6048	Lipid Testing and Statin Dosing After Acute Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	22
6049	Lipid-lowering therapy use and achievement of cholesterol targets in an Australian diabetes clinic. <i>Internal Medicine Journal</i> , 2018, 48, 201-204.	0.5	1
6050	Statin use and the risk of cardiovascular implantable electronic device infection: A cohort study in a veteran population. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2018, 41, 284-289.	0.5	7
6051	Diet for stroke prevention. <i>Stroke and Vascular Neurology</i> , 2018, 3, 44-50.	1.5	42
6052	Implementation of smart technology to improve medication adherence in patients with cardiovascular disease: is it effective?. <i>Expert Review of Medical Devices</i> , 2018, 15, 119-126.	1.4	30
6053	Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2018, 12, 390-396.e8.	0.6	51



#	ARTICLE	IF	CITATIONS
6054	Electronic medical records can be used to emulate target trials of sustained treatment strategies. <i>Journal of Clinical Epidemiology</i> , 2018, 96, 12-22.	2.4	72
6055	Ensayo in vitro de la asociaci3n de simvastatina y fluconazol en cultivos de criptococos de pacientes con meningoencefalitis criptoc3tica que concurren al hospital ngel Padilla de San Miguel de Tucumn. <i>Neurologa Argentina</i> , 2018, 10, 2-7.	0.1	2
6057	Creation of disease-inspired biomaterial environments to mimic pathological events in early calcific aortic valve disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E363-E371.	3.3	36
6058	Se debera intensificar el tratamiento hipolipemiente tras la implantaci3n de un stent farmacoactivo?. <i>Revista Espanola De Cardiologia</i> , 2018, 71, 416-417.	0.6	2
6059	Precision medicine for cardiovascular disease. <i>Herz</i> , 2018, 43, 123-130.	0.4	10
6060	Central and Brachial Blood Pressures, Statins, and Low-Density Lipoprotein Cholesterol. <i>Hypertension</i> , 2018, 71, 415-421.	1.3	13
6061	Could Ceramides Become the New Cholesterol?. <i>Cell Metabolism</i> , 2018, 27, 276-280.	7.2	126
6062	Residual cardiovascular risk in individuals on lipid-lowering treatment: quantifying absolute and relative risk in the community. <i>Open Heart</i> , 2018, 5, e000722.	0.9	27
6063	Isoprenoids and protein prenylation: implications in the pathogenesis and therapeutic intervention of Alzheimers disease. <i>Critical Reviews in Biochemistry and Molecular Biology</i> , 2018, 53, 279-310.	2.3	95
6064	Variations in time to benefit among clinical trials of cholesterol-lowering drugs. <i>Journal of Clinical Lipidology</i> , 2018, 12, 857-862.	0.6	21
6065	Impact of the triglyceride level on coronary plaque components in female patients with coronary artery disease treated with statins. <i>Heart and Vessels</i> , 2018, 33, 1175-1184.	0.5	5
6066	A novel and simply calculated nutritional index serves as a useful prognostic indicator in patients with coronary artery disease. <i>International Journal of Cardiology</i> , 2018, 262, 92-98.	0.8	31
6067	High-Intensity Statin Therapy Is Too Much, Thus Not Indicated for Very Elderly Patients. <i>Pulse</i> , 2018, 6, 19-31.	0.9	3
6069	Lipids and Lipoproteins in Risk Prediction. <i>Cardiology Clinics</i> , 2018, 36, 213-220.	0.9	7
6070	Optimizing Statins and Ezetimibe in Guideline-Focused Management. <i>Cardiology Clinics</i> , 2018, 36, 221-223.	0.9	3
6071	Statin use and mortality in gout: A general population-based cohort study. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 449-455.	1.6	11
6072	Management of Left Main Coronary Artery Disease. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	57
6073	Is exercise-based cardiac rehabilitation effective? A systematic review and meta-analysis to re-examine the evidence. <i>BMJ Open</i> , 2018, 8, e019656.	0.8	71

#	ARTICLE	IF	CITATIONS
6074	Temporal Trends of High-Intensity Statin Therapy Among Veterans Treated With Percutaneous Coronary Intervention. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	9
6075	Prognostic Impact of Statin Intensity in Heart Failure Patients With Ischemic Heart Disease: A Report From the CHART-2 (Chronic Heart Failure Registry and Analysis in the Tohoku District 2) Study. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	12
6076	Partners and Alerts in Medication Adherence: A Randomized Clinical Trial. <i>Journal of General Internal Medicine</i> , 2018, 33, 1536-1542.	1.3	19
6077	Analytical Methods for the Determination of Rosuvastatin in Pharmaceutical Formulations and Biological Fluids: A Critical Review. <i>Critical Reviews in Analytical Chemistry</i> , 2018, 48, 317-329.	1.8	14
6078	A consensus statement on lipid management after acute coronary syndrome. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2018, 7, 532-543.	0.4	27
6080	Ten-year standardization of lipids and high-sensitivity C-reactive protein in a randomized controlled trial to assess the effects of statins on secondary stroke prevention: Japan Statin Treatment Against Recurrent Stroke. <i>Annals of Clinical Biochemistry</i> , 2018, 55, 128-135.	0.8	5
6081	2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. <i>European Heart Journal</i> , 2018, 39, 1131-1143.	1.0	171
6082	Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials. <i>European Heart Journal</i> , 2018, 39, 1172-1180.	1.0	150
6083	Hyaluronan synthase 3 promotes plaque inflammation and atheroprotection. <i>Matrix Biology</i> , 2018, 66, 67-80.	1.5	30
6084	Rosuvastatin pretreatment suppresses distant organ injury following unilateral renal ischemia-reperfusion in hypertensive Dahl salt-sensitive rats. <i>Nephrology</i> , 2018, 23, 1046-1054.	0.7	4
6085	Co-expression analysis reveals key gene modules and pathway of human coronary heart disease. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 2102-2109.	1.2	29
6086	Current drugs, targets, and drug delivery systems for the treatment of dyslipidemia. <i>Journal of Pharmaceutical Investigation</i> , 2018, 48, 233-241.	2.7	3
6087	Impact of nonfasting triglycerides/high-density lipoprotein cholesterol ratio on secondary prevention in patients treated with statins. <i>Journal of Cardiology</i> , 2018, 71, 10-15.	0.8	8
6088	Serum lipid and bone metabolism effects of Toremifene vs. Letrozole as adjuvant therapy for postmenopausal early breast cancer patients: results of a multicenter open randomized study. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 269-275.	1.1	10
6089	Should We Up the Intensity of Statin Therapy After Placing a Drug-eluting Stent?. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2018, 71, 416-417.	0.4	0
6090	Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease. <i>Circulation</i> , 2018, 137, 338-350.	1.6	559
6091	American Association of Clinical Endocrinologists/American College of Endocrinology Management of Dyslipidemia and Prevention of Cardiovascular Disease Clinical Practice Guidelines. <i>Diabetes Spectrum</i> , 2018, 31, 234-245.	0.4	34
6092	Impact of a hospital-based educational intervention on dietary salt-related knowledge and behaviour in a cardiac care unit population in Lebanon. <i>Cardiovascular Diagnosis and Therapy</i> , 2018, 8, 146-155.	0.7	3

#	ARTICLE	IF	CITATIONS
6093	Reduction of Vascular Inflammation, LDL-C, or Both for the Protection from Cardiovascular Events?. Open Cardiovascular Medicine Journal, 2018, 12, 29-40.	0.6	19
6094	Simvastatin exerts anticancer effects in osteosarcoma cell lines via geranylgeranylation and c-Jun activation. International Journal of Oncology, 2018, 52, 1285-1294.	1.4	21
6095	Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. The Cochrane Library, 2018, 11, CD003177.	1.5	129
6096	OBSOLETE: Lipids and Cardiovascular Diseases: Epidemiologic Perspectives. , 2018, , .		0
6097	Time trends in statin use and incidence of recurrent cardiovascular events in secondary prevention between 1999 and 2013: a registry-based study. BMC Cardiovascular Disorders, 2018, 18, 209.	0.7	17
6098	Simvastatin Protects Heart from Pressure Overload Injury by Inhibiting Excessive Autophagy. International Journal of Medical Sciences, 2018, 15, 1508-1516.	1.1	17
6100	Advances in Stroke Prevention. Journal of Translational Internal Medicine, 2018, 6, 105-114.	1.0	15
6101	Moderate-intensity versus high-intensity statin therapy in Korean patients with angina undergoing percutaneous coronary intervention with drug-eluting stents: A propensity-score matching analysis. PLoS ONE, 2018, 13, e0207889.	1.1	9
6102	The Complex Interplay between Lipids, Immune System and Interleukins in Cardio-Metabolic Diseases. International Journal of Molecular Sciences, 2018, 19, 4058.	1.8	46
6104	Effects of Ramelteon and Other Sleep-Promoting Drugs on Serum Low-Density Lipoprotein and Non-high-density Lipoprotein Cholesterol: A Retrospective Comparative Pilot Study. Biological and Pharmaceutical Bulletin, 2018, 41, 1778-1790.	0.6	3
6105	Usefulness of baseline statin therapy in non-obstructive coronary artery disease by coronary computed tomographic angiography: From the CONFIRM (COronary CT Angiography Evaluation For) Tj ETQq0 0 0 rgt /Overlck 10 Tff		
6106	Anti-inflammatory Effects of a Vegan Diet Versus the American Heart Association's Recommended Diet in Coronary Artery Disease Trial. Journal of the American Heart Association, 2018, 7, e011367.	1.6	110
6107	Current concepts in atherosclerosis. Indian Journal of Thoracic and Cardiovascular Surgery, 2018, 34, 198-205.	0.2	4
6108	Discovery of a potent HMG-CoA reductase degrader that eliminates statin-induced reductase accumulation and lowers cholesterol. Nature Communications, 2018, 9, 5138.	5.8	112
6109	Statins and Cardiovascular Disease Outcomes in Chronic Kidney Disease: Reaffirmation vs. Repudiation. International Journal of Environmental Research and Public Health, 2018, 15, 2733.	1.2	14
6110	Hitting Hard and Early: A Novel Paradigm for Lipid Lowering in Primary Prevention. Cardiology, 2018, 140, 68-70.	0.6	0
6111	Legacy effects of statins on cardiovascular and all-cause mortality: a meta-analysis. BMJ Open, 2018, 8, e020584.	0.8	28
6112	Lipids and Cardiovascular Diseases: Epidemiologic Perspectives. , 2018, , 221-229.		0

#	ARTICLE	IF	CITATIONS
6113	Statin-Associated Muscle Disease: Advances in Diagnosis and Management. <i>Neurotherapeutics</i> , 2018, 15, 1006-1017.	2.1	60
6114	Consumption of regular-fat vs reduced-fat cheese reveals gender-specific changes in LDL particle size - a randomized controlled trial. <i>Nutrition and Metabolism</i> , 2018, 15, 61.	1.3	11
6115	Comparative Effectiveness of Combination Therapy with Statins and Angiotensinâ€Converting Enzyme Inhibitors versus Angiotensin <sc>II</sc> Receptor Blockers in Patients with Coronary Heart Disease: A Nationwide Populationâ€Based Cohort Study in Korea. <i>Pharmacotherapy</i> , 2018, 38, 1095-1105.	1.2	6
6116	Effects of medication, treatment, and behavioral beliefs on intentions to take medication in patients with familial hypercholesterolemia. <i>Atherosclerosis</i> , 2018, 277, 493-501.	0.4	18
6117	Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. <i>Lancet, The</i> , 2018, 392, 1311-1320.	6.3	355
6118	Long-term Survival Benefit of Statin in Patients with Coronary Chronic Total Occlusion without Revascularization. <i>Journal of Korean Medical Science</i> , 2018, 33, e134.	1.1	1
6119	Compliance With Dyslipidemia Guidelines in Daily Practice: How Effective Is Cardiovascular Risk Prevention?. <i>Clinical Therapeutics</i> , 2018, 40, 2031-2040.	1.1	0
6120	Managing Clinical Heterogeneity: An Argument for Benefit-Based Action Limits. <i>Journal of Engineering and Science in Medical Diagnostics and Therapy</i> , 2018, 1, .	0.3	4
6121	Safety assessment of concurrent statin treatment and evaluation of drug interactions in China. <i>SAGE Open Medicine</i> , 2018, 6, 205031211879827.	0.7	3
6122	Lipid management in patients with chronic kidney disease. <i>Nature Reviews Nephrology</i> , 2018, 14, 727-749.	4.1	153
6123	Peridinin Is an Exceptionally Potent and Membrane-Embedded Inhibitor of Bilayer Lipid Peroxidation. <i>Journal of the American Chemical Society</i> , 2018, 140, 15227-15240.	6.6	19
6124	Safety and efficacy of statin therapy. <i>Nature Reviews Cardiology</i> , 2018, 15, 757-769.	6.1	239
6125	Statins Reduce Abdominal Aortic Aneurysm Growth, Rupture, and Perioperative Mortality: A Systematic Review and Metaâ€Analysis. <i>Journal of the American Heart Association</i> , 2018, 7, e008657.	1.6	87
6126	Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017. <i>Journal of Atherosclerosis and Thrombosis</i> , 2018, 25, 846-984.	0.9	541
6127	LDL-C does not cause cardiovascular disease: a comprehensive review of the current literature. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 959-970.	1.3	88
6128	Biologic bases of residual risk of cardiovascular events: A flawed concept. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 1831-1835.	0.8	8
6129	Optimising treatment of hyperlipidaemia: Quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease risk. <i>Atherosclerosis</i> , 2018, 278, 135-142.	0.4	20
6130	Associations between very low concentrations of low density lipoprotein cholesterol, high sensitivity C-reactive protein, and health outcomes in the Reasons for Geographical and Racial Differences in Stroke (REGARDS) study. <i>European Heart Journal</i> , 2018, 39, 3641-3653.	1.0	69

#	ARTICLE	IF	CITATIONS
6131	Simvastatin Suppresses Interleukin $\text{IL}^2$ Release in Human Peripheral Blood Mononuclear Cells Stimulated With Cholesterol Crystals. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2018, 23, 509-517.	1.0	19
6132	Low-Density Lipoprotein Cholesterol Goal Attainment Rates by Initial Statin Monotherapy Among Patients With Dyslipidemia and High Cardiovascular Risk in Japan—A Retrospective Database Analysis. <i>Circulation Journal</i> , 2018, 82, 1605-1613.	0.7	10
6133	The Association of Statin Therapy with Incident Diabetes: Evidence, Mechanisms, and Recommendations. <i>Current Cardiology Reports</i> , 2018, 20, 50.	1.3	22
6134	Vascular access in lipoprotein apheresis: a retrospective analysis from the UK's largest lipoprotein apheresis centre. <i>Journal of Vascular Access</i> , 2018, 19, 52-57.	0.5	6
6135	Lipids, Apolipoproteins, and Inflammatory Biomarkers of Cardiovascular Risk: What Have We Learned?. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 244-256.	2.3	14
6137	Have we reached the bottom of the bottomless pit- lessons from the recent lipid-lowering trials?. <i>Indian Heart Journal</i> , 2018, 70, 331-334.	0.2	0
6138	Long-term effect of statins on the risk of new-onset osteoporosis: A nationwide population-based cohort study. <i>PLoS ONE</i> , 2018, 13, e0196713.	1.1	34
6139	Beneficial effect of statins in patients receiving chronic hemodialysis following percutaneous coronary intervention: A nationwide retrospective cohort study. <i>Scientific Reports</i> , 2018, 8, 9692.	1.6	11
6140	Incidence and determinants of cerebrovascular events in outpatients with stable coronary artery disease. <i>European Stroke Journal</i> , 2018, 3, 272-280.	2.7	7
6141	Anti-Inflammatory Treatment. , 2018, , 237-271.		0
6142	Effect of statin use on oncologic outcomes in head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2018, 40, 1697-1706.	0.9	32
6143	Epidemiology of Atherosclerotic Cardiovascular Disease. , 2018, , 248-257.		1
6144	Recent Advances in Primary and Secondary Prevention of Atherosclerotic Stroke. <i>Journal of Stroke</i> , 2018, 20, 145-166.	1.4	39
6145	Is Management of Central Retinal Artery Occlusion the Next Frontier in Cerebrovascular Diseases?. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2018, 27, 2781-2791.	0.7	17
6146	Quality of health economic evaluations for the ACC/AHA stable ischemic heart disease practice guideline: A systematic review. <i>American Heart Journal</i> , 2018, 204, 17-33.	1.2	7
6147	Pyrrole: An insight into recent pharmacological advances with structure activity relationship. <i>European Journal of Medicinal Chemistry</i> , 2018, 157, 527-561.	2.6	153
6148	The association of sex hormone-binding globulin with mortality is mediated by age and testosterone in men with type 2 diabetes. <i>Andrology</i> , 2018, 6, 846-853.	1.9	10
6149	Awareness of Pleiotropic and Cardioprotective Effect of Statins in Patients with Coronary Artery Disease. <i>BioMed Research International</i> , 2018, 2018, 1-7.	0.9	6

#	ARTICLE	IF	CITATIONS
6150	Lowering Low-Density Lipoprotein Particles in Plasma Using Dextran Sulphate Co-Precipitates Procoagulant Extracellular Vesicles. <i>International Journal of Molecular Sciences</i> , 2018, 19, 94.	1.8	23
6151	Molecular Pathways Underlying Cholesterol Homeostasis. <i>Nutrients</i> , 2018, 10, 760.	1.7	97
6152	Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. <i>The Cochrane Library</i> , 2018, 7, CD003177.	1.5	244
6153	Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease. <i>The Cochrane Library</i> , 2018, 7, CD012345.	1.5	83
6154	Cardiovascular Risk Assessment in Patients with Hypertriglyceridemia. <i>Current Cardiology Reports</i> , 2018, 20, 71.	1.3	0
6155	Clinical Lipidology and the Prevention of Vascular Disease: Time for Personalized Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 269-281.	2.3	5
6156	SGLT2 Inhibitors and Cardiovascular Outcomes: Current Perspectives and Future Potentials. <i>Current Diabetes Reports</i> , 2018, 18, 63.	1.7	12
6157	Ongoing activities to optimize the quality and efficiency of lipid-lowering agents in the Scottish national health service: influence and implications. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2018, 18, 655-666.	0.7	32
6158	High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD). <i>Circulation</i> , 2018, 137, 1997-2009.	1.6	174
6159	Therapeutic Agents Targeting Cardiometabolic Risk for Preventing and Treating Atherosclerotic Cardiovascular Diseases. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 257-268.	2.3	12
6160	Sex disparity in the management and outcomes of dyslipidemia of diabetic patients in the Arabian Gulf: findings from the CEPHEUS study. <i>Lipids in Health and Disease</i> , 2018, 17, 25.	1.2	9
6161	Rationale and Design of Randomized Evaluation of Aggressive or Moderate Lipid Lowering Therapy with Pitavastatin in Coronary Artery Disease (REAL-CAD) Trial. <i>International Heart Journal</i> , 2018, 59, 315-320.	0.5	11
6162	Vaccines Targeting PCSK9: A Promising Alternative to Passive Immunization with Monoclonal Antibodies in the Management of Hyperlipidaemia?. <i>Drugs</i> , 2018, 78, 799-808.	4.9	15
6163	Lipid Target in Very High-Risk Cardiovascular Patients: Lesson from PCSK9 Monoclonal Antibodies. <i>Diseases (Basel, Switzerland)</i> , 2018, 6, 22.	1.0	10
6164	Reasons for disparity in statin adherence rates between clinical trials and real-world observations: a review. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 230-236.	1.4	39
6165	Lowering <sc>LDL</sc>â€Cholesterol and <sc>CV</sc> Benefits: Is There a Limit to How Low <sc>LDL</sc>â€C Needs to be for Optimal Health Benefits?. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 290-296.	2.3	6
6166	Effects of Statins on CoronaryâAtherosclerotic Plaques. <i>JACC: Cardiovascular Imaging</i> , 2018, 11, 1475-1484.	2.3	335
6167	Association of <i>LPA</i> Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies. <i>JAMA Cardiology</i> , 2018, 3, 619.	3.0	428

#	ARTICLE	IF	CITATIONS
6168	Response of Lipids and Lipoproteins to Regular Aquatic Endurance Exercise: A Meta-Analysis of Randomized Controlled Trials. <i>Journal of Atherosclerosis and Thrombosis</i> , 2019, 26, 14-30.	0.9	18
6169	Using Genetic Variants in the Targets of Lipid Lowering Therapies to Inform Drug Discovery and Development: Current and Future Treatment Options. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 568-581.	2.3	6
6170	Effects of Statin Treatment on Outcomes after Traumatic Brain Injury. <i>Journal of Neurotrauma</i> , 2019, 36, 118-125.	1.7	9
6171	Different Effects of Atorvastatin on Cardiometabolic Risk Factors in Young Women With and Without Hyperprolactinemia. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 83-89.	1.0	13
6172	Comparison of short-term clinical outcomes of proximal versus nonproximal lesion location in patients treated with primary percutaneous coronary intervention for ST-elevation myocardial infarction: The PROXIMITI study. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 32-40.	0.7	9
6173	Clinical characteristics and biomarkers of coronary microvascular dysfunction and obstructive coronary artery disease. <i>Journal of International Medical Research</i> , 2019, 47, 6149-6159.	0.4	4
6174	Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: current and future options. <i>Lancet, The</i> , 2019, 394, 697-708.	6.3	67
6175	Medications Affecting the Biochemical Conversion to Type 2 Diabetes: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 3986-3995.	1.8	3
6176	Optimizing Dyslipidemia Management for the Prevention of Cardiovascular Disease: a Focus on Risk Assessment and Therapeutic Options. <i>Current Cardiology Reports</i> , 2019, 21, 110.	1.3	24
6177	Modified and Dysfunctional Lipoproteins in Atherosclerosis: Effectors or Biomarkers?. <i>Current Medicinal Chemistry</i> , 2019, 26, 1512-1524.	1.2	17
6178	SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 2965.	1.2	153
6179	Anti-inflammatory effect of statin is continuously working throughout use: a prospective three time point 18F-FDG PET/CT imaging study. <i>International Journal of Cardiovascular Imaging</i> , 2019, 35, 1745-1753.	0.7	8
6180	Powerful three-sample genome-wide design and robust statistical inference in summary-data Mendelian randomization. <i>International Journal of Epidemiology</i> , 2019, 48, 1478-1492.	0.9	121
6181	Impact of Lipid-Lowering Therapy on Mortality According to the Baseline Non-HDL Cholesterol Level: A Meta-Analysis. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2019, 26, 263-272.	1.0	7
6182	Economic evaluation of lipid lowering with PCSK9 inhibitors in patients with familial hypercholesterolemia: Methodological aspects. <i>Atherosclerosis</i> , 2019, 287, 140-146.	0.4	9
6183	Secular Trends in Lipid Profiles in Korean Adults Based on the 2005-2015 KNHANES. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 2555.	1.2	14
6184	PCSK9 inhibitors: what we know, what we should have understood, and what is to come. <i>European Heart Journal</i> , 2022, 43, e29-e31.	1.0	6
6185	Statins in the Prevention and Treatment of Heart Failure: a Review of the Evidence. <i>Current Atherosclerosis Reports</i> , 2019, 21, 41.	2.0	53

#	ARTICLE	IF	CITATIONS
6186	Low-Density Lipoprotein Cholesterol After an Acute Coronary Syndrome: How Low to Go?. <i>Current Cardiology Reports</i> , 2019, 21, 77.	1.3	6
6187	Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials. <i>European Heart Journal</i> , 2022, 43, e17-e25.	1.0	92
6188	NLRP3 inflammasome expression in peripheral blood monocytes of coronary heart disease patients and its modulation by rosuvastatin. <i>Molecular Medicine Reports</i> , 2019, 20, 1826-1836.	1.1	19
6189	Preventive Cardiology as a Subspecialty of Cardiovascular Medicine. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1926-1942.	1.2	39
6190	Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor $\alpha$ Modulator (SPPARM $\alpha$ ): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5537.	1.8	27
6191	Popular Media and Cardiovascular Medicine: "with Great Power There Must Also Come Great Responsibility". <i>Current Atherosclerosis Reports</i> , 2019, 21, 43.	2.0	7
6192	The effect of guideline revisions on vascular complications of type 2 diabetes. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2019, 10, 204201881987540.	1.4	4
6193	IL-1 $\beta$ and Statin Treatment in Patients with Myocardial Infarction and Diabetic Cardiomyopathy. <i>Journal of Clinical Medicine</i> , 2019, 8, 1764.	1.0	21
6194	Highlighting Residual Atherosclerotic Cardiovascular Disease Risk. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, e1-e9.	1.1	45
6195	Statins for Secondary Prevention in the Elderly. <i>Cardiology</i> , 2019, 143, 32-33.	0.6	1
6196	Efficiency and problems of statin therapy in patients with heterozygous familial hypercholesterolemia. <i>Atherosclerosis Supplements</i> , 2019, 40, 79-87.	1.2	7
6197	From Early Pharmacology to Recent Pharmacology Interventions in Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1618-1636.	1.2	33
6198	Cholesterol versus Inflammation as Cause of Chronic Diseases. <i>Nutrients</i> , 2019, 11, 2332.	1.7	18
6199	Metabolic and Vascular Effect of the Mediterranean Diet. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4716.	1.8	144
6200	A cross-sectional survey of coronary plaque composition in individuals on non-statin lipid lowering drug therapies and undergoing coronary computed tomography angiography. <i>Journal of Cardiovascular Computed Tomography</i> , 2019, 13, 99-104.	0.7	2
6201	Diagnosis and Management of Statin Intolerance. <i>Journal of Atherosclerosis and Thrombosis</i> , 2019, 26, 207-215.	0.9	62
6202	Peach Kernel Oil Downregulates Expression of Tissue Factor and Reduces Atherosclerosis in ApoE knockout Mice. <i>International Journal of Molecular Sciences</i> , 2019, 20, 405.	1.8	11
6203	Effect of Statin Therapy on Fibrous Cap Thickness in Coronary Plaque on Optical Coherence Tomography—Review and Meta-Analysis. <i>Circulation Journal</i> , 2019, 83, 1480-1488.	0.7	22



#	ARTICLE	IF	CITATIONS
6204	Effects of Non-statin Lipid-Modifying Agents on Cardiovascular Morbidity and Mortality Among Statin-Treated Patients: A Systematic Review and Network Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2019, 10, 547.	1.6	14
6205	Emerging Role of Coronary Computed Tomography Angiography in Lipid-Lowering Therapy: a Bridge to Image-Guided Personalized Medicine. <i>Current Cardiology Reports</i> , 2019, 21, 72.	1.3	4
6206	Statins exacerbate glucose intolerance and hyperglycemia in a high sucrose fed rodent model. <i>Scientific Reports</i> , 2019, 9, 8825.	1.6	16
6207	Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 2414.	3.8	602
6208	The Habit Formation trial of behavioral economic interventions to improve statin use and reduce the risk of cardiovascular disease: Rationale, design and methodologies. <i>Clinical Trials</i> , 2019, 16, 399-409.	0.7	8
6209	Evidence for changing lipid management strategy to focus on non-high density lipoprotein cholesterol. <i>Lipids in Health and Disease</i> , 2019, 18, 134.	1.2	40
6210	ST-segment elevation myocardial infarction. <i>Nature Reviews Disease Primers</i> , 2019, 5, 39.	18.1	179
6211	Modeling the cost effectiveness and budgetary impact of Polypills for secondary prevention of cardiovascular disease in the United States. <i>American Heart Journal</i> , 2019, 214, 77-87.	1.2	26
6212	Statin therapy is associated with improved survival in patients with ventricular tachyarrhythmias. <i>Lipids in Health and Disease</i> , 2019, 18, 119.	1.2	6
6213	Effect of Statin on Cancer Incidence: An Umbrella Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2019, 8, 819.	1.0	29
6214	Medical Therapy for Heart Failure Caused by Ischemic Heart Disease. <i>Circulation Research</i> , 2019, 124, 1520-1535.	2.0	115
6215	Patients With Chronic Liver Disease/Cirrhosis Should Not Take Statin Medications. <i>Clinical Liver Disease</i> , 2019, 13, 106-110.	1.0	11
6216	Biodegradable polymerized simvastatin stimulates bone formation. <i>Acta Biomaterialia</i> , 2019, 93, 192-199.	4.1	24
6217	Residual cardiovascular risk of lipid origin. Components and pathophysiological aspects. <i>Clínica E Investigaci3n En Arteriosclerosis (English Edition)</i> , 2019, 31, 75-88.	0.1	6
6218	Independent role of low-density lipoprotein cholesterol in subclinical coronary atherosclerosis in the absence of traditional cardiovascular risk factors. <i>European Heart Journal Cardiovascular Imaging</i> , 2019, 20, 866-872.	0.5	22
6219	Efficacy and Safety of Ezetimibe in Combination with Atorvastatin for Acute Coronary Syndrome Patients Accompanied with Type 2 Diabetes: A Single-Center, Non-randomized Cohort Study. <i>Chemical and Pharmaceutical Bulletin</i> , 2019, 67, 419-425.	0.6	4
6220	Postponement of Death by Statin Use: a Systematic Review and Meta-analysis of Randomized Clinical Trials. <i>Journal of General Internal Medicine</i> , 2019, 34, 1607-1614.	1.3	10
6221	Dyslipidemia Profiles in Patients with Peripheral Artery Disease. <i>Current Cardiology Reports</i> , 2019, 21, 42.	1.3	30

#	ARTICLE	IF	CITATIONS
6222	The extent to which statins have improved cardiovascular outcomes: Lessons from randomized trials and observational studies of "real world" practice in people with diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 17-27.	2.2	8
6223	Evidence and mechanisms for statin-induced cognitive decline. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 397-406.	1.3	13
6224	Patterns of statin utilisation for new users and market dynamics in South Korea: a 13-year retrospective cohort study. <i>BMJ Open</i> , 2019, 9, e026603.	0.8	15
6225	A strategy for screening bioactive components from natural products based on two-dimensional cell membrane chromatography and component-knockout approach. <i>Journal of Chromatography A</i> , 2019, 1601, 171-177.	1.8	15
6226	Nutrition and Risk of Stroke. <i>Nutrients</i> , 2019, 11, 647.	1.7	69
6227	Association of Lowering Low-Density Lipoprotein Cholesterol With Contemporary Lipid-Lowering Therapies and Risk of Diabetes Mellitus: A Systematic Review and Meta-Analysis. <i>Journal of the American Heart Association</i> , 2019, 8, e011581.	1.6	46
6228	Screening for High Lipoprotein(a). <i>Circulation</i> , 2019, 139, 1493-1496.	1.6	24
6229	Apolipoprotein profiling as a personalized approach to the diagnosis and treatment of dyslipidaemia. <i>Annals of Clinical Biochemistry</i> , 2019, 56, 338-356.	0.8	27
6230	Statins: Rationale, Mode of Action, and Side Effects. , 2019, , 171-200.		6
6231	Statins for the Primary Prevention of Coronary Heart Disease. <i>BioMed Research International</i> , 2019, 2019, 1-15.	0.9	19
6232	Atherogenic index of plasma is related to arterial stiffness but not to blood pressure in normotensive and never-treated hypertensive subjects. <i>Blood Pressure</i> , 2019, 28, 157-167.	0.7	29
6233	The Role of Statins in the Management of Heart Failure with Preserved Ejection Fraction. <i>Current Pharmacology Reports</i> , 2019, 5, 210-213.	1.5	0
6234	Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 1520-1574.	1.8	305
6235	Trials in "True" Dyslipidemic Patients Are Urged to Reconsider Comprehensive Lipid Management as a Means to Reduce Residual Cardiovascular Risk. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 960-967.	2.3	2
6236	Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkers. <i>American Heart Journal</i> , 2019, 212, 1-12.	1.2	43
6237	Serum Anti-Apo B Antibody Level as Residual CVD Marker in DM Patients under Statin Treatment. <i>Journal of Atherosclerosis and Thrombosis</i> , 2019, 26, 931-943.	0.9	3
6238	Elevated Serum Non-HDL (High-Density Lipoprotein) Cholesterol and Triglyceride Levels as Residual Risks for Myocardial Infarction Recurrence Under Statin Treatment. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 934-944.	1.1	25
6239	Antiplatelet Drugs in the Management of Cerebral Ischemia. , 2019, , 1031-1057.		0

#	ARTICLE	IF	CITATIONS
6240	Lipid Disorders and Familial Hypercholesterolaemia. , 2019, , 1101-1120.		1
6241	Antioxidant and Anti-Diabetic Activities of Polysaccharides from Guava Leaves. <i>Molecules</i> , 2019, 24, 1343.	1.7	63
6242	Impact of Lipoprotein (a) Levels on Long-Term Outcomes in Patients With Coronary Artery Disease and Left Ventricular Systolic Dysfunction. <i>Circulation Journal</i> , 2019, 83, 1047-1053.	0.7	11
6243	A review on coronary artery disease, its risk factors, and therapeutics. <i>Journal of Cellular Physiology</i> , 2019, 234, 16812-16823.	2.0	521
6244	Differential association between the progression of coronary artery calcium score and coronary plaque volume progression according to statins: the Progression of Atherosclerotic Plaque Determined by Computed Tomographic Angiography Imaging (PARADIGM) study. <i>European Heart Journal Cardiovascular Imaging</i> , 2019, 20, 1307-1314.	0.5	60
6246	Nonalcoholic Fatty Liver Disease and the Heart. <i>Journal of the American College of Cardiology</i> , 2019, 73, 948-963.	1.2	259
6247	The importance of cholesterol follow-up testing under current statin treatment guidelines. <i>Preventive Medicine</i> , 2019, 121, 150-157.	1.6	6
6248	Current pharmacotherapies for atherosclerotic cardiovascular diseases. <i>Archives of Pharmacal Research</i> , 2019, 42, 206-223.	2.7	10
6249	Trastuzumab Induced Chemobrain, Atorvastatin Rescued Chemobrain with Enhanced Anticancer Effect and without Hair Loss-Side Effect. <i>Journal of Clinical Medicine</i> , 2019, 8, 234.	1.0	14
6250	The Standard of Care in Type 2 Diabetes: Re-evaluating the Treatment Paradigm. <i>Diabetes Therapy</i> , 2019, 10, 1-13.	1.2	15
6251	Plasma LDL-Cholesterol Level at Admission is Independently Associated with Infarct Size in Patients with ST-Segment Elevation Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention. <i>Cardiology and Therapy</i> , 2019, 8, 55-67.	1.1	5
6252	Dyslipidemia in Special Populations, the Elderly, Women, HIV, Chronic Kidney Disease and ESRD, and Minority Groups. , 0, , .		6
6254	Investigating the cost-effectiveness of structured diabetes education. <i>British Journal of Health Care Management</i> , 2019, 25, 1-15.	0.1	1
6255	Chili Pepper Consumption and Cardiovascular Mortality. <i>Journal of the American College of Cardiology</i> , 2019, 74, 3150-3152.	1.2	11
6256	Cardiovascular Disease in Renal Transplantation. , 2019, , 496-516.		0
6257	Increased carotid plaque burden in patients with family medical history of premature cardiovascular events in the absence of classical risk factors. <i>Archives of Medical Science</i> , 2019, 15, 1388-1396.	0.4	1
6258	Characteristics and Outcomes of Patients Treated With Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (The Mayo Clinic Experience). <i>American Journal of Cardiology</i> , 2019, 124, 1669-1673.	0.7	5
6259	Case-control study examining the association between hip fracture risk and statins therapy in old people. <i>Medicine (United States)</i> , 2019, 98, e17476.	0.4	12

#	ARTICLE	IF	CITATIONS
6260	Statin Use in the U.S. for Secondary Prevention of Cardiovascular Disease Remains Suboptimal. <i>Journal of the American Board of Family Medicine</i> , 2019, 32, 807-817.	0.8	23
6261	Survey of family doctors' attitudes towards statin treatment in patients with type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2019, 148, 81-92.	1.1	0
6262	Pharmacological Options in Atherosclerosis: A Review of the Existing Evidence. <i>Cardiology and Therapy</i> , 2019, 8, 5-20.	1.1	17
6263	Changing predictors of statin initiation in US women over two decades. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 305-314.	0.9	1
6264	Riesgo cardiovascular residual de origen lipídico. Componentes y aspectos fisiopatológicos. <i>Clínica e Investigación En Arteriosclerosis</i> , 2019, 31, 75-88.	0.4	6
6265	Lipoprotein(a) catabolism: a case of multiple receptors. <i>Pathology</i> , 2019, 51, 155-164.	0.3	79
6266	The year in cardiology 2018: acute coronary syndromes. <i>European Heart Journal</i> , 2019, 40, 271-282.	1.0	11
6267	Interaction between Mediterranean diet and statins on mortality risk in patients with cardiovascular disease: Findings from the Moli-sani Study. <i>International Journal of Cardiology</i> , 2019, 276, 248-254.	0.8	19
6268	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. <i>Journal of the American College of Cardiology</i> , 2019, 73, e285-e350.	1.2	1,550
6269	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Circulation</i> , 2019, 139, e1046-e1081.	1.6	361
6270	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Circulation</i> , 2019, 139, e1082-e1143.	1.6	2,380
6271	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary. <i>Journal of the American College of Cardiology</i> , 2019, 73, 3168-3209.	1.2	1,128
6272	PCSK9 inhibitors: clinical evidence and implementation. <i>Nature Reviews Cardiology</i> , 2019, 16, 155-165.	6.1	195
6273	The rise of statins in Denmark: Making the case for a localized approach to the routinization of pharmaceutical prevention of cardiovascular disease. <i>BioSocieties</i> , 2019, 14, 228-250.	0.8	1
6274	Effect of Statins on Mortality in Heart Failure With Preserved Ejection Fraction Without Coronary Artery Disease—Report From the JASPER Study. <i>Circulation Journal</i> , 2019, 83, 357-367.	0.7	24
6275	Intensity-Dependent Benefit of Statins in Survival Among Prospective Kidney Transplant Patients. <i>American Journal of Cardiology</i> , 2019, 123, 254-259.	0.7	7
6276	Prenatal therapeutics and programming of cardiovascular function. <i>Pharmacological Research</i> , 2019, 139, 261-272.	3.1	4
6277	Adjunctive Pharmacologic Therapies in Acute Myocardial Infarction. , 2019, , 117-138.e7.		2

#	ARTICLE	IF	CITATIONS
6278	Beta-blocker, aspirin, and statin usage after first-time myocardial infarction in patients with chronic obstructive pulmonary disease: a nationwide analysis from 1995 to 2015 in Denmark. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2019, 6, 23-31.	1.8	10
6279	Drug Therapy of Dyslipidemia in the Elderly. <i>Drugs and Aging</i> , 2019, 36, 321-340.	1.3	22
6280	HDL and cardiovascular disease. <i>Pathology</i> , 2019, 51, 142-147.	0.3	56
6281	Association of Clinician Knowledge and Statin Beliefs With Statin Therapy Use and Lipid Levels (A) <i>TJ ETQq1 1 0.784314 rgBT/Overload</i>	0.7	16
6282	Incidence of cardiovascular events in patients with stabilized coronary heart disease: the EUROASPIRE IV follow-up study. <i>European Journal of Epidemiology</i> , 2019, 34, 247-258.	2.5	22
6283	Imaging as a surrogate marker of drug efficacy in cardiovascular disease. <i>Heart</i> , 2019, 105, 567-578.	1.2	13
6284	Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, e38-e81.	1.1	431
6285	ANGPTL3 Inhibitors—Their Role in Cardiovascular Disease Through Regulation of Lipid Metabolism • <i>Circulation Journal</i> , 2019, 83, 267-273.	0.7	26
6286	Management of Dyslipidemia. <i>Contemporary Cardiology</i> , 2019, , 39-69.	0.0	0
6287	Nonfasting versus fasting lipid profile for cardiovascular risk prediction. <i>Pathology</i> , 2019, 51, 131-141.	0.3	112
6288	Apolipoproteins A1, B, and apoB/apoA1 ratio are associated with first ST-segment elevation myocardial infarction but not with recurrent events during long-term follow-up. <i>Clinical Research in Cardiology</i> , 2019, 108, 520-538.	1.5	39
6289	Percutaneous coronary intervention for stable coronary artery disease. <i>Heart</i> , 2019, 105, 11-19.	1.2	40
6290	Are current dietary guidelines relevant to subjects on cholesterol-lowering drugs?. <i>Proceedings of the Nutrition Society</i> , 2020, 79, 88-94.	0.4	1
6291	Influence of Ezetimibe on Plaque Morphology in Patients with ST Elevation Myocardial Infarction Assessed by Optical Coherence Tomography: An OCTIVUS Sub-Study. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 1417-1424.	0.3	9
6292	Prevention of Cardiovascular Events with Omega-3 Polyunsaturated Fatty Acids and the Mechanism Involved. <i>Journal of Atherosclerosis and Thrombosis</i> , 2020, 27, 183-198.	0.9	62
6293	Long-term outcomes of chronic coronary syndrome worldwide: insights from the international CLARIFY registry. <i>European Heart Journal</i> , 2020, 41, 347-356.	1.0	55
6294	Association of lowering apolipoprotein B with cardiovascular outcomes across various lipid-lowering therapies: Systematic review and meta-analysis of trials. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1255-1268.	0.8	33
6295	Combining Ubiquinol With a Statin May Benefit Hypercholesterolaemic Patients With Chronic Heart Failure. <i>Heart Lung and Circulation</i> , 2020, 29, 188-195.	0.2	10

#	ARTICLE	IF	CITATIONS
6296	Efficacy and Safety of High-intensity Statins in Patients With Acute Myocardial Infarction: An Asian Perspective. <i>Canadian Journal of Cardiology</i> , 2020, 36, 886-892.	0.8	6
6297	Meta-analysis Comparing Combined Use of Eicosapentaenoic Acid and Statin to Statin Alone. <i>American Journal of Cardiology</i> , 2020, 125, 198-204.	0.7	7
6298	Overall Mortality and LDL Cholesterol Reduction in Secondary Prevention Trials of Cardiovascular Disease. <i>American Journal of Cardiovascular Drugs</i> , 2020, 20, 325-332.	1.0	0
6299	Hyaluronan derived nanoparticle for simvastatin delivery: evaluation of simvastatin induced myotoxicity in tissue engineered skeletal muscle. <i>Biomaterials Science</i> , 2020, 8, 302-312.	2.6	9
6300	The Association of Oral Bisphosphonate Use With Mortality Risk Following a Major Osteoporotic Fracture in the United Kingdom: Population-Based Cohort Study. <i>Journal of the American Medical Directors Association</i> , 2020, 21, 811-816.	1.2	9
6301	“The lower the better” revisited: the new lipid targets in high risk patients. <i>European Heart Journal</i> , 2020, 41, 1-3.	1.0	16
6302	Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies. <i>Mayo Clinic Proceedings</i> , 2020, 95, 77-89.	1.4	97
6303	Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327,037 participants. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 36-49.	5.5	115
6304	Reduced bile acid excretion is an independent risk factor for stroke and mortality: A prospective follow-up study. <i>Atherosclerosis</i> , 2020, 293, 79-85.	0.4	32
6305	Evolving concepts on the management of dyslipidaemia. <i>Acta Clinica Belgica</i> , 2020, 75, 80-90.	0.5	3
6306	Muscle Toxicity of Drugs: When Drugs Turn Physiology into Pathophysiology. <i>Physiological Reviews</i> , 2020, 100, 633-672.	13.1	39
6307	What Proportion of Patients Admitted with Stroke or Transient Ischemic Attack May Be Suitable for Newer Cholesterol-Lowering Treatment?. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2020, 29, 104457.	0.7	3
6308	Lipid-lowering treatment in secondary prevention of ischaemic cerebrovascular disease. <i>Clínica e Investigaci3n En Arteriosclerosis (English Edition)</i> , 2020, 32, 175-182.	0.1	4
6309	Intra-coronary Imaging for the Evaluation of Plaque Modifications Induced by Drug Therapies for Secondary Prevention. <i>Current Atherosclerosis Reports</i> , 2020, 22, 76.	2.0	4
6310	Transendothelial transport of lipoproteins. <i>Atherosclerosis</i> , 2020, 315, 111-125.	0.4	45
6311	Barriers and Facilitators to Using Statins: A Qualitative Study With Patients and Family Physicians. <i>CJC Open</i> , 2020, 2, 530-538.	0.7	20
6312	LDL-C: lower is better for longer” even at low risk. <i>BMC Medicine</i> , 2020, 18, 320.	2.3	78
6313	Examination of physicians’ adherence to the 2013 ACC/AHA statin/cholesterol guidelines using a framework of awareness to adherence: A cross-sectional study. <i>JRSM Cardiovascular Disease</i> , 2020, 9, 204800402094729.	0.4	2

#	ARTICLE	IF	CITATIONS
6314	Five-Year Residual Atherosclerotic Cardiovascular Disease Risk Prediction Model for Statin Treated Patients With Known Cardiovascular Disease. <i>American Journal of Cardiology</i> , 2020, 137, 7-11.	0.7	7
6315	Management of multivessel coronary artery disease in patients with non-ST-elevation myocardial infarction: a complex path to precision medicine. <i>Therapeutic Advances in Chronic Disease</i> , 2020, 11, 204062232093852.	1.1	19
6316	Preventive cardiology as a dedicated clinical service: The past, the present, and the (Magnificent) future. <i>American Journal of Preventive Cardiology</i> , 2020, 1, 100011.	1.3	9
6317	The interplay of membrane cholesterol and substrate on vascular smooth muscle biomechanics. <i>Current Topics in Membranes</i> , 2020, 86, 279-299.	0.5	3
6318	Management of asymptomatic carotid stenosis. <i>Annals of Translational Medicine</i> , 2020, 8, 1262-1262.	0.7	7
6319	Novel Insights From Human Studies on the Role of High-Density Lipoprotein in Mortality and Noncardiovascular Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 128-140.	1.1	30
6320	Statins: HMG-CoA Reductase Inhibitors as Potential Anticancer Agents against Malignant Neoplasms in Women. <i>Pharmaceuticals</i> , 2020, 13, 422.	1.7	14
6321	Role of Lipid-Lowering Therapy in Low-Density Lipoprotein Cholesterol Goal Attainment: Focus on Patients With Acute Coronary Syndrome. <i>Journal of Cardiovascular Pharmacology</i> , 2020, 76, 658-670.	0.8	9
6322	Measuring effects on intima-media thickness: an evaluation of rosuvastatin in Chinese subjects with subclinical atherosclerosis—design, rationale, and methodology of the METEOR-China study. <i>Trials</i> , 2020, 21, 921.	0.7	1
6323	Hitos histÃ3ricos en el tratamiento hipolipemiente antes de la era de los inhibidores de la proproteina convertasa subtilisina/kexina tipo 9. <i>Revista Espanola De Cardiologia Suplementos</i> , 2020, 20, 8-14.	0.2	0
6324	Anticuerpos monoclonales inhibidores de la proproteÃna convertasa subtilisina/kexina tipo 9: nuevas evidencias. <i>Revista Espanola De Cardiologia Suplementos</i> , 2020, 20, 15-20.	0.2	1
6325	The Role of Statins in Current Guidelines. <i>Current Atherosclerosis Reports</i> , 2020, 22, 50.	2.0	17
6326	Japanese Clinical Practice Guideline for Diabetes 2019. <i>Journal of Diabetes Investigation</i> , 2020, 11, 1020-1076.	1.1	159
6327	Risk Differences in Secondary Prevention Patients Who Present With Acute Coronary Syndrome and Implications of Guideline-Directed Cholesterol Management. <i>American Journal of Cardiology</i> , 2020, 133, 1-6.	0.7	0
6328	Statin use and myopathy. Not always guilty. <i>Rheumatology</i> , 2020, 59, 3853-3857.	0.9	1
6329	Time-Dependent Cardiovascular Treatment Benefit Model for Lipid-Lowering Therapies. <i>Journal of the American Heart Association</i> , 2020, 9, e016506.	1.6	8
6330	Integrative Review of Managed Entry Agreements: Chances and Limitations. <i>Pharmacoeconomics</i> , 2020, 38, 1165-1185.	1.7	25
6331	Identification and treatment of those most at risk for premature atherosclerotic cardiovascular disease: We just cannot seem to get it right. <i>American Journal of Preventive Cardiology</i> , 2020, 2, 100040.	1.3	1

#	ARTICLE	IF	CITATIONS
6332	Advances in the Study of Marine Products with Lipid-Lowering Properties. <i>Marine Drugs</i> , 2020, 18, 390.	2.2	9
6333	Japanese Clinical Practice Guideline for Diabetes 2019. <i>Diabetology International</i> , 2020, 11, 165-223.	0.7	266
6334	Lipoproteins and lipids in cardiovascular disease: from mechanistic insights to therapeutic targeting. <i>Advanced Drug Delivery Reviews</i> , 2020, 159, 4-33.	6.6	113
6335	Relation of Low-Density Lipoprotein Cholesterol Level to Plaque Rupture. <i>American Journal of Cardiology</i> , 2020, 134, 48-54.	0.7	8
6336	Evaluation and Management of Patients With Stable Angina: Beyond the Ischemia Paradigm. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2252-2266.	1.2	52
6337	Atherosclerosis Linked to Aberrant Amino Acid Metabolism and Immunosuppressive Amino Acid Catabolizing Enzymes. <i>Frontiers in Immunology</i> , 2020, 11, 551758.	2.2	44
6338	Impact of statin intake on malignant hyperthermia: an in vitro and in vivo swine study. <i>BMC Anesthesiology</i> , 2020, 20, 270.	0.7	1
6339	All-Cause Mortality and Cardiovascular Death between Statins and Omega-3 Supplementation: A Meta-Analysis and Network Meta-Analysis from 55 Randomized Controlled Trials. <i>Nutrients</i> , 2020, 12, 3203.	1.7	4
6340	An Evaluation of Statin Use Among Patients with Type 2 Diabetes at High Risk of Cardiovascular Events Across Multiple Health Care Systems. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2020, 26, 1090-1098.	0.5	1
6341	Reduction in saturated fat intake for cardiovascular disease. <i>The Cochrane Library</i> , 2020, 2020, CD011737.	1.5	65
6342	Application of Anti-Inflammatory Agents in Prostate Cancer. <i>Journal of Clinical Medicine</i> , 2020, 9, 2680.	1.0	12
6343	Loss-of-function genomic variants highlight potential therapeutic targets for cardiovascular disease. <i>Nature Communications</i> , 2020, 11, 6417.	5.8	39
6344	Protective effects of pravastatin on the embryonic cardiovascular system during hypoxic development. <i>FASEB Journal</i> , 2020, 34, 16504-16515.	0.2	6
6345	Higher baseline lipid levels amplify the benefit of secondary prevention therapy with statins in Chinese patients with acute coronary syndrome. <i>Journal of International Medical Research</i> , 2020, 48, 030006052096584.	0.4	0
6346	Gene-based therapy in lipid management: the winding road from promise to practice. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 483-493.	1.9	20
6347	Reduction in saturated fat intake for cardiovascular disease. <i>The Cochrane Library</i> , 2020, 5, CD011737.	1.5	81
6348	Comparing effectiveness of high-dose Atorvastatin and Rosuvastatin among patients undergone Percutaneous Coronary Interventions: A non-concurrent cohort study in India. <i>PLoS ONE</i> , 2020, 15, e0233230.	1.1	9
6349	Lower levels of high-density lipoprotein cholesterol are associated with increased cardiovascular events in patients with acute coronary syndrome. <i>Atherosclerosis</i> , 2020, 303, 21-28.	0.4	9



#	ARTICLE	IF	CITATIONS
6350	Lipid lowering therapy in cardiovascular disease: From myth to molecular reality. , 2020, 213, 107592.		35
6351	Inhibition of HIF-1 $\alpha$ by Atorvastatin During 131I-RTX Therapy in Burkitt's Lymphoma Model. <i>Cancers</i> , 2020, 12, 1203.	1.7	6
6352	High Density Lipoprotein and Its Precursor Protein Apolipoprotein A1 as Potential Therapeutics to Prevent Anthracycline Associated Cardiotoxicity. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 65.	1.1	5
6353	Effectiveness of beta blockers in patients with and without a history of myocardial infarction. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 1161-1168.	0.8	3
6354	Established and Emerging Pharmacological Therapies for Post-Myocardial Infarction Patients with Heart Failure: a Review of the Evidence. <i>Cardiovascular Drugs and Therapy</i> , 2020, 34, 723-735.	1.3	11
6355	Explaining the causal effect of adherence to medication on cholesterol through the marginal patient. <i>Health Economics (United Kingdom)</i> , 2020, 29, 110-126.	0.8	4
6356	Long-Term Prognosis of Patients with Myocardial Infarction Type 1 and Type 2 with and without Involvement of Coronary Vasospasm. <i>Journal of Clinical Medicine</i> , 2020, 9, 1686.	1.0	8
6357	Should We Adjust Low-Density Lipoprotein Cholesterol Management to the Severity of Coronary Artery Disease?. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 1973-1975.	2.3	1
6358	Statins in a Distorted Mirror of Media. <i>Current Atherosclerosis Reports</i> , 2020, 22, 37.	2.0	24
6359	Role of Rare and Low-Frequency Variants in Gene-Alcohol Interactions on Plasma Lipid Levels. <i>Circulation Genomic and Precision Medicine</i> , 2020, 13, e002772.	1.6	11
6360	Reasons Why Combination Therapy Should Be the New Standard of Care to Achieve the LDL-Cholesterol Targets. <i>Current Cardiology Reports</i> , 2020, 22, 66.	1.3	26
6361	Acute Coronary Syndromes and the Nontarget Lesion. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1107-1110.	1.2	1
6362	Discrepancy Between Fasting Flow-Mediated Dilation and Parameter of Lipids in Blood: A Randomized Exploratory Study of the Effect of Omega-3 Fatty Acid Ethyl Esters on Vascular Endothelial Function in Patients With Hyperlipidemia. <i>Advances in Therapy</i> , 2020, 37, 2169-2183.	1.3	1
6363	Schnyder corneal dystrophy-associated UBIAD1 is defective in MK-4 synthesis and resists autophagy-mediated degradation. <i>Journal of Lipid Research</i> , 2020, 61, 746-757.	2.0	12
6364	Impact of Clinical Characteristics and Statins on Coronary Plaque Progression by Serial Computed Tomography Angiography. <i>Circulation: Cardiovascular Imaging</i> , 2020, 13, e009750.	1.3	37
6365	Causal Evidence and Dispositions in Medicine and Public Health. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 1813.	1.2	13
6366	The Legacy Effect in Treating Hypercholesterolemia. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2020, 25, 291-298.	1.0	4
6367	Tendencias en el uso de estatinas tras un ictus isquémico. ¿Hemos cambiado nuestra práctica clínica?. <i>Neurología</i> , 2023, 38, 16-21.	0.3	1

#	ARTICLE	IF	CITATIONS
6368	Cardiovascular mortality after intensive LDL-Cholesterol lowering: Does baseline LDL-Cholesterol really matter?. <i>American Journal of Preventive Cardiology</i> , 2020, 1, 100013.	1.3	10
6369	The history of proprotein convertase subtilisin kexin-9 inhibitors and their role in the treatment of cardiovascular disease. <i>Therapeutic Advances in Chronic Disease</i> , 2020, 11, 204062232092456.	1.1	8
6370	Effect of atorvastatin on muscle symptoms in coronary heart disease patients with self-perceived statin muscle side effects: a randomized, double-blinded crossover trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 507-516.	1.4	15
6371	The Efficacy of Squalene in Cardiovascular Disease Risk-A Systematic Review. <i>Nutrients</i> , 2020, 12, 414.	1.7	41
6372	Cholangiolytic Changes in Statin-Induced Liver Injury. <i>Case Reports in Pathology</i> , 2020, 2020, 1-4.	0.2	1
6373	High-sensitivity cardiac troponin assays for cardiovascular risk stratification in the general population. <i>European Heart Journal</i> , 2020, 41, 4050-4056.	1.0	83
6374	Statin-mediated cholesterol depletion exerts coordinated effects on the alterations in rat vascular smooth muscle cell biomechanics and migration. <i>Journal of Physiology</i> , 2020, 598, 1505-1522.	1.3	22
6375	Prognostic impact of lipoprotein (a) on long-term clinical outcomes in diabetic patients on statin treatment after percutaneous coronary intervention. <i>Journal of Cardiology</i> , 2020, 76, 25-29.	0.8	7
6376	Global mapping of randomised trials related articles published in high-impact-factor medical journals: a cross-sectional analysis. <i>Trials</i> , 2020, 21, 34.	0.7	19
6377	Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. <i>The Cochrane Library</i> , 2020, 2020, CD003177.	1.5	153
6378	Use of Statins in Patients With and Without Liver Disease. <i>Clinical Liver Disease</i> , 2020, 15, 40-45.	1.0	9
6379	The case for statin use to reduce perioperative adverse cardiovascular and cerebrovascular events. <i>British Journal of Anaesthesia</i> , 2020, 124, 525-534.	1.5	1
6381	Protocatechuic Acid Inhibits Vulnerable Atherosclerotic Lesion Progression in Older Apoe <sup>-/-</sup> Mice. <i>Journal of Nutrition</i> , 2020, 150, 1167-1177.	1.3	27
6382	Statin and Cancer Mortality and Survival: An Umbrella Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2020, 9, 326.	1.0	28
6383	Outcomes of lipid control in secondary prevention of coronary artery disease in Finland: A 24-month follow-up after acute coronary syndrome. <i>Atherosclerosis</i> , 2020, 296, 4-10.	0.4	6
6384	Lipid-Lowering Therapy and Low-Density Lipoprotein Cholesterol (LDL-C) Goal Achievement in High-Cardiovascular-Risk Patients in Fuzhou, China. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2020, 25, 307-315.	1.0	4
6385	Predicting Cardiovascular Outcomes by Baseline Lipoprotein(a) Concentrations: A Large Cohort and Long-Term Follow-up Study on Real-World Patients Receiving Percutaneous Coronary Intervention. <i>Journal of the American Heart Association</i> , 2020, 9, e014581.	1.6	37
6386	Impact of LR11 as Residual Risk on Long-Term Clinical Outcomes in Patients with Coronary Artery Disease Treated with Statins after First Percutaneous Coronary Intervention. <i>International Heart Journal</i> , 2020, 61, 470-475.	0.5	2

#	ARTICLE	IF	CITATIONS
6387	Lipid-Modifying Agents, From Statins to PCSK9 Inhibitors. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1945-1955.	1.2	47
6388	Relevance of Fitness to Mortality Risk in Men Receiving Contemporary Medical Care. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1538-1547.	1.2	13
6389	Comprehensive plaque assessment with serial coronary CT angiography: translation to bedside. <i>International Journal of Cardiovascular Imaging</i> , 2020, 36, 2335-2346.	0.7	10
6390	&#x201c;Reasons for Nonadherence to Statins &#x201c; A Systematic Review of Reviews. <i>Patient Preference and Adherence</i> , 2020, Volume 14, 675-691.	0.8	55
6391	Alirocumab and evolocumab: an indirect comparison of cardiovascular benefits. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 236-237.	1.4	0
6392	Effects of different delivering matrices of $\beta$ -glucan on lipids in mildly hypercholesterolaemic individuals: a meta-analysis of randomised controlled trials. <i>British Journal of Nutrition</i> , 2021, 125, 294-307.	1.2	7
6393	Reduction in Revascularization With Icosapent Ethyl. <i>Circulation</i> , 2021, 143, 33-44.	1.6	46
6394	Lipid-lowering therapies in peripheral artery disease: A review. <i>Vascular Medicine</i> , 2021, 26, 71-80.	0.8	8
6395	Revascularization versus medical therapy for the treatment of stable coronary artery disease: A meta-analysis of contemporary randomized controlled trials. <i>International Journal of Cardiology</i> , 2021, 324, 13-21.	0.8	17
6396	Impact of persistent endothelial dysfunction in an infarct-related coronary artery on future major adverse cardiovascular event occurrence in STEMI survivors. <i>Heart and Vessels</i> , 2021, 36, 472-482.	0.5	5
6397	Omega-3 polyunsaturated fatty acids focusing on eicosapentaenoic acid and docosahexaenoic acid in the prevention of cardiovascular diseases: a review of the state-of-the-art. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 79-93.	1.3	21
6398	Efficacy and Safety of PCSK9 Inhibitors in Hypercholesterolemia Associated With Refractory Nephrotic Syndrome. <i>Kidney International Reports</i> , 2021, 6, 101-109.	0.4	19
6399	Statins and atherosclerotic cardiovascular outcomes in patients on incident dialysis and with atherosclerotic heart disease. <i>American Heart Journal</i> , 2021, 231, 36-44.	1.2	9
6400	Impact of expanded FDA indication for icosapent ethyl on enhanced cardiovascular residual risk reduction. <i>Future Cardiology</i> , 2021, 17, 155-174.	0.5	14
6401	Postponement of cardiovascular outcomes by statin use: A systematic review and meta-analysis of randomized clinical trials. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2021, 128, 286-296.	1.2	0
6402	Clinical pre-test probability for obstructive coronary artery disease: insights from the European DISCHARGE pilot study. <i>European Radiology</i> , 2021, 31, 1471-1481.	2.3	10
6403	Diagnosis and Management of Coronary Artery Disease in Athletes. , 2021, , 211-225.		0
6404	Statins can benefit patients with primary membranous nephropathy on venous thromboembolism. <i>Renal Failure</i> , 2021, 43, 302-306.	0.8	2

#	ARTICLE	IF	CITATIONS
6405	Atorvastatin impairs liver mitochondrial function in obese Göttingen Minipigs but heart and skeletal muscle are not affected. <i>Scientific Reports</i> , 2021, 11, 2167.	1.6	5
6406	The association of echocardiographic parameters on renal outcomes in chronic kidney disease. <i>Renal Failure</i> , 2021, 43, 433-444.	0.8	5
6407	Real-World Analyses of the Safety Outcome among a General Population Treated with Statins: An Asian Population-Based Study. <i>Journal of Atherosclerosis and Thrombosis</i> , 2022, 29, 1213-1225.	0.9	5
6408	Dietary Approaches to Lowering LDL-C. <i>Contemporary Cardiology</i> , 2021, , 193-209.	0.0	0
6409	The Questions on Everyone's Mind: What is and Why Do We Need Preventive Cardiology?. <i>Methodist DeBakey Cardiovascular Journal</i> , 2021, 17, 8-14.	0.5	3
6410	Dyslipidemia in Women: Etiology and Management. <i>Stroke Revisited</i> , 2021, , 173-202.	0.2	3
6411	Pravastatin Promotes Endothelial Colony-Forming Cell Function, Angiogenic Signaling and Protein Expression In Vitro. <i>Journal of Clinical Medicine</i> , 2021, 10, 183.	1.0	15
6412	Recent Updates of Lipoprotein(a) and Cardiovascular Disease. <i>Chonnam Medical Journal</i> , 2021, 57, 36.	0.5	14
6413	High Sensitivity C-reactive Protein (hsCRP) and its Implications in Cardiovascular Outcomes. <i>Current Pharmaceutical Design</i> , 2021, 27, 263-275.	0.9	27
6414	Associação entre Terapia com Estatinas e Menor Incidência de Hiperglicemia em Pacientes Internados com Síndromes Coronarianas Agudas. <i>Arquivos Brasileiros De Cardiologia</i> , 2021, 116, 285-294.	0.3	1
6415	Coronary CT Angiography Guided Medical Therapy in Subclinical Atherosclerosis. <i>Journal of Clinical Medicine</i> , 2021, 10, 625.	1.0	10
6416	Effects of different statins application methods on plaques in patients with coronary atherosclerosis. <i>World Journal of Clinical Cases</i> , 2021, 9, 812-821.	0.3	0
6417	Lipid-Lowering Therapy in Patients with Coronary Heart Disease and Prior Stroke: Mission Impossible?. <i>Journal of Clinical Medicine</i> , 2021, 10, 886.	1.0	5
6418	Achieving Optimal Medical Therapy: Insights From the ORBITA Trial. <i>Journal of the American Heart Association</i> , 2021, 10, e017381.	1.6	11
6419	Liver Fibrosis Scoring Systems as Novel Tools for Predicting Cardiovascular Outcomes in Patients Following Elective Percutaneous Coronary Intervention. <i>Journal of the American Heart Association</i> , 2021, 10, e018869.	1.6	20
6420	Association between antecedent statin use and decreased mortality in hospitalized patients with COVID-19. <i>Nature Communications</i> , 2021, 12, 1325.	5.8	133
6421	Effect of redundant clinical trials from mainland China evaluating statins in patients with coronary artery disease: cross sectional study. <i>BMJ, The</i> , 2021, 372, n48.	3.0	11
6422	Atorvastatin pleiotropically decreases intraplaque angiogenesis and intraplaque haemorrhage by inhibiting ANGPT2 release and VE-Cadherin internalization. <i>Angiogenesis</i> , 2021, 24, 567-581.	3.7	11

#	ARTICLE	IF	CITATIONS
6423	Low levels of low-density lipoprotein cholesterol and cognitive decline. <i>Science Bulletin</i> , 2021, 66, 1684-1684.	4.3	41
6424	Emerging views of statin pleiotropy and cholesterol lowering. <i>Cardiovascular Research</i> , 2022, 118, 413-423.	1.8	54
6425	Inference of a causal relation between low-density lipoprotein cholesterol and hypertension using mendelian randomization analysis. <i>Clinical Hypertension</i> , 2021, 27, 7.	0.7	1
6426	Invasive therapy versus conservative therapy for patients with stable coronary artery disease: An updated <sc>meta-analysis</sc>. <i>Clinical Cardiology</i> , 2021, 44, 675-682.	0.7	17
6427	Benefit/Risk Profile of Single-Inhaler Triple Therapy in COPD. <i>International Journal of COPD</i> , 2021, Volume 16, 499-517.	0.9	17
6428	PCSK9 immunization using nanoliposomes: preventive efficacy against hypercholesterolemia and atherosclerosis. <i>Archives of Medical Science</i> , 2021, 17, 1365-1377.	0.4	39
6429	Physical activity and sedentary behaviour in secondary prevention of coronary artery disease: A review. <i>American Journal of Preventive Cardiology</i> , 2021, 5, 100146.	1.3	18
6430	Genetic Risk Stratification. <i>JACC Basic To Translational Science</i> , 2021, 6, 287-304.	1.9	19
6431	Treatment Candidacy for Pharmacologic Therapies for NASH. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1209-1217.	2.4	28
6432	Three Musketeers for Lowering Cholesterol: Statins, Ezetimibe and Evolocumab. <i>Current Medicinal Chemistry</i> , 2021, 28, 1025-1041.	1.2	10
6433	Statin Therapy in Children. , 0, , .		0
6434	Which LDL Value Should Clinicians Look at?. <i>Journal of Laboratory Physicians</i> , 2021, 13, 129-133.	0.4	1
6435	A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 1473-1484.	0.8	32
6436	The safety of JAK-1 inhibitors. <i>Rheumatology</i> , 2021, 60, ii24-ii30.	0.9	59
6437	Qualitative Exploration of Barriers to Statin Adherence and Lipid Control. <i>JAMA Network Open</i> , 2021, 4, e219211.	2.8	4
6438	The Impact of Simvastatin on Lipidomic Markers of Cardiovascular Risk in Human Liver Cells Is Secondary to the Modulation of Intracellular Cholesterol. <i>Metabolites</i> , 2021, 11, 340.	1.3	3
6439	Atherosclerotic Cardiovascular Disease in Rheumatoid Arthritis: Impact of Inflammation and Antirheumatic Treatment. <i>European Cardiology Review</i> , 2021, 16, e18.	0.7	31
6440	What Is the Role of Assessing Ischemia to Optimize Therapy and Outcomes for Patients with Stable Angina and Non-obstructed Coronary Arteries?. <i>Cardiovascular Drugs and Therapy</i> , 2022, 36, 1027-1038.	1.3	2

#	ARTICLE	IF	CITATIONS
6441	Intensity of statin therapy and muscle symptoms: a network meta-analysis of 153 000 patients. <i>BMJ Open</i> , 2021, 11, e043714.	0.8	14
6442	Resilience of the Internal Mammary Artery to Atherogenesis: Shifting From Risk to Resistance to Address Unmet Needs. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 2237-2251.	1.1	16
6443	Special Considerations for Lipid-Lowering Therapy in Women Reflecting Recent Randomized Trials. <i>Current Atherosclerosis Reports</i> , 2021, 23, 42.	2.0	2
6444	Cognition, Statins, and Cholesterol in Elderly Ischemic Stroke Patients: A Neurologist's Perspective. <i>Medicina (Lithuania)</i> , 2021, 57, 616.	0.8	8
6445	A Less than Provocative Approach for the Primary Prevention of CAD. <i>Journal of Cardiovascular Translational Research</i> , 2021, , 1.	1.1	1
6446	Anti-Inflammatory Drugs in Patients with Ischemic Heart Disease. <i>Journal of Clinical Medicine</i> , 2021, 10, 2835.	1.0	5
6447	Comparison of Transcriptomic Profiles of MiaPaCa-2 Pancreatic Cancer Cells Treated with Different Statins. <i>Molecules</i> , 2021, 26, 3528.	1.7	4
6448	Low LAL (Lysosomal Acid Lipase) Expression by Smooth Muscle Cells Relative to Macrophages as a Mechanism for Arterial Foam Cell Formation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, e354-e368.	1.1	23
6449	Is there more to a healthy-heart diet than cholesterol?. <i>Nature</i> , 2021, 594, S12-S13.	13.7	0
6450	Management of Dyslipidemia in Women and Men with Coronary Heart Disease: Results from POLASPIRE Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 2594.	1.0	4
6451	Statin therapy for patients with aortic stenosis who underwent transcatheter aortic valve implantation: a report from a Japanese multicentre registry. <i>BMJ Open</i> , 2021, 11, e044319.	0.8	6
6452	Targeting the Cholesterol Paradigm in the Risk Reduction for Atherosclerotic Cardiovascular Disease: Does the Mechanism of Action of Pharmacotherapy Matter for Clinical Outcomes?. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2021, 26, 107424842110236.	1.0	4
6454	Immigrants, Ethnicity, and Adherence to Secondary Cardiac Prevention Therapy: A Substudy of the ISLAND Trial. <i>CJC Open</i> , 2021, 3, 913-923.	0.7	1
6455	Evolution of Type 2 Diabetes Management from a Gluco-centric Approach to Cardio-Renal Risk Reduction: The New Paradigm of Care. <i>Drugs</i> , 2021, 81, 1373-1379.	4.9	13
6456	Medical Management of Peripheral Arterial Disease: Deciphering the Intricacies of Therapeutic Options. <i>CJC Open</i> , 2021, 3, 936-949.	0.7	6
6457	Statins Protect against Thrombosis of Cannulated Radiocephalic Fistulas in Diabetic Patients. <i>Annals of Vascular Surgery</i> , 2021, 75, 280-286.	0.4	0
6458	Cholesterol: the race to the bottom. <i>European Heart Journal</i> , 2021, 42, 4612-4613.	1.0	10
6459	Human Angiopoietin-like Protein 3/ANGPTL3 Antibodies. <i>Journal of Cardiovascular Pharmacology</i> , 2021, Publish Ahead of Print, e631-e640.	0.8	0

#	ARTICLE	IF	CITATIONS
6460	A New Disease Concept in the Age of Processed Foods—Phosphorus-Burden Disease; including CKD—“MBD Concrete Analysis and the Way to Solution. <i>Nutrients</i> , 2021, 13, 2874.	1.7	2
6461	Three Technologies That Will Guide Revascularization of Chronic Coronary Syndrome Patients into the 21st Century: A Review. <i>International Journal of Angiology</i> , 2021, 30, 212-220.	0.2	0
6462	Preventive implantable cardioverter defibrillator therapy in contemporary clinical practice: need for more stringent selection criteria. <i>ESC Heart Failure</i> , 2021, 8, 3656-3662.	1.4	4
6463	Pharmacoevidence Research-Real-World Evidence for Decision Making. <i>Frontiers in Pharmacology</i> , 2021, 12, 723427.	1.6	7
6464	The role of atorvastatin in collateral circulation formation induced by encephaloduroarteriosynangiosis: a prospective trial. <i>Neurosurgical Focus</i> , 2021, 51, E9.	1.0	9
6465	Greater Change in the Eicosapentaenoic Acid to Arachidonic Acid Ratio Is Associated With Decreased Incidence of Cardiovascular Events in Acute Coronary Syndrome Patients With Elevated Triglyceride Levels. <i>Circulation Journal</i> , 2021, 85, 1746-1753.	0.7	4
6466	Cyclosporine A and Tacrolimus Induce Functional Impairment and Inflammatory Reactions in Endothelial Progenitor Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9696.	1.8	16
6467	Seaweeds and Their Natural Products for Preventing Cardiovascular Associated Dysfunction. <i>Marine Drugs</i> , 2021, 19, 507.	2.2	9
6468	Coenzyme Q nanodisks counteract the effect of statins on C2C12 myotubes. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2021, 37, 102439.	1.7	4
6469	CAVI-Lowering Effect of Pitavastatin May Be Involved in the Prevention of Cardiovascular Disease: Subgroup Analysis of the TOHO-LIP. <i>Journal of Atherosclerosis and Thrombosis</i> , 2021, 28, 1083-1094.	0.9	8
6470	Chronic obstructive pulmonary disease: moving from symptom relief to mortality reduction. <i>Therapeutic Advances in Chronic Disease</i> , 2021, 12, 204062232110140.	1.1	6
6471	Do statins reduce the mortality rate in stroke patients treated with systemic thrombolysis in a 5-year. <i>Neural Regeneration Research</i> , 2021, 16, 1807.	1.6	3
6472	Studies for labeling versus reimbursement. , 2021, , 21-32.		0
6473	Lipoproteins in chronic kidney disease: from bench to bedside. <i>European Heart Journal</i> , 2021, 42, 2170-2185.	1.0	32
6474	A Checklist Approach for Enhanced Outpatient Guideline-Directed Management in the Secondary Prevention of Atherosclerotic Cardiovascular Disease. <i>Methodist DeBakey Cardiovascular Journal</i> , 2021, 17, 79-86.	0.5	3
6475	Treatment With Cardiovascular Medications: Prognosis in Patients With Myocardial Injury. <i>Journal of the American Heart Association</i> , 2021, 10, e017239.	1.6	8
6476	Molecules and Mechanisms to Overcome Oxidative Stress Inducing Cardiovascular Disease in Cancer Patients. <i>Life</i> , 2021, 11, 105.	1.1	22
6477	Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease. <i>The Cochrane Library</i> , 2018, 11, CD012345.	1.5	46

#	ARTICLE	IF	CITATIONS
6481	Statins in Critical Illness. , 2005, , 477-487.		2
6482	Protection of Endothelial Function. Handbook of Experimental Pharmacology, 2005, , 619-644.	0.9	14
6483	Modulation of Macrophage Function and Metabolism. Handbook of Experimental Pharmacology, 2005, , 665-695.	0.9	5
6484	Dyslipidemias. , 2003, , 1019-1029.		1
6486	Lipid Metabolism in Pregnancy. , 1998, , 221-258.		11
6487	Active Vaccine and Drug Surveillance. Profiles in Operations Research, 2013, , 251-279.	0.3	1
6488	Soyfoods: Their Role in Disease Prevention and Treatment. , 1997, , 442-477.		30
6489	Pathogenesis of Atherosclerosis. Developments in Cardiovascular Medicine, 1999, , 3-18.	0.1	1
6490	Managing Menopausal Problems. Cancer Treatment and Research, 2000, 103, 1-23.	0.2	1
6491	Approach to Clinical and Genetic Characterization of Statin-Induced Myopathy. Methods in Molecular Biology, 2014, 1175, 67-90.	0.4	6
6492	Menopausal Hormone Therapy. , 2004, , 321-348.		1
6493	Coronary Atherosclerosis. , 1998, , 133-140.		1
6494	Critical Pathways for Acute Coronary Syndromes. Contemporary Cardiology, 1999, , 611-627.	0.0	5
6495	Obesity and Chronic Disease. , 2005, , 383-401.		3
6496	Lipid Metabolism and Coronary Artery Disease. , 2006, , 130-137.		7
6497	Cardiovascular Disease in Women. , 2007, , 349-368.		2
6498	Dietary Fat Intake: Promotion of Disease in Carotid Artery Disease: Lipid Lowering Versus Side Effects of Statins. , 2010, , 151-184.		2
6499	Paraoxonase 1 Interactions with HDL, Antioxidants and Macrophages Regulate Atherogenesis – A Protective Role for HDL Phospholipids. Advances in Experimental Medicine and Biology, 2010, 660, 153-166.	0.8	48



#	ARTICLE	IF	CITATIONS
6500	History and development of HMG-CoA reductase inhibitors. , 2002, , 1-17.		2
6501	Kardiologie. , 2008, , 343-387.		2
6502	High-Density Lipoprotein: Structural and Functional Changes Under Uremic Conditions and the Therapeutic Consequences. Handbook of Experimental Pharmacology, 2015, 224, 423-453.	0.9	7
6504	Issues in Data Analysis. , 2015, , 403-462.		2
6505	Arzneiverordnungen für Ältere Patienten. , 2008, , 923-960.		2
6506	Statins and Demyelination. Current Topics in Microbiology and Immunology, 2008, 318, 313-324.	0.7	15
6507	Lipidsenkende Mittel. , 2010, , 665-680.		1
6508	Gesundheitspolitische Aspekte und Ausblick. , 2002, , 435-455.		1
6509	Arzneiverordnungen 2003 im Überblick. , 2004, , 3-36.		2
6510	Lipidsenkende Mittel. , 2011, , 683-698.		1
6511	Systemic Hypertension. , 2002, , 1015-1064.		2
6512	Anatomie und Pathologie der Koronararterien. Spezielle Pathologische Anatomie, 2000, , 209-553.	0.0	5
6513	MED-PED: An Integrated Genetic Strategy for Preventing Early Deaths. , 1996, , 35-45.		24
6514	Vaskuläre Erkrankungen. , 1999, , 954-1093.		1
6515	Qualität der Arzneimittelversorgung. , 2003, , 832-852.		1
6516	Akuter Myokardinfarkt. , 2000, , 393-442.		1
6518	Mortality Affected by Health Care and Public Health Policy Interventions. International Handbooks of Population, 2011, , 583-607.	0.2	7
6519	Atherogenic Dyslipidemia and the Metabolic Syndrome: Pathogenesis and Challenge of Therapy. Medical Science Symposia Series, 1996, , 237-247.	0.0	4

#	ARTICLE	IF	CITATIONS
6520	Noncholesterol Serum Sterols in Scandinavian Simvastatin Survival Study. Medical Science Symposia Series, 1996, , 473-476.	0.0	5
6521	Prophylactic Implantation of Implantable Cardioverter/Defibrillators in Post-Myocardial Infarction Patients. Developments in Cardiovascular Medicine, 1998, , 305-310.	0.1	4
6522	Introduction to Invasive Assessment of the Coronary Circulation. Developments in Cardiovascular Medicine, 2000, , 25-49.	0.1	1
6523	Homocysteine as a Risk Factor for Coronary Artery Disease. Developments in Cardiovascular Medicine, 2000, , 173-202.	0.1	4
6524	An Overview of the Homocysteine Lowering Clinical Trials. Developments in Cardiovascular Medicine, 2000, , 413-429.	0.1	11
6525	Lipid-Modifying Drugs: Pharmacology and Perspectives. Advances in Experimental Medicine and Biology, 2020, 1177, 133-148.	0.8	6
6526	Hyperlipidaemia, diet and simvastatin therapy in steroid-resistant nephrotic syndrome of childhood. Pediatric Nephrology, 1996, 10, 171-174.	0.9	2
6527	Vascular Biology and Atherosclerosis of Cerebral Arteries. , 2004, , 763-774.		1
6528	Impact of Nontraditional Antiarrhythmic Drugs on Sudden Cardiac Death. , 2004, , 950-958.		2
6529	Carotid Occlusive Disease. , 2011, , 3615-3620.		1
6530	Epidemiology of Stroke. , 2011, , 198-218.		2
6531	Lipid-Lowering Strategies and Reduction of Coronary Heart Disease Risk. , 2010, , 81-86.e2.		3
6533	High-Density Lipoprotein Metabolism. , 2009, , 45-55.		3
6534	Special Patient Populations: Diabetes and Metabolic Syndrome. , 2009, , 443-462.		1
6535	Actualizaci3n de las tablas de planificaci3n terap3utica hipocolesterolemiantes orientadas a la obtenci3n de los objetivos terap3uticos. Cl3nica E Investigaci3n En Arteriosclerosis, 2019, 31, 271-277.	0.4	13
6536	Tratamiento hipolipemiente en la prevenci3n secundaria de la enfermedad cerebrovascular isqu3mica. Cl3nica E Investigaci3n En Arteriosclerosis, 2020, 32, 175-182.	0.4	7
6537	Balancing cardiovascular benefit and diabetogenic harm of therapy with statins: Real-world evidence from Italy. Diabetes Research and Clinical Practice, 2020, 164, 108197.	1.1	3
6538	A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins. Journal of Cardiology, 2017, 70, 537-544.	0.8	134

#	ARTICLE	IF	CITATIONS
6539	Aspects m�dico-�conomiques de la polyarthrite rhumato�de. Bulletin De L'Academie Nationale De Medecine, 2012, 196, 1295-1306.	0.0	5
6540	Effect of ER-27856, a novel squalene synthase inhibitor, on plasma cholesterol in rhesus monkeys: comparison with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors. Journal of Lipid Research, 2000, 41, 1136-1144.	2.0	57
6541	Ubiquinone supplementation during lovastatin treatment: effect on LDL oxidation ex vivo. Journal of Lipid Research, 1998, 39, 1430-1437.	2.0	50
6542	Effects of legume consumption on serum cholesterol, biliary lipids, and sterol metabolism in humans. Journal of Lipid Research, 1997, 38, 1120-1128.	2.0	82
6543	Prolonged inhibition of cholesterol synthesis explains the efficacy of atorvastatin. Journal of Lipid Research, 1997, 38, 1496-1500.	2.0	70
6544	Ro 48-8.071, a new 2,3-oxidosqualene:lanosterol cyclase inhibitor lowering plasma cholesterol in hamsters, squirrel monkeys, and minipigs: comparison to simvastatin. Journal of Lipid Research, 1997, 38, 373-390.	2.0	144
6545	Effects of a novel 2,3-oxidosqualene cyclase inhibitor on the regulation of cholesterol biosynthesis in HepG2 cells.. Journal of Lipid Research, 1996, 37, 148-158.	2.0	78
6546	Determination of triglycerides in lipoproteins separated by agarose gel electrophoresis.. Journal of Lipid Research, 1995, 36, 1839-1847.	2.0	14
6547	Perioperative cardiovascular evaluation: heads or tails?. Revista Da Associa�o M�dica Brasileira, 2012, 58, 505-512.	0.3	1
6548	Una historia resumida. Impacto de los avances en cardiopat�a isqu�mica. Revista Espanola De Cardiologia Suplementos, 2017, 17, 2-6.	0.2	1
6550	PCSK9 inhibition for LDL lowering and beyond â€“ implications for patients with peripheral artery disease. Vasa - European Journal of Vascular Medicine, 2018, 47, 165-176.	0.6	7
6551	Feedback and Hormonal Regulation of Hepatic 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase: The Concept of Cholesterol Buffering Capacity. Proceedings of the Society for Experimental Biology and Medicine, 2000, 224, 8-19.	2.0	125
6553	The new European guidelines for prevention of cardiovascular disease are misleading. Expert Review of Clinical Pharmacology, 2020, 13, 1289-1294.	1.3	9
6554	ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU/SIMG/SIMII/SISA Joint Consensus Document on cholesterol and cardiovascular risk: diagnosticâ€“therapeutic pathway in Italy. European Heart Journal Supplements, 2017, 19, D3-D54.	0.0	19
6555	Traditional Coronary Risk Factors in African Americans. American Journal of the Medical Sciences, 1999, 317, 189-192.	0.4	25
6556	Acceleration of confirmed coronary artery disease among HIV-infected patients on potent antiretroviral therapy. Aids, 2000, 14, 2790-2792.	1.0	47
6557	Multicenter Comparison of Micronized Fenofibrate and Simvastatin in Patients with Primary Type IIA or IIB Hyperlipoproteinemia. Journal of Cardiovascular Pharmacology, 1996, 27, 563-570.	0.8	54
6558	Effects of Lipid-Lowering Drugs on Left Ventricular Function and Exercise Tolerance in Dyslipidemic Coronary Patients. Journal of Cardiovascular Pharmacology, 1999, 33, 473-478.	0.8	44

#	ARTICLE	IF	CITATIONS
6559	Lipophilic HMG-CoA Reductase Inhibitors Increase Myocardial Stunning in Dogs. <i>Journal of Cardiovascular Pharmacology</i> , 2000, 35, 256-262.	0.8	47
6560	Efficacy and Tolerability of Fluvastatin and Bezafibrate in Patients with Hyperlipidemia and Persistently High Triglyceride Levels. <i>Journal of Cardiovascular Pharmacology</i> , 2000, 35, 361-365.	0.8	32
6561	Use of Statins and Blood Pressure Control in Treated Hypertensive Patients with Hypercholesterolemia. <i>Journal of Cardiovascular Pharmacology</i> , 2000, 35, 549-555.	0.8	133
6562	EVALUATION OF FLUVASTATIN IN THE TREATMENT OF HYPERCHOLESTEROLEMIA IN RENAL TRANSPLANT RECIPIENTS TAKING CYCLOSPORINE1. <i>Transplantation</i> , 1996, 62, 1559-1564.	0.5	78
6563	HYPERLIPIDEMIA IN SOLID ORGAN TRANSPLANTATION. <i>Transplantation</i> , 1997, 63, 331-338.	0.5	289
6564	CHOLESTEROL AS AN INDEPENDENT PREDICTOR OF OUTCOME AFTER RENAL TRANSPLANTATION. <i>Transplantation</i> , 2000, 69, 1704-1710.	0.5	78
6565	Endothelial Dysfunction and Coronary Risk Reduction. <i>Journal of Cardiopulmonary Rehabilitation and Prevention</i> , 1998, 18, 60-67.	0.5	10
6566	Comprehensive Cardiac Rehabilitation Improves the Control of Dyslipidemia in Secondary Prevention. <i>Journal of Cardiopulmonary Rehabilitation and Prevention</i> , 1998, 18, 408-415.	0.5	21
6567	Recent advances in stroke therapy. <i>Current Opinion in Neurology</i> , 1998, 11, 57-64.	1.8	9
6568	Lipoprotein classes and coronary disease regression. <i>Current Opinion in Lipidology</i> , 1998, 9, 329-336.	1.2	21
6569	Association between achieving treatment goals for lipid-lowering and cardiovascular events in real clinical practice. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2005, 12, 530-534.	3.1	10
6570	Statins Unmasking a Mitochondrial Myopathy: A Case Report and Proposed Mechanism of Disease. <i>Southern Medical Journal</i> , 2003, 96, 318-320.	0.3	18
6571	Treatment of Patients with Lipid Disorders in the Primary Care Setting: New Treatment Guidelines and their Implications. <i>Southern Medical Journal</i> , 2003, 96, 266-275.	0.3	5
6572	Medical Prevention of Stroke, 2003. <i>Southern Medical Journal</i> , 2003, 96, 354-358.	0.3	13
6573	Statin Therapy in Rheumatoid Arthritis. <i>Southern Medical Journal</i> , 2005, 98, 534-540.	0.3	9
6574	Simvastatin Restores Ischemic Preconditioning in the Presence of Hyperglycemia through a Nitric Oxide-mediated Mechanism. <i>Anesthesiology</i> , 2008, 108, 634-642.	1.3	28
6575	The systemic implication of novel non-statin therapies in cardiovascular diabetology: PCSK9 as a case model. <i>Cardiovascular Endocrinology and Metabolism</i> , 2020, 9, 143-152.	0.5	1
6577	Feedback and Hormonal Regulation of Hepatic 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase: The Concept of Cholesterol Buffering Capacity. <i>Proceedings of the Society for Experimental Biology and Medicine</i> , 2000, 224, 8-19.	2.0	18

#	ARTICLE	IF	CITATIONS
6578	Hepatitis, rhabdomyolysis and multi-organ failure resulting from statin use. <i>BMJ Case Reports</i> , 2009, 2009, bcr0720080412-bcr0720080412.	0.2	2
6579	Commentary: Having too much evidence (depression, suicide, and low serum cholesterol). <i>BMJ: British Medical Journal</i> , 1996, 313, 651-652.	2.4	18
6580	Secondary prevention clinics for coronary heart disease: randomised trial of effect on health. <i>BMJ: British Medical Journal</i> , 1998, 316, 1434-1437.	2.4	145
6581	Cholesterol: how low is low enough?. <i>BMJ: British Medical Journal</i> , 1998, 317, 425-426.	2.4	12
6582	Simvastatin seems unlikely to cause impotence. <i>BMJ: British Medical Journal</i> , 1999, 318, 192-192.	2.4	26
6583	Using thresholds based on risk of cardiovascular disease to target treatment for hypertension: modelling events averted and number treated. <i>BMJ: British Medical Journal</i> , 2000, 320, 680-685.	2.4	46
6584	Statins as the new aspirin. <i>BMJ: British Medical Journal</i> , 2002, 324, 789-789.	2.4	6
6585	Might money spent on statins be better spent?. <i>BMJ: British Medical Journal</i> , 2003, 327, 933-b-933.	2.4	4
6586	Low Atherosclerotic Response of a Strain of Rabbits to Diet-Induced Hypercholesterolemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1995, 15, 1181-1188.	1.1	10
6587	Effects of Colestipol Alone and in Combination With Simvastatin on Apolipoprotein B Metabolism. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1996, 16, 236-249.	1.1	22
6588	Isolated Low HDL Cholesterol As a Risk Factor for Coronary Heart Disease Mortality. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997, 17, 107-113.	1.1	325
6589	No Influence of Simvastatin Treatment on Platelet Function In Vivo in Patients With Hypercholesterolemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997, 17, 273-278.	1.1	26
6590	Impact of a Combination of a Calcium Antagonist and a $\beta$ -Blocker on Cell- and Copper-Mediated Oxidation of LDL and on the Accumulation and Efflux of Cholesterol in Human Macrophages and Murine J774 Cells. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997, 17, 979-988.	1.1	24
6591	Cellular Consequences of the Association of ApoB Lipoproteins With Proteoglycans. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997, 17, 1011-1017.	1.1	119
6592	Effects of Lipid Lowering by Pravastatin on Progression and Regression of Coronary Artery Disease in Symptomatic Men With Normal to Moderately Elevated Serum Cholesterol Levels. <i>Circulation</i> , 1995, 91, 2528-2540.	1.6	718
6593	Molecular Bases of the Acute Coronary Syndromes. <i>Circulation</i> , 1995, 91, 2844-2850.	1.6	1,620
6594	Thrombolysis for Acute Myocardial Infarction. <i>Circulation</i> , 1995, 91, 2862-2864.	1.6	28
6595	Cholesterol Reduction Yields Clinical Benefit. <i>Circulation</i> , 1995, 91, 2274-2282.	1.6	195

#	ARTICLE	IF	CITATIONS
6596	Angiographic and Clinical Progression in Unstable Angina. <i>Circulation</i> , 1995, 91, 2295-2298.	1.6	25
6598	Coronary Plaque Disruption. <i>Circulation</i> , 1995, 92, 657-671.	1.6	2,863
6599	Our Preoccupation With Coronary Luminology. <i>Circulation</i> , 1995, 92, 2333-2342.	1.6	945
6600	Late Outcome After Coronary Artery Bypass Graft Surgery in Patients <40 Years Old. <i>Circulation</i> , 1995, 92, 14-19.	1.6	21
6601	Effects of Cholesterol Lowering on the Progression of Coronary Atherosclerosis in Women. <i>Circulation</i> , 1995, 92, 2404-2410.	1.6	54
6602	Reduction in Cardiovascular Events During Pravastatin Therapy. <i>Circulation</i> , 1995, 92, 2419-2425.	1.6	240
6603	Compliance Enhancement. <i>Circulation</i> , 1996, 93, 4-6.	1.6	45
6604	Cost of Prevention. <i>Circulation</i> , 1996, 93, 1774-1776.	1.6	47
6605	Cholesterol Lowering and the Use of Healthcare Resources. <i>Circulation</i> , 1996, 93, 1796-1802.	1.6	155
6606	LDL-Apheresis Atherosclerosis Regression Study (LAARS). <i>Circulation</i> , 1996, 93, 1826-1835.	1.6	239
6607	Cardiovascular Effects of Estrogen and Lipid-Lowering Therapies in Postmenopausal Women. <i>Circulation</i> , 1996, 93, 1928-1937.	1.6	150
6608	Risk-Reduction Therapy: The Challenge to Change. <i>Circulation</i> , 1996, 93, 2205-2211.	1.6	64
6609	Cholesterol Screening in Asymptomatic Adults. <i>Circulation</i> , 1996, 93, 1067-1068.	1.6	8
6610	Levels of Soluble Cell Adhesion Molecules in Patients With Dyslipidemia. <i>Circulation</i> , 1996, 93, 1334-1338.	1.6	256
6611	Cardiovascular Disease Epidemiology. <i>Circulation</i> , 1996, 93, 1755-1764.	1.6	71
6612	Coronary Heart Disease Risk Factors in Men and Women Aged 60 Years and Older. <i>Circulation</i> , 1996, 94, 26-34.	1.6	59
6613	Serum Lipids and Incidence of Coronary Heart Disease. <i>Circulation</i> , 1996, 94, 2381-2388.	1.6	126
6614	Estrogens for Prevention of Coronary Heart Disease. <i>Circulation</i> , 1996, 94, 2982-2985.	1.6	60

#	ARTICLE	IF	CITATIONS
6615	Diagnosis and Treatment of Chronic Arterial Insufficiency of the Lower Extremities: A Critical Review. <i>Circulation</i> , 1996, 94, 3026-3049.	1.6	755
6616	Decline of Coronary Heart Disease Mortality in Finland During 1983 to 1992: Roles of Incidence, Recurrence, and Case-Fatality. <i>Circulation</i> , 1996, 94, 3130-3137.	1.6	75
6617	Coronary Artery Calcification: Pathophysiology, Epidemiology, Imaging Methods, and Clinical Implications. <i>Circulation</i> , 1996, 94, 1175-1192.	1.6	903
6618	Reduction of Transient Myocardial Ischemia With Pravastatin in Addition to the Conventional Treatment in Patients With Angina Pectoris. <i>Circulation</i> , 1996, 94, 1503-1505.	1.6	140
6619	Estrogen Therapy, Atherosclerosis, and Clinical Cardiovascular Events. <i>Circulation</i> , 1996, 94, 1809-1811.	1.6	9
6620	Stability and Instability: Two Faces of Coronary Atherosclerosis. <i>Circulation</i> , 1996, 94, 2013-2020.	1.6	730
6621	Small LDL, Atherogenic Dyslipidemia, and the Metabolic Syndrome. <i>Circulation</i> , 1997, 95, 1-4.	1.6	288
6622	Atherogenic Lipids, Vascular Dysfunction, and Clinical Signs of Ischemic Heart Disease. <i>Circulation</i> , 1997, 95, 5-7.	1.6	75
6623	Clinical Reality of Lowering Total and LDL Cholesterol. <i>Circulation</i> , 1997, 95, 306-307.	1.6	6
6624	Effect of Cholesterol Reduction on Myocardial Ischemia in Patients With Coronary Disease. <i>Circulation</i> , 1997, 95, 324-328.	1.6	180
6625	Lewis A. Conner Memorial Lecture. <i>Circulation</i> , 1997, 95, 1062-1071.	1.6	619
6626	The Multilevel Compliance Challenge: Recommendations for a Call to Action. <i>Circulation</i> , 1997, 95, 1085-1090.	1.6	375
6627	Simvastatin, an HMGâ€œCoenzyme A Reductase Inhibitor, Improves Endothelial Function Within 1 Month. <i>Circulation</i> , 1997, 95, 1126-1131.	1.6	801
6628	Remarks About Postinfarction Prognosis in Light of the Experience With the Gruppo Italiano per lo Studio della Sopravvivenza nell' Infarto Miocardico (GISSI) Trials. <i>Circulation</i> , 1997, 95, 1341-1345.	1.6	30
6629	Tamoxifen Decreases Cholesterol Sevenfold and Abolishes Lipid Lesion Development in Apolipoprotein E Knockout Mice. <i>Circulation</i> , 1997, 95, 1542-1548.	1.6	80
6630	Cholesterol Screening Guidelines. <i>Circulation</i> , 1997, 95, 1651-1653.	1.6	10
6631	When to Start Cholesterol-Lowering Therapy in Patients With Coronary Heart Disease. <i>Circulation</i> , 1997, 95, 1683-1685.	1.6	117
6632	Silent Myocardial Ischemia: Some Good News. <i>Circulation</i> , 1997, 95, 1992-1993.	1.6	4

#	ARTICLE	IF	CITATIONS
6633	Asymptomatic Cardiac Ischemia Pilot (ACIP) Study Two-Year Follow-up. <i>Circulation</i> , 1997, 95, 2037-2043.	1.6	378
6634	Total, LDL, and HDL Cholesterol Decrease With Age in Older Men and Women. <i>Circulation</i> , 1997, 96, 37-43.	1.6	195
6635	Prognostic Influence of Increased Fibrinogen and C-Reactive Protein Levels in Unstable Coronary Artery Disease. <i>Circulation</i> , 1997, 96, 4204-4210.	1.6	430
6636	Cholesterol-Lowering Therapy in Women and Elderly Patients With Myocardial Infarction or Angina Pectoris. <i>Circulation</i> , 1997, 96, 4211-4218.	1.6	436
6637	Reduction of Serum Cholesterol in Postmenopausal Women With Previous Myocardial Infarction and Cholesterol Malabsorption Induced by Dietary Sitostanol Ester Margarine. <i>Circulation</i> , 1997, 96, 4226-4231.	1.6	189
6638	Cholesterol Management in Theory and Practice. <i>Circulation</i> , 1997, 96, 4424-4430.	1.6	65
6639	Lipid Lowering Versus Revascularization. <i>Circulation</i> , 1997, 96, 1360-1362.	1.6	44
6640	Simvastatin Reduces Graft Vessel Disease and Mortality After Heart Transplantation. <i>Circulation</i> , 1997, 96, 1398-1402.	1.6	402
6641	The M $\ddot{u}$ l $\ddot{u}$ nster Heart Study (PROCAM). <i>Circulation</i> , 1997, 96, 2128-2136.	1.6	117
6642	Prevention of the Angiographic Progression of Coronary and Vein-Graft Atherosclerosis by Gemfibrozil After Coronary Bypass Surgery in Men With Low Levels of HDL Cholesterol. <i>Circulation</i> , 1997, 96, 2137-2143.	1.6	338
6643	Coronary Risk Estimation and Treatment of Hypercholesterolemia. <i>Circulation</i> , 1997, 96, 2449-2452.	1.6	39
6644	Attenuated Progression of Coronary Artery Disease After 6 Years of Multifactorial Risk Intervention. <i>Circulation</i> , 1997, 96, 2534-2541.	1.6	294
6645	Heart Rate Adjustment of Exercise-Induced ST-Segment Depression Identifies Men Who Benefit From a Risk Factor Reduction Program. <i>Circulation</i> , 1997, 96, 2899-2904.	1.6	20
6646	Beneficial Effects of Pravastatin on Fasting Hyperinsulinemia in Elderly Hypertensive Hypercholesterolemic Subjects. <i>Hypertension</i> , 1996, 28, 647-651.	1.3	23
6647	The Intima. <i>Circulation Research</i> , 1995, 77, 445-465.	2.0	755
6648	Echolucent Carotid Artery Plaques Are Associated With Elevated Levels of Fasting and Postprandial Triglyceride-Rich Lipoproteins. <i>Stroke</i> , 1996, 27, 2166-2172.	1.0	51
6649	Effect of Short-term Regression of Atherosclerosis on Reactivity of Carotid and Retinal Arteries. <i>Stroke</i> , 1996, 27, 927-933.	1.0	15
6650	High-Density Lipoprotein Cholesterol and Risk of Ischemic Stroke Mortality. <i>Stroke</i> , 1997, 28, 83-87.	1.0	117



#	ARTICLE	IF	CITATIONS
6651	Vascular Effects of Statins in Stroke. <i>Stroke</i> , 1997, 28, 2315-2320.	1.0	116
6652	Stroke, Statins, and Cholesterol. <i>Stroke</i> , 1997, 28, 946-950.	1.0	260
6653	Stroke Incidence and Mortality Correlated to Stroke Risk Factors in the WHO MONICA Project. <i>Stroke</i> , 1997, 28, 1367-1374.	1.0	104
6655	Risk Reduction. <i>Circulation</i> , 2000, 102, .	1.6	3
6656	Eligibility for Lipid-Lowering Drug Therapy in Primary Prevention. <i>Circulation</i> , 2002, 105, 136-139.	1.6	5
6657	Smooth muscle glucose metabolism promotes monocyte recruitment and atherosclerosis in a mouse model of metabolic syndrome. <i>JCI Insight</i> , 2018, 3, .	2.3	21
6658	Isoprenoids as mediators of the biological effects of statins. <i>Journal of Clinical Investigation</i> , 2002, 110, 285-288.	3.9	327
6659	Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. <i>Journal of Clinical Investigation</i> , 2001, 108, 1429-1437.	3.9	429
6660	Isoprenoids as mediators of the biological effects of statins. <i>Journal of Clinical Investigation</i> , 2002, 110, 285-288.	3.9	210
6661	Effect of Statins on Insulin Requirements during Non-Cardiac Surgery. <i>Anaesthesia and Intensive Care</i> , 2014, 42, 350-355.	0.2	1
6662	2016 Chinese guidelines for the management of dyslipidemia in adults. <i>Journal of Geriatric Cardiology</i> , 2018, 15, 1-29.	0.2	226
6663	2018 Chinese Guidelines for Prevention and Treatment of Hypertension-A report of the Revision Committee of Chinese Guidelines for Prevention and Treatment of Hypertension. <i>Journal of Geriatric Cardiology</i> , 2019, 16, 182-241.	0.2	380
6664	Vitamin D and Cardiovascular Disease. <i>Oxidative Stress and Disease</i> , 2012, , 363-384.	0.3	2
6665	Does Estrogen Have a Role in the Prevention of Cardiovascular Disease?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 1806-1812.	1.8	2
6666	JCS 2018 Guideline on Diagnosis and Treatment of Acute Coronary Syndrome. <i>Circulation Journal</i> , 2019, 83, 1085-1196.	0.7	324
6667	Apolipoprotein B-containing lipoproteins and atherosclerotic cardiovascular disease. <i>F1000Research</i> , 2017, 6, 134.	0.8	63
6668	Current Status of Lipid Management of Hypertensive Patients. <i>Hypertension Research</i> , 2003, 26, 699-704.	1.5	13
6669	The Pleiotropic Effects of Simvastatin on Retinal Microvascular Endothelium Has Important Implications for Ischaemic Retinopathies. <i>PLoS ONE</i> , 2008, 3, e2584.	1.1	52

#	ARTICLE	IF	CITATIONS
6670	The Relationships of Markers of Cholesterol Homeostasis with Carotid Intima-Media Thickness. PLoS ONE, 2010, 5, e13467.	1.1	39
6671	Atorvastatin Therapy during the Peri-Infarct Period Attenuates Left Ventricular Dysfunction and Remodeling after Myocardial Infarction. PLoS ONE, 2011, 6, e25320.	1.1	22
6672	Changes in Clinical Profile, Treatment, and Mortality in Patients Hospitalised for Acute Myocardial Infarction between 1985 and 2008. PLoS ONE, 2011, 6, e26917.	1.1	34
6673	LDL-Induced Impairment of Human Vascular Smooth Muscle Cells Repair Function Is Reversed by HMG-CoA Reductase Inhibition. PLoS ONE, 2012, 7, e38935.	1.1	10
6674	Statin Therapy and Mortality in HIV-Infected Individuals; A Danish Nationwide Population-Based Cohort Study. PLoS ONE, 2013, 8, e52828.	1.1	43
6675	Total Serum Cholesterol and Cancer Incidence in the Metabolic Syndrome and Cancer Project (Me-Can). PLoS ONE, 2013, 8, e54242.	1.1	97
6676	Patient Factors Influencing the Prescribing of Lipid Lowering Drugs for Primary Prevention of Cardiovascular Disease in UK General Practice: A National Retrospective Cohort Study. PLoS ONE, 2013, 8, e67611.	1.1	59
6677	The Effect of Statins on Mortality in Septic Patients: A Meta-Analysis of Randomized Controlled Trials. PLoS ONE, 2013, 8, e82775.	1.1	33
6678	Statins for the Prevention of Stroke: A Meta-Analysis of Randomized Controlled Trials. PLoS ONE, 2014, 9, e92388.	1.1	35
6679	Lower Intensified Target LDL-c Level of Statin Therapy Results in a Higher Risk of Incident Diabetes: A Meta-Analysis. PLoS ONE, 2014, 9, e104922.	1.1	33
6680	If Itâ€™s Not One Thing, Itâ€™s Another: An Inverse Relationship of Malignancy and Atherosclerotic Disease. PLoS ONE, 2015, 10, e0126855.	1.1	7
6681	Strategies for Primary Prevention of Coronary Heart Disease Based on Risk Stratification by the ACC/AHA Lipid Guidelines, ATP III Guidelines, Coronary Calcium Scoring, and C-Reactive Protein, and a Global Treat-All Strategy: A Comparative-Effectiveness Modeling Study. PLoS ONE, 2015, 10, e0138092.	1.1	32
6682	Genetic Variants of LDLR and PCSK9 Associated with Variations in Response to Antihypercholesterolemic Effects of Armolipid Plus with Berberine. PLoS ONE, 2016, 11, e0150785.	1.1	21
6683	High Dose Atorvastatin Associated with Increased Risk of Significant Hepatotoxicity in Comparison to Simvastatin in UK GPRD Cohort. PLoS ONE, 2016, 11, e0151587.	1.1	48
6684	Rapid Increase in Serum Low-Density Lipoprotein Cholesterol Concentration during Hepatitis C Interferon-Free Treatment. PLoS ONE, 2016, 11, e0163644.	1.1	79
6685	Association of Cognitive Impairment in Patients on 3-Hydroxy-3-Methyl-Glutaryl-CoA Reductase Inhibitors. Journal of Clinical Medicine Research, 2017, 9, 638-649.	0.6	17
6686	Statins: Then and Now. Methodist DeBakey Cardiovascular Journal, 2021, 15, 23.	0.5	54
6687	Cardiovascular outcomes trials with statins in diabetes. British Journal of Diabetes, 2018, 18, 7-13.	0.1	12

#	ARTICLE	IF	CITATIONS
6688	The Effects of Lipid-Lowering Therapy on Graft Patency in Coronary Bypass Surgery Patients. Heart Surgery Forum, 2006, 9, E626-E629.	0.2	4
6689	Changing Lifestyle Habits as Secondary Prophylaxis after Coronary Artery Bypass Grafting. Heart Surgery Forum, 2008, 11, E243-E247.	0.2	8
6690	Impact of Aspirin Treatment on Long-Term Outcome (Over 10Years) After Percutaneous Coronary Intervention. International Heart Journal, 2006, 47, 37-45.	0.5	2
6691	Angioscopic Evaluation of Stabilizing Effects of an Antilipemic Agent, Bezafibrate, on Coronary Plaques in Patients with Coronary Artery Disease.. International Heart Journal, 2002, 43, 319-331.	0.6	8
6692	Comparison of Intermittent With Continuous Simvastatin Treatment in Hypercholesterolemic Patients With End Stage Renal Failure. International Heart Journal, 2004, 45, 959-968.	0.6	6
6693	Effects of Statins on Circulating Oxidized Low-density Lipoprotein in Patients With Hypercholesterolemia. International Heart Journal, 2004, 45, 969-975.	0.6	26
6694	The Effects of Atorvastatin Treatment on the Fibrinolytic System in Dyslipidemic Patients. International Heart Journal, 2004, 45, 977-987.	0.6	11
6695	Acceptability and Long-Term Compliance with Drug Treatment for Hypercholesterolemia in Japanese Male Workers: I. Acceptability of Drug Treatment. Journal of Occupational Health, 2002, 44, 166-175.	1.0	3
6696	Beyond confusion and controversy, can we evaluate the real efficacy and safety of cholesterol-lowering with statins?. Journal of Controversies in Biomedical Research, 2015, 1, 67-92.	0.5	6
6697	Atorvastatin: evidence base 15 years later. Cardiovascular Therapy and Prevention (Russian) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tj 9,4 4	0.784314	10
6700	Management of Hypertension and Dyslipidemia for Primary Prevention of Cardiovascular Disease. , 2017, , 389-404.		9
6701	Chronic Effects of Lovastatin and Bezafibrate on Cortical and Medullary Hemodynamics in Deoxycorticosterone Acetate-Salt Hypertensive Mice. Journal of the American Society of Nephrology: JASN, 1999, 10, 1430-1439.	3.0	39
6702	Statin use and non-melanoma skin cancer risk: a meta-analysis of randomized controlled trials and observational studies. Oncotarget, 2017, 8, 75411-75417.	0.8	16
6704	Management of hyperlipidemia with statins in the older patient. Clinical Interventions in Aging, 2006, 1, 433-438.	1.3	10
6705	A new paradigm of cardiovascular risk factor modification. Vascular Health and Risk Management, 2005, 1, 101-109.	1.0	4
6706	Fasting serum triglyceride and high-density lipoprotein cholesterol levels in patients intended to be treated for dyslipidemia. Vascular Health and Risk Management, 2005, 1, 155-161.	1.0	11
6707	Optimal lipid modification: the rationale for combination therapy. Vascular Health and Risk Management, 2005, 1, 317-331.	1.0	21
6708	Efficacy and safety of atorvastatin in South Asian patients with dyslipidemia: an open label noncomparative pilot study. Vascular Health and Risk Management, 2005, 1, 351-356.	1.0	9

#	ARTICLE	IF	CITATIONS
6709	Plant sterols as dietary adjuvants in the reduction of cardiovascular risk: theory and evidence. <i>Vascular Health and Risk Management</i> , 2006, 2, 157-162.	1.0	59
6710	Who should receive a statin drug to lower cardiovascular risk? Does the drug and the dose of the drug matter?. <i>Vascular Health and Risk Management</i> , 2006, 2, 441-446.	1.0	2
6711	High density lipoprotein cholesterol: an evolving target of therapy in the management of cardiovascular disease. <i>Vascular Health and Risk Management</i> , 2008, 4, 39-57.	1.0	44
6712	Perioperative use of statins in noncardiac surgery. <i>Vascular Health and Risk Management</i> , 2008, 4, 75-81.	1.0	11
6713	Cardiovascular risk reduction in African Americans: Current concepts and controversies. <i>Global Cardiology Science &amp; Practice</i> , 2016, 2016, e201602.	0.3	7
6714	Role of Lipid-Lowering Pharmacotherapy in Children. <i>Paediatric Drugs</i> , 2000, 2, 11-22.	1.3	9
6715	Statins in Stroke. <i>Current Medicinal Chemistry</i> , 2019, 26, 6174-6185.	1.2	14
6716	Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors, Reality or Dream in Managing Patients with Cardiovascular Disease. <i>Current Drug Metabolism</i> , 2019, 20, 72-82.	0.7	12
6717	The Many Roles of Statins in Ischemic Stroke. <i>Current Neuropharmacology</i> , 2015, 12, 564-574.	1.4	39
6718	The Anti-Inflammatory Effects of Statins on Coronary Artery Disease: An Updated Review of the Literature. <i>Current Cardiology Reviews</i> , 2017, 13, 209-216.	0.6	132
6719	Relationship between Hyperlipidemia, Cardiovascular Disease and Stroke: A Systematic Review. <i>Current Cardiology Reviews</i> , 2021, 17, .	0.6	48
6720	Statin Treatment, Carotid Atherosclerotic Plaque Macrophage Infiltration and Circulating Inflammatory Markers. <i>Open Cardiovascular Medicine Journal</i> , 2008, 2, 110-114.	0.6	10
6721	The Link Between Human and Transgenic Animal Studies Involving Postprandial Hypertriglyceridemia and CETP Gene Polymorphisms. <i>Open Cardiovascular Medicine Journal</i> , 2009, 3, 48-50.	0.6	6
6722	Trends in the Use of Evidence-based Therapies Early in the Course of Acute Myocardial Infarction and its Influence on Short Term Patient Outcomes. <i>Open Cardiovascular Medicine Journal</i> , 2011, 5, 171-178.	0.6	6
6723	Telemedicine in Primary Care for Patients With Chronic Conditions: The ValCr <sup>2</sup> nic Quasi-Experimental Study. <i>Journal of Medical Internet Research</i> , 2017, 19, e400.	2.1	55
6724	IN VITRO EVALUATION OF HYPOLIPIDEMIC EFFECT OF EXTRACTS OF MEDICINAL DRACAENA CINNABARI BALF. F. RESIN. <i>Asian Journal of Pharmaceutical and Clinical Research</i> , 0, , 118-120.	0.3	1
6725	Role of niacin in current clinical practice. <i>Minerva Medica</i> , 2019, 110, 79-83.	0.3	8
6728	Trends in Cardiovascular Risk Factors Among Patients With Coronary Heart Disease. <i>Deutsches A&amp;#x0308;rztblatt International</i> , 2012, 109, 303-10.	0.6	20

#	ARTICLE	IF	CITATIONS
6729	The Treatment of Disorders of Lipid Metabolism. Deutsches A&#x0308;rzteblatt International, 2016, 113, 261-8.	0.6	55
6730	Optimal strategies for monitoring lipid levels in patients at risk or with cardiovascular disease: a systematic review with statistical and cost-effectiveness modelling. Health Technology Assessment, 2015, 19, 1-402.	1.3	30
6731	Association of Carotid Intraplaque Hemorrhage and Territorial Acute Infarction in Patients with Acute Neurological Symptoms Using Carotid Magnetization-Prepared Rapid Acquisition with Gradient-Echo. Journal of Korean Neurosurgical Society, 2015, 57, 94.	0.5	11
6732	Identifying Markers of Cardiovascular Event-Free Survival in Familial Hypercholesterolemia. Journal of Clinical Medicine, 2021, 10, 64.	1.0	9
6733	A Randomized Controlled Study to Compare the Effects of Rosuvastatin 5 mg and Atorvastatin 10 mg on the Plasma Lipid Profile in Japanese Patients with Hypercholesterolemia (ASTRO-2). Annals of Vascular Diseases, 2009, 2, 159-73.	0.2	5
6734	First-line eradication of Helicobacter pylori: Are the standard triple therapies obsolete? A different perspective. World Journal of Gastroenterology, 2010, 16, 3865.	1.4	24
6735	From blood to gut: direct secretion of cholesterol via transintestinal cholesterol efflux. World Journal of Gastroenterology, 2010, 16, 5953-7.	1.4	34
6736	Pleiotropic effects of statins in the diseases of the liver. World Journal of Gastroenterology, 2016, 22, 6201.	1.4	42
6737	Clinical Significance of On-Treatment Triglyceride Level in Patients Treated by Percutaneous Coronary Intervention for Non-ST-Segment Elevation Acute Coronary Syndrome. Korean Journal of Internal Medicine, 2009, 24, 330.	0.7	1
6738	Effects of intensive versus mild lipid lowering by statins in patients with ischemic congestive heart failure: Korean Pitavastatin Heart Failure (SAPHIRE) study. Korean Journal of Internal Medicine, 2014, 29, 754.	0.7	11
6739	Severely frail elderly patients do not need lipid-lowering drugs. Cleveland Clinic Journal of Medicine, 2017, 84, 131-142.	0.6	14
6740	Switching to Pitavastatin in Statin-Treated Low HDL-C Patients Further Improves the Lipid Profile and Attenuates Minute Myocardial Damage. Journal of Clinical Medicine Research, 2012, 4, 385-92.	0.6	7
6741	Nitric oxide and cardiovascular risk factors. Heart International, 2007, 3, 18.	0.4	14
6742	Martin's Equation as the Most Suitable Method for Estimation of Low-Density Lipoprotein Cholesterol Levels in Korean Adults. Korean Journal of Family Medicine, 2017, 38, 263.	0.4	26
6743	Statins: Past and Present. Heart Views, 2011, 12, 121.	0.1	44
6744	Correlation of Friedewald's calculated low-density lipoprotein cholesterol levels with direct low-density lipoprotein cholesterol levels in a tertiary care hospital. International Journal of Applied & Basic Medical Research, 2017, 7, 57.	0.2	10
6745	Statins: Cholesterol guidelines and Indian perspective. Indian Journal of Endocrinology and Metabolism, 2015, 19, 546.	0.2	13
6746	Pleiotropic effects of statins. Indian Journal of Endocrinology and Metabolism, 2015, 19, 554.	0.2	125

#	ARTICLE	IF	CITATIONS
6747	Statin therapy and hepatotoxicity: Appraisal of the safety profile of atorvastatin in hyperlipidemic patients. <i>Advanced Biomedical Research</i> , 2014, 3, 168.	0.2	8
6748	Effect of omega-3 supplementation on inflammatory parameters in patients on chronic ambulatory peritoneal dialysis. <i>Advanced Biomedical Research</i> , 2015, 4, 167.	0.2	11
6749	An integer based risk score for predicting 30-day major adverse cardiac or cerebrovascular events after percutaneous coronary intervention with drug-eluting stents: results from a large prospective multicentre registry, the STENT Group. <i>EuroIntervention</i> , 2011, 6, 942-948.	1.4	6
6750	Evaluation of a pharmacist-managed diabetes medication therapy adherence clinic. <i>Pharmacy Practice</i> , 2010, 8, 250-4.	0.8	29
6751	Endothelial progenitor cells: Exploring the pleiotropic effects of statins. <i>World Journal of Cardiology</i> , 2017, 9, 1.	0.5	27
6752	Prevention of Coronary Artery Disease – Time for Action!. <i>Annals of Saudi Medicine</i> , 1995, 15, 309-310.	0.5	4
6753	Dietary Management in Japan Atherosclerosis Society (JAS) Guidelines for the Prevention of Atherosclerotic Cardiovascular Diseases in Japanese – 2012 Version. <i>The Japanese Journal of Nutrition and Dietetics</i> , 2013, 71, 3-13.	0.1	5
6754	Oxidative stress, NADPH oxidases, and arteries. <i>Hamostaseologie</i> , 2016, 36, 77-88.	0.9	20
6755	Plaque-Stabilizing Effect of Pitavastatin in Watanabe Heritable Hyperlipidemic (WHHL) Rabbits. <i>Journal of Atherosclerosis and Thrombosis</i> , 2003, 10, 109-116.	0.9	38
6756	Related Factors of Meeting National Cholesterol Education Program-recommended Goals with Atorvastatin. <i>Journal of Atherosclerosis and Thrombosis</i> , 2003, 10, 19-24.	0.9	1
6757	Effect of Low- and High-Dose Atorvastatin on Carotid Artery Distensibility Using Carotid Magnetic Resonance Imaging – A Post-Hoc Sub Group Analysis of ATHEROMA (Atorvastatin Therapy). <i>Journal of Atherosclerosis and Thrombosis</i> , 2014, 21, 46-56.	0.9	14
6758	Gender Disparities In Optimal Lipid Control Among Patients with Coronary Artery Disease. <i>Journal of Atherosclerosis and Thrombosis</i> , 2014, 21 Suppl 1, S20-S28.	0.9	17
6759	Effects of Low-Dose Simvastatin on the Distribution of Plasma Cholesterol and Oxidized Low-Density Lipoprotein in Three Ultra-centrifugally Separated Low-Density Lipoprotein Subfractions: 12-Month, Open-Label Trial. <i>Journal of Atherosclerosis and Thrombosis</i> , 2010, 17, 1049-1053.	0.9	10
6760	Association between Lowering Low-Density Lipoprotein Cholesterol with Pravastatin and Primary Prevention of Cardiovascular Disease in Mild to Moderate Hypercholesterolemic Japanese. <i>Journal of Atherosclerosis and Thrombosis</i> , 2010, 17, 879-887.	0.9	24
6761	Association between Preheparin Serum Lipoprotein Lipase Mass and Acute Myocardial Infarction in Japanese Men. <i>Journal of Atherosclerosis and Thrombosis</i> , 2002, 9, 163-169.	0.9	24
6762	Mechanism of Statin-Induced Myopathy Investigated Using Microarray Technology. <i>Journal of Atherosclerosis and Thrombosis</i> , 2009, 16, 30-32.	0.9	4
6763	A Coronary Primary Intervention Study of Japanese Men: Study Design, Implementation and Baseline Data. <i>Journal of Atherosclerosis and Thrombosis</i> , 1996, 3, 95-104.	0.9	15
6764	Atherosclerotic Plaques Composed of a Large Core of Foam Cells Covered with Thin Fibrous Caps in Twice-injured Carotid Arterial Specimens Obtained From High Cholesterol Diet-Fed Rabbits. <i>Journal of Atherosclerosis and Thrombosis</i> , 2000, 7, 83-90.	0.9	13

#	ARTICLE	IF	CITATIONS
6765	Relationship between Target Lesion Revascularization after PCI and Serum Cholesterol levels, and Influence of HMG-CoA Reductase Inhibitors in This Respect. <i>Iryo Yakugaku (Japanese Journal of)</i> Tj ETQq0 0 0 rgBT /00erlock 10 Tf 50 73		
6766	Economic Impact Associated with Pharmaceutical Interventions in Cardiovascular Disease. <i>Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)</i> , 2017, 43, 680-690.	0.0	2
6767	Effect of Yogurt Supplemented with Brewer's Yeast Cell Wall on Levels of Blood Lipids in Normal and Hypercholesterolemic Adults.. <i>Journal of Oleo Science</i> , 2002, 51, 323-334.	0.6	2
6768	Vegetable Oil Enriched with Phytosterol Ester and the Degree of Serum Cholesterol Lowering Effect in Healthy Subjects. <i>Journal of Oleo Science</i> , 2003, 52, 285-294.	0.6	6
6769	Effects of Diacylglycerol Containing Phytosterol on Reducing Blood Cholesterol Level. <i>Journal of Japan Oil Chemists' Society</i> , 1999, 48, 235-240,260.	0.3	13
6770	Current perspectives on the use of statins in the treatment of dyslipidaemic patients: focus on pitavastatin. <i>Drugs in Context</i> , 2020, 9, 1-11.	1.0	3
6771	Closing the knowledge gap on cardiovascular disease in type 2 diabetes: the EMPA-REG OUTCOME trial and beyond. <i>Drugs in Context</i> , 2016, 5, 1-10.	1.0	4
6772	Psychological Stress as a Risk Factor for Cardiovascular Disease: A Case-Control Study. <i>Cureus</i> , 2020, 12, e10757.	0.2	9
6773	The B-SMART Appropriate Medication-Use Process: A Guide for Clinicians to Help Patientsâ€™ Part 1: Barriers, Solutions, and Motivation</i>. , 2009, 13, 62-69.		13
6774	Collaborative Cardiac Care Service: A Multidisciplinary Approach to Caring for Patients with Coronary Artery Disease. , 2008, 12, 4-11.		23
6775	Repeated In-Stent Restenosis Despite Aggressive Lipid Loweringby PCSK-9 Inhibitor Treatment: A Case Report. <i>Tohoku Journal of Experimental Medicine</i> , 2021, 255, 123-126.	0.5	4
6776	Association of eNOS (G894T, rs1799983) and KCNJ11 (E23K, rs5219) gene polymorphism with coronary artery disease in North Indian population. <i>African Health Sciences</i> , 2021, 21, 1163-1171.	0.3	4
6777	Effect of Financial Incentives for Process, Outcomes, or Both on Cholesterol Level Change. <i>JAMA Network Open</i> , 2021, 4, e2121908.	2.8	1
6778	Efficacy and Safety of Lipid-Lowering Drugs of Different Intensity on Clinical Outcomes: A Systematic Review and Network Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2021, 12, 713007.	1.6	6
6779	Low-density lipoprotein cholesterol levels and adverse clinical outcomes in chronic kidney disease: Results from the KNOW-CKD. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, 32, 410-419.	1.1	8
6780	Stratification Analysis of Statin Effect on Major Adverse Cardiac Events after Percutaneous Coronary Intervention in Patients on Hemodialysis. <i>Journal of Cardiovascular Pharmacology</i> , 2021, Publish Ahead of Print, .	0.8	0
6781	Anatomie und Pathologie des KoronargefÃ¶sssystems, Physiologie und Pathophysiologie der Koronardurchlutung, Pathogenese der Atherosklerose. , 2000, , 295-326.		0
6782	Multi-center prospective study in Japanese male workers with hyperlipidemia: Changes in lipid profile with diet therapy and simvastatin treatment. <i>The Journal of Japan Atherosclerosis Society</i> , 2000, 28, 23-34.	0.0	0

#	ARTICLE	IF	CITATIONS
6783	Klinik und Diagnostik der koronaren Herzkrankheit. , 2000, , 327-353.		0
6784	Insulin resistance: A pathogenic link between cardiovascular risk factors and atherosclerosis. , 2000, , 171-178.		0
6785	Koronare Herzkrankheit. , 2000, , 503-510.		0
6786	Role Of Lipid Concentrations and Apolipoproteins In Altering ApoB Metabolism and Promoting Coronary Events. , 2000, , 12-18.		0
6787	è™šè;€æ€Šâ;fç–¾æ,£ã@â†...çŠ'æ²»ç™, Juntendoì, Igaku, 2000, 46, 180-186.	0.1	0
6788	Lipidsenker und Reokklusionsprophylaxe. , 2000, , 69-88.		0
6789	Arterielle Hypertonie. , 2000, , 259-268.		0
6790	The BEST + ICD Trial: Is ICD Also Effective in the Presence of Optimized Î²-Blocking Therapy?. , 2000, , 386-397.		0
6791	SekundÄre FettstoffwechselstÄrungen: Welche Bedeutung â€” welche Therapie?. , 2000, , 333-337.		0
6793	Coronary Heart Disease, Lipid Metabolism, and Steroid Hormones in Women. , 2000, , 839-854.		0
6794	Gender Differences in Coronary Risk Factors and Risk Interventions. , 2000, , 213-236.		0
6795	Does the Gene Encoding Apolipoprotein A-IMilano Protect the Heart?. , 2000, , 67-81.		0
6796	Prevention of Heart Disease. , 2000, , 176-191.		0
6797	Stoffwechsel und endokrine Erkrankungen. , 2000, , 255-310.		0
6798	Target Level of Pravastatin Therapy to Improve Hemodynamics in Patients with Hypercholesterolemia.. Japanese Journal of Clinical Pharmacology and Therapeutics, 2000, 31, 19-24.	0.1	0
6799	Lipid-Lowering Drugs. , 2000, , 155-177.		0
6800	Weitere kardiovaskulÄre Risikofaktoren. , 2000, , 269-291.		0
6801	Therapie der stabilen und instabilen Angina pectoris. , 2000, , 355-391.		0



#	ARTICLE	IF	CITATIONS
6802	Durchblutungsfördernde Mittel. , 2000, , 306-316.		0
6803	Lipidsenkende Mittel. , 2000, , 382-391.		0
6804	Atherosclerosis Research after the Second World War. , 2000, , 323-342.		0
6805	Circadian Variation in Myocardial Ischemia and Infarction. Developments in Cardiovascular Medicine, 2000, , 247-261.	0.1	0
6806	Ernährungsverhalten im mittleren und höheren Lebensalter. , 2000, , 273-288.		1
6807	Lipid-Lowering Drugs. , 2000, , 215-238.		1
6808	Ökonomische Aspekte in der Kardiologie. , 2000, , 1389-1396.		0
6810	Grundprinzipien medikamentöser Therapie und allgemeiner Lebensweise. , 2000, , 331-338.		0
6811	How far does the treatment of coronary arterial lesion link up to preventing acute MI?. The Journal of Japan Atherosclerosis Society, 2000, 27, 159-164.	0.0	0
6812	Therapie von Fettstoffwechselstörungen, Harnsäuremetabolismus bzw. Gicht. , 2000, , 504-522.		0
6813	Fettstoffwechsel, Übergewicht und Ernährung, Diabetes. , 2000, , 239-257.		0
6814	Title is missing!. Neurosonology, 2000, 13, 71-74.	0.0	0
6815	Pharmacologic Treatment of Dyslipidemia. American Journal of Nursing, 2000, 100, 55-60.	0.2	0
6816	A case for lipid-lowering?. Diabetic Medicine, 2000, 17, 4-5.	1.2	1
6817	The Aging Heart. , 2001, , 401-410.		0
6818	Lipoproteins and Atherosclerosis. Developments in Cardiovascular Medicine, 2001, , 51-58.	0.1	0
6819	From the Heartland. , 2001, , 141-162.		1
6820	Dietary Fat, Blood Lipids, and Coronary Heart Disease Risk. , 2001, , 121-134.		0

#	ARTICLE	IF	CITATIONS
6821	Epidemiologie zerebrovaskulärer Erkrankungen. , 2001, , 123-149.		0
6822	Plötzlicher Tod: ACE-Hemmer und ß-Blocker. , 2001, , 60-66.		0
6823	In Vivo Assessment of Rat Hearts with and without Myocardial Infarction by Cine NMR - Comparison of the NMR Method to Invasive Techniques and Application to Intervention Studies. Lecture Notes in Computer Science, 2001, , 97-103.	1.0	0
6824	How To Make A Mountain and A Mint Out of, At Most, A Molehill: Statin Drugs. , 2001, , 95-116.		0
6825	Sekundärprävention zerebraler Durchblutungsstörungen. , 2001, , 463-476.		0
6826	é...âCE-LDLâ...çj-âCE-. Japanese Journal of Geriatrics, 2001, 38, 447-451.	0.0	0
6827	Ärztlicher Blick über die Arzneiverordnungen im Jahr 2000. , 2001, , 1-22.		2
6828	Lipidsenkende Mittel. , 2001, , 483-493.		0
6829	Lipidsenkende Mittel. , 2001, , 444-454.		0
6830	Genetic Influences on Blood Lipids and Cardiovascular Disease Risk. , 2001, , 157-182.		0
6831	Praxis der Lipid senkenden Therapie in der kardiologischen Rehabilitation. , 2001, , 125-131.		0
6832	New Approaches to Atherosclerosis Based on Endothelial Function. , 2001, , 1-14.		3
6833	Q-Wave Myocardial Infarction. , 2001, , 177-193.		1
6834	An Analysis of Antiarteriosclerotic Agents Using a Prescription Database.. Iryo Yakugaku (Japanese) Tj ETQq1 1 0.784314 rgBj /Overlo	0.0	0
6835	é...âCE-LDLâ...çj-âCE-. Japanese Journal of Geriatrics, 2001, 38, 625-627.	0.0	1
6836	â...çj-âCE-â...çj-âCE-. Japanese Journal of Geriatrics, 2001, 38, 296-299.	0.0	0
6837	Risk Factors for Atherosclerosis in the Elderly. , 2001, , 448-459.		0
6838	Obesity and Chronic Disease. , 2001, , 205-221.		3

#	ARTICLE	IF	CITATIONS
6839	Lipidstoffwechsel und Diabetes. , 2001, , 271-286.		0
6840	Zerebrale Durchblutungsstörungen und Herzerkrankungen: â€žSitzten Neurologen und Kardiologen im gleichen Boot?â€œ. , 2001, , 75-79.		0
6841	Ursachen der koronaren Herzkrankheit â€” die Rolle von Hyperlipidämie, Bluthochdruck und Rauchen. , 2001, , 86-98.		0
6842	Risk Factors for and Prevention of Atherosclerotic Cardiovascular Disease. , 2001, , 97-106.		0
6843	Coronary artery disease: Part 2. Treatment. Western Journal of Medicine, 2001, 174, 330-335.	0.3	1
6844	Cost effectiveness of ramipril treatment for cardiovascular risk reduction. Heart, 2001, 85, 539-543.	1.2	0
6845	Clinical Assessment of Endothelial Function. , 2002, , 691-700.		2
6846	Renal Vascular Diseases. , 2002, , 1751-1786.		0
6847	Coronary Atherosclerosis: Chronic Coronary Syndromes. , 2002, , 779-820.		0
6848	Hormone Replacement Therapy and Cardiovascular Disease in Women. , 2002, , 1832-1836.		0
6849	Coronary Artery Disease and Endothelial Function. , 2002, , 887-912.		0
6850	Koronarpharmaka. Springer-Lehrbuch, 2002, , 343-360.	0.1	0
6851	Indications and contra-indications for statin treatment (primary and secondary prevention of) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 262		0
6852	Clinical experience: studies with HMG-CoA reductase inhibitors. , 2002, , 121-133.		0
6853	Women and CHD: The Case for Prevention. Medical Science Symposia Series, 2002, , 377-385.	0.0	0
6854	Reducing Cardiovascular Risk in Postmenopausal Women: Estrogen or Statins?. Medical Science Symposia Series, 2002, , 123-130.	0.0	0
6857	Vascular Disease in Diabetes Mellitus. , 2002, , 995-1008.		0
6858	Effects of combined therapy using HMG-CoA reductase inhibitor and colestimide on refractory hypercholesterolemia. The Journal of Japan Atherosclerosis Society, 2002, 29, 51-56.	0.0	0

#	ARTICLE	IF	CITATIONS
6859	PPAR $\alpha$ , Lipoprotein Metabolism, Metabolic Diseases, and Atherosclerosis. Medical Science Symposia Series, 2002, , 63-79.	0.0	0
6860	Effect of Plant Sterols and Stanols on Blood Cholesterol Level: Clinical Evidence of Minimum Effective Dose.. Nihon EiyÅ•ShokuryÅ•Gakkai Shi = Nippon EiyÅ•ShokuryÅ•Gakkaishi = Journal of Japanese Society of Nutrition and Food Science, 2002, 55, 177-189.	0.2	9
6861	Hyperlipidemia Pharmacy Practice. , 2002, , 461-468.		0
6862	Statine. Pharma-Kritik (discontinued), 2002, 24, .	0.0	0
6865	Leukocyte-Endothelial Interactions Following Myocardial Ischemia. , 2003, , 427-438.		0
6867	Inflammation and Cardiovascular Disease. Progress in Experimental Cardiology, 2003, , 3-18.	0.0	0
6868	Cardiovascular Risk Factors and Peripheral Arterial Disease. , 2003, , 113-120.		0
6869	The effect of early treatment by cerivastatin on the serum level of C-reactive protein, interleukin-6, and interleukin-8 in the patients with unstable angina and non-Q-wave myocardial infarction. , 2003, , 45-50.		10
6870	Koronarinsuffizienz und Herzinfarkt. , 2003, , 3-29.		0
6871	Lipidsenkende Mittel. , 2003, , 517-529.		0
6872	Primary and Secondary Prevention of Coronary Heart Disease. , 2003, , 145-174.		0
6873	What do cardiologists want from vascular ultrasound?. , 2003, , 3-27.		0
6874	Therapie von FettstoffwechselstÅ•rungen, HarnsÅ•ureidiathese bzw. Gicht. , 2003, , 533-552.		0
6875	Lipid-Lowering Drugs. , 2003, , 165-191.		0
6876	FettstoffwechselstÅ•rungen. , 2003, , 854-866.		0
6877	Reducing Cardiovascular Risk with HMG CoA Reductase Inhibitors, Potential Contribution from Platelets. Progress in Experimental Cardiology, 2003, , 107-118.	0.0	0
6879	7.ã»Šã¼4CEã•æŠ—é«~è,,è;€ç—tè—ã•è†ã°Šè© é““. Japanese Journal of Clinical Pharmacology and Therapeutics, 2003, 34, 543S-544S.		0
6880	Prevention of Stroke. , 2003, , 349-362.		0

#	ARTICLE	IF	CITATIONS
6882	Management of Acute Coronary Syndromes. , 2003, , 15-36.		1
6883	Gender Differences in Coronary Risk Factors and Risk Interventions. , 2003, , 235-258.		0
6884	Prevention of Heart Failureâ€”A Clinical Reality?. Progress in Experimental Cardiology, 2003, , 549-561.	0.0	0
6886	Treatment of diabetic nephropathy. , 2003, , 135-141.		1
6887	Management of Unstable Angina and Non-ST Elevation Myocardial Infarction. , 2003, , 109-125.		0
6888	Epidemiology of Atherosclerosis and Its Modification. , 2003, , .		0
6890	The discovery and development of the statins. , 2003, , 31-43.		0
6891	Vascular Function, Aging, and the Impact of Diet. , 2004, , 379-398.		0
6892	Treatment Strategies for Women With Stable Angina. , 2004, , 197-214.		0
6893	Cardiovascular Disease, Genes, and Nutrition: Gender Matters. , 2004, , 737-751.		0
6894	Primary Prevention of Sudden Death in Post-Infarction Patients: When ICD Implantation is Really Cost-effective. , 2004, , 497-504.		0
6895	Verordnungsprofil der Internisten. , 2004, , 1013-1041.		0
6896	Risk Detection and Primary Prevention in Women. , 2004, , 29-45.		0
6897	Elevated high-sensitivity C-reactive protein and interleukin-6 in chronic stroke patients-Effects of statin agents and subtype of stroke-. Nosotchu, 2004, 26, 423-429.	0.0	0
6898	Immunosuppression in Pancreas Transplantation. , 2004, , 267-347.		3
6899	Lipidsenkende Mittel. , 2004, , 570-583.		0
6900	PrÃvention der koronaren Herzerkrankung. , 2004, , 1119-1147.		0
6901	Expanding ICD Indications: Can We Afford It?. , 2004, , 511-517.		0

#	ARTICLE	IF	CITATIONS
6902	Molekulare VerÄnderungen beim ischÄmischen Schlaganfall. , 2004, , 228-255.		0
6904	Kardiologie. , 2004, , 313-356.		0
6905	Lipidsenkende Mittel. , 2004, , 641-658.		0
6907	The poorly controlled type 2 diabetic patient. , 2004, , 197-231.		1
6908	Tutorials in Therapeutics Should Cholesterol Level be lowered below "Normal": Insights from the Heart Protection Study. Qatar Medical Journal, 2004, 2004, .	0.2	0
6909	Bedside Platelet Monitoring. , 2004, , 495-520.		0
6910	Treatment of Vulnerable Plaques. , 2004, , 164-202.		0
6912	Diabetes Mellitus and the Cardiovascular Metabolic Syndrome: Reducing Cardiovascular and Renal Events. , 2005, , 543-556.		0
6914	Usefulness of Preheparin Lipoprotein Lipase Mass as a Parameter for Predicting the Efficacy of Colestimide. Journal of Atherosclerosis and Thrombosis, 2005, 12, 218-224.	0.9	2
6915	NONINVASIVE MYOCARDIAL ENDOTHELIAL INTERVENTION IN THE PERSISTENCE OF CORONARY STENOSIS: A CONCEPT OF MYOCARDIAL ENDOTHELIAL NITRIC OXIDE ACTIVATOR THROUGH HEART FAILURE RESEARCH ON CLINICAL DEMAND. Fukushima Journal of Medical Sciences, 2005, 51, 51-66.	0.1	0
6916	Advances in the Acute Treatment and Secondary Prevention of Stroke. , 2005, , 21-33.		0
6918	Statin prescribing in primary care. Independent Nurse, 2005, 2005, .	0.0	0
6919	Management of Hypertension in Carotid Stenosis. Neurological Disease and Therapy, 2005, , 151-158.	0.0	0
6920	Stroke Prevention, Blood Cholesterol and Statins. Neurological Disease and Therapy, 2005, , 123-150.	0.0	0
6921	Diet in the Management of Patients with Carotid Stenosis. Neurological Disease and Therapy, 2005, , 175-180.	0.0	0
6923	Pharmacological Treatments of Lipid Abnormalities. , 2005, , 183-212.		0
6924	Pharmacogenetics: Focus on the Liver. , 2006, , 53-66.		0
6925	Is er nog plaats voor fibrinaten allÄ©n, of moet altijd een statine eerst worden gebruikt en bij slecht resultaat een fbraat toegevoegd?. , 2006, , 2137-2137.		0

#	ARTICLE	IF	CITATIONS
6926	Medical Treatment of Peripheral Arterial Disease. , 2006, , 271-292.		0
6927	Epidemiology of Cerebrovascular Disease * *This work was supported in part by the National Institute of Neurological Disorders and Stroke Grant No. 5R01 NS17950 and the National Heart, Lung, and Blood Institute's Framingham Heart Study Contract No. N01-HC-25195.. , 2006, , 411-432.		0
6928	Is het gerechtigd om bij diabetes mellitus II statines voor te schrijven onafhankelijk van de cholesterolwaarden?. , 2006, , 2153-2154.		0
6929	Preventive Heart Disease: Dyslipidemia and Hypertension (Systemic). , 2006, , 373-385.		0
6930	Antianginal drugs. , 2006, , 260-263.		0
6931	Lower Extremity Arterial Reconstruction in Patients With Diabetes Mellitus. , 2006, , 473-492.		1
6932	Pharmacological interventions in reperfusion therapy for acute myocardial infarction. , 2006, , 111-128.		0
6933	Statins and Toxicity. , 2006, , 273-295.		1
6934	Secondary Prevention of Coronary Heart Disease in Primary Health Care. Bosnian Journal of Basic Medical Sciences, 2018, 6, 37-41.	0.6	2
6935	Pharmacogenetics and Metabolic Disease. , 2006, , 243-272.		0
6936	The case for a generic statin. Independent Nurse, 2006, 2006, .	0.0	0
6937	Sudden cardiac death: the size of the problem. , 2006, , 25-36.		0
6938	Cardiac Rehabilitation: Statins and the Rationale for Implementation of Lipid-Lowering Therapy. , 2007, , 141-156.		0
6939	Frequently cited criticisms. , 2007, , 205-213.		0
6940	Pharmacological Therapy for Cardiovascular Disease. , 2007, , 121-148.		1
6941	Chronic Stable Angina. , 2007, , 290-313.		0
6942	4. Primary Prevention of Hypertension. Japanese Journal of Clinical Pharmacology and Therapeutics, 2007, 38, 197-203.	0.1	0
6943	Dietary Prescriptions to Control Dyslipidemias and Coronary Disease Risk. , 2007, , 113-120.		0

#	ARTICLE	IF	CITATIONS
6944	Management of Cholesterol Disorders. , 2007, , 2667-2691.		0
6945	Management of Lipids in the Elderly. , 2007, , 369-387.		0
6946	Management of Diabetic Dyslipidaemia. , 2007, , 173-186.		1
6947	Familial Hypercholesterolemia and Lipid Apheresis. , 2007, , 267-289.		1
6948	Title is missing!. Japanese Journal of Clinical Pharmacology and Therapeutics, 2007, 38, 299-304.	0.1	0
6949	Statins, Oxidative Stress, and Polycystic Ovary Syndrome. , 2007, , 263-278.		1
6950	Lipid-lowering agents. , 2007, , 155-170.		0
6951	Common hyperlipidaemia. , 2007, , 125-168.		0
6952	Genetic Factors that Contribute to Interindividual Variations in Plasma Low Density Lipoproteinâ€Cholesterol Levels. Novartis Foundation Symposium, 1996, 197, 194-210.	1.2	1
6953	Dyslipidemia and Diabetes. , 2007, , 405-416.		1
6956	Lipidsenkende Mittel. , 2008, , 645-659.		0
6957	Overview of Evidence Supporting the Treatment of Hyperlipidemia. , 2008, , 1-13.		0
6958	Traitement des dyslipidÃ©mies. , 2008, , 443-462.		0
6959	Traitement de l'infarctus du myocarde avec sus-dÃ©calage du segment ST. , 2008, , 127-155.		0
6961	Ereigniszeiten und konkurrierende Risiken â€œ zur Planung und Auswertung der 4D -Studie. , 2008, , 379-398.		0
6963	Evolving Targets of Therapy. , 2009, , 387-395.		0
6964	Prise en charge des diabÃ©tiques. , 2009, , 105-117.		0
6966	Carotid Artery Stenosis Prevalence and Medical Therapy. Contemporary Cardiology, 2009, , 3-19.	0.0	0



#	ARTICLE	IF	CITATIONS
6967	Lipidsenkende Mittel. , 2009, , 637-652.		0
6968	Invasive Imaging Modalities and Atherosclerosis: The Role of Intravascular Ultrasound. , 2009, , 410-419.		1
6971	Nutrition and Lifestyle Change in Older Adults with Diabetes Mellitus and Metabolic Syndrome. , 2009, , 279-317.		1
6972	Coronary Artery Disease Prevention. , 2009, , 17-32.		0
6973	Lipid Disorders. , 2009, , 65-75.		0
6975	NHG-Standaard Cardiovasculair risicomanagement. , 2009, , 106-152.		4
6976	Stratégies pédagogiques et outils pragmatiques pour réduire le risque cardiovasculaire. , 2009, , 163-171.		0
6977	Intravascular Ultrasound. , 2009, , 83-93.		0
6978	Special Patient Populations: Acute Coronary Syndromes. , 2009, , 473-485.		0
6979	NHG-Standaard Beleid na een doorgemaakt myocardinfarct. , 2009, , 87-105.		1
6980	Are the upper limits for serum cholesterol levels necessary?. Journal of Lipid Nutrition, 2009, 18, 33-50.	0.1	0
6981	Nutrition, Metabolic Syndrome, and Diabetes in the Senior Years. , 2010, , 389-417.		1
6984	Kidney Disease and Medications. , 2010, , 208-217.		0
6991	Lower Limb Claudication Due to Iliac Artery Occlusive Disease. , 2010, , 173-185.		0
6992	Childhood Obesity, Atherogenesis, and Adult Cardiovascular Disease. , 2010, , 265-278.		0
6993	Ezetimibe in the Treatment of Patients with Metabolic Diseases. European Endocrinology, 2010, 9, 55.	0.8	0
6994	Willingness to Pay for Over-the-counter Pravastatin in Self-medication for the Primary Prevention of Myocardial Infarction. Japanese Journal of Pharmacoepidemiology/Yakuzai Ekigaku, 2010, 15, 1-9.	0.0	0
6995	Bewegungstherapie bei koronarer Herzkrankheit. , 2010, , 115-142.		1

#	ARTICLE	IF	CITATIONS
6997	Cardiovascular Risk Factors in Infancy and Childhood. , 2010, , 1219-1227.		0
6998	Lipoprotein Metabolism and the Treatment of Lipid Disorders. , 2010, , 788-807.		0
6999	Should We Aggressively Treat the Patient with High Levels of Cholesterol Even in Japanese?. Health Evaluation and Promotion, 2010, 37, 673-678.	0.0	0
7000	Pharmacoeconomics. , 2010, , 999-1010.		0
7001	Management of Dyslipidemia. , 2011, , 59-89.		0
7002	Coronary Artery Bypass Surgery. , 2011, , 263-279.		1
7003	Unstable Angina and Non-ST Elevation Myocardial Infarction. , 2011, , 195-225.		0
7004	Risk Reduction in the Diabetic Patient. , 2011, , 281-315.		1
7005	Strategies for Treating Abnormal Lipid Profiles with Drugs. , 2011, , 163-193.		1
7006	Gender Differences in Coronary Risk Factors and Risk Interventions. , 2011, , 253-299.		0
7007	Diabetic Dyslipidemia. , 2011, , 213-238.		1
7010	NHG-Standaard Beleid na een doorgemaakt myocardinfarct. , 2011, , 341-359.		0
7011	Stabilizing unstable plaque in acute coronary syndromes. , 2011, , 338-345.		0
7013	Plaque Passivation and Endothelial Therapy. , 2011, , 289-298.		0
7015	Disorders of Lipid Metabolism. , 2011, , 1633-1674.		5
7017	4 Statistical expressions of benefit and harm. , 2011, , 36-45.		0
7019	Stable Angina. , 2012, , 1-18.		0
7020	Secondary Prevention Strategies. , 2012, , 169-182.		0

#	ARTICLE	IF	CITATIONS
7023	Controversy about cholesterol lowering therapy. Health Evaluation and Promotion, 2012, 39, 764-770.	0.0	0
7026	Lifestyle Interventions and Behavior Change. , 2012, , 100-111.		0
7028	The Impact of Diabetes in Older Adults. , 2012, , 453-475.		0
7029	Lipidsenkende Mittel. , 2012, , 697-711.		0
7032	Predictors of plaque area for culprit lesion in patients with ischemic heart disease who underwent percutaneous coronary intervention. Journal of the Japanese Coronary Association, 2012, 18, 21-29.	0.0	0
7035	Clinical perspectives on the management of advanced stable coronary disease. , 2012, , 377-384.		0
7038	The Role and Potential of Surrogate Outcomes in Clinical Trials: Have We Made Any Progress in the Past Decade?. Lecture Notes in Statistics, 2013, , 3-19.	0.1	1
7039	Mid-term Angioscopic Assessment of Saphenous Vein Grafts after Coronary Bypass. Journal of the Japanese Coronary Association, 2013, 19, 328-332.	0.0	0
7040	Umsatzveränderungen in einzelnen Indikationsgruppen. , 2013, , 43-376.		0
7041	Hormone Replacement Therapy and Cardiovascular Disease in Women. , 2013, , 1-10.		0
7042	Lipidsenkende Mittel. , 2013, , 687-702.		0
7044	PCSK9 - A New and Potent Approach to Lowering Cholesterol. Oman Medical Journal, 2013, 28, 155-158.	0.3	0
7047	Dyslipidemia. , 2014, , 489-502.		1
7048	How Lipid-Lowering Agents Work: The Good, the Bad, and the Ugly. , 2014, , 45-65.		0
7049	Lipidsenkende Mittel. , 2014, , 733-746.		0
7050	Statins: Practical Considerations – A Review. European Cardiology Review, 2014, 9, 71.	0.7	5
7051	Oxidative Stress in Diabetes Mellitus and Possible Interventions. Oxidative Stress in Applied Basic Research and Clinical Practice, 2014, , 237-261.	0.4	0
7053	Umsatzveränderungen in einzelnen Indikationsgruppen. , 2014, , 49-376.		0

#	ARTICLE	IF	CITATIONS
7054	Effect of Pitavastatin on Vascular Reactivity in Hypercholesterolemic Rabbits. Arquivos Brasileiros De Cardiologia, 2014, 103, 4-12.	0.3	3
7055	Medical Management of Coronary Artery Disease. , 2014, , 1-17.		0
7056	Cardiovascular Disease in Renal Transplantation. , 2014, , 472-490.		1
7058	Cholesterol-Lowering Coronary Angiography Trials: An Overview. Medical Science Symposia Series, 1995, , 321-333.	0.0	0
7060	Doctors, research funds and marketing. Medical Journal of Australia, 1995, 162, 670-672.	0.8	0
7061	Clinical efficacy and safety of pravastatin treatment in symptomatic patients – the REGRESS trial. Developments in Cardiovascular Medicine, 1996, , 85-106.	0.1	0
7062	Hydroxymethylglutaryl CoA Reductase. The Journal of Japan Atherosclerosis Society, 1996, 23, 389-396.	0.0	0
7063	Simvastatin-Induced Reduction in Risk of Major Coronary Events is Related Mainly to Reduction in Ldl Cholesterol But also to Increase in Hdl Cholesterol. Medical Science Symposia Series, 1996, , 169-174.	0.0	0
7064	Treatment of Hyperlipidemia in Women. Medical Science Symposia Series, 1996, , 425-438.	0.0	0
7065	Impact upon angiographic disease progression following step drug therapy in normolipidaemic patients: results of the Harvard Atherosclerosis Reversibility Project (HARP). Developments in Cardiovascular Medicine, 1996, , 179-191.	0.1	0
7067	Epidemiologie und Prävention der koronaren Herzkrankheit. , 1996, , 601-623.		0
7068	Koronare Herzkrankheit. , 1996, , 241-255.		0
7069	The Effect of Simvastatin on the Lipids in the Plasma Lipoprotein Fraction. The Journal of Japan Atherosclerosis Society, 1996, 23, 459-468.	0.0	0
7070	Treatment goal. The Journal of Japan Atherosclerosis Society, 1996, 23, 643-644.	0.0	0
7071	Drug Treatment of Hyperlipidemia in the Elderly: Hmg-Coa Reductase Inhibitors and Fibrin Acid Derivatives. Medical Science Symposia Series, 1996, , 459-464.	0.0	0
7072	Defining the Clinical Benefit of Cholesterol Lowering. Medical Science Symposia Series, 1996, , 145-149.	0.0	0
7073	Prevention of Osteoporosis. , 1996, , 275-285.		0
7074	Effect of aggressive versus conventional lipid-lowering treatment on coronary and peripheral atherosclerosis: design and baseline characteristics of the LDL-Apheresis Atherosclerosis Regression Study (LAARS). Developments in Cardiovascular Medicine, 1996, , 193-202.	0.1	0

#	ARTICLE	IF	CITATIONS
7075	Assessment of the coronary arteries with electron beam computed tomography. Developments in Cardiovascular Medicine, 1996, , 545-558.	0.1	0
7076	Koronare Herzkrankheit und Herzinfarkt. , 1996, , 421-554.		0
7077	Diabetes and Atherosclerosis: The Diabetes Atherosclerosis Intervention Study (Dais). Medical Science Symposia Series, 1996, , 405-411.	0.0	0
7078	Secondary prevention of myocardial infarction: the roles of $\beta$ -adrenergic blockers, calcium-channel blockers, angiotensin converting enzyme inhibitors, and aspirin. Developments in Cardiovascular Medicine, 1996, , 367-394.	0.1	7
7079	The role of coronary vasomotor tone in coronary artery disease. Developments in Cardiovascular Medicine, 1996, , 219-236.	0.1	0
7081	Long-Term Effect of Ldl-Apheresis on Coronary Heart Disease. Medical Science Symposia Series, 1996, , 513-519.	0.0	0
7082	Medical Management of Postmyocardial Infarction Patients. Medical Science Symposia Series, 1996, , 477-482.	0.0	0
7083	Clinical Consequences of Lowering Cholesterol. Medical Science Symposia Series, 1996, , 137-143.	0.0	0
7084	Extending the Benefit of Lipid Lowering: A Look Ahead. Medical Science Symposia Series, 1996, , 151-155.	0.0	0
7085	Pharmakotherapie bei Dyslipoproteinämien. , 1996, , 651-666.		1
7086	what are criteria for treatment of dyslipidemia in women?. Medical Science Symposia Series, 1996, , 413-423.	0.0	0
7087	Battling Heart Disease. Science, 1996, 273, 15-16.	6.0	0
7088	Spezielle Erkrankungen mit präventivem Potential. , 1997, , 193-569.		0
7089	Primär- und Sekundärprävention des Schlaganfalls. , 1997, , 73-84.		0
7090	Impaired Regulation of Vascular Tone by Endothelial Cells in Atherosclerosis. The Journal of Japan Atherosclerosis Society, 1997, 24, 443-448.	0.0	0
7091	Title is missing!. The Journal of Japan Atherosclerosis Society, 1997, 25, 83-91.	0.0	0
7092	Primary and Secondary Prevention of Cardiovascular Diseases in Menopausal Women: Alternative Treatment to Hormonal Replacement Therapy. Medical Science Symposia Series, 1997, , 327-338.	0.0	0
7093	Cerebrovascular Disease: Precursors and Prevention.. Nosotchu, 1997, 19, 87-97.	0.0	0

#	ARTICLE	IF	CITATIONS
7094	Introduction to Invasive Assessment of the Coronary Circulation. Developments in Cardiovascular Medicine, 1997, , 25-47.	0.1	0
7095	Approaches for the Design of Novel Anti-Atherogenic Compounds. Sub-Cellular Biochemistry, 1997, 28, 507-539.	1.0	0
7096	Effects of dietary therapy in people with hypercholesterolemia in a medical examination system. The Journal of Japan Atherosclerosis Society, 1997, 25, 147-152.	0.0	0
7097	Rationale Therapie bei koronarer Herzkrankheit. , 1997, , 49-55.		0
7099	Lipid nutrition guideline in the satiation age. Background of the chairman summary 1997.. Journal of Lipid Nutrition, 1997, 6, 6-42.	0.1	0
7100	Endothelial (dys)Function, Lipid Reduction and Balloon Angioplasty. Developments in Cardiovascular Medicine, 1997, , 55-82.	0.1	1
7101	Effects of Renovascular Disease and Autotransplantation on Blood Pressure and Renal Function. , 1997, , 1-20.		0
7102	Koronarpharmaka. Springer-Lehrbuch, 1997, , 331-348.	0.1	0
7103	Serum Total, Fractionated Cholesterol Concentration Distribution and Prevalence of Hypercholesterolemia in Saudi Arabia, Regional Variation. Annals of Saudi Medicine, 1997, 17, 179-184.	0.5	1
7104	Moderatormanual Koronare Herzkrankheit. , 1998, , 129-165.		0
7105	Prophylaxe ischämischer Insulte. , 1998, , 1328-1333.		0
7106	Atherosclerosis: Implications of Angiotensin II and the AT-1 Receptor. Progress in Experimental Cardiology, 1998, , 233-243.	0.0	0
7107	Perspectives on Lipid-Lowering Therapy: Past and Present. Medical Science Symposia Series, 1998, , 25-33.	0.0	0
7108	When and How to Treat Hypercholesterolemia in the Elderly?. , 1998, , 219-225.		0
7109	Pathophysiology of Atherosclerosis. Developments in Cardiovascular Medicine, 1998, , 3-58.	0.1	0
7110	Effect of Statins Beyond Lowering Cholesterol: Where Do We Stand?. Medical Science Symposia Series, 1998, , 253-265.	0.0	0
7111	Dyslipidemias. , 1998, , 1056-1065.		0
7115	Lipoproteins and Cardiovascular Risk: From Genetics to Prevention of Coronary Heart Disease. Medical Science Symposia Series, 1998, , 217-228.	0.0	1

#	ARTICLE	IF	CITATIONS
7118	European Action on Secondary Prevention. Medical Science Symposia Series, 1998, , 109-117.	0.0	0
7119	Lipid Lowering Drugs and the Arterial Wall. Medical Science Symposia Series, 1998, , 19-24.	0.0	0
7120	Improving the Cost Effectiveness of Lipid Lowering Therapy in Coronary Heart Disease Prevention. Medical Science Symposia Series, 1998, , 275-284.	0.0	0
7123	Therapie von DyslipoproteinÄmien. , 1998, , 957-972.		0
7124	Das metabolische Syndrom bei Frauen. , 1998, , 9-16.		0
7125	Medical Treatment in the Case of Severe Coronary Artery Disease. , 1998, , 67-77.		0
7126	LETTERS TO THE EDITOR. Annals of Surgery, 1998, 227, 314-315.	2.1	1
7127	Cholestanol and survival with simvastatin. BMJ: British Medical Journal, 1998, 317, 1252-1252.	2.4	0
7128	Hyperlipidaemia and cardiovascular disease. Current Opinion in Lipidology, 1998, 9, 507-510.	1.2	0
7129	Therapy and clinical trials. Current Opinion in Lipidology, 1998, 9, 519-520.	1.2	0
7130	The management of lipids Are we being effective?. Primary Health Care, 1998, 8, 21-26.	0.0	0
7131	Secondary prevention in coronary heart disease. BMJ: British Medical Journal, 1998, 317, 1592-1592.	2.4	1
7132	Zerebrale DurchblutungsstÄrungen. , 1999, , 1151-1166.		0
7133	Homocysteine-a independent risk factor for atherosclerosis. The Journal of Japan Atherosclerosis Society, 1999, 26, 249-257.	0.0	0
7134	FettstoffwechselstÄrungen. , 1999, , 770-782.		0
7135	Is Selective Reporting of Well-Designed Clinical Research Unethical as Well as Unscientific?. , 1999, , 90-98.		0
7136	Title is missing!. Journal of Lipid Nutrition, 1999, 8, 25-36.	0.1	0
7137	Standardization of Serum Total Cholesterol by CDC/CRMLN Protocol. The Journal of Japan Atherosclerosis Society, 1999, 27, 7-15.	0.0	2

#	ARTICLE	IF	CITATIONS
7138	Human Diseases as Models of Accelerated Aging. , 1999, , 51-58.		0
7139	Risk Factor Modification. Developments in Cardiovascular Medicine, 1999, , 107-126.	0.1	0
7140	Cholesterol Lowering. Contemporary Cardiology, 1999, , 571-592.	0.0	0
7141	Secondary Prevention of Myocardial Infarction. Contemporary Cardiology, 1999, , 593-600.	0.0	0
7142	Lipid Lowering Therapy. Developments in Cardiovascular Medicine, 1999, , 69-101.	0.1	0
7143	Der Blutdruck im Alter " Hypertonie und Hypotonie. , 1999, , 36-66.		0
7144	Das Herz des alternden Menschen. , 1999, , 67-125.		0
7146	Koronarinsuffizienz und Herzinfarkt. , 1999, , 3-31.		0
7147	Megatrial of cholesterol lowering therapy. The Journal of Japan Atherosclerosis Society, 1999, 26, 205-209.	0.0	0
7148	Effects of Combined Therapy Using Two Kinds of HMG-CoA Reductase Inhibitors in Heterozygous Familial Hypercholesterolemia. The Journal of Japan Atherosclerosis Society, 1999, 27, 1-6.	0.0	0
7149	Management of Stable Angina Pectoris. Developments in Cardiovascular Medicine, 1999, , 19-39.	0.1	0
7150	Koronarpharmaka. Springer-Lehrbuch, 1999, , 331-348.	0.1	0
7151	Durchblutungsfördernde Mittel. , 1999, , 281-290.		0
7152	Lipidsenkende Mittel. , 1999, , 356-365.		0
7153	Coronary Intervention. Developments in Cardiovascular Medicine, 1999, , 225-237.	0.1	0
7154	Glukosetoleranz und Diabetes mellitus im Alter. , 1999, , 203-243.		0
7156	Ärberblick über die Arzneverordnungen im Jahre 1997. , 1999, , 1-19.		0
7157	Economic Evaluation of the Use of HMG-CoA Reductase Inhibitors (Statins for the Primary Prevention) Tj ETQq1 1 0,784314 rgBT /Overl 0,0	0,0	0



#	ARTICLE	IF	CITATIONS
7158	Secondary prevention in coronary heart disease. <i>BMJ: British Medical Journal</i> , 1999, 318, 1419-1419.	2.4	0
7159	Maybe the time has come for the primacy of the patient in the NHS. <i>BMJ: British Medical Journal</i> , 1999, 318, 1700-1700.	2.4	0
7161	Nuclear Cardiology 2: Myocardial Perfusion, Metabolism, Infarction, and Receptor Imaging. , 2015, , 463-528.		0
7162	When 4.5 million people become patients. <i>Drug and Therapeutics Bulletin</i> , 2014, 52, 85-85.	0.3	0
7164	Medical Management of Coronary Artery Disease. , 2015, , 2369-2382.		0
7165	Hormone Replacement Therapy and Cardiovascular Disease in Women. , 2015, , 4671-4679.		0
7166	Principles of Primary and Secondary Prevention of Cardiovascular Disease. , 2015, , 1627-1664.		0
7167	Epidemiology of Cardiovascular Disease. , 2015, , 1-20.		0
7168	Evidence for Preventing Cardiovascular Disease. , 2015, , 301-308.		0
7169	Pharmacological Intervention. , 2015, , 217-227.		0
7170	The unity of approaches to preventing coronary heart disease and cerebrovascular diseases. <i>Profilakticheskaya Meditsina</i> , 2015, 18, 24.	0.2	3
7172	From Framingham to Hunt 2: 60 Years Blaming the Wrong Culprit?. <i>Journal of Cardiology &amp; Current Research</i> , 2015, 4, .	0.1	0
7174	è,,è³³ç•°â„ç—†æ²»ç™,ã©ç³/4çš¶ã•ãžfè;€ç©;ç—...æ®•ä½2™ãf³ã,1ã,ãã®ã³/4ãžœ. <i>Journal of JCS Cardiologists</i> , 2016, 21, 230-236.		0
7176	Acute toxicity and antihyperlipidemic activity of rhizome of <i>Tectaria coadunata</i> (Kukkutnakhi): A folklore herb. <i>AYU: an International Quarterly Journal of Research in Ayurveda</i> , 2016, 37, 238.	0.3	1
7177	Associated factors for the development of acute coronary syndrome or stable coronary artery disease. <i>Journal of the Japanese Coronary Association</i> , 2016, 22, 139-144.	0.0	0
7178	Additional Lipid Targets to Modulate Atherosclerotic Plaques beyond LDL-C Lowering. <i>Journal of the Japanese Coronary Association</i> , 2016, 22, 217-227.	0.0	0
7179	Endothelial Effect of Statin Therapy at a High Dose Versus Low Dose Associated with Ezetimibe. <i>Arquivos Brasileiros De Cardiologia</i> , 2016, 106, 279-88.	0.3	8
7180	Measurement of Lipoproteins: Upping the Game in Characterizing the Lipid Phenotype. <i>Journal of applied laboratory medicine</i> , The, 2016, 1, 243-246.	0.6	0

#	ARTICLE	IF	CITATIONS
7182	Lipertance - jeden krok v léčbě kardiovaskulárního rizika, aneb nikdy to nebylo jednoduše. Cor Et Vasa, 2016, 58, 648-652.	0.1	0
7185	Coronary atherosclerosis regression - theory, facts and clinical relevance. Intervencni A Akutni Kardiologie, 2016, 15, 179-182.	0.0	0
7186	Perioperative Considerations for Surgical Emergencies. , 2017, , 31-41.		0
7187	Paradigm Shift of the Treatment of Dyslipidemia for Prevention of Atherosclerotic Cardiovascular Diseases. Nihon Ika Daigaku Igakkai Zasshi, 2017, 13, 199-204.	0.0	0
7188	The target level and the difference of pathway on lipid lowering therapy. Journal of the Japanese Coronary Association, 2017, 23, 165-169.	0.0	0
7189	Cardiovascular Comorbidities. Deutsches Arzteblatt International, 2017, 114, 560.	0.6	0
7190	Chinese Herbal Medicine in the Management of Atherosclerosis-Related Chronic Conditions in an Aging Population. Advances in Medical Diagnosis, Treatment, and Care, 2018, , 320-342.	0.1	0
7191	Traitement de l'infarctus du myocarde avec sus-décalage du segment ST. , 2018, , 99-122.e3.		0
7192	Primärprävention und Sekundärprävention des Hirninfarkts. Springer Reference Medizin, 2018, , 1-31.	0.0	0
7193	Coronary Intervention in the Chronic Kidney Disease, Diabetic and Elderly Populations. , 2018, , 291-303.		0
7194	Optimal Strategies for Mitigating Sudden Cardiac Death Risk in At-risk Patients with Structural Heart Disease. Journal of Innovations in Cardiac Rhythm Management, 2018, 9, 3025-3032.	0.2	0
7195	OBSOLETE: Epidemiology of Atherosclerotic Cardiovascular Disease. , 2018, , .		0
7196	ã–ç•CEã®áŸ°çŽãCE»ã–ã–ë†ã°ŠãCE»ã–ã–ã•ãŸã,1ã,zãfãf³. Kagaku To Seibutsu, 2018, 56, 156-160.	0.0	0
7197	Statins: is the net being thrown too wide?. , 2018, , 93-100.		0
7198	Features of the treatment of elderly patients with coronary heart disease at the stages of 1990, 2010 and 2017 examinations.. Medicni Perspektivi, 2018, 23, 20-30.	0.1	0
7199	Ischaemic Heart Disease. , 2019, , 355-363.		0
7200	Chinese Herbal Medicine in the Management of Atherosclerosis-Related Chronic Conditions in an Aging Population. , 2019, , 218-240.		0
7201	Chinese Herbal Medicine in the Management of Atherosclerosis-Related Chronic Conditions in an Aging Population. , 2019, , 593-615.		0

#	ARTICLE	IF	CITATIONS
7202	Primärprävention und Sekundärprävention des Hirninfarkts. Springer Reference Medizin, 2019, , 1-31.	0.0	0
7203	Prevention of cardiovascular event targeted vascular inflammation, and pathology of thrombosis. Japanese Journal of Thrombosis and Hemostasis, 2019, 30, 837-844.	0.1	0
7205	The Use of Statins in Respiratory Diseases. Current Respiratory Medicine Reviews, 2019, 15, 2-3.	0.1	0
7206	Evaluation of the effectiveness of lipid-lowering agents. UÄenye Zapiski Sankt-Peterburgskogo Gosudarstvennogo Medicinskogo Universiteta Im Akad I P Pavlova, 2020, 26, 78-85.	0.0	0
7207	Achievement of LDL-C Targets Defined by ESC/EAS (2011) Guidelines in Risk-Stratified Korean Patients with Dyslipidemia Receiving Lipid-Modifying Treatments. Endocrinology and Metabolism, 2020, 35, 367-376.	1.3	9
7208	Coronary artery bypass surgery versus medical therapy alone for ischaemic heart disease. The Cochrane Library, 0, , .	1.5	0
7210	Discontinuity in care: Practice closures among primary care providers and patient health care utilization. Journal of Health Economics, 2021, 80, 102551.	1.3	7
7211	Management of Hypertriglyceridemia (Including Fibrates and n-3 FattyÄAcids). Contemporary Cardiology, 2021, , 295-306.	0.0	1
7212	Preventive Cardiology as Specialized Medical Art. Contemporary Cardiology, 2021, , 733-743.	0.0	0
7213	Personalised Medicine: Problems of Translation into the Human Domain. , 2020, , 19-48.		0
7214	Cardiovascular Health. Healthy Ageing and Longevity, 2020, , 163-177.	0.2	0
7216	Comparison of Formulas for Low-Density Lipoprotein (LDL) Calculation for Predicting the Risk of Metabolic Syndrome. , 2020, 9, 1607.		2
7217	Primärprävention und Sekundärprävention des Hirninfarkts. Springer Reference Medizin, 2020, , 883-913.	0.0	0
7218	Delayed progression of atherosclerosis and cardiovascular events in asymptomatic patients with atherosclerotic plaques: 3-year prevention with the supplementation with Pycnogenol®+Centellicum®. Minerva Cardioangiologica, 2020, 68, 15-21.	1.2	5
7219	Effects of colchicine on tissue factor in oxLDL-activated T-lymphocytes. Journal of Thrombosis and Thrombolysis, 2022, 53, 739-749.	1.0	5
7220	A practical approach to lipid management in the elderly. Journal of Nutrition, Health and Aging, 0, , .	1.5	0
7221	Implications of changing national cholesterol education program goals for the treatment and control of hypercholesterolemia. Journal of General Internal Medicine, 2006, 21, 171-6.	1.3	14
7222	Koronarinsuffizienz und Herzinfarkt. , 2005, , 3-33.		0

#	ARTICLE	IF	CITATIONS
7223	Fettstoffwechselstörungen. , 2005, , 898-911.		0
7224	Störungen des Lipidstoffwechsels. , 2005, , 418-423.		0
7228	Lipidsenkende Mittel. , 0, , 698-715.		0
7230	Spezielle therapeutische Probleme im höheren Alter. , 2005, , 98-122.		0
7231	Arterielle Verschlusskrankheit (AVK). , 2005, , 146-149.		0
7232	Lipide. , 2005, , 362-377.		0
7233	Kardiovaskuläre Pharmakologie. , 2006, , 1-30.		0
7234	Pathogenesis of the Acute Coronary Syndromes: Hypotheses Generated from Clinical Experience. , 1997, , 183-205.		0
7235	Coronary Atherothrombosis: Pathophysiology and Clinical Implications. , 1999, , 57-75.		0
7236	Atherosclerotic Coronary Disease. , 2006, , 121-129.		0
7237	Women and Coronary Artery Disease. , 2006, , 217-235.		0
7238	Metabolic and Endocrine Effects of Statins in Polycystic Ovary Syndrome. , 2008, , 241-258.		1
7240	Omega-3 Fatty Acids and Cardiovascular Disease: The Epidemiological Evidence.. Environmental Health and Preventive Medicine, 2002, 6, 203-209.	1.4	4
7241	Clinical Role of Antiarrhythmic Drugs in the Prevention of Sudden Death. , 2008, , 733-759.		0
7242	Basis of Cardiac Imaging 2: Myocardial Perfusion, Metabolism, Infarction, and Receptor Imaging in Coronary Artery Disease and Congestive Heart Failure. , 2006, , 352-394.		0
7243	Cardiovascular Medications: Pharmacokinetics and Pharmacodynamics. , 2009, , 425-452.		0
7244	Impact of changing reimbursement criteria on statin treatment patterns among patients with atherosclerotic cardiovascular disease or cardiovascular risk factors. Journal of Clinical Pharmacy and Therapeutics, 2021, 46, 415-423.	0.7	1
7245	Clinical pharmacology and clinical trials in Japan. Journal of Molecular Medicine, 1996, 74, 479-486.	1.7	3

#	ARTICLE	IF	CITATIONS
7246	Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. Homocysteine Lowering Trialists' Collaboration. <i>BMJ: British Medical Journal</i> , 1998, 316, 894-8.	2.4	145
7247	Fatality outside hospital from acute coronary events in three British health districts, 1994-5. United Kingdom Heart Attack Study Collaborative Group. <i>BMJ: British Medical Journal</i> , 1998, 316, 1065-70.	2.4	39
7248	Lipid screening to prevent coronary artery disease: a quantitative evaluation of evolving guidelines. <i>Cmaj</i> , 2000, 163, 1263-9.	0.9	6
7249	Did the major clinical trials of statins affect prescribing behaviour?. <i>Cmaj</i> , 2001, 164, 1695-6.	0.9	10
7250	A qualitative study of evidence in primary care: what the practitioners are saying. <i>Cmaj</i> , 2002, 166, 1525-30.	0.9	24
7251	Risks and benefits of hormone replacement therapy: the evidence speaks. <i>Cmaj</i> , 2003, 168, 1001-10.	0.9	19
7252	The use of cholesterol-lowering medications after coronary revascularization. <i>Cmaj</i> , 2003, 169, 1153-7.	0.9	1
7253	Communicating risk reductions. Data were selectively used. <i>BMJ: British Medical Journal</i> , 1999, 318, 602; author reply 603-4.	2.4	0
7254	Statins for stroke should be considered in biologically fit people over 75. <i>BMJ: British Medical Journal</i> , 2000, 320, 1278.	2.4	0
7255	Long standing heart disease should be better screened. <i>BMJ: British Medical Journal</i> , 2000, 321, 1083-4.	2.4	0
7256	Familial hypercholesterolaemia is underdiagnosed after AMI. <i>BMJ: British Medical Journal</i> , 2001, 322, 111.	2.4	5
7257	Cholesterol levels and statin use in patients with coronary heart disease treated in primary care settings. <i>Preventing Chronic Disease</i> , 2005, 2, A05.	1.7	3
7258	Coronary heart disease prevention and age inequalities: the first year of the National Service Framework for CHD. <i>British Journal of General Practice</i> , 2005, 55, 369-75.	0.7	15
7259	Diagnosis and treatment of non-hemodynamically significant coronary heart disease: where to start?. <i>Transactions of the American Clinical and Climatological Association</i> , 2005, 116, 273-80; discussion 281.	0.9	0
7260	Medicare prescription coverage and congressional gridlock. <i>Journal of General Internal Medicine</i> , 2001, 16, 864-6.	1.3	0
7261	Management strategies of dyslipidemia in the elderly: 2005. <i>MedGenMed: Medscape General Medicine</i> , 2005, 7, 8.	0.2	0
7262	A glimpse at HDL-based therapy for atherosclerosis. <i>Clinical Biochemist Reviews</i> , 2004, 25, 3-5.	3.3	27
7264	Radiology rounds. Cerebellar astrocytoma. <i>Canadian Family Physician</i> , 1995, 41, 1298, 1305-9.	0.1	0

#	ARTICLE	IF	CITATIONS
7265	Family practice patients' adherence to statin medications. <i>Canadian Family Physician</i> , 2007, 53, 2144-5.	0.1	21
7266	Implementing NCEP guidelines in a Web-based disease-management system. <i>Proceedings: A Conference of the American Medical Informatics Association</i> , 1997, , 764-8.	0.7	2
7267	Are patients with hyperlipidemia undertreated? Study of patients admitted to hospital with coronary events. <i>Canadian Family Physician</i> , 2007, 53, 1502-7.	0.1	0
7268	Cholesterol lowering for secondary prevention: what statin dose should we use?. <i>Vascular Health and Risk Management</i> , 2007, 3, 615-27.	1.0	8
7269	Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? The single pill of amlodipine/atorvastatin. <i>Vascular Health and Risk Management</i> , 2007, 3, 711-9.	1.0	3
7270	Secular trends in lipid-lowering treatment and lipid levels after a first acute myocardial infarction. <i>Vascular Health and Risk Management</i> , 2007, 3, 1045-51.	1.0	3
7271	Beneficial effects of the addition of fenofibrate to statin therapy in patients with acute coronary syndrome after percutaneous coronary interventions. <i>Experimental and Clinical Cardiology</i> , 2007, 12, 91-6.	1.3	3
7272	Type II diabetes mellitus and cardiovascular risk factors: Current therapeutic approaches. <i>Experimental and Clinical Cardiology</i> , 2007, 12, 17-28.	1.3	60
7273	Common and rare gene variants affecting plasma LDL cholesterol. <i>Clinical Biochemist Reviews</i> , 2008, 29, 11-26.	3.3	45
7274	Reaching target lipid levels and the natural history of diabetes mellitus in patients surviving acute coronary syndrome: A retrospective cohort study from a tertiary care outpatient clinic. <i>Experimental and Clinical Cardiology</i> , 2008, 13, 25-8.	1.3	2
7275	Statins improve human coronary atherosclerotic plaque morphology. <i>Texas Heart Institute Journal</i> , 2008, 35, 99-103.	0.1	11
7276	Recommendations for management of dyslipidemia in high cardiovascular risk patients. <i>Experimental and Clinical Cardiology</i> , 2008, 13, 71-4.	1.3	2
7277	Statins in the first-line therapy of acute coronary syndrome - similar to aspirin?. <i>Experimental and Clinical Cardiology</i> , 2005, 10, 9-16.	1.3	2
7278	Stroke Best Practices: a team approach to evidence-based care. <i>Journal of the National Medical Association</i> , 2004, 96, 5S-20S.	0.6	2
7280	Statin induced myopathy presenting as mechanical musculoskeletal pain observed in two chiropractic patients. <i>Journal of the Canadian Chiropractic Association</i> , 2010, 54, 43-51.	0.2	4
7282	Statins do not decrease small, dense low-density lipoprotein. <i>Texas Heart Institute Journal</i> , 2010, 37, 421-8.	0.1	23
7283	Jeremiah Metzger Lecture: cholesterol, inflammation and atherosclerotic cardiovascular disease: is it all LDL?. <i>Transactions of the American Clinical and Climatological Association</i> , 2011, 122, 256-89.	0.9	35
7284	The effect of statin therapy in stroke outcome: a double blind clinical trial. <i>International Journal of Preventive Medicine</i> , 2012, 3, 68-72.	0.2	5

#	ARTICLE	IF	CITATIONS
7285	Fish oil in cardiovascular prevention. <i>Ochsner Journal</i> , 2002, 4, 83-91.	0.5	6
7286	A Randomized Controlled Study to Compare the Effects of Rosuvastatin 2.5 mg and Pravastatin 10 mg on the Plasma Lipid Profile in Japanese Patients with Hypercholesterolemia (ASTRO-1). <i>Annals of Vascular Diseases</i> , 2009, 2, 148-58.	0.2	0
7287	Statins as first-line therapy for acute coronary syndrome?. <i>Experimental and Clinical Cardiology</i> , 2012, 17, 227-36.	1.3	9
7288	Cholesterol and cardiovascular disease in the elderly. <i>Facts and gaps.</i> , 2013, 4, 154-69.		41
7289	Heart rate variability as an indicator of left ventricular systolic dysfunction. <i>Cardiovascular Journal of Africa</i> , 2009, 20, 278-83.	0.2	9
7290	High-dose atorvastatin pretreatment could diminishes microvascular impairment in patients undergoing elective percutaneous coronary intervention. <i>Journal of Geriatric Cardiology</i> , 2013, 10, 355-60.	0.2	4
7291	Statins: emerging role in chemoprevention for hepatocellular carcinoma?. <i>Hepatobiliary Surgery and Nutrition</i> , 2013, 2, 117-20.	0.7	0
7292	An overview of lipid abnormalities in patients with inflammatory bowel disease. <i>Annals of Gastroenterology</i> , 2011, 24, 181-187.	0.4	67
7293	A multicentre, open-label, observational local study to evaluate the low-density lipoprotein cholesterol-lowering effect of ezetimibe as prescribed in daily routine practice in the South African population. <i>Cardiovascular Journal of Africa</i> , 2007, 18, 325-9.	0.2	1
7294	Gender Differences in the Association between Lipid Profile and Sexual Function among Patients with Coronary Artery Disease. , 2014, 8, 9-14.		11
7295	Method of LDL cholesterol measurement influences classification of LDL cholesterol treatment goals: clinical research study. <i>Journal of Investigative Medicine</i> , 2010, 58, 945-9.	0.7	10
7296	Recurrent stroke: what have we learnt?. <i>Malaysian Family Physician</i> , 2007, 2, 70-3.	0.2	0
7297	Sex-specific association of the SPTY2D1 rs7934205 polymorphism and serum lipid levels. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 665-81.	0.5	9
7298	The effects of different doses of atorvastatin on serum lipid profile, glycemic control, and liver enzymes in patients with ischemic cerebrovascular accident. <i>ARYA Atherosclerosis</i> , 2014, 10, 298-304.	0.4	5
7299	ATP-dependent potassium channels are implicated in simvastatin pretreatment-induced inhibition of apoptotic cell death after renal ischemia/reperfusion injury. <i>Medical Journal of the Islamic Republic of Iran</i> , 2015, 29, 191.	0.9	1
7300	Statin therapy for heart failure: to prescribe or not?. <i>Journal of Thoracic Disease</i> , 2015, 7, 1702-3.	0.6	0
7301	Zontivity (Vorapaxar), First-in-Class PAR-1 Antagonist, Receives FDA Approval for Risk Reduction of Heart Attack, Stroke, and Cardiovascular Death. <i>American Health and Drug Benefits</i> , 2015, 8, 148-51.	0.5	24
7302	Lack of Association between High-Density Lipoprotein Cholesterol and Angiographic Coronary Lesion Severity in Chinese Patients with Low Background Low-Density Lipoprotein Cholesterol. <i>Acta Cardiologica Sinica</i> , 2015, 31, 528-35.	0.1	4

#	ARTICLE	IF	CITATIONS
7303	Praluent (Alirocumab): First PCSK9 Inhibitor Approved by the FDA for Hypercholesterolemia. American Health and Drug Benefits, 2016, 9, 123-6.	0.5	9
7304	The Cost-Benefit Balance of Statins in Hawai'i: A Moving Target. Hawai'i Journal of Medicine & Public Health: A Journal of Asia Pacific Medicine & Public Health, 2017, 76, 99-102.	0.4	2
7305	Risk factor control five years after coronary bypass grafting. Journal of the Royal College of Physicians of London, 1996, 30, 136-41.	0.2	2
7306	Screening for hyperlipidaemia in childhood. Recommendations of the British Hyperlipidaemia Association. Journal of the Royal College of Physicians of London, 1996, 30, 115-8.	0.2	11
7307	ANMCO/GICR-IACPR/SICI-GISE Consensus Document: the clinical management of chronic ischaemic cardiomyopathy. European Heart Journal Supplements, 2017, 19, D163-D189.	0.0	0
7309	Comparison of the low-density lipoprotein cholesterol target value and the preventive effect of statins in elderly patients and younger patients. Journal of Geriatric Cardiology, 2017, 14, 383-391.	0.2	0
7310	Statin-prescribing trends for primary and secondary prevention of cardiovascular disease. Canadian Family Physician, 2017, 63, e495-e503.	0.1	18
7312	Lipid Lowering Therapy for Acute Coronary Syndrome and Coronary Artery Disease: Highlights of the 2017 Taiwan Lipid Guidelines for High Risk Patients. Acta Cardiologica Sinica, 2018, 34, 371-378.	0.1	12
7313	Diabetes Mellitus and Cardiovascular Disease. Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 2003, 14, 74-77.	0.7	0
7314	Red yeast rice for dyslipidemia. Missouri Medicine, 2013, 110, 349-54.	0.3	4
7315	Significant reduction in the LDL cholesterol increases the risk of intracerebral hemorrhage: a systematic review and meta-analysis of 33 randomized controlled trials. American Journal of Translational Research (discontinued), 2020, 12, 463-477.	0.0	6
7317	PREVENTIVE CARDIOLOGY AS NEW SUBSPECIALTY OF CARDIOVASCULAR MEDICINE. Transactions of the American Clinical and Climatological Association, 2020, 131, 33-41.	0.9	2
7318	The Effectiveness of Target Low-Density Lipoprotein Cholesterol Achieved with Strict Management in Secondary Prevention of Long-Term Coronary Events in Japanese Patients. Acta Cardiologica Sinica, 2021, 37, 65-73.	0.1	0
7319	Fish Oil Supplements for Prevention of Cardiovascular Disease: The Jury Is Still Out: CON: Fish Oil is Useful to Prevent or Treat Cardiovascular Disease. Missouri Medicine, 2021, 118, 219-225.	0.3	1
7320	Vulnerable atherosclerotic plaque features: findings from coronary imaging. Journal of Geriatric Cardiology, 2021, 18, 577-584.	0.2	1
7321	Impact of statin intensity on adverse cardiac and cerebrovascular events in older adult patients with myocardial infarction. Journal of Geriatric Cardiology, 2021, 18, 609-622.	0.2	0
7322	Statins for Patients Undergoing Thoracic Aortic Aneurysm Repair Surgery: What to Do?. Aorta, 2021, 09, 169-170.	0.1	1
7323	The Magnitude of the Survival Benefit of Internal Thoracic Artery Grafting: Absolute Risk Reduction. JTCVS Open, 2021, , .	0.2	0



#	ARTICLE	IF	CITATIONS
7324	Gas Chromatography and Flame-Ionization Detection of Non-Cholesterol Sterols as Indicators of Cholesterol Absorption and Synthesis in 158 Chinese Individuals with Normolipidemia, Hyperlipidemia, and Familial Hypercholesterolemia. <i>Medical Science Monitor</i> , 2022, 28, e934471.	0.5	0
7325	Nutrients, Cognitive Function, and Brain Aging: What We Have Learned from Dogs. <i>Medical Sciences (Basel, Switzerland)</i> , 2021, 9, 72.	1.3	2
7326	Assessing the Overall Validity of Randomised Controlled Trials. <i>International Studies in the Philosophy of Science</i> , 0, , 1-24.	0.2	0
7327	Statin Therapy in Very Old Patients: Lights and Shadows. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 779044.	1.1	7
7328	Characteristics associated with early- vs. later-onset adult diabetes: The CARDIA study. <i>Diabetes Research and Clinical Practice</i> , 2021, 182, 109144.	1.1	6
7329	Clinical observation of kaixin capsule in treating type 2 diabetes mellitus complicated with abnormal lipidemia. , 2002, 8, 179-182.		0
7330	Coronary Atherosclerotic Plaque Regression. <i>Journal of the American College of Cardiology</i> , 2022, 79, 66-82.	1.2	44
7331	PCSK9 inhibition in patients with heart failure: neutral or harmful intervention?. <i>European Heart Journal</i> , 2022, 43, 1566-1568.	1.0	6
7332	Prevalence of statin intolerance: a meta-analysis. <i>European Heart Journal</i> , 2022, 43, 3213-3223.	1.0	151
7333	The efficacy of the combined antihypertensive and statin therapy in patients with hypertension and excessive body mass. <i>Ukrainian Therapeutical Journal</i> , 2020, .	0.0	0
7334	Rosuvastatin Alleviates Coronary Microembolization-Induced Cardiac Injury by Suppressing Nox2-Induced ROS Overproduction and Myocardial Apoptosis. <i>Cardiovascular Toxicology</i> , 2022, 22, 341-351.	1.1	4
7335	Cholesterol in the Cell Membrane—An Emerging Player in Atherogenesis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 533.	1.8	17
7336	Should a Statin be Given to All Hypertensive Patients?. <i>Current Hypertension Reports</i> , 2022, 24, 21-27.	1.5	1
7337	The Protective Effects of Lipid-Lowering Agents on Cardiovascular Disease and Mortality in Maintenance Dialysis Patients: Propensity Score Analysis of a Population-Based Cohort Study. <i>Frontiers in Pharmacology</i> , 2021, 12, 804000.	1.6	2
7338	Statin Induced Myopathy Among Patients Attending the National Center for Diabetes, endocrinology, & genetics. <i>Annals of Medicine and Surgery</i> , 2022, 74, 103304.	0.5	11
7339	Prognostic Value of Serial Coronary CT Angiography in Atherosclerotic Plaque Modification: What Have We Learnt?. <i>Current Cardiovascular Imaging Reports</i> , 2022, 15, 1.	0.4	2
7340	Hyperlipidemia and hypertension have synergistic interaction on ischemic stroke: insights from a general population survey in China. <i>BMC Cardiovascular Disorders</i> , 2022, 22, 47.	0.7	9
7342	The effect of early treatment by cerivastatin on the serum level of C-reactive protein, interleukin-6, and interleukin-8 in the patients with unstable angina and non-Q-wave myocardial infarction. <i>Molecular and Cellular Biochemistry</i> , 2003, 246, 45-50.	1.4	12

#	ARTICLE	IF	CITATIONS
7343	Cholesterol lowering with simvastatin in people with diabetes. <i>Current Atherosclerosis Reports</i> , 2004, 6, 85-6.	2.0	0
7344	Intensive versus moderate lipid lowering with statins in acute coronary syndromes. <i>Current Atherosclerosis Reports</i> , 2005, 7, 85-6.	2.0	1
7345	Aggressive low-density lipoprotein cholesterol lowering in secondary prevention of coronary heart disease. <i>Current Atherosclerosis Reports</i> , 2006, 8, 7-8.	2.0	0
7346	Clinical significance of single nucleotide polymorphisms in PCSK9. <i>Current Atherosclerosis Reports</i> , 2007, 9, 175-6.	2.0	1
7347	HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. <i>Current Atherosclerosis Reports</i> , 2008, 10, 281.	2.0	3
7349	A Propensity Score Matched Analysis of Statin Effects on Major Adverse Cardiac Events after Percutaneous Coronary Intervention in Patients Over 75 Years Old. <i>Internal Medicine</i> , 2022, , .	0.3	2
7350	Clinical efficacy and safety outcomes of bempedoic acid for LDL-C lowering therapy in patients at high cardiovascular risk: a systematic review and meta-analysis. <i>BMJ Open</i> , 2022, 12, e048893.	0.8	20
7351	Association between Adipose Tissue Depots and Dyslipidemia: The KORA-MRI Population-Based Study. <i>Nutrients</i> , 2022, 14, 797.	1.7	6
7352	Evaluating the Association Between Low-Density Lipoprotein Cholesterol Reduction and Relative and Absolute Effects of Statin Treatment. <i>JAMA Internal Medicine</i> , 2022, 182, 474.	2.6	37
7353	Contemporary Management of Dyslipidemia. <i>Drugs</i> , 2022, 82, 559-576.	4.9	14
7354	The Cost-Effectiveness of Hyperlipidemia Medication in Low- and Middle-Income Countries: A Review. <i>Global Heart</i> , 2022, 17, 18.	0.9	3
7355	Simultaneous evaluation of fatty acid and triglycerides after percutaneous coronary intervention. <i>Journal of Cardiology</i> , 2022, 80, 149-154.	0.8	5
7356	Team-based strategies to prevent heart failure. <i>Current Opinion in Cardiology</i> , 2022, Publish Ahead of Print, .	0.8	0
7357	Lipid-Targeted Atherosclerotic Risk Reduction in Older Adults: A Review. <i>Geriatrics (Switzerland)</i> , 2022, 7, 38.	0.6	0
7358	Molecular Biological and Clinical Understanding of the Statin Residual Cardiovascular Disease Risk and Peroxisome Proliferator-Activated Receptor Alpha Agonists and Ezetimibe for Its Treatment. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3418.	1.8	8
7359	What characterizes event-free elderly FH patients? A comprehensive lipoprotein profiling. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, 32, 1651-1660.	1.1	3
7360	Association between statin use and Parkinson's disease in Korean patients with hyperlipidemia. <i>Parkinsonism and Related Disorders</i> , 2022, 97, 15-24.	1.1	6
7361	Statin-associated muscle symptoms—a review: Individualizing the approach to optimize care. <i>Pharmacotherapy</i> , 2022, 42, 428-438.	1.2	10

#	ARTICLE	IF	CITATIONS
7362	Lipid-lowering therapy of cardiovascular diseases (literature review). Bukovinian Medical Herald, 2021, 25, 112-116.	0.1	0
7363	Comparison of High-Statins Therapy vs Moderate-Statins Therapy in Achieving Positive Low-Density Lipoprotein Change in Patients After Acute Coronary Syndrome: A Randomized-Control Trial. Cureus, 2021, 13, e20710.	0.2	0
7364	COPD â€œ do the right thing. BMC Family Practice, 2021, 22, 244.	2.9	23
7365	Efficacy, Safety and Protective Effects of Lipid Lowering Drugs in Patients with Diabetes. European Journal of Medical and Health Sciences, 2022, 4, 89-92.	0.1	1
7366	Poor achievement of lipid targets after acute coronary syndrome: what can we improve?. Medical Journal of Australia, 2022, , .	0.8	0
7367	Statins, the mass media and side effects. British Journal of Cardiac Nursing, 0, , 1-3.	0.0	0
7368	Gender, Hyperlipidemia, and Coronary Artery Disease. Comprehensive Therapy, 2003, 29, 07-17.	0.2	0
7380	Blood lipids and molecular pathways of atherogenesis. , 2022, , 623-637.		0
7381	Association between Indoor Temperature in Winter and Serum Cholesterol: A Cross-Sectional Analysis of the Smart Wellness Housing Survey in Japan. Journal of Atherosclerosis and Thrombosis, 2022, , .	0.9	5
7382	Cholesterol Metabolic Markers for Differential Evaluation of Patients with Hyperlipidemia and Familial Hypercholesterolemia. Disease Markers, 2022, 2022, 1-9.	0.6	3
7383	Low-Density Lipoprotein Cholesterol Levels in Coronary Artery Disease Patients: Opportunities for Improvement. Cardiology Research and Practice, 2022, 2022, 1-7.	0.5	1
7384	New Treatment Targets and Innovative Lipid-Lowering Therapies in Very-High-Risk Patients with Cardiovascular Disease. Biomedicines, 2022, 10, 970.	1.4	8
7385	Undertreatment or Overtreatment With Statins: Where Are We?. Frontiers in Cardiovascular Medicine, 2022, 9, 808712.	1.1	9
7386	Hypertension and dyslipidemia treatment in stroke. Vnitri Lekarstvi, 2022, 68, 172-177.	0.1	1
7387	Availability of bioactive flax lignan from foods and supplements. Critical Reviews in Food Science and Nutrition, 2023, 63, 9843-9858.	5.4	5
7388	The current status of low-density lipoprotein cholesterol for primary prevention of coronary artery disease in late-stage elderly persons with type 2 diabetes mellitus: A retrospective, single-center study. Journal of Diabetes Investigation, 2022, , .	1.1	2
7389	Assessment of the appropriateness of cardiovascular preventive medication in older people: using the RAND/UCLA Appropriateness Method. BMC Geriatrics, 2022, 22, 394.	1.1	1
7390	Commentary: Involvement of LDL and ox-LDL in Cancer Development and Its Therapeutical Potential. Frontiers in Oncology, 2022, 12, 891352.	1.3	1

#	ARTICLE	IF	CITATIONS
7391	Lipid-modifying and antiatherosclerotic drugs. , 2013, , 398-435.		3
7392	LDL-C: The Only Causal Risk Factor for ASCVD. Why Is It Still Overlooked and Underestimated?. Current Atherosclerosis Reports, 2022, 24, 635-642.	2.0	7
7393	A Comparison of Rehospitalization Risks on Diabetic and Non-Diabetic Patients after Recovery from Acute Coronary Syndrome. Healthcare (Switzerland), 2022, 10, 1003.	1.0	0
7394	Colchicina en prevenci3n del ictus. �Es hora de cambiar nuestra pr�ctica cl�nica?. Neurolog�a, 2022, , .	0.3	0
7396	Epidemiology of Coronary Artery Disease. Surgical Clinics of North America, 2022, 102, 499-516.	0.5	52
7397	Implication of Lipids in Calcified Aortic Valve Pathogenesis: Why Did Statins Fail?. Journal of Clinical Medicine, 2022, 11, 3331.	1.0	2
7398	A new and automated risk prediction of coronary artery disease using clinical endpoints and medical imaging-derived patient-specific insights: protocol for the retrospective GeoCAD cohort study. BMJ Open, 2022, 12, e054881.	0.8	2
7399	Chasing LDL cholesterol to the bottom � PCSK9 in perspective. , 2022, 1, 554-561.		13
7400	Proprotein convertase subtilisin/kexin type 9 inhibition after acute coronary syndrome or prior myocardial infarction. Current Opinion in Lipidology, 2022, 33, 147-159.	1.2	7
7401	SAMSON and the Nocebo Effect: Management of Statin Intolerance. Current Cardiology Reports, 2022, 24, 1101-1108.	1.3	9
7402	Prevalence and initiation of statin therapy in the oldest old�a longitudinal population-based study. European Journal of Clinical Pharmacology, 0, , .	0.8	0
7403	Harmonisation of large-scale, heterogeneous individual participant adverse event data from randomised trials of statin therapy. Clinical Trials, 2022, 19, 593-604.	0.7	2
7404	Serial Changes in Coronary Plaque Formation Using CT Angiography in Patients Undergoing PCSK9-Inhibitor Therapy With 1-year Follow-up. Journal of Thoracic Imaging, 0, Publish Ahead of Print, .	0.8	0
7405	LDL Cholesterol�How Low Can We Go?. Endocrinology and Metabolism Clinics of North America, 2022, 51, 681-690.	1.2	3
7408	Combination therapy in the guidelines: from high-intensity statins to high-intensity lipid-lowering therapies: Combination therapy in the guideline. , 2022, 1, 25-29.		2
7410	PCSK9 Monoclonal Antibodies: New Developments and Their Relevance in a Nucleic Acid�Based Therapy Era. Current Atherosclerosis Reports, 2022, 24, 779-790.	2.0	5
7411	Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics. Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	78
7412	Treatment of heart failure with preserved ejection fraction with SGLT2 inhibitors: new therapy standard?. Herz, 0, , .	0.4	1

#	ARTICLE	IF	CITATIONS
7414	Polypharmacology in Clinical Applications: Cardiovascular Polypharmacology. , 2022, , 133-198.		0
7415	Cold shock domain-containing protein E1 is a posttranscriptional regulator of the LDL receptor. Science Translational Medicine, 2022, 14, .	5.8	8
7416	Optimal target of LDL cholesterol level for statin treatment: challenges to monotonic relationship with cardiovascular events. BMC Medicine, 2022, 20, .	2.3	6
7421	European, Russian and American Clinical Guidelines on dyslipidemias management – where do we stand? European, Russian, and US guidelines on dyslipidemias. , 2022, 1, 48-53.		0
7422	Lipid-Lowering Trials Are Not Representative of Patients Managed in Clinical Practice: A Systematic Review and Meta-Analysis of Exclusion Criteria. Journal of the American Heart Association, 2023, 12, .	1.6	11
7423	Prevalence and Effects of High-Intensity Statins for Japanese Patients Presenting With Acute Coronary Syndrome – A Post Hoc Secondary Analysis of STOPDAPT-2 ACS –. Circulation Journal, 2022, , .	0.7	0
7424	Long-term statins administration exacerbates diabetic nephropathy via ectopic fat deposition in diabetic mice. Nature Communications, 2023, 14, .	5.8	17
7425	How Low Can You Go? New Evidence Supports No Lower Bound to Low-Density Lipoprotein Cholesterol Level in Secondary Prevention. Circulation, 2023, 147, 1204-1207.	1.6	0
7426	Comparative efficacy and safety among high-intensity statins. Systematic Review and Meta-Analysis. Journal of Comparative Effectiveness Research, 2023, 12, .	0.6	3
7427	A Novel Drug Delivery System: Hyodeoxycholic Acid-Modified Metformin Liposomes for Type 2 Diabetes Treatment. Molecules, 2023, 28, 2471.	1.7	0
7428	Association between Lipid Level and Revascularization at Routine Coronary Angiography Follow-up among Patients with Acute Coronary Syndrome: A Case-control Study. Iryo Yakugaku (Japanese Journal) Tj ETQq0 000rgBT /Overlock 10		
7429	Gender disparities in prevalence by diagnostic criteria, treatment and mortality of newly diagnosed acute myocardial infarction in Korean adults. Scientific Reports, 2023, 13, .	1.6	2
7430	Recent Trials on the Cardioprotective Effects of New Generation Anti-diabetic and Lipid-Lowering Agents. Frontiers in Clinical Drug Research Diabetes and Obesity, 2023, , 117-167.	0.1	0
7431	Understanding the molecular mechanisms of statin pleiotropic effects. Archives of Toxicology, 2023, 97, 1529-1545.	1.9	9